<SEC-DOCUMENT>0001104506-19-000009.txt : 20190222
<SEC-HEADER>0001104506-19-000009.hdr.sgml : 20190222
<ACCEPTANCE-DATETIME>20190222073035
ACCESSION NUMBER:		0001104506-19-000009
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190222
DATE AS OF CHANGE:		20190222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30739
		FILM NUMBER:		19623957

	BUSINESS ADDRESS:	
		STREET 1:		10 FINDERNE AVENUE
		STREET 2:		BUILDING 10
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		10 FINDERNE AVENUE
		STREET 2:		BUILDING 10
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>insmed10k2018.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:D5E2847653D05454911934D613100435,x:ff49589f55794ae39e79a29619d4c0f1-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2019 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:insm="http://www.insmed.com/20181231" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:AmendmentFlag" id="Fact-71B44FD80380B850FBBCC80C6441BC57-wk-Fact-71B44FD80380B850FBBCC80C6441BC57" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-B3AEA95179E72A7590D7C80C643D0015-wk-Fact-B3AEA95179E72A7590D7C80C643D0015">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-3DE9432CE88B341DF268C80C643BD716-wk-Fact-3DE9432CE88B341DF268C80C643BD716">FY</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:DocumentFiscalYearFocus" id="Fact-DF1273AA09DD43B84916C80C643948E9-wk-Fact-DF1273AA09DD43B84916C80C643948E9">2018</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:DocumentPeriodEndDate" id="Fact-F14876D9F917A568E917C80C64380136-wk-Fact-F14876D9F917A568E917C80C64380136">2018-12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:EntityCentralIndexKey" id="Fact-4EBC7A90C76AD19367E0C80C64379DB5-wk-Fact-4EBC7A90C76AD19367E0C80C64379DB5">0001104506</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:EntityCurrentReportingStatus" id="Fact-90C38765419BBE187289C80C6441BB81-wk-Fact-90C38765419BBE187289C80C6441BB81">Yes</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:EntityEmergingGrowthCompany" id="Fact-9AC056370091BF7DF909579A2E4C2FF4-wk-Fact-9AC056370091BF7DF909579A2E4C2FF4" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:EntityFilerCategory" id="Fact-085F5561A3E0DEAE00F6C80C643AD701-wk-Fact-085F5561A3E0DEAE00F6C80C643AD701">Large Accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:EntityRegistrantName" id="Fact-77167C5A14C2A331A2A9C80C643F8C97-wk-Fact-77167C5A14C2A331A2A9C80C643F8C97">INSMED INC</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:EntityShellCompany" id="Fact-8F9D4B1BDF3B7EF37A27579984C98E2C-wk-Fact-8F9D4B1BDF3B7EF37A27579984C98E2C" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:EntitySmallBusiness" id="Fact-1DF37062A1AE6765ABBE579BAAF43366-wk-Fact-1DF37062A1AE6765ABBE579BAAF43366" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:EntityVoluntaryFilers" id="Fact-5EA7374172D3AB3E6B94C80C643A8F8A-wk-Fact-5EA7374172D3AB3E6B94C80C643A8F8A">No</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD" name="dei:EntityWellKnownSeasonedIssuer" id="Fact-3C79888DFD224ADC672CC80C643FEEF0-wk-Fact-3C79888DFD224ADC672CC80C643FEEF0">Yes</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="security" contextRef="FI2017Q4" name="insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" id="Fact-EBDE1BCD170547E68FA3C80C645ABDC1-wk-Fact-EBDE1BCD170547E68FA3C80C645ABDC1">0</ix:nonFraction><ix:nonNumeric contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_insm_CommercialFilVFinishServicesAgreementMember" name="insm:CommercialServicesAgreementExtensionPeriod" id="Fact-C46CB54EB96BEDD97F5CC80C64668C1D-wk-Fact-C46CB54EB96BEDD97F5CC80C64668C1D">P2Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2017Q4YTD" name="insm:FairValueLevel1Level2Level3TransfersAmount" id="Fact-D605ED0AA3131C8588101A5D1C01B53A-wk-Fact-D605ED0AA3131C8588101A5D1C01B53A">0</ix:nonFraction><ix:nonNumeric contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" name="insm:RoyaltyPaymentPeriod" id="Fact-4E1C65EC05A16A8D124CC80C645CA355-wk-Fact-4E1C65EC05A16A8D124CC80C645CA355">P3Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2017Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-C79848154B3F91BF6D0FC80C64370C29-wk-Fact-C79848154B3F91BF6D0FC80C64370C29">0.01</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-87C6E35A778346618DE0C80C643CF194-wk-Fact-87C6E35A778346618DE0C80C643CF194">500000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-BF16B39EEE35C8798604C80C643602E5-wk-Fact-BF16B39EEE35C8798604C80C643602E5">76610508</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-B3B7BC8015CB98624A84C80C6438E103-wk-Fact-B3B7BC8015CB98624A84C80C6438E103">77307521</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-E6427A52FCF99DB6B849C80C64365386-wk-Fact-E6427A52FCF99DB6B849C80C64365386">76610508</ix:nonFraction><ix:nonFraction decimals="7" unitRef="number" contextRef="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="Fact-299BA43F9CB8E34560291B3DB68932ED-wk-Fact-299BA43F9CB8E34560291B3DB68932ED">0.0255384</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" name="us-gaap:DebtInstrumentFaceAmount" id="Fact-E63E78ADC6EFA5AD48A41A6250CAA0CA-wk-Fact-E63E78ADC6EFA5AD48A41A6250CAA0CA">450000000.0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" id="Fact-65FFEE9714E2E152417E9AF2D7AD9689-wk-Fact-65FFEE9714E2E152417E9AF2D7AD9689">5000000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" id="Fact-23E234C2FC5ACE1BB6559B651D197C72-wk-Fact-23E234C2FC5ACE1BB6559B651D197C72">5000000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" id="Fact-44C99EC6AE03A17CD2E89B64D5603258-wk-Fact-44C99EC6AE03A17CD2E89B64D5603258">5000000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" id="Fact-770E1A9E4786CF973F939B5F7CF2B9D4-wk-Fact-770E1A9E4786CF973F939B5F7CF2B9D4">5000000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" id="Fact-8B785C65401E140F93F99B5F28BB3348-wk-Fact-8B785C65401E140F93F99B5F28BB3348">5000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="I2019Q1Jan01_srt_RangeAxis_srt_MaximumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact-FC61AEFA0E3CCD784E740143187DB0DC-wk-Fact-FC61AEFA0E3CCD784E740143187DB0DC">49000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="I2019Q1Jan01_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact-CDB0F6D9FF18FD0C2DA60142910BE80C-wk-Fact-CDB0F6D9FF18FD0C2DA60142910BE80C">44000000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" name="us-gaap:OperatingLossCarryforwards" id="Fact-E173BD8A7EDFF80D7912C9F1A4D61825-wk-Fact-E173BD8A7EDFF80D7912C9F1A4D61825">1300000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2017Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-EEE1340DDAE87B3653E4C80C6470758C-wk-Fact-EEE1340DDAE87B3653E4C80C6470758C">0.01</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-97D2A27B46C907460981C80C6477E39C-wk-Fact-97D2A27B46C907460981C80C6477E39C">200000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-89FD8E03353A0A8D3154C80C6471417F-wk-Fact-89FD8E03353A0A8D3154C80C6471417F">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-506CBBC8F10EF5C02F42C80C64748D22-wk-Fact-506CBBC8F10EF5C02F42C80C64748D22">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-BE3D088BF4060383673AC80C6471B68C-wk-Fact-BE3D088BF4060383673AC80C6471B68C">0</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2016Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-50055C2BCF80B1099135C80C645E2D3D-wk-Fact-50055C2BCF80B1099135C80C645E2D3D">0.77</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2016Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-EA50553AA123930B10F0C80C642532B4-wk-Fact-EA50553AA123930B10F0C80C642532B4">0.74</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-CA420385469BF20C75FCC80C64230B0C-wk-Fact-CA420385469BF20C75FCC80C64230B0C">0.79</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-120B2E5818E39AB19F9DC80C642D5AC1-wk-Fact-120B2E5818E39AB19F9DC80C642D5AC1">0.71</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-087413CE40C4B1F4C4F6C80C642C8975-wk-Fact-087413CE40C4B1F4C4F6C80C642C8975">0.68</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-F82F610FB923C5E5843EC80C64206428-wk-Fact-F82F610FB923C5E5843EC80C64206428">0.66</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2016Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-878CD1D2358B154C5899C80C64253B43-wk-Fact-878CD1D2358B154C5899C80C64253B43">0.0190</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2016Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-2E9F381BAE854BA2D3A0C80C641FA10A-wk-Fact-2E9F381BAE854BA2D3A0C80C641FA10A">0.0100</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-438EB0D98E61B9CECC1EC80C641ADC84-wk-Fact-438EB0D98E61B9CECC1EC80C641ADC84">0.0213</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-538C3E4B02CA52BAF7C0C80C6462C9A0-wk-Fact-538C3E4B02CA52BAF7C0C80C6462C9A0">0.0173</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-904CF5813BC517DBAB96C80C645BF1A3-wk-Fact-904CF5813BC517DBAB96C80C645BF1A3">0.0296</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-E06CE7DFBD2BEEBC2AE8C80C641F1C18-wk-Fact-E06CE7DFBD2BEEBC2AE8C80C641F1C18">0.0225</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2017Q4" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" id="Fact-0BF8A6AB06D738699331C80C64292726-wk-Fact-0BF8A6AB06D738699331C80C64292726">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="insm-20181231.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Q1Feb19">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_EquipmentFurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan01_srt_RangeAxis_srt_MaximumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan01_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Jan01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Jan01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep28-Sep28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-28</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ManufacturingEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ManufacturingEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ManufacturingEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermivMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermivMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermiiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb2018_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiiiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermiiiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Sept17">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2May18">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range6Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range9Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range7Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range10Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range7Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range5Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range4Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range4Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range10Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range8Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range5Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range8Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range9Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range6Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_NewJerseyDivisionOfTaxationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_insm_CommercialFilVFinishServicesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CommercialFilVFinishServicesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q4OCT01-OCT31_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q3JUL01-JUL31_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2004Q4JAN01-DEC31_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2004-01-01</xbrli:startDate>
			<xbrli:endDate>2004-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2008Q2APR01-APR30_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-04-01</xbrli:startDate>
			<xbrli:endDate>2008-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Oct31_us-gaap_TypeOfArrangementAxis_insm_SupplyAgreementWithPatheonUKLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:SupplyAgreementWithPatheonUKLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q1FEB01-FEB28_us-gaap_TypeOfArrangementAxis_insm_TherapureBiopharmaIncContractManufacturingAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:TherapureBiopharmaIncContractManufacturingAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-02-01</xbrli:startDate>
			<xbrli:endDate>2014-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q3JUL01-JUL31_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2008Q2APR01-APR30_insm_MilestonePaymentAxis_insm_MilestoneNewDrugApplicationMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="insm:MilestonePaymentAxis">insm:MilestoneNewDrugApplicationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-04-01</xbrli:startDate>
			<xbrli:endDate>2008-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2008Q2APR01-APR30_insm_MilestonePaymentAxis_insm_MilestoneFDAApprovalMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="insm:MilestonePaymentAxis">insm:MilestoneFDAApprovalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-04-01</xbrli:startDate>
			<xbrli:endDate>2008-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q4DEC01-DEC31_us-gaap_TypeOfArrangementAxis_insm_AgreementWithSynteractHCRInc.For212StudyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:AgreementWithSynteractHCRInc.For212StudyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-12-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q4OCT01-OCT31_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4OCT31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q3_us-gaap_TypeOfArrangementAxis_insm_CommercialFilVFinishServicesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CommercialFilVFinishServicesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q4DEC01-DEC31_us-gaap_TypeOfArrangementAxis_insm_AgreementWithSyneosHealthForWillowStudyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:AgreementWithSyneosHealthForWillowStudyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-12-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2009Q4JAN01-DEC31_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2009-01-01</xbrli:startDate>
			<xbrli:endDate>2009-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_insm_BridgewaterNewJerseyFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:BridgewaterNewJerseyFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_insm_BridgewaterNewJerseyFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:BridgewaterNewJerseyFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="segment">
		<xbrli:measure>insm:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="security">
		<xbrli:measure>insm:security</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="day">
		<xbrli:measure>insm:day</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="eur">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s48F786A86F48504BB6F2F2B4737983F3"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d14995944e864-wk-Fact-A16B48F0E7D8DA5A6F6B1455D059E3A9" name="dei:DocumentType" contextRef="FD2018Q4YTD"><span style="font-size:18pt;font-weight:bold;">10-K</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:78px;"></td><td style="width:5px;"></td><td style="width:598px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(Mark One)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Wingdings;font-size:9pt;">&#253;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the fiscal year ended December&#160;31, 2018</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">OR</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Wingdings;font-size:9pt;">o</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the transition period from </span><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:9pt;">&#160;to </span><span style="font-family:inherit;font-size:9pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number&#160;0-30739</span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:584px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:272px;"></td><td style="width:5px;"></td><td style="width:306px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Virginia</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(State or other jurisdiction of incorporation or</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">organization)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">54-1972729</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(I.R.S. employer identification no.)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">10 Finderne Avenue, Building 10</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Bridgewater, New Jersey 08807</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Address of principal executive offices)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(908)&#160;977-9900</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Registrant's telephone number including area code)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:460px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:246px;"></td><td style="width:5px;"></td><td style="width:208px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock, par value $0.01 per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nasdaq Global Select Market</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;Yes&#160;[</span><span style="font-family:Wingdings;font-size:8.5pt;">&#252;</span><span style="font-family:inherit;font-size:8.5pt;">]&#160;&#160;&#160;&#160;No&#160;[&#160;&#160;]</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;Yes&#160;[&#160;&#160;]&#160;&#160;&#160;&#160;No [</span><span style="font-family:Wingdings;font-size:8.5pt;">&#252;</span><span style="font-family:inherit;font-size:8.5pt;">]</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. Yes [</span><span style="font-family:Wingdings;font-size:8.5pt;">&#252;</span><span style="font-family:inherit;font-size:8.5pt;">]&#160;&#160;&#160;&#160;No [&#160;&#160;]</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;Yes&#160;[</span><span style="font-family:Wingdings;font-size:8.5pt;">&#252;</span><span style="font-family:inherit;font-size:8.5pt;">]&#160;&#160;&#160;&#160;No [&#160;&#160;]</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.&#160;[&#160;&#160;]</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company (See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act). Large accelerated filer [</span><span style="font-family:Wingdings;font-size:8.5pt;">&#252;</span><span style="font-family:inherit;font-size:8.5pt;">] Accelerated filer [&#160;&#160;] Non-accelerated filer [&#160;&#160;] Smaller reporting company [&#160;&#160;]  Emerging growth company [&#160;&#160;]</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act [&#160;&#160;]</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Indicate by check mark whether the registrant is a Shell Company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;Yes&#160;[&#160;&#160;]&#160;&#160;&#160;&#160;No&#160;[</span><span style="font-family:Wingdings;font-size:8.5pt;">&#252;</span><span style="font-family:inherit;font-size:8.5pt;">]</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on June&#160;30, 2018, was </span><span style="font-family:inherit;font-size:8.5pt;"><span>$<ix:nonFraction id="d14995944e1166-wk-Fact-5AF76CB0F12A94E87B3F807EEDCE4AF5" name="dei:EntityPublicFloat" contextRef="FI2018Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,803</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8.5pt;"> (based on the closing price for shares of the registrant's common stock as reported on the Nasdaq Global Select Market on that date). In determining this figure, the registrant has assumed solely for this purpose that all of its directors, executive officers, persons beneficially owning 10% or more of the registrant's outstanding common stock and certain other stockholders of the registrant may be considered to be affiliates. This assumption shall not be deemed conclusive as to affiliate status for this or any other purpose.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">On </span><span style="font-family:inherit;font-size:8.5pt;">February&#160;15, 2019</span><span style="font-family:inherit;font-size:8.5pt;">, there were </span><span style="font-family:inherit;font-size:8.5pt;"><span><ix:nonFraction id="d14995944e1177-wk-Fact-18668FFCB01F9FF05913145B7CF118B6" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2019Q1Q1Feb19" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">77,538,562</ix:nonFraction></span></span><span style="font-family:inherit;font-size:8.5pt;"> shares of the registrant's common stock, $0.01 par value, outstanding.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">____________________________________________________________________________</span></div><div><br/></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:68px;font-size:8.5pt;"><span style="font-family:inherit;font-size:8.5pt;">Portions of the registrant's definitive Proxy Statement for its </span><span style="font-family:inherit;font-size:8.5pt;">2019</span><span style="font-family:inherit;font-size:8.5pt;"> Annual Meeting of Shareholders to be filed with the Securities and Exchange Commission no later than April 30, 2019 and to be delivered to shareholders in connection with the </span><span style="font-family:inherit;font-size:8.5pt;">2019</span><span style="font-family:inherit;font-size:8.5pt;"> Annual Meeting of Shareholders, are herein incorporated by reference in Part&#160;III of this Form&#160;10-K.</span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sEF273818EA82535FAF5190DF314E61C0"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</span></div><div style="line-height:120%;text-align:center;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:11%;"></td><td style="width:10%;"></td><td style="width:68%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PAGE</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REPORT:</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s528752F1F3A6573B9A519E7C552C02B9"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s528752F1F3A6573B9A519E7C552C02B9">4</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s699C080C21495868B2C9AF09E048E871"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s699C080C21495868B2C9AF09E048E871">6</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s64652A1C77C854CB9B46705A44BD6DA0"><span style="font-family:inherit;font-size:10pt;">ITEM 1</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s64652A1C77C854CB9B46705A44BD6DA0"><span style="font-family:inherit;font-size:10pt;">BUSINESS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s94BF00621ABE54FF93C5A949C79CD622">6</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4597C5707E95561D930FAE327D8D2CAA"><span style="font-family:inherit;font-size:10pt;">ITEM 1A</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4597C5707E95561D930FAE327D8D2CAA"><span style="font-family:inherit;font-size:10pt;">RISK FACTORS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4597C5707E95561D930FAE327D8D2CAA">28</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFF819F4176415EFDABD9A6DD165177F8"><span style="font-family:inherit;font-size:10pt;">ITEM 1B</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFF819F4176415EFDABD9A6DD165177F8"><span style="font-family:inherit;font-size:10pt;">UNRESOLVED STAFF COMMENTS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFF819F4176415EFDABD9A6DD165177F8">49</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s41A8953836C756ED8FA385825370FC87"><span style="font-family:inherit;font-size:10pt;">ITEM 2</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s41A8953836C756ED8FA385825370FC87"><span style="font-family:inherit;font-size:10pt;">PROPERTIES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s41A8953836C756ED8FA385825370FC87">50</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA89BFB577FA754128B4D7017BF3D6268"><span style="font-family:inherit;font-size:10pt;">ITEM 3</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA89BFB577FA754128B4D7017BF3D6268"><span style="font-family:inherit;font-size:10pt;">LEGAL PROCEEDINGS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA89BFB577FA754128B4D7017BF3D6268">50</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s41A9287AD20353EAAEEC5E32B22F9FA1"><span style="font-family:inherit;font-size:10pt;">ITEM 4</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s41A9287AD20353EAAEEC5E32B22F9FA1"><span style="font-family:inherit;font-size:10pt;">MINE SAFETY DISCLOSURES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s41A9287AD20353EAAEEC5E32B22F9FA1">50</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s88AFF8A4E7FE589D9AB5F755C2C09C74"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s88AFF8A4E7FE589D9AB5F755C2C09C74">51</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3D32A62FC6FC55EA82516D3B96B07E60"><span style="font-family:inherit;font-size:10pt;">ITEM 5</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3D32A62FC6FC55EA82516D3B96B07E60"><span style="font-family:inherit;font-size:10pt;">MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3D32A62FC6FC55EA82516D3B96B07E60">51</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2C0E1FE14584529DA10237334941F286"><span style="font-family:inherit;font-size:10pt;">ITEM 6</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2C0E1FE14584529DA10237334941F286"><span style="font-family:inherit;font-size:10pt;">SELECTED FINANCIAL DATA</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2C0E1FE14584529DA10237334941F286">52</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA43CC2209F295B34806FE5EF76892FB2"><span style="font-family:inherit;font-size:10pt;">ITEM 7</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA43CC2209F295B34806FE5EF76892FB2"><span style="font-family:inherit;font-size:10pt;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1DF343B1218D5492BAD0E6DC08AB6198">54</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C216FA74F54515AAEE1544CD69745C7"><span style="font-family:inherit;font-size:10pt;">ITEM 7A</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C216FA74F54515AAEE1544CD69745C7"><span style="font-family:inherit;font-size:10pt;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C216FA74F54515AAEE1544CD69745C7">66</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s533E4FE3B91B51CD9E999DF759F2B413"><span style="font-family:inherit;font-size:10pt;">ITEM 8</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s533E4FE3B91B51CD9E999DF759F2B413"><span style="font-family:inherit;font-size:10pt;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s533E4FE3B91B51CD9E999DF759F2B413">66</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7F3D6B907EE257DE849A50760EDA458B"><span style="font-family:inherit;font-size:10pt;">ITEM 9</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7F3D6B907EE257DE849A50760EDA458B"><span style="font-family:inherit;font-size:10pt;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7F3D6B907EE257DE849A50760EDA458B">67</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0551798FB7305FB2B557B11969AAADB9"><span style="font-family:inherit;font-size:10pt;">ITEM 9A</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0551798FB7305FB2B557B11969AAADB9"><span style="font-family:inherit;font-size:10pt;">CONTROLS AND PROCEDURES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0551798FB7305FB2B557B11969AAADB9">67</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s465C90B6D44C5FB59BECA0774B418A12"><span style="font-family:inherit;font-size:10pt;">ITEM 9B</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s465C90B6D44C5FB59BECA0774B418A12"><span style="font-family:inherit;font-size:10pt;">OTHER INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s465C90B6D44C5FB59BECA0774B418A12">68</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sF72FB7CA185E5C7794C3D46C52F3D858"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF72FB7CA185E5C7794C3D46C52F3D858">69</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s39FE7D9D2F2E5A42B782B18698E8A5E5"><span style="font-family:inherit;font-size:10pt;">ITEM 10</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s39FE7D9D2F2E5A42B782B18698E8A5E5"><span style="font-family:inherit;font-size:10pt;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s39FE7D9D2F2E5A42B782B18698E8A5E5">69</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A591F8011D3511E9E2FB471ED187E82"><span style="font-family:inherit;font-size:10pt;">ITEM 11</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A591F8011D3511E9E2FB471ED187E82"><span style="font-family:inherit;font-size:10pt;">EXECUTIVE COMPENSATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A591F8011D3511E9E2FB471ED187E82">69</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1B7BF7C314115F75AF363E2AD72AA74A"><span style="font-family:inherit;font-size:10pt;">ITEM 12</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1B7BF7C314115F75AF363E2AD72AA74A"><span style="font-family:inherit;font-size:10pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1B7BF7C314115F75AF363E2AD72AA74A">69</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s38C09CAB1C1F5698BEBAD2C4E9A59CBF"><span style="font-family:inherit;font-size:10pt;">ITEM 13</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s38C09CAB1C1F5698BEBAD2C4E9A59CBF"><span style="font-family:inherit;font-size:10pt;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s38C09CAB1C1F5698BEBAD2C4E9A59CBF">69</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE27E7690A517590FA6890506E0C74BF2"><span style="font-family:inherit;font-size:10pt;">ITEM 14</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE27E7690A517590FA6890506E0C74BF2"><span style="font-family:inherit;font-size:10pt;">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE27E7690A517590FA6890506E0C74BF2">69</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sE9B46AB1484F5A688E0EFFFB0640645F"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE9B46AB1484F5A688E0EFFFB0640645F">70</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8475B346D90B5B4BACE23D6F37AC86DF"><span style="font-family:inherit;font-size:10pt;">ITEM 15</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8475B346D90B5B4BACE23D6F37AC86DF"><span style="font-family:inherit;font-size:10pt;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8475B346D90B5B4BACE23D6F37AC86DF">70</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s37BB1C2C5EFC5AC2AFB9B4FE2431CA76"><span style="font-family:inherit;font-size:10pt;">ITEM 16</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s37BB1C2C5EFC5AC2AFB9B4FE2431CA76"><span style="font-family:inherit;font-size:10pt;">FORM 10-K SUMMARY</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s37BB1C2C5EFC5AC2AFB9B4FE2431CA76">73</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s4586AA1A06475DF8820A58C06C3C5DD9"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REPORTS OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4586AA1A06475DF8820A58C06C3C5DD9">75</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s243AF3EBDD175252A026EFCFD64B1705"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s243AF3EBDD175252A026EFCFD64B1705">77</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless the context otherwise indicates, references in this Form&#160;10-K to &#8220;Insmed Incorporated&#8221; refers to Insmed Incorporated, a Virginia corporation, and &#8220;Company,&#8221; &#8220;Insmed,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Insmed Incorporated together with its consolidated subsidiaries. INSMED, CONVERT and ARIKAYCE are trademarks of Insmed Incorporated. This Form&#160;10-K also contains trademarks of third parties. Each trademark of another company appearing in this Form&#160;10-K is the property of its owner.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><a id="s528752F1F3A6573B9A519E7C552C02B9"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">This Annual Report on Form&#160;10-K contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Forward-looking statements are based on our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following:</span></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">failure to successfully commercialize or maintain US approval for ARIKAYCE</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> (amikacin liposome inhalation suspension), our only approved product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">uncertainties in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payors and others in the health-care community;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our inability to obtain full approval of ARIKAYCE from the US Food and Drug Administration (FDA), including the risk that we will not successfully complete the confirmatory post-marketing study required for full approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">inability of us, PARI Pharma GmbH (PARI) or our third-party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira Nebulizer System (Lamira);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices for ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">development of unexpected safety or efficacy concerns related to ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">inaccuracies in our estimates of the size of the potential markets for ARIKAYCE or in data we have used to identify physicians;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">failure to obtain regulatory approval to expand ARIKAYCE&#8217;s indication to a broader patient population;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">failure to successfully conduct future clinical trials for ARIKAYCE and our product candidates, including due to our limited experience in conducting preclinical development activities and clinical trials necessary for regulatory approval and our inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">risks that our clinical studies will be delayed or that serious side effects will be identified during drug development;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">failure to obtain regulatory approvals for ARIKAYCE outside the US or for our product candidates in the US, Europe, Japan or other markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">failure of third parties on which we are dependent to manufacture sufficient quantities of ARIKAYCE or our product candidates for commercial or clinical needs, to conduct our clinical trials, or to comply with our agreements or laws and regulations that impact our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our inability to attract and retain key personnel or to effectively manage our growth;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our inability to adapt to our highly competitive and changing environment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our inability to adequately protect our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">restrictions or other obligations imposed on us by agreements related to ARIKAYCE or our product candidates, including our license agreements with PARI and AstraZeneca AB (AstraZeneca), and failure to comply with our obligations under such agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">the cost and potential reputational damage resulting from litigation to which we are or may become a party, including product liability claims;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">limited experience operating internationally;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">changes in laws and regulations applicable to our business and failure to comply with such laws and regulations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">inability to repay our existing indebtedness and uncertainties with respect to our ability to access future capital.</span></div></td></tr></table><div style="line-height:174%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Any forward-looking statement is based on information current as of the date of this Annual Report on 10-K and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results, plans, intentions or expectations anticipated in these forward-looking statements as a result of a variety of factors, many of which are beyond our control. More information on factors that could cause actual results to differ materially from those anticipated is included from time to time in our reports filed with the Securities and Exchange Commission (SEC), including, but not limited to, those described in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in this Annual Report on Form 10-K. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="s699C080C21495868B2C9AF09E048E871"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</span></div><div><a id="s64652A1C77C854CB9B46705A44BD6DA0"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div><a id="s94BF00621ABE54FF93C5A949C79CD622"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Overview</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), received accelerated approval in the United States (US) on September 28, 2018 for the treatment of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Mycobacterium avium</span><span style="font-family:inherit;font-size:10pt;"> complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting, as defined by patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Our clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) with therapeutic potential in non-cystic fibrosis (non-CF) bronchiectasis and other inflammatory diseases. INS1009 is an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension (PAH).</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the current status and anticipated milestones for ARIKAYCE and our product candidates INS1007 and INS1009.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal Product/Product&#160;Candidate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Status</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Next&#160;Expected&#160;Milestones</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">ARIKAYCE for&#160;MAC lung&#160;disease</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; We continue to focus on having a successful commercial launch of ARIKAYCE in the US for appropriate patients. We began commercial shipments of ARIKAYCE in October 2018.</span></div><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/>&#8226; In September 2018, the FDA granted accelerated approval of ARIKAYCE for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options.<br/></span><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;"><br/>&#8226; The FDA has designated ARIKAYCE as an orphan drug and a qua</span><span style="font-family:inherit;font-size:9pt;">lified infectious disease product (QIDP) for nontuberculous mycobacterial (NTM) lung disease, and the European Commission has granted an orphan designation for ARIKAYCE for the treatment of NTM lung disease. <br/></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; We intend to submit regulatory filings for ARIKAYCE in Europe in mid-2019 and Japan in the first half of 2020. If approved, we expect ARIKAYCE would be the first inhaled therapy specifically indicated for the treatment of MAC lung disease in Europe and Japan.<br/><br/>&#8226; If approved, we plan to commercialize ARIKAYCE in certain countries in Europe, Japan and certain other countries. </span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; We intend to collaborate with the FDA on, and invest in, the post-approval confirmatory clinical trial required by the FDA to support full approval and intend to complete the design and protocol of the confirmatory study during the first half of 2019. We also intend to collaborate with the FDA on lifecycle management programs.<br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">INS1007 (oral reversible&#160;inhibitor of&#160;DPP1)&#160;for non-CF&#160;bronchiectasis and other rare diseases</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; We are enrolling patients in the WILLOW study, a global phase 2, randomized, double-blind, placebo-controlled, parallel-group, multi-center clinical study to assess the efficacy, safety and tolerability, and pharmacokinetics of INS1007 administered once daily for 24 weeks in subjects with non-CF bronchiectasis.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; We expect to complete enrollment in the WILLOW clinical study of INS1007 in mid-2019.</span></div><div style="text-align:left;padding-left:18px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; We are exploring the potential of INS1007 in various neutrophil-driven inflammatory conditions.</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">INS1009 (inhaled formulation of a treprostinil prodrug) for rare pulmonary disorders</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; The results of our phase&#160;1 study of INS1009 were presented at the European Respiratory Society international congress in September 2016.</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; We believe INS1009 may offer a differentiated product profile for rare pulmonary disorders, including PAH, and we are currently evaluating our options to advance its development including exploring its use as an inhaled dry powder formulation.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our earlier-stage pipeline includes preclinical compounds that we are evaluating in multiple rare diseases of unmet medical need, including gram positive pulmonary infections in CF, NTM lung disease and refractory localized infections involving biofilm. To complement our internal research and development, we actively evaluate in-licensing and acquisition opportunities for a broad range of rare diseases. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Strategy</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our strategy focuses on the needs of patients with rare diseases. We secured US regulatory approval of ARIKAYCE for the treatment of refractory MAC lung disease in patients with limited or no alternative treatment options. We are currently primarily focused on the US commercial launch of ARIKAYCE. We are not aware of any other approved inhaled therapies specifically indicated to treat MAC lung disease in North America, Europe or Japan. We believe that ARIKAYCE has the potential to prove beneficial in other patients with MAC, as well as in other infections. We are also advancing earlier-stage programs in other rare pulmonary disorders.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our current priorities are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Continue our efforts to ensure a successful US launch of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Complete the design and protocol of the confirmatory clinical trial during the first half of 2019 required for the full US approval of ARIKAYCE by the FDA in patients with MAC;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerate our global expansion efforts to support potential regulatory filings for ARIKAYCE in Europe in mid-2019 and Japan in the first half of 2020;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Advance our pipeline, which is intended to bring additional therapies to market for patients with serious and rare diseases, including completing enrollment in the WILLOW study, our six-month Phase 2 trial of INS1007 in patients with non-cystic fibrosis bronchiectasis, in mid-2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ensure our product supply chain will support the global commercialization and potential future lifecycle management programs of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Develop the core value dossier to support the reimbursement for ARIKAYCE in the US, Europe and Japan;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obtain determinations of coverage and reimbursement in the US for ARIKAYCE from governmental and other third-party payors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Support further research and lifecycle management strategies for ARIKAYCE in the US, including exploring the potential use of ARIKAYCE as part of a front-line, multi-drug regimen and as a maintenance therapy to prevent recurrence (defined as true relapse or reinfection) of MAC lung disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Explore INS1009 for use as an inhaled dry powder formulation and generating preclinical findings from our earlier-stage programs; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expand our rare disease pipeline through corporate development.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ARIKAYCE for Patients with MAC Lung Disease</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE is our first approved product. ARIKAYCE received accelerated approval in the US on September 28, 2018 for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Amikacin solution for parenteral administration is an established drug that has activity against a variety of NTM; however, its use is limited by the need to administer it intravenously and by toxicity to hearing, balance, and kidney function (Peloquin et al., 2004). Unlike amikacin solution for intravenous administration, our proprietary Pulmovance&#8482; technology uses charge-neutral liposomes to deliver amikacin directly to the lungs where liposomal amikacin is taken up by the lung macrophages where the MAC infection resides. This technology also prolongs the release of amikacin in the lungs, while minimizing systemic exposure, thereby offering the potential for decreased systemic toxicities. ARIKAYCE's ability to deliver high levels of amikacin directly to the lung and sites of MAC infection via the use of our Pulmovance technology, distinguishes it from intravenous amikacin. ARIKAYCE is administered once-daily, using Lamira&#174;, an inhalation device developed and manufactured by PARI. Lamira is a portable nebulizer that enables aerosolization of liquid medications via a vibrating, perforated membrane, and was designed specifically for ARIKAYCE delivery.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has designated ARIKAYCE as an orphan drug and a QIDP for NTM lung disease. Orphan designated drugs are eligible for seven years of exclusivity for the orphan indication. QIDP designation features an additional five years of exclusivity for the designated indication. The FDA granted a total of 12 years of exclusivity in the indication for which ARIKAYCE was approved.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">US Marketing Approval</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2018, we submitted a new drug application (NDA) for ARIKAYCE to the FDA pursuant to Section 506(c) of the Federal Food Drug and Cosmetic Act and 21 C.F.R. Part 314 Subpart H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses) (Subpart H). Accelerated approval allows drugs that (i) are being developed to treat a serious or life-threatening disease or condition and (ii) provide a meaningful therapeutic benefit over existing treatments to be approved substantially based on an intermediate endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit, rather than a clinical endpoint such as survival or irreversible morbidity. The FDA granted our request for a priority review and set a Prescription Drug Use Fee Act (PDUFA) action date of September 28, 2018. On August 7, 2018, the FDA Antimicrobial Drugs Advisory Committee voted in favor of the safety and effectiveness of ARIKAYCE as part of a combination antibacterial drug regimen for adults with MAC lung disease who have limited or no treatment options. The committee also voted in favor of the surrogate endpoint of sputum culture conversion used in the Phase 3 CONVERT study being reasonably likely to predict clinical benefit. In a separate vote, the committee voted that there was insufficient existing evidence of the safety and effectiveness of ARIKAYCE in the broader population of adult patients with MAC lung disease. On September 28, 2018, the FDA granted approval for ARIKAYCE under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options via the accelerated approval pathway. LPAD, which was enacted as part of the 21st Century Cures Act, serves to advance the development of new antibacterial drugs to treat serious or life-threatening infections in limited populations of patients with unmet needs.&#160;As required for drugs approved under the LPAD pathway,&#160;labeling for ARIKAYCE includes certain statements to convey that the drug has been shown to be safe and effective only for use in a limited population.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a condition of accelerated approval, we must conduct a post-approval confirmatory clinical trial. The required confirmatory trial, which is currently under discussion with FDA, is proposed to be a randomized, double-blind, placebo-controlled clinical trial to assess and describe the clinical benefit of ARIKAYCE in patients with MAC lung disease. The trial will evaluate the effect of ARIKAYCE on a clinically meaningful endpoint, as compared to an appropriate control, in the intended patient population of patients with MAC lung disease. Pursuant to the timetable agreed upon with the FDA, the study protocol is expected to be finalized during the first half of 2019, with trial results to be reported by 2024. Continued approval of ARIKAYCE will be contingent upon verification and description of clinical benefit in this study.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical Trials</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated approval of ARIKAYCE was supported by preliminary data from our CONVERT study, a global Phase 3 study evaluating the safety and efficacy of ARIKAYCE in adult patients with refractory MAC lung disease, using achievement of sputum culture conversion (defined as three consecutive negative monthly sputum cultures) by Month 6 as the primary endpoint. Patients who achieved sputum culture conversion by Month 6 continued in the CONVERT study for an additional 12 months of treatment following the first monthly negative sputum culture in order to assess the durability of culture conversion, as defined by patients that have completed treatment and continued in the CONVERT study off all therapy for three months. We previously reported interim durability data as of December 2017, in which 60.9% of patients (28/46) who had achieved the primary endpoint at Month 6 on ARIKAYCE plus guidelines-based therapy (GBT) remained culture negative three months off all therapy, compared to 0.0% of patients (0/7) who had achieved the primary endpoint at Month 6 on GBT only. Final durability data for patients three months off all therapy were consistent with these interim data, and safety data for these patients were consistent with safety data previously reported for patients by Month 6 of the CONVERT study. The CONVERT study is ongoing.  </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patients who did not culture convert by Month 6 may have been eligible to enroll in our 312 study, an open-label extension study for these non-converting patients who completed six months of treatment in the CONVERT study. The primary objective of the 312 study was to evaluate the long-term safety and tolerability of ARIKAYCE in combination with a standard multi-drug regimen. The secondary objectives of the 312 study included evaluating the proportion of subjects achieving culture conversion (defined in the same way as the CONVERT study) by Month 6 and the proportion of subjects achieving culture conversion by Month 12, which was the end of treatment. We previously reported interim data as of December 2017 for patients in the 312 study, with 28.4% of patients who received GBT only in the CONVERT study (19/67) and 12.3% of patients who had received ARIKAYCE plus GBT in the CONVERT study (7/57) achieving culture conversion by Month 6 of the 312 study. The 312 study has concluded. Final efficacy data regarding culture conversion were consistent with these interim data. We are continuing to analyze the safety and efficacy data from the 312 study, but we have not identified any new safety signals.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Further Research and Lifecycle Management</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently exploring and supporting research and lifecycle management programs for ARIKAYCE in the US beyond treatment of refractory MAC lung disease as part of a combination antibacterial regimen for adult patients who have limited or no treatment options. Specifically, we are evaluating future study designs focusing on the MAC lung disease </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">treatment pathway, including front-line treatment and maintenance to prevent recurrence (defined as true relapse or reinfection) of MAC lung disease. As noted above, we plan to conduct our required confirmatory trial to assess and describe the clinical benefit of ARIKAYCE in patients with MAC lung disease.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the data from the CONVERT study are sufficient to support our marketing authorization applications (MAAs) in Europe and Japan and those regulatory bodies approve ARIKAYCE, lifecycle management studies could potentially enable us to reach more patients worldwide. In addition, the use of ARIKAYCE to treat infections caused by non-MAC NTM species, such as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">M. abscessus,</span><span style="font-family:inherit;font-size:10pt;"> is being evaluated. These initiatives include investigator-initiated studies, which are clinical studies initiated and sponsored by physicians or research institutions with funding from us, and may also include new clinical studies sponsored by us. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Market Opportunity for ARIKAYCE in MAC Lung Disease</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NTM lung disease is associated with increased rates of morbidity and mortality, and MAC is the predominant pathogenic species in NTM lung disease in the US, Europe and Japan. The prevalence of NTM lung disease has increased over the past two decades, and we believe it is an emerging public health concern worldwide. Based on an analysis conducted in 2017 using information from external sources, including market research funded by us and third parties, and internal analyses and calculations, we estimated potential patient populations for 2018 in the US, the EU5 (comprised of France, Germany, Italy, Spain and the United Kingdom) and Japan as follows:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.6640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:19%;"></td><td style="width:9%;"></td><td style="width:24%;"></td><td style="width:24%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Potential Market</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Number of Patients with Diagnosed NTM Lung Disease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Number of Patients Treated for MAC Lung Disease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Number of MAC lung disease Patients Refractory to Treatment**</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75,000-105,000</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40,000-50,000</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,000-15,000</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EU5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,000</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,400</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,400</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Japan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">125,000-145,000</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60,000-70,000</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,000-18,000</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">** ARIKAYCE received accelerated approval for this population in the US in September 2018.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are not aware of any other approved inhaled therapies specifically indicated for NTM lung disease in North America, Europe or Japan. Current guideline-based approaches for NTM lung disease, including those from the American Thoracic Society and Infectious Diseases Society of America, involve multi-drug regimens not approved for the treatment of NTM lung disease and treatment that could last two years or more. Based on a burden of illness study that we conducted in the US with a major medical benefits provider, we previously concluded that patients with NTM lung disease are costly to healthcare plans, while a recent claims-based study in the US has shown that patients with NTM lung disease have higher resource utilization and costs than their age and gender-matched controls. Accordingly, we believe that a significant market opportunity for ARIKAYCE in NTM lung disease exists in the US and internationally.&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently exploring the MAC lung disease market opportunity for ARIKAYCE in Japan and Europe. The CONVERT study included a comprehensive pharmacokinetic sub-study in Japanese subjects in lieu of a separate local pharmacokinetic study in Japan, as agreed with the Pharmaceuticals and Medical Devices Agency (PMDA). If the data from the CONVERT study are sufficient to support our MAAs, we expect to submit regulatory filings in Europe in mid-2019 and Japan in the first half of 2020. We established a Japanese subsidiary and, in 2018, began hiring local employees, including a general manager, to manage our regulatory and pre-commercial activities.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Pipeline</span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INS1007</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INS1007 is a small molecule, oral, reversible inhibitor of DPP1, which we licensed from AstraZeneca in October 2016. DPP1 is an enzyme responsible for activating neutrophil serine proteases in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Neutrophils contain the neutrophil serine proteases (including neutrophil elastase, proteinase 3, and cathepsin G) that have been implicated in a variety of inflammatory diseases. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and release active neutrophil serine proteases in excess that cause lung destruction and inflammation. INS1007 may decrease the damaging effects of inflammatory diseases, such as non-CF bronchiectasis, by inhibiting DPP1 and its activation of neutrophil serine proteases. Non-CF bronchiectasis is a progressive pulmonary disorder in which the bronchi become permanently dilated due to chronic inflammation and infection. Currently, there is no cure, and we are not aware of any FDA-approved therapies specifically indicated for non-CF bronchiectasis.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The WILLOW Study</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The WILLOW study is a global phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center clinical study to assess the efficacy, safety and tolerability, and pharmacokinetics of&#160;INS1007 administered once daily for 24 weeks in subjects with non-CF bronchiectasis. We commenced enrollment in the WILLOW study in December 2017, which we expect to complete in mid-2019. In addition, we are exploring the potential of INS1007 in various neutrophil-driven inflammatory conditions.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INS1009</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INS1009 is an investigational inhaled treprostinil prodrug formulation that has the potential to address certain of the current limitations of existing prostanoid therapies. We believe that INS1009 prolongs duration of effect and may provide PAH patients with greater consistency in pulmonary arterial pressure reduction over time. Current inhaled prostanoid therapies must be dosed four to nine times per day for the treatment of PAH. Reducing dose frequency has the potential to ease patient burden and improve compliance. Additionally, we believe that INS1009 may be associated with fewer side effects, including elevated heart rate, low blood pressure, and severity and/or frequency of cough, associated with high initial drug levels and local upper airway exposure when using current inhaled prostanoid therapies. We believe INS1009 may offer a differentiated product profile for rare pulmonary disorders, including PAH, and we are currently evaluating our options to advance its development, including exploring its use as an inhaled dry powder formulation.&#160;</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate Development</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2016, we exclusively licensed global rights to INS1007 from AstraZeneca and we plan to continue to develop, acquire, in license or co-promote other products and product candidates that address rare diseases. We are focused broadly on rare disease therapeutics and prioritizing those areas that best align with our core competencies.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have any in-house manufacturing capability other than for small-scale pre-clinical development programs, and depend completely on a small number of third-party manufacturers and suppliers for the manufacture of our product candidates for use in clinical trials. We plan to rely on third-party manufacturers and suppliers for the commercial manufacture and supply of any product candidates that we commercialize. ARIKAYCE is manufactured currently by Therapure Biopharma&#160;Inc. (Therapure) in Canada at a 200 kilogram (kg) scale and by Ajinimoto Althea,&#160;Inc. (Althea) in the US at a 50 kg scale. For additional information about our agreements with Therapure and Althea, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">License and Other Agreements&#8212;ARIKAYCE-Related Agreements</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, we entered into certain agreements with Patheon UK Limited (Patheon) related to increasing our long-term production capacity for ARIKAYCE commercial inventory. The agreements provide for Patheon to manufacture and supply ARIKAYCE for our long-term anticipated commercial needs.&#160;Under these agreements, we are required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.&#160;The investment in the long-term production capacity build-out, including these agreements, and related agreements or purchase orders with third parties for raw materials and fixed assets, is estimated to be approximately $60 million. In addition, we have a commercialization agreement with PARI, the manufacturer of our drug delivery nebulizer for ARIKAYCE, to address our commercial supply needs (Commercialization Agreement).</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, we entered into a commercial supply agreement with AstraZeneca related to certain short-term production needs for INS1007. We expect our future requirements for INS1007, beyond phase&#160;2, will be manufactured by a contract manufacturing organization (CMO).</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently produce INS1009 and plan to utilize third parties to manufacture INS1009 at a larger scale and to manufacture the delivery device.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We own or license rights to more than 350 issued patents and pending patent applications in the US and in foreign countries, including more than 175 issued patents and pending patent applications related to ARIKAYCE. Our success depends in large part on our ability to maintain proprietary protection surrounding our product candidates, technology and know-how; to operate without infringing the proprietary rights of others; and to prevent others from infringing our proprietary rights. We actively seek patent protection by filing patent applications, including on inventions that are important to the development of our business in the US, Europe, Japan, Canada, and selected other foreign markets that we consider key for our product candidates. These international markets generally include Australia, China, India, Israel, and Mexico.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our patent strategy includes obtaining patent protection, where possible, on compositions of matter, methods of manufacture, methods of use, methods of treatment, dosing and administration regimens and formulations. We also rely on trade secrets, know-how, continuing technological innovation, in-licensing and partnership opportunities to develop and maintain our proprietary position.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We monitor for activities that may infringe our proprietary rights, as well as the progression of third-party patent applications that may have the potential to create blocks to our products or otherwise interfere with the development of our business. We are aware, for example, of US patents, and corresponding international counterparts, owned by third parties that contain claims related to treating lung infections using inhaled antibiotics. If any of these patents were to be asserted against us, we do not believe that our proposed products would be found to infringe any valid claim of these patents.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reflecting our commitment to safeguarding proprietary information, we require our employees, consultants, advisors, collaborators and other third-party partners to sign confidentiality agreements to protect the exchange of proprietary materials and information. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ARIKAYCE Patents and Trade Secrets</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Of the patents and applications related to ARIKAYCE, there are nine issued US patents that cover the ARIKAYCE composition and its use in treating NTM. These patents are listed in the FDA Orange Book. These patents and their expiration dates are as follows:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US Patent No.&#160;7,718,189 (expires June&#160;6, 2025)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US Patent No.&#160;8,226,975 (expires August&#160;15, 2028)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US Patent No.&#160;8,632,804 (expires December&#160;5, 2026)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US Patent No.&#160;8,802,137 (expires April&#160;8, 2024)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US Patent No.&#160;8,679,532 (expires December&#160;5, 2026)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US Patent No.&#160;8,642,075 (expires December&#160;5, 2026)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US Patent No.&#160;9,566,234 (expires January&#160;18, 2034)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US Patent No.&#160;9,827,317 (expires April&#160;8, 2024)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US Patent No. 9,895,385 (expires May 15, 2035)</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we own six pending US patent applications that cover the ARIKAYCE composition and/or its use in treating NTM. We also own a pending US application that covers methods for making ARIKAYCE. These patent applications, if issued as patents in their current form, may be eligible for listing in the FDA Orange Book for ARIKAYCE. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Four patents have been granted by the European Patent Office (EPO) (European Patent Nos.&#160;1581236, 1909759, 1962805 and 2363114) that relate to ARIKAYCE and its use in treating NTM. In addition, we have five applications pending before the EPO that relate to ARIKAYCE and its use in treating NTM lung disease. We also have a pending European application that describes certain methods of making ARIKAYCE. More than 40 patents have also been issued in other major foreign markets, e.g.,&#160;Japan, China, Korea, Australia, and India, that relate to ARIKAYCE and/or methods of using ARIKAYCE for treating various pulmonary disorders, including NTM lung disease. More than 60&#160;foreign patent applications are pending that relate to the ARIKAYCE composition and/or its use in treating various pulmonary disorders, including NTM lung disease. We anticipate that in the US, we will have potential patent coverage for ARIKAYCE and its use in treating NTM lung disease, through May 15, 2035.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">European Patent No.&#160;2363114 was opposed by Generics (UK)&#160;Ltd, a wholly-owned subsidiary of Mylan&#160;NV, and was revoked in November 2017. We have appealed that decision, and the patent remains enforceable during the appeal. European Patent No.&#160;1909759 (the '759 patent), owned by us, was previously opposed by Generics (UK)&#160;Ltd. A hearing was held on October&#160;19, 2015, during which we submitted amended claims. The European Patent Office Opposition Division (EPOOD) maintained the patent as amended and Generics (UK) Ltd appealed the decision. The EPO Technical Board of Appeals heard arguments related to the appeal on January 8, 2019 and the product claims of the patent were held invalid. The method of manufacture claims was remitted to the EPOOD for further consideration, and remain enforceable. We have a divisional application pending that claims priority from the &#8216;759 patent where we are pursuing product claims of varying scope. European Patent No. 1962805, which expires approximately five months after the &#8216;759 patent (December 5, 2026 vs. July 19, 2026), also includes claims related to ARIKAYCE and its use in treating NTM lung disease.&#160;All of our issued European patents have expiration dates that would fall within the regulatory exclusivity period for ARIKAYCE, should ARIKAYCE ultimately gain approval by the EMA.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Through our agreements with PARI, we have license rights to US and foreign patents and applications that cover the Lamira Nebulizer System medical device through January 18, 2034. We have entered into a commercial supply agreement with PARI and we also have rights to use the nebulizers in expanded access programs and clinical trials.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The basic terms of utility patents issued in the US are the longer of 17&#160;years from the issue date or 20&#160;years from the earliest effective filing date, if the patent was in force on or was issued from a patent application that was filed prior to June&#160;8, 1995; or 20&#160;years from the earliest effective filing date, if the patent application was filed on or after June&#160;8, 1995. All ARIKAYCE patent applications have earliest effective filing dates falling after June&#160;8, 1995. The basic term of foreign utility patents may vary in accordance with provisions of applicable local law, but is typically 20&#160;years from the earliest effective filing date.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">INS1007 Patents</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Through our agreement with AstraZeneca, we have licensed US Patent Nos.&#160;9,522,894 and 9,815,805, which have claims directed to INS1007 and methods for using INS1007. Each expires January&#160;21, 2035 (not taking into account any potential patent term extension). Counterpart patent applications are pending throughout the world and a continuation application is pending in the US.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">INS1009 Patents</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We own US Patent No.&#160;9,255,064 (expires October&#160;24, 2034), which is the first patent to issue with claims covering hexadecyl-treprostinil, the treprostinil component of INS1009. Other treprostinil prodrugs are also claimed and described in the patent. We also own US Patent No.&#160;9,469,600, which has claims directed to INS1009 and other treprostinil prodrug formulations and expires October&#160;24, 2034. We also own US Patent No. 10,010,518, which has claims directed to methods of treating pulmonary hypertension, including PAH, with INS1009 and other treprostinil prodrug formulations and expires October&#160;24, 2034. Counterpart patent applications to these US Patents are pending in Europe, Japan and other foreign jurisdictions.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We own pending patent applications that relate to methods for using treprostinil prodrugs and formulations comprising the same, including INS1009 in treating patients with PAH and other diseases, as well as methods for manufacturing such treprostinil prodrugs and formulations.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Trademarks</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to our patents and trade secrets, we have filed applications to register certain trademarks in the US and/or abroad, including INSMED and ARIKAYCE. At present, we have received a registration for the INSMED and ARIKAYCE marks from the US Patent and Trademark Office (USPTO). We have also received foreign notices of allowance or registrations for the INSMED and ARIKAYCE marks, among others. The European Medicines Agency (EMA) has indicated it has no objection to our use of the name ARIKAYCE, and the FDA has approved our use of the name ARIKAYCE as the trade name for amikacin liposome inhalation suspension. Our ability to obtain and maintain trademark registrations will in certain geographical locations depend on making use of the mark in commerce on or in connection with our products and approval of the trademarks for our products by regulatory authorities in each country.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">License and Other Agreements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ARIKAYCE-related Agreements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently rely, and will continue to rely, on agreements with a number of third parties in connection with the development and manufacture of ARIKAYCE.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">PARI Pharma&#160;GmbH</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a licensing agreement with PARI for use of the optimized Lamira Nebulizer System for delivery of ARIKAYCE in treating patients with NTM lung infections, cystic fibrosis (CF) and bronchiectasis. Under the licensing agreement, we have rights under several US and foreign issued patents, and patent applications involving improvements to the optimized Lamira Nebulizer System, to exploit such system with ARIKAYCE for the treatment of such indications, but we cannot manufacture such nebulizers except as permitted under our Commercialization Agreement with PARI. We currently have rights to use the nebulizers in expanded access programs and clinical trials. The Lamira Nebulizer System is labeled as investigational for use in our clinical trials in Japan, Canada and Australia and must receive regulatory approval before we can market ARIKAYCE; the Lamira Nebulizer System has been approved for use in the US (in combination with ARIKAYCE) and EU.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have certain obligations under this licensing agreement in relation to specified licensed indications. With respect to CF, we are obligated to use commercially reasonable efforts to develop, obtain regulatory and reimbursement approval, market and sell ARIKAYCE in two or more major European countries. With respect to NTM and bronchiectasis, we have specific obligations to use commercially reasonable efforts to achieve certain developmental and regulatory milestones by set deadlines. Additionally, for NTM, we are obligated to use commercially reasonable efforts to achieve certain commercial milestones in the US and Europe. The consequences of our failing to use commercially reasonable efforts to achieve these milestones are context-specific, but include ending PARI's non-compete obligation, making the license non-exclusive and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">terminating the license, in each case with respect to the applicable indication. Termination of the licensing agreement or loss of exclusive rights may occur if we fail to meet our obligations, including payment of royalties to PARI, or if we do not meet certain milestones contained in the licensing agreement such as obtaining marketing approval in an EU country.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the licensing agreement, we paid PARI an upfront license fee and milestone payments.  Upon FDA acceptance of our NDA and the subsequent FDA approval of ARIKAYCE, we paid PARI additional milestone payments of &#8364;1.0 million and &#8364;1.5&#160;million, respectively. In addition, PARI is entitled to receive future milestone payments up to &#8364;0.5&#160;million in cash based on achievement of first receipt of marketing approval in a major EU country for ARIKAYCE and the device. In October 2017, we exercised an option to buy-down the royalties payable to PARI. PARI is now entitled to receive royalty payments in the mid-single digits on the annual global net sales of ARIKAYCE pursuant to the licensing agreement, subject to certain specified annual minimum royalties.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This licensing agreement will remain in effect on a country-by-country basis until the final royalty payments have been made with respect to the last country in which ARIKAYCE is sold, or until the agreement is otherwise terminated by either party. We have the right to terminate this licensing agreement upon written notice for PARI's uncured material breach, if PARI is the subject of specified bankruptcy or liquidation events, or if PARI fails to reach certain specified obligations. PARI has the right to terminate this licensing agreement upon written notice for our uncured material breach, if we are the subject of specified bankruptcy or liquidation events, if we assign or otherwise transfer the agreement to a third-party that does not agree to assume all of our rights and obligations set forth in the agreement, or if we fail to reach certain specified milestones.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2014, we entered into a Commercialization Agreement with PARI for the manufacture and supply of Lamira nebulizer systems and related accessories (the Device) as optimized for use with ARIKAYCE. Under the Commercialization Agreement, PARI manufactures the Device except in the case of certain defined supply failures, when we will have the right to make the Device and have it made by third parties (but not certain third parties deemed under the Commercialization Agreement to compete with PARI). The Commercialization Agreement has an initial term of 15 years that began to run in October 2018 (the Initial Term). The term of the Commercialization Agreement may be extended by us for an additional five years by providing written notice to PARI at least one year prior to the expiration of the Initial Term.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Althea</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2015, we entered into a Commercial Fill/Finish Services Agreement (the Fill/Finish Agreement) with Althea to produce, on a non-exclusive basis, ARIKAYCE in finished dosage form at a 50 kg scale. We are obligated to pay a minimum of $2.7&#160;million for the batches of ARIKAYCE produced by Althea each calendar year during the term of the Fill/Finish Agreement. The Fill/Finish Agreement became effective as of January&#160;1, 2015, and, following an extension in 2018, will remain in effect through December 31, 2021. The Fill/Finish Agreement may be extended for additional two-year periods upon mutual written agreement of the Company and Althea at least one year prior to the expiration of its then-current term. We have expensed at least the required minimum in each year of the contract.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Either we or Althea may terminate the Fill/Finish Agreement upon the occurrence of certain events, including (i)&#160;material breach of the Fill/Finish Agreement by either party, provided such breach is not cured within 30&#160;days after receipt by the breaching party of written notice of the breach or (ii)&#160;insolvency or bankruptcy of the other party. In addition, we may terminate the Fill/Finish Agreement without cause with 12&#160;months' prior written notice to Althea, and Althea may terminate the Agreement without cause with 24&#160;months' prior written notice to us.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Therapure</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2014, we entered into a contract manufacturing agreement with Therapure for the manufacture of ARIKAYCE, on a non-exclusive basis, at a 200 kg scale. Pursuant to the agreement, we collaborated with Therapure to construct a production area for the manufacture of ARIKAYCE in Therapure's existing manufacturing facility in Mississauga, Ontario, Canada. The agreement has an initial term of five years, which began in October 2018, and will renew automatically for successive periods of two years each, unless terminated by either party by providing the required two years' prior written notice to the other party. Notwithstanding the foregoing, the parties have rights and obligations under the agreement prior to the commencement of the initial term. Under the agreement, we are obligated to pay certain minimum amounts for the batches of ARIKAYCE produced each calendar year. The agreement allows for termination by either party upon the occurrence of certain events, including (i)&#160;the material breach by the other party of any provision of the agreement or the quality agreement expected to be entered into between the parties, and (ii)&#160;the default or bankruptcy of the other party. In addition, we may terminate the agreement for any reason upon no fewer than 180&#160;days' advance notice.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Patheon and related agreements</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, we entered into certain agreements with Patheon related to the increase of our long-term production capacity for ARIKAYCE. The agreements provide for Patheon to manufacture and supply ARIKAYCE for our anticipated commercial needs.&#160;Under these agreements, we are required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.&#160;Patheon's supply obligations will </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">commence once certain technology transfer and construction services are completed. Our manufacturing and supply agreement with Patheon will remain in effect for a fixed initial term, after which it will continue for successive renewal terms unless either we or Patheon have given written notice of termination. The technology transfer agreement will expire when the parties agree that the technology transfer services have been completed. The agreements may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party&#8217;s insolvency. These early termination clauses may reduce the amounts due to the relevant parties. The investment in our long-term production capacity build-out, including under the Patheon agreements and related agreements or purchase orders with third parties for raw materials and fixed assets, is estimated to be approximately $60 million.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">SynteractHCR,&#160;Inc. (Synteract)</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into a services agreement with Synteract pursuant to which we retained Synteract to perform implementation and management services in connection with the CONVERT study. We may terminate the services agreement or any work order for any reason and without cause with 30&#160;days' written notice. Either party may terminate the agreement in the event of a material breach or bankruptcy petition by the other party or, if any approval from a regulatory authority is revoked, suspended or expires without renewal. We anticipate that aggregate costs relating to all work orders for the CONVERT study will be approximately $48&#160;million over the period of the study. In April 2015, we entered into a work order with Synteract to perform implementation and management services for the 312&#160;study. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cystic Fibrosis Foundation Therapeutics,&#160;Inc. (CFFT)</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2004 and 2009, we entered into research funding agreements with CFFT whereby we received $1.7&#160;million and $2.2&#160;million for each respective agreement in research funding for the development of ARIKAYCE. If ARIKAYCE becomes an approved product for certain infections in CF patients or such infections in human pulmonary disease in the US, we will owe a payment to CFFT of up to $13.4&#160;million that is payable over a three-year period after regulatory approval in the US. Furthermore, if certain global sales milestones are met within five years of the drug commercialization, we would owe additional payments of $3.9&#160;million. Under the 2009 agreement, in the event we terminate development of ARIKAYCE for CF prior to first commercial sale of a product containing ARIKAYCE for a period of 360 continuous days, and such termination is not for reasons outside of our reasonable control, then at CFFT's election and within 180&#160;days of such termination, CFFT (1)&#160;may elect to develop ARIKAYCE for CF and (2)&#160;will have the right to receive from us an exclusive (subject to certain exceptions), royalty-free, sub-licensable license to use, develop, sell and commercialize a product containing ARIKAYCE in the treatment of certain infections in CF patients or pulmonary disease associated with CF.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">INS1007-related Agreements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Syneos Health</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into a services agreement with Syneos Health (Syneos) pursuant to which we retained Syneos to perform implementation and management services in connection with the WILLOW study. We may terminate the services agreement or any work order for any reason and without cause with 30&#160;days' written notice. Either party may terminate the agreement in the event of a material breach or bankruptcy petition by the other party or, if any approval from a regulatory authority is revoked, suspended or expires without renewal. We anticipate that aggregate costs relating to all work orders for the WILLOW study will be approximately $</span><span style="font-family:inherit;font-size:10pt;">21 million</span><span style="font-family:inherit;font-size:10pt;"> over the period of the study.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">AstraZeneca</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2016, we entered into the AZ License Agreement, pursuant to which AstraZeneca granted us exclusive global rights for the purpose of developing and commercializing AZD7986 (renamed INS1007). In consideration of the licenses and other rights granted by AstraZeneca, we made an upfront payment of $30.0&#160;million in late October 2016. We are obligated to make a series of contingent milestone payments to AstraZeneca totaling up to an additional $85.0&#160;million upon the achievement of clinical development and regulatory filing milestones. If we elect to develop INS1007 for a second indication, we will be obligated to make an additional series of contingent milestone payments totaling up to $42.5&#160;million. We are not obligated to make any additional milestone payments for additional indications. In addition, we have agreed to pay AstraZeneca tiered royalties ranging from a high single-digit to mid-teens on net sales of any approved product based on INS1007 and one additional payment of $35.0&#160;million upon the first achievement of $1&#160;billion in annual net sales. The AZ License Agreement provides AstraZeneca with the option to negotiate a future agreement with us for commercialization of INS1007 in chronic obstructive pulmonary disease or asthma. If we fail to comply with our obligations under our agreements with AstraZeneca (including, among other things, if we fail to use commercially reasonable efforts to develop and commercialize a product based on INS1007, or we are subject to a bankruptcy or insolvency), AstraZeneca would have the right to terminate the license.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Competition</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The biotechnology and pharmaceutical industries are highly competitive. We face potential competitors from many different areas including commercial pharmaceutical, biotechnology and device companies, academic institutions and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">scientists, other smaller or earlier stage companies and non-profit organizations developing anti-infective drugs and drugs for respiratory diseases. Many of these companies have greater human and financial resources and may have product candidates in more advanced stages of development and may reach the market before our product candidates. Competitors may develop products that are more effective, safer or less expensive or that have better tolerability or convenience. We also may face generic competitors where third-party payors will encourage use of the generic products. Although we believe that our formulation delivery technology, respiratory and anti-infective expertise, experience and knowledge in our specific areas of focus provide us with competitive advantages, these potential competitors could reduce our commercial opportunity. Additionally, there currently are, and in the future there may be, already-approved products for certain of the indications for which we are developing, or in the future may choose to develop, product candidates. For instance, PAH is a competitive indication with established products, including other formulations of treprostinil.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NTM lung disease competitive overview</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the NTM lung disease market, our major competitors include pharmaceutical and biotechnology companies that have approved therapies or therapies in development for the treatment of chronic lung infections. There are other companies that are currently conducting early stage clinical trials for the treatment of NTM lung disease. We are not aware of any approved inhaled therapies specifically indicated for refractory NTM lung infections in North America, Europe or Japan, but, as previously described, there is an ATS/IDSA-recommended treatment regimen that is utilized.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Orphan Drug Designation</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">United States</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Orphan Drug Act (ODA), the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, defined as a disease or condition for which the drug is intended affects fewer than 200,000 people in the US, if it meets certain criteria specified by the ODA and FDA. After the FDA grants orphan drug designation, the drug and the specific intended use(s) for which it has obtained designation are listed by the FDA in a publicly-accessible database. The FDA has designated ARIKAYCE as an orphan drug for treatment of (i)&#160;infections caused by NTM, (ii)&#160;bronchiectasis in patients with </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pseudomonas</span><span style="font-family:inherit;font-size:10pt;"> aeruginosa or other susceptible microbial pathogens and (iii)&#160;bronchopulmonary </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pseudomonas</span><span style="font-family:inherit;font-size:10pt;"> aeruginosa infections in CF patients.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Orphan drug designation qualifies the sponsor for various development incentives of the ODA, including tax credits for qualified clinical testing, and a waiver of the PDUFA application fee (unless the application seeks approval for an indication not included in the orphan drug designation). Orphan drug designation also affords the company a period of exclusivity for the orphan indication upon approval of the drug. Specifically, the first NDA applicant with an FDA orphan drug designation for a particular active moiety to receive FDA approval of the drug for an indication covered by the orphan designation is entitled to a seven-year exclusive marketing period, often referred to as orphan drug exclusivity, in the US for that drug in that indication. A product that has several separate orphan designations may have several separate exclusivities for separate orphan indications. During the orphan drug exclusivity period, the FDA may not approve any other applications to market the same drug for the same indication for use, except in limited circumstances, such as a showing of clinical superiority to the product that has orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition or the same drug for a different disease or condition, and it does not alter the timing or scope of the regulatory review and approval process; the sponsor must still submit evidence from clinical and non-clinical studies sufficient to demonstrate the safety and effectiveness of the drug.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">European Union</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The European Commission grants orphan drug designation to promote the development of drugs or biologics (1)&#160;for life-threatening or chronically debilitating conditions affecting not more than five in 10,000 people in the EU, or (2)&#160;for life threatening, seriously debilitating or serious and chronic condition in the EU where, without incentives, sales of the drug in the European Economic Area (the EU plus Iceland, Lichtenstein, and Norway) (EEA) are unlikely to be sufficient to justify its development. Orphan drug designation is available either if no other satisfactory method of diagnosing, preventing or treating the condition is approved in the EEA or if such a method does exist but the proposed orphan drug will be of significant benefit to patients. The European Commission has granted an orphan designation for ARIKAYCE for the treatment of NTM lung disease.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If a drug with an orphan drug designation subsequently receives a marketing authorization for a therapeutic indication which is covered by such designation, the drug is entitled to orphan exclusivity. Orphan exclusivity means that the EMA or a national medicines agency may not accept another application for authorization, or grant an authorization, for a same or similar drug for the same therapeutic indication. Competitors may receive such a marketing authorization despite orphan exclusivity, provided that they demonstrate that the existing orphan product is not supplied in sufficient quantities or that the 'second' drug or biologic is clinically superior to the existing orphan product. The 'second' drug may but need not have an </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">orphan designation as well. The period of orphan exclusivity is ten years, which can be extended by two years where an agreed pediatric investigation plan has been implemented. The exclusivity period may also be reduced to six years if the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Each orphan designation carries the potential for one market exclusivity for all the therapeutic indications that are covered by the designation. A product that has several separate orphan designations may have several separate market exclusivities.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Orphan drug designation also provides opportunities for free protocol assistance and fee reductions for access to the centralized regulatory procedure or fee exemptions for companies with a small and medium enterprises status. In addition, Member States may provide national benefits to orphan drugs, such as early access to the reimbursement procedure or exemption from any turnover tax imposed on pharmaceutical companies.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The orphan designation may be applied for at any time during the development of the drug but before the application for marketing authorization. At the time of marketing authorization, the criteria for orphan designation are examined again, and the European Commission decides on the maintenance of the orphan designation. The non-maintenance of the orphan designation means that the drug loses its orphan status and thus no longer benefits from orphan exclusivity, fee reductions or exemptions, and national benefits.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Japan</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Ministry of Health, Labour and Welfare (MHLW) may, after hearing the opinion of the Pharmaceutical Affairs and Food Sanitation Council, grant orphan drug designation to a drug intended to treat a rare disease or condition if the drug meets the following conditions: (i) the number of target patients is less than 50,000 in Japan, (ii) the necessity of orphan drug designation is high from a medical point of view, (iii) there are sufficient theoretical grounds to use the drug for the target disease, and (iv) the plan for development of the drug is appropriate. Even if a drug is granted orphan drug designation, however, it does not always receive the manufacturing and marketing approval that is necessary for the drug to be sold or marketed in Japan. ARIKAYCE did not qualify for orphan drug designation in Japan due to the estimated number of NTM patients in Japan exceeding 50,000.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Drug Approval</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">United States</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the US, pharmaceutical products are subject to extensive regulation by the FDA and other government bodies. The US Federal Food, Drug and Cosmetic Act (FDCA) and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling and import and export of pharmaceutical products. Failure to comply with applicable US requirements at any time during product development, approval, or after approval may subject a company to a variety of administrative or judicial sanctions, such as imposition of clinical holds, FDA refusal to file or approve new drug applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, civil penalties, and criminal prosecution. The description below summarizes the current approval process in the US for our product and product candidates.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Preclinical Studies</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preclinical studies include laboratory evaluation of product chemistry, formulation and toxicity, and pharmacology, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including the FDA's good laboratory practices (GLP) regulations and the US Department of Agriculture's regulations implementing the Animal Welfare Act. An Investigational New Drug (IND) sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical trial protocol, among other things, to the FDA as part of an IND application. Certain non-clinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue even after the IND is submitted. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Clinical Trials</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical trials involve the administration of the investigational new drug to human subjects (healthy volunteers or patients) under the supervision of a qualified investigator. Clinical trials must be conducted (i)&#160;in compliance with all applicable federal regulations and guidance, including those pertaining to good clinical practice (GCP) standards that are meant to protect the rights, safety, and welfare of human subjects and to define the roles of clinical trial sponsors, investigators, and monitors as well as (ii)&#160;under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">safety, and the effectiveness criteria to be evaluated. Each protocol involving testing of a new drug in the US (whether in patients or healthy volunteers) must be included as a submission to the IND, and the FDA must be notified of subsequent protocol amendments, including new protocols. In addition, the protocol must be reviewed and approved by an institutional review board (IRB), and all study subjects must provide informed consent. Typically, before any clinical trial, each institution participating in the trial will require review of the protocol before the trial commences at that institution. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and there are additional, more frequent reporting requirements for certain adverse events.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A study sponsor might choose to discontinue a clinical trial or a clinical development program for a variety of reasons. The FDA may impose a temporary or permanent clinical hold, or other sanctions, if it believes that the clinical trial either is not being conducted in accordance with the FDA requirements or presents an unacceptable risk to the clinical trial subjects. An IRB also may require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential pre-approval phases, but the phases may overlap or be combined. In Phase&#160;1, short term (typically less than a few months) testing is conducted in a small group of subjects (typically 20-100), who may be patients with the target disease or condition or healthy volunteers, to evaluate its safety, determine a safe dosage range, and identify side effects. In Phase&#160;2, the drug is given to a larger group of subjects (typically up to several hundred) with the target condition to further evaluate its safety and gather preliminary evidence of efficacy. Phase&#160;3 studies typically last between several months and two years. In Phase&#160;3, the drug is given to a large group of subjects with the target disease or condition (typically several hundred to several thousand), often at multiple geographical sites, to confirm its effectiveness, monitor side effects, and collect data to support drug approval. Only a small percentage of investigational drugs complete all three phases of development and obtain marketing approval.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">NDA</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After completion of the required clinical testing, an NDA can be prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the US. The NDA is a large submission that must include, among other things, the results of all preclinical, clinical and other testing and a compilation of data relating to the product's pharmacology, chemistry, manufacture, and controls. The application also includes representative samples, copies of the proposed product labeling, patent information, and a financial certification or disclosure statement. The cost of preparing and submitting an NDA is substantial. Additionally, under federal law (as amended by the most recent reauthorization of the Prescription Drug User Fee Act (PDUFA VI) in the FDA Reauthorization Act of 2017), most NDAs are subject to a substantial application fee and, upon approval, the applicant will be assessed an annual prescription drug program fee, both of which are adjusted annually. NDAs for orphan drugs are not subject to an application fee, unless the application includes an indication other than the orphan-designated indication. FDA also has the authority to grant waivers of certain user fees, pursuant to the FDCA.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has 60&#160;days from its receipt of an NDA to determine whether the application is accepted for filing based on the FDA's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins a substantive review. The FDA may refer applications for novel drug products or drug products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes outside clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will typically inspect the facility or the facilities at which the drug is manufactured. FDA will not approve the product unless compliance with current good manufacturing practices (cGMP) is satisfactory and the NDA contains data that provide substantial evidence of effectiveness for the proposed indication, generally consisting of adequate and well-controlled clinical investigations, and that the drug is safe for use under the conditions of use in the proposed labeling. The FDA also reviews the proposed labeling submitted with the NDA and typically requires changes in the labeling text.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After the FDA evaluates the NDA and the manufacturing and testing facilities, it issues either an approval letter or a complete response letter. Complete response letters generally outline the deficiencies in the submission and delineate the additional testing or information needed in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA's satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. An approval letter, which may specify post approval requirements, authorizes commercial marketing of the drug for the approved indication or indications and the other conditions of use set out in the approved prescribing information. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. Under priority review status, the FDA has 180&#160;days from either the 60 day filing date (in the case of NME NDA submissions) or the date of receipt of the NDA (in the case of non-NME original NDA submissions) to issue either an approval letter or a complete response letter, unless the review period is adjusted by mutual agreement between the FDA and the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">applicant or as a result of the applicant submitting a major amendment. The FDA's current performance goals call for the FDA to complete review of 90&#160;percent of standard (non-priority) NDAs within 10&#160;months and priority NDAs within six months of NDA filing or receipt.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a condition of NDA approval, the FDA may require substantial post-approval testing, known as phase&#160;4 studies, to be conducted in order to gather additional information on the drug's effect in various populations and any side effects associated with long-term use. Beyond routine post marketing safety surveillance, the FDA may require specific additional surveillance to monitor the drug's safety or efficacy and may impose other conditions, including labeling restrictions that can materially affect the potential market and profitability of the drug. As a condition of approval, or after approval, the FDA also may require submission of a risk evaluation and mitigation strategy (REMS) or a REMS with elements to assure safe use to mitigate any identified or suspected serious risks. The REMS may include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. Further post-approval requirements are discussed below.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Expedited Review and Approval of Eligible Drugs</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the FDA's accelerated approval program, the FDA may approve certain drugs for serious or life-threatening conditions on the basis of a surrogate or intermediate endpoint that is reasonably likely to predict clinical benefit, which can substantially reduce time to approval. A surrogate endpoint used for accelerated approval is a marker&#8212;a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than irreversible morbidity and mortality (IMM) that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA bases its decision on whether to accept the proposed surrogate or intermediate clinical endpoint on the scientific support for that endpoint.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a condition of accelerated approval, the FDA typically requires certain post-marketing clinical studies to verify and describe clinical benefit of the product, and may impose restrictions on distribution to assure safe use. Post marketing studies would usually be required to be studies already underway at the time of the accelerated approval. In addition, promotional materials for an accelerated approval drug to be used in the first 120&#160;days post-approval must be submitted to the FDA prior to approval, and materials to be used after that 120-day period must be submitted 30&#160;days prior to first use. If the required post-marketing studies fail to verify the clinical benefit of the drug, or if the applicant fails to perform the required post-marketing studies with due diligence, the FDA may withdraw approval of the drug under streamlined procedures in accordance with the agency's regulations. The agency may also withdraw approval of a drug if, among other things, the promotional materials for the product are false or misleading, or other evidence demonstrates that the drug product is not shown to be safe or effective under its conditions of use.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA also has various programs&#8212;fast track designation, priority review, and breakthrough designation&#8212;that are intended to expedite or streamline the process for the development and FDA review of drugs that meet certain qualifications. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. The programs each have different eligibility criteria and provide different benefits, and can be applied either alone or in combination depending on an applicant's circumstances. Fast track designation applies to a drug that is intended to treat a serious condition and for which nonclinical or clinical data demonstrate the potential to address unmet medical need. It should be requested at the time of IND submission or ideally no later than the pre-NDA meeting. The FDA must respond to requests for fast track designation within 60&#160;days of receipt of the request. If granted, the applicant is eligible for actions to expedite development and review, such as frequent interaction with the review team, as well as for rolling review, meaning that the applicant may submit sections of the application as they are available. The timing of FDA's review of these sections depends on a number of factors, and the review clock does not start running until the agency has received a complete NDA submission. The FDA may withdraw fast track designation if the agency determines that the designation is no longer supported by data emerging in the clinical trial process.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Priority review applies to an application (both original and efficacy supplement) for a drug that treats a serious condition and that, if approved, would provide a significant improvement in safety or effectiveness. It also applies to any supplement that proposes a labeling change pursuant to a report on a pediatric study. A request for priority review is submitted at the time of NDA or supplemental NDA submission. The FDA must respond within 60&#160;days of receipt of the request. If granted, the review time is shortened from the standard 10&#160;months to 6&#160;months, beginning either at the 60 day filing date (in the case of NME NDA submissions) or the date of receipt (in the case of non-NME original NDA submissions).</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breakthrough therapy designation applies to a drug that is intended to treat a serious condition and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies. It can be requested with the IND submission and ideally no later than the end-of-phase&#160;2 meeting. The FDA must respond within 60&#160;days of receipt of the request. If granted, the applicant receives intensive guidance on efficient drug development, intensive involvement of senior managers and experienced review and regulatory health project </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">management staff in a proactive, collaborative, cross-disciplinary review, rolling review, and other actions to expedite review. Designation may be rescinded if the product no longer meets the criteria for breakthrough therapy designation.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Drugs that are designated as QIDPs are eligible for priority review and fast track designation, and well as market exclusivity. A product is eligible if it is an antibacterial or anti-fungal drug for human use that is intended to treat serious or life-threatening infections, including: those caused by an anti-bacterial or anti-fungal resistant pathogen, including novel or emerging infectious pathogens; or caused by qualifying pathogens listed by the FDA. A drug sponsor may request that the FDA designate its product as a QIDP at any time prior to NDA submission. The FDA must make a QIDP determination within 60&#160;days of receiving the designation request. ARIKAYCE has been designated as a QIDP for NTM lung disease.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, the FDA may approve eligible drugs under the LPAD. A product is eligible if it is intended to treat a serious or life-threatening infection in a limited population of patients with unmet needs, the drug otherwise meets the standards of approval, and the FDA receives a written request from the sponsor to approve the drug under this pathway. An antibacterial or antifungal drug approved through this pathway may follow a streamlined clinical development program involving smaller, shorter, or fewer clinical trials. Approval is based on a benefit-risk assessment in the intended limited population, taking into account the severity, rarity, or prevalence of the infection the drug is intended to treat and the availability or lack of alternative treatment for the patient population. Such drugs may not have favorable benefit-risk profiles in a broader population. Drugs approved under LPAD are subject to additional regulatory requirements, including labeling and advertising statements regarding the limited population and submission of promotional materials to the FDA at least 30 days prior to dissemination.&#160; The FDA may remove these additional requirements if the agency approves the drug for a broader population.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exclusivities</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After NDA approval, owners of relevant drug patents may apply for up to a five-year patent extension on a single patent. The allowable patent term extension is calculated as half of the drug's testing phase (the time between IND application and NDA submission) and all of the review phase (the time between NDA submission and approval) up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed 14&#160;years. For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A variety of non-patent exclusivity periods are available under the FDCA that can delay the submission or approval of certain applications for competing products.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A five-year period of non-patent exclusivity within the US is granted to the first applicant to gain approval of an NDA for a new chemical entity (NCE). An NCE is a drug that contains no active moiety (the molecule or ion responsible for the action of the drug substance) that has been approved by the FDA in any other application submitted under section&#160;505(b) of the FDCA. During the exclusivity period for a NCE, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company that references (i.e.,&#160;relies on FDA prior approval of) the NCE drug. However, an ANDA or 505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity or non-infringement with respect to a patent listed with the FDA for the reference NDA.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A three-year period of non-patent exclusivity is granted for a drug product that contains an active moiety that has been previously approved, when the application contains reports of new clinical investigations (other than bioavailability studies) conducted or sponsored by the sponsor that were essential to approval of the application, for example, for new indications, dosages, strengths or dosage forms of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations, which means that the FDA may approve applications for other versions of the original, unmodified drug product. Where this form of exclusivity applies, it prevents FDA approval of an ANDA or 505(b)(2) NDA subject to the exclusivity for the three-year period; however, the FDA may accept and review ANDAs or 505(b)(2) NDAs during the three-year period.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These exclusivities also do not preclude FDA approval of a 505(b)(1) application for a duplicate version of the drug during the period of exclusivity, provided that the applicant conducts or obtains a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Products with QIDP designation may receive a five-year extension of other non-patent exclusivities for which the drug is also eligible. The exclusivity does not prevent the FDA from approving a subsequent application for a change to the QIDP-designated drug that results in a new indication, route of administration, dosing, schedule, dosage form, delivery system, delivery device or strength. For example, a drug that has been designated as both an orphan drug and a QIDP for the same indication, like ARIKAYCE, could be eligible for a combined 12&#160;years of exclusivity for that indication.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Medical Device Regulation</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical devices, such as the Lamira Nebulizer System, may receive marketing authorization from the FDA as stand-alone devices, or in some cases, may receive marketing authorization as part of a combination product. In either case, the ultimate product will need to satisfy FDA requirements. The primary pathways for marketing authorization for devices in the US are 510(k) clearance or premarket approval (PMA).</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical devices are also subject to certain post-clearance, post-approval requirements. Those requirements include continuing Quality System Regulation compliance, Medical Device Reporting, Correction and Removal, and requirements governing labeling and promotional advertising.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDCA permits medical devices intended for investigational use to be shipped to clinical sites if such devices comply with prescribed procedures and conditions. Devices intended for investigational use may be exempted from premarket notification and premarket approval requirements when shipped for use in clinical trials, but they must bear a label indicating that they are for investigational use. This labeling may not represent that the device is safe or effective for the purposes for which it is being investigated.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Combination Products</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A combination product is a product comprising two or more regulated components (e.g.,&#160;a drug and device) that are combined into a single product, co-packaged, or sold separately but intended for co-administration, as evidenced by the labeling for the products. Drugs that are administered using a nebulizer or another device, such as ARIKAYCE or INS1009, are examples of combination drug/device products.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA is divided into various Centers, which each have authority over a specific type of product. NDAs are reviewed by personnel within the Center for Drug Evaluation and Research, while device applications and premarket notifications are reviewed by the Center for Devices and Radiological Health. Combination products, such as drug/device combinations, generally will be reviewed by the Center that regulates the product's primary mode of action (PMOA), which is the single mode of a combination product that provides the most important therapeutic action of the combination product. If the PMOA is unclear or in dispute, a sponsor may file a Request for Designation with FDA&#8217;s Office of Combination Products (OCP), which will render a determination and assign a lead Center. OCP generally assigns jurisdiction based on PMOA. If there are two independent modes of action, neither of which is subordinate to the other, the FDA makes a determination as to which Center to assign the product based on consistency with other combination products raising similar types of safety and effectiveness questions or to the Center with the most expertise in evaluating the most significant safety and effectiveness questions raised by the combination product. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When evaluating an application for a combination product, a lead Center may consult other Centers and apply the standards that would be applicable but still retain reviewing authority, or it may assign review of a specific section of the application to another Center, delegating its review authority for that section. Depending on the type of combination product, approval or clearance could be obtained through submission of a single marketing application or through separate applications for the individual constituent parts (e.g.,&#160;an NDA for the drug and a premarket notification for the device). The FDCA directs the FDA to conduct a review of a combination product under a single marketing application whenever appropriate. The agency has the discretion to require separate applications to more than one Center, and applicants may choose to submit separate applications for constituent parts of a combination (unless the FDA determines one application is necessary). One reason to submit multiple applications is if the applicant wishes to receive some benefit that accrues only from approval under a particular type of application, like new drug product exclusivity. If multiple applications are submitted, each application is generally reviewed by the Center with authority over each application type. For combination products that contain an approved constituent part (such as a drug-device combination product in which the device has previously received clearance), the FDA may require that the application(s) include only such information as is necessary to meet the standard for clearance or approval, taking into account any prior finding of safety or effectiveness for the approved constituent part.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Like their constituent products&#8212;e.g.,&#160;drugs and devices&#8212;combination products are highly regulated and subject to a broad range of post marketing requirements including cGMPs, adverse event reporting, periodic reports, labeling and advertising and promotion requirements and restrictions.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Disclosure of Clinical Trial Information</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under US and certain foreign laws intended to improve clinical trial transparency, sponsors of clinical trials may be required to register and disclose certain information about their clinical trials. This can include information related to the investigational drug, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial. This information is then made publicly available. Under a recently revised regulation in the US, sponsors are obligated to disclose the results of these trials after completion (prior to the new rulemaking, disclosure of results was only required if the product or new indication was approved by the FDA). In the US, disclosure of the results of these trials can be delayed for up </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">to two years if the sponsor is seeking approval of the product or a new indication. Competitors may use this publicly-available information to gain knowledge regarding the progress of development programs.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Post-approval Regulatory Requirements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Once an NDA is approved, a product will be subject to certain post-approval requirements, including those relating to advertising, promotion, adverse event reporting, recordkeeping, and cGMP, as well as registration, listing, and inspection. There also are continuing, annual user fee requirements, as well as new application fees for supplemental applications with clinical data.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA regulates the content and format of prescription drug labeling, advertising, and promotion, including direct-to-consumer advertising and promotional Internet communications. FDA also establishes parameters for permissible non-promotional communications between industry and the medical community, including industry-supported scientific and educational activities. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion for uses not consistent with the approved labeling, and a company that is found to have improperly promoted off-label uses or otherwise not to have met applicable promotion rules may be subject to significant liability under both the FDCA and other statutes, including the False Claims Act.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturers are subject to requirements for adverse event reporting and submission of periodic reports following FDA approval of an NDA.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All aspects of pharmaceutical manufacture must conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the FDA inspects manufacturing facilities to assess compliance with cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, product formulation, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement, in some cases before the change may be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously mentioned, the FDA also may require phase&#160;4 studies and may require a REMS, which could restrict the distribution or use of the product.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA), which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">European Union</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">MAA</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To obtain approval of a drug under the EU regulatory system, an application for a marketing authorization may be submitted under a centralized, a decentralized or a national procedure. The centralized procedure, which is compulsory for medicines produced by certain biotechnological processes or for orphan drugs, provides for the grant of a single marketing authorization that is valid for all EU member states, which grants the same rights and obligations in each member state as a national marketing authorization. As a general rule, only one marketing authorization may be granted for drugs approved through the centralized procedure and the marketing authorization is also relevant for the EEA countries.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the centralized procedure, the Committee for Medicinal Products for Human Use (CHMP) is required to adopt an opinion on a valid application within 210&#160;days, excluding clock stops when additional information is to be provided by the applicant in response to questions. More specifically, on day 120 of the procedure, once the CHMP has received the preliminary assessment reports and opinions from the Rapporteur and Co-Rapporteur designated by the CHMP, it adopts a list of questions, which are sent to the applicant together with the CHMP's overall conclusions. Applicants then have three months to respond to the CHMP (and can request a three-month extension). The Rapporteur and Co-Rapporteur assess the applicant's replies, revise the assessment report as necessary and may prepare a list of outstanding issues. The revised assessment report and list of outstanding issues are sent to the applicant together with the CHMP's recommendation by day 180 of the procedure. Applicants then have one month to respond to the CHMP (and can request a one or two-month extension). The Rapporteur and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Co-Rapporteur assess the applicant's replies, submit them for discussion to the CHMP and prepare a final assessment report. Once its scientific evaluation is completed, the CHMP gives a favorable or unfavorable opinion as to whether to grant the marketing authorization. After the adoption of the CHMP opinion, a decision must be adopted by the European Commission, after consulting the Standing Committee of the Member States. The European Commission prepares a draft decision and circulates it to the member states; if the draft decision differs from the CHMP opinion, the Commission must provide detailed explanations. The European Commission adopts a decision within 15&#160;days of the end of the consultation procedure.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Accelerated Procedure, Conditional Approval and Approval Under Exceptional Circumstances</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Various programs, including accelerated procedure, conditional approval and approval under exceptional circumstances, are intended to expedite or simplify the approval of drugs that meet certain qualifications. The purpose of these programs is to provide important new drugs to patients earlier than under standard approval procedures.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For drugs which are of major interest from the point of view of public health, in particular from the viewpoint of therapeutic innovation, applicants may submit a substantiated request for accelerated assessment. If the CHMP accepts the request, the review time is reduced from 210 to 150&#160;days.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, for certain categories of medicinal products, marketing authorizations may be granted on the basis of less complete data than is normally required in order to meet unmet medical needs of patients or in the interest of public health. In such cases, the company may request, or the CHMP may recommend, the granting of a marketing authorization, subject to certain specific obligations; such marketing authorization may be conditional or under exceptional circumstances. The timelines for the centralized procedure described above also apply with respect to applications for a conditional marketing authorization or marketing authorization under exceptional circumstances.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Conditional marketing authorizations may be granted for products designated as orphan medicinal products, if all of the following conditions are met: (1)&#160;the risk-benefit balance of the product is positive, (2)&#160;the applicant will likely be in a position to provide the required comprehensive clinical trial data, (3)&#160;the product fulfills unmet medical needs, and (4)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Conditional marketing authorizations are valid for one year, on a renewable basis until the holder provides a comprehensive data package. The granting of conditional marketing authorization depends on the applicant's ability to fulfill the conditions imposed within the agreed upon deadline. They are subject to "conditions", i.e.&#160;the holder is required to complete ongoing studies or to conduct new studies with a view to confirming that the benefit-risk balance is positive or to fulfill specific obligations in relation to pharmacovigilance. Once the holder has provided a comprehensive data package, the conditional marketing authorization is replaced by a 'regular' marketing authorization.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketing authorizations under exceptional circumstances may be granted where the applicant demonstrates that, for objective and verifiable reasons, they are unable to provide comprehensive data on the efficacy and safety of the drug under normal conditions of use. Such marketing authorizations are subject to certain conditions, in particular relating to safety of the drug, notification of incidents relating to its use or actions to be taken. They are valid for an indefinite period of time, but the conditions upon which they are based are subject to an annual reassessment in order to ensure that the risk-benefit balance remains positive.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exclusivities</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an approved drug contains a new active substance, it is protected by data exclusivity for eight years from the notification of the Commission decision granting the marketing authorization and then by marketing protection for an additional two or three years. Overall, the drug is protected for ten or eleven years against generic competition, and no additional exclusivity protection is granted for any new development of the active substance it contains.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the eight-year period of data exclusivity, competitors may not refer to the marketing authorization dossier of the approved drug for regulatory purposes. During the period of marketing protection, competitors may not market their generic drugs. The period of marketing protection is normally two years but may become three years if, during the eight-year data exclusivity period, a new therapeutic indication is approved that is considered as bringing a significant clinical benefit over existing therapies.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Medical Devices Regulations</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the EU, the marketing of medical devices is not subject to a prior approval by a health authority, but, depending on the class of device, may require prior review by a Notified Body. Notified Bodies are technical review bodies that are accredited and supervised by national health authorities. They conduct conformity assessment procedures of, among others, medical devices.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical devices are generally governed by Directive 93/42/EEC on Medical Devices that harmonizes the conditions for placing medical devices on the European market. This Directive however does not regulate certain important marketing aspects, such as advertising or pricing and reimbursement, which remain governed by national law.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Directive 93/42 requires medical devices to meet the essential requirements which are enumerated in the annexes to the Directive. Compliance with those requirements is demonstrated by the CE mark as the manufacturer may only affix the CE mark if it may declare conformity with the essential requirement for each medical device that is marketed. Directive 93/42 provides recourse to harmonized European standards in order to facilitate compliance with the essential requirements. Harmonized standards provide a presumption of conformity with the essential requirements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Directive 93/42 institutes several conformity assessment procedures. The relevant conformity assessment procedure depends on the type of medical device and the risks involved. Devices are divided in four groups: Class&#160;I, Class&#160;IIa, Class&#160;IIb, and Class&#160;III. Class&#160;I devices present the lowest level of risk so that, for most of these devices the manufacturer can self-certify the product and need not rely on certification by a Notified Body. For the other classes, a Notified Body must review the manufacturer's procedures and/or the product. Every device is initially classified by the manufacturer. However, the Notified Body may dispute the classification and assert that the device should be included in a class requiring stricter conformity assessment procedures. Specific rules apply to custom-made medical devices, medical devices that are used in clinical trials, and medical devices that incorporate a medicinal ingredient.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For classes of devices other than Class&#160;I, a manufacturer must have a Notified Body test and certify conformity of its design and production procedures or its products with the essential requirements of Directive 93/42. Certification takes the form of a certificate of conformity issued by the Notified Body, which is valid throughout the European Union. Upon certification by the Notified Body, the manufacturer affixes the CE mark to the medical device, which allows the product to move freely within the EU and thus prevents EU Member States from restricting sales and marketing of the devices, unless such measure is justified on the basis of evidence of non-compliance. Ultimately, the manufacturer is responsible for the conformity of the device with the essential requirements and for the affixing of the CE mark. The Lamira Nebulizer System is CE marked by PARI in the EU.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturers of medical devices are subject to materiovigilance obligations that require reporting of incidents or near incidents related to the use of a medical device, which incidents may demonstrate the need for corrective action by the manufacturer. In addition, Notified Bodies regularly re-assess the conformity of a medical device to the essential requirements of Directive 93/42 and may from time to time audit the manufacturer and may, where needed, suspend or withdraw the manufacturer's certificate of conformity.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2017, the EU adopted a new Medical Devices Regulation (EU) 2017/745 (MDR), which will repeal and replace Directive 93/42 with effect from May 26, 2020.  The MDR envisages, among other things, stricter controls of medical devices, including strengthening of the conformity assessment procedures, increased expectations as regards clinical data for devices and pre-market regulatory review of high-risk devices. Under transitional provisions, medical devices with notified body certificates issued under Directive 93/42 prior to May 26, 2020 may continue to be placed on the market for the remaining validity of the certificate, until May 27, 2024 at the latest. After the expiry of any applicable transitional period, only devices that have been CE marked under the MDR may be placed on the market in the EU.</span></div><div style="line-height:120%;padding-bottom:4px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Japan</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Japanese regulatory system administered by the MHLW and the PMDA (which is responsible for product review and evaluations under the supervision of the MHLW), pre-marketing approval and clinical studies are required for all pharmaceutical products. The Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145 of 1960) requires a license for marketing authorization when importing to Japan and selling pharmaceutical products manufactured in other countries. It also requires a foreign manufacturer to get each of its manufacturing sites certified as a manufacturing site of pharmaceutical products to be marketed in Japan. To receive a license for marketing authorization, the manufacturer or seller must, at the very least, employ certain manufacturing marketing, quality and safety personnel. A license for marketing authorization may not be granted if the quality management methods and post marketing safety management methods applied with respect to the pharmaceutical product fail to conform to the standards stipulated in the ordinances promulgated by the MHLW. To obtain manufacturing/marketing approval for a new product, a Company must submit an application for approval to the MHLW with results of nonclinical and clinical studies to show the quality, efficacy and safety of the product candidate. A data compliance review, on-site inspection for good clinical practice, audit and detailed data review for compliance with current good manufacturing practices are undertaken by the PMDA. The application is then discussed by the committees of the Pharmaceutical Affairs and Food Sanitation Council. Based on the results of these reviews, the final decision on approval is made by the MHLW. The time required for the approval process varies depending on the product, but it can take years. The product also needs approval for pricing to be applied for redemption of health insurance. The medical products which once are approved and marketed are also subject to regular post-marketing vigilance of safety and quality under the standards of Good Manufacturing Practice. In Japan, the National Health Insurance </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">system maintains a Drug Price List specifying which pharmaceutical products are eligible for reimbursement, and the MHLW sets the prices of the products on this list. After receipt of marketing approval, negotiations regarding the reimbursement price with the MHLW would begin. Price would be determined within 60 to 90 days unless the applicant disagrees, which may result in extended pricing negotiations. The government generally introduces price cut rounds every other year and also mandates price decreases for specific products. New products judged innovative or useful, that are indicated for pediatric use, or that target orphan or small population diseases, however, may be eligible for a pricing premium. The government has also promoted the use of generics, where available.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pediatric Information</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">United States</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Pediatric Research Equity Act of 2003 (PREA), certain NDAs and supplements must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may, on its own initiative or at the request of an applicant, grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, and subject to an exception for certain oncology drugs, PREA does not apply to any drug for an indication for which orphan designation has been granted. Under the Best Pharmaceuticals for Children Act (BPCA), pediatric research is incentivized by the possibility of six additional months of pediatric exclusivity, which if granted, is added to existing exclusivity periods and patent-based exclusivity listed for the applicable drug in the FDA's Orange Book at the time the sponsor satisfies the FDA's "written request" for pediatric research. Sponsors may seek to negotiate the terms of a written request during drug development. While the sponsor of an orphan designated drug may not be required to perform pediatric studies under PREA unless one of the above exceptions applies, they are eligible to participate in the incentives under the BPCA if the FDA issues a written request.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">European Union</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the EU, new drugs (i.e.&#160;drugs containing a new active substance) for adults, must also be tested in children. This mandatory pediatric testing is carried out through the implementation of a pediatric investigation plan, or PIP, which is proposed by the applicant and approved by the EMA. A PIP contains all the studies to be conducted and measures to be taken in order to support the approval of the new drug, including pediatric pharmaceutical forms, in all subsets of the pediatric population. Validation of the MAA for adults is subject to the implementation of the PIP, subject to one or more waivers or deferrals. On the one hand, the PIP may allow a deferral for one or more of the studies or measures included therein in order not to delay the approval of the drug in adults, and, on another hand, the EMA may grant either a product-specific waiver for the (adult) disease/condition or one or more pediatric subsets or a class waiver for the disease/condition. PIPs are subject to modifications from time to time, when they no longer are workable. Prior to obtaining the validation of a MAA for adults, the applicant has to demonstrate compliance with the PIP at the time of submission of the application. In the case of orphan medicinal products, completion of an approved PIP can result in an extension of the market exclusivity period from ten to twelve years.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Japan</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In Japan, there is no statutory rule which imposes any obligation on pharmaceutical manufacturers engaging in pediatric drug development. However, the guidelines of the MHLW (Handling of Pharmaceuticals during the Reexamination Interval Period (Issue No. 107, February 1, 1999 and No. 1324, December 27, 2000)) state as follows: (i) since information on pediatric patients obtained in clinical trials may be limited, the MHLW recommends that pharmaceutical manufacturers conduct adequate post-marketing surveillance during the reexamination interval period and collect as much information as possible for proper use of drugs for pediatric patients; and (ii) if a pharmaceutical manufacturer plans to conduct a clinical trial to set the dose of a pediatric drug to prepare application for manufacturing/marketing approval or after receiving the same approval, the reexamination interval period may be extended up to 10 years. In addition, since 2010 the MHLW has been promoting the development of children&#8217;s drugs that have been approved for use in Europe and the US but are not yet approved in Japan, so that they can be used as early as possible in Japan as well. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulation Outside the US, Europe and Japan</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to regulations in the US, Europe and Japan, we will be subject to a variety of regulations in other jurisdictions governing clinical studies of our candidate products, including medical devices. Regardless of whether we obtain FDA approval for a product candidate, we must obtain approval of the product candidate (including a medical device) by the comparable regulatory authorities of countries outside the US before we can commence clinical studies or marketing of the product candidate in those countries. The requirements for approval and the approval process vary from country to country, and the time may be longer or shorter than that required for FDA approval. Under certain harmonized medical device approval/clearance regulations outside the US, reference to US clearance permits fast-tracking of market clearance. Other regions are harmonized with EU standards, and therefore recognize the CE mark as a declaration of conformity to applicable standards. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, we must obtain any required pricing approvals in addition to regulatory approval prior to launching a product candidate in the approving country.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Early Access Programs</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under EU law, member states are authorized to adopt national legal regimes for the supply or use of non-authorized drugs in case of therapeutic needs. The most common national legal regimes are compassionate use programs and named patient sales, but other national regimes for early access may be available, depending on the member state. For drugs that must be approved through the centralized procedure, such as orphan drugs, compassionate use programs are also regulated at the European level. ARIKAYCE is available in certain countries under early access programs.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Special programs can be set up to make available to patients with an unmet medical need a promising drug which has not yet been authorized for their condition (compassionate use). As a general rule, compassionate use programs can only be put in place for drugs or biologics that are expected to help patients with life-threatening, long-lasting or seriously disabling illnesses who currently cannot be treated satisfactorily with authorized medicines, or who have a disease for which no medicine has yet been authorized. The compassionate use route may be a way for patients who cannot enroll in an ongoing clinical trial to obtain treatment with a potentially life-saving medicine. Compassionate use programs are coordinated and implemented by the EU member states, which decide independently how and when to open such programs according to national rules and legislation. Generally, doctors who wish to obtain a promising drug for their seriously ill patients will need to contact the relevant national authority in their respective country and follow the procedure that has been set up. Typically, the national authority keeps a register of the patients treated with the drug within the compassionate use program, and a system is in place to record any side effects reported by the patients or their doctors. Orphan drugs very often are subject to compassionate use programs due to their very nature (rare diseases are life-threatening, long-lasting or seriously disabling diseases) and the long time required for both their approval and effective marketing.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Doctors can also obtain certain drugs for their patients by requesting a supply of a drug from the manufacturer or a pharmacist located in another country, to be used for an individual patient under their direct responsibility. This is often called treatment on a 'named-patient basis' and is distinct from compassionate use programs. In this case, the doctor responsible for the treatment will either contact the manufacturer directly or issue a prescription to be fulfilled by a pharmacist. While manufacturers or pharmacists do record what they supply, there is no central register of the patients that are being treated in this way.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Reimbursement of Pharmaceutical Products</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the US, many independent third-party payors, as well as the Medicare and state Medicaid programs, reimburse dispensers of pharmaceutical products. Medicare is the federal program that provides health care benefits to senior citizens and certain disabled and chronically ill persons. Medicaid is the need-based federal and state program administered by the states to provide health care benefits to certain persons.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As one of the conditions for obtaining Medicaid and, if applicable, Medicare Part&#160;B coverage for our marketed pharmaceutical products, we will need to agree to pay a rebate to state Medicaid agencies that provide reimbursement for those products. We will also have to agree to sell our commercial products under contracts with the Department of Veterans Affairs, Department of Defense, Public Health Service, and numerous other federal agencies as well as certain hospitals that are designated by federal statutes to receive drugs at prices that are significantly below the price we charge to commercial pharmaceutical distributors. These programs and contracts are highly regulated and will impose restrictions on our business. Failure to comply with these regulations and restrictions could result in adverse consequences such as civil money penalties, imposition of a Corporate Integrity Agreement and/or a loss of our ability to continue receiving Medicare and Medicaid reimbursement for our drugs. In January 2019, the Department of Health and Human Services released a proposed rule to reform the system of rebates paid to Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers. We are currently reviewing the proposed rule, the impact of which is uncertain at this time.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Private healthcare payors also attempt to control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others within a therapeutic class. payors also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The US President has indicated an interest in taking steps to lower drug prices, such as having the federal government negotiate drug prices with pharmaceutical manufacturers and/or in indexing certain federally reimbursement payments to international drug prices. In May 2018, the Administration issued "American Patients First," a multi-faceted blueprint to lower drug prices.&#160; The Administration has taken administrative steps to implement the blueprint, including through proposing sweeping demonstration projects aimed at putting downward pressure on drug prices.&#160; In addition, members of Congress have indicated an interest in legislative measures designed to lower drug costs.&#160;Drug pricing is an active area for </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory reform at both the federal and state levels, and significant changes to current drug pricing and reimbursement structures in the US could be forthcoming</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of drugs through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to patients. Some jurisdictions operate positive and negative list systems under which drugs may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular drug candidate to currently available therapies. Other member states allow companies to fix their own prices for drugs, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new drugs. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for drugs will allow favorable reimbursement and pricing arrangements for any of our products.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In Japan, drugs can be sold on the market if they undergo the PMDA&#8217;s review of safety, effectiveness and quality and receive manufacturing/marketing approval. However, in order for drugs to be covered by the National Health Insurance, they must be included in a Drug Price List.  The "Drug Pricing Organization," which is a division of the Central Social Insurance Medical Council (CSIMC), calculates the price of drugs, the general meeting of the CSIMC approves the calculated price, and the MHLW includes the drugs and the calculated price in the Drug Price List. After receiving manufacturing/marketing approval, drugs are included in the Drug Price List within 60 to 90 days unless the applicant disagrees, which may result in extended pricing negotiations. The MHLW updates the Drug Price List biennially after taking into account the survey result of the actual sales price of drugs and hearing the opinion of the CSIMC.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fraud and Abuse and Other Laws</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Physicians and other healthcare providers and third-party payors (government or private) often play a primary role in the recommendation and prescription of health care products. In the US and most other jurisdictions, numerous detailed requirements apply to government and private health care programs, and a broad range of fraud and abuse laws, transparency laws, and other laws are relevant to pharmaceutical companies. US federal and state healthcare laws and regulations in these areas include the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal anti-kickback statute;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal civil False Claims Act;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health Act;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal criminal false statements statute;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The price reporting requirements under the Medicaid Drug Rebate Program and the Veterans Health Care Act of 1992;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal Physician Payment Sunshine Act, being implemented as the Open Payments Program; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Analogous and similar state laws and regulations.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Similar restrictions apply in the member states of the EU and Japan, which have been set out by laws or industry codes of conduct. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had a total of </span><span style="font-family:inherit;font-size:10pt;">373</span><span style="font-family:inherit;font-size:10pt;"> employees, including: </span><span style="font-family:inherit;font-size:10pt;">130</span><span style="font-family:inherit;font-size:10pt;"> in research, clinical, regulatory, medical affairs and quality assurance; </span><span style="font-family:inherit;font-size:10pt;">31</span><span style="font-family:inherit;font-size:10pt;"> in technical operations, manufacturing and quality control; </span><span style="font-family:inherit;font-size:10pt;">84</span><span style="font-family:inherit;font-size:10pt;"> in general and administrative functions; and </span><span style="font-family:inherit;font-size:10pt;">128</span><span style="font-family:inherit;font-size:10pt;"> in commercial activities. We had </span><span style="font-family:inherit;font-size:10pt;">339</span><span style="font-family:inherit;font-size:10pt;"> employees in the US, </span><span style="font-family:inherit;font-size:10pt;">28</span><span style="font-family:inherit;font-size:10pt;"> employees in Europe and </span><span style="font-family:inherit;font-size:10pt;">6</span><span style="font-family:inherit;font-size:10pt;"> employees in Japan. We anticipate increasing our headcount in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None of our employees are represented by a labor union and we believe that our relations with our employees are generally good. Generally, our employees are at-will employees; however, we have entered into employment agreements with certain of our executive officers.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Available Information</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We file electronically with the SEC our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K, and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (Exchange Act). We make available on our website at http://www.insmed.com, free of charge, copies of these reports as soon as reasonably practicable after filing, or furnishing them to, the SEC. The public can also obtain materials that we file with the SEC through the SEC's website at http://www.sec.gov.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also available through our website's "Investor Relations Corporate Governance" page are charters for the Audit, Compensation and Nominations and Governance Committees of our board of directors, our Corporate Governance Guidelines, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and our Code of Business Conduct and Ethics. We intend to satisfy the disclosure requirements regarding any amendment to, or waiver from, a provision of the Code of Business Conduct and Ethics by making disclosures concerning such matters available on our website.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The references to our website and the SEC's website are intended to be inactive textual references only. Neither the information in or that can be accessed through our website, nor the contents of the SEC's website, are incorporated by reference in this Annual Report on Form&#160;10-K.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Information</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial information required under this Item&#160;1 is incorporated herein by reference to Item&#160;8 of this Annual Report on Form&#160;10-K.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4597C5707E95561D930FAE327D8D2CAA"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Our business is subject to substantial risks and uncertainties. Any of the risks and uncertainties described below, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations, prospects for growth, and the value of an investment in our common stock. In addition, these risks and uncertainties could cause actual results to differ materially from those expressed or implied by forward-looking statements contained in this Annual Report on Form 10-K (please read the Cautionary Note Regarding Forward-Looking Statements appearing at the beginning of this Annual Report on Form 10-K). </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to the Commercialization and Continued Approval of ARIKAYCE</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our prospects are highly dependent on the success of our only approved product, ARIKAYCE, which was approved in the United States (US) under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) and accelerated approval pathways. If we are unable to successfully commercialize or maintain approval for ARIKAYCE, our business, financial condition, results of operations and prospects and the value of our common stock will be materially adversely affected.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our long-term viability and growth depend on the successful commercialization of ARIKAYCE, our only approved product, which has been approved in the US for the treatment of patients with refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. We have invested and continue to invest significant efforts and financial resources in the launch of ARIKAYCE, and our ability to generate revenue from ARIKAYCE will depend heavily on successfully commercializing and obtaining full regulatory approval for ARIKAYCE by conducting an appropriate confirmatory post-marketing study. ARIKAYCE is our first commercial launch, and its successful commercialization and our receipt of full regulatory approval for ARIKAYCE in the US are subject to many risks.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The commercial success of ARIKAYCE will depend on the degree of market acceptance by physicians, patients, third-party payors and others in the health care community.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite receiving US Food and Drug Administration (FDA) approval of ARIKAYCE, the product may not gain, or over time may not retain, market acceptance by physicians, patients, third-party payors or others in the health care community. ARIKAYCE was the first product approved via the LPAD pathway, and there is limited information on how this approval may impact market acceptance of the product. If ARIKAYCE does not achieve and maintain an adequate level of acceptance, it is likely that we will not generate significant revenue or become profitable. The degree of market acceptance of ARIKAYCE, which we launched in the US early in the fourth quarter of 2018, is also dependent on a number of additional factors, including the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The willingness of the target patient population to use, and of physicians to prescribe, ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The efficacy and potential advantages of ARIKAYCE over alternative treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The risk and safety profile of ARIKAYCE, including, among other things, physician and patient concern regarding the boxed warning and other safety precautions resulting from its association with an increased risk of respiratory adverse reactions, and any adverse safety information that becomes available as a result of longer-term use of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Relative convenience and ease of administration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ability of the patient to tolerate ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The pricing of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ability and willingness of the patient to pay out of pocket costs for ARIKAYCE, for example, co-payments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sufficient third-party insurance coverage and reimbursement; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The strength of marketing and distribution support and timing of market introduction of competitive products and treatments; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Publicity concerning ARIKAYCE or any potential competitive products and treatments.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our efforts to educate physicians, patients, third-party payors and others in the health care community on the benefits of ARIKAYCE will require significant resources, which may be greater than those required to commercialize more established technologies and may never be successful.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We obtained regulatory approval of ARIKAYCE in the US through an accelerated approval process, and full approval will be contingent on successful completion of a confirmatory post-marketing study. Failure to obtain full approval or otherwise meet our post-marketing requirements and commitments would have a material adverse effect on our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA approved ARIKAYCE under the LPAD and accelerated approval pathways, and full approval will be based on results from a post-approval confirmatory clinical trial. Accelerated approval allows drugs that (i) are being developed to </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">treat a serious or life-threatening disease or condition and (ii) provide a meaningful therapeutic benefit over existing treatments to be approved substantially based on an intermediate endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit, rather than a clinical endpoint such as survival or irreversible morbidity. Accelerated approval of ARIKAYCE was supported by preliminary data from the Phase 3 CONVERT study, which evaluated the safety and efficacy of ARIKAYCE in adult patients with refractory MAC lung disease, using achievement of sputum culture conversion (defined as three consecutive negative monthly sputum cultures) by Month 6 as the primary endpoint. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The required confirmatory trial, which is currently under discussion with FDA, is proposed to be a randomized, double-blind, placebo-controlled clinical trial to assess and describe the clinical benefit of ARIKAYCE in patients with MAC lung disease. The trial will evaluate the effect of ARIKAYCE on a clinically meaningful endpoint, as compared to an appropriate control in the intended patient population of patients with MAC lung disease. Pursuant to the timetable agreed upon with the FDA, the study protocol is scheduled to be finalized during the first half of 2019, with trial results to be reported by 2024. There is little precedent for clinical development and regulatory expectations for agents to treat MAC lung disease. As a result, we may encounter challenges designing this trial, including developing and reaching agreement with the FDA on the appropriate clinical endpoints. We may encounter substantial delays in enrolling and conducting the trial, and we may not be able to enroll and conduct the trial in a manner satisfactory to the FDA or within the time period required by the FDA. If the confirmatory trial is not successful or we are unable to meet the timelines required by the FDA, the FDA could, among other things, withdraw its approval of ARIKAYCE. Separate from the confirmatory trial, additional results from ongoing and recently completed studies may affect the FDA&#8217;s benefit-risk analysis for the product. Additionally, ARIKAYCE is subject to post-marketing commitments consisting of implementation of a healthcare provider communication plan, conducting a drug utilization assessment, and conducting further studies to identify an optimal quality control in vitro drug release method. Failure to meet post-marketing commitments may raise additional regulatory challenges.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We remain subject to substantial, ongoing regulatory requirements in the US related to ARIKAYCE, and failure to comply with these requirements could lead to enforcement action or otherwise materially harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE is subject to a variety of manufacturing, packaging, storage, labeling, advertising, promotion, and record-keeping requirements, including requirements to:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Conduct sales, marketing and promotion, scientific exchange, speaker programs, charitable donations and educational grant programs in compliance with federal and state laws; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Disclose clinical trial results and payments to health care professionals and health care organizations on publicly available databases; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Monitor and report complaints, adverse events and instances of failure to meet product specifications; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comply with current good manufacturing practices (cGMP) and certain quality systems requirements for device components. </span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure to comply with these ongoing regulatory obligations could have significant negative consequences, including:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of warning letters or untitled letters by FDA asserting that we are in violation of the law;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Imposition of injunctions or civil monetary penalties or pursuit by regulators of civil or criminal prosecutions and fines against us or our responsible officers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suspension or withdrawal of regulatory approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suspension or termination of ongoing clinical trials or refusal by regulators to approve pending marketing applications or supplements to approved applications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Seizure of products, required product recalls or refusal to allow us to enter into supply contracts, including government contracts, or to import or export products;&#160;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suspension of, or imposition of restrictions on, our operations, including costly new manufacturing requirements with respect to ARIKAYCE; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Negative publicity, including communications issued by regulatory authorities, which could negatively impact the perception of us or ARIKAYCE by patients, physicians, third-party payors or the health care community.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We provide financial assistance with out-of-pocket costs to patients enrolled in commercial health insurance plans.  In addition, independent foundations may assist with out-of-pocket financial obligations. The ability of these organizations to provide assistance to patients is dependent on funding from external sources, and we cannot guarantee that such funding will be available at adequate levels, if at all.  Patient assistance programs, whether provided directly by manufacturers or charitable foundations, have come under recent government scrutiny. If we are deemed to fail to comply with relevant laws, regulations or government guidance with respect to these programs, we could be subject to significant fines or penalties.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of these events could reduce market acceptance of ARIKAYCE, substantially reduce our revenue, increase the costs of operating our business, and cause us significant reputational damage, among other consequences.  If we ultimately receive approval for ARIKAYCE in other jurisdictions, we expect to be subject to similar ongoing regulatory oversight by the relevant foreign regulatory authorities.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or if we are unable to obtain acceptable prices for ARIKAYCE, our prospects for generating revenue and achieving profitability will be materially adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our prospects for generating revenue and achieving profitability depend heavily upon the availability of adequate reimbursement for the use of ARIKAYCE from governmental and other third-party payors, both in the US and in other markets. We expect a substantial majority of ARIKAYCE revenue will come from Medicare reimbursement. Reimbursement by a third-party payor depends upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A covered benefit under its health plan;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Safe, effective and medically necessary;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Appropriate for the specific patient;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost-effective; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neither experimental nor investigational.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE's potential addition to or exclusion from the guidelines of the American Thoracic Society and Infection Diseases Society of America may also be a factor in this determination. Obtaining a determination of coverage and reimbursement for a product from each government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to each payor. We expect that, during the first six to twelve months that we commercialize ARIKAYCE, the payors will evaluate it for inclusion on formularies, during which time patients will need to rely primarily on the medical exception process to secure coverage. For sales after that time, we may not be able to provide data sufficient to gain a positive coverage and reimbursement determination or we might need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of ARIKAYCE to such payors&#8217; satisfaction. Such studies might require us to commit a significant amount of management time and financial and other resources.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even when a payor determines that a product is eligible for reimbursement, the payor may impose coverage limitations that preclude payment for some uses that are approved by the FDA or non-US regulatory authorities and/or may set a reimbursement rate that is too low to support a profitable sales price for the product. Subsequent approvals of competitive products could result in a detrimental change to the reimbursement of our products. The occurrence of any of these events likely would adversely impact market acceptance and demand for ARIKAYCE, which, in turn, could affect our ability to successfully commercialize ARIKAYCE and adversely impact our business, financial condition, results of operations and prospects and the value of our common stock. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is a significant focus in the US healthcare industry and elsewhere on drug prices and value, and public and private payors are taking increasingly aggressive steps to control their expenditures for pharmaceuticals by, inter alia, negotiating manufacturer discounts and placing restrictions on reimbursement, and patient access to, medications. These pressures could negatively affect our business. We expect changes in the Medicare program and state Medicaid programs, as well as managed care organizations and other third-party payors, to continue to put pressure on pharmaceutical product pricing. For instance, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) expanded Medicare outpatient prescription drug coverage for the elderly through Part D prescription drug plans sponsored by private entities and authorized such plans to use formularies where they can limit the number of drugs that will be covered in any therapeutic class. The plans generally negotiate significant price concessions as a condition of formulary placement. The MMA also introduced a new reimbursement methodology based on average sales prices for physician-administered drugs, which is generally believed to have resulted in lower Medicare reimbursement for physician-administered drugs. These cost reduction initiatives and other provisions of this legislation provide additional pressure to contain and reduce drug prices and could decrease the coverage and price that we receive for any approved products and could seriously harm our business. Although the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations when setting their own reimbursement rates, and any reimbursement reduction resulting from the MMA may result in a similar reduction in payments from private payors. Additionally, the Patient Protection and Affordable Care Act (ACA) revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes and increased the minimum percentage for Medicaid drug rebates to states, required drug manufacturers to provide a significant discount (70% as of January 1, 2019) on prescriptions for branded drugs filled while the beneficiary is in the Medicare Part D coverage gap (also known as the donut hole), and imposed </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a significant annual fee on companies that manufacture or import branded prescription drug products. We believe it is likely that the ACA, or any legislation enacted to amend or replace it, will continue the pressure on pharmaceutical pricing, especially under the Medicare program, and also may increase our regulatory burdens and operating costs. Such changes may have a significant impact on our ability to set a product price we believe is fair and may adversely affect our ability to generate revenue and achieve or maintain profitability. We expect further federal and state proposals and health care reforms to continue to be proposed by legislators and/or the US President, which could limit the prices that can be charged for the products we develop or may otherwise limit our commercial opportunity. See Reimbursement of Pharmaceutical Products in Item 1 of Part I of this 10-K for more information. In addition, in connection with various government programs, we are required to report certain pricing information to the government, and the failure to do so may subject us to penalties.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payors may also restrict coverage of some products, particularly those for higher-priced drugs such as ARIKAYCE, by using a variable co-payment structure that imposes higher costs on patients for drugs that are not preferred by the payor and by imposing requirements for prior authorization or step edits. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In markets outside the US, including countries in the European Union (EU), Japan and Canada, pricing of pharmaceutical products is subject to governmental control. Evaluation criteria used by many EU government agencies for the purposes of pricing and reimbursement typically focus on a product&#8217;s degree of innovation and its ability to meet a clinical need unfulfilled by currently available therapies. The ACA created a similar entity, the Patient-Centered Outcomes Research Institute, designed to review the effectiveness of treatments and medications in federally-funded health care programs. An adverse result could lead to a treatment or product being removed from Medicare or Medicare coverage. The decisions of such governmental agencies could affect our ability to sell our products profitably.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have had discussions with third-party payors regarding our price for ARIKAYCE, but our pricing may meet resistance from them and the public generally. If we are unable to obtain adequate reimbursement of ARIKAYCE, the adoption of ARIKAYCE by physicians and patients may be limited. This, in turn, could affect our ability to successfully commercialize ARIKAYCE and adversely impact our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ARIKAYCE could develop unexpected safety or efficacy concerns, which would likely have a material adverse effect on us.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE was granted accelerated approval from the FDA based on Month 6 data from the CONVERT study. In the US, ARIKAYCE will now be used by larger numbers of patients, potentially for longer periods of time, and we and others (including regulatory agencies and private payors) will collect extensive information on the efficacy and safety of ARIKAYCE by monitoring its use in the marketplace. In addition, we will conduct a confirmatory trial to assess and describe the clinical benefit of ARIKAYCE in patients with MAC lung disease and may conduct additional trials in connection with lifecycle management programs for ARIKAYCE in the US. New safety or efficacy data from both market surveillance and our clinical trials may result in negative consequences including the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Modification to product labeling or promotional statements, such as additional boxed or other warnings or contraindications, or the issuance of additional &#8220;Dear Doctor Letters&#8221; or similar communications to healthcare professionals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Required changes in the administration of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Imposition of additional post-marketing surveillance, post-marketing clinical trial requirements, distribution restrictions or other risk management measures, such as a risk evaluation and mitigation strategy (REMS) or a REMS with elements to assure safe use;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suspension or withdrawal of regulatory approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suspension or termination of ongoing clinical trials or refusal by regulators to approve pending marketing applications or supplements to approved applications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suspension of, or imposition of restrictions on, our operations, including costly new manufacturing requirements with respect to ARIKAYCE; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Voluntary or mandatory product recalls or withdrawals from the market and costly product liability claims.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of these circumstances could reduce ARIKAYCE&#8217;s market acceptance and would be likely to materially adversely affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If estimates of the size of the potential markets for ARIKAYCE are overstated or data we have used to identify physicians is inaccurate, our ability to earn revenue to support our business could be materially adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have relied on our 2017 analysis of external sources, including market research funded by us and third parties, and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">internal analyses and calculations to estimate the potential market opportunities for MAC lung disease in the US, where ARIKAYCE has obtained regulatory approval, as well as future jurisdictions in which we may seek approval, including the EU5 (comprised of France, Germany, Italy, Spain and the United Kingdom) and Japan. The externally sourced information used to develop these estimates has been obtained from sources we believe to be reliable, but we have not verified the data from such sources, and their accuracy and completeness cannot be assured. Similarly, our internal analyses and calculations are based upon management&#8217;s understanding and assessment of numerous inputs and market conditions, including, but not limited to, the projected increase in prevalence of MAC lung disease, Medicare patient population growth and ongoing population shifts to geographies with increased rates of MAC lung disease. These understandings and assessments necessarily require assumptions subject to significant judgment and may prove to be inaccurate. As a result, our estimates of the size of these potential markets for ARIKAYCE could prove to be overstated, perhaps materially. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we are relying on third-party data to identify the physicians who treat the majority of MAC lung disease patients in the US and to determine how to deploy our resources to market to those physicians; however, we may not be marketing to the appropriate physicians and may therefore be limiting our market opportunity. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may develop estimates with respect to market opportunities for product candidates in the future, and such estimates would be subject to similar risks. In addition, a potential market opportunity could be reduced if a regulator limits the proposed treatment population for one of our product candidates, similar to the limited population for which ARIKAYCE was approved. In either circumstance, even if we obtain regulatory approval, we may be unable to commercialize the product on a scale sufficient to generate significant revenue, which could have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently are building our marketing and sales organization, and we have limited experience as a company in marketing drug products. If we are unable to successfully market and sell ARIKAYCE, our ability to generate revenue will be adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to commercialize ARIKAYCE, we must develop marketing, market access, sales and distribution capabilities on our own or make arrangements with third parties for its marketing, sale and distribution. We have commenced commercialization of ARIKAYCE in the US, but we may not be successful in these efforts. The establishment and development of our own sales force is and will continue to be expensive and time-consuming. As a result, we may seek one or more partners to handle some or all of the sales and marketing of ARIKAYCE in certain markets outside the US following approval by the relevant regulatory authority in those markets. However, we may not be able to enter into arrangements with third parties to sell ARIKAYCE on favorable terms or at all. In the event that either our own marketing, market access, and sales force or third-party marketing, market access, and sales organizations are not effective, we would not be able to successfully commercialize ARIKAYCE, which would adversely affect our ability to generate revenue and materially harm us. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ARIKAYCE was approved for treatment in a limited population of patients with refractory MAC lung disease, and additional clinical studies and regulatory applications will be required to expand its indication. We may not be successful in these trials or in obtaining such regulatory approval, which may materially adversely affect our prospects and the value of our common stock.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA granted accelerated approval of ARIKAYCE for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Our CONVERT study and 312 study focused on this refractory population, and we do not anticipate obtaining an indication for a broader population of patients with MAC lung disease or any other illnesses or infections without additional clinical data. Additional clinical trials will require additional time and expense. We expect to conduct our confirmatory clinical trial for full approval of ARIKAYCE in the broader population of patients with MAC lung disease, but this trial, along with any other clinical trials of ARIKAYCE may not be successful. Additional results from ongoing and recently completed studies may affect the FDA&#8217;s benefit-risk analysis for the product. If we are unable to expand the indication for use of ARIKAYCE, our prospects and the value of our common stock may be materially adversely affected.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to the Development and Regulatory Approval of Our Product Candidates Generally</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pharmaceutical research and development is very costly and highly uncertain, and we may not succeed in developing product candidates in the future.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product development in the pharmaceutical industry is an expensive, high-risk, lengthy, complicated, resource intensive process. In order to develop a product successfully, we must, among other things:</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identify potential product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Submit for and receive regulatory approval to perform clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Design and conduct appropriate preclinical and clinical trials, including confirmatory clinical trials, according to good laboratory practices and good clinical practices and disease-specific expectations of the FDA and other regulatory bodies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Select and recruit clinical investigators and subjects for our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obtain and correctly interpret data establishing adequate safety of our product candidates and demonstrating with statistical significance that our product candidates are effective for their proposed indications, as indicated by satisfaction of pre-established endpoints;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Submit for and receive regulatory approvals for marketing; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacture the product candidates and device components according to cGMP and other applicable standards and regulations.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is a high rate of failure inherent in this process, and potential products that appear promising at early stages of development may fail for a number of reasons. Importantly, positive results from preclinical studies of a product candidate may not be predictive of similar results in human clinical trials, and promising results from earlier clinical trials of a product candidate may not be replicated in later clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late&#8209;stage clinical trials even after achieving positive results in earlier stages of development and have abandoned development efforts or sought partnerships in order to continue development.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, there are many other difficulties and uncertainties inherent in pharmaceutical research and development that could significantly delay or otherwise materially impair our ability to develop future product candidates, including the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Conditions imposed by regulators, ethics committees or institutional review boards for preclinical testing and clinical trials relating to the scope or design of our clinical trials, including selection of endpoints and number of required patients or clinical sites; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Challenges in designing our clinical trials to support potential claims of superiority over current standard of care or future competitive therapies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restrictions placed upon, or other difficulties with respect to, clinical trials and clinical trial sites, including with respect to potential clinical holds or suspension or termination of clinical trials due to, among other things, potential safety or ethical concerns or noncompliance with regulatory requirements;  </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Delayed or reduced enrollment in clinical trials, or high discontinuation rates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure by third-party contractors, contract research organizations (CROs), clinical investigators, clinical laboratories, or suppliers to comply with regulatory requirements or meet their contractual obligations in a timely manner;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Greater than anticipated cost of our clinical trials; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Insufficient product supply or inadequate product quality.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure to successfully develop future product candidates for any of these reasons may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to obtain regulatory approvals for ARIKAYCE outside of the US or for our product candidates in the US, Europe, Japan or other markets. Any such failure to obtain regulatory approvals may materially adversely affect us.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are required to obtain various regulatory approvals prior to studying our products in humans and then again before we market and distribute our products, and the failure to obtain such approvals will prevent us from commercializing our products, which would materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock. While we have obtained accelerated approval for ARIKAYCE in the US, seeking approval for ARIKAYCE in other jurisdictions as well as approval for our product candidates in the US and foreign markets presents significant obstacles. Approval processes in the US, Europe and Japan require the submission of extensive preclinical and clinical data, manufacturing and quality information regarding the process and facility, scientific data characterizing our product and other supporting data in order to establish safety and effectiveness. These processes are complex, lengthy, expensive, resource intensive and uncertain. Regulators will also conduct a rigorous review of any trade name we intend to use for our products. Even after they approve a trade name, these regulators may request that we adopt an alternative name for the product if adverse event reports indicate a potential for confusion with other trade names and medication error. If we are required to adopt an alternative name, potential commercialization of ARIKAYCE or our product candidates could be delayed or interrupted. We have limited experience in submitting and pursuing applications necessary to obtain these regulatory approvals. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Data submitted to regulators are subject to varying interpretations that could delay, limit or prevent regulatory agency approval. Even if we believe our clinical trial results are promising, regulators may disagree with our interpretation of data, study design or execution and may refuse to accept our application for review or decline to grant approval. For example, in the fourth quarter of 2014, we filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) for ARIKAYCE as a treatment for, among other things, MAC lung disease in adult patients. The filing was based in part on data from our phase 2 study in patients with refractory MAC lung disease. We subsequently withdrew our MAA after the Committee for Medicinal Products for Human Use concluded that the data submitted did not provide enough evidence to support an approval. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the grant of a designation by the FDA or approval by the FDA does not ensure a similar decision by the regulatory authorities of other countries, and a decision by one foreign regulatory authority does not ensure regulatory authorities in other foreign countries or the FDA will agree with the decision. For instance, although ARIKAYCE received orphan drug designation in the US, ARIKAYCE did not qualify for orphan drug designation in Japan due to the estimated number of NTM patients in Japan exceeding 50,000. Similarly, clinical studies conducted in one country may not be accepted by regulatory authorities in other countries. Approval procedures vary among countries and can involve additional product testing, including additional preclinical studies or clinical trials, and administrative review periods. The time required to obtain approval in these other territories might differ from that required to obtain FDA approval. We may never obtain approval for ARIKAYCE outside of the US or for our product candidates in the US or other jurisdictions, which would limit our market opportunities and materially adversely affect our business. Even if a product candidate is approved, regulators may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently assessing regulatory strategies which could expedite the development and regulatory review of INS1007 in the US and the EU, but we may be unsuccessful in pursuing such strategies. The FDA has denied our request for orphan drug designation for INS1007 in on-cystic fibrosis (non-CF) bronchiectasis. In addition, although we believe that INS1009 could be eligible for approval under Section 505(b)(2), and thus could rely at least in part on studies not conducted by or for us and for which we do not have a right of reference, we may not obtain approval from the FDA to use this pathway.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may also encounter delays or rejections based on changes in regulatory agency policies during the period in which we develop a product and the period required for review of any application for regulatory agency approval of a particular product. Resolving such delays could force us or third parties to incur significant costs, limit our allowed activities or the allowed activities of third parties, diminish any competitive advantages that we or our third parties may attain or adversely affect our ability to receive royalties, any of which could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">For ARIKAYCE to be commercialized in a given market, in addition to regulatory approvals required for ARIKAYCE, the Lamira Nebulizer System must satisfy certain regulatory requirements and its use as a delivery system for ARIKAYCE must be approved or cleared by regulators.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE is administered using the Lamira Nebulizer System, and the Lamira Nebulizer System must receive regulatory approval or clearance on its own or in conjunction with ARIKAYCE as a combination product in order for us to develop and commercialize ARIKAYCE in a given market. The FDA granted accelerated approval of the Lamira Nebulizer System with ARIKAYCE as part of the approval of the drug/device combination product, and the Lamira Nebulizer System is CE marked by PARI in the EU. However, outside the US and EU, the Lamira Nebulizer System is labeled as investigational for use in our clinical trials, including in Japan, Canada and Australia, and is not approved for commercial use in Japan, Canada or certain other markets in which we may seek to commercialize ARIKAYCE in the future.  </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we seek regulatory approval in markets in which the Lamira Nebulizer System is not approved and we and PARI are not successful in obtaining approval for the Lamira Nebulizer System, our ability to commercialize ARIKAYCE in those markets would be materially impaired.  In addition, failure to maintain regulatory approval or clearance of the Lamira Nebulizer System could result in increased development costs, withdrawal of regulatory approval, and delays in ARIKAYCE reaching the market. Failure to obtain or maintain regulatory approval or clearance of the Lamira Nebulizer System could result in potential loss of regulatory approval or otherwise materially harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have limited experience conducting and managing the preclinical development activities and clinical trials necessary to obtain regulatory approvals, and we may not succeed in doing so in the future.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE is our first approved product candidate since our merger with Transave, and we have limited experience in conducting and managing the preclinical development activities and clinical trials necessary to obtain regulatory approvals, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">including approval by the FDA, EMA, Ministry of Health, Labour and Welfare (MHLW), and Pharmaceuticals and Medical Devices Agency (PMDA), which might prevent us from successfully designing, implementing, or completing the clinical trials required to support regulatory approval of our product candidates. The application processes for the FDA, MHLW, PMDA, EMA and other regulatory agencies are complex and difficult and vary by regulatory agency, and we might not be able to demonstrate that our product candidates meet the appropriate standards for regulatory approval or commercialize our product candidates in the US or elsewhere, or commercialize ARIKAYCE in jurisdictions outside of the US, or we might be significantly delayed in doing so. In such circumstances, our business, financial condition, results of operations and prospects and the value of our common stock may be materially adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our clinical studies do not produce positive results or our clinical trials are delayed, or if serious side effects are identified during drug development, we may experience delays, incur additional costs and ultimately be unable to commercialize our product candidates in the US, Europe, Japan or other markets.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Before obtaining regulatory approval for the sale of our product candidates, we must conduct, at our own expense, extensive preclinical tests to demonstrate the safety of our product candidates in animals, and clinical trials to demonstrate the safety and efficacy of our product candidates in humans. If we experience delays in our clinical trials or other testing or the results of these trials or tests are not positive or are only modestly positive, including with respect to safety, we may:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Experience increased product development costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Be delayed in obtaining, or be unable to obtain, regulatory approval for one or more of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obtain approval for indications or patient populations that are not as broad as intended or entirely different than those indications for which we sought approval or with labeling with boxed warnings or other warnings or contraindications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Need to change the way the product is administered; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Have regulatory authorities withdraw, or suspend, their approval of the product or impose risk mitigation strategies such as restrictions on distribution or other REMS;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Face a shortened patent protection period during which we may have the exclusive right to commercialize our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Have competitors that are able to bring similar products to market before us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Be sued for alleged injuries caused to patients using our products&#894; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suffer reputational damage.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Such circumstances would impair our ability to commercialize our products and harm our business and results of operations.</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to enroll enough patients to conduct and complete our clinical trials or retain a sufficient number of patients in our clinical trials to generate the data necessary for regulatory approval of our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The completion rate of our clinical trials is dependent on, among other factors, the patient enrollment rate. Patient enrollment is a function of many factors, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investigator identification and recruitment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory approvals to initiate study sites;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient population size;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The nature of the protocol to be used in the trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient proximity to clinical sites;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Eligibility criteria for the trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient willingness to participate in the trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinuation rates; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Competition from other companies&#8217; potential clinical trials for the same patient population.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Delays in patient enrollment for our clinical trials, including in the confirmatory clinical trial for ARIKAYCE and the WILLOW study, our global phase 2 study of INS1007 in non-CF bronchiectasis that currently is enrolling patients, like those we encountered in enrolling the CONVERT study, could increase costs and delay commercialization and sales, if any, of our products. Once enrolled, patients may elect to discontinue participation in a clinical trial at any time. If patients elect to discontinue participation in our clinical trials at a higher rate than expected, we may be unable to generate the data required by regulators for approval of our product candidates. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:174%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Reliance on Third Parties</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on third parties including collaborators, CROs, clinical and analytical laboratories, contract manufacturing organizations (CMOs) and other providers for many services that are critical to our business. If we are unable to form and sustain these relationships, or if any third-party arrangements that we may enter into are unsuccessful, including due to non-compliance by such third parties with our agreements or applicable law, our ability to develop and commercialize our products may be materially adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently rely, and expect to continue to rely, on third parties for significant research, analytical services, preclinical development, clinical development and manufacturing of our product candidates and commercial scale manufacturing of ARIKAYCE and the Lamira Nebulizer System. For example, we do not own facilities for clinical-scale or commercial manufacturing of our product candidates, and we currently rely on Therapure Biopharma Inc. (Therapure) and Ajinimoto Althea,&#160;Inc. (Althea) to provide our clinical and commercial supply of ARIKAYCE. Additionally, almost all of our clinical trial work is done by CROs, such as SynteractHCR, Inc., our CRO for both the CONVERT and 312 studies, and clinical laboratories. Reliance on these third parties poses a number of risks, including the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The diversion of management time and cost of third-party advisers associated with the negotiation, documentation and implementation of agreements with third parties in the pharmaceutical industry;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The inability to control whether third parties devote sufficient resources to our programs or products, including with respect to meeting contractual deadlines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The inability to control the regulatory and contractual compliance of third parties, including their quality systems, processes and procedures, systems utilized to collect and analyze data, and equipment used to test drug product and/or clinical supplies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The inability to establish and implement collaborations or other alternative arrangements on favorable terms;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Disputes with third parties, including CROs, leading to loss of intellectual property rights, delay or termination of research, development, or commercialization of product candidates or litigation or arbitration; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contracts with our collaborators fail to provide sufficient protection of our intellectual property; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Difficulty enforcing our contractual rights if one of these third parties fails to perform.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also rely on third parties to select and enter into agreements with clinical investigators to conduct clinical trials to support approval of our product candidates, and the failure of these third parties to appropriately carry out such evaluation and selection can adversely affect the quality of the data from these studies and, potentially, the approval of our products. In particular, as part of future drug approval submissions to the FDA, we must disclose certain financial interests of investigators who participated in any of the clinical studies being submitted in support of approval, or must certify to the absence of such financial interests. The FDA evaluates the information contained in such disclosures to determine whether disclosed interests may have an impact on the reliability of a study. If the FDA determines that financial interests of any clinical investigator raise serious questions of data integrity, the FDA can institute a data audit, request that we submit further data analyses, conduct additional independent studies to confirm the results of the questioned study, or refuse to use the data from the questioned study as a basis for approval. A finding by the FDA that a financial relationship of an investigator raises serious questions of data integrity could delay or otherwise adversely affect approval of our products.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These risks could materially harm our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not have, or may be unable to obtain, sufficient quantities of ARIKAYCE, the Lamira Nebulizer System or our product candidates to meet our required supply for commercialization or clinical studies, which would materially harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have any in-house manufacturing capability other than for small-scale pre-clinical development programs and depend completely on a small number of third-party manufacturers and suppliers for the manufacture of our product candidates on a clinical or commercial scale. For instance, we are and expect to remain dependent upon Therapure, Althea and eventually Patheon to supply ARIKAYCE both for our clinical trials and commercial sale. Althea manufactures ARIKAYCE at a relatively small scale; Therapure, operates at a larger scale than Althea. ARIKAYCE currently has a limited shelf life, and we may not be able to maintain adequate quantities to meet future demand. As additional supporting data become available, we believe the current approved shelf life for product manufactured at our CMOs will increase. If we encounter delays or difficulties in the manufacturing process that disrupt our ability to supply our distributors with ARIKAYCE, we may experience a product stock-out, which would likely have a material adverse effect on our business and reputation. In addition, we have entered into certain agreements with Patheon related to increasing our long-term production capacity for ARIKAYCE commercial inventory, although Patheon&#8217;s supply obligations will commence only after certain technology transfer and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">construction services are completed. Any delay in the commencement of Patheon&#8217;s supply obligations, whether due to delays in technology transfer and construction or from adding Patheon to our NDA as a CMO, would increase the risks associated with either Therapure or Althea being unable to provide us with an adequate supply of ARIKAYCE. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also dependent upon PARI being able to provide an adequate supply of nebulizers both for commercial sale of ARIKAYCE and any ongoing clinical trials, as PARI is the sole manufacturer of the Lamira Nebulizer System. We have no alternative supplier for the nebulizer, and because significant effort and time were expended in the optimization of the nebulizer for use with ARIKAYCE, we do not intend to seek an alternative or secondary supplier. In the event PARI cannot provide us with sufficient quantities of the nebulizer, replication of the optimized device by another party would likely require considerable time and additional regulatory approval. In the case of certain specified supply failures, we have the right under our commercialization agreement with PARI to make the nebulizer and have it made by certain third parties, but not those deemed under the commercialization agreement to compete with PARI.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have long-term commercial agreements with all of our suppliers and if any of our suppliers are unable or unwilling to perform for any reason, we may not be able to locate suppliers or enter into favorable agreements with them. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An inadequate supply of ARIKAYCE or the Lamira Nebulizer System could harm our commercial efforts or delay or impair clinical trials of ARIKAYCE or our product candidates and adversely affect our business, financial condition, results of operations and prospects and the value of our common stock. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The manufacturing facilities of our third-party manufacturers are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we and our manufacturing partners fail to comply with the regulations or maintain the approvals.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturers of ARIKAYCE, the Lamira Nebulizer System and our product candidates are subject to cGMP, Quality System Regulations and similar standards. While we have policies and procedures in place to select third-party manufacturers for our product and product candidates that adhere, and monitor their adherence to, such standards, they may nonetheless fail to do so. Similarly, while we have entered into a Commercialization Agreement with PARI for the manufacture of the Lamira Nebulizer System for use with ARIKAYCE, PARI may fail to adhere to applicable standards. These manufacturers and their facilities will be subject to periodic review and inspections by the FDA and other regulatory authorities following regulatory approval of our products, as with ARIKAYCE. For instance, to monitor compliance with applicable regulations, the FDA routinely conducts inspections of facilities and may identify potential deficiencies. The FDA issues what are referred to as &#8220;FDA Form 483s&#8221; that set forth observations and concerns identified during its inspections. Failure to satisfactorily address the concerns or potential deficiencies identified in a Form 483 could result in the issuance of a warning letter, which is a notice of the issues that the FDA believes to be significant regulatory violations requiring prompt corrective actions. Failure to respond adequately to a warning letter, or to otherwise fail to comply with applicable regulatory requirements could result in enforcement, remedial and/or punitive actions by the FDA or other regulatory authorities.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If one of these manufacturers fails to maintain compliance with regulatory requirements or experiences supply problems, including in the scale-up of commercial production, the production of ARIKAYCE, the Lamira Nebulizer System and our product candidates could be interrupted, resulting in delays, additional costs or restrictions on the marketing or sale of our products. An alternative manufacturer would need to be qualified, through regulatory filings, which could result in further delay. The regulatory authorities may also require additional testing if a new manufacturer is relied upon for commercial production.  In addition, with respect to our product candidates, our manufacturers and their facilities are subject to pre-approval cGMP inspection by the FDA and other regulatory authorities, and the findings of the cGMP inspection could result in a failure to obtain, or a delay in obtaining, regulatory approval for future product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to the Operation of our Business</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent upon retaining and attracting key personnel, the loss of whose services could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We depend heavily on our management team and our principal clinical and commercial personnel, the loss of whose services might significantly delay or prevent the achievement of our research, development or commercialization objectives. Our success depends, in large part, on our ability to attract and retain qualified management, clinical and commercial personnel, and on our ability to develop and maintain important relationships with commercial partners, leading research institutions and key distributors. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Competition for skilled personnel in our industry and market is intense because of the numerous pharmaceutical and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">biotechnology companies that seek similar personnel. These companies may have greater financial and other resources, offer a greater opportunity for career advancement and have a longer history in the industry than we do. We also experience competition for the hiring of our clinical and commercial personnel from universities, research institutions, and other third parties. We cannot assure that we will attract and retain such persons or maintain such relationships. Our inability to retain and attract qualified employees would materially harm our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our commercial launch of ARIKAYCE and international expansion, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, quality, commercial compliance, medical affairs, and sales and marketing. For example, we plan to hire additional personnel in connection with our commercial launch of ARIKAYCE and preparation for potential regulatory filings for ARIKAYCE in other markets. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to the limited experience of our management team in managing a company with this anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. We may not be able to effectively manage the expansion of our operations, which could delay the execution of our business plans or disrupt our operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Any acquisitions we make, or collaborative relationships we enter into, may not be clinically or commercially successful, and may require financing or a significant amount of our available cash, which could adversely affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of our business strategy, we may effect acquisitions to obtain additional businesses, products, technologies, capabilities and personnel. Acquisitions involve a number of operational risks, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure to achieve expected synergies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Difficulty and expense of assimilating the operations, technology and personnel of any acquired business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The inability to retain the management, key personnel and other employees of any acquired business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The inability to maintain any acquired company&#8217;s relationship with key third parties, such as alliance partners;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exposure to legal claims for activities of any acquired business prior to acquisition;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diversion of our management&#8217;s attention from our core business; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential impairment of intangible assets, adversely affecting our reported results of operations and financial condition.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also may enter into collaborative relationships that would involve our collaborators conducting proprietary development programs. Disagreements with collaborators may develop over the rights to our intellectual property, and any conflict with our collaborators could limit our ability to obtain future collaboration agreements and negatively influence our relationship with existing collaborators. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we make one or more significant acquisitions or enter into a significant collaboration in which the consideration includes cash, we may be required to use a substantial portion of our available cash and/or need to raise additional capital, which could adversely affect our financial condition. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to product liability claims, and we have only limited product liability insurance.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The manufacture and sale of human therapeutic products involve an inherent risk of product liability claims, particularly as we now commercialize ARIKAYCE in the US. Regardless of merit or eventual outcome, liability claims may result in:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">decreased demand for ARIKAYCE and any other products that we may commercialize, and a corresponding loss of revenue&#894;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">substantial monetary awards to patients or trial participants;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">significant time and costs to defend the related litigation&#894;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">withdrawal or reduced enrollment of clinical trial participants; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reputational harm and significant negative media attention.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently have only limited product liability insurance for our products. We do not know if we will be able to maintain existing, or obtain additional, product liability insurance on acceptable terms or with adequate coverage against potential liabilities. This type of insurance is expensive and may not be available on acceptable terms. If we are unable to obtain or maintain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims, we may be unable to commercialize our products. A successful product liability claim brought against us in excess of our insurance coverage, if any, may require us to pay substantial amounts and may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business and operations, including our drug development programs, could be materially disrupted in the event of system failures, security breaches, violations of data protection laws or data loss or damage by us or our CROs or other contractors or consultants.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could have a material adverse effect on our business operations, including a material disruption of our drug development and commercialization programs. Unauthorized disclosure of sensitive or confidential patient or employee data, including personally identifiable information, whether through breach of computer systems, systems failure, employee negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems and networks, whether by our employees or third parties, could result in negative publicity, legal liability and damage to our reputation. Unauthorized disclosure of personally identifiable information could also expose us to sanctions for violations of data privacy laws and regulations around the world. To the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. For example, the loss of or damage to clinical trial data, such as from completed or ongoing clinical trials, for any of our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we have general liability insurance coverage, including coverage for errors and omissions, our insurance may not cover all claims, continue to be available on reasonable terms or be sufficient in amount to cover one or more large claims; additionally, the insurer may disclaim coverage as to any claim. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have limited experience operating internationally, are subject to a number of risks associated with our international activities and operations and may not be successful in our efforts to expand internationally.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently have limited operations outside of the US. As of December 31, 2018, we had 28 employees located in Europe and 6 employees located in Japan, although we have clinical trial sites and suppliers located around the world. In order to meet our long-term goals, we expect to grow our international operations over the next several years, including in Europe and Japan, and continue to source material used in the manufacture of our product candidates from abroad. Consequently, we are and will continue to be subject to risks related to operating in foreign countries, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Limited experience with international regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An inability to achieve optimal pricing and reimbursement for ARIKAYCE, if approved in another jurisdiction, or subsequent changes in reimbursement, pricing and other regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any implementation of, or changes to, tariffs, trade barriers and other import-export regulations in the US or other countries in which we, or our third-party partners, operate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unexpected adverse events related to ARIKAYCE or our product candidates occurring in foreign markets that we have not experienced in the US;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Economic and political conditions, including geopolitical events, such as war and terrorism, foreign currency fluctuations and inflation, which could result in reduced revenue, increased or unpredictable operating expenses and other obligations incident to doing business in, or with a company located in, another country;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes resulting from the UK's vote to exit the EU, including: (i) the uncertainty and instability in economic and market conditions; (ii) the uncertainty regarding the UK&#8217;s access to the EU Single Market and the impact on the wider trading, legal, regulatory and labor environments; and (iii) the uncertainty in the European regulatory framework, including the relocation of the EMA from the UK to the Netherlands, and the subsequent potential disruption and delay of EMA regulatory actions; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compliance with foreign or US laws, rules and regulations, including data privacy requirements, labor relations laws, </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-left:48px;text-align:left;"><span style="font-family:inherit;font-size:10pt;">tax laws, anti-competition regulations, import, export and trade restrictions, anti-bribery/anti-corruption laws, regulations or rules, which could lead to actions by us or our licensees, distributors, manufacturers, other third parties who act on our behalf or with whom we do business in foreign countries or our employees who are working abroad that could subject us to investigation or prosecution under such foreign or US laws.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These and other risks associated with our international operations may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We operate in a highly competitive and changing environment, and if we are unable to adapt to our environment, we may be unable to compete successfully.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biotechnology and related pharmaceutical technology have undergone and are likely to continue to experience rapid and significant change. Our future success will depend in large part on our ability to maintain a competitive position with respect to these technologies and to obtain and maintain protection for our intellectual property. Compounds, products or processes that we develop may become obsolete before we recover any expenses incurred in connection with their development. We face substantial competition from pharmaceutical, biotechnology and other companies, universities and research institutions with respect to nontuberculous mycobacteria (NTM) lung disease, bronchiectasis, and pulmonary arterial hypertension (PAH). Relative to us, most of these entities have substantially greater capital resources, research and development staffs, facilities and experience in conducting clinical studies, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. Many of our competitors may achieve product commercialization or obtain patent protection earlier than us. Furthermore, we believe that our competitors have used, and may continue to use, litigation to gain a competitive advantage. Our competitors may also use different technologies or approaches to develop products similar to ARIKAYCE and our product candidates.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that competing successfully will depend, among other things, on the relative speed with which we can develop products, complete the clinical testing and regulatory approval processes and supply commercial quantities of the product to the market, as well as product efficacy, safety, reliability, availability, timing and scope of regulatory approval and price. We expect competition to increase as technological advances are made and commercial applications broaden. There are potential competitive products, both approved and in development, which include oral, systemic, or inhaled antibiotic products to treat chronic respiratory infections. For instance, certain entities have expressed interest in studying their products for NTM lung disease and are seeking to advance studies in NTM lung disease caused by mycobacterial species other than MAC; however, we are not aware of any entities currently conducting clinical trials for the treatment of refractory MAC lung disease or of any other approved inhaled therapies specifically indicated for NTM lung disease in North America, Europe or Japan. If any of our competitors develops a product that is more effective, safe, tolerable or, convenient or less expensive than ARIKAYCE or our product candidates, it would likely materially adversely affect our ability to generate revenue. We also may face lower priced generic competitors if third-party payors encourage use of generic or lower-priced versions of our product or if competing products are imported into the US or other countries where we may sell ARIKAYCE. In addition, in an effort to put downward pressure on drug pricing, Congress and the FDA are working to facilitate generic competition, which could result in our experiencing competition earlier than otherwise would be the case.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are also other amikacin products that have been approved by the FDA, MHLW and other regulatory agencies for use in other indications, and physicians may elect to prescribe those products rather than ARIKAYCE to treat the indications for which ARIKAYCE has received approval, which is commonly referred to as off-label use. Although regulations prohibit a drug company from promoting off-label use of its product, the FDA and other regulatory agencies do not regulate the practice of medicine and cannot direct physicians as to what product to prescribe to their patients. As a result, we would have limited ability to prevent any off-label use of a competitor&#8217;s product to treat diseases for which we have received FDA or other regulatory agency approval, even if this use violates our patents or any statutory exclusivities that the FDA may grant for the use of amikacin to treat such diseases. If we are unable to compete successfully, it will materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect our intellectual property rights adequately, the value of ARIKAYCE and our product candidates could be materially diminished.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal, technical, scientific and factual questions, and our success depends in large part on our ability to protect our proprietary technology and to obtain and maintain patent protection for our products, prevent third parties from infringing our patents, both domestically and internationally. We have sought to protect our proprietary position by filing patent applications in the US and abroad related to our novel technologies and products that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technologies or from developing competing products and technologies.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection or otherwise provide us with any competitive advantage. Any conclusions we may reach regarding non-infringement, inapplicability or invalidity of a third-party&#8217;s intellectual property vis-&#224;-vis our proprietary rights, or those of a licensor, are based in significant part on a review of publicly available databases and other information. There may be information not available to us or otherwise not reviewed by us that could render these conclusions inaccurate. Our competitors may also be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, patents issued to us or our licensors may be challenged, narrowed, invalidated, held to be unenforceable or circumvented through litigation, which could limit our ability to stop competitors from marketing similar products or reduce the term of patent protection for amikacin liposome inhalation suspension or our product candidates. US patents and patent applications may also be subject to interference or derivation proceedings, and US patents may be subject to re-examination proceedings, reissue, post-grant review and/or </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review in the USPTO. Our foreign patents have been and may be in the future subject to opposition or comparable proceedings in the corresponding foreign patent office, which could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intellectual Property - ARIKAYCE Patents and Trade Secrets</span><span style="font-family:inherit;font-size:10pt;"> in Item 1 of Part I of this 10-K for more information on our European patents that have been previously opposed.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in either patent laws or in interpretations of patent laws in the US and other countries may also diminish the value of our intellectual property or narrow the scope of our patent protection, including making it easier for competitors to challenge our patents. For example, the America Invents Act included a number of changes to established practices, including the transition to a first-inventor-to-file system and new procedures for challenging patents and implementation of different methods for invalidating patents.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of ARIKAYCE and our product candidates could be materially diminished.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, advisors, collaborators, and other third parties and partners to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information or may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, third parties may independently develop or discover our trade secrets and proprietary information. Regulators also may disclose information we consider to be proprietary to third parties under certain circumstances, including in response to third-party requests for such disclosure under the Freedom of Information Act or comparable laws. Additionally, the FDA, as part of its Transparency Initiative, continues to consider whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time whether and how the FDA&#8217;s disclosure policies may change in the future.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to enforce our intellectual property rights throughout the world, which could harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The legal systems of some foreign countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. Many companies have encountered significant problems in protecting and defending intellectual property rights in such foreign jurisdictions.  For example, certain foreign countries have compulsory licensing laws under which a patent owner may be required to grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. This legal environment could make it difficult for us to stop the infringement of our patents or in-licensed patents or the misappropriation of our other intellectual property rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, and our efforts to protect our intellectual property rights in such countries may be inadequate. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The drug research and development industry has a history of intellectual property litigation, and we could become involved in costly intellectual property disputes, which could delay or impair our product development efforts or prevent us from, or </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">increase the cost of, commercializing ARIKAYCE or any other approved product candidate.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Third parties may claim that we have infringed upon or misappropriated their proprietary rights. Any existing third-party patents, or patents that may later issue to third parties, could negatively affect our commercialization of ARIKAYCE, INS1007, INS1009 or any other product candidate that receives regulatory approval. For instance, PAH is a competitive indication with established products, including other formulations of treprostinil. Our supply of the active pharmaceutical ingredient for INS1009 is dependent upon a single supplier. The supplier owns patents on its manufacturing process, and we have filed patent applications for INS1009; however, a competitor in the PAH indication may claim that we or our supplier have infringed upon or misappropriated its proprietary rights. Moreover, in the event that we pursue approval of INS1009, or any other product candidate, via the 505(b)(2) regulatory pathway, we will be required to file a certification against any unexpired patents listed in the Orange Book for the third-party drug we rely upon as part of our regulatory submission. This certification process may lead to litigation and could also delay launch of a product candidate, if approved by regulators.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the event of successful litigation or settlement of claims against us for infringement or misappropriation of a third-party&#8217;s proprietary rights, as in 2007 with respect to IPLEX, we may be required to take actions including but not limited to the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Paying damages, including up to treble damages, royalties, and the other party&#8217;s attorneys&#8217; fees, which may be substantial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceasing development, manufacture, marketing and sale of products or use of processes that infringe the proprietary rights of others;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expending significant resources to redesign our products or our processes so that they do not infringe the proprietary rights of others, which may not be possible, or may result in significant regulatory delays associated with conducting additional clinical trials or other steps to obtain regulatory approval; and/or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquiring one or more licenses from third parties, which may not be available to us on acceptable terms or at all.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may also have to undertake costly litigation or engage in other proceedings, such as interference or </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review, to enforce or defend the validity of any patents issued or licensed to us, to confirm the scope and validity of our or a licensor&#8217;s proprietary rights or to defend against allegations that we have infringed a third-party&#8217;s intellectual property rights. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any proceedings regarding our intellectual property rights are likely to be time consuming and may divert management attention from operation of our business, and could have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Certain of the agreements to which we are, or may become, a party relating to ARIKAYCE and our product candidates impose, or may in the future impose, restrictions on our business or other material obligations on us. If we fail to comply with these obligations, our business could be adversely affected, including as a result of the loss of license rights that are important to our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to various agreements related to ARIKAYCE and our product candidates, including licensing agreements with PARI and AstraZeneca, which we view as material to our business. For additional information regarding the terms of these agreements, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business - License and Other Agreements</span><span style="font-family:inherit;font-size:10pt;"> in Item 1 of Part I of this 10-K. These agreements impose a number of obligations on us and our business, including restrictions on our ability to freely develop or commercialize our product candidates and requirements to make milestone and royalty agreements to our counterparties upon certain events. Under our license agreement with AstraZeneca, AstraZeneca retains a right of first negotiation pursuant to which it may exclusively negotiate with us before we can negotiate with a third-party regarding any transaction to develop or commercialize INS1007, subject to certain exceptions. While this right of first negotiation is not triggered by a change of control, it may impede or delay our ability to consummate certain other transactions involving INS1007.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we fail to comply with our obligations under these agreements, our counterparties may have the right to take action against us, up to and including termination of a relevant license. For instance, under our licensing agreement with PARI, with respect to NTM lung disease and bronchiectasis, we have specific obligations to use commercially reasonable efforts to achieve certain developmental and regulatory milestones by set deadlines. Additionally, for NTM lung disease, we are obligated to use commercially reasonable efforts to achieve certain commercial milestones in Europe. The consequences of our failing to use commercially reasonable efforts to achieve certain commercial milestones are context-specific, but include ending PARI&#8217;s non-compete obligation, making the license non-exclusive and terminating the license, in each case with respect to the applicable indication. Similarly, under our license agreement with AstraZeneca, AstraZeneca may terminate our license to INS1007 if we fail to use commercially reasonable efforts to develop and commercialize a product based on INS1007, or we are subject to a bankruptcy or insolvency. Reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms and may materially harm our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finally, if we do not proceed with the development of our ARIKAYCE program in the NTM lung disease or CF indications, certain of our contract counterparties may elect to proceed with the development of these indications.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Government Regulation </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Government health care reform could materially increase our costs, which could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our industry is highly regulated and changes in or revisions to laws and regulations that make gaining regulatory approval, reimbursement and pricing more difficult or subject to different criteria and standards may adversely impact our business, operations or financial results. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Administration and the majority party in the Senate have indicated their ongoing desire to repeal the ACA and, in December 2017, Congress repealed the ACA's individual mandate, i.e., the penalty imposed on individuals who do not obtain health care coverage. It is unclear what the effect of this partial repeal will be and whether, when and how repeal of other sections of the law may be effectuated and what the effect on the healthcare sector will be. In December 2018, a federal district court judge in Texas found the ACA to be unconstitutional, although the ruling was stayed while the case is appealed. It is unclear what the outcome of this litigation and other pending challenges to the ACA's constitutionality, as well as the effect of these matters on the healthcare sector, will be. The US President has indicated an interest in taking steps to lower drug prices, such as having the federal government negotiate drug prices with pharmaceutical manufacturers and/or in indexing certain federally reimbursement payments to international drug prices. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reimbursement of Pharmaceutical Products</span><span style="font-family:inherit;font-size:10pt;"> in Item 1 of Part I of this 10-K for more information. Changes to the ACA, to the Medicare or Medicaid programs, or to the ability of the federal government to negotiate or otherwise affect drug prices, or other federal legislation regarding healthcare access, financing or legislation in individual states, could affect our business, financial condition, results of operations and prospects and the value of our common stock. It remains unclear how any new legislation or regulation might affect the prices we may obtain for ARIKAYCE or any of our product candidates for which regulatory approval is obtained. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are found in violation of federal or state &#8220;fraud and abuse&#8221; laws, we may be required to pay a penalty or may be suspended from participation in federal or state health care programs, which may adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the US, we are subject to various federal and state health care &#8220;fraud and abuse&#8221; laws, including anti&#8209;kickback laws, false claims laws and other laws intended to reduce fraud and abuse in federal and state health care programs. Although we seek to structure our business arrangements in compliance with all applicable requirements, these laws are broadly written, and it is often difficult to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our practices may be challenged under these laws. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines or exclusion or suspension from federal and state health care programs such as Medicare and Medicaid and debarment from contracting with the US government, and our business, financial condition, results of operations and prospects and the value of our common stock may be adversely affected. Our reputation could also suffer. In addition, private individuals have the ability to bring actions on behalf of the government under the federal False Claims Act as well as under the false claims laws of several states.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the ACA, we are required to report information on payments or transfers of value to US physicians and teaching hospitals as well as investment interests held by physicians and their immediate family members, which is posted in searchable form on a public website. Failure to submit required information may result in civil monetary penalties. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. In addition to the federal government, some states, as well as other countries, including France, require the disclosure of certain payments to health care professionals. The federal privacy regulations under HIPAA, state, and foreign medical record privacy laws may limit access to information identifying those individuals who may be prospective users. There are ambiguities as to what is required to comply with these state requirements, and we could be subject to penalties if a state determines that we have failed to comply with an applicable state law requirement. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to anti-corruption laws and trade control laws, as well as other laws governing our operations. If we fail to comply with these laws, we could be subject to negative publicity, civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations are subject to anti-corruption laws, including the US Foreign Corrupt Practices Act (FCPA), the UK </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bribery Act and other anti-corruption laws that apply in countries where we do business. The FCPA, UK Bribery Act and these other laws generally prohibit us, our employees and our intermediaries from making prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. The CONVERT study includes more than 125 sites in 18 countries, and we conducted the 312 study and plan to conduct the WILLOW study, our global phase 2 study of INS1007 in non-CF bronchiectasis, at a broad range of trial sites around the world. Certain of these jurisdictions pose a risk of potential FCPA violations, and we have relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the US Department of Commerce&#8217;s Bureau of Industry and Security, the US Department of Treasury&#8217;s Office of Foreign Assets Control, and various non-US government entities, including applicable export control regulations, economic sanctions on countries and persons, customs requirements, currency exchange regulations and transfer pricing regulations (collectively, Trade Control laws).</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not be effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and prospects and the value of our common stock. Likewise, even an investigation by US or foreign authorities of potential violations of the FCPA other anti-corruption laws or Trade Control laws could have an adverse impact on our reputation, business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If another party obtains orphan drug exclusivity for a product that is essentially the same as a product we are developing for a particular indication, we may be precluded or delayed from commercializing the product in that indication.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the ODA, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition. The company that obtains the first regulatory approval from the FDA for a designated orphan drug for a rare disease generally receives marketing exclusivity for use of that drug for the designated condition for a period of seven years. Similar laws exist in the EU with a term of ten years. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business - Government Regulation - Orphan Drug Designation</span><span style="font-family:inherit;font-size:10pt;"> in Item 1 of Part I of this 10-K for additional information. If a competitor obtains approval of the same drug for the same indication or disease before us, and the FDA grants such orphan drug exclusivity, we would be prohibited from obtaining approval for our product for seven or more years, unless our product can be shown to be clinically superior. In addition, even if we obtain orphan exclusivity, the FDA may approve another product during our orphan exclusivity period for the same indication under certain circumstances.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our research, development and manufacturing activities used in the production of ARIKAYCE and our product candidates involve the use of hazardous materials, which could expose us to damages, fines, penalties and sanctions and materially adversely affect our results of operations and financial condition.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development program and manufacturing activities for ARIKAYCE and our product candidates involve the controlled use of hazardous materials and chemicals. We generally contract with third parties for the disposal of these materials and wastes. Although we strive to comply with all pertinent regulations, the risk of environmental contamination, damage to facilities or injury to personnel from the accidental or improper use or control of these materials remains. In addition to any liability we could have for any misuse by us of hazardous materials and chemicals, we could also potentially be liable for activities of our CMOs or other third parties. Any such liability, or even allegations of such liability, could materially adversely affect our results of operations and financial condition. We also could incur significant costs as a result of civil or criminal fines and penalties.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we may incur substantial costs to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Financial Condition and Need for Additional Capital</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have a history of operating losses, expect to incur operating losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have incurred losses each previous year of our operation, except in 2009, when we sold our manufacturing facility and certain other assets to Merck, and we did not generate significant revenue during the years ended December 31, 2018, 2017 or 2016. As of December 31, 2018, our accumulated deficit was </span><span style="font-family:inherit;font-size:10pt;">$1,282.2 million</span><span style="font-family:inherit;font-size:10pt;">. For the years ended December 31, 2018, 2017 and 2016, our consolidated net loss was </span><span style="font-family:inherit;font-size:10pt;">$324.3 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$192.6 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$176.3 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. Our ability to generate revenue will depend on the success of commercial sales of ARIKAYCE; however, we do not anticipate our revenue from the sale of ARIKAYCE will be sufficient for us to become profitable without reductions in our operating expenses. Despite our recent launch of ARIKAYCE in the US, we expect to continue to incur substantial operating expenses, and resulting operating losses, for the foreseeable future as we:</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup>&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">initiate or continue clinical studies of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">initiate a post-marketing clinical trial of ARIKAYCE, as required by the FDA&#894;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek to discover or in-license additional product candidates&#894;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek regulatory approvals for ARIKAYCE in foreign markets&#894; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">scale-up manufacturing capabilities for future ARIKAYCE production, including the build-out of production capacity at Patheon and process improvements in order to manufacture at a commercial scale&#894; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">enhance operational, compliance, financial, quality and information management systems and hire more personnel, including personnel to support our commercialization efforts and development of our product candidates.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.   </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may need to raise additional funds to continue our operations, but we face uncertainties with respect to our ability to access capital.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations have consumed substantial amounts of cash since our inception. We expect to expend substantial financial resources to commercialize ARIKAYCE, including expenditures on product sales, marketing, manufacturing and distribution, fund the confirmatory post-marketing study and continue research and development of and, where applicable, seek regulatory approval for ARIKAYCE and our product candidates. We may need to raise additional capital to fund these activities, including due to changes in our product development plans or misjudgment of expected costs, to fund corporate development, to maintain our intellectual property portfolio or to resolve litigation. As of December 31, 2018, we had </span><span style="font-family:inherit;font-size:10pt;">$495.1 million</span><span style="font-family:inherit;font-size:10pt;"> of cash and cash equivalents on hand. Our operating expenses, capital expenditures and long-term investments were significantly higher in 2018 than in 2017, reflecting our investment in the build-out of our commercial organization to support global expansion activities for ARIKAYCE, including the launch of ARIKAYCE in the US in the fourth quarter of 2018, the build-up of third-party manufacturing capacity and manufacture of commercial inventory, which includes capital and long-term investments, and continued investment in research and development as well as selling, general and administrative expenses. We do not know whether additional financing will be available when needed, or, if available, whether the terms will be favorable. If adequate funds are not available to us when needed, we may be forced to delay, restrict or eliminate all or a portion of our development programs or commercialization efforts.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have outstanding indebtedness in the form of convertible senior notes, and may incur additional indebtedness in the future, which could adversely affect our financial position, prevent us from implementing our strategy, and dilute the ownership interest of our existing shareholders.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, we completed an underwritten public offering of 1.75% convertible senior notes due 2025 (the Convertible Notes). The Convertible Notes may be convertible into common stock at an initial conversion rate of 25.5384 shares of common stock per $1,000 principal amount of Convertible Notes. We sold $450.0 million aggregate principal amount of the Convertible Notes, including the exercise in full of the underwriters&#8217; option to purchase additional Convertible Notes, resulting in net proceeds of approximately $435.8 million. Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding October 15, 2024 only under certain circumstances. On or after October 15, 2024 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their Convertible Notes at any time. Upon conversion of the Convertible Notes, we may deliver cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The degree to which we are leveraged could have negative consequences, such as the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may be more vulnerable to economic downturns, less able to withstand competitive pressures, and less flexible in responding to changing economic conditions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain financing in the future may be limited;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a substantial portion of our cash flows from operations in the future may be required for the payment of the principal amount of the Convertible Notes when they or any additional indebtedness become due&#894;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may elect to make cash payments upon conversion of the Convertible Notes, which would reduce our available cash.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to pay principal or interest on or, if desired, to refinance our indebtedness, including the Convertible Notes, depends on our future performance, which is subject to economic, financial, competitive and other factors, some of which are beyond our control. Our business may not generate cash flow from operations in the future sufficient to satisfy any obligations under the Convertible Notes to make cash payments to noteholders or our obligations under any future indebtedness we may incur. If we are unable to generate such cash flow, we may be required to delay, restrict or eliminate all or a portion of our development programs or commercialization efforts or refinance or obtain additional equity capital on terms that may be onerous or highly dilutive. If we do not meet our debt obligations, it could materially adversely affect our results of operations, financial condition and the value of our common stock.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The conversion of some or all of the Convertible Notes will dilute the ownership interests of our existing shareholders to the extent we deliver shares upon their conversion. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Convertible Notes may encourage short selling by market participants because the conversion of the Convertible Notes could be used to satisfy short positions, or anticipated conversion of the Convertible Notes into shares of our common stock could depress the price of our common stock. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The accounting method for the Convertible Notes may have an adverse effect on our reported financial results.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounting guidance requires that we separately account for the liability and equity components of the Convertible Notes because they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. As a result, the equity component of the Convertible Notes is required to be included in the additional paid-in capital section of shareholders&#8217; equity on our consolidated balance sheet, and the value of the equity component is treated as original issue discount for purposes of accounting for the debt component of the Convertible Notes. We may report greater net loss (or lower net income) in our financial results because this guidance requires interest to include both the current period&#8217;s amortization of the debt discount and the instrument&#8217;s coupon interest, which could adversely affect our reported or future financial results, the market price of our common stock and the trading price of the Convertible Notes.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding October 15, 2024 only under certain circumstances. For example, holders may convert their Convertible Notes at their option during any quarter commencing after the quarter ending March 31, 2018 (and only during such quarter) if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding quarter is greater than or equal to 130% of the conversion price on each applicable trading day. If the Convertible Notes become convertible prior to October 15, 2024, we may be required to reclassify our Convertible Notes and the related debt issuance costs as current liabilities and certain portions of our equity outside of equity to mezzanine equity, which would have an adverse impact on our reported financial results for such quarter, and could have an adverse impact on the market price of our common stock and the trading price of the Convertible Notes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible assets comprised approximately </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">10%</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> of our total assets as of December 31, 2018. A reduction in the value of our intangible assets could have a material adverse effect on our results of operations, financial condition and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the merger with Transave in 2010, we recorded an intangible in-process research and development (IPRD) asset of $77.9 million and goodwill of $6.3 million on our balance sheet. As a result of the clinical hold on ARIKAYCE announced in late 2011, we recorded a charge of $26.0 million in the fourth quarter of 2011 that reduced the value of IPRD to $58.2 million and reduced goodwill to zero. In addition, in September 2018 we recorded an additional $1.7 million in intangible assets related to a milestone to PARI as a result of FDA approval of ARIKAYCE. As of December 31, 2018, the balance of these intangibles, net of amortization was $57.0 million and $1.7 million, respectively. Future activities or events could result in additional write-downs of these intangible assets, which could materially adversely affect our results of operations, financial condition and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to use certain of our net operating losses and other tax assets.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have substantial tax loss carry forwards for US federal income tax and state income tax purposes, and beginning in </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015, we had tax loss carry forwards in Ireland as well. In general, our net operating losses and tax credits have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. In particular, our ability to fully use certain US tax loss carry forwards and general business tax credit carry forwards recorded prior to December 2010 to offset future income or tax liability is limited under section 382 of the Internal Revenue Code of 1986, as amended (the Code). Changes in the ownership of our stock, including those resulting from the issuance of shares of our common stock offerings or upon exercise of outstanding options, may limit or eliminate our ability to use certain net operating losses and tax credit carry forwards in the future.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Ownership of Our Common Stock </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The market price of our stock has been and may continue to be highly volatile, which could lead to shareholder litigation against us.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our common stock is listed on the Nasdaq Global Select Market under the ticker symbol &#8220;INSM&#8221;. The market price of our stock has been and may continue to be highly volatile and could be subject to wide fluctuations in price in response to various factors, including those discussed herein, many of which are beyond our control. In addition, the stock market has from time to time experienced extreme price and volume fluctuations, which have particularly affected the market prices for emerging biotechnology and pharmaceutical companies like us, and which have often been unrelated to their operating performance. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Historically, when the market price of a stock has been volatile, shareholders are more likely to institute securities and derivative class action litigation against the issuer of such stock. We previously faced a shareholder suit following a decline in our stock price. If any of our shareholders bring a lawsuit against us in the future, it could have a material adverse effect on our business. We have insurance policies related to some of the risks associated with our business, including directors&#8217; and officers&#8217; liability insurance policies; however, our insurance coverage may not be sufficient and our insurance carriers may not cover all claims in a given litigation. If we are not successful in our defense of claims asserted in shareholder litigation, those claims are not covered by insurance or they exceed our insurance coverage, we may have to pay damage awards, indemnify our executive officers, directors and third parties from damage awards that may be entered against them and pay our and their costs and expenses incurred in defense of, or in any settlement of, such claims. In addition, such shareholder suits could divert the time and attention of management from our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Certain provisions of Virginia law, our articles of incorporation and amended and restated bylaws and arrangements between us and our employees could hamper a third-party&#8217;s acquisition of, or discourage a third-party from attempting to acquire control of us.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain provisions of Virginia law, our articles of incorporation and amended and restated bylaws and arrangements with our employees could hamper a third-party&#8217;s acquisition of, or discourage a third-party from attempting to acquire control of, us or limit the price that investors might be willing to pay for shares of our common stock. These provisions or arrangements include:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ability to issue preferred stock with rights senior to those of our common stock without any further vote or action by the holders of our common stock. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of our common stock or could adversely affect the rights and powers, including voting rights, of the holders of our common stock. In certain circumstances, such issuance could have the effect of decreasing the market price of our common stock.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The existence of a staggered board of directors in which there are three classes of directors serving staggered three-year terms, thus expanding the time required to change the composition of a majority of directors.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The requirement that shareholders provide advance notice when nominating director candidates to serve on our Board of Directors.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The inability of shareholders to convene a shareholders&#8217; meeting without the chairman of the board, the president or a majority of the board of directors first calling the meeting.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The prohibition against entering into a business combination with the beneficial owner of 10% or more of our outstanding voting stock for a period of three years after the 10% or greater owner first reached that level of stock ownership, unless certain criteria are met.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to severance agreements with our officers and provisions in our incentive plans that permit acceleration of equity awards upon a change in control, a severance plan for eligible full-time employees that provides such employees with severance equal to six months of their then-current base salaries in connection with a termination of employment without cause upon, or within 18 months following, a change in control.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We previously had a shareholder rights plan, or &#8220;poison pill,&#8221; which expired in May 2011. Under Virginia law, our Board of Directors may implement a new shareholders&#8217; rights plan without shareholder approval. Our Board of Directors intends to regularly consider this matter, even in the absence of specific circumstances or takeover proposals, to facilitate its future ability to quickly and effectively protect shareholder value.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFF819F4176415EFDABD9A6DD165177F8"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><a id="s41A8953836C756ED8FA385825370FC87"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently lease 56,617 square feet of laboratory and office space in Bridgewater, New Jersey. The initial term of the lease will expire in November 2019. We do not intend to exercise the option to extend the lease beyond the initial term. In September 2018, the Company entered into a new lease for 117,022 square feet of office space for our new corporate headquarters in Bridgewater.  We have a one-time option to expand the new leased premises by up to 50,000 square feet prior to the fifth anniversary of the initial lease commencement. The initial term of the new lease will expire in 2030.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also lease additional laboratory space located in Bridgewater, NJ for which the initial lease term expires in September 2021.  In October 2018, the Company expanded this lease to a total of 28,002 square feet. In addition, we lease office space in Ireland, the Netherlands and Japan.</span></div><div><a id="sA89BFB577FA754128B4D7017BF3D6268"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we are a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on our consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s41A9287AD20353EAAEEC5E32B22F9FA1"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><a id="s88AFF8A4E7FE589D9AB5F755C2C09C74"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</span></div><div><a id="s3D32A62FC6FC55EA82516D3B96B07E60"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our trading symbol is "INSM." Our common stock currently trades on the Nasdaq Global Select Market. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">February&#160;15, 2019</span><span style="font-family:inherit;font-size:10pt;">, the last reported sale price for our common stock on the Nasdaq Global Select Market was $27.07 per share. As of </span><span style="font-family:inherit;font-size:10pt;">February&#160;15, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were 137 holders of record of our common stock.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never declared or paid cash dividends on our common stock. We anticipate that we will retain all earnings, if any, to support operations and to finance the growth and development of our business for the foreseeable future. Any future determination as to the payment of dividends will be dependent upon these and any contractual or other restrictions to which we may be subject and, to the extent permissible thereunder, will be at the sole discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements and other factors our board of directors deems relevant at that time.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Among Insmed Incorporated, the NASDAQ Composite Index,</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the S&amp;P 500 Index, the NASDAQ Pharmaceutical Index and the NASDAQ Biotechnology Index</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;"><img src="chart-803421e59edbca9d8b7.jpg" alt="chart-803421e59edbca9d8b7.jpg" style="height:408px;width:613px;"></img></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">_________________________________</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*&#160;&#160;&#160;&#160;$100 invested on 12/31/13 in stock or index, including reinvestment of dividends.</span></div><div style="line-height:120%;padding-bottom:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fiscal year ending December&#160;31.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Copyright&#169; 2019 Standard&#160;&amp; Poor's, a division of S&amp;P Global. All rights reserved.</span></div><div><a id="s2C0E1FE14584529DA10237334941F286"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6.&#160;&#160;&#160;&#160;SELECTED FINANCIAL DATA</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following selected financial data reflects our consolidated statements of operations and consolidated balance sheets for and as of the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2014</span><span style="font-family:inherit;font-size:10pt;">. The data below should be read in conjunction with, and is qualified by reference to, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:inherit;font-size:10pt;"> and our consolidated financial statements and notes thereto contained elsewhere in this Annual Report on Form&#160;10-K. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</span></div></td></tr><tr><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Statement of Operations Data:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,835</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs and expenses:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenues (excluding amortization of intangible assets)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,423</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">145,283</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">109,749</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">122,721</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74,277</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56,292</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">168,218</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79,171</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50,679</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43,216</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31,073</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;Amortization of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,249</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">317,173</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">188,920</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">173,400</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">117,493</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">87,365</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(307,338</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(188,920</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(173,400</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(117,493</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(87,365</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,341</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,624</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">604</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">261</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(25,472</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(5,925</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3,498</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,889</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,415</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,209</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">602</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">300</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">119</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(33</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">141</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(324,076</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(192,921</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(176,175</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(120,154</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(89,581</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">201</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(272</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">98</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,971</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(10,422</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(324,277</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(192,649</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(176,273</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(118,183</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(79,159</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4.22</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2.89</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2.85</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2.02</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1.84</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average basic and diluted common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">76,889</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66,576</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61,892</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58,633</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43,095</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Data:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">495,072</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">381,165</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">162,591</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">282,876</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">159,226</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">604,556</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">462,047</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">237,956</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">356,556</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">230,864</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,113</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt, long-term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">316,558</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55,567</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54,791</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22,027</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,856</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total shareholders' equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">208,266</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">361,059</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">154,483</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">311,698</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">186,237</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1DF343B1218D5492BAD0E6DC08AB6198"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion also should be read in conjunction with our consolidated financial statements and the notes thereto contained elsewhere in this Annual Report on Form&#160;10-K. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under the section entitled Risk Factors, Cautionary Note Regarding Forward-Looking Statements and elsewhere herein, our actual results may differ materially from those anticipated in these forward-looking statements.</span></div><div><a id="s5ECC0CAA765C5763B471512512D44AD2"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EXECUTIVE OVERVIEW</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), received accelerated approval in the United States (US) on September 28, 2018 for the treatment of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Mycobacterium avium</span><span style="font-family:inherit;font-size:10pt;"> complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting as defined by patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Our clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) with therapeutic potential in non-cystic fibrosis (non-CF) bronchiectasis and other inflammatory diseases. INS1009 is an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension (PAH). We have legal entities in the US, Ireland, Germany, France, the United Kingdom (UK), the Netherlands, Japan and Bermuda.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have not generated significant revenue since inception, and through </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">$1,282.2 million</span><span style="font-family:inherit;font-size:10pt;">. We have financed our operations primarily through the public offerings of our equity securities and debt financings. Although it is difficult to predict our future funding requirements, based upon our current operating plan, we anticipate that our cash and cash equivalents as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> will enable us to fund our operations for at least the next 12&#160;months.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that over the next few years we will continue to incur losses from operations due to, among other things, research and development expenses in connection with our ongoing and future clinical trials and expenses related to the commercial launch of ARIKAYCE globally, if approved outside the US.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APPROVED PRODUCT - ARIKAYCE</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE is our first approved product. Accelerated approval of ARIKAYCE was supported by preliminary data from our CONVERT study, a global Phase 3 study evaluating the safety and efficacy of ARIKAYCE in adult patients with refractory MAC lung disease, using achievement of sputum culture conversion (defined as three consecutive negative monthly sputum cultures) by Month 6 as the primary endpoint. Patients who achieved sputum culture conversion by Month 6 continued in the CONVERT study for an additional 12 months of treatment following the first monthly negative sputum culture in order to assess the durability of culture conversion, as defined by patients that have completed treatment and continued in the CONVERT study off all therapy for three months. The CONVERT study is ongoing.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Patients who did not culture convert by Month 6 may have been eligible to enroll in our 312 study, an open-label extension study for these non-converting patients who completed six months of treatment in the CONVERT study.  The primary objective of the 312 study was to evaluate the long-term safety and tolerability of ARIKAYCE in combination with a standard multi-drug regimen. The secondary endpoints of the 312 study included evaluating the proportion of subjects achieving culture conversion (defined in the same way as the CONVERT study) by Month 6 and the proportion of subjects achieving culture conversion by Month 12, which was the end of treatment. The 312 study has completed.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a condition of accelerated approval, we must conduct a post-approval confirmatory clinical trial. The required confirmatory trial, which is currently under discussion with the FDA, is proposed to be a randomized, double-blind, placebo-controlled clinical trial to assess and describe the clinical benefit of ARIKAYCE in patients with MAC lung disease. The trial will evaluate the effect of ARIKAYCE on a clinically meaningful endpoint, as compared to an appropriate control, in the intended patient population of patients with MAC lung disease. Pursuant to the timetable agreed upon with the FDA, the study protocol is expected to be finalized during the first half of 2019, with trial results to be reported by 2024. Continued approval of ARIKAYCE will be contingent upon verification and description of clinical benefit in this study.</span></div><div><a id="sA578634C67CC5477AFCAE9CACAAE93A5"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PIPELINE PROGRESS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INS1007</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INS1007 is a small molecule, oral, reversible inhibitor of DPP1, which we licensed from AstraZeneca in October 2016. DPP1 is an enzyme responsible for activating neutrophil serine proteases in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Neutrophils contain the neutrophil serine proteases (including neutrophil elastase, proteinase 3, and cathepsin G) that have been implicated in a variety of inflammatory diseases. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and release active neutrophil serine proteases in excess that cause lung destruction and inflammation. INS1007 may decrease the damaging effects of inflammatory diseases, such as non-CF bronchiectasis, by inhibiting DPP1 and its activation of neutrophil serine proteases. Non-CF bronchiectasis is a progressive pulmonary disorder in which the bronchi become permanently dilated due to chronic inflammation and infection. Currently, there is no cure, and we are not aware of any FDA-approved therapies specifically indicated for non-CF bronchiectasis.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The WILLOW Study</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The WILLOW study is a global phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center clinical study to assess the efficacy, safety and tolerability, and pharmacokinetics of&#160;INS1007 administered once daily for 24 weeks in subjects with non-CF bronchiectasis. We commenced enrollment in the WILLOW study in December 2017 and we expect to complete enrollment in mid-2019. In addition, we are exploring the potential of INS1007 in various neutrophil-driven inflammatory conditions.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INS1009</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INS1009 is an investigational inhaled treprostinil prodrug formulation that has the potential to address certain of the current limitations of existing prostanoid therapies. We believe that INS1009 prolongs duration of effect and may provide PAH patients with greater consistency in pulmonary arterial pressure reduction over time. Current inhaled prostanoid therapies must be dosed four to nine times per day for the treatment of PAH. Reducing dose frequency has the potential to ease patient burden and improve compliance. Additionally, we believe that INS1009 may be associated with fewer side effects, including elevated heart rate, low blood pressure, and severity and/or frequency of cough, associated with high initial drug levels and local upper airway exposure when using current inhaled prostanoid therapies. We believe INS1009 may offer a differentiated product profile for rare pulmonary disorders, including PAH, and we are currently evaluating our options to advance its development, including exploring its use as an inhaled dry powder formulation.&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Development Activities</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our earlier-stage pipeline includes preclinical compounds that we are evaluating in multiple rare diseases of unmet medical need, including gram positive pulmonary infections in CF, NTM lung disease and refractory localized infections involving biofilm. To complement our internal research and development, we actively evaluate in-licensing and acquisition opportunities for a broad range of rare diseases.</span></div><div><a id="sFA5E09F86FFA5B1BAEF6959E0FBEB50C"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">KEY COMPONENTS OF OUR RESULTS OF OPERATIONS</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenues consist primarily of net sales of ARIKAYCE in the US. In October 2018, we began shipping ARIKAYCE to our customers in the US, which include specialty pharmacies and specialty distributors.&#160;We recognize revenue for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, prompt pay discounts, returns, service fees, and government rebates, such as Medicaid rebates and Medicare Part D coverage gap reimbursements in the US. We also began recognizing revenue from sales to the French National Agency for Medicines and Health Products Safety (ANSM), which granted ARIKAYCE a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost of product revenues (excluding amortization of intangible assets)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, allocation of overhead costs, and inventory adjustment charges, in addition to royalty expenses due to PARI. We began capitalizing inventory upon FDA approval of ARIKAYCE.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development (R&amp;D) Expenses</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses consist of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our research and development functions, including medical affairs. Expenses also include other internal operating </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expenses, the cost of manufacturing our drug candidate(s)&#160;for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, our R&amp;D expenses include payments to third parties for the license rights to products in development (prior to marketing approval), such as for INS1007. Our expenses related to manufacturing our drug candidate(s)&#160;for clinical study are primarily related to activities at contract manufacturing organizations (CMOs) that manufacture our product candidates for our use, including purchases of active pharmaceutical ingredients. Our expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on our behalf.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since 2011, we have focused our development activities principally on our proprietary, advanced liposomal technology designed specifically for inhaled therapies. Our development efforts in 2018 and 2017 principally related to the development of ARIKAYCE in NTM lung disease.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Selling, General and Administrative (SG&amp;A) Expenses</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SG&amp;A expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for our non-employee directors and personnel serving in our executive, finance and accounting, legal and compliance, commercial and pre-commercial, corporate development, field sales, information technology, program management and human resource functions. SG&amp;A expenses also include professional fees for legal services, consulting services, including pre-commercial planning activities such as non-branded disease awareness, insurance, board of director fees, tax and accounting services.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization of Intangible Assets</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon commercialization of ARIKAYCE, our intangible assets began to be amortized over their estimated useful lives. The fair values assigned to our intangible assets are based on estimates and assumptions we believe are reasonable based on available facts and circumstances. Unanticipated events or circumstances may occur that require us to review the assets for impairment. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Investment Income and Interest Expense</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment income consists of interest and dividend income earned on our cash and cash equivalents. Interest expense consists primarily of the accretion of debt discount, contractual interest costs and the amortization of debt issuance costs related to our accretion of debt. Debt discount is accreted, and debt issuance costs are amortized, to interest expense using the effective interest rate method over the term of the debt. Our balance sheet reflects debt, net of the debt discount, debt issuance costs paid to the lender, and other third-party costs. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sA43CC2209F295B34806FE5EF76892FB2"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RESULTS OF OPERATIONS</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of the Years Ended </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> and </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview - Operating Results</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operating results for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, included the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues of </span><span style="font-family:inherit;font-size:10pt;">$9.8 million</span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, as a result of the fourth quarter launch of ARIKAYCE, following US FDA approval on September 28, 2018;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenues (excluding amortization of intangibles) of </span><span style="font-family:inherit;font-size:10pt;">$2.4 million</span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> related to sales of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses increased </span><span style="font-family:inherit;font-size:10pt;">$35.5 million</span><span style="font-family:inherit;font-size:10pt;"> primarily resulting from an increase in external manufacturing expenses and higher compensation and related expenses due to an increase in headcount, as compared to the prior year;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SG&amp;A expenses increased </span><span style="font-family:inherit;font-size:10pt;">$89.0 million</span><span style="font-family:inherit;font-size:10pt;"> resulting from higher compensation and related expenses due to an increase in headcount, and an increase in consulting fees relating to pre-commercial planning activities in preparation for the launch of ARIKAYCE, as compared to the prior year; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of intangible assets of </span><span style="font-family:inherit;font-size:10pt;">$1.2 million</span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense increased </span><span style="font-family:inherit;font-size:10pt;">$19.5 million</span><span style="font-family:inherit;font-size:10pt;"> from the issuance of $450.0 million aggregate principal amount of 1.75% convertible senior notes due 2025 (the Convertible Notes) in January 2018.</span></div></td></tr></table><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$324.3 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">$4.22</span><span style="font-family:inherit;font-size:10pt;"> per share&#8212;basic and diluted, compared with a net loss of </span><span style="font-family:inherit;font-size:10pt;">$192.6 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">$2.89</span><span style="font-family:inherit;font-size:10pt;"> per share&#8212;basic and diluted, for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue consists of net sales of ARIKAYCE, which was approved by the FDA on September 28, 2018 and launched in the US in October 2018. The following table summarizes the sources of revenue for the year ended December 31, 2018 (in thousands):</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:53px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:347px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:214px;"></td><td style="width:9px;"></td><td style="width:119px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Year Ended December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product revenues, US</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,265</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product revenues, France ATU</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">570</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,835</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost of Product Revenues (excluding amortization of intangibles)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, allocation of overhead costs, and inventory adjustment charges, in addition to royalty expenses due to PARI. We began capitalizing inventory upon FDA approval of ARIKAYCE. Cost of product revenues (excluding amortization of intangible assets) was </span><span style="font-family:inherit;font-size:10pt;">$2.4 million</span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All product costs incurred prior to FDA approval of ARIKAYCE in September 2018 were expensed as R&amp;D expenses. As mentioned above, our cost of product revenues includes certain expenses which are fixed, other expenses that were incurred after FDA approval and royalties based on net sales. We expect our cost of product revenues (excluding amortization of intangible assets), as a percentage of total revenue, to decrease in 2019 as compared to the fourth quarter of 2018.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">R&amp;D Expenses</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were comprised of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase (decrease)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">External Expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical development and research</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30,287</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40,511</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(10,224</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(25.2)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43,824</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19,808</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">121.2%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory, quality assurance, and medical affairs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,290</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,308</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,982</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68.2%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal&#8212;external expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86,401</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67,627</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18,774</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27.8%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Internal Expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and benefit related expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38,794</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27,689</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,105</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40.1%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,395</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,491</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,904</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44.7%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other internal operating expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,693</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,942</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,751</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34.6%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal&#8212;internal expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58,882</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42,122</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,760</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39.8%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">145,283</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">109,749</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35,534</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.4%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses increased to </span><span style="font-family:inherit;font-size:10pt;">$145.3 million</span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$109.7 million</span><span style="font-family:inherit;font-size:10pt;"> in the same period in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">$35.5 million</span><span style="font-family:inherit;font-size:10pt;"> increase was primarily due to an increase of </span><span style="font-family:inherit;font-size:10pt;">$24.0 million</span><span style="font-family:inherit;font-size:10pt;"> in external manufacturing expenses, specifically related to: pre-approval purchases of ARIKAYCE raw materials; pre-approval CMO expenses related to ARIKAYCE commercial inventory production; and construction costs relating to the build-out of a third-party CMO production facility. In addition, there was a </span><span style="font-family:inherit;font-size:10pt;">$11.1 million</span><span style="font-family:inherit;font-size:10pt;"> increase in compensation and related expenses due to an increase in headcount in the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared to the prior year period. These increases were partially offset by a decrease in clinical development and research expenses related to the CONVERT and 312 clinical trials.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, external R&amp;D expenses of </span><span style="font-family:inherit;font-size:10pt;">$86.4 million</span><span style="font-family:inherit;font-size:10pt;"> consisted of </span><span style="font-family:inherit;font-size:10pt;">$69.2 million</span><span style="font-family:inherit;font-size:10pt;"> related to ARIKAYCE, </span><span style="font-family:inherit;font-size:10pt;">$13.9 million</span><span style="font-family:inherit;font-size:10pt;"> related to INS1007, and </span><span style="font-family:inherit;font-size:10pt;">$3.3 million</span><span style="font-family:inherit;font-size:10pt;"> related to other research expenses. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, external R&amp;D expenses of </span><span style="font-family:inherit;font-size:10pt;">$67.6 million</span><span style="font-family:inherit;font-size:10pt;"> consisted of </span><span style="font-family:inherit;font-size:10pt;">$54.6 million</span><span style="font-family:inherit;font-size:10pt;"> related to ARIKAYCE, </span><span style="font-family:inherit;font-size:10pt;">$10.2 million</span><span style="font-family:inherit;font-size:10pt;"> related to INS1007, and </span><span style="font-family:inherit;font-size:10pt;">$2.8 million</span><span style="font-family:inherit;font-size:10pt;"> related to other research expenses.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SG&amp;A Expenses</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SG&amp;A expenses for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were comprised of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase (decrease)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and benefit related expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62,592</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23,218</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,374</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">169.6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,845</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,582</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,263</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional fees and other external expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70,248</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30,700</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,548</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">128.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Facility related and other internal expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18,533</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,671</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,862</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total SG&amp;A expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">168,218</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79,171</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">89,047</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">112.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SG&amp;A expenses increased to </span><span style="font-family:inherit;font-size:10pt;">$168.2 million</span><span style="font-family:inherit;font-size:10pt;"> during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$79.2 million</span><span style="font-family:inherit;font-size:10pt;"> in the same period in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">$89.0 million</span><span style="font-family:inherit;font-size:10pt;"> increase was primarily due to </span><span style="font-family:inherit;font-size:10pt;">$39.4 million</span><span style="font-family:inherit;font-size:10pt;"> in higher compensation and related expenses due to an increase in headcount, including the hiring of our field force, and </span><span style="font-family:inherit;font-size:10pt;">$39.5 million</span><span style="font-family:inherit;font-size:10pt;"> in professional fees relating to pre-commercial planning activities in preparation for the launch of ARIKAYCE, including non-branded disease awareness, patient support planning, field operations and other consulting fees.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization of Intangible Assets</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">Amortization of intangible assets for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;font-weight:normal;">$1.2 million</span><span style="font-family:inherit;font-size:10pt;"> and is comprised of amortization of acquired ARIKAYCE R&amp;D and amortization of the milestone paid to PARI for the FDA approval of ARIKAYCE.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest Expense</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense was </span><span style="font-family:inherit;font-size:10pt;">$25.5 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared to </span><span style="font-family:inherit;font-size:10pt;">$5.9 million</span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">$19.5 million</span><span style="font-family:inherit;font-size:10pt;"> increase in interest expense in the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared to the prior year period relates to the&#160;issuance of </span><span style="font-family:inherit;font-size:10pt;">$450.0 million</span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of Convertible Notes in January 2018. The interest expense on the Convertible Notes is based on an effective interest rate of 7.6%.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income tax provision (benefit)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The income tax provision (benefit) was </span><span style="font-family:inherit;font-size:10pt;">$0.2 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$(0.3) million</span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. The income tax provision for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> reflects the current income tax expense recorded as a result of taxable income in certain of our subsidiaries in Europe and Japan. The income tax (benefit) for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> reflects the reversal of the valuation allowance related to alternative minimum tax (AMT) that we paid in 2009 and became refundable as a result of the Tax Act.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the US government enacted comprehensive tax legislation, referred to as the Tax Cuts and Jobs Act (the Tax Act). The Tax Act significantly revised US tax law by, among other provisions, lowering the US federal statutory corporate tax rate from 35% to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Tax Act did not have a material impact on our financial statements because our deferred temporary differences are fully offset by a valuation allowance and we did not have any significant offshore earnings from which to record the mandatory transition tax. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of the Years Ended </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> and </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss for the year ended December&#160;31, 2017 was $192.6&#160;million, or $2.89 per share&#8212;basic and diluted, compared with a net loss of $176.3&#160;million, or $2.85 per share&#8212;basic and diluted, for the year ended December&#160;31, 2016. The $16.4&#160;million increase in our net loss for the year ended December&#160;31, 2017 as compared to the same period in 2016 was due to:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decreased R&amp;D expenses of $13.0 million primarily resulting from the $30.0&#160;million upfront payment for the license agreement entered into with AstraZeneca for exclusive global rights to INS1007 in October 2016, offset in part by, an increase in expenses related to the WILLOW study and higher compensation and related expenses due to an increase in headcount; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increased SG&amp;A expenses of $28.5 million resulting from an increase in pre-commercial planning activities, including external consulting expenses, and higher compensation and related expenses due to an increase in headcount.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, there was a $2.4&#160;million increase in interest expense resulting from the increase in our debt in the second half of 2016.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">R&amp;D Expenses</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses for the years ended December&#160;31, 2017 and 2016 were comprised of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.0625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase (decrease)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">External Expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical development and research </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40,511</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35,890</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,621</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INS1007 license payment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30,000</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(30,000</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(100.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19,808</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17,313</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,495</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory, quality assurance, and medical affairs</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,308</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,064</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,244</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal&#8212;external expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67,627</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">87,267</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(19,640</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(22.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Internal Expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and benefit related expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27,689</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22,321</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,368</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,491</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,192</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">299</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other internal operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,942</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,941</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,001</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal&#8212;internal expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42,122</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35,454</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,668</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">109,749</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">122,721</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(12,972</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(10.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses decreased to </span><span style="font-family:inherit;font-size:10pt;">$109.7 million</span><span style="font-family:inherit;font-size:10pt;"> during the year ended December&#160;31, 2017 from </span><span style="font-family:inherit;font-size:10pt;">$122.7 million</span><span style="font-family:inherit;font-size:10pt;"> in the same period in 2016. The </span><span style="font-family:inherit;font-size:10pt;">$13.0 million</span><span style="font-family:inherit;font-size:10pt;"> decrease was due to a $30.0&#160;million upfront payment under the AZ License Agreement related to INS1007 in October 2016 and a $3.7&#160;million decrease in expenses relating to INS1009. These decreases were partially offset by a $10.2 million increase in raw materials purchases and expenses related to the WILLOW trial for INS1007 and a </span><span style="font-family:inherit;font-size:10pt;">$5.4 million</span><span style="font-family:inherit;font-size:10pt;"> increase in compensation and related expenses due to an increase in headcount. There was also an increase of </span><span style="font-family:inherit;font-size:10pt;">$3.2 million</span><span style="font-family:inherit;font-size:10pt;"> due to increased regulatory, quality assurance and medical affairs consulting expenses and medical grants.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SG&amp;A Expenses</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SG&amp;A expenses for the year ended December&#160;31, 2017 and 2016 were comprised of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.84375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase (decrease)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and benefit related expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23,218</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,550</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,668</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,582</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,841</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(259</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional fees and other external expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30,700</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17,763</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,937</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Facility related and other internal expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,671</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,525</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,146</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">147.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total SG&amp;A expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79,171</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50,679</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28,492</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SG&amp;A expenses increased to </span><span style="font-family:inherit;font-size:10pt;">$79.2 million</span><span style="font-family:inherit;font-size:10pt;"> during the year ended December&#160;31, 2017 from </span><span style="font-family:inherit;font-size:10pt;">$50.7 million</span><span style="font-family:inherit;font-size:10pt;"> in the same period in 2016. The </span><span style="font-family:inherit;font-size:10pt;">$28.5 million</span><span style="font-family:inherit;font-size:10pt;"> increase was due to an increase of </span><span style="font-family:inherit;font-size:10pt;">$12.9 million</span><span style="font-family:inherit;font-size:10pt;"> in consulting fees relating to pre-commercial planning activities, primarily resulting from a one-time payment in October 2017 related to the buy-down of future royalties payable to PARI on the global net sales of ARIKAYCE, an increase of </span><span style="font-family:inherit;font-size:10pt;">$7.7 million</span><span style="font-family:inherit;font-size:10pt;"> due to higher compensation costs related to an increase in headcount, and an increase of </span><span style="font-family:inherit;font-size:10pt;">$8.1 million</span><span style="font-family:inherit;font-size:10pt;"> due to higher facility related expenses.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest Expense</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense was $5.9&#160;million during the year ended December&#160;31, 2017 as compared to $3.5&#160;million in the same period in 2016. The $2.4&#160;million increase in interest expense in 2017 relates primarily to an increase in our borrowings from Hercules Capital (Hercules) in September and October of 2016. We entered into an Amended and Restated Loan Agreement (A&amp;R Loan Agreement) with Hercules which increased our borrowing capacity by an additional $30.0&#160;million to an aggregate total of $55.0&#160;million. The increase in borrowings under the A&amp;R Loan Agreement was used to fund the upfront payment owed under the AZ License Agreement for the exclusive global rights to INS1007. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income tax (benefit) provision</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The income tax (benefit) provision was $(0.3) million and $0.1 million for the years ended December&#160;31, 2017 and 2016, respectively. The income tax (benefit) for the year ended December 31, 2017 reflects the reversal of the valuation allowance related to AMT that we paid in 2009. As a result of the Tax Act, we recorded a noncurrent receivable to reflect the tax amount due to us in future periods relating to a refund due for the prior AMT paid. In addition, the income tax (benefit) provision for the years ended December&#160;31, 2017 and 2016 reflects current income tax expense recorded as a result of taxable income in certain of our subsidiaries in Europe.</span></div><div><a id="s86ABDBDCD08854188BEFE78D6A342C35"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is considerable time and cost associated with developing potential pharmaceutical products to the point of regulatory approval and commercialization. We commenced commercial shipments of ARIKAYCE in October 2018, and to date, have not generated significant revenue from sales of ARIKAYCE. In recent years, we have funded our operations through public offerings of equity securities and debt financings. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, we completed an underwritten public offering of $450.0 million aggregate principal amount of Convertible Notes, including the exercise in full of the underwriter's option to purchase additional Convertible Notes. Our net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of </span><span style="font-family:inherit;font-size:10pt;">$14.2 million</span><span style="font-family:inherit;font-size:10pt;">, were </span><span style="font-family:inherit;font-size:10pt;">$435.8 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In&#160;September&#160;2017, we completed an underwritten public offering of&#160;</span><span style="font-family:inherit;font-size:10pt;">14,123,150</span><span style="font-family:inherit;font-size:10pt;">&#160;shares of our common stock, which included the underwriter&#8217;s exercise in full of its over-allotment option of&#160;</span><span style="font-family:inherit;font-size:10pt;">1,842,150</span><span style="font-family:inherit;font-size:10pt;"> shares, at a price to the public of&#160;</span><span style="font-family:inherit;font-size:10pt;">$28.50</span><span style="font-family:inherit;font-size:10pt;">&#160;per share.&#160; Our net proceeds from the sale of the shares, after deducting underwriting discounts and offering expenses of&#160;</span><span style="font-family:inherit;font-size:10pt;">$24.8 million</span><span style="font-family:inherit;font-size:10pt;">, were </span><span style="font-family:inherit;font-size:10pt;">$377.7 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to continue to incur operating losses both in our US and certain international entities, as we plan to fund research and development activities and commercial launch activities for ARIKAYCE. We may need to raise additional capital to fund our operations, including the continued commercialization of ARIKAYCE, future clinical trials related to ARIKAYCE, development of INS1007 and INS1009, and the potential development, acquisition, in-license or co-promotion of other products or product candidates that address orphan or rare diseases. We believe we currently have sufficient funds to meet our financial needs for at least the next 12&#160;months. We may opportunistically raise additional capital through equity or debt financing(s), strategic transactions or otherwise. We expect such additional funding, if any, would be used to continue to commercialize ARIKAYCE, to conduct further trials of ARIKAYCE, to develop our product candidates, or to pursue the license or purchase of other technologies or products or product candidates. In 2019, we plan to continue to support the commercial launch of ARIKAYCE in the US, to fund further clinical development of ARIKAYCE and INS1007, and support efforts to obtain regulatory approvals for ARIKAYCE outside the US. Our cash requirements in 2019 will be impacted by a number of factors, the most significant of which are expenses related to the commercialization efforts for ARIKAYCE, and to a lesser extent, expenses related to INS1007 and future ARIKAYCE clinical trials.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of </span><span style="font-family:inherit;font-size:10pt;">$495.1 million</span><span style="font-family:inherit;font-size:10pt;">, as compared with </span><span style="font-family:inherit;font-size:10pt;">$381.2 million</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">$113.9 million</span><span style="font-family:inherit;font-size:10pt;"> increase was due primarily to the net cash proceeds from our issuance of Convertible Notes in January 2018, partially offset by cash used in operating activities and, to a lesser extent, cash used in investing activities. Our working capital was </span><span style="font-family:inherit;font-size:10pt;">$439.2 million</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared with </span><span style="font-family:inherit;font-size:10pt;">$344.8 million</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities was </span><span style="font-family:inherit;font-size:10pt;">$258.0 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$159.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. The net cash used in operating activities during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was primarily for the pre-commercialization efforts and clinical activities related to ARIKAYCE, as well as general and administrative expenses. In addition, net cash used in operating activities during the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> included commercialization efforts and clinical trial expenses related to INS1007.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities was </span><span style="font-family:inherit;font-size:10pt;">$14.8 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$3.0 million</span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. The net cash used in investing activities during </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> was primarily related to the investment in our long-term production capacity build-out at Patheon. The net cash used in investing activities during </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was primarily related to the investment in our long-term production capacity build-out at Patheon and for the build out of our lab facility in Bridgewater, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">New Jersey. We expect our net cash used in investing activities will increase in 2019 as compared to 2018 as a result of our continuing investment in the build-out of Patheon and our new headquarters facility.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities was </span><span style="font-family:inherit;font-size:10pt;">$386.7 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$381.1 million</span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. Net cash provided by financing activities for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> included net cash proceeds of </span><span style="font-family:inherit;font-size:10pt;">$435.8 million</span><span style="font-family:inherit;font-size:10pt;"> from our issuance of Convertible Notes in January 2018 and cash proceeds from stock option exercises, partially offset by the February 2018 repayment of our outstanding debt to Hercules in the amount of $55.0 million. Net cash provided by financing activities during </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> included net cash proceeds of $377.7 million from our issuance of 14.1 million shares of common stock in September 2017 and cash proceeds received from stock option exercises.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, we completed an underwritten public offering of $450.0 million aggregate principal amount of Convertible Notes pursuant to an indenture between the Company and Wells Fargo Bank, National Association, as trustee. Our net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of </span><span style="font-family:inherit;font-size:10pt;">$14.2 million</span><span style="font-family:inherit;font-size:10pt;">, were approximately </span><span style="font-family:inherit;font-size:10pt;">$435.8 million</span><span style="font-family:inherit;font-size:10pt;">. The Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. The Convertible Notes are convertible into common stock of the Company under certain circumstances described in the indenture. For more information, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 7 - Debt</span><span style="font-family:inherit;font-size:10pt;"> in our notes to the consolidated financial statements. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have an operating lease for office and laboratory space located in Bridgewater, NJ, our corporate headquarters, for which the initial lease term expires in November 2019. Future minimum rental payments under this lease total approximately </span><span style="font-family:inherit;font-size:10pt;">$1.0 million</span><span style="font-family:inherit;font-size:10pt;">. In July 2016, we signed an operating lease for additional laboratory space located in Bridgewater, NJ, for which the initial lease term expires in September 2021, and in October 2018, the Company expanded this lease. Future minimum rental payments under this, and the initial lease, are </span><span style="font-family:inherit;font-size:10pt;">$3.3 million</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, we entered into an agreement (the Lease) with Exeter 700 Route 202/206, LLC to lease approximately 117,000 rentable square feet of office space located at 700 Route 202/206, Bridgewater, New Jersey for our future headquarters. Subject to certain conditions, we have the one-time option to expand the leased premises by up to 50,000 rentable square feet, exercisable prior to the fifth anniversary of the Commencement Date (as defined below). The Lease provides for a commencement date of the earlier of (1) September 1, 2019, subject to completion of certain improvements by specified dates, and (2) the date on which we take possession of the premises to commence its business operations therein (the Commencement Date). The initial Lease term runs 130 months from the Commencement Date (plus any partial month from the Commencement Date until the first day of the next full calendar month during the term) and we have the option to extend that term for up to three additional five-year periods. In addition, we are also responsible for operating expenses and taxes pursuant to the Lease. Future minimum payments under the Lease during the initial Lease Term are expected to approximate </span><span style="font-family:inherit;font-size:10pt;">$32.3 million</span><span style="font-family:inherit;font-size:10pt;">. The Lease contains customary default provisions, including those relating to payment defaults, performance defaults and events of bankruptcy.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2014, we entered into a contract manufacturing agreement with Therapure for the manufacture of ARIKAYCE, on a non-exclusive basis, at a 200 kg scale. Pursuant to the agreement, we collaborated with Therapure to construct a production area for the manufacture of ARIKAYCE in Therapure's existing manufacturing facility in Canada. The agreement has an initial term of five years from the first date on which Therapure delivers ARIKAYCE to us after we obtain permits related to the manufacture of ARIKAYCE, and will renew automatically for successive periods of two years each, unless terminated by either party by providing the required two years' prior written notice to the other party. Under the agreement, we are obligated to pay certain minimum amounts for the batches of ARIKAYCE produced each calendar year.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2015, we entered into a Commercial Fill/Finish Services Agreement (the Fill/Finish Agreement) with Althea, for Althea to produce, on a non-exclusive basis, ARIKAYCE in finished dosage form at a 50 kg scale. Under the Fill/Finish Agreement, we are obligated to pay a minimum of $2.7&#160;million for the batches of ARIKAYCE produced each calendar year during the term of the Fill/Finish Agreement.  The Fill/Finish Agreement became effective as of January&#160;1, 2015, and following an extension in 2018, the agreement remains in effect through December 31, 2021. The Fill/Finish Agreement may be extended for additional </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;">-year periods upon mutual written agreement of the Company and Althea at least </span><span style="font-family:inherit;font-size:10pt;">one year</span><span style="font-family:inherit;font-size:10pt;"> prior to the expiration of its then-current term.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently have a licensing agreement with PARI for the use of the optimized Lamira Nebulizer System for delivery of ARIKAYCE in treating patients with NTM lung infections, CF and bronchiectasis. Under the licensing agreement, we have rights under several US and foreign issued patents, and patent applications involving improvements to the optimized Lamira Nebulizer System, to exploit such system with ARIKAYCE for the treatment of such indications, but we cannot manufacture such nebulizers except as permitted under our Commercialization Agreement with PARI. Under the licensing </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">agreement, we paid PARI an upfront license fee and milestone payments. Upon FDA acceptance of our New Drug Application and the subsequent FDA approval of ARIKAYCE, we paid PARI additional milestone payments of &#8364;1.0 million and &#8364;1.5&#160;million, respectively. In addition, PARI is entitled to receive a future milestone payment of &#8364;0.5&#160;million in cash based on achievement of first receipt of marketing approval in a major EU country for ARIKAYCE and the device. In October 2017, we exercised an option to buy-down the royalties payable to PARI, which was included within selling, general and administrative expenses in the fourth quarter of 2017. PARI is now entitled to receive royalty payments in the mid-single digits on the annual global net sales of ARIKAYCE, pursuant to the licensing agreement, subject to certain specified annual minimum royalties.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2014, we entered into a Commercialization Agreement with PARI for the manufacture and supply of the Lamira Nebulizer Systems and related accessories (the Device) as optimized for use with ARIKAYCE. Under the Commercialization Agreement, PARI manufactures the Device except in the case of certain defined supply failures, when the Company will have the right to make the Device and have it made by third parties (but not certain third parties deemed under the Commercialization Agreement to compete with PARI). The Commercialization Agreement has an initial term of 15 years that began in October 2018 (the Initial Term). The term of the Commercialization Agreement may be extended by us for an additional five years by providing written notice to PARI at least one year prior to the expiration of the Initial Term.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, we entered into certain agreements with Patheon related to the increase of our long-term production capacity for ARIKAYCE. The agreements provide for Patheon to manufacture and supply ARIKAYCE for our anticipated commercial needs.&#160;Under these agreements, we are required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.&#160;Patheon's supply obligations will commence once certain technology transfer and construction services are completed. Our manufacturing and supply agreement with Patheon will remain in effect for a fixed initial term, after which it will continue for successive renewal terms unless either we or Patheon have given written notice of termination. The technology transfer agreement will expire when the parties agree that the technology transfer services have been completed. The agreements may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party&#8217;s insolvency. These early termination clauses may reduce the amounts due to the relevant parties. The investment in our long-term production capacity build-out, including under the Patheon agreements and related agreements or purchase orders with third parties for raw materials and fixed assets, is estimated to be approximately $60 million. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, future payments under our long-term debt agreements, minimum future payments under non-cancellable leases and minimum future payment obligations are as follows:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.6640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018<br/>Payments Due By Period</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Less than<br/>1 year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1&#160;-&#160;3 Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3&#160;-&#160;5 Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">More than 5 Years</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt obligations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">450,000</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">450,000</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51,209</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,875</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,750</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,750</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,834</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32,250</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">244</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,944</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,370</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,692</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,425</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,881</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,543</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86,383</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,029</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,579</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,650</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55,125</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total contractual obligations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">626,267</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,029</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35,816</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27,771</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">538,651</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This table does not include: (a)&#160;any milestone payments which may become payable to third parties under our license and collaboration agreements as the timing and likelihood of such payments are not known; (b)&#160;the royalty payments specified below, as the amounts of such payments, timing and/or the likelihood of such payments are not known; (c)&#160;contracts that are entered into in the ordinary course of business which are not material in the aggregate in any period presented above; and (d)&#160;any payments related to the agreements mentioned below.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into a services agreement with Syneos Health (Syneos) pursuant to which we retained Syneos to perform implementation and management services in connection with the WILLOW study. We may terminate the services agreement or any work order for any reason and without cause with 30&#160;days' written notice. Either party may terminate the agreement in the event of a material breach or bankruptcy petition by the other party or, if any approval from a regulatory authority is revoked, suspended or expires without renewal. We anticipate that aggregate costs relating to all work orders for the WILLOW study will be approximately $21 million over the period of the study.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2016, we entered into the AZ License Agreement, pursuant to which AstraZeneca granted us exclusive global rights for the purpose of developing and commercializing AZD7986 (which we renamed INS1007). In consideration of the licenses and other rights granted by AstraZeneca, we made an upfront payment of $30.0&#160;million, which was included as research and development expense in the fourth quarter of 2016. We are obligated to make a series of contingent milestone payments to AstraZeneca totaling up to an additional $85.0&#160;million upon the achievement of clinical development and regulatory filing milestones. If we elect to develop INS1007 for a second indication, we will be obligated to make an additional series of contingent milestone payments totaling up to $42.5&#160;million. We are not obligated to make any additional milestone payments for any additional indications. In addition, we have agreed to pay AstraZeneca tiered royalties ranging from a high single-digit to mid-teens on net sales of any approved product based on INS1007 and one additional payment of $35.0&#160;million upon the first achievement of $1&#160;billion in annual net sales. The AZ License Agreement provides AstraZeneca with the option to negotiate a future agreement with us for commercialization of INS1007 in chronic obstructive pulmonary disease or asthma.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2014, we entered into a services agreement with SynteractHCR,&#160;Inc. (Synteract) pursuant to which we retained Synteract to perform implementation and management services in connection with the CONVERT study. We anticipate that aggregate costs relating to all work orders for the CONVERT&#160;study will be approximately $48&#160;million over the period of the study. In April 2015, we entered into a work order with Synteract to perform implementation and management services for the completed 312&#160;study. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2004 and 2009, we entered into research funding agreements with Cystic Fibrosis Foundation Therapeutics,&#160;Inc. (CFFT) whereby we received $1.7&#160;million and $2.2&#160;million for each respective agreement in research funding for the development of ARIKAYCE. If ARIKAYCE becomes an approved product for certain infections in CF patients or such infections in human pulmonary disease in the US, we will owe a payment to CFFT of up to $13.4&#160;million that is payable over a three-year period after regulatory approval in the US. Furthermore, if certain global sales milestones are met within five years of the drug's commercialization, we would owe additional payments of $3.9&#160;million. Because there is significant development and regulatory risk associated with ARIKAYCE, including with respect to the CF indication, we have not accrued these obligations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Future Funding Requirements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may need to raise additional capital to fund our operations, including the continued commercialization of ARIKAYCE, future clinical trials related to ARIKAYCE, development of INS1007 and INS1009, and the potential development, acquisition, in-license or co-promotion of other products or product candidates that address orphan or rare diseases. We expect that our future capital requirements may be substantial and will depend on many factors, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing and cost of our future clinical trials of ARIKAYCE for the treatment of patients with NTM lung infections;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the decisions of the EMA, MHLW and PMDA with respect to our applications for marketing approval of ARIKAYCE in Europe and Japan; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs of activities related to the regulatory approval process and the timing of approvals, if received;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of supporting the sales and marketing efforts necessary to support the continued commercial efforts of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of filing, prosecuting, defending, and enforcing patent claims;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing and cost of our anticipated clinical trials, including INS1007 and the related milestone payments due to AstraZeneca;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs of our manufacturing-related activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs associated with commercializing ARIKAYCE outside the US, if approved; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">subject to receipt of marketing approval, the levels, timing and collection of revenue received from sales of approved products, if any, in the future.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have raised $813.5 million in net proceeds from securities offerings since September 2017. We believe we currently have sufficient funds to meet our financial needs for at least the next 12&#160;months. However, our business strategy may require us to raise additional capital at any time through equity or debt financing(s), strategic transactions or otherwise.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have any off-balance sheet arrangements, other than operating leases, that have or are reasonably likely to have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We do not have any interest in special purpose entities, structured finance entities or other variable interest entities.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s7E91C45D0F075A0E936D54DDFE982ADB"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CRITICAL ACCOUNTING POLICIES</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preparation of financial statements in accordance with generally accepted accounting principles in the US requires us to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues and expenses and the disclosures of contingent assets and liabilities. We use our historical experience and other relevant factors when developing our estimates and assumptions. We continually evaluate these estimates and assumptions. The amounts of assets and liabilities reported in our consolidated balance sheets and the amounts reported in our consolidated statements of comprehensive loss are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue recognition, research and development, stock-based compensation, inventory, identifiable intangible assets, and accrued expenses. The accounting policies discussed below are considered critical to an understanding of our consolidated financial statements because their application involves the most significant judgment. Actual results could differ materially from our estimates. For additional accounting policies, see Note&#160;2 to our Consolidated Financial Statements&#8212;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with Accounting Standards Codification 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (</span><span style="font-family:inherit;font-size:10pt;">ASC 606), we recognize revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration we expect to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, we perform the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, we assess the goods or services promised within each contract and determine those that are distinct performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, we have identified one performance obligation: the delivery of ARIKAYCE to our customers. We did not incur or capitalize any incremental costs associated with obtaining contracts with customers.</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenues consist primarily of sales of ARIKAYCE in the US. Product revenues are recognized once we perform all five steps mentioned above. In October 2018, we began shipping ARIKAYCE to our customers in the US, which include specialty pharmacies and specialty distributors.&#160;We recognize revenues for product received by our customers net of allowances for customer credits, including estimated rebates, chargebacks, prompt pay discounts, returns, service fees, and government rebates, such as Medicaid rebates and Medicare Part D coverage gap reimbursements in the US.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Customer credits:&#160;</span><span style="font-family:inherit;font-size:10pt;">Our customers are offered various forms of consideration, including service fees and prompt payment discounts. We anticipate that our customers will earn prompt payment discounts and, therefore, deduct the full amount of these discounts from total gross product revenues when revenues are recognized. Service fees are also deducted from total gross product revenues as they are earned.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Rebates: </span><span style="font-family:inherit;font-size:10pt;">We contract with Medicaid, other government agencies and various private organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. We estimate the rebates we will provide to third-party payors and deduct these estimated amounts from total gross product revenues at the time the revenues are recognized.</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-bottom:17px;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Chargebacks:</span><span style="font-family:inherit;font-size:10pt;"> Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from our specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to us the difference between the price they initially paid and the discounted price paid by the contracted customers. We estimate the chargebacks provided to the specialty distributor and deduct these estimated amounts from gross product revenues at the time revenues are recognized.</span></div><div style="line-height:120%;padding-bottom:17px;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Co-payment assistance:</span><span style="font-family:inherit;font-size:10pt;"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by a third-party administrator.</span></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any, or all, of our actual experience vary from the estimates above, we may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, upon US FDA approval of ARIKAYCE, we began recognizing revenue from sales under an ATU program in France. Pursuant to this program, we ship product to pharmacies after receiving requests from physicians for patients in France. We are initiating expanded access programs (EAPs) in Europe and other countries, some of which may be </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fully reimbursed. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses consist of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our research and development functions, including medical affairs. Expenses also include other internal operating expenses, the cost of manufacturing our drug candidate(s)&#160;for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, our R&amp;D expenses include payments to third parties for the license rights to products in development (prior to marketing approval), such as for INS1007. Our expenses related to manufacturing our drug candidate(s)&#160;for clinical study are primarily related to activities at CMOs that manufacture our product candidates for our use, including purchases of active pharmaceutical ingredients. Our expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on our behalf.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since 2011, we have focused our development activities principally on our proprietary, advanced technologies designed specifically for inhaled therapies. Our development efforts in 2018 and 2017 principally related to the development of ARIKAYCE in NTM lung disease.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize stock-based compensation expense for awards of equity instruments to employees and directors based on the grant-date fair value of those awards. The grant-date fair value of the award is recognized as compensation expense ratably over the requisite service period, which generally equals the vesting period of the award, and if applicable, is adjusted for expected forfeitures. We also grant performance-based stock options to employees. The grant-date fair value of the performance-based stock options is recognized as compensation expense over the implicit service period using the accelerated attribution method once it is probable that the performance condition will be achieved. Stock-based compensation expense is included in both R&amp;D expenses and SG&amp;A expenses in the consolidated statements of comprehensive loss.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the assumptions used in determining the fair value of stock options granted during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66% - 68%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71% - 79%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74% - 77%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25% - 2.96%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.73% - 2.13%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.00% - 1.90%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.0%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.0%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.0%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected option term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.09</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.25</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.25</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, the volatility factor was based on our historical volatility during the expected term or since the closing of our merger with Transave,&#160;Inc. in December 2010. The risk-free interest rate is based on the US Treasury yield in effect at the date of grant. Estimated forfeitures were based on the actual percentage of option forfeitures since the closing of the Company&#8217;s merger with Transave, Inc. in December&#160;2010 for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">. Beginning with the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, estimated forfeitures were based on the actual percentage of option forfeitures over the expected option term.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued Expenses</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are required to estimate accrued expenses as part of our process of preparing financial statements. This process involves estimating the level of service performed on our behalf and the associated cost incurred in instances where we have not been invoiced or otherwise notified of actual costs. Examples of areas in which subjective judgments may be required include costs associated with services provided by contract organizations for preclinical development, clinical trials and manufacturing of clinical materials. We accrue for expenses associated with these external services by determining the total cost of a given study based on the terms of the related contract as the services are being provided by monitoring the status of the trials and the invoices received from our external service providers. In the case of clinical trials, the estimated cost normally relates to the projected costs of having subjects enrolled in our trials, which we recognize over the estimated term of the trial according to the number of subjects enrolled in the trial on an ongoing basis, beginning with subject enrollment. As actual costs become known to us, we adjust our accruals. To date, the number of clinical trials and related research service agreements has been relatively limited and our estimates have not differed significantly from the actual costs incurred.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">New Accounting Pronouncements&#8212;Adopted</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</span><span style="font-family:inherit;font-size:10pt;">, which addressed eight specific cash flow issues with the objective of reducing the existing diversity in practice. Among the updates, the standard requires debt extinguishment costs to be classified as cash outflows for financing activities. This standard update became effective as of the first quarter of 2018. As a result of the adoption of the standard, in the first quarter of 2018, the Company reported a </span><span style="font-family:inherit;font-size:10pt;">$2.2 million</span><span style="font-family:inherit;font-size:10pt;"> loss on extinguishment of debt in the financing activities section of its consolidated statement of cash flows. The Company had no material debt extinguishment costs prior to the first quarter of 2018. The impact of adopting this standard was not material to the Company.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic&#160;606)</span><span style="font-family:inherit;font-size:10pt;"> which amended the then-existing accounting standards for revenue recognition. ASU 2014-09 establishes principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services. In July 2015, the FASB deferred the effective date for annual reporting periods beginning after December&#160;15, 2017. We adopted ASU 2014-09 in the first quarter of 2018 and the impact of adopting the standard was not material to our consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements&#8212;Not Yet Adopted</span></div><div style="line-height:120%;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018 (including interim periods within those periods) and early adoption is permitted. In August 2018, the FASB issued ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements to ASC 842</span><span style="font-family:inherit;font-size:10pt;">, which provides a new transition option in which an entity initially applies ASU 2016-02 at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. We will use the new transition option and will be also utilizing the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any expired or existing leases. We will also use the short-term lease exception for leases with a term of twelve months or less. Additionally, we expect to use the practical expedient that allows us to treat the lease and non-lease components of our leases as a single component. We have identified approximately ten leasing arrangements and estimate the impact on our consolidated balance sheet to be approximately </span><span style="font-family:inherit;font-size:10pt;">$44.0 million</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">$49.0 million</span><span style="font-family:inherit;font-size:10pt;">. There will be no adjustment recognized through retained earnings as a result of adoption. We will adopt ASU 2016-02 effective January 1, 2019, and we are continuing to evaluate the impact of adoption on our consolidated financial statements and our internal control over financial reporting. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses</span><span style="font-family:inherit;font-size:10pt;"> which requires financial assets measured at an amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. ASU 2016-13 is effective for fiscal years effective for fiscal years after beginning after December 15, 2019. Different aspects of the guidance require modified retrospective or prospective adoption. We are currently evaluating the impact of adoption on our consolidated financial statements. </span></div><div><a id="s4C216FA74F54515AAEE1544CD69745C7"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, our cash and cash equivalents were in cash accounts or were invested in US treasury bills and money market funds. Our investments in US treasury bills and money market funds are not insured by the federal government.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had $450.0&#160;million of Convertible Notes outstanding which bear interest at a coupon rate of 1.75%. If a 10% change in interest rates had occurred on </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, it would not have had a material effect on the fair value of our debt as of that date, nor would it have had a material effect on our future earnings or cash flows.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of our business is conducted in US dollars. However, we do conduct certain transactions in other currencies, including Euros, British Pounds and Japanese Yen. Historically, fluctuations in foreign currency exchange rates have not materially affected our results of operations. During the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, our results of operations were not materially affected by fluctuations in foreign currency exchange rates.</span></div><div><a id="s533E4FE3B91B51CD9E999DF759F2B413"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by Item&#160;8 is included in our Financial Statements and Supplementary Data set forth in Item&#160;15 of Part&#160;IV of this Annual Report on Form 10-K.</span></div><div><a id="s7F3D6B907EE257DE849A50760EDA458B"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><a id="s0551798FB7305FB2B557B11969AAADB9"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">. The term "disclosure controls and procedures," as defined in Rules&#160;13a-15(e) and 15d- 15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act) means controls and other procedures that are designed to provide reasonable assurance that information required to be disclosed by us in the periodic reports that we file or submit with the SEC is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on that evaluation, as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Management's Report on Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule&#160;13a-15(f) and 15d-15(f) under the Exchange Act , as a process designed by, or under the supervision of, our principal executive and principal financial and accounting officers and effected by our board of directors and management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with US generally accepted accounting principles, and that receipts and expenditures of our company are being made only in accordance with authorizations of our management and board of directors; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Our management assessed the effectiveness of our internal control over financial reporting as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#8212;Integrated Framework. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company's annual or interim financial statements will not be prevented or detected on a timely basis. Based on management's assessment, management concluded that the Company's internal control over financial reporting was effective as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2018, we implemented processes and internal controls to record product revenue, cost of product revenues, and inventory as a result of the FDA approval and the US commercial launch of ARIKAYCE. The implementation of these processes resulted in material changes to our internal controls over financial reporting. There were no other changes in our internal controls over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the year ended December 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Attestation Report on Internal Control over Financial Reporting</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ernst&#160;&amp; Young&#160;LLP, our independent registered public accounting firm, issued an attestation report on our internal control over financial reporting. The report of Ernst&#160;&amp; Young&#160;LLP is contained in Item&#160;15 of Part&#160;IV of this Annual Report on Form&#160;10-K.</span></div><div><a id="s465C90B6D44C5FB59BECA0774B418A12"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF72FB7CA185E5C7794C3D46C52F3D858"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</span></div><div><a id="s39FE7D9D2F2E5A42B782B18698E8A5E5"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by Item&#160;10 of Form&#160;10-K is incorporated by reference from the discussion responsive thereto under the captions </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Election of Class I Directors, Corporate Governance</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Section&#160;16(a) Beneficial Ownership Reporting Compliance</span><span style="font-family:inherit;font-size:10pt;"> in our definitive proxy statement for our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> annual meeting of shareholders to be filed with the SEC no later than 120&#160;days after the close of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div><a id="s5A591F8011D3511E9E2FB471ED187E82"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by Item&#160;11 of Form&#160;10-K is incorporated by reference from the discussion responsive thereto under the captions </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation Discussion and Analysis</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation Committee Report</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation Committee Interlocks and Insider Participation</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Director Compensation</span><span style="font-family:inherit;font-size:10pt;"> in our definitive proxy statement for our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> annual meeting of shareholders to be filed with the SEC no later than 120&#160;days after the close of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div><a id="s1B7BF7C314115F75AF363E2AD72AA74A"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by Item&#160;12 of Form&#160;10-K is incorporated by reference from the discussion responsive thereto under the captions </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation Discussion and Analysis</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Security Ownership of Certain Beneficial Owners, Directors and Management</span><span style="font-family:inherit;font-size:10pt;"> in our definitive proxy statement for our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> annual meeting of shareholders to be filed with the SEC no later than 120&#160;days after the close of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div><a id="s38C09CAB1C1F5698BEBAD2C4E9A59CBF"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by Item&#160;13 of Form&#160;10-K is incorporated by reference from the discussion responsive thereto under the captions </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Election of Class&#160;I Directors</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Certain Relationships and Related Transactions</span><span style="font-family:inherit;font-size:10pt;"> in our definitive proxy statement for our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> annual meeting of shareholders to be filed with the SEC no later than 120&#160;days after the close of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div><a id="sE27E7690A517590FA6890506E0C74BF2"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information required by Item&#160;14 of Form&#160;10-K is incorporated by reference from the discussion responsive thereto under the caption </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Corporate Governance</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Ratification of the Appointment of Independent Registered Public Accounting Firm</span><span style="font-family:inherit;font-size:10pt;"> in our definitive proxy statement for our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> annual meeting of shareholders to be filed with the SEC no later than 120&#160;days after the close of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE9B46AB1484F5A688E0EFFFB0640645F"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</span></div><div><a id="s8475B346D90B5B4BACE23D6F37AC86DF"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Documents filed as part of this report.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160; FINANCIAL STATEMENTS</span><span style="font-family:inherit;font-size:10pt;">. The following consolidated financial statements of the Company are set forth herein, beginning on </span><a style="font-family:inherit;font-size:10pt;" href="#s4586AA1A06475DF8820A58C06C3C5DD9"><span style="font-family:inherit;font-size:10pt;">page&#160;76</span></a><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;padding-top:8px;text-indent:0px;"><span style="padding-bottom:8px;padding-top:8px;font-family:inherit;font-size:10pt;padding-right:48px;">(i)</span><span style="font-family:inherit;font-size:10pt;">Reports of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;padding-top:8px;text-indent:0px;"><span style="padding-bottom:8px;padding-top:8px;font-family:inherit;font-size:10pt;padding-right:48px;">(ii)</span><span style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;padding-top:8px;text-indent:0px;"><span style="padding-bottom:8px;padding-top:8px;font-family:inherit;font-size:10pt;padding-right:48px;">(iii)</span><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Comprehensive Loss for the Years Ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;padding-top:8px;text-indent:0px;"><span style="padding-bottom:8px;padding-top:8px;font-family:inherit;font-size:10pt;padding-right:48px;">(iv)</span><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Shareholders' Equity for the Years Ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;padding-top:8px;text-indent:0px;"><span style="padding-bottom:8px;padding-top:8px;font-family:inherit;font-size:10pt;padding-right:48px;">(v)</span><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows for the Years Ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;padding-top:8px;text-indent:0px;"><span style="padding-bottom:8px;padding-top:8px;font-family:inherit;font-size:10pt;padding-right:48px;">(vi)</span><span style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;FINANCIAL STATEMENT SCHEDULES.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None required.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;EXHIBITS.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The exhibits that are required to be filed or incorporated by reference herein are listed in the Exhibit Index.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sA10B486405F75EC1B66CF7411D10F0E2"></a></div><div style="line-height:120%;padding-bottom:20px;padding-top:10px;text-align:center;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000114036113012797/ex3_1.htm"><span style="font-family:inherit;font-size:10pt;">3.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Articles of Incorporation of Insmed Incorporated, as amended through June&#160;14, 2012 (incorporated by reference from Exhibit&#160;3.1 to Insmed Incorporated's Annual Report on Form&#160;10-K filed on March&#160;18, 2013 (SEC file no. 000-30739)).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465915056784/a15-12110_1ex3d1.htm"><span style="font-family:inherit;font-size:10pt;">3.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amended and Restated Bylaws of Insmed Incorporated (incorporated by reference from Exhibit&#160;3.1 to Insmed Incorporated's Quarterly Report on Form&#160;10-Q filed on August&#160;6, 2015).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000091664100000328/0000916641-00-000328.txt"><span style="font-family:inherit;font-size:10pt;">4.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Specimen stock certificate representing common stock, $0.01 par value per share, of the Registrant (incorporated by reference from Exhibit&#160;4.2 to Insmed Incorporated's Registration Statement on Form&#160;S-4/A (Registration No.&#160;333-30098) filed on March&#160;24, 2000).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465918004153/a18-3168_7ex4d1.htm"><span style="font-family:inherit;font-size:10pt;">4.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indenture, dated as of January 26, 2018, by and between the Company and Wells Fargo Bank, National Association (incorporated by reference from Exhibit 4.1 to Insmed Incorporated&#8217;s Current Report on Form 8-K filed on January 26, 2018).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465918004153/a18-3168_7ex4d2.htm"><span style="font-family:inherit;font-size:10pt;">4.3</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">First Supplemental Indenture, dated as of January 26, 2018, by and between the Company and Wells Fargo Bank, National Association (incorporated by reference from Exhibit 4.2 to Insmed Incorporated&#8217;s Current Report on Form 8-K filed on January 26, 2018).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465918004153/a18-3168_7ex4d2.htm"><span style="font-family:inherit;font-size:10pt;">4.4</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form of 1.75% Convertible Senior Note due 2025 (included in Exhibit 4.3).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465913037892/a13-10493_1ex10d3.htm"><span style="font-family:inherit;font-size:10pt;">10.1**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Insmed Incorporated Amended and Restated 2000 Stock Incentive Plan (incorporated by reference from Exhibit&#160;10.3 to Insmed Incorporated's Form&#160;10-Q filed on May&#160;8, 2013 (SEC file no. 000-30739)).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465913044678/a13-12881_1ex99d1.htm"><span style="font-family:inherit;font-size:10pt;">10.2**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Insmed Incorporated 2013 Incentive Plan (incorporated by reference from Exhibit&#160;99.1 to Insmed Incorporated's Registration Statement on Form&#160;S-8 filed on May&#160;24, 2013 (SEC file no. 333-188852)).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465915041594/a15-12882_1ex99d1.htm"><span style="font-family:inherit;font-size:10pt;">10.3**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Insmed Incorporated 2015 Incentive Plan (incorporated by reference from Exhibit&#160;99.1 to Insmed Incorporated's Registration Statement on Form&#160;S-8 filed on May&#160;28, 2015).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d3.htm"><span style="font-family:inherit;font-size:10pt;">10.4**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Insmed Incorporated 2017 Incentive Plan (incorporated by reference from Exhibit 10.3 to Insmed Incorporated&#8217;s Form 10-Q filed August 3, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746914001864/a2218603zex-10_3.htm"><span style="font-family:inherit;font-size:10pt;">10.5**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form of Award Agreement for Restricted Stock Units issued to employees pursuant to the Insmed Incorporated 2013 Incentive Plan (incorporated by reference from Exhibit&#160;10.3 to Insmed Incorporated's Form&#160;10-K filed on March&#160;6, 2014).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746914001864/a2218603zex-10_4.htm"><span style="font-family:inherit;font-size:10pt;">10.6**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form of Award Agreement for Restricted Stock Units issued to directors pursuant to the Insmed Incorporated 2013 Incentive Plan (incorporated by reference from Exhibit&#160;10.4 to Insmed Incorporated's Form&#160;10-K filed on March&#160;6, 2014).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917029170/a17-8848_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.7**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form of Award Agreement for Restricted Stock Units issued to directors pursuant to the Insmed Incorporated 2015 Incentive Plan (incorporated by reference from Exhibit 10.1 to Insmed Incorporated&#8217;s Form 10-Q filed May 3, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d4.htm"><span style="font-family:inherit;font-size:10pt;">10.8**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form of Restricted Unit Award Agreement under the Insmed Incorporated 2017 Incentive Plan (incorporated by reference from Exhibit 10.4 to Insmed Incorporated&#8217;s Form 10-Q filed August 3, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746914001864/a2218603zex-10_5.htm"><span style="font-family:inherit;font-size:10pt;">10.9**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form of Award Agreement for an Incentive Stock Option pursuant to the Insmed Incorporated 2013 Incentive Plan (incorporated by reference from Exhibit&#160;10.5 to Insmed Incorporated's Form&#160;10-K filed on March&#160;6, 2014).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746914001864/a2218603zex-10_6.htm"><span style="font-family:inherit;font-size:10pt;">10.10**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form of Award Agreement for a Non-Qualified Stock Option pursuant to the Insmed Incorporated 2013 Incentive Plan (incorporated by reference from Exhibit&#160;10.6 to Insmed Incorporated's Form&#160;10-K filed on March&#160;6, 2014).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917029170/a17-8848_1ex10d2.htm"><span style="font-family:inherit;font-size:10pt;">10.11**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form of Award Agreement for a Non-Qualified Stock Option pursuant to the Insmed Incorporated 2015 Incentive Plan (incorporated by reference from Exhibit 10.2 to Insmed Incorporated&#8217;s Form 10-Q filed May 3, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d5.htm"><span style="font-family:inherit;font-size:10pt;">10.12**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form of Non-Qualified Stock Option Agreement pursuant to the Insmed Incorporated 2017 Incentive Plan (incorporated by reference from Exhibit 10.5 to Insmed Incorporated&#8217;s Form 10-Q filed August 3, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d6.htm"><span style="font-family:inherit;font-size:10pt;">10.13**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form of Non-Qualified Stock Option Inducement Award Agreement pursuant to the Insmed Incorporated 2017 Incentive Plan (incorporated by reference from Exhibit 10.6 to Insmed Incorporated&#8217;s Form 10-Q filed August 3, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000114036112040054/ex10_1.htm"><span style="font-family:inherit;font-size:10pt;">10.14**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employment Agreement, effective as of September&#160;10, 2012, between Insmed Incorporated and William Lewis (incorporated by reference from Exhibit&#160;10.1 to Insmed Incorporated's Current Report on Form&#160;8-K filed on September&#160;11, 2012).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746916010395/a2227323zex-10_141.htm"><span style="font-family:inherit;font-size:10pt;">10.15*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License agreement, dated April&#160;25, 2008, between Transave,&#160;Inc. and PARI Pharma&#160;GmbH, and Amendments No.&#160;1-4 thereto (incorporated by reference from Exhibit&#160;10.22 to Insmed Incorporated's Annual Report on Form&#160;10-K filed on March&#160;18, 2013).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746916010395/a2227323zex-10_141.htm"><span style="font-family:inherit;font-size:10pt;">10.15.1*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amendment No.&#160;5 to License Agreement between Insmed&#160;Incorporated and PARI Pharma&#160;GmbH, effective as of October&#160;5, 2015 (incorporated by reference from Exhibit&#160;10.14.1 to Insmed Incorporated's Annual Report on Form&#160;10-K filed on February&#160;25, 2016).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746916010395/a2227323zex-10_142.htm"><span style="font-family:inherit;font-size:10pt;">10.15.2*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amendment No.&#160;6 to License Agreement between Insmed&#160;Incorporated and PARI Pharma&#160;GmbH, effective as of October&#160;9, 2015 (incorporated by reference from Exhibit&#160;10.14.2 to Insmed Incorporated's Annual Report on Form&#160;10-K filed on February&#160;25, 2016).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746916010395/a2227323zex-10_142.htm"><span style="font-family:inherit;font-size:10pt;">10.15.3*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amendment No. 7 to License Agreement between Insmed Incorporated and PARI Pharma GmbH, effective as of July 21, 2017 (incorporated by reference from Exhibit 10.1 to Insmed Incorporated&#8217;s Form 10-Q filed on November 2, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="insm-20181231xex10154.htm"><span style="font-family:inherit;font-size:10pt;">10.15.4*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amendment No. 8 to License Agreement between Insmed Incorporated and PARI Pharma GmbH, effective as of December 19, 2018 (filed herewith).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465913080816/a13-19824_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.16**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employment Agreement, effective as of July&#160;29, 2013, between Insmed Incorporated and Christine Pellizzari (incorporated by reference from Exhibit&#160;10.1 to Insmed Incorporated's Form&#160;10-Q filed on November&#160;5, 2013 (SEC file no. 000-30739)).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465913080816/a13-19824_1ex10d2.htm"><span style="font-family:inherit;font-size:10pt;">10.17**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Insmed Incorporated Senior Executive Bonus Plan (incorporated by reference from Exhibit&#160;10.2 to Insmed Incorporated's Form&#160;10-Q filed on November&#160;5, 2013).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465914000364/a13-25887_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.18</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease, dated December&#160;31, 2013, between Denver Road,&#160;LLC and Insmed Incorporated (incorporated by reference from Exhibit&#160;10.1 to Insmed Incorporated's Current Report on  Form&#160;8-K filed on January&#160;3, 2014 (SEC file no. 000-30739)).</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746916010395/a2227323zex-10_171.htm"><span style="font-family:inherit;font-size:10pt;">10.18.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">First Amendment to Lease, dated April&#160;29, 2014, between Denver Road,&#160;LLC and Insmed Incorporated (incorporated by reference from Exhibit&#160;10.17.1 to Insmed Incorporated's Annual Report on Form&#160;10-K filed on February&#160;25, 2016).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746916010395/a2227323zex-10_172.htm"><span style="font-family:inherit;font-size:10pt;">10.18.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Second Amendment to Lease, dated November&#160;20, 2015, between Denver Road,&#160;LLC and Insmed Incorporated (incorporated by reference from Exhibit&#160;10.17.2 to Insmed Incorporated's Annual Report on Form&#160;10-K filed on February&#160;25, 2016).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465914002807/a14-3554_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.19</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Form of Indemnification Agreement entered into with each of the Company's directors and officers (incorporated by reference from Exhibit&#160;10.1 to Insmed Incorporated's Current Report on Form&#160;8-K filed on January&#160;16, 2014 (SEC file no. 000-30739)).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465914036103/a14-9766_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.20*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract Manufacturing Agreement, dated February&#160;7, 2014, between Insmed Incorporated and Therapure Biopharma&#160;Inc. (incorporated by reference from Exhibit&#160;10.1 to Insmed Incorporated's Form&#160;10-Q filed on May&#160;8, 2014).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465914036103/a14-9766_1ex10d2.htm"><span style="font-family:inherit;font-size:10pt;">10.21*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amending Agreement, dated March&#160;13, 2014, between Insmed Incorporated and Therapure Biopharma&#160;Inc. (incorporated by reference from Exhibit&#160;10.2 to Insmed Incorporated's Form&#160;10-Q filed on May&#160;8, 2014).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465914077304/a14-19864_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.22*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercialization Agreement dated July&#160;8, 2014 between Insmed Incorporated and PARI Pharma&#160;GmbH (incorporated by reference from Exhibit&#160;10.1 to Insmed Incorporated's Form&#160;10-Q filed on November&#160;6, 2014).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465914077304/a14-19864_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.22.1*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amendment No. 1 to Commercialization Agreement between Insmed Incorporated and PARI Pharma GmbH, effective as of July 21, 2017 (incorporated by reference from Exhibit 10.2 to Insmed Incorporated&#8217;s Form 10-Q filed on November 2, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746915001346/a2222985zex-10_29.htm"><span style="font-family:inherit;font-size:10pt;">10.25*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Master Agreement for Services, dated as of August&#160;27, 2014, by and between Insmed Incorporated and SynteractHCR,&#160;Inc. (incorporated by reference from Exhibit&#160;10.29 to Insmed Incorporated's Form&#160;10-K filed on February&#160;27, 2015).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746915001346/a2222985zex-10_30.htm"><span style="font-family:inherit;font-size:10pt;">10.26*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work Order 1, dated as of December&#160;30, 2014, by and between Insmed Incorporated and SynteractHCR,&#160;Inc. (incorporated by reference from Exhibit&#160;10.30 to Insmed Incorporated's Form&#160;10-K filed on February&#160;27, 2015).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465916136806/a16-11538_1ex10d2.htm"><span style="font-family:inherit;font-size:10pt;">10.27*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in Scope 1 to Work Order 1, dated as of May&#160;27, 2016, by and between Insmed Incorporated and SynteractHCR,&#160;Inc. (incorporated by reference from Exhibit&#160;10.2 to Insmed Incorporated's Form&#160;10-Q filed August&#160;4, 2016).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465915035191/a15-7891_1ex10d2.htm"><span style="font-family:inherit;font-size:10pt;">10.28**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employment Agreement, effective as of January&#160;2, 2013, between Insmed Incorporated and S. Nicole Schaeffer (incorporated by reference from Exhibit&#160;10.2 to Insmed Incorporated's Form&#160;10-Q filed on May&#160;7, 2015).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465915076446/a15-18005_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.29*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial Fill/Finish Services Agreement between Insmed Incorporated and Ajinomoto Althea,&#160;Inc., dated as of September&#160;15, 2015 (incorporated by reference from Exhibit&#160;10.1 to Insmed Incorporated's Form&#160;10-Q filed November&#160;6, 2015).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465915076446/a15-18005_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.29.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Extension of Commercial Fill/Finish Services Agreement between Insmed Incorporated and Ajinomoto Althea,&#160;Inc., dated as of November&#160;30, 2016 (incorporated by reference from Exhibit 10.30 to Insmed Incorporated&#8217;s Form 10-K filed February 23, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="insm-20181231xex10292.htm"><span style="font-family:inherit;font-size:10pt;">10.29.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Extension of Commercial Fill/Finish Services Agreement between Insmed Incorporated and Ajinomoto Althea, Inc., dated as of December 18, 2018 (filed herewith).</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465916136806/a16-11538_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.30</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease Agreement, effective as of July&#160;1, 2016, by and between Insmed Incorporated and CIP II/AR Bridgewater Holdings,&#160;LLC (incorporated by reference from Exhibit&#160;10.1 to Insmed Incorporated's Form&#160;10-Q filed August&#160;4, 2016).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465916154364/a16-17150_1ex10d2.htm"><span style="font-family:inherit;font-size:10pt;">10.31**</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employment Agreement, effective as of September&#160;27, 2016, between Insmed Incorporated and Roger Adsett (incorporated by reference from Exhibit&#160;10.2 to Insmed Incorporated's Form&#160;10-Q filed November&#160;3, 2016).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746917000856/a2230968zex-10_29.htm"><span style="font-family:inherit;font-size:10pt;">10.32*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License Agreement, dated October&#160;4, 2016, between Insmed Incorporated and AstraZeneca AB (incorporated by reference from Exhibit 10.29 to Insmed Incorporated&#8217;s Form 10-K filed February 23, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746917000856/a2230968zex-10_31.htm"><span style="font-family:inherit;font-size:10pt;">10.33</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amendment to Employment Agreement, effective as of September&#160;26, 2016, between Insmed Incorporated and Christine Pellizzari (incorporated by reference from Exhibit 10.31 to Insmed Incorporated&#8217;s Form 10-K filed February 23, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746917000856/a2230968zex-10_32.htm"><span style="font-family:inherit;font-size:10pt;">10.34</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amendment to Employment Agreement, effective as of September&#160;26, 2016, between Insmed Incorporated and S. Nicole Schaeffer (incorporated by reference from Exhibit 10.32 to Insmed Incorporated&#8217;s Form 10-K filed February 23, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.35</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employment Agreement, effective as of June 1, 2017, between Insmed Incorporated and Paolo Tombesi (incorporated by reference from Exhibit 10.1 to Insmed Incorporated&#8217;s Form 10-Q filed August 3, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d2.htm"><span style="font-family:inherit;font-size:10pt;">10.36</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employment Agreement, effective as of June 1, 2017, between Insmed Incorporated and Paul D. Streck (incorporated by reference from Exhibit 10.2 to Insmed Incorporated&#8217;s Form 10-Q filed August 3, 2017).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450618000002/insm-20171231xex1039.htm"><span style="font-family:inherit;font-size:10pt;">10.37*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing and Supply Agreement between Insmed Incorporated and Patheon UK Limited, dated as of October&#160;20, 2017 (incorporated by reference from Exhibit 10.39 to Insmed Incorporated's Form 10-K filed February 23, 2018).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450618000002/insm-20171231xex1040.htm"><span style="font-family:inherit;font-size:10pt;">10.38*</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology Transfer Agreement between Insmed Incorporated and Patheon UK Limited, dated as of October&#160;20, 2017 (incorporated by reference from Exhibit 10.39 to Insmed Incorporated's Form 10-K filed February 23, 2018).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465918057228/a18-29057_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.39</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease Agreement, dated September 11, 2018, by and between Insmed Incorporated and Exeter 700 Route 202/206, LLC (incorporated by reference from Exhibit 10.1 to Insmed Incorporated&#8217;s Current Report on Form 8-K filed on September 17, 2018).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="insm-20181231xex211.htm"><span style="font-family:inherit;font-size:10pt;">21.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subsidiaries of Insmed Incorporated (filed herewith).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="insm-20181231xex231.htm"><span style="font-family:inherit;font-size:10pt;">23.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consent of Ernst&#160;&amp; Young&#160;LLP (filed herewith).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="insm-20181231xex311.htm"><span style="font-family:inherit;font-size:10pt;">31.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification of William H. Lewis, Chairman and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to Rules&#160;13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes Oxley Act of 2003 (filed herewith).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="insm-20181231xex312.htm"><span style="font-family:inherit;font-size:10pt;">31.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification of Paolo Tombesi, Chief Financial Officer (Principal Financial and Accounting Officer) of Insmed Incorporated, pursuant to Rules&#160;13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes Oxley Act of 2003 (filed herewith).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="insm-20181231xex321.htm"><span style="font-family:inherit;font-size:10pt;">32.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification of William H. Lewis, Chairman and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to 18 USC Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes Oxley Act of 2003 (filed herewith).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="insm-20181231xex322.htm"><span style="font-family:inherit;font-size:10pt;">32.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification of Paolo Tombesi, Chief Financial Officer (Principal Financial and Accounting Officer) of Insmed Incorporated, pursuant to 18 USC Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes Oxley Act of 2003 (filed herewith).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Confidential treatment has been granted for certain portions of this exhibit. The confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">**</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management contract or compensatory plan or arrangement of the Company required to be filed as an exhibit.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s37BB1C2C5EFC5AC2AFB9B4FE2431CA76"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">73</span></div></div><hr style="page-break-after:always"></hr><div><a id="s71AC4CBE59085B2CBFD9BEF34A61185A"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on </span><span style="font-family:inherit;font-size:10pt;">February&#160;22, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INSMED INCORPORATED<br/>a Virginia corporation<br/>(Registrant)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;WILLIAM H. LEWIS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">William H. Lewis</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Chairman and Chief Executive Officer</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on </span><span style="font-family:inherit;font-size:10pt;">February&#160;22, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Signature</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Title</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;WILLIAM H. LEWIS</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chairman and Chief Executive Officer</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">William H. Lewis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;PAOLO TOMBESI</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Paolo Tombesi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;DONALD HAYDEN, JR.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Donald Hayden, Jr.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;ALFRED F. ALTOMARI</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alfred F. Altomari</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;DAVID R. BRENNAN</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">David R. Brennan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;STEINAR J. ENGELSEN, M.D.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Steinar J. Engelsen, M.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;DAVID W.J. MCGIRR</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">David W.J. McGirr</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;ELIZABETH MCKEE ANDERSON</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Elizabeth McKee Anderson</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;MELVIN SHAROKY, M.D.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Melvin Sharoky, M.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;LEO LEE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leo Lee</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4586AA1A06475DF8820A58C06C3C5DD9"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the Shareholders and the Board of Directors of Insmed Incorporated</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on the Financial Statements</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Insmed Incorporated (the Company) as of December 31, 2018 and 2017, the related consolidated statements of comprehensive loss, shareholders' equity and cash flows for each of the three years in the period ended December 31, 2018, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company at December 31, 2018 and 2017, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2018, in conformity with U.S. generally accepted accounting principles.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 22, 2019 expressed an unqualified opinion thereon.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have served as the Company&#8217;s auditor since at least 1999, but we are unable to determine the specific year.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Iselin, New Jersey</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;22, 2019</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the Shareholders and the Board of Directors of Insmed Incorporated</span></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have audited Insmed Incorporated&#8217;s internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Insmed Incorporated (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018, based on</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">the COSO criteria</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">.</span><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2018 and 2017, and the consolidated statements of comprehensive loss, shareholders' equity and cash flows for each of the three years in the period ended December 31, 2018 of the Company and our report dated February 22, 2019 expressed an unqualified opinion thereon.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;/s/ Ernst&#160;&amp; Young&#160;LLP</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Iselin, New Jersey</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;22, 2019</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">76</span></div></div><hr style="page-break-after:always"></hr><div><a id="s243AF3EBDD175252A026EFCFD64B1705"></a></div><div><div style="line-height:120%;text-align:left;font-size:9pt;"><a style="font-family:inherit;font-size:9pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:9pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except par value and share data)&#160;</span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s73F6FF760EFF5E02BADB6FC1CA55C68E"></a></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Current assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1068-wk-Fact-427FBC64188DA71D9DF1C80C64763291" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">495,072</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1087-wk-Fact-51D76EC3E2C2D919A799C80C64749C4F" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accounts receivable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1107-wk-Fact-90EB21BBF15DD6EB987D199A58854276" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,515</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1126-wk-Fact-B2B07187A8162BD0FE53199A5894A613" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1151-wk-Fact-1DBCE8064A0BCB536A421995AF92293F" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1170-wk-Fact-D1A7F3048148B1BBDA191995AF96F5A1" name="us-gaap:InventoryNet" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1195-wk-Fact-92C077B8EB60ED9317CEC80C6464B0B4" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,327</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1214-wk-Fact-80D353DD6BFF5C89D38CC80C6471C8F0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1239-wk-Fact-BE68755F148F352A7BAEC80C646F97AD" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">518,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1258-wk-Fact-BE449DFA902D22237F15C80C64783F9D" name="us-gaap:AssetsCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">389,444</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangibles, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1329-wk-Fact-37DB01866B7D3BE6F66CC80C6466A9B9" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1348-wk-Fact-5F4E1E308F165E3B6678C80C64771C5C" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed assets, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1374-wk-Fact-E1B09700CAF1045121D4C80C647C57EB" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1393-wk-Fact-00C9FAFCE2A161EA3686C80C646A5ED4" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1418-wk-Fact-1AB2611DDB602C70DC48C80C6462E308" name="us-gaap:OtherAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1437-wk-Fact-218F5300BC5DFB8E7ABCC80C64748E9A" name="us-gaap:OtherAssets" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,971</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1467-wk-Fact-0DF9EE5DDB5713B5CE18C80C64762419" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">604,556</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1486-wk-Fact-E22C8E2E35242923225DC80C646A359E" name="us-gaap:Assets" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">462,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Liabilities and shareholders' equity</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1645-wk-Fact-897AAECFE4E1F2FAA531C80C6477EEBC" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1664-wk-Fact-0C8D758F4BE6405901AEC80C647ADAB6" name="us-gaap:AccountsPayableCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1684-wk-Fact-5D090E567899D78AEC44C80C647E734C" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1703-wk-Fact-71F7BB0080BFEB1A3989C80C646A1E6C" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1728-wk-Fact-614E126349829E5B91438084237C8E1A" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1747-wk-Fact-2CFE5BAD035C11BCEE7780843B6C9A06" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1772-wk-Fact-412E17813E194C04EBD6C80C6474FFD7" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1791-wk-Fact-423F823D1F0D339C5853C80C647130CE" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">646</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1816-wk-Fact-D8FA475AFB5E0ED3F1F4C80C64787E52" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,732</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1835-wk-Fact-2292CFA9A88FE5A04550C80C64795D93" name="us-gaap:LiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Debt, long-term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1905-wk-Fact-2E25EFE980C3474A3F0EC80C647C1254" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">316,558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1924-wk-Fact-0889BF9A7343EB1D9B84C80C64658185" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,567</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1949-wk-Fact-85F46ACE66FEB53C250EC80C64727493" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1968-wk-Fact-E2FCD139D76F330845BDC80C646FFF1C" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">765</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e1993-wk-Fact-4DB683B889EFAE225C05C80C646CB94A" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">396,290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e2012-wk-Fact-0717CFE7A8E4FC72A1ADC80C6465FDAD" name="us-gaap:Liabilities" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">100,988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Shareholders' equity:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock, $0.01 par value; 500,000,000 authorized shares, 77,307,521 and 76,610,508 issued and outstanding shares at December&#160;31, 2018 and December&#160;31, 2017, respectively</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e2129-wk-Fact-588C55B7879C279BCC66C80C647B81F0" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">773</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e2148-wk-Fact-0B457D664EDC98483331C80C6467622A" name="us-gaap:CommonStockValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">766</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Additional paid-in capital</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e2173-wk-Fact-46184AD89A7A2C616164C80C6472FB44" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,489,664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e2192-wk-Fact-A9FD4D51BE263DDC9E38C80C64696533" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,318,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15032183e2217-wk-Fact-CC574BBE44F93BDBCC14C80C647DF7FD" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,282,162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15032183e2237-wk-Fact-A50145461DBF576017F6C80C647EEAC9" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">957,885</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accumulated other comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15032183e2263-wk-Fact-917152A732ABC720BDA0C80C647BA7A0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15032183e2283-wk-Fact-4824CB9301E839D4FA7CC80C6468AE6B" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total shareholders' equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e2309-wk-Fact-B75D79B791B3584126F9C80C647031BB" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">208,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e2328-wk-Fact-DCE7F8BE5E46B6FEC90DC80C6465F0C6" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">361,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total liabilities and shareholders' equity</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e2359-wk-Fact-A334E7D7BF3172A5CF5DC80C6472FC6A" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">604,556</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15032183e2378-wk-Fact-498BC1AB2095D286A15EC80C64796EF1" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">462,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to consolidated financial statements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">77</span></div></div><hr style="page-break-after:always"></hr><div><a id="s61FC098F36485B8DA0F2A50ED658D849"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Comprehensive Loss</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.44834307992203%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1067-wk-Fact-0CE9CA24C5A1FC8486371AD4F405D7F5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1086-wk-Fact-386BA215910B5BD7882B19A235C5AC3A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1105-wk-Fact-7FD3E4DB733DAA82E07119A24A457D43" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1121-wk-Fact-0CE9CA24C5A1FC8486371AD4F405D7F5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1140-wk-Fact-386BA215910B5BD7882B19A235C5AC3A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1159-wk-Fact-7FD3E4DB733DAA82E07119A24A457D43" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Costs and expenses:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenues (excluding amortization of intangible assets)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1301-wk-Fact-5ABE2B07153213A344EC1ADE1929033C" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,423</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1320-wk-Fact-4000BD3A37997FB14A771ADE19229D92" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1339-wk-Fact-7F3DDBA768CE9677928A1ADE1926AE4F" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1360-wk-Fact-319DC661D7F4FFE6C715C80C6442BD89" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1379-wk-Fact-43281E1F2620A921EBFAC80C6432DE5C" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">109,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1398-wk-Fact-A326D7B0541A8BC8C541C80C64334850" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122,721</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1419-wk-Fact-92EB997E01FEB1B1410DC80C643BADD9" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">168,218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1438-wk-Fact-F0FE99C8725DC17858CDC80C643F751B" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1457-wk-Fact-FE401B3B74530F86F764C80C643BD76B" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1478-wk-Fact-E12E542CC2BAF2409A4719A92EAC878F" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1497-wk-Fact-8C100FA5E0B9F66560EA19A96A097229" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1516-wk-Fact-D7A9152B906156D1403F19A9A330A7AF" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1538-wk-Fact-CF4283EBC4B7F77CED65C80C642E37D6" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">317,173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1557-wk-Fact-DED48228298CB04EB1DEC80C6430F5BA" name="us-gaap:CostsAndExpenses" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1576-wk-Fact-6A265CAB491AE29E3243C80C64324C3B" name="us-gaap:CostsAndExpenses" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">173,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Operating loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e1659-wk-Fact-94636DE7E0B2D950EF3EC80C64407EF0" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">307,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e1679-wk-Fact-9A1B732379CE71D1D61EC80C643B8C9A" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">188,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e1699-wk-Fact-D235A19CD8A61BD5CBDCC80C643BDD41" name="us-gaap:OperatingIncomeLoss" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">173,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Investment income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1783-wk-Fact-CBCAC97E51EDCE9CB62EC80C643D4DF1" name="us-gaap:InvestmentIncomeNonoperating" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1802-wk-Fact-2C237DDB03100D8B0A1EC80C642CAAF4" name="us-gaap:InvestmentIncomeNonoperating" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,624</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1821-wk-Fact-4BCDFC5F765DD74505D0C80C6441F2B4" name="us-gaap:InvestmentIncomeNonoperating" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e1842-wk-Fact-BEE70880F81C17F6C423C80C6433566B" name="us-gaap:InterestExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,472</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e1862-wk-Fact-321A472A693B36955FECC80C64408854" name="us-gaap:InterestExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,925</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e1882-wk-Fact-9AAEF84C59D4D4710955C80C643BB756" name="us-gaap:InterestExpense" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,498</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e1904-wk-Fact-79144B5414C6CFB1FC8E808979A5D4CF" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1924-wk-Fact-8EFABA5FA4D897D3438180899DAEBDFC" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1943-wk-Fact-EEC990E7E9A002C1F1EB8089B090FE9E" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1964-wk-Fact-E9AB1DB6A2349186701DC80C643CCD8F" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e1983-wk-Fact-2DACF4031849687CDE2FC80C643C0A49" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e2002-wk-Fact-5947E43724AC6F68A3E4C80C64467F52" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Loss before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2023-wk-Fact-12A725180DFC88524CFCC80C64387A24" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">324,076</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2043-wk-Fact-A15D7F28ADF1B4BED74EC80C642BF891" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192,921</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2063-wk-Fact-885B0511759F68EBB430C80C642DAEE3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">176,175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Provision (benefit) for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e2147-wk-Fact-8D74C5FB87F23963EC01C80C64442BB1" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2166-wk-Fact-DE237BCC7B9D2B1576DAC80C64408AF8" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">272</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e2186-wk-Fact-EEB607607F1CA43AAEDDC80C6430DE13" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2275-wk-Fact-B42634276C7A9632D85AC80C6434F487" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">324,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2295-wk-Fact-04977BE1C74AC80F3F04C80C643AC548" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2315-wk-Fact-7F7EDEF8E2CD9E9CBE90C80C642F7957" name="us-gaap:NetIncomeLoss" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">176,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2399-wk-Fact-518DC39F637E8302275EC80C64362527" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">4.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2419-wk-Fact-E7AA589AA67B3269D3FEC80C6440E3D2" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2439-wk-Fact-392E31090CD7F1536356C80C6432E7FF" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2016Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Weighted average basic and diluted common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e2518-wk-Fact-0731903F1DC62230D922C80C643EAD1F" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">76,889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e2537-wk-Fact-764806C4124A807A428DC80C64341125" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">66,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e2556-wk-Fact-D2DB4889A1B537702B8AC80C642E3F3B" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2016Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">61,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2644-wk-Fact-3F5C1FF348013389AAF7C80C6446F8B4" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">324,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2664-wk-Fact-B79973E21F1101F13969C80C6442F1A0" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2684-wk-Fact-C4A58318AE76A8EB42A9C80C643E352C" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">176,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Other comprehensive income (loss):</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation (losses) gains</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2822-wk-Fact-D0E153C1F918FBA1591EC80C64436E77" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15023556e2842-wk-Fact-F7E99A649F603644FBC8C80C6443594A" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2861-wk-Fact-1F8186588345698F33F4C80C64378A3A" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2889-wk-Fact-2757970DCC73604ECC65C80C6432A7C5" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">324,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2909-wk-Fact-6AD3D75DFD18420B9DECC80C642BCE66" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192,587</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15023556e2929-wk-Fact-87105D960B6C6E07F00DC80C6442BEE4" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">176,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to audited consolidated financial statements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78</span></div></div><hr style="page-break-after:always"></hr><div><a id="s69E24D59501055B1A1F057636D59335B"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Shareholders' Equity</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></div><div><br/></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:31%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Paid-in</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Capital</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Deficit</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;font-weight:bold;">Balance at January 1, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1147-wk-Fact-2A48278BE08E5A353208C80C64579E1D" name="us-gaap:SharesOutstanding" contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">61,814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1166-wk-Fact-2D4E63DEF1505751511EC80C6482A9C9" name="us-gaap:StockholdersEquity" contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">618</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1185-wk-Fact-90DD0B89E39D08324E91C80C641B86C9" name="us-gaap:StockholdersEquity" contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">900,043</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e1205-wk-Fact-7F67D23F831D540399DBC80C6463DB26" name="us-gaap:StockholdersEquity" contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">588,963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1225-wk-Fact-035BCFDE1B6C5D09DE50C80C646126F0" name="us-gaap:StockholdersEquity" contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1244-wk-Fact-D4243DFCEFD996E3A84AC80C6456C1E0" name="us-gaap:StockholdersEquity" contextRef="FI2015Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">311,698</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprehensive loss:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e1425-wk-Fact-2C8C5A1E224088205195C80C64600739" name="us-gaap:NetIncomeLoss" contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">176,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e1464-wk-Fact-7F7EDEF8E2CD9E9CBE90C80C642F7957" name="us-gaap:NetIncomeLoss" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">176,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e1562-wk-Fact-94D551901D0F50340504C80C64801F83" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e1582-wk-Fact-16E2AE0E7D92D53BFB88C80C6481CB49" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Exercise of stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1604-wk-Fact-0B180CA73A935F4495DAC80C64598083" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1618-wk-Fact-FB449EE2F5509E208AB2C80C646515A4" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1637-wk-Fact-FBAB77BB0BC75D84F476C80C645A60DC" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1695-wk-Fact-E92CB3DBCAF7788E359AC80C644F2117" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issuance of common stock for vesting of RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1716-wk-Fact-12C2EE9B3FE5BA583BD1C80C6454D8F9" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1807-wk-Fact-9AC3E442F5C216A45F761AB276B3FE6F" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Stock compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1861-wk-Fact-AB9F3919FBD0B790FDA0C80C6451BFBE" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,039</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1919-wk-Fact-0B4317C6F86C0A4918B4C80C6460BCAF" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,039</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1940-wk-Fact-DFCC6AD42506B0AF030FC80C6457876E" name="us-gaap:SharesOutstanding" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">62,020</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1959-wk-Fact-322011EB862A7EFF4B6AC80C645276D3" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">620</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e1978-wk-Fact-0928514A062F9114E36FC80C6462BABB" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">919,164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e1998-wk-Fact-B60BE7B5940EE7FAD32EC80C6452F9D2" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">765,236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e2018-wk-Fact-C573DD62C7EAE617C734C80C6455DE27" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2038-wk-Fact-0F189D575FA156BA45AEC80C647FDEB3" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,483</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Comprehensive loss:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e2220-wk-Fact-69831BBA751461425C49C80C645B7E87" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e2259-wk-Fact-04977BE1C74AC80F3F04C80C643AC548" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2353-wk-Fact-0556C473D8585607CB23C80C64594653" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2372-wk-Fact-6E512521CAF6A9EDA685C80C64676E53" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exercise of stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2393-wk-Fact-6540229C63FAD94B307BC80C64581F41" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">379</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2407-wk-Fact-DBD6CF17D4A927EB0B40C80C64617A0E" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2426-wk-Fact-48861F50A2B9B0DD484CC80C6466D6CE" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,429</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2484-wk-Fact-494D9FAE9B7DE261F15DC80C645C10F2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Net proceeds from issuance of common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2505-wk-Fact-1FC20A3278F68E3225C2C80C64539FC9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">14,123</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2519-wk-Fact-AC1900DAF94DDDBF720AC80C645333BF" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2538-wk-Fact-1614285A8D79FDC4EC99C80C645889BA" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">377,515</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2598-wk-Fact-E586115F74F3C3AFDF3CC80C645E4ED1" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">377,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issuance of common stock for vesting of RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2619-wk-Fact-29C7C03E5317701C15B0C80C6451FD1F" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2633-wk-Fact-DA5609AD22470FAF1875C80C645FB6D3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2710-wk-Fact-F339702F0210C6B6027AC80C645E1F63" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Stock compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2764-wk-Fact-4FB4640A86A6AF5002B8C80C645FD4C9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2822-wk-Fact-66EC6A46829C86DF09CBC80C645C99AF" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2843-wk-Fact-6791043C668C8BA861F8C80C6450EF13" name="us-gaap:SharesOutstanding" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">76,611</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2862-wk-Fact-0F875F4C57415C3DAB5EC80C6450305F" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">766</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2881-wk-Fact-4FEDB1CF49C2B93EF437C80C644F4C54" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,318,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e2901-wk-Fact-E97D6D08028DA32DD5ACC80C6455C360" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">957,885</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e2921-wk-Fact-2725C690BFC3960FB2A1C80C647FB71D" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e2941-wk-Fact-DCE7F8BE5E46B6FEC90DC80C6465F0C6" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">361,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Comprehensive loss:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e3122-wk-Fact-6AE169FF092815D59E6E808B0A3BB06E" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">324,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e3161-wk-Fact-B42634276C7A9632D85AC80C6434F487" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">324,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e3255-wk-Fact-A449FDA1F9AD2F6EF872808B0A155C5B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e3275-wk-Fact-9D3C7CC6F871F81281861AB42EC28D2E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Exercise of stock options and ESPP shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3297-wk-Fact-6FE5149D1D01D1627CAC808B0A1EAE8D" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">645</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3311-wk-Fact-E57A440615F1FB187C5E808B0A28C4E5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3330-wk-Fact-2BFF6C727DF10345DAB1808B0A0864CB" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3388-wk-Fact-1FD3C95911E10A3B90741AB57945BA4D" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,815</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Equity component of convertible debt issuance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3443-wk-Fact-670A9875945AB16ADCC2808C8EAF051C" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3503-wk-Fact-49A8158429DCCA93B6A41ABA4F701A28" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issuance of common stock for vesting of RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3524-wk-Fact-7D06EB53A4A425756C2F808B09FE8D6C" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3538-wk-Fact-CE0AC1D804C19DDABBA3808B0A110EF0" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3615-wk-Fact-25860F8EDAE1011AACBA1AB63AA2569F" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;background-color:#cceeff;">Stock compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3669-wk-Fact-38CA5CF9A20C5C71AE7E808B0A3179AF" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3727-wk-Fact-4ED8A016F97727C4BFFD1AB76C9FDCDA" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3748-wk-Fact-2BF28B55D7B73A55BC251AAE9CF3CB81" name="us-gaap:SharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">77,308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3767-wk-Fact-469EC9E651EAD656274C1AAE2BB1387F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">773</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3786-wk-Fact-A5339A35FCC6CAD6D35D1AAE427B1E4F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,489,664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e3806-wk-Fact-927C3C5E2A10798F58111AAE56C5F961" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,282,162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d15024959e3826-wk-Fact-5EC49E262E93DF8F2DD41AAE6D204E3E" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d15024959e3846-wk-Fact-B75D79B791B3584126F9C80C647031BB" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">208,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to audited consolidated financial statements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79</span></div></div><hr style="page-break-after:always"></hr><div><a id="s952A71E46D985D0683FE9B17FC2662FA"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Cash Flows</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:609px;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:413px;"></td><td style="width:9px;"></td><td style="width:48px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:48px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:48px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e1068-wk-Fact-B42634276C7A9632D85AC80C6434F487" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">324,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e1088-wk-Fact-04977BE1C74AC80F3F04C80C643AC548" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e1108-wk-Fact-7F7EDEF8E2CD9E9CBE90C80C642F7957" name="us-gaap:NetIncomeLoss" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">176,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1186-wk-Fact-A8731CDF0DE81CD6EFE4C80C6462AD43" name="us-gaap:Depreciation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,577</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1205-wk-Fact-2E01AFC1B8BC8A0F103FC80C646A89AE" name="us-gaap:Depreciation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1224-wk-Fact-05F194E562CA20D89096C80C646B74A2" name="us-gaap:Depreciation" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,438</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1245-wk-Fact-E12E542CC2BAF2409A4719A92EAC878F" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1264-wk-Fact-8C100FA5E0B9F66560EA19A96A097229" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1283-wk-Fact-D7A9152B906156D1403F19A9A330A7AF" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Stock-based compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1304-wk-Fact-DD83F5BF9FA7C72A6ECCC80C64814481" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1323-wk-Fact-058E77C5D7C04F6A3AA6C80C64715123" name="us-gaap:ShareBasedCompensation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1342-wk-Fact-E5C58CC410A8DD17C537C80C6460D335" name="us-gaap:ShareBasedCompensation" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,039</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1363-wk-Fact-79144B5414C6CFB1FC8E808979A5D4CF" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1382-wk-Fact-8EFABA5FA4D897D3438180899DAEBDFC" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1401-wk-Fact-EEC990E7E9A002C1F1EB8089B090FE9E" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Amortization of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1422-wk-Fact-1951FFB1CE8756B9CCA2808E44B8513F" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1441-wk-Fact-4D61271764D612683EEFC80C6468F59A" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1460-wk-Fact-80FDCF9EC974B8A7524FC80C647AD8E9" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">281</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of debt discount</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1481-wk-Fact-42A6C5C1F47FF3A7E489813ECD4C0895" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1500-wk-Fact-2A93B44B9EAA7AA79760813EE3E27930" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1519-wk-Fact-F847EBD8C5ABBA016F19813EF939958D" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2016Q4YTD" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accretion of back-end fee on debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1540-wk-Fact-5934124C5B657E4E1D5E808E44D46198" name="us-gaap:AccretionExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1559-wk-Fact-E40DDB88F29A1B9F8A2AC80C64806C42" name="us-gaap:AccretionExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">658</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1578-wk-Fact-712C68D6D0DCF4A68055C80C6476BA5A" name="us-gaap:AccretionExpense" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e1660-wk-Fact-43D577DB8EEA36169FEC19AE178ECF17" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,515</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1680-wk-Fact-AEAF72389CFC539722E919AE17B67EFD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1699-wk-Fact-0AED4611C3466C720BC819AE17D057A7" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e1720-wk-Fact-04F3A921FC18942281E019AE17D4DA26" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1740-wk-Fact-7E1BE50DB5D7BFE8010219AE177B8615" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1759-wk-Fact-EA78196B325A1307F4E819AE17A2C2CE" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e1780-wk-Fact-A59B0719E555014A5AD3C80C6477E0A7" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e1800-wk-Fact-D83234C91AEE15B8C5B9C80C647695E6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1820-wk-Fact-A4E0CFB65598A640E8D4C80C6472B857" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">191</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1841-wk-Fact-FAE5D4C23B3978733B8DC80C646D7D4D" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1860-wk-Fact-6430BE4F65D32C35B79EC80C6472F4F4" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1879-wk-Fact-5364E074DE4C30C8A8C3C80C6475483F" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,767</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1900-wk-Fact-66C52A8E4247A050367CC80C645D006A" name="insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,916</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1919-wk-Fact-91AFCD62ED45C79A69C2C80C647FA7B2" name="insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1938-wk-Fact-AF217592A82124D36955C80C645F5F2F" name="insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,043</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1959-wk-Fact-8174BB42583C564346EC808FB5202712" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1978-wk-Fact-674A33198352EBF3D037808FF8C36ECA" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e1997-wk-Fact-2D8B8442D6F22006419A809026263B6D" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,635</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Net cash used in operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2018-wk-Fact-248A658F9B4C22946315C80C64603B60" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">257,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2038-wk-Fact-05630F79F07C1B84BB64C80C6477653D" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">159,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2058-wk-Fact-33D16192453658B23094C80C6479E698" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">146,708</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Purchase of fixed assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2139-wk-Fact-B2C8286A735E085860F8C80C647330FF" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2159-wk-Fact-3F3B761EA115E95B2F79C80C64654010" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2179-wk-Fact-8682D546DE4951E26778C80C6463C203" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PARI milestone upon FDA approval</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2202-wk-Fact-A82209BD79A224E29E4081362E310250" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,724</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2222-wk-Fact-BC9EDD34A0C5F9569664813671B82643" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2241-wk-Fact-A8271004D3B3E58E94EC81368E45D8CA" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Net cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2262-wk-Fact-C1505E7E82674544B888C80C647C03C9" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2282-wk-Fact-AEB940781367D8492D98C80C646FF319" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2302-wk-Fact-DB69BDE37C07D9FA9338C80C648133FB" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Proceeds from issuance of 1.75% convertible senior notes due 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2383-wk-Fact-4F3A950C29E99B92310819AE17CC9D08" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">450,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2402-wk-Fact-8EA276C7082E41A2DBD5808E44DDA825" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2421-wk-Fact-C48253AC3DADF4A7FCFD808E4501FEA2" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment on extinguishment of debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2442-wk-Fact-7AB1DAA83E8241368D5E19AE17B2ECF0" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2462-wk-Fact-7A9F9FFDBCA4C0494E47808E45041363" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2481-wk-Fact-38692E432A2E3E2F6987808E44C0CF85" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Payment of debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2502-wk-Fact-6ED1CD9175A3879BA5C719AE17AEA6ED" name="us-gaap:RepaymentsOfDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2522-wk-Fact-D229255C5700BD4C66FB808E44E5C6F9" name="us-gaap:RepaymentsOfDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2541-wk-Fact-464A105FC1CD7913D9EC808E44D1A8DA" name="us-gaap:RepaymentsOfDebt" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2562-wk-Fact-DBF9E021873F2273C5EFC80C647E694F" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2581-wk-Fact-07FCA54C51CE956AE1F7C80C645F2BC7" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2600-wk-Fact-AE9FFF6A56E203DC5936C80C64756E5F" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Proceeds from issuance of common stock, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2621-wk-Fact-0B21BE595A6A300FB6FDC80C646B0C17" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2640-wk-Fact-8DFE884DBD577AADCCB6C80C647BEEB3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">377,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2659-wk-Fact-E2262C1C68C0A1DB42EDC80C6475C530" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from exercise of stock options and ESPP</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2680-wk-Fact-FC1AD0C074A03149042719AE17A7DBFE" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,815</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2699-wk-Fact-CDC9615D415D7E00C114C80C64680D6D" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2718-wk-Fact-829507C24FD1A57B0DC8C80C6478D55C" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Payment of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2739-wk-Fact-F9C535027D38ECEE4632C80C64628BFE" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2759-wk-Fact-1EFB301D2B93AA528122C80C6475EF43" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2778-wk-Fact-2E5CE69799AEF3B41ECBC80C64702267" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">411</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2800-wk-Fact-3C5E36D748A531FBCF1FC80C647FDA38" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">386,743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2819-wk-Fact-49505E0FB9782829059AC80C641D72F9" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2838-wk-Fact-5DDABBA30404087F58FCC80C6463312B" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,673</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Effect of exchange rates on cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2860-wk-Fact-EE7937103E6E7E183C39808E44F987C3" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2880-wk-Fact-58A9DD44FA8930E466E0C80C647EEDAB" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2899-wk-Fact-04E110093DC64A054AA5C80C6479312E" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2921-wk-Fact-0D019ACA93FE46D78AF3C80C647D78E0" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">113,907</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2940-wk-Fact-A58C06CE392D89AC5A49C80C64740D69" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">218,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15031429e2959-wk-Fact-36EDF4FBF7199B4DAE04C80C646A57D8" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">120,285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e2981-wk-Fact-51D76EC3E2C2D919A799C80C64749C4F" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e3000-wk-Fact-748B101BA8C6641AC63BC80C647FB856" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e3019-wk-Fact-06AF0A34E81C9BE262E9C80C645EA6BE" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2015Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">282,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e3045-wk-Fact-427FBC64188DA71D9DF1C80C64763291" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">495,072</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e3064-wk-Fact-51D76EC3E2C2D919A799C80C64749C4F" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e3083-wk-Fact-748B101BA8C6641AC63BC80C647FB856" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Supplemental disclosures of cash flow information:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for interest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e3163-wk-Fact-D64AE895F2926B86D626C80C6469104A" name="us-gaap:InterestPaidNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,289</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e3182-wk-Fact-257C6BA4DE27B1070181C80C647ABC00" name="us-gaap:InterestPaidNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e3201-wk-Fact-0B115CFDB5EE74E23988C80C647FE320" name="us-gaap:InterestPaidNet" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Cash paid for taxes, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e3222-wk-Fact-02EA68BE7D72B0291327C80C6478EFF5" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e3241-wk-Fact-661A37F26CDCB56C71BEC80C646E0083" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15031429e3260-wk-Fact-99BA2E9ABC6B675F3883C80C641B1060" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to audited consolidated financial statements</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">80</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8BD49CDE497F534583A97E5971FFD57E"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;"><br/></span></div><div><a id="s570999BB0B0F56B29A787BD7877BC8BD"></a></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="TextSelection-D28F72440837709E1F5CC80C648A8421-0-wk-Fact-CE32415E24167246C9DEC80C645215E6" continuedAt="TextSelection-D28F72440837709E1F5CC80C648A8421-1" escape="true">Description of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-D28F72440837709E1F5CC80C648A8421-1" continuedAt="TextSelection-D28F72440837709E1F5CC80C648A8421-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Description of Business</span><span style="font-family:inherit;font-size:10pt;">&#8212;Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), received accelerated approval in the United States (US) on September 28, 2018 for the treatment of refractory </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Mycobacterium avium</span><span style="font-family:inherit;font-size:10pt;"> complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) with therapeutic potential in non-cystic fibrosis (non-CF) bronchiectasis and other inflammatory diseases. INS1009 is an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension (PAH).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, Ireland, Germany, France, the United Kingdom (UK), the Netherlands, Bermuda and Japan.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15017886e874-wk-Fact-8B26CB98D40AB4553E27A617EA64BBC9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">495.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and reported a net loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15017886e882-wk-Fact-21EC0C135BCC4F6D9251A5F4EDC890F4" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">324.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Historically, the Company has funded its operations through public offerings of equity securities and debt financings. To date, the Company has not generated significant revenue from ARIKAYCE. The Company commenced commercial shipments in October 2018. The Company expects to continue to incur operating losses while funding commercial launch efforts for ARIKAYCE, research and development (R&amp;D) activities, regulatory submissions outside the US, and selling, general and administrative (SG&amp;A) expenses. The Company expects its future cash requirements to be substantial, and it may need to raise additional capital to fund operations, including the commercialization of ARIKAYCE and additional clinical trials related to ARIKAYCE, to develop INS1007 and INS1009 and to develop, acquire, in-license or co-promote other products that address orphan or rare diseases.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#8217;s commercial, regulatory and development activities. Any equity or debt financing will also be contingent upon equity and debt market conditions and interest rates at the time. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts. The Company believes it currently has sufficient funds to meet its financial needs for at least the next 12&#160;months.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><ix:continuation id="TextSelection-D28F72440837709E1F5CC80C648A8421-2" continuedAt="TextSelection-D28F72440837709E1F5CC80C648A8421-3"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-F1D1A71F3F73F2BFC0F1C80C648A7924-0-wk-Fact-4B569F02A324EA0EC6C1C80C6453182D" continuedAt="TextSelection-F1D1A71F3F73F2BFC0F1C80C648A7924-1" escape="true">Basis of Presentation</ix:nonNumeric></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-D28F72440837709E1F5CC80C648A8421-3"><ix:continuation id="TextSelection-F1D1A71F3F73F2BFC0F1C80C648A7924-1">&#8212;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Insmed Limited, Celtrix Pharmaceuticals,&#160;Inc., Insmed Holdings Limited, Insmed Ireland Limited, Insmed France SAS, Insmed Germany&#160;GmbH, Insmed Netherlands&#160;B.V., Insmed Bermuda Limited and Insmed Godo Kaisha. All intercompany transactions and balances have been eliminated in consolidation and certain prior year amounts have been restated to conform to the current year presentation.</ix:continuation> In the prior year, accrued compensation was presented within the accrued expense line in the consolidated balance sheet. In the current year, accrued compensation is presented as a discrete line on the face of the consolidated balance sheet.</ix:continuation></span></div><div><a id="s950334BC85E55FA193C8DB64660529C7"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-8662E0A15332C9838894C80C648C8906-0-wk-Fact-25DC1C8BDD52BA8BCD56C80C6481398F" continuedAt="TextSelection-8662E0A15332C9838894C80C648C8906-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-8662E0A15332C9838894C80C648C8906-1" continuedAt="TextSelection-8662E0A15332C9838894C80C648C8906-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:UseOfEstimates" id="TextSelection-04C40125A79E2F4CD327C80C648BAA3B-0-wk-Fact-E205A0B067A866BE2694C80C6480B9F9" continuedAt="TextSelection-04C40125A79E2F4CD327C80C648BAA3B-1" escape="true">Use of Estimates</ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-04C40125A79E2F4CD327C80C648BAA3B-1">&#8212;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, and accounting for research and development costs. Actual results could differ from those estimates.</ix:continuation></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="insm:InvestmentIncomeExpensePolicyTextBlock" id="TextSelection-D788A6CD9AD5706BF99CC80C648C2314-0-wk-Fact-11F9E44CA88ED5541BE7C80C648269FD" continuedAt="TextSelection-D788A6CD9AD5706BF99CC80C648C2314-1" escape="true">Investment Income and Interest Expense</ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-D788A6CD9AD5706BF99CC80C648C2314-1">&#8212;Investment income consists of interest income earned on the Company's cash and cash equivalents. Interest expense consists primarily of interest costs related to the Company's debt.</ix:continuation></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="TextSelection-81C008BBE735A3CF14E0C80C648B11A3-0-wk-Fact-C50C8F1F3DC69E975F92C80C6479FC7C" continuedAt="TextSelection-81C008BBE735A3CF14E0C80C648B11A3-1" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-81C008BBE735A3CF14E0C80C648B11A3-1">&#8212;The Company considers cash equivalents to be highly liquid investments with maturities of three months or less from the date of purchase.</ix:continuation></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8662E0A15332C9838894C80C648C8906-2" continuedAt="TextSelection-8662E0A15332C9838894C80C648C8906-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="TextSelection-09B1B28141E114FA8B29C80C648B12C5-0-wk-Fact-57047539A99E38A04168C80C641B326C" continuedAt="TextSelection-09B1B28141E114FA8B29C80C648B12C5-1" escape="true">Fixed Assets, Net</ix:nonNumeric></span><ix:continuation id="TextSelection-09B1B28141E114FA8B29C80C648B12C5-1" continuedAt="TextSelection-09B1B28141E114FA8B29C80C648B12C5-2"><span style="font-family:inherit;font-size:10pt;">&#8212;Fixed assets are recorded at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. Estimated useful lives of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15037063e901-wk-Fact-18696D317CF507F8343BC80C641CABA3" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15037063e905-wk-Fact-5478C22FCDC5D3B78B20C80C641B763D" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> are used for computer equipment. Estimated useful lives of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15037063e909-wk-Fact-5A40D00E829A56BF6617C80C647A85F0" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_EquipmentFurnitureAndFixturesMember" format="ixt-sec:durwordsen">seven years</ix:nonNumeric></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-09B1B28141E114FA8B29C80C648B12C5-2"> are used for laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset.</ix:continuation></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="TextSelection-D2124733E6CC0BE6607DC80C648BD7BB-0-wk-Fact-6A64E989C40D11977B91C80C6480A591" continuedAt="TextSelection-D2124733E6CC0BE6607DC80C648BD7BB-1" escape="true">Identifiable Intangible Assets</ix:nonNumeric></span><ix:continuation id="TextSelection-D2124733E6CC0BE6607DC80C648BD7BB-1" continuedAt="TextSelection-D2124733E6CC0BE6607DC80C648BD7BB-2"><span style="font-family:inherit;font-size:10pt;">&#8212;Identifiable intangible assets are measured at their respective fair values and began amortizing over their estimated useful lives upon commercialization. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. Unanticipated events or circumstances may occur that may require the Company to review the assets for impairment. Events or circumstances that may require an impairment assessment include negative clinical trial results, the non-approval of a new drug application by a regulatory agency, material delays in the Company's development program or a sustained decline in market capitalization. The Company performs its annual impairment test as of October&#160;1 of each year.</span></ix:continuation></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-D2124733E6CC0BE6607DC80C648BD7BB-2">The Company performed a qualitative assessment to evaluate whether there was an impairment of the assets. This assessment did not identify any indicators of impairment of the intangible assets as of that date.</ix:continuation></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:DebtPolicyTextBlock" id="TextSelection-9BEFA7008D4AABE5762AC80C648B8AF4-0-wk-Fact-1F0B54FD8E1DF17628FEC80C6480D443" continuedAt="TextSelection-9BEFA7008D4AABE5762AC80C648B8AF4-1" escape="true">Debt Issuance Costs</ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-9BEFA7008D4AABE5762AC80C648B8AF4-1">&#8212;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</ix:continuation></span></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="TextSelection-29127A07CC357E975727C80C648C2DE1-0-wk-Fact-ECDF65B56C3081A24824C80C645217D3" continuedAt="TextSelection-29127A07CC357E975727C80C648C2DE1-1" escape="true">Fair Value Measurements</ix:nonNumeric></span><ix:continuation id="TextSelection-29127A07CC357E975727C80C648C2DE1-1" continuedAt="TextSelection-29127A07CC357E975727C80C648C2DE1-2"><span style="font-family:inherit;font-size:10pt;">&#8212;The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></ix:continuation></div><ix:continuation id="TextSelection-29127A07CC357E975727C80C648C2DE1-2" continuedAt="TextSelection-29127A07CC357E975727C80C648C2DE1-3"><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's only financial assets and liabilities which were measured at fair value as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> were Level 1 assets comprised of cash and cash equivalents. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. <ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-91C668D3D9FB55C5CD061A3A1537B434-0-wk-Fact-8C103EB212FCE424EA581A52E05B7D81" continuedAt="TextSelection-91C668D3D9FB55C5CD061A3A1537B434-1" escape="true">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</ix:nonNumeric></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8662E0A15332C9838894C80C648C8906-3" continuedAt="TextSelection-8662E0A15332C9838894C80C648C8906-4"><ix:continuation id="TextSelection-29127A07CC357E975727C80C648C2DE1-3" continuedAt="TextSelection-29127A07CC357E975727C80C648C2DE1-4"><ix:continuation id="TextSelection-91C668D3D9FB55C5CD061A3A1537B434-1" continuedAt="TextSelection-91C668D3D9FB55C5CD061A3A1537B434-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.04873294346979%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1281-wk-Fact-3660B12AE6C87FB744CEA5D94BC43AE7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">495.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1300-wk-Fact-40EF15115473A4FF91F4A5D94BD184BC" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">495.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1319-wk-Fact-EC9E59385733F981F308DD8D0202FDFE" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1339-wk-Fact-FB3CE297316D237D0B02DD7C184C1476" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1685-wk-Fact-AC55023CF7CD5670D828A5FB876E5E05" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">381.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1704-wk-Fact-A0B4C037EE05F54E65FBA5FB6B742BCD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">381.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1723-wk-Fact-3F175F37362471A78D42DD7C79901871" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1743-wk-Fact-C7A0B2AAE3F516FC90AADD7C81648852" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-91C668D3D9FB55C5CD061A3A1537B434-2" continuedAt="TextSelection-91C668D3D9FB55C5CD061A3A1537B434-3"><span style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-91C668D3D9FB55C5CD061A3A1537B434-3"></ix:continuation>The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1756-wk-Fact-BD10EA8EB7F5B75FD3B71A58A5DCC85D" name="insm:FairValueLevel1Level2Level3TransfersAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> transfers in or out of Level&#160;1, Level&#160;2 or Level&#160;3 during </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company held </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1782-wk-Fact-7E06FF47992752D71913C80C647A9FDB" name="insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" contextRef="FI2018Q4" unitRef="security" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> securities that were in an unrealized loss or gain position.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-29127A07CC357E975727C80C648C2DE1-4">The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the security was rated below investment grade; (3)&#160;how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover.</ix:continuation></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of the liability component of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1798-wk-Fact-5F5CB767749920DD4B8652FB10DFBDEE" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.75</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2025 (the Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15037063e1806-wk-Fact-B187C6EA398F5930DA8D1A881432964B" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">313.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the Convertible Notes. The </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15037063e1810-wk-Fact-9B1D719D13062A905A41DD82C476D281" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">316.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> carrying value of the Convertible Notes as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> excludes the $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1819-wk-Fact-B6B4C3F17966D16FF7A11A4408B0DAE0" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of the unamortized portion of the debt discount.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="TextSelection-97C740DA89EE6694C237C80C648CA85D-0-wk-Fact-9F47DCAD3C9E5DE50D95C80C647E9F4A" continuedAt="TextSelection-97C740DA89EE6694C237C80C648CA85D-1" escape="true">Foreign Currency</ix:nonNumeric></span><ix:continuation id="TextSelection-97C740DA89EE6694C237C80C648CA85D-1" continuedAt="TextSelection-97C740DA89EE6694C237C80C648CA85D-2"><span style="font-family:inherit;font-size:10pt;">&#8212;The Company has operations in the US, Ireland, Germany, France, the UK, the Netherlands and Japan. The results of its non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' equity, as a component of other comprehensive loss.</span></ix:continuation></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-97C740DA89EE6694C237C80C648CA85D-2">The Company realizes foreign currency transaction gains (losses) in the normal course of business based on movements in the applicable exchange rates. These gains (losses) are included as a component of other income, net.</ix:continuation></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ConcentrationRiskCreditRisk" id="TextSelection-6D61090D6B59C200C710C80C648C88D0-0-wk-Fact-76770CDF47BA9F166F6EC80C64786AA1" continuedAt="TextSelection-6D61090D6B59C200C710C80C648C88D0-1" escape="true">Concentration of Credit Risk</ix:nonNumeric></span><ix:continuation id="TextSelection-6D61090D6B59C200C710C80C648C88D0-1" continuedAt="TextSelection-6D61090D6B59C200C710C80C648C88D0-2"><span style="font-family:inherit;font-size:10pt;">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></ix:continuation></div><ix:continuation id="TextSelection-6D61090D6B59C200C710C80C648C88D0-2" continuedAt="TextSelection-6D61090D6B59C200C710C80C648C88D0-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. <ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="TextSelection-2C484BDA0748FBFB8026533381033D49-0-wk-Fact-25D5CD2401EEB51F8E7458D6303256EC" continuedAt="TextSelection-2C484BDA0748FBFB8026533381033D49-1" escape="true">The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended </ix:nonNumeric></span><ix:continuation id="TextSelection-2C484BDA0748FBFB8026533381033D49-1" continuedAt="TextSelection-2C484BDA0748FBFB8026533381033D49-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></ix:continuation></div><div style="line-height:120%;padding-bottom:17px;padding-top:17px;text-align:center;text-indent:0px;font-size:11pt;"><ix:continuation id="TextSelection-2C484BDA0748FBFB8026533381033D49-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:357px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:181px;"></td><td style="width:176px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage of Total Gross Product Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1883-wk-Fact-6E379A0BF5A1E8D1356258DBCE490518" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">37</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1894-wk-Fact-F4C2268BCF2C1D04F0D358DBCE51A1B5" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">27</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e1905-wk-Fact-7F2226FDC7DD3C3F426358DBCE42C443" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">19</ix:nonFraction>%</span></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">83</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8662E0A15332C9838894C80C648C8906-4" continuedAt="TextSelection-8662E0A15332C9838894C80C648C8906-5"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-6D61090D6B59C200C710C80C648C88D0-3">The Company did not have product revenue prior to US FDA approval of ARIKAYCE in 2018. The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially impact future operating results.</ix:continuation></span></div><div style="line-height:120%;text-align:left;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-37401FEE94FE8BC2AEBFC80C648A3968-0-wk-Fact-C2B2438678024AC9EF9AC80C647B22B6" continuedAt="TextSelection-37401FEE94FE8BC2AEBFC80C648A3968-1" escape="true">Revenue Recognition</ix:nonNumeric></span><ix:continuation id="TextSelection-37401FEE94FE8BC2AEBFC80C648A3968-1" continuedAt="TextSelection-37401FEE94FE8BC2AEBFC80C648A3968-2"><span style="font-family:inherit;font-size:10pt;">&#8212;In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company did not incur or capitalize any incremental costs associated with obtaining contracts with customers.</span></ix:continuation></div><ix:continuation id="TextSelection-37401FEE94FE8BC2AEBFC80C648A3968-2" continuedAt="TextSelection-37401FEE94FE8BC2AEBFC80C648A3968-3"><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenues consist primarily of sales of ARIKAYCE in the US. Product revenues are recognized once the Company performs and satisfies all five steps mentioned above. In October 2018, the Company began shipping ARIKAYCE to its customers in the US, which include specialty pharmacies and specialty distributors.&#160;The Company recognizes revenues for product received by its customers net of allowances for customer credits, including estimated rebates, chargebacks, prompt pay discounts, returns, service fees, and government rebates, such as Medicaid rebates and Medicare Part D coverage gap reimbursements in the US.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Customer credits:</span><span style="font-family:inherit;font-size:10pt;">&#160;The Company&#8217;s customers are offered various forms of consideration, including service fees and prompt payment discounts. The Company anticipates that its customers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total gross product revenues when revenues are recognized. Service fees are also deducted from total gross product revenues as they are earned.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Rebates:</span><span style="font-family:inherit;font-size:10pt;"> The Company contracts with Medicaid, other government agencies and various private organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized.</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-bottom:17px;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Chargebacks:</span><span style="font-family:inherit;font-size:10pt;"> Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price initially paid by the specialty distributor and the discounted price paid by the contracted customers. The Company estimates the chargebacks it provides to the specialty distributor and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized.</span></div><div style="line-height:120%;padding-bottom:17px;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Co-payment assistance:</span><span style="font-family:inherit;font-size:10pt;"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by a third-party administrator.</span></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any, or all, of the Company&#8217;s actual experience vary from the estimates above, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="insm:ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock" id="TextSelection-F7D0DD45D85C53489B30ECB8A40925BD-0-wk-Fact-B027DEA30E215C168821ECBB948E7653" continuedAt="TextSelection-F7D0DD45D85C53489B30ECB8A40925BD-1" escape="true">The following table provides a summary roll-forward of our sales allowances and related accruals for the year ended </ix:nonNumeric></span><ix:continuation id="TextSelection-F7D0DD45D85C53489B30ECB8A40925BD-1" continuedAt="TextSelection-F7D0DD45D85C53489B30ECB8A40925BD-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands), which have been deducted in arriving at net product revenue:</span></ix:continuation></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8662E0A15332C9838894C80C648C8906-5" continuedAt="TextSelection-8662E0A15332C9838894C80C648C8906-6"><ix:continuation id="TextSelection-37401FEE94FE8BC2AEBFC80C648A3968-3" continuedAt="TextSelection-37401FEE94FE8BC2AEBFC80C648A3968-4"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:53px;font-size:10pt;"><ix:continuation id="TextSelection-F7D0DD45D85C53489B30ECB8A40925BD-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Customer fees, discounts and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rebates, chargebacks and co-pay assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Balance as of January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2064-wk-Fact-313A124974909A8BC3C5EDC5FFBD2218" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="FI2017Q4_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2083-wk-Fact-2DCE6178D599F6F20B6AEDC5FFB5128B" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="FI2017Q4_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2102-wk-Fact-C8EDF2FF7D1FC5504DF5EDC5FFAC4DBD" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Allowances for current period sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2118-wk-Fact-4329A9ED75689934BA82EDCD6FD8BA17" name="insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2137-wk-Fact-3A5939A41A88B0900D29EDCD6FC69146" name="insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">849</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2156-wk-Fact-BBEBAB18619955AABFE0EDCD6FABD347" name="insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;&#160;&#160;Payments and credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15037063e2177-wk-Fact-2E78BBB246E4823FD521EDCFB3C95B5B" name="insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15037063e2197-wk-Fact-1E83B6E37D7006182669EDCFB3D4D286" name="insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15037063e2217-wk-Fact-540269A501C4BD0CC4D2EDCFB3CE6E89" name="insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2244-wk-Fact-19C8F1314930051CACC8EDC6F2194EF9" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="FI2018Q4_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2263-wk-Fact-122A5B16BD91E3E6E8C9EDC6F4B46B0A" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="FI2018Q4_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2282-wk-Fact-9604004A15D5F6D6F110EDC6F74D9EE4" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, upon US FDA approval of ARIKAYCE, the Company began recognizing revenue from sales to the French National Agency for Medicines and Health Products Safety (ANSM), which granted ARIKAYCE a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU). Pursuant to this program, the Company ships product to pharmacies after receiving requests from physicians for patients in France. The Company is initiating expanded access programs (EAPs) in Europe and other countries, some of which may be fully reimbursed. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:continuation id="TextSelection-37401FEE94FE8BC2AEBFC80C648A3968-4"></ix:continuation><ix:nonNumeric contextRef="FD2018Q4YTD" name="insm:InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" id="TextSelection-3513FCE137D4C96EB9DA57B9A9F0CCAC-0-wk-Fact-2A67225DEFB0BE9AB1B157BA079E3049" continuedAt="TextSelection-3513FCE137D4C96EB9DA57B9A9F0CCAC-1" escape="true">Inventory and cost of product revenues (excluding amortization of intangible assets)</ix:nonNumeric></span><ix:continuation id="TextSelection-3513FCE137D4C96EB9DA57B9A9F0CCAC-1" continuedAt="TextSelection-3513FCE137D4C96EB9DA57B9A9F0CCAC-2"><span style="font-family:inherit;font-size:10pt;">&#8212;Inventory is stated at the lower of cost and net realizable value with cost determined on a standard costing method. The Company capitalized inventory costs following regulatory approval of ARIKAYCE from the FDA on September 28, 2018. Inventory is sold on a first-in, first out basis. Manufacturing variances, such as material usage variance and yield variance, are capitalized in inventory until the respective units are sold, at which point the variances are recognized in cost of product revenues. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, records a write-down accordingly. The Company also performs strict quality control throughout the manufacturing processes of products; however, certain batches or units of product may not meet quality specifications and result in a charge to cost of product revenues in the period incurred.</span></ix:continuation></div><ix:continuation id="TextSelection-3513FCE137D4C96EB9DA57B9A9F0CCAC-2" continuedAt="TextSelection-3513FCE137D4C96EB9DA57B9A9F0CCAC-3"><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred; therefore, inventory is not included in the </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> consolidated balance sheet. Inventory that is used for clinical development purposes is expensed to research and development expense when consumed.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-3513FCE137D4C96EB9DA57B9A9F0CCAC-3">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight-in, allocation of overhead costs, and inventory adjustment charges, in addition to royalty expenses due to PARI. </ix:continuation></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="TextSelection-BFE13860BF34B34F1177C80C648C2CAF-0-wk-Fact-AAFCDFDD06252FC4F14AC80C647C5820" continuedAt="TextSelection-BFE13860BF34B34F1177C80C648C2CAF-1" escape="true">Research and Development</ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-BFE13860BF34B34F1177C80C648C2CAF-1">&#8212;Research and development expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in the Company's research and development functions, and other internal operating expenses, the cost of manufacturing a drug candidate, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, research and development expenses include payments to third parties for the license rights to products in development (prior to marketing approval). The Company's expenses related to manufacturing its drug candidate and medical devices for clinical study are primarily related to activities at contract manufacturing organizations that manufacture ARIKAYCE, INS1007, and INS1009 and the medical devices for the Company's use. The Company's expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on the Company's behalf. These contracts set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided.</ix:continuation></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="TextSelection-CF2CB8B5750FF43B4228C80C648D53EA-0-wk-Fact-077CDA20B00E2ECB404BC80C6450EA4D" continuedAt="TextSelection-CF2CB8B5750FF43B4228C80C648D53EA-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span><ix:continuation id="TextSelection-CF2CB8B5750FF43B4228C80C648D53EA-1" continuedAt="TextSelection-CF2CB8B5750FF43B4228C80C648D53EA-2"><span style="font-family:inherit;font-size:10pt;">&#8212;The Company recognizes stock-based compensation expense for awards of equity instruments to employees and directors based on the grant-date fair value of those awards. The grant-date fair value of the award is recognized as compensation expense ratably over the requisite service period, which generally equals the vesting period of the award, and if applicable, is adjusted for expected forfeitures. The Company also grants performance-based stock options to employees. The grant-date fair value of the performance-based stock options is recognized as compensation expense over the implicit service period using the accelerated attribution method once it is probable that the performance condition will </span></ix:continuation></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">85</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8662E0A15332C9838894C80C648C8906-6" continuedAt="TextSelection-8662E0A15332C9838894C80C648C8906-7"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-CF2CB8B5750FF43B4228C80C648D53EA-2">be achieved. Stock-based compensation expense is included in both R&amp;D and SG&amp;A expenses in the consolidated statements of comprehensive loss.</ix:continuation></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:IncomeTaxPolicyTextBlock" id="TextSelection-283D233C1041E7644AC2C80C648B3BF1-0-wk-Fact-3DE63C9C8A1B85293C05C80C647A26DA" continuedAt="TextSelection-283D233C1041E7644AC2C80C648B3BF1-1" escape="true">Income Taxes</ix:nonNumeric></span><ix:continuation id="TextSelection-283D233C1041E7644AC2C80C648B3BF1-1" continuedAt="TextSelection-283D233C1041E7644AC2C80C648B3BF1-2"><span style="font-family:inherit;font-size:10pt;">&#8212;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span></ix:continuation></div><ix:continuation id="TextSelection-283D233C1041E7644AC2C80C648B3BF1-2" continuedAt="TextSelection-283D233C1041E7644AC2C80C648B3BF1-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A valuation allowance is recorded to reduce the deferred tax assets to the amount that is expected to be realized. In evaluating the need for a valuation allowance, the Company takes into account various factors, including the expected level of future taxable income and available tax planning strategies. If actual results differ from the assumptions made in the evaluation of a valuation allowance, the Company records a change in valuation allowance through income tax expense in the period such determination is made.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based solely on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than </span><span style="font-family:inherit;font-size:10pt;">50%</span><span style="font-family:inherit;font-size:10pt;"> likelihood to be sustained upon ultimate settlement. As any adjustment to the Company&#8217;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-283D233C1041E7644AC2C80C648B3BF1-3">The Company's policy for interest and penalties related to income tax exposures is to recognize interest and penalties as a component of the income tax provision (benefit) in the consolidated statements of comprehensive loss.</ix:continuation></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:EarningsPerSharePolicyTextBlock" id="TextSelection-0DCF28C612DD2FC8E743C80C648C7128-0-wk-Fact-D761A6844E656F5996EEC80C647C948A" continuedAt="TextSelection-0DCF28C612DD2FC8E743C80C648C7128-1" escape="true">Net Loss Per Share</ix:nonNumeric></span><ix:continuation id="TextSelection-0DCF28C612DD2FC8E743C80C648C7128-1" continuedAt="TextSelection-0DCF28C612DD2FC8E743C80C648C7128-2"><span style="font-family:inherit;font-size:10pt;">&#8212;Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options and restricted stock units would be anti-dilutive as the Company incurred a net loss in all periods presented. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options would be determined based on the treasury stock method.</span></ix:continuation></div><ix:continuation id="TextSelection-0DCF28C612DD2FC8E743C80C648C7128-2" continuedAt="TextSelection-0DCF28C612DD2FC8E743C80C648C7128-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="TextSelection-1E49B9DA74C690094DB8C80C648BF43F-0-wk-Fact-F40077E01F3ECAAA9D27C80C64596AA6" continuedAt="TextSelection-1E49B9DA74C690094DB8C80C648BF43F-1" escape="true">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended </ix:nonNumeric></span><ix:continuation id="TextSelection-1E49B9DA74C690094DB8C80C648BF43F-1" continuedAt="TextSelection-1E49B9DA74C690094DB8C80C648BF43F-2"><span style="font-family:inherit;font-size:10pt;">December 31,</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></ix:continuation></div><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-1E49B9DA74C690094DB8C80C648BF43F-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15037063e2690-wk-Fact-B42634276C7A9632D85AC80C6434F487" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">324,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15037063e2710-wk-Fact-04977BE1C74AC80F3F04C80C643AC548" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15037063e2730-wk-Fact-7F7EDEF8E2CD9E9CBE90C80C642F7957" name="us-gaap:NetIncomeLoss" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">176,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares used in calculation of basic net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2806-wk-Fact-31F42F46DB6574DFBE34C80C646871D8" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">76,889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2825-wk-Fact-A121841324E659209E0FC80C64630925" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">66,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2844-wk-Fact-1DFD161E563E2CB5D32CC80C6461DA35" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2016Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">61,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2924-wk-Fact-A968F2037E484AB84156C80C646D98CF" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2943-wk-Fact-3560213C156077375321C80C645D56E9" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2962-wk-Fact-2C60FAAC50A0786CA216C80C646926F3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e2983-wk-Fact-EEE971BE376A98B5BCEBC80C6465E9B8" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3002-wk-Fact-E5FF182BD6F9C3880E45C80C645B1D97" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3021-wk-Fact-A06265FAEBB412229A8AC80C64687797" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding used in calculation of diluted net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3042-wk-Fact-39E1AB39F73419995A39C80C64648E3D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">76,889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3061-wk-Fact-470C3DD88378548D680BC80C6467F11C" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">66,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3080-wk-Fact-FAFC75174D34AD128004C80C645DC4F0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2016Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">61,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15037063e3166-wk-Fact-518DC39F637E8302275EC80C64362527" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">4.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15037063e3186-wk-Fact-E7AA589AA67B3269D3FEC80C6440E3D2" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15037063e3206-wk-Fact-392E31090CD7F1536356C80C6432E7FF" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2016Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8662E0A15332C9838894C80C648C8906-7" continuedAt="TextSelection-8662E0A15332C9838894C80C648C8906-8"><ix:continuation id="TextSelection-0DCF28C612DD2FC8E743C80C648C7128-3" continuedAt="TextSelection-0DCF28C612DD2FC8E743C80C648C7128-4"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-B6EDC26957B1A62AF918C80C648A5F33-0-wk-Fact-686CF8AFA16695C7E4EAC80C648189D6" continuedAt="TextSelection-B6EDC26957B1A62AF918C80C648A5F33-1" escape="true">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of </ix:nonNumeric></span><ix:continuation id="TextSelection-B6EDC26957B1A62AF918C80C648A5F33-1" continuedAt="TextSelection-B6EDC26957B1A62AF918C80C648A5F33-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> as their effect would have been anti-dilutive (in thousands).</span></ix:continuation></div></ix:continuation><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-0DCF28C612DD2FC8E743C80C648C7128-4"><ix:continuation id="TextSelection-B6EDC26957B1A62AF918C80C648A5F33-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3310-wk-Fact-30924E24C58F1DAE183CC80C64444C53" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">9,382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3324-wk-Fact-3C87C6EDEBB22DF7F120C80C64462DC1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">8,609</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3338-wk-Fact-600C33E1371052F59210C80C6447AFAB" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">7,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3353-wk-Fact-17BB04D0B5F9A8F0087DC80C64473042" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3367-wk-Fact-DA79F9FFF5DE9D5F4DC4C80C6444FBAA" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3381-wk-Fact-52A86C847D3FE5AB5747C80C64469896" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3396-wk-Fact-61E01799EE8083939FF39727AC78CFAF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,492</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3410-wk-Fact-465679CC65A4E1CDF8D3972879C094C7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3424-wk-Fact-1A4CEE2EB8C0C0BE056097289A4FF66F" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="TextSelection-6591A9D56318745967D0C80C648AB2D2-0-wk-Fact-5EAC0197AAF6ADEC636BC80C647FAD37" continuedAt="TextSelection-6591A9D56318745967D0C80C648AB2D2-1" escape="true">Segment Information</ix:nonNumeric></span><ix:continuation id="TextSelection-6591A9D56318745967D0C80C648AB2D2-1" continuedAt="TextSelection-6591A9D56318745967D0C80C648AB2D2-2"><span style="font-family:inherit;font-size:10pt;">&#8212;The Company currently operates in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3442-wk-Fact-4B1EC734327F927FFB3DC80C6481E70E" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2018Q4YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> business segment, which is the development and commercialization of therapies for patients with rare diseases. A single management team that reports to the Chief Executive Officer comprehensively manages the entire business. The Company does not operate separate lines of business with respect to its products or product candidates. Accordingly, the Company has </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15037063e3446-wk-Fact-23CB31D02903EB5FB79314EA27D49F45" name="us-gaap:NumberOfReportableSegments" contextRef="FD2018Q4YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-6591A9D56318745967D0C80C648AB2D2-2"> reportable segment.</ix:continuation></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-74C3521C8D799BFE2F09C80C648B8884-0-wk-Fact-2693E70D8DBFFDB78AC3C80C647BC9EA" continuedAt="TextSelection-74C3521C8D799BFE2F09C80C648B8884-1" escape="true">New Accounting Pronouncements (Adopted)</ix:nonNumeric></span><ix:continuation id="TextSelection-74C3521C8D799BFE2F09C80C648B8884-1" continuedAt="TextSelection-74C3521C8D799BFE2F09C80C648B8884-2"><span style="font-family:inherit;font-size:10pt;">&#8212;In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</span><span style="font-family:inherit;font-size:10pt;">, which addressed eight specific cash flow issues with the objective of reducing the existing diversity in practice. Among the updates, the standard requires debt extinguishment costs to be classified as cash outflows for financing activities. This standard update became effective as of the first quarter of 2018. As a result of the adoption of the standard, in the first quarter of 2018, the Company reported a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15037063e3469-wk-Fact-056404937DC6727DB9B60DE84AE8EB8F" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on extinguishment of debt in the operating activities section of its consolidated statement of cash flows. The Company had no material debt extinguishment costs prior to the first quarter of 2018. The impact of adopting this standard was not material to the Company.</span></ix:continuation></div><ix:continuation id="TextSelection-74C3521C8D799BFE2F09C80C648B8884-2" continuedAt="TextSelection-74C3521C8D799BFE2F09C80C648B8884-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU&#160;2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span><span style="font-family:inherit;font-size:10pt;"> which amended the existing accounting standards for revenue recognition. ASU 2014-09 establishes principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services. In July 2015, the FASB deferred the effective date for annual reporting periods beginning after December&#160;15, 2017. The Company adopted ASU 2014-09 in the first quarter of 2018.  The adoption did not have a material impact on the Company's consolidated financial statements.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><ix:continuation id="TextSelection-74C3521C8D799BFE2F09C80C648B8884-3" continuedAt="TextSelection-74C3521C8D799BFE2F09C80C648B8884-4"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Pronouncements (Not Yet Adopted)</span><span style="font-family:inherit;font-size:10pt;">&#8212;In February 2016, the FASB issued ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018 (including interim periods within those periods) and early adoption is permitted. In August 2018, the FASB issued ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements to ASC 842</span><span style="font-family:inherit;font-size:10pt;">, which provides a new transition option in which an entity initially applies ASU 2016-02 at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will use the new transition option and will be also utilizing the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any expired or existing leases. The Company will also use the short-term lease exception for leases with a term of twelve months or less. Additionally, the Company expects to use the practical expedient that allows it to treat the lease and non-lease components of its leases as a single component. The Company has identified approximately ten leasing arrangements and estimates the impact on its consolidated balance sheet to be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15037063e3495-wk-Fact-12022F5B785B309BED9CDD5B3F9DE0F3" name="us-gaap:OperatingLeaseLiability" contextRef="I2019Q1Jan01_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15037063e3499-wk-Fact-2AE7ED581DE8583427AADD6F425E850E" name="us-gaap:OperatingLeaseLiability" contextRef="I2019Q1Jan01_srt_RangeAxis_srt_MaximumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-74C3521C8D799BFE2F09C80C648B8884-4">. There will be no adjustment recognized through retained earnings as a result of adoption. The Company will adopt ASU 2016-02 effective January 1, 2019, and is continuing to evaluate the impact of adoption on its consolidated financial statements and its internal control over financial reporting. </ix:continuation></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses</span><span style="font-family:inherit;font-size:10pt;"> which requires financial assets measured at an amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. ASU 2016-13 is effective for fiscal years effective for fiscal years after beginning after December 15, 2019. Different aspects of the guidance require modified </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">87</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-8662E0A15332C9838894C80C648C8906-8">retrospective or prospective adoption. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</ix:continuation> </span></div><div><a id="s26d72aa0b3af4f79a341903dc98c7cc9"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-A38EF5728C23D73BF1291590E3359B85-0-wk-Fact-19F89575F02A8C424214159276639BE7" continuedAt="TextSelection-A38EF5728C23D73BF1291590E3359B85-1" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="TextSelection-A38EF5728C23D73BF1291590E3359B85-1" continuedAt="TextSelection-A38EF5728C23D73BF1291590E3359B85-2"><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-3114E0F93D1FE570D670159298175405-0-wk-Fact-1E4B59EA0F8021308C881595919F4A91" continuedAt="TextSelection-3114E0F93D1FE570D670159298175405-1" escape="true">As of December 31, 2018, the Company's inventory balance consists of the following (in thousands): </ix:nonNumeric></span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-3114E0F93D1FE570D670159298175405-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:407px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:274px;"></td><td style="width:9px;"></td><td style="width:119px;"></td><td style="width:4px;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15029005e929-wk-Fact-696332621182DB3735C115A64FC403E6" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15029005e944-wk-Fact-D24B4AB3BEC14B3C8FD715A80F8ABC7F" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,567</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15029005e964-wk-Fact-75B64BE58E68766F1B6F15AA1E7E3DB2" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15029005e989-wk-Fact-1DBCE8064A0BCB536A421995AF92293F" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-A38EF5728C23D73BF1291590E3359B85-2">Inventory is stated at the lower of cost or net realizable value and consists of raw materials, work-in-process and finished goods. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE on September 28, 2018. The Company has not recorded any inventory write downs since that time. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.</ix:continuation> </span></div><div><a id="sDB71F36512DB5C308A7B1A54C259B25C"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="TextSelection-0297DBE2657B18DD6168C80C648DE850-0-wk-Fact-5EAE7F125F859347C8C1C80C644357DC" continuedAt="TextSelection-0297DBE2657B18DD6168C80C648DE850-1" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="TextSelection-0297DBE2657B18DD6168C80C648DE850-1" continuedAt="TextSelection-0297DBE2657B18DD6168C80C648DE850-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="TextSelection-88E5DDC6CE60E979EAA2C80C648D9085-0-wk-Fact-C054CF22CB138893ADBBC80C6442B826" continuedAt="TextSelection-88E5DDC6CE60E979EAA2C80C648D9085-1" escape="true">Accrued expenses consist of the following:</ix:nonNumeric></span></div></ix:continuation><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-88E5DDC6CE60E979EAA2C80C648D9085-1"><ix:continuation id="TextSelection-0297DBE2657B18DD6168C80C648DE850-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trial expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1016-wk-Fact-62D2BB9CEC6D33E73E3AC80C6422F559" name="insm:AccruedClinicalTrialExpenses" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,635</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1035-wk-Fact-EE6527851203C449ABF9C80C644A4863" name="insm:AccruedClinicalTrialExpenses" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1050-wk-Fact-E325643DC0D4A624ED0EC80C641DA9E3" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1069-wk-Fact-132CE3A20CD2D1601EC5C80C641FCAEC" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued technical operation expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1089-wk-Fact-6DB046C28350C7487A5AC80C64202A0B" name="insm:AccruedTechnicalOperationExpenses" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1108-wk-Fact-C5BB6490508F042C0501C80C6422E27E" name="insm:AccruedTechnicalOperationExpenses" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1128-wk-Fact-5DA24597D43D316660BEC80C641F6E13" name="us-gaap:InterestPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,631</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1147-wk-Fact-51CA7067ABE99B843CDCC80C644D3EBE" name="us-gaap:InterestPayableCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">423</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued sales allowances and related costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1167-wk-Fact-1933ECD73B4169D6759780A06F2A1BF3" name="insm:AccruedSalesAllowancesandRelatedCosts" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1186-wk-Fact-6920CE1C08BA8CAD279080A06F2E8535" name="insm:AccruedSalesAllowancesandRelatedCosts" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued construction costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1206-wk-Fact-ACD570A65F3B6FD67FADC80C641E0267" name="insm:AccruedConstructionLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1225-wk-Fact-71AAA0674EEF87358E8414C8F85A9244" name="insm:AccruedConstructionLiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1245-wk-Fact-1D80F81920A4F2BE567FC80C644B12CF" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1264-wk-Fact-9A0C0F33C31ED7C01DD5C80C644C02DE" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1289-wk-Fact-5D090E567899D78AEC44C80C647E734C" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038244e1308-wk-Fact-71F7BB0080BFEB1A3989C80C646A1E6C" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sF84FB9791FF6536FA38098EB8909BC28"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="TextSelection-7A5C10C763A25C74E45FC80C648D93DB-0-wk-Fact-B2D4ACBCBB29DD1B8DCAC80C6480D115" continuedAt="TextSelection-7A5C10C763A25C74E45FC80C648D93DB-1" escape="true">Intangibles, net</ix:nonNumeric></span></div><ix:continuation id="TextSelection-7A5C10C763A25C74E45FC80C648D93DB-1" continuedAt="TextSelection-7A5C10C763A25C74E45FC80C648D93DB-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company's identifiable intangible assets consisted of acquired ARIKAYCE R&amp;D, formerly referred to as in-process research and development, and a milestone paid to PARI Pharma GmbH (PARI) for the license to use PARI's Lamira&#174; Nebulizer System for the delivery of ARIKAYCE to patients. The Company's only identifiable intangible asset was in-process research and development (IPRD) related to ARIKAYCE as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, which resulted from the initial amount recorded at the time of the Company's merger with Transave in 2010 and subsequent adjustments in the value. On September 28, 2018, as a result of the FDA approval of ARIKAYCE, the Company recorded a milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15039921e871-wk-Fact-B86CBA3438C421D79685812E9FF53FF2" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D2018Q3Sep28-Sep28" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> due to PARI. Total intangible assets, net was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15039921e875-wk-Fact-B9FB144BBC30B53A00D5A6061E762BCE" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15039921e879-wk-Fact-0C06D2B0EC2B98F0B963A6061E8516DC" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the Acquired ARIKAYCE milestone, at the date of subsequent adjustments of fair value. The Company began amortizing its </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intangibles, net (Continued)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-7A5C10C763A25C74E45FC80C648D93DB-2" continuedAt="TextSelection-7A5C10C763A25C74E45FC80C648D93DB-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">intangible assets October 1, 2018, over ARIKAYCE's initial regulatory exclusivity period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15039921e899-wk-Fact-9E7EB770EB48C59ADD281AC1F87114F1" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2018Q4YTD" format="ixt-sec:duryear">12</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">. Amortization of intangible assets during each of the next five years is estimated to be approximately </span><span style="font-family:inherit;font-size:10pt;">$5.0 million</span><span style="font-family:inherit;font-size:10pt;"> per year. The Company performed its annual impairment test as of October&#160;1, 2018. The Company performed a qualitative assessment to evaluate whether there was an impairment of the assets. This assessment did not identify any indicators of impairment of the intangible assets as of that date.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-4DD6628C4DA2EC2B39D815746850693F-0-wk-Fact-FAC48973C1AC6B25D8A41575B9090159" continuedAt="TextSelection-4DD6628C4DA2EC2B39D815746850693F-1" escape="true">A rollforward of the Company's intangible assets for the years ended </ix:nonNumeric></span><ix:continuation id="TextSelection-4DD6628C4DA2EC2B39D815746850693F-1" continuedAt="TextSelection-4DD6628C4DA2EC2B39D815746850693F-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> follows:</span></ix:continuation></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:56px;font-size:10pt;"><ix:continuation id="TextSelection-7A5C10C763A25C74E45FC80C648D93DB-3"><ix:continuation id="TextSelection-4DD6628C4DA2EC2B39D815746850693F-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Intangible Asset</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">January 1,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Additions</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Acquired ARIKAYCE R&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1088-wk-Fact-5FD0B3B197962CEEA384585607225507" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="I2018Q1Jan01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1102-wk-Fact-DACB9F8B2CDD3872584858C794DFE600" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15039921e1116-wk-Fact-35F16FD06CBFCE6FD4085869108697CB" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1132-wk-Fact-061C64DAE5159570E8DA5855B6B064F3" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PARI milestone upon FDA approval</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1147-wk-Fact-875C6A7FCF33DD1ECCF058C7222485B7" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="I2018Q1Jan01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1161-wk-Fact-9207CE9CC8717B9E58E158517995E003" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,724</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15039921e1175-wk-Fact-D5AB01DBCC50AD173705586E537E3092" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1190-wk-Fact-B0A918F4505115A60135585AF004CA57" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1216-wk-Fact-271023C74E3197BFC69A5856969A542E" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="I2018Q1Jan01" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1230-wk-Fact-974A9E0C63F9C015A7415860463A9419" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,724</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15039921e1244-wk-Fact-772A6D335720DB6DEBB9586E9AC2D4D7" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1260-wk-Fact-37DB01866B7D3BE6F66CC80C6466A9B9" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Intangible Asset</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">January 1,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Additions</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired ARIKAYCE IPRD</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1480-wk-Fact-3D14D4306A488705CF6F1ACA2BCAFA40" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="I2017Q1Jan01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1494-wk-Fact-9F76A1D15548D179DDC958C812B012E2" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1508-wk-Fact-67B476CC35D975C6630158C853BE5BEA" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1523-wk-Fact-27365AF1525A7BF6A1DA1ACBB4AC2AF7" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1543-wk-Fact-253F5CCF3814CFBB78EB5853E166D344" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="I2017Q1Jan01" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1557-wk-Fact-CEE342E594AD76AE6DAF58C7F4DD2079" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1571-wk-Fact-56B79B5AEB9D1073654058C86BA5C5C4" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15039921e1586-wk-Fact-5F4E1E308F165E3B6678C80C64771C5C" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s76E727AB2D695ADFA44A594D3478CC51"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-5C6A1CB3776DB60DB6CBC80C648D0EE8-0-wk-Fact-FC198E993C4DA695C83AC80C6455E544" continuedAt="TextSelection-5C6A1CB3776DB60DB6CBC80C648D0EE8-1" escape="true">Fixed Assets, net</ix:nonNumeric></span></div><ix:continuation id="TextSelection-5C6A1CB3776DB60DB6CBC80C648D0EE8-1" continuedAt="TextSelection-5C6A1CB3776DB60DB6CBC80C648D0EE8-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-A26C5405FC82FCA80637C80C648D674B-0-wk-Fact-B83CA8B1E621A3E12705C80C6453AD9B" continuedAt="TextSelection-A26C5405FC82FCA80637C80C648D674B-1" escape="true">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows:</ix:nonNumeric></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-A26C5405FC82FCA80637C80C648D674B-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:55%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Useful Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Asset Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lab equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15038311e1046-wk-Fact-75A139B863A10C01C429C80C644484B4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" format="ixt-sec:duryear">7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1061-wk-Fact-B1ABE8FE6F32333DD8BCC80C644D7041" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1080-wk-Fact-0494A4A1D33F564EA2DFC80C644BC688" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,055</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15038311e1095-wk-Fact-6A0BB7EB8FECFDD16CE1C80C6448EBA4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear">7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1105-wk-Fact-4D6910A4BFDCB9442906C80C6447ADFD" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1124-wk-Fact-4B34B6AFF56F207C1C94C80C644A53DE" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,937</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer hardware and software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3&#160;-&#160;5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1154-wk-Fact-EF2661335317D97020A2C80C644DD11B" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1173-wk-Fact-FB3024F46C836D8BD029C80C64459D14" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15038311e1193-wk-Fact-0B67097D6B333141AC45C80C64516649" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear">7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1203-wk-Fact-35BCF4411ADE355A01B1C80C644AFC3B" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1222-wk-Fact-7C3F3C21D93907A189BCC80C645095FD" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15038311e1242-wk-Fact-A5C8C6804B215E031CCBC80C64518807" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ManufacturingEquipmentMember" format="ixt-sec:duryear">7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1252-wk-Fact-8FCAB3E9E10EAF8D1238C80C644860D2" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ManufacturingEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1271-wk-Fact-9D0C733FCBF4DDDD3BCEC80C644D4499" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ManufacturingEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,436</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lease term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1301-wk-Fact-5E0F5C4314D51A71E726C80C644C45D3" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1320-wk-Fact-1D773ED475237B6F72B9C80C644C13B1" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,939</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress (CIP)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1349-wk-Fact-331EE2FDBFF3850D2585C80C644F3B28" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1367-wk-Fact-AEA37E3641777897DD61C80C644947C5" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1397-wk-Fact-F7175FB2A6F4E393BE50C80C644C9A68" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1416-wk-Fact-2F7BAD73F2BD9CB7C104C80C6446281D" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,077</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15038311e1447-wk-Fact-284681DCCA49F683DAFEC80C644526D6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15038311e1467-wk-Fact-B135541307F17185E66CC80C6448CB01" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,645</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed assets, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1503-wk-Fact-E1B09700CAF1045121D4C80C647C57EB" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15038311e1522-wk-Fact-00C9FAFCE2A161EA3686C80C646A5ED4" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15038311e1535-wk-Fact-827C823920930786AB28C80C64532E54" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15038311e1539-wk-Fact-83F098927BCA82323818C80C64540DAE" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15038311e1543-wk-Fact-7B94A07CC816EB375CFBC80C64532B92" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:17px;padding-top:17px;text-align:justify;text-indent:52px;font-size:10pt;"><ix:continuation id="TextSelection-5C6A1CB3776DB60DB6CBC80C648D0EE8-2" continuedAt="TextSelection-5C6A1CB3776DB60DB6CBC80C648D0EE8-3"><span style="font-family:inherit;font-size:10pt;">Fixed assets, net of depreciation, increased to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15038311e1564-wk-Fact-0B05CD40AA31471DAF64BEBB795C6DF4" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended December 31, 2018 from </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15038311e1568-wk-Fact-C371E2C10E6623B57D3853980882C3AD" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2017. The </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15038311e1572-wk-Fact-95438133956EDD862C86A57530A3226A" name="us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> increase was primarily due to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15038311e1576-wk-Fact-8424EF6A3E337A035578A57579905CF0" name="us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease" contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-5C6A1CB3776DB60DB6CBC80C648D0EE8-3"> in construction in progress related to the long-term capacity build-out at the Patheon manufacturing facility.</ix:continuation> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">89</span></div></div><hr style="page-break-after:always"></hr><div><a id="s56B1D9E0C1E75337A5828D62E9618A61"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt (Continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-103FB603671155CB790FC80C648DEF02-0-wk-Fact-0EDB22428745C778BDE5C80C642DB674" continuedAt="TextSelection-103FB603671155CB790FC80C648DEF02-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="TextSelection-103FB603671155CB790FC80C648DEF02-1" continuedAt="TextSelection-103FB603671155CB790FC80C648DEF02-2"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, the Company completed an underwritten public offering of the Convertible Notes, in which the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041894e864-wk-Fact-F211D101D4C839E09BF11AF90DB30CC0" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">450.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of Convertible Notes, including the exercise in full of the underwriters' option to purchase additional Convertible Notes of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041894e868-wk-Fact-50AB1379B0E54D9EEF951AFAE7D8FBEC" name="insm:DebtInstrumentOptionToPurchaseAdditionalDebt" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041894e872-wk-Fact-47386DFF1571BEF1483B1AFDF158478F" name="us-gaap:DeferredFinanceCostsNet" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041894e876-wk-Fact-49FA42A3709FB47568F91AFF1B8FACCC" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">435.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On or after October&#160;15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their Convertible Notes at any time. Upon conversion, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The initial conversion rate is </span><span style="font-family:inherit;font-size:10pt;">25.5384</span><span style="font-family:inherit;font-size:10pt;"> shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041894e890-wk-Fact-D051B4A03AA995BCBDF41B07A384814B" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">39.16</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Holders may convert their Convertible Notes prior to October 15, 2024, only under the following circumstances, subject to the conditions set forth in an indenture, dated as of January 26, 2018, between the Company and Wells Fargo Bank, National Association (Wells Fargo), as trustee, as supplemented by the first supplemental indenture, dated January 26, 2018, between the Company and Wells Fargo (as supplemented, the Indenture): (i) during the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e900-wk-Fact-BF2E44937DDCE1EF25511B2CE999C218" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> business day period immediately after any </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e904-wk-Fact-9605E65D0F0943D931CB1B2E199DFAC5" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of convertible notes, as determined following a request by a holder of the convertible notes, for each trading day of the measurement period was less than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e908-wk-Fact-B5DE4F9741E6AFF91D5C1B09678E118B" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">98</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e912-wk-Fact-7CBFCFCEFB96C0D77EC21B1348369E67" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">45</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e916-wk-Fact-64B3F0BB3172903537A91B16DEC21A74" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">10</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company&#8217;s assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e921-wk-Fact-328BBC28FCB7D2CB6EC41B178875AEAB" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the Convertible Notes may be surrendered by a holder for conversion at any time from or after the date that is </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e925-wk-Fact-A606FFEFBD521043C30E1B29462C4990" name="insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiiiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2018 (and only during such calendar quarter), the last reported sale price of the common stock for at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e929-wk-Fact-70D5CBF78B106571F5241B1A00CC77A0" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermivMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during the period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e933-wk-Fact-8928303EC80241D145DC1B1B81782441" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermivMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e937-wk-Fact-F504BA15BD15EA2A8B671B1E86F69160" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermivMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">130</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price on each applicable trading day, or, (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its Convertible Notes, to which the notice of redemption relates, for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in the convertible notes are not required to be separately accounted for as a derivative. However, since the Convertible Notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated equity component. The fair value was based on data from readily available pricing </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-103FB603671155CB790FC80C648DEF02-2" continuedAt="TextSelection-103FB603671155CB790FC80C648DEF02-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option was determined by deducting the fair value of the liability component from the gross proceeds of the Convertible Notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity&#8217;s own equity.  The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041894e951-wk-Fact-EE09E77FE418FBDA938E1B1F99D08864" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">309.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> using an effective interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e955-wk-Fact-8D50076BDBD0A8C94DE81B206FD55583" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">7.6</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, and accordingly, the residual equity component on the date of issuance was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041894e959-wk-Fact-B876F1813E8A832E74C31B229B6180AC" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">140.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The discount is being amortized to interest expense over the term of the Convertible Notes and has a remaining period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15041894e963-wk-Fact-93814DF0E67AAB8D2C911B2357DD4234" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" contextRef="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" format="ixt-sec:duryear">6.04</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">twelve months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, total interest expense related to the Convertible Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041894e980-wk-Fact-6E7B9482E78867E2E5A01B24C21B8E85" name="us-gaap:InterestExpense" contextRef="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount, as described in the table below. <ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfDebtTableTextBlock" id="TextSelection-7B2C1ED90B6C9A155ED8C80C648EBF87-0-wk-Fact-DB752A450454A8327A02C80C64358089" continuedAt="TextSelection-7B2C1ED90B6C9A155ED8C80C648EBF87-1" escape="true">The following table presents the carrying value of the Company&#8217;s debt balance as of </ix:nonNumeric></span><ix:continuation id="TextSelection-7B2C1ED90B6C9A155ED8C80C648EBF87-1" continuedAt="TextSelection-7B2C1ED90B6C9A155ED8C80C648EBF87-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></ix:continuation></div><ix:continuation id="TextSelection-7B2C1ED90B6C9A155ED8C80C648EBF87-2" continuedAt="TextSelection-7B2C1ED90B6C9A155ED8C80C648EBF87-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-7B2C1ED90B6C9A155ED8C80C648EBF87-3"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.8635477582846%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;1.75% convertible senior notes due 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e1040-wk-Fact-06EA1C2E0904D5B52C841B5A158195DB" name="us-gaap:SecuredDebt" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">450,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;Debt issuance costs, unamortized</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15041894e1055-wk-Fact-117C7C74F0CAF4EDF53F1B5B90FA17B3" name="us-gaap:DeferredFinanceCostsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;Discount on debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15041894e1076-wk-Fact-BB55628CC86E222401E91B5CD1F6B13D" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">125,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e1102-wk-Fact-2E25EFE980C3474A3F0EC80C647C1254" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">316,558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="TextSelection-D9DB53D8EFE0912AF2E5C80C648E1C8A-0-wk-Fact-D0A5A8338B54F94B68BEC80C642E3ECD" continuedAt="TextSelection-D9DB53D8EFE0912AF2E5C80C648E1C8A-1" escape="true">As of </ix:nonNumeric></span><ix:continuation id="TextSelection-D9DB53D8EFE0912AF2E5C80C648E1C8A-1" continuedAt="TextSelection-D9DB53D8EFE0912AF2E5C80C648E1C8A-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):&#160;</span></ix:continuation></div><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-D9DB53D8EFE0912AF2E5C80C648E1C8A-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:38.01169590643275%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:36%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December&#160;31:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e1164-wk-Fact-DEA74D1848ABCCCD54EA1B61E025D9D1" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e1179-wk-Fact-F31EAA0294F68157E2441B62AA7BABA0" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e1199-wk-Fact-0CC7A965F62261F6567F1B6330F3CA17" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e1219-wk-Fact-26DA41463126013F996D1B637FDACA42" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e1239-wk-Fact-5546CFFB008262F62C281B66C65175BF" name="insm:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">450,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041894e1264-wk-Fact-63F1332BCB2F0215DCAA1B67700FE48F" name="us-gaap:LongTermDebt" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">450,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the Company used part of the net proceeds from the issuance of the Convertible Notes to pay off its outstanding debt to Hercules Capital (Hercules). The payments to Hercules consisted of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041894e1279-wk-Fact-486750B118C6F4F2C31F1B4343C30ACC" name="us-gaap:RepaymentsOfDebt" contextRef="D2018Q1Feb2018_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the principal amount and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041894e1283-wk-Fact-5E5FBB3BADAA991903441B474677B347" name="insm:RepaymentsOfDebtFeesAndOutstandingInterest" contextRef="D2018Q1Feb2018_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in back-end fees, outstanding interest, and prepayment penalty fees, which resulted in a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041894e1287-wk-Fact-056404937DC6727DB9B60DE84AE8EB8F" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on extinguishment of debt in the quarter ended March 31, 2018.&#160;&#160;&#160;&#160;</span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-103FB603671155CB790FC80C648DEF02-3" continuedAt="TextSelection-103FB603671155CB790FC80C648DEF02-4"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of the debt (categorized as a Level&#160;2 liability for fair value measurement purposes) is determined using current market factors and the ability of the Company to obtain debt at comparable terms to those that are currently in place. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-103FB603671155CB790FC80C648DEF02-4">, the fair value of the Company's debt approximated the carrying amount.</ix:continuation></span></div><div><a id="s402FA5CFDE435432B85C51E248B1C6FB"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-7F53B3DBC7A25B1307ADC80C648E0FE1-0-wk-Fact-47D38DD2C09A72E8E8AFC80C6464F807" continuedAt="TextSelection-7F53B3DBC7A25B1307ADC80C648E0FE1-1" escape="true">Shareholders' Equity</ix:nonNumeric></span></div><ix:continuation id="TextSelection-7F53B3DBC7A25B1307ADC80C648E0FE1-1" continuedAt="TextSelection-7F53B3DBC7A25B1307ADC80C648E0FE1-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span style="font-family:inherit;font-size:10pt;">&#8212;As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15036687e869-wk-Fact-80A4FEC10D98CBD51703C80C643AE1DA" name="us-gaap:CommonStockSharesAuthorized" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">500,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock authorized with a par value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15036687e873-wk-Fact-8EC0BAB1272807ACB403C80C643DF6C6" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15036687e877-wk-Fact-D035E33264095F31F5C2C80C6435D784" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">77,307,521</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock issued and outstanding. In addition, as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had reserved </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15036687e886-wk-Fact-C9693E8DE38C3CB3181B1545D2652E62" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9,381,730</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock for issuance upon the exercise of outstanding common stock options and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15036687e890-wk-Fact-9CB974F409E8156A48031547760D7E4E" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">227,826</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock for issuance upon the vesting of restricted stock units.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-7F53B3DBC7A25B1307ADC80C648E0FE1-2" continuedAt="TextSelection-7F53B3DBC7A25B1307ADC80C648E0FE1-3"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In&#160;September&#160;2017, the Company completed an underwritten public offering of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15036687e898-wk-Fact-F7502527BF35B35FDE96C80C6469BF10" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2017Q3Sept17" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,123,150</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of the Company&#8217;s common stock, which included the underwriter&#8217;s exercise in full of its over-allotment option of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15036687e902-wk-Fact-2B44191BA82B4660F1B4C80C646CE271" name="insm:CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" contextRef="FI2017Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,842,150</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares, at a price to the public of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15036687e906-wk-Fact-6ADD3F9E97CC500BBA71C80C6470397F" name="us-gaap:SharePrice" contextRef="FI2017Q3" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">28.50</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share.&#160; The Company&#8217;s net proceeds from the sale of the shares, after deducting underwriting discounts and offering expenses of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15036687e910-wk-Fact-BCB24E75C0894DAF0673C80C647D8E1F" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="D2017Q3Sept17" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15036687e914-wk-Fact-4AF3DD5EB7216BA8216BC80C646B0243" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2017Q3Sept17" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">377.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:54px;font-size:10pt;"><ix:continuation id="TextSelection-7F53B3DBC7A25B1307ADC80C648E0FE1-3" continuedAt="TextSelection-7F53B3DBC7A25B1307ADC80C648E0FE1-4"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</span><span style="font-family:inherit;font-size:10pt;">&#8212;As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15036687e931-wk-Fact-AF49F5A6715E5F0E1F4BC80C646C8211" name="us-gaap:PreferredStockSharesAuthorized" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock authorized with a par value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15036687e935-wk-Fact-E2147C6D81463875DF97C80C646D07D2" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15036687e939-wk-Fact-BBE601BC38AE6F43A753C80C6466B224" name="us-gaap:PreferredStockSharesIssued" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-7F53B3DBC7A25B1307ADC80C648E0FE1-4"> shares of preferred stock were issued and outstanding.</ix:continuation></span></div><div><a id="s1CC261119F7C57D1B43F2AF4CBE18A5E"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-0-wk-Fact-E722C60268F12E1A92DBC80C6466F7D8" continuedAt="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-1" continuedAt="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-2"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s current equity compensation plan, the 2017 Incentive Plan, was approved by shareholders at the Company&#8217;s Annual Meeting of Shareholders on May&#160;18, 2017.&#160;The 2017 Incentive Plan is administered by the Compensation Committee and the Board of Directors of the Company.&#160;Under the terms of the 2017 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards, as well as pay incentive bonuses to eligible employees and non-employee directors.&#160;On May&#160;18, 2017, upon the approval of the 2017 Incentive Plan by shareholders,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e864-wk-Fact-094E8843A5928BF88E3E19E9993CBBB7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="I2017Q2May18" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. As of&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e872-wk-Fact-45B1800B5CFDFDC2FD54C80C6471F7A7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,622,830</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares remained for future issuance under the 2017 Incentive Plan. The 2017 Incentive Plan will terminate on April&#160;3, 2027 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options.&#160;These awards are made pursuant to the Nasdaq inducement grant exception as a component of new hires&#8217; employment compensation in connection with the Company&#8217;s equity grant program. During the&#160;</span><span style="font-family:inherit;font-size:10pt;">twelve months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company granted inducement stock options covering </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e889-wk-Fact-A9A26E9B3A1C5AB9B47D19EA78D12AB6" name="insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">295,720</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e893-wk-Fact-E6DEAA00AFCD55862D6DC80C646D64D1" name="insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" contextRef="FD2017Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">266,230</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively,&#160;shares of the Company's common stock to new employees.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</span><span style="font-family:inherit;font-size:10pt;">&#8212;The Company calculates the fair value of stock options granted using the Black-Scholes valuation model. <ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-D62B3AE82DDDC53AEF03C80C648F6E42-0-wk-Fact-2A861480819F7B9AF91EC80C646C6170" continuedAt="TextSelection-D62B3AE82DDDC53AEF03C80C648F6E42-1" escape="true">The following table summarizes the grant date fair value and assumptions used in determining the fair value of all stock options granted, including grants of inducement options, during the years ended </ix:nonNumeric></span><ix:continuation id="TextSelection-D62B3AE82DDDC53AEF03C80C648F6E42-1" continuedAt="TextSelection-D62B3AE82DDDC53AEF03C80C648F6E42-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></ix:continuation></div><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-D62B3AE82DDDC53AEF03C80C648F6E42-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:373px;"></td><td style="width:100px;"></td><td style="width:5px;"></td><td style="width:100px;"></td><td style="width:5px;"></td><td style="width:100px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66% - 68%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71% - 79%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74% - 77%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25% - 2.96%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.73% - 2.13%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.00% - 1.90%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1033-wk-Fact-B3DDF340CB19749C511DC80C643E3C16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1043-wk-Fact-8ED64EEF5C94C0331CFBC80C643F65EA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1053-wk-Fact-B5AF6AD6F1E6785F4206C80C6434A44B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected option term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e1064-wk-Fact-DE392918EFAB1F1C8764C80C64317B0C" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">5.09</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e1074-wk-Fact-5AA3A3794E7F990AB1A3C80C643EB1C7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">6.25</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e1084-wk-Fact-2C40BE615D20B01A9164C80C64521295" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">6.25</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average fair value of stock options granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15052227e1095-wk-Fact-B3D8DB6C2D17BB00539AC80C643237EC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15052227e1105-wk-Fact-3D02420747F04D1C9E93C80C643DFACF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15052227e1115-wk-Fact-2DA1248E8185B0CDF8C6C80C643A67CB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.77</ix:nonFraction></span></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, the volatility factor was based on the Company&#8217;s historical volatility during the expected option term.&#160;Estimated forfeitures were based on the actual percentage of option forfeitures since the closing of the Company&#8217;s merger with Transave, Inc. in December&#160;2010 for the year ended </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">. Beginning with the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, estimated forfeitures were based on the actual percentage of option forfeitures over the expected option term.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company grants performance-condition options to certain employees. Vesting of these options is subject to the Company achieving certain performance criteria established at the date of grant and the individuals fulfilling a service condition (continued employment). As a result of the FDA approval of ARIKAYCE in September 2018, the vesting of performance options totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15052227e1147-wk-Fact-54AE505F2E13BE9B66A1E778BDB70D29" name="us-gaap:StockOptionPlanExpense" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded as non-cash compensation expense in the third quarter of </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">92</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-Based Compensation (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-2" continuedAt="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-8770D801F4A2FC152B7DC80C648E8005-0-wk-Fact-16285284548C40D125F1C80C646DE78C" continuedAt="TextSelection-8770D801F4A2FC152B7DC80C648E8005-1" escape="true">The following table summarizes stock option activity for stock options granted for the years ended </ix:nonNumeric></span><ix:continuation id="TextSelection-8770D801F4A2FC152B7DC80C648E8005-1" continuedAt="TextSelection-8770D801F4A2FC152B7DC80C648E8005-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> as follows:</span></ix:continuation></div><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-8770D801F4A2FC152B7DC80C648E8005-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:321px;"></td><td style="width:82px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:72px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:86px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:72px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Life in Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in '000)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at January 1, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1303-wk-Fact-161E08C3188729AC7468C80C6430638A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2015Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,273,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1322-wk-Fact-69C6D32ED0430EDA244AC80C644E285B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2015Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1367-wk-Fact-EC7CFF85E92E4BADDB69C80C64388D1D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2016Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,532,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1386-wk-Fact-3330D7E27289BF7B31DBC80C643FDD3D" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2016Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15052227e1431-wk-Fact-97296609BE495D0C4804C80C6455AA3B" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2016Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">162,340</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1451-wk-Fact-3905FEB55C245F7D5F53C80C64297145" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2016Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited and expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15052227e1496-wk-Fact-35BF8E4B8D98A31D08FDC80C64526E5F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="FD2016Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">527,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1516-wk-Fact-A8B7853DDFE8FD799DA6C80C6457D0A0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2016Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1561-wk-Fact-4BC402C542CFABAB3826C80C6431A894" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2016Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,116,706</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1580-wk-Fact-45E8B83E2C73059C2EA9C80C64307855" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2016Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1625-wk-Fact-2531CB4CC7A5E9F108C0C80C644C9768" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2016Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,850,658</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1644-wk-Fact-B7CEE3CB4D2E044D39B3C80C644375B5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2016Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1689-wk-Fact-1F95604930822DDFD65DC80C6442F78E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2016Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,113,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1708-wk-Fact-A6BD123F9F3612609F1CC80C644737C8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2016Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Options outstanding at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1753-wk-Fact-4BC402C542CFABAB3826C80C6431A894" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2016Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,116,706</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1772-wk-Fact-45E8B83E2C73059C2EA9C80C64307855" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2016Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1817-wk-Fact-BBD550BCE5723CB064D6C80C6454C6CA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2017Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,284,710</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1836-wk-Fact-D46E3D3CE40E3BE93985C80C645096C2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15052227e1881-wk-Fact-CB8B12EAEF80E23FA288C80C64432F5C" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">378,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1901-wk-Fact-BB72E26E957CEB7A3158C80C6453AF81" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited and expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15052227e1947-wk-Fact-DED3BEBB684236E3BBBBC80C64417F48" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="FD2017Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">414,220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e1967-wk-Fact-3285560EA94272B948A3C80C6461B0BF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Options outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2012-wk-Fact-2548D07248FDB369B30EC80C645786EC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2017Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,608,921</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2031-wk-Fact-98C55E17F67CBB9770FCC80C642B6F6E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2017Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2077-wk-Fact-6CFC694D32F377A37050C80C6454CE12" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2017Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,325,255</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2096-wk-Fact-542016ADE819C157E74EC80C64563782" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2017Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Exercisable at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2142-wk-Fact-8B226CBA722228E5D079C80C645572A5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2017Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,229,478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2161-wk-Fact-C3C04A270DBA2878A368C80C6455D2F7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2017Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2207-wk-Fact-2548D07248FDB369B30EC80C645786EC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2017Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,608,921</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2226-wk-Fact-98C55E17F67CBB9770FCC80C642B6F6E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2017Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2272-wk-Fact-96DBCF2B85776D0C958080ACF300441A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,755,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2291-wk-Fact-EF1F7DDD293F2DAAC98A80ACF30DB4E0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">27.63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15052227e2336-wk-Fact-2F6B8D9F5F240FCCE7D680ACF37A260F" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">494,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2356-wk-Fact-0ADB8F432E85981350BB80ACF35281A0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited and expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15052227e2401-wk-Fact-66124EB6F41637606F6380ACF3270916" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="FD2018Q4YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">488,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2421-wk-Fact-F2E22BED237E0BD2E4B180ACF3345A30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">19.79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2467-wk-Fact-68C0F294EDC2D689494180ACF32B69A8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9,381,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2486-wk-Fact-2321B2B386A67526D95A80ACF35BD50B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e2500-wk-Fact-7CF20C80E5B371C2248A80ACF3167200" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD" format="ixt-sec:duryear">6.69</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2516-wk-Fact-E55E268DACD77657C35180ACF347CBBE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,052</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2531-wk-Fact-C320315AB325EEF647E380ACF2F25860" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,693,635</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2550-wk-Fact-8C23D0B40AEF86B4C0E480ACF364B9D7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e2564-wk-Fact-8EA509F9B1F8B11784C980ACF304DB87" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="FD2018Q4YTD" format="ixt-sec:duryear">6.51</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2580-wk-Fact-F4B2C44BA9B9BA23447F80ACF377EEB9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,926</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2595-wk-Fact-DA15BC444C01A67D0E1380ACF34F0C6B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,649,698</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2614-wk-Fact-184728B800D03F076F7580ACF36D346D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e2628-wk-Fact-A713C5EA0C1288084F0980ACF33EAAB3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2018Q4YTD" format="ixt-sec:duryear">5.58</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2644-wk-Fact-3A0CF8984C13544AE08A80ACF31F23A8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total intrinsic value of stock options exercised during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15052227e2669-wk-Fact-343DC27FDAEB3C25AAAAC80C647BACD9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15052227e2673-wk-Fact-712C9C08C78D51962EBFC80C64666327" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15052227e2678-wk-Fact-EB092BCE4F98D95C673DC80C6475E3C1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15052227e2689-wk-Fact-E6A177084DE77F5FF1BDC80C64688CCF" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e2693-wk-Fact-11D20D14EA8935B33E3BC80C6463B99E" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">2.4</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">. <ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="TextSelection-B3FA912AB64DBB167B4FC80C648ED503-0-wk-Fact-0732CB45FFD07446A86BC80C6476DAE2" continuedAt="TextSelection-B3FA912AB64DBB167B4FC80C648ED503-1" escape="true">The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable as of </ix:nonNumeric></span><ix:continuation id="TextSelection-B3FA912AB64DBB167B4FC80C648ED503-1" continuedAt="TextSelection-B3FA912AB64DBB167B4FC80C648ED503-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></ix:continuation></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">93</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-Based Compensation (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-3" continuedAt="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-4"><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-B3FA912AB64DBB167B4FC80C648ED503-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding as of December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable as of<br/>December&#160;31, 2018</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of<br/>Exercise Prices</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of<br/>Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted<br/>Average<br/>Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of<br/>Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2979-wk-Fact-7086D2D616172EE40EDF19E0DAD0F226" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e2998-wk-Fact-9F4910E7FF73D7C39B5619E0DAD4B956" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3012-wk-Fact-B18E8C7B2F5090295C9DA5EA8C5BE205" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">960,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e3027-wk-Fact-F1015617348758F15FFC19E0DAE2B66B" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" format="ixt-sec:duryear">3.62</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3042-wk-Fact-3EA1E46BE0FF684E97A219E0DAD9ABBD" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3056-wk-Fact-5493FDCE547F030904F119E0DAC8DC50" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">960,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3075-wk-Fact-64A266F244DC8EB9B43019E0DADDB8E4" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3091-wk-Fact-F1F5E644DC96CB1C3FCEA5EA8CA3B90D" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3110-wk-Fact-8E6796E1F8CC54519E3EA5EA8C354F8B" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3124-wk-Fact-F0FE3EB46A07EF692BB3A5EA8CB4DB7D" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">120,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e3139-wk-Fact-C8BB3E1D681EF746880CA5EA8C0A2938" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" format="ixt-sec:duryear">4.13</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3154-wk-Fact-4EEF2F82C9B30BF5218BA5EA8D025431" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3168-wk-Fact-6AFDAA479BFEF6326C07A5EA8D27D287" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">120,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3187-wk-Fact-158790FA9EC3D390456FA5EA8C9243B4" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3203-wk-Fact-8F6F8298C5ECF6CEFFDDA5EA8CCA2800" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3222-wk-Fact-50A84D1903175B9CC933A5EA8C8E53AE" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3236-wk-Fact-436296D126AB0D523CD4A5EA8C3F1DDA" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">953,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e3251-wk-Fact-6532508C577F3016BD04A5EA8D1A125A" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" format="ixt-sec:duryear">6.85</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3266-wk-Fact-3FB3806D91166DC10DB5A5EA8C26BC4B" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3280-wk-Fact-7BCC67056911C7B3D4F4A5EA8C04E440" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">604,037</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3299-wk-Fact-8E8AFA8E31594F9B2F79A5EA8C9B5632" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3315-wk-Fact-BCEF0B133CB3F73F84DEA5EA8C16E4F2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3334-wk-Fact-92841C356234A69E1869A5EA8CF7920E" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3348-wk-Fact-5978FBC5AE78B8A8466CA5EA8CFCD868" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">947,839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e3363-wk-Fact-937235DD233FD3218092A5EA8C1B93C9" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" format="ixt-sec:duryear">4.72</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3378-wk-Fact-910277BC54C522310B50A5EA8C9F753A" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3392-wk-Fact-2EA732A5F529DC4447D0A5EA8C8923CE" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">887,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3411-wk-Fact-C955605FBFA2D419D847A5EA8CCF3184" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3427-wk-Fact-621B4CA3EB919207966AA5EA8C214331" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3446-wk-Fact-170C91F49801A5822DC2A5EA8D1F4DB2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3460-wk-Fact-845E7424934E449374C2A5EA8C96D1DF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">967,420</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e3475-wk-Fact-C5D6FE4A9DDC9F22C2FCA5EA8BE85EAE" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" format="ixt-sec:duryear">7.31</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3490-wk-Fact-2E83FF07646EADC4592AA5EA8C72C20C" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3504-wk-Fact-10CE20AF6F4DCA073627A5EA8CAD726E" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">455,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3523-wk-Fact-7DD354A0FC3027F36C5BA5EA8C6A0FB1" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3539-wk-Fact-7AD5476D4BB8E1F0B20FA5EA8C50E582" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3558-wk-Fact-715E8FA08E262CEAF887A5EA8C4BBD64" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3572-wk-Fact-6DA4B92290252AF5A465A5EA8D2CA494" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,142,513</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e3587-wk-Fact-C0F118A498CCC5338901A5EA8CBF6376" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" format="ixt-sec:duryear">5.76</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3602-wk-Fact-4B93846543D6330C2DD2A5EA8CC5DF79" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3616-wk-Fact-7DFB56AAA181CDED4CDAA5EA8D0DD779" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">782,818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3635-wk-Fact-B3D167AA856A0A00D510A5EA8C6EA4F6" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3651-wk-Fact-3D7DF9B1C1567C4E1583A5EA8C6058D0" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.09</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3670-wk-Fact-558BD7D223E38F31BE00A5EA8CD4C895" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3684-wk-Fact-58E5F6FA1DA6164DE9D7A5EA8CE64E04" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,380,220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e3699-wk-Fact-071584CD2A9346FDBC38A5EA8C459593" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" format="ixt-sec:duryear">7.58</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3714-wk-Fact-C5E8D8F015EC014DEF17A5EA8BFF4885" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3728-wk-Fact-134BF850D0321F2FD310A5EA8C55583B" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">687,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3747-wk-Fact-E6FDC6683C2B1A0BDB79A5EA8BEF281C" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3763-wk-Fact-C42C6CCE114365ACA39CA5EA8CF13364" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3782-wk-Fact-1AE9007B76398B2A7C61A5EA8CA8DE68" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">22.76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3796-wk-Fact-09F2C32915F16F61E78BA5EA8D082EE5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,387,909</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e3811-wk-Fact-713A96BF54D15A09A776A5EA8CB991BE" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" format="ixt-sec:duryear">6.51</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3826-wk-Fact-672A5A7176FE9B971424A5EA8BFAAB22" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.04</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3840-wk-Fact-E8A704923E6087E9BEF7A5EA8C30F2FD" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,081,677</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3859-wk-Fact-97EF5BC07C603D9D0761A5EA8D239755" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3875-wk-Fact-340BEA265E2A9CAAC984A5EA8CEC7FB2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">22.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3894-wk-Fact-982FD23F22E69972A725A5EA8BF40946" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">30.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3908-wk-Fact-EFC77A2E8FFF61B13BA9A5EA8C39CE5D" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,355,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e3923-wk-Fact-8D50D0D31C569E2C159CA5EA8C6545F1" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" format="ixt-sec:duryear">8.37</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3938-wk-Fact-813F8C186DAB44819DE1A5EA8C2BDA07" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">28.54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3952-wk-Fact-05A187AC3E4DB73F8F27A5EA8D137B08" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">57,644</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3971-wk-Fact-275420F121A62914003CA5EA8C800B7E" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">25.41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e3988-wk-Fact-75CB0D9D573BC3159B1FA5EA8C858939" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">30.86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4007-wk-Fact-D04973ACFA9703850719A5EA8D3198DA" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">32.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4021-wk-Fact-19EC138C96C15FDD1C02A5EA8C77E9DC" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">166,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e4036-wk-Fact-69E0B9149C161F769853A5EA8CDF9F93" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" format="ixt-sec:duryear">8.60</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4051-wk-Fact-37344ACABCC94AE9E7FDA5EA8CD938AD" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">31.20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4065-wk-Fact-146D596637D0C5659E31A5EA8C112F96" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,069</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4084-wk-Fact-A0106F4DB1F046F92A3FA5EA8C7B35A3" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">31.57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock and Restricted Stock Units</span><span style="font-family:inherit;font-size:10pt;">&#8212;The Company may grant Restricted Stock (RS) and Restricted Stock Units (RSUs) to employees and non-employee directors. Each share of RS vests upon and each RSU represents a right to receive </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4101-wk-Fact-89BB2BEC84816D85A2B6C80C6473DA8F" name="insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> share of the Company's common stock upon the completion of a specific period of continued service.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RS and RSU awards granted are valued at the market price of the Company's common stock on the date of grant. The Company recognizes noncash compensation expense for the fair values of these RS and RSUs on a straight-line basis over the requisite service period of these awards.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="TextSelection-5A380E0844CDAC758722C80C648E22B8-0-wk-Fact-64F19B8F7653D2CA0DE7C80C646DE0C2" continuedAt="TextSelection-5A380E0844CDAC758722C80C648E22B8-1" escape="true">The following table summarizes RSU awards granted during the years ended </ix:nonNumeric></span><ix:continuation id="TextSelection-5A380E0844CDAC758722C80C648E22B8-1" continuedAt="TextSelection-5A380E0844CDAC758722C80C648E22B8-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">:</span></ix:continuation></div><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-5A380E0844CDAC758722C80C648E22B8-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Price</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4205-wk-Fact-39D95FD868CC2DE1CBA6C80C642A4D3F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">43,554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4224-wk-Fact-B8EB4AB9C635204AEC7CC80C642CAAF3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">19.47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4244-wk-Fact-0D52EDBB77882286A069C80C6433899F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">89,194</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4263-wk-Fact-61C7197BE23EEF0ED71EC80C64256BC5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15052227e4283-wk-Fact-AC1AE797C261406CA4E1C80C64303E82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">43,554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4303-wk-Fact-85D5D9FAC2E0A8C5E78DC80C64343724" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4323-wk-Fact-3A73BC4224F2E1048C32C80C6439EEFD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4342-wk-Fact-2B14D5BA635E0F6B4EFFC80C64269489" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4362-wk-Fact-427C97FC2259D829915FC80C6435519A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">89,194</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4381-wk-Fact-6D0D3251DADE72CE6BC4C80C64260E68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4401-wk-Fact-00F68B21F189A111B8F4C80C6428C33E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">46,914</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4420-wk-Fact-5E507C0C7EEDBC077670C80C6430F95F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15052227e4440-wk-Fact-85D6B46E3BCEE85AB993C80C641E5421" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">89,194</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4460-wk-Fact-CC08D9F9A2980A893CEBC80C6425A5ED" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4480-wk-Fact-8E4816B3BD5D773A6601C80C6422EBB8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4499-wk-Fact-D7C89B4EEAE0BCC69A67C80C6420270E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4519-wk-Fact-A8220C05DB110A06C4C7C80C642801A9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">46,914</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4538-wk-Fact-4F34018F807F95AAA4C5C80C642FD6A4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4558-wk-Fact-63EA2FA97A4E26C307D019CF12877BC2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">253,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4577-wk-Fact-3AFA0AE7EC3D4FA452CA19CF30552A15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">29.16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15052227e4598-wk-Fact-5234E5381931D8D9C5F119CF54FC7030" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">51,992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4618-wk-Fact-A8369C222FFDDB2E409F19CF6E3EEDCE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">18.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15052227e4638-wk-Fact-88EBF3167A02D60006AF19CF89EFF461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">20,682</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4658-wk-Fact-BCEC1495BC0C449C894619CFA6E49758" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">29.05</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4678-wk-Fact-95C6DE3F1236D237799819CFC3ABD308" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">227,826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4697-wk-Fact-B6BCFAF093487D18025419CFDE4B5836" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">29.14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">94</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-Based Compensation (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-4" continuedAt="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-5"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15052227e4714-wk-Fact-1C70732A039DF6D6990EC8D419CF5BF5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to unvested awards, which is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15052227e4718-wk-Fact-276FB24AFBC1DE2E7325DD9499B141CB" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember" format="ixt-sec:duryear">2.8</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-B08E1E746F54BCC5052CC80C648ED6AA-0-wk-Fact-156A989A32E2E7673C21C80C647DF4B1" continuedAt="TextSelection-B08E1E746F54BCC5052CC80C648ED6AA-1" escape="true">The following table summarizes the stock-based compensation recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the years ended </ix:nonNumeric></span><ix:continuation id="TextSelection-B08E1E746F54BCC5052CC80C648ED6AA-1" continuedAt="TextSelection-B08E1E746F54BCC5052CC80C648ED6AA-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> (in millions):</span></ix:continuation></div><ix:continuation id="TextSelection-B08E1E746F54BCC5052CC80C648ED6AA-2" continuedAt="TextSelection-B08E1E746F54BCC5052CC80C648ED6AA-3"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4837-wk-Fact-A7BD853BB6ED63E4F4E2C80C64497A04" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4856-wk-Fact-A8974F69FD4714B348E1C80C6449FB98" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4875-wk-Fact-9A40E94A96B8C31FBDB7C80C64461153" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4891-wk-Fact-D04820307BBD8C094D80C80C644A6650" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4910-wk-Fact-2590CBF49F4E33758029C80C644AD22E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4929-wk-Fact-EC5506F4B1D1C8F0F141C80C6446EC01" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total (1)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4955-wk-Fact-B1F45FE0CAE8B7D4D274C80C6448CC43" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4974-wk-Fact-6FE92E7BB57A27EBF2DCC80C6448DA3F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e4993-wk-Fact-D580FB950E4FE1A79246C80C64469606" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">_________________________________</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-B08E1E746F54BCC5052CC80C648ED6AA-3" continuedAt="TextSelection-B08E1E746F54BCC5052CC80C648ED6AA-4"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-B08E1E746F54BCC5052CC80C648ED6AA-4" continuedAt="TextSelection-B08E1E746F54BCC5052CC80C648ED6AA-5"><span style="font-family:inherit;font-size:10pt;">Includes </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15052227e5015-wk-Fact-513523D05905B525A16BC80C647373A8" name="insm:AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15052227e5019-wk-Fact-DE54EB387B755AD07599C80C647661F8" name="insm:AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15052227e5023-wk-Fact-9E1F88E3D7EA7F1491E0C80C646E070D" name="insm:AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-B08E1E746F54BCC5052CC80C648ED6AA-5">, respectively, for the remeasurement of certain stock options and RSUs that occurred during May 2013.</ix:continuation></span></div></td></tr></table></ix:continuation><div style="line-height:120%;padding-bottom:10px;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-5" continuedAt="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-6"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan </span><span style="font-family:inherit;font-size:10pt;">- On May 15, 2018, the Company's shareholders approved the Company&#8217;s 2018 Employee Stock Purchase Plan (ESPP). As part of the ESPP, eligible employees may acquire an ownership interest in the Company by purchasing common stock, at a discount, through payroll deductions. The ESPP is compensatory under GAAP and the Company recorded stock compensation expense of $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15052227e5051-wk-Fact-28A355BAB5DFE79224F6A64E932E7850" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-6"> in 2018.</ix:continuation>  </span></div><div><a id="s2D87A8C19EAA57CCAAEAB074545056A8"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-0-wk-Fact-89A565CACC434697B772C80C6443F169" continuedAt="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-1" continuedAt="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The income tax provision (benefit) was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15047081e863-wk-Fact-C3F87DAFF7AA94E53AE3C80C64246AEE" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$(<ix:nonFraction id="d15047081e867-wk-Fact-7E1F90F7742924259264C80C64230364" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction>) million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15047081e871-wk-Fact-56863E29648D69FCF493C80C646A2585" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and the effective rates were approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e875-wk-Fact-3B7DFACEB29ACC01298FC80C6464968B" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e879-wk-Fact-236A89997E0688536A4FC80C6428BB52" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e884-wk-Fact-ABDA33B72E601F9F5BE2C80C641ED71E" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2016Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively. The income tax (benefit) for the year ended December 31, 2017 reflects the reversal of the valuation allowance related to alternative minimum tax (AMT) that the Company paid in 2009. As a result of the Tax Cuts and Jobs Act (the Tax Act), the Company recorded a noncurrent receivable to reflect the refund due to the Company in future periods relating to the previously paid AMT. In addition, the income tax provision (benefit) for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflected current income tax expense recorded as a result of the taxable income in certain of the Company's non-US subsidiaries.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company was also subject to foreign income taxes as a result of legal entities established for activities in Europe and Japan. <ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="TextSelection-43B6722E62DD3ED8A4C3C80C648F63F1-0-wk-Fact-891235CF56B36C621149C80C643DF042" continuedAt="TextSelection-43B6722E62DD3ED8A4C3C80C648F63F1-1" escape="true">The Company's loss before income taxes in the US and globally was as follows (in thousands):</ix:nonNumeric></span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-43B6722E62DD3ED8A4C3C80C648F63F1-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e1086-wk-Fact-61DC0E78F82C35C6E3A0C80C64260A03" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">286,211</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e1106-wk-Fact-CA01ECBCBF8D16BFECE4C80C642B4539" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">136,682</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e1126-wk-Fact-966CC710101385BC1F90C80C642A4135" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">140,354</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e1143-wk-Fact-4B743C503381BD50DE98C80C64287460" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e1163-wk-Fact-3E1029C7E5770D584FB6C80C64340FD4" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">56,239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e1183-wk-Fact-EFA2DE983037115AEE6FC80C6428CBF0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35,821</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e1210-wk-Fact-12A725180DFC88524CFCC80C64387A24" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">324,076</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e1230-wk-Fact-A15D7F28ADF1B4BED74EC80C642BF891" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192,921</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e1250-wk-Fact-885B0511759F68EBB430C80C642DAEE3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">176,175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">95</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Income Taxes (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-2" continuedAt="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="TextSelection-1ADD89DFCB5743E228C9C80C648FBB43-0-wk-Fact-4C0E765CB16E42AA3942C80C6434EA52" continuedAt="TextSelection-1ADD89DFCB5743E228C9C80C648FBB43-1" escape="true">The Company's income tax (benefit) provision consisted of the following (in thousands):</ix:nonNumeric></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-1ADD89DFCB5743E228C9C80C648FBB43-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1484-wk-Fact-A69FCCA0A07B35BB49FEC80C643AE0DB" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1503-wk-Fact-4B0D2D3CC0FEE792F547C80C642F200A" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1522-wk-Fact-0F814CD227253A3F5E96C80C642FA3A5" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1538-wk-Fact-086B17D2D8BD21C4C735C80C643E7718" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1557-wk-Fact-A9D6C1E9DE02A92C4905C80C64364DBD" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1576-wk-Fact-91FF67D5542C2085FEABC80C642352D0" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1597-wk-Fact-819CD01056B8B5A0FD29C80C643AAD08" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1616-wk-Fact-CFD0009881ACDC8053ABC80C6435B444" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1635-wk-Fact-72202E0738E9774B6B0FC80C64417454" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">95</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1656-wk-Fact-5F65043746EF9BCBAC70C80C64272452" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1675-wk-Fact-52B298E5B4F6AB95CA41C80C642EA44D" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1694-wk-Fact-E34E0154E537E198454DC80C64320BC8" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1774-wk-Fact-E88DCF00FEBE02231317C80C643BC869" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e1793-wk-Fact-236BA9508C636AE4BE7AC80C64310221" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1813-wk-Fact-1B14F6BDD248A2FCEDBFC80C6432092D" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1834-wk-Fact-832D3D036C1C8878D284C80C6431351D" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1853-wk-Fact-CC2170961ECEDC858A40C80C642D8493" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1872-wk-Fact-A0E28B75C7BD125C0BC9C80C6429DDB7" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1893-wk-Fact-864706EE3974C621ECE0C80C642A6A26" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1912-wk-Fact-66168C8531D13EC3A538C80C642269B9" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1931-wk-Fact-4AADE11964E7E417BF06C80C643E4994" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1953-wk-Fact-F1576C4EB8F3B584E9A4C80C64243781" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e1972-wk-Fact-9AF8ADAC622F8102F74DC80C6435BC1B" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e1992-wk-Fact-F39159D1EE512192EED1C80C642D2503" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2018-wk-Fact-8D74C5FB87F23963EC01C80C64442BB1" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e2037-wk-Fact-DE237BCC7B9D2B1576DAC80C64408AF8" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">272</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2057-wk-Fact-EEB607607F1CA43AAEDDC80C6430DE13" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="TextSelection-CD3EB6A201BE0DFF44EDC80C648FBBC6-0-wk-Fact-B000843DB077C273385CC80C641EC891" continuedAt="TextSelection-CD3EB6A201BE0DFF44EDC80C648FBBC6-1" escape="true">The reconciliation between the federal statutory tax rates and the Company's effective tax rate is as follows:</ix:nonNumeric></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-CD3EB6A201BE0DFF44EDC80C648FBBC6-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory federal tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2190-wk-Fact-34AA558ECF55E318B993C80C64583FAB" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2018Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2205-wk-Fact-F7EC8209732F7268224BC80C645D5ADF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2017Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2220-wk-Fact-E2A9E0BD738A1C735FDEC80C644F68CF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2016Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Permanent items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2236-wk-Fact-5E0C7A37AC176C07E3E9C80C644F1F5B" name="insm:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e2251-wk-Fact-E68C650E06A111B8C2A1C80C645F5249" name="insm:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e2266-wk-Fact-F5644B75AF752CB9B1C6C80C64507050" name="insm:EffectiveIncomeTaxRateReconciliationPermanentItems" contextRef="FD2016Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State income taxes, net of federal benefit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2282-wk-Fact-F82B6FBCE6C8533838B2C80C6456E814" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2297-wk-Fact-6F51F4FF9874B4B6E76AC80C644ED824" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2312-wk-Fact-40BB822038C14204A818C80C6456AF4B" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2016Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D and other tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2328-wk-Fact-53B379BF4B31541A0E5CC80C645AB9B9" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2343-wk-Fact-52AD47A6E81F0E31899DC80C64614E7F" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2358-wk-Fact-91B6A85F9F271C3C452CC80C644742BA" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="FD2016Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e2374-wk-Fact-03BC6D6DB24B2D903B8BC80C64646F95" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e2389-wk-Fact-5FCEC425DAB3B56C66C5C80C64573980" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e2404-wk-Fact-AA73FEC1AC867FE08126C80C6460951C" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2016Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of Tax Act</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2420-wk-Fact-A5F168E383FA3BC305EFC80C64592A0B" name="insm:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e2435-wk-Fact-7E96E7B7293E419FD5FAC80C645BA9C7" name="insm:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2450-wk-Fact-88B9322A9C6A49CBCB05C80C645F4720" name="insm:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" contextRef="FD2016Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e2466-wk-Fact-20947D400ED1596C22AAC80C64443685" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2481-wk-Fact-69FC26FEB0D37F7C2F48C80C645EFCAB" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e2496-wk-Fact-B4A0A90C466896899957C80C645963CE" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2016Q4YTD" unitRef="number" decimals="2" scale="-2" sign="-" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2512-wk-Fact-F606B7D34BF4AA84A773C80C64583860" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2527-wk-Fact-0EBFA375433C8F44E9ECC80C6453019C" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2542-wk-Fact-ECEA60BA25EA08B281F2C80C64632E97" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2016Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2558-wk-Fact-3B7DFACEB29ACC01298FC80C6464968B" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2018Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2573-wk-Fact-236A89997E0688536A4FC80C6428BB52" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2017Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2588-wk-Fact-ABDA33B72E601F9F5BE2C80C641ED71E" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2016Q4YTD" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">96</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Income Taxes (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-3" continuedAt="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-4"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. <ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="TextSelection-94FC5732E76D79344F34C80C648F3AA1-0-wk-Fact-4ABE3189AF0C78C70475C80C642650CF" continuedAt="TextSelection-94FC5732E76D79344F34C80C648F3AA1-1" escape="true">The components of the deferred tax assets and liabilities consist of the following:</ix:nonNumeric></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-94FC5732E76D79344F34C80C648F3AA1-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:505px;"></td><td style="width:9px;"></td><td style="width:72px;"></td><td style="width:4px;"></td><td style="width:5px;"></td><td style="width:9px;"></td><td style="width:72px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2756-wk-Fact-0852B35D91E1B1E138B6C80C6426E71E" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">231,918</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2775-wk-Fact-0803D5AD9B5EE8123A43C80C642361E7" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">186,342</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General business credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2790-wk-Fact-DC1E08A0BE0FC576213DC80C64235818" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">109,502</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2809-wk-Fact-46EC64DBFEBEA95EBB91C80C642B1644" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product license</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2829-wk-Fact-DF6502F55C3E81B05B9DC80C6424DFC9" name="insm:DeferredTaxAssetsLicensePayment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2848-wk-Fact-CB3BA8ABDE663E298E93C80C6420811E" name="insm:DeferredTaxAssetsLicensePayment" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2868-wk-Fact-BEBDF563816F1A9A8541C80C641D455C" name="us-gaap:DeferredTaxAssetsInventory" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,651</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2887-wk-Fact-DEC2A79F8D229C5F0602C80C641FBF5A" name="us-gaap:DeferredTaxAssetsInventory" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2907-wk-Fact-184CD5F7D8D5C501A88FC80C64274FF3" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,855</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2926-wk-Fact-1DD99689A50CE3A88DC5C80C6422342B" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2951-wk-Fact-92F20D5513008B95D752C80C642257D5" name="us-gaap:DeferredTaxAssetsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">380,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e2970-wk-Fact-2E13664352C48A323A46C80C6421892A" name="us-gaap:DeferredTaxAssetsGross" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">277,660</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangibles</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e3029-wk-Fact-313562BBA3D0E51929D1C80C642207B0" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e3049-wk-Fact-4DF323C0F3C55206B23DC80C641B5AAB" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e3066-wk-Fact-6657853B95396708C257C8EA246B1540" name="insm:DeferredTaxLiabilitiesConvertibleDebt" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,799</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3086-wk-Fact-1853D89DA3104BB16C3DC8EA2477F132" name="insm:DeferredTaxLiabilitiesConvertibleDebt" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e3111-wk-Fact-514AD791057418AB0672C80C64201460" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e3131-wk-Fact-407D538243D5829BC180C80C642AB6CD" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3152-wk-Fact-793796E126568FC7EBD2C80C64246C01" name="insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332,605</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3171-wk-Fact-3FC14764B63E7E61839AC80C6429EDEB" name="insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">261,300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e3186-wk-Fact-1D9764BF435197B25AB4C80C64210D68" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332,605</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15047081e3206-wk-Fact-ED60CE990B171D099794C80C64213A7A" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">261,300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3232-wk-Fact-7E900776B0DA90B0E647C80C6420E9CB" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3251-wk-Fact-AC3E332B849E10CBCCCDC80C641C352B" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The net deferred tax assets (prior to applying the valuation allowance) of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15047081e3264-wk-Fact-E00AF5165694AFE6D0FBC80C6427BB41" name="insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">332.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15047081e3268-wk-Fact-CBD7AF784A388E0C6F5AC80C642A32E2" name="insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">261.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, primarily consist of net operating loss carryforwards for income tax purposes. Due to the Company's history of operating losses, the Company recorded a full valuation allowance on its net deferred tax assets by increasing the valuation allowance by </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15047081e3280-wk-Fact-B5FC6619220F6EDE6E2FC80C642B205C" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and decreasing by </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15047081e3289-wk-Fact-2B48299538494B42CB96C80C645A1AAE" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">23.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, as it was more likely than not that such tax benefits will not be realized. As of December 31, 2017, the Company's gross deferred tax assets were also impacted by the Tax Act which required the change to a 21% US tax rate (see below for further discussion on the Tax Act).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had federal net operating loss carryforwards for income tax purposes of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15047081e3305-wk-Fact-F4D9FDF6247B8E57102AC80C6426D61D" name="insm:OperatingLossCarryforwardsTotal" contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">880.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. Due to the limitation on NOLs as more fully discussed below, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15047081e3309-wk-Fact-4BD92C0A251534E7F45FC80C64252A6F" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">709.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of the NOLs are available to offset future taxable income, if any. The NOL carryovers and general business tax credits expire in various years beginning in 2018. For state tax purposes, the Company has approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15047081e3313-wk-Fact-D0A84670CB9D6FCA13ECC80C642A45B4" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_NewJerseyDivisionOfTaxationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">515.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of New Jersey NOLs available to offset against future taxable income. The Company also has California and Virginia NOLs that are entirely limited due to Section&#160;382 (as discussed below).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From 2014 through 2017, the Company completed an Internal Revenue Code Section&#160;382 (Section&#160;382) analysis in order to determine the amount of losses that are currently available for potential offset against future taxable income, if any. It was determined that the utilization of the Company's NOL and general business tax credit carryforwards generated in tax periods up to and including December 2010 were subject to substantial limitations under Section&#160;382 due to ownership changes that occurred at various points from the Company's original organization through December 2010. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of shareholders that own, directly or indirectly, 5% or more of a corporation's stock, in the stock of a corporation by more than 50 percentage points over a testing period (usually </span><span style="font-family:inherit;font-size:10pt;">3</span><span style="font-family:inherit;font-size:10pt;"> years). Since the Company's formation, it has raised capital through the issuance of common stock on several occasions which, combined with the purchasing shareholders' subsequent disposition of those shares, have resulted in multiple changes in ownership, as defined by Section&#160;382, since the Company's formation in 1999. These ownership changes resulted in substantial limitations on the use of the Company's NOLs and general business tax credit carryforwards up to and including December 2010. The Company continues to track all of its NOLs and tax credit carryforwards but has provided a full valuation allowance to offset those amounts.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">97</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Income Taxes (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-4" continuedAt="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-5"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the US government enacted the Tax Act. The Tax Act significantly revises US tax law by, among other provisions, lowering the US federal statutory income tax rate from 35% to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Tax Act</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC</span><span style="font-family:inherit;font-size:10pt;"> 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the Tax Act&#8217;s provisions, the SEC staff issued SAB 118, which allowed companies to record the tax effects of the Tax Act on a provisional basis based on a reasonable estimate, and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Tax Act did not have a material impact on the Company's financial statements because its deferred temporary differences are fully offset by a valuation allowance and the Company does not have any significant offshore earnings from which to record the mandatory transition tax. The Company completed its analysis during the fourth quarter of 2018 and no additional tax effects of the Act were required to be recorded for the year ended December 31, 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement. If such unrecognized tax benefits were realized and not subject to valuation allowances, we would recognize a tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15047081e3360-wk-Fact-1319FE027A070B55B99DC9DA22FFFBFC" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. <ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="TextSelection-6221D242344CF6ECBFE1C9C9CB2B55CB-0-wk-Fact-A58A5AC61A3D4AD0365AC9CED91D4EB3" continuedAt="TextSelection-6221D242344CF6ECBFE1C9C9CB2B55CB-1" escape="true">The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-6221D242344CF6ECBFE1C9C9CB2B55CB-1" continuedAt="TextSelection-6221D242344CF6ECBFE1C9C9CB2B55CB-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-6221D242344CF6ECBFE1C9C9CB2B55CB-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.16764132553607%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Deferred Tax Assets</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Balance as of January 1,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3438-wk-Fact-7BF5F60932B76FF804E9C9D30A1ECFF5" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3457-wk-Fact-64737D1460153AD34E87C9D32084BE49" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions related to prior period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3472-wk-Fact-13791593F502046BBC8BC9D7BC631F7F" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,345</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3491-wk-Fact-6719058237196ADCF0D0C9D7BF249AEA" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Additions related to current period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3511-wk-Fact-BE862A3844FA5BDC3556C9D7E84B749E" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3530-wk-Fact-A7F2AD1ACB5CFDBC463DC9D7EAEE309E" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31,</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3555-wk-Fact-E52AE06A245B587220E2C9D38C740627" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,087</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15047081e3574-wk-Fact-7BF5F60932B76FF804E9C9D30A1ECFF5" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to US federal and state income taxes and the statute of limitations for tax audit is open for the federal tax returns for the years ended 2014 and later, and is generally open for certain states for the years 2013 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><ix:continuation id="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-5" continuedAt="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-6"><span style="font-family:inherit;font-size:10pt;">The Company's policy is to recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense. The Company has recorded no such expense. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company has recorded reserves for unrecognized income tax benefits of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15047081e3598-wk-Fact-1319FE027A070B55B99DC9DA22FFFBFC" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15047081e3602-wk-Fact-853BE8B2C94102D66F3AC9F9B326EDCE" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.0</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-6">, respectively. As any adjustment to the Company&#8217;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12&#160;months.</ix:continuation></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">98</span></div></div><hr style="page-break-after:always"></hr><div><a id="sDBDA33FA4DA65F689C1DF8EF8846D02C"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="insm:LicenseAndOtherAgreementsTextBlock" id="TextSelection-841EF0395AE2C6CA1B2CC80C648F6221-0-wk-Fact-F0657875F19786A9BFD8C80C6473BFF7" continuedAt="TextSelection-841EF0395AE2C6CA1B2CC80C648F6221-1" escape="true">License and Other Agreements</ix:nonNumeric></span></div><ix:continuation id="TextSelection-841EF0395AE2C6CA1B2CC80C648F6221-1" continuedAt="TextSelection-841EF0395AE2C6CA1B2CC80C648F6221-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">In-License Agreements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">PARI Pharma&#160;GmbH</span><span style="font-family:inherit;font-size:10pt;">&#8212;In April 2008, the Company entered into a licensing agreement with PARI Pharma&#160;GmbH (PARI) for use of the optimized Lamira Nebulizer System for delivery of ARIKAYCE in treating patients with NTM lung infections, CF and bronchiectasis. Under the licensing agreement, the Company has rights under several US and foreign issued patents and patent applications involving improvements to the optimized Lamira Nebulizer System, to exploit such system with ARIKAYCE for the treatment of such indications, but the Company cannot manufacture such nebulizers except as permitted under the Commercialization Agreement with PARI. Under the licensing agreement, the Company paid PARI an upfront license fee and certain milestone payments. Upon FDA acceptance of the Company's New Drug Application and the subsequent FDA approval of ARIKAYCE, the Company paid PARI additional milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;<ix:nonFraction id="d15041899e867-wk-Fact-8231AF3BFC2D1767D64B3DB34ED45698" name="insm:CollaborativeArrangementMilestonePayment" contextRef="D2008Q2APR01-APR30_insm_MilestonePaymentAxis_insm_MilestoneNewDrugApplicationMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember" unitRef="eur" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;<ix:nonFraction id="d15041899e871-wk-Fact-2AFF5A23580BA099B95A3DB5A8652A00" name="insm:CollaborativeArrangementMilestonePayment" contextRef="D2008Q2APR01-APR30_insm_MilestonePaymentAxis_insm_MilestoneFDAApprovalMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember" unitRef="eur" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. In addition, PARI is entitled to receive a future milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;<ix:nonFraction id="d15041899e875-wk-Fact-91D8CA90EB8DD074F8A4C80C6469D566" name="insm:FutureMilestonePayments" contextRef="D2008Q2APR01-APR30_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember" unitRef="eur" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash based on achievement of first receipt of marketing approval in a major EU country for ARIKAYCE and the device. PARI is entitled to receive royalty payments in the mid-single digits on the annual global net sales of ARIKAYCE, pursuant to the licensing agreement, subject to certain specified annual minimum royalties. In October 2017, the Company exercised an option to buy-down the royalties that will be paid to PARI on ARIKAYCE net sales. The payment to PARI was included as a component of SG&amp;A expenses in the fourth quarter of 2017. See below for information related to the commercialization agreement with PARI. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Agreements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cystic Fibrosis Foundation Therapeutics,&#160;Inc.</span><span style="font-family:inherit;font-size:10pt;">&#8212;In 2004 and 2009, the Company entered into research funding agreements with Cystic Fibrosis Foundation Therapeutics,&#160;Inc. (CFFT) whereby it received </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041899e887-wk-Fact-449532D80D6940A58C16C80C645FB992" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="D2004Q4JAN01-DEC31_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041899e891-wk-Fact-C2F10591422A8589C84BC80C64657FC6" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="D2009Q4JAN01-DEC31_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for each respective agreement in research funding for the development of ARIKAYCE. If ARIKAYCE becomes an approved product for certain infections in CF patients or such infections in human pulmonary disease in the US, the Company will owe a payment to CFFT of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041899e895-wk-Fact-24930568D6F37823638EC80C64625B18" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> that is payable over a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year period after regulatory approval in the US. Furthermore, if certain global sales milestones are met within </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15041899e903-wk-Fact-ABDAE9E69617627AB77DC80C646C8B6F" name="insm:PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> of the drug's commercialization, the Company would owe an additional payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041899e908-wk-Fact-A6BFCF0D300C69C57772C80C64720C47" name="insm:AdditionalRoyaltyGuaranteesCommitmentsAmount" contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. Because there is significant development and regulatory risk associated with ARIKAYCE, including with respect to the CF indication, the Company has not accrued these obligations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Therapure Biopharma&#160;Inc.</span><span style="font-family:inherit;font-size:10pt;">&#8212;In February 2014, the Company entered into a contract manufacturing agreement with Therapure Biopharma&#160;Inc. (Therapure) for the manufacture of ARIKAYCE, on a non-exclusive basis, at a 200 kg scale. Pursuant to the agreement, the Company and Therapure collaborated to construct a production area for the manufacture of ARIKAYCE in Therapure's existing manufacturing facility in Canada. The agreement has an initial term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15041899e917-wk-Fact-B0E85922C30ADA064F21C80C6468A8A1" name="insm:InitialTermOfContractManufacturingAgreement" contextRef="D2014Q1FEB01-FEB28_us-gaap_TypeOfArrangementAxis_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">, which began in October 2018, and will renew automatically for successive periods of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15041899e921-wk-Fact-11534175543AA7149C83C80C645E16DA" name="insm:PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" contextRef="D2014Q1FEB01-FEB28_us-gaap_TypeOfArrangementAxis_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> each, unless terminated by either party by providing the required </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15041899e925-wk-Fact-B02853FA6B35B9A35D6AC80C6479EB6C" name="insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" contextRef="D2014Q1FEB01-FEB28_us-gaap_TypeOfArrangementAxis_insm_TherapureBiopharmaIncContractManufacturingAgreementMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> prior written notice to the other party. Notwithstanding the foregoing, the parties have rights and obligations under the agreement prior to the commencement of the initial term. Under the agreement, the Company is obligated to pay certain minimum amounts for the batches of ARIKAYCE produced each calendar year.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">PARI Pharma&#160;GmbH</span><span style="font-family:inherit;font-size:10pt;">&#8212;In July 2014, the Company entered into a Commercialization Agreement with PARI for the manufacture and supply of Lamira Nebulizer Systems and related accessories (the Device) as optimized for use with ARIKAYCE. Under the Commercialization Agreement, PARI manufactures the Device except in the case of certain defined supply failures, when the Company will have the right to make the Device and have it made by third parties (but not certain third parties deemed under the Commercialization Agreement to compete with PARI). The Commercialization Agreement has an initial term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15041899e934-wk-Fact-94EF42EA00544446BA28C80C646CE818" name="insm:InitialTermOfContractManufacturingAgreement" contextRef="D2014Q3JUL01-JUL31_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember" format="ixt-sec:durwordsen">fifteen years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> from the first commercial sale of ARIKAYCE in October 2018 (the Initial Term). The term of the agreement may be extended by the Company for an additional </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15041899e938-wk-Fact-467BF003E34E70CBFFF8C80C646E3B17" name="insm:AdditionalTermOfContractManufacturingAgreement" contextRef="D2014Q3JUL01-JUL31_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> by providing written notice to PARI at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15041899e942-wk-Fact-AF168650A8EAF29D9261C80C646DDE39" name="insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" contextRef="D2014Q3JUL01-JUL31_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> prior to the expiration of the Initial Term. Notwithstanding the foregoing, the parties have certain rights and obligations under the agreement prior to the commencement of the Initial Term. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">SynteractHCR,&#160;Inc.</span><span style="font-family:inherit;font-size:10pt;">&#8212;In December 2014, the Company entered into a services agreement with SynteractHCR,&#160;Inc. (Synteract) pursuant to which the Company retained Synteract to perform implementation and management services in connection with the CONVERT study. The Company anticipates that aggregate costs relating to all work orders for the CONVERT study will be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041899e951-wk-Fact-F5B43375E96A940E3210C8ABE2CE8E31" name="insm:ImplementationAndManagementServicesAgreementAggregateCosts" contextRef="D2014Q4DEC01-DEC31_us-gaap_TypeOfArrangementAxis_insm_AgreementWithSynteractHCRInc.For212StudyMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> over the period of the study. In April 2015, the Company entered into a work order with Synteract to perform implementation and management services for the completed 312 study. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Ajinomoto Althea,&#160;Inc.</span><span style="font-family:inherit;font-size:10pt;">&#8212;In September 2015, the Company entered into a Commercial Fill/Finish Services Agreement (the Fill/Finish Agreement) with Ajinomoto Althea,&#160;Inc., a Delaware corporation (Althea), for Althea to produce, on a non-</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;License and Other Agreements (Continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-841EF0395AE2C6CA1B2CC80C648F6221-2" continuedAt="TextSelection-841EF0395AE2C6CA1B2CC80C648F6221-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">exclusive basis, ARIKAYCE in finished dosage form at a 50 kg scale. Under the Fill/Finish Agreement, the Company is obligated to pay a minimum of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041899e963-wk-Fact-9004DB6DFC94A95D118CC80C64639A51" name="insm:CommercialServicesAgreementMinimumObligation" contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_insm_CommercialFilVFinishServicesAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the batches of ARIKAYCE produced by Althea each calendar year during the term of the Fill/Finish Agreement. The Fill/Finish Agreement became effective as of January&#160;1, 2015, and following an extension in 2018, is expected to remain in effect through December 31, 2021. The Fill/Finish Agreement may be extended for additional </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;">-year periods upon mutual written agreement of the Company and Althea at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d15041899e971-wk-Fact-819E348014904F3272FEC80C64255773" name="insm:CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_insm_CommercialFilVFinishServicesAgreementMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> prior to the expiration of its then-current term. The Company has expensed at least the required minimum in each year of the contract.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">AstraZeneca AB</span><span style="font-family:inherit;font-size:10pt;">&#8212;In October 2016, the Company entered into a license agreement (AZ License Agreement) with AstraZeneca AB, a Swedish corporation (AstraZeneca). Pursuant to the terms of the AZ License Agreement, AstraZeneca granted the Company exclusive global rights for the purpose of developing and commercializing AZD7986 (renamed INS 1007). In consideration of the licenses and other rights granted by AstraZeneca, the Company made an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041899e980-wk-Fact-2A0C43EC1621B4671C43C80C646BC396" name="insm:CollaborativeArrangementUpfrontPayment" contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was included as research and development expense in the fourth quarter of 2016. The Company is also obligated to make a series of contingent milestone payments totaling up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041899e984-wk-Fact-42F520FC9C0BA5FE308EC80C6470FE22" name="insm:PaymentsUponAchievementOfClinicalMilestonesAmount" contextRef="I2016Q4OCT31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of clinical development and regulatory filing milestones. If the Company elects to develop INS1007 for a second indication, the Company will be obligated to make an additional series of contingent milestone payments to AstraZeneca totaling up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041899e988-wk-Fact-C572ECD5B03DF56C3826C80C6464378B" name="insm:CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" contextRef="I2016Q4OCT31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company is not obligated to make any additional milestone payments for additional indications. In addition, the Company will pay AstraZeneca tiered royalties ranging from a high single-digit to mid-teens on net sales of any approved product based on INS1007 and one additional payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041899e992-wk-Fact-B046254C37B3AAFC226FC80C64674628" name="us-gaap:PaymentsForRoyalties" contextRef="D2016Q4OCT01-OCT31_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the first achievement of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041899e996-wk-Fact-04A9B9406BDE7AA25D25C80C64656F7C" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="D2016Q4OCT01-OCT31_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> in annual net sales. The AZ License Agreement provides AstraZeneca with the option to negotiate a future agreement with the Company for commercialization of INS1007 in chronic obstructive pulmonary disease or asthma.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Patheon UK Limited</span><span style="font-family:inherit;font-size:10pt;">&#8212;In October 2017, the Company entered into certain agreements with Patheon UK Limited (Patheon) related to the increase of its long-term production capacity for ARIKAYCE commercial inventory. The agreements provide for Patheon to manufacture and supply ARIKAYCE for its anticipated commercial needs.&#160;Under these agreements, the Company is required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.&#160;Patheon's supply obligations will commence once certain technology transfer and construction services are completed. The Company's manufacturing and supply agreement with Patheon will remain in effect for a fixed initial term, after which it will continue for successive renewal terms unless either party has given written notice of termination. The technology transfer agreement will expire when the parties agree that the technology transfer services have been completed. The agreements may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party&#8217;s insolvency. These early termination clauses may reduce the amounts due to the relevant parties. The investment in our long-term production capacity build-out, including under the Patheon agreements and related agreements or purchase orders with third parties for raw materials and fixed assets, is estimated to be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041899e1008-wk-Fact-A2292B807609BAD04D44C80C645C5691" name="insm:ManufactureAndSupplyAgreementEstimatedCosts" contextRef="I2017Q4Oct31_us-gaap_TypeOfArrangementAxis_insm_SupplyAgreementWithPatheonUKLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><ix:continuation id="TextSelection-841EF0395AE2C6CA1B2CC80C648F6221-3" continuedAt="TextSelection-841EF0395AE2C6CA1B2CC80C648F6221-4"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Syneos Health</span><span style="font-family:inherit;font-size:10pt;">&#8212;We entered into a services agreement with Syneos Health (Syneos) pursuant to which we retained Syneos to perform implementation and management services in connection with the WILLOW study. We may terminate the services agreement or any work order for any reason and without cause with </span><span style="font-family:inherit;font-size:10pt;">30</span><span style="font-family:inherit;font-size:10pt;">&#160;days' written notice. Either party may terminate the agreement in the event of a material breach or bankruptcy petition by the other party or, if any approval from a regulatory authority is revoked, suspended or expires without renewal. We anticipate that aggregate costs relating to all work orders for the WILLOW study will be approximately $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041899e1021-wk-Fact-DEF136E62D8AEC8A9CB19BCCBAB0838B" name="insm:ImplementationAndManagementServicesAgreementAggregateCosts" contextRef="D2014Q4DEC01-DEC31_us-gaap_TypeOfArrangementAxis_insm_AgreementWithSyneosHealthForWillowStudyMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-841EF0395AE2C6CA1B2CC80C648F6221-4"> over the period of the study.</ix:continuation></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s0E6A682C4A3F5400ACB40506EA0074F6"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-7F4957570EDEAE041985C80C648F8A81-0-wk-Fact-A0623F012E15BF946845C80C647D832F" continuedAt="TextSelection-7F4957570EDEAE041985C80C648F8A81-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-7F4957570EDEAE041985C80C648F8A81-1" continuedAt="TextSelection-7F4957570EDEAE041985C80C648F8A81-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has an operating lease for office and laboratory space located in Bridgewater, NJ for which the initial lease term expires in November 2019. Future minimum rental payments under this lease are </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15040144e865-wk-Fact-B25CD4D8F2F0902D75EBC80C647C5D8F" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2018Q4_srt_StatementGeographicalAxis_insm_BridgewaterNewJerseyFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. In July 2016, the Company signed an operating lease for additional laboratory space located in Bridgewater, NJ for which the initial lease term expires in September 2021. In October 2018, the Company expanded its lease for additional laboratory space located in Bridgewater, NJ. Future minimum rental payments under this, and the initial lease, are </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15040144e869-wk-Fact-093EF3BAE16B48448E9514F1D9A076AA" name="insm:AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2018Q4_srt_StatementGeographicalAxis_insm_BridgewaterNewJerseyFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. In September 2018, the Company entered into a new lease for its new corporate headquarters in Bridgewater, NJ for which the initial lease term expires in June 2030. Future minimum rental payments under this lease are </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15040144e873-wk-Fact-F494A5C5C33D014644A5C80C646A20E2" name="insm:AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2017Q4_srt_StatementGeographicalAxis_insm_BridgewaterNewJerseyFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><ix:continuation id="TextSelection-7F4957570EDEAE041985C80C648F8A81-2" continuedAt="TextSelection-7F4957570EDEAE041985C80C648F8A81-3"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rent expense charged to operations was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15040144e880-wk-Fact-E0A86B482BD89E3E25FBC80C646A085F" name="us-gaap:LeaseAndRentalExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15040144e884-wk-Fact-ECCB17DF577AB547E9CBC80C647C8F22" name="us-gaap:LeaseAndRentalExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15040144e888-wk-Fact-60EDD9920E9A1C2D8171C80C647E2795" name="us-gaap:LeaseAndRentalExpense" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively. Rent expense is recorded on a straight-line basis over the term of the applicable leases. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="TextSelection-E377FC6D37F457A784BCC80C64907244-0-wk-Fact-009D289585101805A8F8C80C647D95D2" continuedAt="TextSelection-E377FC6D37F457A784BCC80C64907244-1" escape="true">Future minimum lease payments under the Company's lease obligations as of </ix:nonNumeric></span><ix:continuation id="TextSelection-E377FC6D37F457A784BCC80C64907244-1" continuedAt="TextSelection-E377FC6D37F457A784BCC80C64907244-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span></ix:continuation></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:continuation id="TextSelection-E377FC6D37F457A784BCC80C64907244-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Year Ending December&#160;31:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15040144e961-wk-Fact-E65AD37091A1E99DCCB7C80C6470AFE2" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15040144e976-wk-Fact-AA357D7C336BE01AD569C80C646FDC33" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15040144e996-wk-Fact-A177FE240A0487679743C80C648008CC" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15040144e1016-wk-Fact-D4B789D3C5792A692BA4C80C645C35D0" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,027</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15040144e1036-wk-Fact-86C797892F13D13EDC27C80C6478AB76" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Total future minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15040144e1061-wk-Fact-4468B71805DBFC045FA6C80C646740C3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to rent, the Company has several firm purchase commitments, primarily related to the manufacturing of ARIKAYCE and annual minimum royalties on global net sales of ARIKAYCE. Future firm purchase commitments under these agreements, the last of which ends in 2034, total </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15040144e1074-wk-Fact-5260BE62EE8523E88878810C8021F3F4" name="us-gaap:PurchaseObligation" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">86.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. These amounts do not represent our entire anticipated purchases in the future, but instead represent only purchases that are the subject of contractually obligated minimum purchases. The minimum commitments disclosed are determined based on noncancelable minimum spend amounts or termination amounts.  Additionally, we purchase products and services as needed with no firm commitment. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</span></div></ix:continuation><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-7F4957570EDEAE041985C80C648F8A81-3">From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations or cash flows.</ix:continuation></span></div><div><a id="sF142B964C0275DE1BA9BC28D4ECF7956"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="TextSelection-93D1F321A267523A7D48C80C6490AD8B-0-wk-Fact-8D66CDD70BF60BCA6D39C80C6480B4F8" continuedAt="TextSelection-93D1F321A267523A7D48C80C6490AD8B-1" escape="true">Quarterly Financial Data (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="TextSelection-93D1F321A267523A7D48C80C6490AD8B-1" continuedAt="TextSelection-93D1F321A267523A7D48C80C6490AD8B-2"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="TextSelection-FB55405ED03A56D04676C80C649091A9-0-wk-Fact-E67687394E8C1112B840C80C6428EE45" continuedAt="TextSelection-FB55405ED03A56D04676C80C649091A9-1" escape="true">The following table summarizes unaudited quarterly financial data for the years ended </ix:nonNumeric></span><ix:continuation id="TextSelection-FB55405ED03A56D04676C80C649091A9-1" continuedAt="TextSelection-FB55405ED03A56D04676C80C649091A9-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data).</span></ix:continuation></div><ix:continuation id="TextSelection-FB55405ED03A56D04676C80C649091A9-2" continuedAt="TextSelection-FB55405ED03A56D04676C80C649091A9-3"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1130-wk-Fact-B4BA31C3951C92EF2542C80C64376E80" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1149-wk-Fact-4B60665E9AF306818D4FC80C647AAB5F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1168-wk-Fact-897DC7D226AA5D8DEE4CC80C646E98D1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1188-wk-Fact-82571F1E6C67BFD384C0C80C647AFE67" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1207-wk-Fact-0CE9CA24C5A1FC8486371AD4F405D7F5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenues*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1227-wk-Fact-E8312B778B1F1B49E7A3033F6114A3C7" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1246-wk-Fact-07CB1B59188C52F91543033F610CFC28" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1265-wk-Fact-7D1AD6291EEAF40173C9033F61189A6E" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1285-wk-Fact-12EAE753A99C06FC09AF033F611097CB" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,423</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1304-wk-Fact-5ABE2B07153213A344EC1ADE1929033C" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,423</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1324-wk-Fact-5984FC3E94A5368EDF9BC80C641B3794" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">62,751</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1344-wk-Fact-0CC5FA57DFCCCA2D75B6C80C6456516B" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1364-wk-Fact-F8742BA27F81ACA66BE7C80C6476507D" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,983</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1385-wk-Fact-61FAE81285CFC56321CEC80C645D2464" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">87,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1405-wk-Fact-94636DE7E0B2D950EF3EC80C64407EF0" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">307,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1426-wk-Fact-D7752B30B2EC5C85A0A2C80C647B0D04" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">68,524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1446-wk-Fact-6B67474644AAAFF8B931C80C6472D5B7" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">76,437</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1466-wk-Fact-82C2127E1AFBA750992AC80C6478C7AE" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">87,743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1487-wk-Fact-1205D822AEF71B9B8696C80C64736800" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">91,573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1507-wk-Fact-B42634276C7A9632D85AC80C6434F487" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">324,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1528-wk-Fact-6BEC1180FE51BDEE37CBC80C646D16F8" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1548-wk-Fact-E458D441137EB9E087A3C80C6474017A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1568-wk-Fact-60D1AB8879185E217254C80C64777C0B" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1589-wk-Fact-F95353F7DF17A5E24908C80C64766C5A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e1609-wk-Fact-518DC39F637E8302275EC80C64362527" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">4.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF273818EA82535FAF5190DF314E61C0"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quarterly Financial Data (Unaudited) (Continued)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-FB55405ED03A56D04676C80C649091A9-3" continuedAt="TextSelection-FB55405ED03A56D04676C80C649091A9-4"><ix:continuation id="TextSelection-93D1F321A267523A7D48C80C6490AD8B-2" continuedAt="TextSelection-93D1F321A267523A7D48C80C6490AD8B-3"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total**</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1876-wk-Fact-2B073775EFD4A5559189C80C647518FF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1895-wk-Fact-FF66C5371B44947F9E0FC80C642ECC29" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1914-wk-Fact-0074733BCA80AE23D651C80C64274A9F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1934-wk-Fact-66B5E4B8462B10A1CA16C80C647F3603" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1953-wk-Fact-386BA215910B5BD7882B19A235C5AC3A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenues*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1973-wk-Fact-7EDAECB07C8958FE6A32033FC8E5EB5B" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2017Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e1992-wk-Fact-FC3804240BE948B653CD033FC8EFABB8" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e2011-wk-Fact-1DB4208886274C4135F7033FC8F84A78" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e2031-wk-Fact-A2597345888D2BFFE8AB033FC8FFB51C" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2017Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15044529e2050-wk-Fact-4000BD3A37997FB14A771ADE19229D92" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2070-wk-Fact-1FC400B5269F5C274F78C80C648236F7" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35,969</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2090-wk-Fact-AF5E0BEBAD94C5918662C80C641C2F0F" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">43,515</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2110-wk-Fact-BECC6E022579AC17CCE6C80C641D2718" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">44,083</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2131-wk-Fact-828EE623C8C8E9F81104C80C64746053" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q4QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65,353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2151-wk-Fact-9A1B732379CE71D1D61EC80C643B8C9A" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">188,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2172-wk-Fact-73DB1B2B31E889CB9F7FC80C641CB1E3" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37,414</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2192-wk-Fact-67DFD485E06F4B50E280C80C6426CB29" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">44,672</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2212-wk-Fact-3ECF88A8B83601E96EA2C80C641FF407" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">45,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2233-wk-Fact-7803669ADFA032789AF2C80C6420DD15" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65,384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2253-wk-Fact-04977BE1C74AC80F3F04C80C643AC548" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">192,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2274-wk-Fact-28EDEAF9096D752F5A68C80C641B8ED2" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2294-wk-Fact-B24D055AF08493BCB1BDC80C6424067A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2314-wk-Fact-8BA0CF5B87696B11287AC80C647E8F92" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2335-wk-Fact-053B7678166B7C5E831EC80C6422B48B" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15044529e2355-wk-Fact-E7AA589AA67B3269D3FEC80C6440E3D2" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">________________</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:81px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*   Excludes amortization of intangible assets.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:81px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">** Includes a one-time payment in October 2017 related to the buy-down of royalties payable to PARI on the global net sales of ARIKAYCE.</span></div></ix:continuation></ix:continuation><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-93D1F321A267523A7D48C80C6490AD8B-3"><ix:continuation id="TextSelection-FB55405ED03A56D04676C80C649091A9-4"></ix:continuation>Basic and diluted net loss per share amounts included in the above table were computed independently for each of the quarters presented. Accordingly, the sum of the quarterly basic and diluted net loss per share amounts may not agree to the total for the year.</ix:continuation></span></div><div><a id="sAA6C79359AF25FD3B4C5EC78B5257D80"></a></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2018Q4YTD" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="TextSelection-C8CC996C14031CF8CDC0C80C6490964F-0-wk-Fact-A08E10B3EDCD266A7362C80C643806B7" continuedAt="TextSelection-C8CC996C14031CF8CDC0C80C6490964F-1" escape="true">Retirement Plan</ix:nonNumeric></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><ix:continuation id="TextSelection-C8CC996C14031CF8CDC0C80C6490964F-1" continuedAt="TextSelection-C8CC996C14031CF8CDC0C80C6490964F-2"><span style="font-family:inherit;font-size:10pt;">The Company has a 401(k) defined contribution plan for the benefit for all US employees and permits voluntary contributions by employees subject to IRS-imposed limitations. Effective January 1, 2018, the Company matched </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15040134e862-wk-Fact-04A6AB6EFE21CFA63F9C57AFC44D068C" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="FD2018Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of eligible employee contributions on the first </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15040134e866-wk-Fact-2E55E68E9075B72EA718C80C6459F505" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="FD2018Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of employee salary (up to the IRS maximum). Employer contributions for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15040134e883-wk-Fact-4661A070C3B56EF1E9FFC80C643B9A22" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15040134e887-wk-Fact-9011045E5301EC83A0E0C80C645FBAEF" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15040134e891-wk-Fact-638E3DB25EF62068AC40C80C6444D131" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Prior to </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company matched </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15040134e901-wk-Fact-68B3F419D7E0D7BFCB8BC80C64452930" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="FD2017Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of eligible employee contributions on the first </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15040134e905-wk-Fact-6241C33430D64BB595E0C80C643C072D" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="FD2017Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-C8CC996C14031CF8CDC0C80C6490964F-2"> of employee salary (up to the IRS maximum).</ix:continuation> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15.4
<SEQUENCE>2
<FILENAME>insm-20181231xex10154.htm
<DESCRIPTION>EXHIBIT 10.15.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s847c69d9ab3c4eda8972768d92753ae8"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH ASTERISKS [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendment No. 8</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">To License Agreement Between</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INSMED INCORPORATED and PARI Pharma GmbH</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This eighth amendment (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendment No. 8</font><font style="font-family:inherit;font-size:12pt;">&#8221;) effective 19</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;December 2018 (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendment No. 8 Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;) to the License Agreement dated and effective the 25</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;of April 2008 between PARI Pharma GmbH, a German corporation with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PARI</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and Transave, Inc., a Delaware corporation, as amended by Amendment No. 1 the 24</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of June 2009, Assignment and Amendment No. 2 the 22</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">nd</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of December 2010, Amendment No. 3 the 6</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of March 2012, Amendment No. 4 the 21</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of May 2012, Amendment No. 5 the 5</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of October 2015, Amendment No. 6 the 9</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of October 2015 and Amendment No. 7 the 21</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;day of July 2017 (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), is entered into between PARI and Insmed Incorporated (successor in interest to Transave, Inc.), with registered offices at 10 Finderne Avenue, Building 10, Bridgewater, NJ&#160; 08807-3365 (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Insmed</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  PARI and Insmed shall be referred to collectively as the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:12pt;">&#8221;. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, the Parties entered into a certain commercialization agreement effective as of July 8</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">, 2014 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercialization Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;); and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, the Parties now desire to amend the terms and conditions of the Agreement to reflect certain business discussions between the Parties.  </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, in consideration of the recitals set forth above, the mutual covenants, terms and conditions set forth below, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Definitions.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;Capitalized terms used but not defined in this Amendment No. 8 shall have the meanings ascribed to them in the Agreement.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:46px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:49px;">2.</font><font style="font-family:inherit;font-size:12pt;">The Parties agree Section [***] of the Agreement is not applicable. </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:46px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:49px;">3.</font><font style="font-family:inherit;font-size:12pt;">A new Section 6.5 is hereby added which shall read as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.5 </font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Training.</font><font style="font-family:inherit;font-size:12pt;">&#32;[***]&#8221;</font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Royalty Report</font><font style="font-family:inherit;font-size:12pt;">. Section 9.2 of the Agreement is hereby amended by adding the following to the end of the section:</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;The report and calculation of royalties as set forth in this Section 9.2 of the Agreement shall contain a detailed listing of all deductions (i) as set forth in the definition of the term &#8220;Net Sales&#8221;, (ii) [***] and (iii) [***].  A sample report and calculation of royalties, for example and illustrative purposes only, is attached as Exhibit 9.2.&#8221; </font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit 9.2</font><font style="font-family:inherit;font-size:12pt;">.  The Agreement is hereby amended by adding the attached Exhibit 9.2 as Exhibit 9.2 to the Agreement.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">*** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Miscellaneous.  </font><font style="font-family:inherit;font-size:12pt;">Upon execution, this Amendment No. 8 shall be made part of the Agreement and shall be incorporated therein by reference.  Except as provided herein, all other terms and conditions of the Agreement shall remain in full force and effect.</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">-  signature page follows -</font></div><div style="line-height:120%;text-align:center;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">*** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the Parties have executed this Amendment No. 8 as of the Amendment No. 8 Effective Date indicated above. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Insmed Incorporated</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PARI Pharma GmbH</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ William H. Lewis</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/  Dr. Martin Knoch</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: William H. Lewis</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Name: Dr. Martin Knoch</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: CEO &amp; President</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Title: President</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date:</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">December 21, 2018</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Date:</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">December 19, 2018</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">*** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit 9.2</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">See attached page</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">*** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:4%;"></td><td style="width:5%;"></td><td style="width:10%;"></td><td style="width:11%;"></td><td style="width:2%;"></td><td style="width:7%;"></td><td style="width:12%;"></td><td style="width:2%;"></td><td style="width:9%;"></td><td style="width:2%;"></td><td style="width:24%;"></td></tr><tr><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note: Example purposes only for Royalty calculations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;US </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Country A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The report should be on a country-by-country basis (in accordance with Section 9.2 of the License Agreement)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">All amounts in USD</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Arikyace Kits  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Arikyace Kits  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Notes</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Sold </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Sold </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Totals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">WAC (includes drug kit/aerosol head)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***] </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Units sold for Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***] </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Gross sales invoiced</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***] </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***] </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Gross-to-net deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net sales-GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Royalty owed to PARI for quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[***]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash payment to PARI for applicable quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">[***]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">*** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29.2
<SEQUENCE>3
<FILENAME>insm-20181231xex10292.htm
<DESCRIPTION>EXHIBIT 10.29.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sb27ba69c04a84367b6e5fde487569dbf"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.8125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10 Finderne Avenue, Building 10</font><font style="font-family:Arial;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;color:#3dade1;font-weight:bold;">|</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:9pt;">Bridgewater, NJ 08807 </font><font style="font-family:inherit;font-size:9pt;color:#3dade1;font-weight:bold;">|</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:9pt;color:#6c64b4;font-weight:bold;">Phone:</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:9pt;">908-977-9900</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:9pt;color:#3dade1;font-weight:bold;">|</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:9pt;color:#6c64b4;font-weight:bold;">Fax:</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">908-526-4026 </font><font style="font-family:Arial;font-size:9pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#3dade1;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#6c64b4;font-weight:bold;">www.insmed.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">December 18, 2018</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">VIA E-MAIL</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Craig Logan</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VP of Finance and Chief Financial Officer</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ajinomoto Althea, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11040 Roselle Street</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">San Diego, CA  92121</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">RE:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Extension of Commercial Fill/Finish Services Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dear Mr. Logan,</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As you know, Ajinomoto Althea, Inc. (&#8220;Althea&#8221;) and Insmed Incorporated (&#8220;Insmed&#8221;) are parties to the Commercial Fill/Finish Supply Agreement, dated January 1, 2015 (the &#8220;Agreement&#8221;).  Per Section 7.1 of the Agreement, the Initial Term (as defined in the Agreement) of the Agreement was extended to, and now expires on, December 31, 2019 and the parties may mutually agree to extend the Agreement for an additional two (2) year period at least one (1) year prior to the expiration.  Insmed kindly requests that Althea acknowledge and agree to a two (2) year extension of the Agreement until December 31, 2021 by signing below.  </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">We appreciate all of the efforts made to date by Althea and look forward to continuing our relationship.  Please contact me at 908-947-4309 with any questions.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:192px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Sincerely,</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:192px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Don Nociolo</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:192px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Don Nociolo</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:192px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Vice President, Technical Operations </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AGREED AND ACKNOWLEDGED</font><font style="font-family:inherit;font-size:11pt;">:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Ajinomoto Althea, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:  /s/ Craig W. Logan</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: Craig W. Logan</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title: VP of Finance and Chief Financial Officer</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>insm-20181231xex211.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD06270D0C3E3526A912BBEE2D4E698C1"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">EXHIBIT 21.1&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">LIST OF SUBSIDIARIES&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.2109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:76%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Jurisdiction of Incorporation</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Celtrix Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insmed Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">England and Wales</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insmed Holdings Limited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insmed Ireland Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insmed Germany GmbH</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insmed France SAS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insmed Netherlands B.V.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insmed Godo Kaisha</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insmed Bermuda Limited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bermuda</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>insm-20181231xex231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5570AEC5B0EE5F7CB994EC5ECB95A15A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">EXHIBIT 23.1&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consent to the incorporation by reference in the following Registration Statements:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement on Form S-3 No. 333-218118 of Insmed Incorporated, and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:34px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statements on Form S-8 Nos. 333-39200, 333-87878, 333-129479, 333-175532, 333-188852, 333-204503, 33-218668 and 333-225323 of Insmed Incorporated;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of our reports dated February 22, 2019, with respect to the consolidated financial statements of Insmed Incorporated and the effectiveness of internal control over financial reporting of Insmed Incorporated included in this Annual Report (Form 10-K) of Insmed Incorporated for the year ended December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:340px;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:340px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Iselin, New Jersey</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;22, 2019</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>insm-20181231xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD64801A0A7415CCCB5975A5000177F6B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section&#160;302 Certification&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, William H. Lewis, Chairman and Chief Executive Officer of Insmed Incorporated, certify that:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) I have reviewed this annual report on Form&#160;10-K of Insmed Incorporated;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: February&#160;22, 2019</font></div><div style="line-height:120%;padding-bottom:8px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:53.7109375%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William H. Lewis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">William H. Lewis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman and Chief Executive Officer</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>insm-20181231xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s13107437318C5B0CBE84B1B8FAFCDD1C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">EXHIBIT 31.2&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Section&#160;302 Certification&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">I, Paolo Tombesi, Chief Financial Officer of Insmed Incorporated, certify that:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1) I have reviewed this annual report on Form&#160;10-K of Insmed Incorporated;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(c)&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(d)&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5)&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Date: February&#160;22, 2019</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:54.296875%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Paolo Tombesi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paolo Tombesi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>insm-20181231xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD820A65A6E86587CA7BC11BC5DB73ABB"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">EXHIBIT 32.1&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">CERTIFICATION PURSUANT TO&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">18 USC. SECTION&#160;1350,&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">AS ADOPTED PURSUANT TO&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2003&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">In connection with this Annual Report on Form&#160;10-K of Insmed Incorporated (the "Company") for the period ended December&#160;31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, William H. Lewis, Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 USC. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2003, that:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1)&#160;&#160;the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2)&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:55.2734375%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William H. Lewis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">William H. Lewis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman and Chief Executive Officer</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">February&#160;22, 2019</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">This certification accompanies the Form&#160;10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>insm-20181231xex322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s21A74D83A33A5ABC90BC13EBA2126E0E"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">EXHIBIT 32.2&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">CERTIFICATION PURSUANT TO&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">18 USC. SECTION&#160;1350,&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">AS ADOPTED PURSUANT TO&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2003&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">In connection with this Annual Report on Form&#160;10-K of Insmed Incorporated (the "Company") for the period ended December&#160;31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Paolo Tombesi, Chief Financial Officer of the Company, certify, pursuant to 18 USC. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2003, that:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1)&#160;&#160;the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2)&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:54.296875%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Paolo Tombesi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paolo Tombesi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">February&#160;22, 2019</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">This certification accompanies the Form&#160;10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>insm-20181231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.insmed.com/20181231" xmlns:insm="http://www.insmed.com/20181231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpenses" roleURI="http://www.insmed.com/role/AccruedExpenses">
        <link:definition>2104100 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.insmed.com/role/AccruedExpensesDetails">
        <link:definition>2404402 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.insmed.com/role/AccruedExpensesTables">
        <link:definition>2304301 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.insmed.com/role/CommitmentsAndContingencies">
        <link:definition>2112100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesMinimumRentalPaymentsDetails" roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails">
        <link:definition>2412403 - Disclosure - Commitments and Contingencies - Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2412402 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2312301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1002000 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfShareholdersEquity" roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity">
        <link:definition>1003000 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.insmed.com/role/Debt">
        <link:definition>2107100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtComponentsOfDebtDetails" roleURI="http://www.insmed.com/role/DebtComponentsOfDebtDetails">
        <link:definition>2407403 - Disclosure - Debt - Components of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.insmed.com/role/DebtDetails">
        <link:definition>2407402 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtFuturePrincipalRepaymentsOfDebtDetails" roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails">
        <link:definition>2407404 - Disclosure - Debt - Future Principal Repayments of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.insmed.com/role/DebtTables">
        <link:definition>2307301 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessAndBasisOfPresentation" roleURI="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentation">
        <link:definition>2101100 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails" roleURI="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails">
        <link:definition>2401401 - Disclosure - Description of Business and Basis of Presentation Description of Business and Basis of Presentation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.insmed.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsNet" roleURI="http://www.insmed.com/role/FixedAssetsNet">
        <link:definition>2106100 - Disclosure - Fixed Assets, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsNetDetails" roleURI="http://www.insmed.com/role/FixedAssetsNetDetails">
        <link:definition>2406402 - Disclosure - Fixed Assets, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsNetTables" roleURI="http://www.insmed.com/role/FixedAssetsNetTables">
        <link:definition>2306301 - Disclosure - Fixed Assets, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.insmed.com/role/IncomeTaxes">
        <link:definition>2110100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2410406 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxBenefitProvisionDetails" roleURI="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails">
        <link:definition>2410404 - Disclosure - Income Taxes - Income Tax (Benefit) Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails" roleURI="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails">
        <link:definition>2410403 - Disclosure - Income Taxes - Loss Before Income Taxes in the US and Globally (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.insmed.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2410402 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails" roleURI="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails">
        <link:definition>2410405 - Disclosure - Income Taxes - Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" roleURI="http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails">
        <link:definition>2410407 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.insmed.com/role/IncomeTaxesTables">
        <link:definition>2310301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesNet" roleURI="http://www.insmed.com/role/IntangiblesNet">
        <link:definition>2105100 - Disclosure - Intangibles, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesNetDetails" roleURI="http://www.insmed.com/role/IntangiblesNetDetails">
        <link:definition>2405402 - Disclosure - Intangibles, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesNetTables" roleURI="http://www.insmed.com/role/IntangiblesNetTables">
        <link:definition>2305301 - Disclosure - Intangibles, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.insmed.com/role/Inventory">
        <link:definition>2103100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleOfInventoryCurrentDetails" roleURI="http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails">
        <link:definition>2403402 - Disclosure - Inventory - Schedule of Inventory, Current (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.insmed.com/role/InventoryTables">
        <link:definition>2303301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAndOtherAgreements" roleURI="http://www.insmed.com/role/LicenseAndOtherAgreements">
        <link:definition>2111100 - Disclosure - License and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAndOtherAgreementsDetails" roleURI="http://www.insmed.com/role/LicenseAndOtherAgreementsDetails">
        <link:definition>2411401 - Disclosure - License and Other Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.insmed.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2113100 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetails" roleURI="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails">
        <link:definition>2413402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2313301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlan" roleURI="http://www.insmed.com/role/RetirementPlan">
        <link:definition>2114100 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlanDetails" roleURI="http://www.insmed.com/role/RetirementPlanDetails">
        <link:definition>2414401 - Disclosure - Retirement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.insmed.com/role/ShareholdersEquity">
        <link:definition>2108100 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://www.insmed.com/role/ShareholdersEquityDetails">
        <link:definition>2408401 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.insmed.com/role/StockBasedCompensation">
        <link:definition>2109100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2409402 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRangeOfExercisePricesDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails">
        <link:definition>2409404 - Disclosure - Stock-Based Compensation - Range of Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails">
        <link:definition>2409405 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails">
        <link:definition>2409403 - Disclosure - Stock-Based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.insmed.com/role/StockBasedCompensationTables">
        <link:definition>2309301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails">
        <link:definition>2402406 - Disclosure - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails">
        <link:definition>2402408 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Fixed Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails">
        <link:definition>2402407 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails">
        <link:definition>2402410 - Disclosure - Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>2402409 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="insm_AccruedClinicalTrialExpenses" name="AccruedClinicalTrialExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_AccruedConstructionLiabilitiesCurrent" name="AccruedConstructionLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_AccruedSalesAllowancesandRelatedCosts" name="AccruedSalesAllowancesandRelatedCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_AccruedTechnicalOperationExpenses" name="AccruedTechnicalOperationExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" name="AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" name="AdditionalRoyaltyGuaranteesCommitmentsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_AdditionalTermOfContractManufacturingAgreement" name="AdditionalTermOfContractManufacturingAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_AgreementWithSyneosHealthForWillowStudyMember" name="AgreementWithSyneosHealthForWillowStudyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_AgreementWithSynteractHCRInc.For212StudyMember" name="AgreementWithSynteractHCRInc.For212StudyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" name="AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" name="AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="insm_BridgewaterNewJerseyFacilityMember" name="BridgewaterNewJerseyFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" name="CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_CollaborativeArrangementMilestonePayment" name="CollaborativeArrangementMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="insm_CollaborativeArrangementUpfrontPayment" name="CollaborativeArrangementUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_CommercialFilVFinishServicesAgreementMember" name="CommercialFilVFinishServicesAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_CommercialServicesAgreementExtensionPeriod" name="CommercialServicesAgreementExtensionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" name="CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_CommercialServicesAgreementMinimumObligation" name="CommercialServicesAgreementMinimumObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" name="CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="insm_ComputerHardwareAndSoftwareMember" name="ComputerHardwareAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales" name="ContractWithCustomerAssetAllowanceForCurrentPeriodSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" name="ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems" name="ContractwithCustomerAssetAllowanceforCreditLossLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward" name="ContractwithCustomerAssetAllowanceforCreditLossRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_ContractwithCustomerAssetAllowanceforCreditLossTable" name="ContractwithCustomerAssetAllowanceforCreditLossTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock" name="ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_ConversionTermiMember" name="ConversionTermiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_ConversionTermiiMember" name="ConversionTermiiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_ConversionTermiiiMember" name="ConversionTermiiiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_ConversionTermivMember" name="ConversionTermivMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_CustomerAMember" name="CustomerAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_CustomerBMember" name="CustomerBMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_CustomerCMember" name="CustomerCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_CustomerFeesDiscountsandOtherMember" name="CustomerFeesDiscountsandOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" name="CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_DebtInstrumentConversionTermAxis" name="DebtInstrumentConversionTermAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_DebtInstrumentConversionTermDomain" name="DebtInstrumentConversionTermDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" name="DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_DebtInstrumentOptionToPurchaseAdditionalDebt" name="DebtInstrumentOptionToPurchaseAdditionalDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" name="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="insm_DeferredTaxAssetsLicensePayment" name="DeferredTaxAssetsLicensePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="insm_DeferredTaxLiabilitiesConvertibleDebt" name="DeferredTaxLiabilitiesConvertibleDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="insm_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" name="EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_EmployeeAndDirectorsStockOptionsMember" name="EmployeeAndDirectorsStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_EquipmentFurnitureAndFixturesMember" name="EquipmentFurnitureAndFixturesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_FairValueLevel1Level2Level3TransfersAmount" name="FairValueLevel1Level2Level3TransfersAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="insm_FutureMilestonePayments" name="FutureMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="insm_ImplementationAndManagementServicesAgreementAggregateCosts" name="ImplementationAndManagementServicesAgreementAggregateCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="insm_InitialTermOfContractManufacturingAgreement" name="InitialTermOfContractManufacturingAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" name="InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_InvestmentIncomeExpensePolicyTextBlock" name="InvestmentIncomeExpensePolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_LicenseAgreementWithAstrazenecaMember" name="LicenseAgreementWithAstrazenecaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_LicenseAndOtherAgreementsAbstract" name="LicenseAndOtherAgreementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_LicenseAndOtherAgreementsTextBlock" name="LicenseAndOtherAgreementsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" name="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_ManufactureAndSupplyAgreementEstimatedCosts" name="ManufactureAndSupplyAgreementEstimatedCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="insm_ManufacturingEquipmentMember" name="ManufacturingEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_MilestoneFDAApprovalMember" name="MilestoneFDAApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_MilestoneNewDrugApplicationMember" name="MilestoneNewDrugApplicationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_MilestonePaymentAxis" name="MilestonePaymentAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_MilestonePaymentDomain" name="MilestonePaymentDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" name="NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" name="OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_OperatingLossCarryforwardsTotal" name="OperatingLossCarryforwardsTotal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="insm_PRIPharmaGmbhCommercializationAgreementMember" name="PRIPharmaGmbhCommercializationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_PaymentsUponAchievementOfClinicalMilestonesAmount" name="PaymentsUponAchievementOfClinicalMilestonesAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" name="PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" name="PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range10Member" name="Range10Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range1Member" name="Range1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range2Member" name="Range2Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range3Member" name="Range3Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range4Member" name="Range4Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range5Member" name="Range5Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range6Member" name="Range6Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range7Member" name="Range7Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range8Member" name="Range8Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range9Member" name="Range9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_RebatesChargebacksandCoPayAssistanceMember" name="RebatesChargebacksandCoPayAssistanceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_RepaymentsOfDebtFeesAndOutstandingInterest" name="RepaymentsOfDebtFeesAndOutstandingInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_RestrictedStockAndRestrictedStockUnitsMember" name="RestrictedStockAndRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_RoyaltyPaymentPeriod" name="RoyaltyPaymentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" name="ScheduleofEarningsPerShareBasicandDilutedLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_ScheduleofEarningsPerShareBasicandDilutedTable" name="ScheduleofEarningsPerShareBasicandDilutedTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_StockOptionsAndRestrictedStockUnitsMember" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_SummaryOfSignificantPoliciesLineItems" name="SummaryOfSignificantPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_SummaryOfSignificantPoliciesTable" name="SummaryOfSignificantPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_SupplyAgreementWithPatheonUKLimitedMember" name="SupplyAgreementWithPatheonUKLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_TherapureBiopharmaIncContractManufacturingAgreementMember" name="TherapureBiopharmaIncContractManufacturingAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_WeightedAverageRemainingContractualLifeInYearsAbstract" name="WeightedAverageRemainingContractualLifeInYearsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" name="WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>insm-20181231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpenses" xlink:href="insm-20181231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesDetails" xlink:href="insm-20181231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesTables" xlink:href="insm-20181231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingencies" xlink:href="insm-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:href="insm-20181231.xsd#CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="insm-20181231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesTables" xlink:href="insm-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:href="insm-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="insm-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="insm-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="insm-20181231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity" xlink:href="insm-20181231.xsd#ConsolidatedStatementsOfShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/Debt" xlink:href="insm-20181231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtComponentsOfDebtDetails" xlink:href="insm-20181231.xsd#DebtComponentsOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtDetails" xlink:href="insm-20181231.xsd#DebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:href="insm-20181231.xsd#DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtTables" xlink:href="insm-20181231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="insm-20181231.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails" xlink:href="insm-20181231.xsd#DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:href="insm-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNet" xlink:href="insm-20181231.xsd#FixedAssetsNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:href="insm-20181231.xsd#FixedAssetsNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetTables" xlink:href="insm-20181231.xsd#FixedAssetsNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxes" xlink:href="insm-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="insm-20181231.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:href="insm-20181231.xsd#IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails" xlink:href="insm-20181231.xsd#IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesNarrativeDetails" xlink:href="insm-20181231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:href="insm-20181231.xsd#IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="insm-20181231.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesTables" xlink:href="insm-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNet" xlink:href="insm-20181231.xsd#IntangiblesNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetDetails" xlink:href="insm-20181231.xsd#IntangiblesNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetTables" xlink:href="insm-20181231.xsd#IntangiblesNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/Inventory" xlink:href="insm-20181231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails" xlink:href="insm-20181231.xsd#InventoryScheduleOfInventoryCurrentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryTables" xlink:href="insm-20181231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/LicenseAndOtherAgreements" xlink:href="insm-20181231.xsd#LicenseAndOtherAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/LicenseAndOtherAgreementsDetails" xlink:href="insm-20181231.xsd#LicenseAndOtherAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/QuarterlyFinancialDataUnaudited" xlink:href="insm-20181231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="insm-20181231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="insm-20181231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/RetirementPlan" xlink:href="insm-20181231.xsd#RetirementPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/RetirementPlanDetails" xlink:href="insm-20181231.xsd#RetirementPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquity" xlink:href="insm-20181231.xsd#ShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:href="insm-20181231.xsd#ShareholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensation" xlink:href="insm-20181231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:href="insm-20181231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails" xlink:href="insm-20181231.xsd#StockBasedCompensationRangeOfExercisePricesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:href="insm-20181231.xsd#StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:href="insm-20181231.xsd#StockBasedCompensationStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationTables" xlink:href="insm-20181231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/AccruedExpenses" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AccruedClinicalTrialExpenses" xlink:label="loc_insm_AccruedClinicalTrialExpenses_13a55ce4-50a5-b740-2ede-c80c72289604" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_insm_AccruedClinicalTrialExpenses_13a55ce4-50a5-b740-2ede-c80c72289604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_113b0150-367f-99b9-4773-3f3df4696704" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AccruedTechnicalOperationExpenses" xlink:label="loc_insm_AccruedTechnicalOperationExpenses_f3f9744c-7194-0bad-72b0-c80c734aeb7e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_insm_AccruedTechnicalOperationExpenses_f3f9744c-7194-0bad-72b0-c80c734aeb7e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_84c97d53-d75c-0fec-d05e-498cb2460450" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_InterestPayableCurrent_84c97d53-d75c-0fec-d05e-498cb2460450" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AccruedSalesAllowancesandRelatedCosts" xlink:label="loc_insm_AccruedSalesAllowancesandRelatedCosts_344306814905945B150180A06651310E" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_insm_AccruedSalesAllowancesandRelatedCosts_344306814905945B150180A06651310E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AccruedConstructionLiabilitiesCurrent" xlink:label="loc_insm_AccruedConstructionLiabilitiesCurrent_1d60a289-674d-c28f-5186-c80c73980461" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_insm_AccruedConstructionLiabilitiesCurrent_1d60a289-674d-c28f-5186-c80c73980461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_fe404cae-7fcc-3489-844f-4d90e9776180" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_fe404cae-7fcc-3489-844f-4d90e9776180" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_36c616b1-40de-90d4-3c05-7e224ce1169a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_36c616b1-40de-90d4-3c05-7e224ce1169a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8422f2c5-408e-d123-b935-f3115e023941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_806083e9-63fa-5acf-a0c8-803a67715508" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssets_806083e9-63fa-5acf-a0c8-803a67715508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_38b416a4-4707-fba3-1084-9b8a37fd745a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_Depreciation_38b416a4-4707-fba3-1084-9b8a37fd745a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b412c390-dfec-d4c8-f13e-036e3b49278c" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b412c390-dfec-d4c8-f13e-036e3b49278c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_d883e212-a0a2-0f3a-80cd-5a5472a7f783" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_d883e212-a0a2-0f3a-80cd-5a5472a7f783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_fa48b618-5ae2-f7b8-8931-833813d7bf84" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AccretionExpense_fa48b618-5ae2-f7b8-8931-833813d7bf84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_29513f30-d210-75c6-f948-c80c72a8e2d3" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_29513f30-d210-75c6-f948-c80c72a8e2d3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_bb8c0c41-60b6-6ad9-c835-6a671aae07c5" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_bb8c0c41-60b6-6ad9-c835-6a671aae07c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1e99261d-1af1-2d77-636d-890a4a9c4511" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1e99261d-1af1-2d77-636d-890a4a9c4511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_212a3895-370b-f5d5-9315-668e76c6ad50" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_212a3895-370b-f5d5-9315-668e76c6ad50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_204acd11-57b2-232a-d32d-d0824032cd6a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_204acd11-57b2-232a-d32d-d0824032cd6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_7d42c724-e395-d9cd-4d02-38341e761dae" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfDebt_7d42c724-e395-d9cd-4d02-38341e761dae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_51c81063-9b68-dd0f-b2a1-9bda45041695" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_51c81063-9b68-dd0f-b2a1-9bda45041695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6accd1a2-f190-7888-29dd-29802af49bdc" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6accd1a2-f190-7888-29dd-29802af49bdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e0089888-8677-d95e-95e6-00fe630f2dcb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_ad8f5587-cd30-97dd-9cf0-81ed4f58516c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_e0089888-8677-d95e-95e6-00fe630f2dcb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_29b707e4-876d-47bd-8655-71c027f42964" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_29b707e4-876d-47bd-8655-71c027f42964" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c604cfe-da19-5194-72b6-98be0130cfb7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_41f55a94-ade0-0e57-7055-ac01c4897210" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_41f55a94-ade0-0e57-7055-ac01c4897210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11620bd8-431c-98f6-ac51-02db9613dc06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtComponentsOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_07f69f5d-1693-d29d-ef9d-db0691482fe5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:to="loc_us-gaap_SecuredDebt_07f69f5d-1693-d29d-ef9d-db0691482fe5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_450782c6-2839-854f-cd33-795c87a08ecc" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_450782c6-2839-854f-cd33-795c87a08ecc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c4b02274-72e3-29b7-85b4-945f4b5c02e0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_fcfc6b17-bfc5-2ebc-3fc1-751aa446a572" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c4b02274-72e3-29b7-85b4-945f4b5c02e0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5cb3949c-1d57-8f66-f002-a3389de7aec0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5cb3949c-1d57-8f66-f002-a3389de7aec0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_53634569-cdf7-3d1b-42b0-596cb4175c67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_53634569-cdf7-3d1b-42b0-596cb4175c67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c4573bf7-1f66-8dfe-59b9-b6903f55406f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c4573bf7-1f66-8dfe-59b9-b6903f55406f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e00da32d-ed06-bb21-8b28-7e7ede769972" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e00da32d-ed06-bb21-8b28-7e7ede769972" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="loc_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_39D3D91554609A350FE752CA81B12E3B" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:to="loc_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_39D3D91554609A350FE752CA81B12E3B" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/FixedAssetsNet" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/FixedAssetsNetTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c003e837-c7c9-cd10-ae74-916131fdc333" xlink:type="locator" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_5f37fdee-ad84-d0b6-ea20-c80c726c4b1c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c003e837-c7c9-cd10-ae74-916131fdc333" xlink:to="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_5f37fdee-ad84-d0b6-ea20-c80c726c4b1c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_5f37fdee-ad84-d0b6-ea20-c80c726c4b1c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_42b61cde-44f6-df44-52b0-1b84b1e28a47" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_42b61cde-44f6-df44-52b0-1b84b1e28a47" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DeferredTaxLiabilitiesConvertibleDebt" xlink:label="loc_insm_DeferredTaxLiabilitiesConvertibleDebt_260905E6CA271CD87A26DD9D6ADD692C" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5ca8e732-540c-5527-8ee3-c835dafc5838" xlink:to="loc_insm_DeferredTaxLiabilitiesConvertibleDebt_260905E6CA271CD87A26DD9D6ADD692C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_5f37fdee-ad84-d0b6-ea20-c80c726c4b1c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_42d6dc70-681e-0021-93df-54cb89738713" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_42d6dc70-681e-0021-93df-54cb89738713" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DeferredTaxAssetsLicensePayment" xlink:label="loc_insm_DeferredTaxAssetsLicensePayment_a170b2b8-e3db-ee3c-d2cf-c80c72f816d6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_insm_DeferredTaxAssetsLicensePayment_a170b2b8-e3db-ee3c-d2cf-c80c72f816d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_475c85ca-97e4-c8e8-9ee2-6c534eb18ace" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_475c85ca-97e4-c8e8-9ee2-6c534eb18ace" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0cc13c2f-6b23-b741-4f28-07325c7e7169" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_d91ede05-f13f-9c89-cfbf-3dfb1dd1a1a6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0cc13c2f-6b23-b741-4f28-07325c7e7169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c003e837-c7c9-cd10-ae74-916131fdc333" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bbb5a6cc-fe5e-18f1-e9f0-76884d58b714" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bbb5a6cc-fe5e-18f1-e9f0-76884d58b714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_840ca4a2-1542-fad2-992c-40136594b396" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_840ca4a2-1542-fad2-992c-40136594b396" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e6f9d43e-fcd6-745d-b634-9ed4792095b2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e6f9d43e-fcd6-745d-b634-9ed4792095b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a4e74316-f31b-80bc-a44a-3464e9dcdb33" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a4e74316-f31b-80bc-a44a-3464e9dcdb33" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_0470433b-e52e-ba46-7412-c80c7366a834" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_0470433b-e52e-ba46-7412-c80c7366a834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_48e0835c-c850-4d13-3096-958714c66dc4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_48e0835c-c850-4d13-3096-958714c66dc4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2159a283-2879-8644-198d-34cde06e5374" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2159a283-2879-8644-198d-34cde06e5374" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_7a7de0c4-00a4-1ed6-022c-c80c736888d2" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_7a7de0c4-00a4-1ed6-022c-c80c736888d2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_082942cb-e31f-ff03-a943-7f4739f70da9" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_082942cb-e31f-ff03-a943-7f4739f70da9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_00f37689-1982-1c68-c80b-43003f810247" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_00f37689-1982-1c68-c80b-43003f810247" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IntangiblesNet" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IntangiblesNetDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IntangiblesNetTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a979ceab-3c76-a4d5-9d1d-ca902d5e8595" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a979ceab-3c76-a4d5-9d1d-ca902d5e8595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_02cb866c-0b1c-51f5-8ed3-3272dfc8c769" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_02cb866c-0b1c-51f5-8ed3-3272dfc8c769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c2dd0840-de07-383b-bde9-fb229532490d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c2dd0840-de07-383b-bde9-fb229532490d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/LicenseAndOtherAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/LicenseAndOtherAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/RetirementPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/RetirementPlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/ShareholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e52bef3f-d63a-d129-8b6a-48192f5d97b3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e52bef3f-d63a-d129-8b6a-48192f5d97b3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dd9a981-e559-d141-f1c2-4db79f71a7ef" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dd9a981-e559-d141-f1c2-4db79f71a7ef" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>insm-20181231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpenses" xlink:href="insm-20181231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesDetails" xlink:href="insm-20181231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesTables" xlink:href="insm-20181231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingencies" xlink:href="insm-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:href="insm-20181231.xsd#CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="insm-20181231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesTables" xlink:href="insm-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:href="insm-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="insm-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="insm-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="insm-20181231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity" xlink:href="insm-20181231.xsd#ConsolidatedStatementsOfShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/Debt" xlink:href="insm-20181231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtComponentsOfDebtDetails" xlink:href="insm-20181231.xsd#DebtComponentsOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtDetails" xlink:href="insm-20181231.xsd#DebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:href="insm-20181231.xsd#DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtTables" xlink:href="insm-20181231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="insm-20181231.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails" xlink:href="insm-20181231.xsd#DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:href="insm-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNet" xlink:href="insm-20181231.xsd#FixedAssetsNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:href="insm-20181231.xsd#FixedAssetsNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetTables" xlink:href="insm-20181231.xsd#FixedAssetsNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxes" xlink:href="insm-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="insm-20181231.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:href="insm-20181231.xsd#IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails" xlink:href="insm-20181231.xsd#IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesNarrativeDetails" xlink:href="insm-20181231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:href="insm-20181231.xsd#IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="insm-20181231.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesTables" xlink:href="insm-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNet" xlink:href="insm-20181231.xsd#IntangiblesNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetDetails" xlink:href="insm-20181231.xsd#IntangiblesNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetTables" xlink:href="insm-20181231.xsd#IntangiblesNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/Inventory" xlink:href="insm-20181231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails" xlink:href="insm-20181231.xsd#InventoryScheduleOfInventoryCurrentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryTables" xlink:href="insm-20181231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/LicenseAndOtherAgreements" xlink:href="insm-20181231.xsd#LicenseAndOtherAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/LicenseAndOtherAgreementsDetails" xlink:href="insm-20181231.xsd#LicenseAndOtherAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/QuarterlyFinancialDataUnaudited" xlink:href="insm-20181231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="insm-20181231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="insm-20181231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/RetirementPlan" xlink:href="insm-20181231.xsd#RetirementPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/RetirementPlanDetails" xlink:href="insm-20181231.xsd#RetirementPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquity" xlink:href="insm-20181231.xsd#ShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:href="insm-20181231.xsd#ShareholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensation" xlink:href="insm-20181231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:href="insm-20181231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails" xlink:href="insm-20181231.xsd#StockBasedCompensationRangeOfExercisePricesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:href="insm-20181231.xsd#StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:href="insm-20181231.xsd#StockBasedCompensationStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationTables" xlink:href="insm-20181231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/AccruedExpenses" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/AccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7" xlink:to="loc_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93" xlink:to="loc_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93" xlink:to="loc_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_BridgewaterNewJerseyFacilityMember" xlink:label="loc_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC" xlink:to="loc_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:to="loc_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_DC3B3ADE5A08C1BC27FBBAA235FAAEB4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:to="loc_us-gaap_LeaseAndRentalExpense_DC3B3ADE5A08C1BC27FBBAA235FAAEB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_A716BF0AA9AC8098DEA1BAB566C3334E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:to="loc_us-gaap_PurchaseObligation_A716BF0AA9AC8098DEA1BAB566C3334E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0E77313F69933601EF0DBAA235FA564F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0E77313F69933601EF0DBAA235FA564F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C5188F092562072457410C93D4A91068" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:to="loc_us-gaap_DebtInstrumentAxis_C5188F092562072457410C93D4A91068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44C923B0813BB715A8470C93D4A975C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_C5188F092562072457410C93D4A91068" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44C923B0813BB715A8470C93D4A975C5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44C923B0813BB715A8470C93D4A975C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_C5188F092562072457410C93D4A91068" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44C923B0813BB715A8470C93D4A975C5" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_0D4AC9018D779B2E0D440C93D4AAFE4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44C923B0813BB715A8470C93D4A975C5" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_0D4AC9018D779B2E0D440C93D4AAFE4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2E51DFDCCFC2ABF65DC10C93D4AA1C61" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2E51DFDCCFC2ABF65DC10C93D4AA1C61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_69886BC5417EE938B3D40C93D4AAF1D3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2E51DFDCCFC2ABF65DC10C93D4AA1C61" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_69886BC5417EE938B3D40C93D4AAF1D3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_69886BC5417EE938B3D40C93D4AAF1D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2E51DFDCCFC2ABF65DC10C93D4AA1C61" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_69886BC5417EE938B3D40C93D4AAF1D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_3E2DAC133DCEA887C8830C93D4AA5C67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69886BC5417EE938B3D40C93D4AAF1D3" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_3E2DAC133DCEA887C8830C93D4AA5C67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A4AFAEF73DFABD21AFE80C93D4AB1546" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:to="loc_us-gaap_NetIncomeLoss_A4AFAEF73DFABD21AFE80C93D4AB1546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_278DBCDD33E18A74FDA80C93D4AC939E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_Depreciation_278DBCDD33E18A74FDA80C93D4AC939E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_78E277EE2B7B5F29BE570C93D4ACA1FE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_78E277EE2B7B5F29BE570C93D4ACA1FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A8B568EAA8A4F87DA1780C93D4AD711A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_ShareBasedCompensation_A8B568EAA8A4F87DA1780C93D4AD711A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_24E20B141B8689034A9F0C93D4AD1FFC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_24E20B141B8689034A9F0C93D4AD1FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_663151FA7AF44821EC940C9678A432B4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_663151FA7AF44821EC940C9678A432B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_E7F518F7AEBE3F821F4F0C93D4ADD922" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_E7F518F7AEBE3F821F4F0C93D4ADD922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_09B6785031A2A146FE110C93D4ADE9A3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_AccretionExpense_09B6785031A2A146FE110C93D4ADE9A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_CE03F10ECB5D81C0C2880C93D4AEC369" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_CE03F10ECB5D81C0C2880C93D4AEC369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_14E5B153496501427D810C93D4AE8C06" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_14E5B153496501427D810C93D4AE8C06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B7AAF1DA83F0F445571F0C93D4AE15D0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B7AAF1DA83F0F445571F0C93D4AE15D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9ED0A30F626F314FCD010C93D4AE673E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9ED0A30F626F314FCD010C93D4AE673E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3195AFCBD8C639CBC4FF0C93D4AF98A7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3195AFCBD8C639CBC4FF0C93D4AF98A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0A48BB7215B317E5F1BE0C93D4AFDF8D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0A48BB7215B317E5F1BE0C93D4AFDF8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45E41025C777BB78F7420C93D4AF26BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45E41025C777BB78F7420C93D4AF26BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_09CAA61361022BB04E590C93D4B01D77" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_09CAA61361022BB04E590C93D4B01D77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_330E2CF10306994C6D590C93D4B0B480" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_330E2CF10306994C6D590C93D4B0B480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_4EEE6D6E06433A445B2D0C93D4B0C87B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_4EEE6D6E06433A445B2D0C93D4B0C87B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7E4D9DF066D68AE2483F0C93D4B12FD6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7E4D9DF066D68AE2483F0C93D4B12FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_618F08679033118676350C93D4B195F2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_RepaymentsOfDebt_618F08679033118676350C93D4B195F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_DDD448DE9E856CA08B7D0C93D4B18361" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_DDD448DE9E856CA08B7D0C93D4B18361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_860366CE10231D15EBF20C93D4B10B3E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_860366CE10231D15EBF20C93D4B10B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7DD5C5382DD48011C6C80C93D4B12181" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7DD5C5382DD48011C6C80C93D4B12181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_C86021248EB400E181280C93D4B2A1FC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_C86021248EB400E181280C93D4B2A1FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2CDA63217499ED916F9A0C93D4B29F78" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2CDA63217499ED916F9A0C93D4B29F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8E010265053963D520D90C93D4B25D9E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8E010265053963D520D90C93D4B25D9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E1A695987984950FB6060C93D4B2C1AA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E1A695987984950FB6060C93D4B2C1AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AFEBCC5EBDDBE0EBDE7B0C93D4B2AA4D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AFEBCC5EBDDBE0EBDE7B0C93D4B2AA4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_17623CE87AB346DBCD2F0C93D4B8A3B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:to="loc_us-gaap_InterestPaidNet_17623CE87AB346DBCD2F0C93D4B8A3B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_436EBEC3FF37467E6E8A0C93D4B8223F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_436EBEC3FF37467E6E8A0C93D4B8223F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1C94F51B79F6C9117D8B807FFD78B34A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6BB5DA2E69D3EDDB758D807FFD767843" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1C94F51B79F6C9117D8B807FFD78B34A" xlink:to="loc_us-gaap_StatementTable_6BB5DA2E69D3EDDB758D807FFD767843" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6BB5DA2E69D3EDDB758D807FFD767843" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3" xlink:to="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3" xlink:to="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_67D9812FA89DE4BEA295807FFD77A807" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:to="loc_us-gaap_CommonStockMember_67D9812FA89DE4BEA295807FFD77A807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_AD15C0334D055B9B1C55807FFD77F114" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_AD15C0334D055B9B1C55807FFD77F114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_F38403F16A203911FD90807FFD77E481" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:to="loc_us-gaap_RetainedEarningsMember_F38403F16A203911FD90807FFD77E481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CCF39A1FD996CE103504807FFD77373E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CCF39A1FD996CE103504807FFD77373E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1C94F51B79F6C9117D8B807FFD78B34A" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_DC2D59A97C6440B58B16807FFD78A421" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockholdersEquity_DC2D59A97C6440B58B16807FFD78A421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_7513838A60039BE2F41E807FFD781491" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_SharesOutstanding_7513838A60039BE2F41E807FFD781491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DE5EB00C127FE19A65BE807FFD79FD58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:to="loc_us-gaap_NetIncomeLoss_DE5EB00C127FE19A65BE807FFD79FD58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3C9707AA3B39D6764C8F807FFD797CC6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3C9707AA3B39D6764C8F807FFD797CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_D09A8257BF8A0BCCFC8F807FFD79D7DC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_D09A8257BF8A0BCCFC8F807FFD79D7DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9F7A74B301B690A78220807FFD79604A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9F7A74B301B690A78220807FFD79604A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0E869170F73862C35F92807FFD799821" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0E869170F73862C35F92807FFD799821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89E9B6272B28E465714E807FFD7A4A87" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89E9B6272B28E465714E807FFD7A4A87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9272184B92AF89EE0967807FFD7A929B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9272184B92AF89EE0967807FFD7A929B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_94F0E1F24A5F8D9CF128807FFD7AA4D2" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_94F0E1F24A5F8D9CF128807FFD7AA4D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16D109FD69DC56659FDA807FFD7A8F16" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16D109FD69DC56659FDA807FFD7A8F16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0A9EB13863865C36730F807FFD7A4AE0" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0A9EB13863865C36730F807FFD7A4AE0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtComponentsOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_59BCE71C25EDBB3901DB5752D4F8FC72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:to="loc_us-gaap_DebtInstrumentTable_59BCE71C25EDBB3901DB5752D4F8FC72" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_800F0F745D6021F07EAF5752D4F93E67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59BCE71C25EDBB3901DB5752D4F8FC72" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_800F0F745D6021F07EAF5752D4F93E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A9B64D2A5873C12F8BE55752D4F9F7DA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_800F0F745D6021F07EAF5752D4F93E67" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_A9B64D2A5873C12F8BE55752D4F9F7DA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A9B64D2A5873C12F8BE55752D4F9F7DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_800F0F745D6021F07EAF5752D4F93E67" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_A9B64D2A5873C12F8BE55752D4F9F7DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_F179802E54B5771361AF5752D4F9558E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_A9B64D2A5873C12F8BE55752D4F9F7DA" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_F179802E54B5771361AF5752D4F9558E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8FD6F48BB1A773098FC45752D4FAF6EF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_59BCE71C25EDBB3901DB5752D4F8FC72" xlink:to="loc_us-gaap_DebtInstrumentAxis_8FD6F48BB1A773098FC45752D4FAF6EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_532E311E0BA197BA13FC5752D4FA061E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8FD6F48BB1A773098FC45752D4FAF6EF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_532E311E0BA197BA13FC5752D4FA061E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_532E311E0BA197BA13FC5752D4FA061E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8FD6F48BB1A773098FC45752D4FAF6EF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_532E311E0BA197BA13FC5752D4FA061E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_D5BD3D701075837BEC035752D4FB10E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_532E311E0BA197BA13FC5752D4FA061E" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_D5BD3D701075837BEC035752D4FB10E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_2CDE5A6BB150DF9309555752D4FB708C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:to="loc_us-gaap_SecuredDebt_2CDE5A6BB150DF9309555752D4FB708C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_21674C05B821831D380D5752D4FC47D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_21674C05B821831D380D5752D4FC47D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9ED95C30CC5CB642D6FA5752D4FCA444" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9ED95C30CC5CB642D6FA5752D4FCA444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_372A143DA394CCC803E25752D4FCCF10" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_372A143DA394CCC803E25752D4FCCF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9B6B3F24B665BFC3F9455752D4FC349D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9B6B3F24B665BFC3F9455752D4FC349D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentConversionTermAxis" xlink:label="loc_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:to="loc_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentConversionTermDomain" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6_default" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentConversionTermDomain" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ConversionTermiMember" xlink:label="loc_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:to="loc_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ConversionTermiiMember" xlink:label="loc_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:to="loc_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ConversionTermiiiMember" xlink:label="loc_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:to="loc_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ConversionTermivMember" xlink:label="loc_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:to="loc_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FACC58C95A3CEFB6C4560DE7EBDE82AF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_FACC58C95A3CEFB6C4560DE7EBDE82AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_44E72205592D48E71A7C0DE7EBDEA147_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FACC58C95A3CEFB6C4560DE7EBDE82AF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_44E72205592D48E71A7C0DE7EBDEA147_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_44E72205592D48E71A7C0DE7EBDEA147" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FACC58C95A3CEFB6C4560DE7EBDE82AF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_44E72205592D48E71A7C0DE7EBDEA147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_A473FBAF9B02DC9FC3B40DE7EBDF7ED3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_44E72205592D48E71A7C0DE7EBDEA147" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_A473FBAF9B02DC9FC3B40DE7EBDF7ED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C1F21E5ACD55CB1EE3380DE7EBDFAAC6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:to="loc_us-gaap_DebtInstrumentAxis_C1F21E5ACD55CB1EE3380DE7EBDFAAC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A08936F2E8D37E6B01410DE7EBDFB24D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_C1F21E5ACD55CB1EE3380DE7EBDFAAC6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A08936F2E8D37E6B01410DE7EBDFB24D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A08936F2E8D37E6B01410DE7EBDFB24D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_C1F21E5ACD55CB1EE3380DE7EBDFAAC6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A08936F2E8D37E6B01410DE7EBDFB24D" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_F34FC0089A584E94114A0DE7EBE0DD38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A08936F2E8D37E6B01410DE7EBDFB24D" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_F34FC0089A584E94114A0DE7EBE0DD38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_FD4B8CCEFB7D11145B700DE7EBE15D9F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A08936F2E8D37E6B01410DE7EBDFB24D" xlink:to="loc_us-gaap_LineOfCreditMember_FD4B8CCEFB7D11145B700DE7EBE15D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_B930345FD856C65255920DE7EBE1B352" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_B930345FD856C65255920DE7EBE1B352" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_593BFDEED0B60A9C203E0DE7EBE297FB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_593BFDEED0B60A9C203E0DE7EBE297FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_95E6B2B2D6E2CBC420FC0DE7EBE24AA3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_95E6B2B2D6E2CBC420FC0DE7EBE24AA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_0A387B9BEAC401AB49990DE7EBE28840" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_0A387B9BEAC401AB49990DE7EBE28840" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0472DAC8E0394D63DEEA0DE7EBE266C3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0472DAC8E0394D63DEEA0DE7EBE266C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A905463F2AC3CE0FD43E0DE7EBE2E7CA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A905463F2AC3CE0FD43E0DE7EBE2E7CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_AA528A012E1CA591C4C50DE7EBE2468B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_AA528A012E1CA591C4C50DE7EBE2468B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90756108AE32198A68010DE7EBE32827" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90756108AE32198A68010DE7EBE32827" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_ACE70DB48BA7899683440DE7EBE396B4" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_ACE70DB48BA7899683440DE7EBE396B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_D89957ED619FE909EEB30DE7EBE3CB9D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_D89957ED619FE909EEB30DE7EBE3CB9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5A9DC37622DC5BE416CC0DE7EBE3C70A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5A9DC37622DC5BE416CC0DE7EBE3C70A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_22FB3873BCC12411166C0DE7EBE38C22" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_22FB3873BCC12411166C0DE7EBE38C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D80187B1C148611107C70DE7EBE4166B" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_InterestExpense_D80187B1C148611107C70DE7EBE4166B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_7E5A8894AB7E324DCCE60DE7EBE49923" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_RepaymentsOfDebt_7E5A8894AB7E324DCCE60DE7EBE49923" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_RepaymentsOfDebtFeesAndOutstandingInterest" xlink:label="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5AEF1A5F5AA5AEE12570DE7EBE41583" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5AEF1A5F5AA5AEE12570DE7EBE41583" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/FixedAssetsNet" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_4C7332D7EC1F48419932BE8FADA00622" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_us-gaap_EquipmentMember_4C7332D7EC1F48419932BE8FADA00622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2A05F085882D53907B75BE8FADA2EE5E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2A05F085882D53907B75BE8FADA2EE5E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ComputerHardwareAndSoftwareMember" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_1E827B8596318CDABE4EBE8FADA2BE83" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_us-gaap_OfficeEquipmentMember_1E827B8596318CDABE4EBE8FADA2BE83" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ManufacturingEquipmentMember" xlink:label="loc_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7B6280AB4C7E913004C8BE8FADA2AD30" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7B6280AB4C7E913004C8BE8FADA2AD30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_6583E3435A7335AB2B8BBE8FADA25308" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_us-gaap_ConstructionInProgressMember_6583E3435A7335AB2B8BBE8FADA25308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14577A462730A64EA0A1BE8FADA25F89" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:to="loc_srt_RangeAxis_14577A462730A64EA0A1BE8FADA25F89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_E44AB9372E851821008BBE8FADA25A39_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_14577A462730A64EA0A1BE8FADA25F89" xlink:to="loc_srt_RangeMember_E44AB9372E851821008BBE8FADA25A39_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_E44AB9372E851821008BBE8FADA25A39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_14577A462730A64EA0A1BE8FADA25F89" xlink:to="loc_srt_RangeMember_E44AB9372E851821008BBE8FADA25A39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C9A7730FA0E4E2E11932BE8FADA2F428" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_E44AB9372E851821008BBE8FADA25A39" xlink:to="loc_srt_MinimumMember_C9A7730FA0E4E2E11932BE8FADA2F428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_33476AB3684A1F246385BE8FADA27704" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_E44AB9372E851821008BBE8FADA25A39" xlink:to="loc_srt_MaximumMember_33476AB3684A1F246385BE8FADA27704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_587209B7F92301EA665BBE8FADA2C11B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_587209B7F92301EA665BBE8FADA2C11B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EA4F08417D911622DDC6BE8FADA558B5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EA4F08417D911622DDC6BE8FADA558B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_47989EA0008F9131FC32BE8FADA56D92" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_47989EA0008F9131FC32BE8FADA56D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_07EB0C2E0E79B33D9DEDBE8FADA5827E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_07EB0C2E0E79B33D9DEDBE8FADA5827E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_A8015064194583E59421BE8FADA5D26A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_A8015064194583E59421BE8FADA5D26A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_4629103785249527514BBE8FADA52FB6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_4629103785249527514BBE8FADA52FB6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/FixedAssetsNetTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_A14527FD60B1C0722DC4C9F686C28A3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_A14527FD60B1C0722DC4C9F686C28A3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_7AF31B5C1F84467478DCC8B4E01BB0BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:to="loc_us-gaap_DomesticCountryMember_7AF31B5C1F84467478DCC8B4E01BB0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_695DDE5874EF3DA06159C8B4E01A15EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_695DDE5874EF3DA06159C8B4E01A15EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E239B7FE07B9B2728AFFC8B4E01C955E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E239B7FE07B9B2728AFFC8B4E01C955E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58605D08494716690590C8B4E01CE3E2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58605D08494716690590C8B4E01CE3E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6431F38A5374FBD770ADC8B4E01CDB21" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6431F38A5374FBD770ADC8B4E01CDB21" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_614D554622436A55EE8BC8B4E01DE022" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_614D554622436A55EE8BC8B4E01DE022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B0527100D9A8BD081AF0C8B4E01D3BBB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B0527100D9A8BD081AF0C8B4E01D3BBB" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_OperatingLossCarryforwardsTotal" xlink:label="loc_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2F4984D5DF26F5326317C8B4E01FD7F1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2F4984D5DF26F5326317C8B4E01FD7F1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IntangiblesNet" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IntangiblesNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_68E405F80C4835C8B654A60239273A83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_68E405F80C4835C8B654A60239273A83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_F949594D428D4C158DE9A6023927A01B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:to="loc_us-gaap_LicensingAgreementsMember_F949594D428D4C158DE9A6023927A01B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_39C7FC2A76D867A90629A602392865D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_39C7FC2A76D867A90629A602392865D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_76FB13C030901290F05EA6023928F335" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_76FB13C030901290F05EA6023928F335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_F96120BC1E736882B457A60239291D93" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_F96120BC1E736882B457A60239291D93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_836A0949B9B037E2F171A6023929208D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_836A0949B9B037E2F171A6023929208D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IntangiblesNetTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/LicenseAndOtherAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/LicenseAndOtherAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestonePaymentAxis" xlink:label="loc_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:to="loc_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestonePaymentDomain" xlink:label="loc_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:to="loc_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53_default" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestonePaymentDomain" xlink:label="loc_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:to="loc_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestoneNewDrugApplicationMember" xlink:label="loc_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:to="loc_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestoneFDAApprovalMember" xlink:label="loc_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:to="loc_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:to="loc_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17" xlink:to="loc_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17" xlink:to="loc_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_A6C7B632FCC827DD2C3CE7727212F85B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314" xlink:to="loc_us-gaap_LicenseAndServiceMember_A6C7B632FCC827DD2C3CE7727212F85B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_PRIPharmaGmbhCommercializationAgreementMember" xlink:label="loc_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:label="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:label="loc_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AgreementWithSynteractHCRInc.For212StudyMember" xlink:label="loc_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CommercialFilVFinishServicesAgreementMember" xlink:label="loc_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_LicenseAgreementWithAstrazenecaMember" xlink:label="loc_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_SupplyAgreementWithPatheonUKLimitedMember" xlink:label="loc_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AgreementWithSyneosHealthForWillowStudyMember" xlink:label="loc_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:to="loc_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5" xlink:to="loc_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5" xlink:to="loc_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_F0C432D4F2BCEA52FF55E772721794FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:to="loc_srt_MaximumMember_F0C432D4F2BCEA52FF55E772721794FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4051280A8F29AA36FD62E772721709B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:to="loc_srt_MinimumMember_4051280A8F29AA36FD62E772721709B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65D55831FEE0DDDF322FE7727219101F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65D55831FEE0DDDF322FE7727219101F" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CollaborativeArrangementMilestonePayment" xlink:label="loc_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_FutureMilestonePayments" xlink:label="loc_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_345B317E624013DD1771E772721ACFD8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_345B317E624013DD1771E772721ACFD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_AC21BF1DF3C6F0C9FFCAE772721AE9A2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_AC21BF1DF3C6F0C9FFCAE772721AE9A2" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_RoyaltyPaymentPeriod" xlink:label="loc_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:label="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_InitialTermOfContractManufacturingAgreement" xlink:label="loc_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:label="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:label="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AdditionalTermOfContractManufacturingAgreement" xlink:label="loc_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ImplementationAndManagementServicesAgreementAggregateCosts" xlink:label="loc_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CommercialServicesAgreementMinimumObligation" xlink:label="loc_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CommercialServicesAgreementExtensionPeriod" xlink:label="loc_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" xlink:label="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CollaborativeArrangementUpfrontPayment" xlink:label="loc_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_PaymentsUponAchievementOfClinicalMilestonesAmount" xlink:label="loc_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" xlink:label="loc_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_DB3B3DBB67A283258C55E772721EB91C" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_us-gaap_PaymentsForRoyalties_DB3B3DBB67A283258C55E772721EB91C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_235EF3FBB079B767271CE772721E25B5" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_235EF3FBB079B767271CE772721E25B5" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ManufactureAndSupplyAgreementEstimatedCosts" xlink:label="loc_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/RetirementPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/RetirementPlanDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ShareholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4FAF5906DBC1EA5F5C7B153C73BC8230" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143" xlink:to="loc_us-gaap_AwardTypeAxis_4FAF5906DBC1EA5F5C7B153C73BC8230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CF682F6AE73168B10A5153C73BC8F88_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4FAF5906DBC1EA5F5C7B153C73BC8230" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CF682F6AE73168B10A5153C73BC8F88_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CF682F6AE73168B10A5153C73BC8F88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4FAF5906DBC1EA5F5C7B153C73BC8230" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CF682F6AE73168B10A5153C73BC8F88" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_D1DF21346C606A5F33EA153C73BC4C8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CF682F6AE73168B10A5153C73BC8F88" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_D1DF21346C606A5F33EA153C73BC4C8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_00A143F8396E9AD4549B153C73BDB744" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CF682F6AE73168B10A5153C73BC8F88" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_00A143F8396E9AD4549B153C73BDB744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_450C2C95AE705214EFFD153C73BD33BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_450C2C95AE705214EFFD153C73BD33BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_85B7D6097D6A51E1DB87153C73BEE6A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_85B7D6097D6A51E1DB87153C73BEE6A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A11C7C9721CBF3762408153C73BE4BD7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_CommonStockSharesIssued_A11C7C9721CBF3762408153C73BE4BD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_F8F307570067ECD69E5D153C73BFB27C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_F8F307570067ECD69E5D153C73BFB27C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E7210374FEFFC6CBF42E153C73BF5EC0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E7210374FEFFC6CBF42E153C73BF5EC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C4E8328BA862C3280452153C73BFA02D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C4E8328BA862C3280452153C73BFA02D" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:label="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_3AE64906F275F91388DB153C73C04B8C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_SharePrice_3AE64906F275F91388DB153C73C04B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_E2B3A7C43FD664F514FF153C73C00395" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_E2B3A7C43FD664F514FF153C73C00395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DC2D3096C50B5DC7A63A153C73C5DF16" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DC2D3096C50B5DC7A63A153C73C5DF16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_49189DC7B80A686CD952153C73C591F0" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_49189DC7B80A686CD952153C73C591F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BB3F608D01625B7102A153C73C5A57A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BB3F608D01625B7102A153C73C5A57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1F51066B83EA75F3863D153C73C6CAEE" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1F51066B83EA75F3863D153C73C6CAEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_719708F3B3DD32710132153C73C63813" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_719708F3B3DD32710132153C73C63813" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range1Member" xlink:label="loc_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range2Member" xlink:label="loc_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range3Member" xlink:label="loc_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range4Member" xlink:label="loc_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range5Member" xlink:label="loc_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range6Member" xlink:label="loc_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range7Member" xlink:label="loc_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range8Member" xlink:label="loc_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range9Member" xlink:label="loc_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range10Member" xlink:label="loc_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C506716EAFB080FE77E4807FFC3D068C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:to="loc_us-gaap_AwardTypeAxis_C506716EAFB080FE77E4807FFC3D068C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC7874DCFE62BC7FD4DB807FFC3D41F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_C506716EAFB080FE77E4807FFC3D068C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC7874DCFE62BC7FD4DB807FFC3D41F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC7874DCFE62BC7FD4DB807FFC3D41F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_C506716EAFB080FE77E4807FFC3D068C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC7874DCFE62BC7FD4DB807FFC3D41F5" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_8ADC80B5CA792CFFC1D7807FFC3D5509" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC7874DCFE62BC7FD4DB807FFC3D41F5" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_8ADC80B5CA792CFFC1D7807FFC3D5509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_ED678AD332AE941AD365807FFC3E3441" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC7874DCFE62BC7FD4DB807FFC3D41F5" xlink:to="loc_us-gaap_PerformanceSharesMember_ED678AD332AE941AD365807FFC3E3441" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05A46263CC6617C6CD51807FFC3E3B06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05A46263CC6617C6CD51807FFC3E3B06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26FFC6253D453629FA35807FFC3EE6E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26FFC6253D453629FA35807FFC3EE6E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_FE2ADA979ABACB5F13F3807FFC3FCFCB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_FE2ADA979ABACB5F13F3807FFC3FCFCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_06AAC493F366650B4D97807FFC3F86BA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_06AAC493F366650B4D97807FFC3F86BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_6D831E308E75F43DC7F4807FFC3F3F2F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_6D831E308E75F43DC7F4807FFC3F3F2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_68B9FFBBCFC17B4013ED807FFC3F4BCD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_68B9FFBBCFC17B4013ED807FFC3F4BCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1721D092FE5AD253B646807FFC3F0B0C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1721D092FE5AD253B646807FFC3F0B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_F4F469D51DC68C77F8DF807FFC40E57F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_F4F469D51DC68C77F8DF807FFC40E57F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_D015E674FD509EEA55D3807FFC40E967" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_D015E674FD509EEA55D3807FFC40E967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2AB4AC4AB96508B70EE7807FFC403A98" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2AB4AC4AB96508B70EE7807FFC403A98" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AEBDE45EB5BD268EBACEFDBA3029AB33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AEBDE45EB5BD268EBACEFDBA3029AB33" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8FB8C0ABF38D3A1071ABFDBA3029BCB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AEBDE45EB5BD268EBACEFDBA3029AB33" xlink:to="loc_us-gaap_AwardTypeAxis_8FB8C0ABF38D3A1071ABFDBA3029BCB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8FB8C0ABF38D3A1071ABFDBA3029BCB7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8FB8C0ABF38D3A1071ABFDBA3029BCB7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD" xlink:to="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B30BAC965F0B79ED2009FDBA302A8E11" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_B30BAC965F0B79ED2009FDBA302A8E11" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_StockOptionsAndRestrictedStockUnitsMember" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_DAB0218FDEF783E8F8B9FDBA302BB56F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD" xlink:to="loc_us-gaap_EmployeeStockMember_DAB0218FDEF783E8F8B9FDBA302BB56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D715A7212E8D8466FC04FDBA302B8ABE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AEBDE45EB5BD268EBACEFDBA3029AB33" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_D715A7212E8D8466FC04FDBA302B8ABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73F60B7F7078EDAC0533FDBA302BD08E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D715A7212E8D8466FC04FDBA302B8ABE" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73F60B7F7078EDAC0533FDBA302BD08E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73F60B7F7078EDAC0533FDBA302BD08E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D715A7212E8D8466FC04FDBA302B8ABE" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73F60B7F7078EDAC0533FDBA302BD08E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F6AA64ECF99607B477E8FDBA302CF928" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73F60B7F7078EDAC0533FDBA302BD08E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F6AA64ECF99607B477E8FDBA302CF928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_883AE2A18A017815EBC8FDBA302C0BB4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73F60B7F7078EDAC0533FDBA302BD08E" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_883AE2A18A017815EBC8FDBA302C0BB4" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" xlink:label="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE11B65043AFE7948EA7FE160FA281F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE11B65043AFE7948EA7FE160FA281F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_115EABBD059AEBC2D6BAFDBA302D748C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_115EABBD059AEBC2D6BAFDBA302D748C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58C53ED28DE3E178CC23FDBA302D29B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58C53ED28DE3E178CC23FDBA302D29B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31827335BB384557A61BFDBA302E4E59" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31827335BB384557A61BFDBA302E4E59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ED180B981B2D96F2A45AFDBA302E3186" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ED180B981B2D96F2A45AFDBA302E3186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2C7A0BD2975F81D07790FDBA302E5E46" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2C7A0BD2975F81D07790FDBA302E5E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_69EC712A65F6E69A23CCFDBA302F39F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_69EC712A65F6E69A23CCFDBA302F39F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D692A23C5C1BF119D6B1FDBA302F8BAA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D692A23C5C1BF119D6B1FDBA302F8BAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_33F845ABBB4721BB8F4FFDBA302F555A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_33F845ABBB4721BB8F4FFDBA302F555A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6AB13B6D9DC3449917D8FDBA3030C657" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6AB13B6D9DC3449917D8FDBA3030C657" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:label="loc_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_41F1C33E78C70B8535A8FDBA3030E30D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_41F1C33E78C70B8535A8FDBA3030E30D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:to="loc_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_93143804113477315143E77272BA2DE6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:to="loc_us-gaap_PerformanceSharesMember_93143804113477315143E77272BA2DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_0DFAFC59279A54B57880E77272BA50B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:to="loc_srt_RangeAxis_0DFAFC59279A54B57880E77272BA50B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FDE2ECBFA973CC683761E77272BA339A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0DFAFC59279A54B57880E77272BA50B8" xlink:to="loc_srt_RangeMember_FDE2ECBFA973CC683761E77272BA339A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FDE2ECBFA973CC683761E77272BA339A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0DFAFC59279A54B57880E77272BA50B8" xlink:to="loc_srt_RangeMember_FDE2ECBFA973CC683761E77272BA339A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_104B8AE4D4A815133BB5E77272BB2BF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_FDE2ECBFA973CC683761E77272BA339A" xlink:to="loc_srt_MinimumMember_104B8AE4D4A815133BB5E77272BB2BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_4553DDB2DD083C3D907AE77272BBCF04" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_FDE2ECBFA973CC683761E77272BA339A" xlink:to="loc_srt_MaximumMember_4553DDB2DD083C3D907AE77272BBCF04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_E168FB0F2BD5509DF3ADE77272BC685C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_StockOptionPlanExpense_E168FB0F2BD5509DF3ADE77272BC685C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_25580AEF3C2AE9516666E77272BD1A33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_25580AEF3C2AE9516666E77272BD1A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1A21D0C912989D988B1FE77272BD6CDE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1A21D0C912989D988B1FE77272BD6CDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0A69ABEDD4B65D2088B5E77272BECE49" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0A69ABEDD4B65D2088B5E77272BECE49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C05DF76708E272D7F60AE77272BE5A4F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C05DF76708E272D7F60AE77272BE5A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E3738B1180BA0246407E77272BF1B98" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E3738B1180BA0246407E77272BF1B98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB30005DF10EF06D7023E77272BFC171" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB30005DF10EF06D7023E77272BFC171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6787B0B84DC880EC80A3E77272BF0F36" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6787B0B84DC880EC80A3E77272BF0F36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8CFDE7D31EAF7F8D62C2E77272C08033" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8CFDE7D31EAF7F8D62C2E77272C08033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2377ECDEF2C1EDB20BD2E77272C0DA44" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2377ECDEF2C1EDB20BD2E77272C0DA44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_C1F476D824D0C536CC0FE77272C082AE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_C1F476D824D0C536CC0FE77272C082AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CB299E2D56BD3A14A236E77272C17C8B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CB299E2D56BD3A14A236E77272C17C8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20D3B83726BABC840BECE77272C1CD59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20D3B83726BABC840BECE77272C1CD59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41069C08A98916666F53E77272C2E6CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41069C08A98916666F53E77272C2E6CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3AE07D4DBD5FA8DF4FAEE77272C228A2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3AE07D4DBD5FA8DF4FAEE77272C228A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9933D2D57EA3A4725152E77272C24B99" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9933D2D57EA3A4725152E77272C24B99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_742BE4942D8DAD60A332E77272C24662" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_742BE4942D8DAD60A332E77272C24662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0B959100D54AE32B7E6FE77272C3C740" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0B959100D54AE32B7E6FE77272C3C740" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:label="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30536A72E0E12DE8D4FDE77272C35973" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30536A72E0E12DE8D4FDE77272C35973" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_D62DD0F1E495148D4789E77272C39274" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_D62DD0F1E495148D4789E77272C39274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_280E2970552DC1BC4A21E77272C44090" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_280E2970552DC1BC4A21E77272C44090" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3C6A701DE883405CF1ACE77272C417C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3C6A701DE883405CF1ACE77272C417C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5AB1C7CD9A99A43F7EA0E77272C4E57E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5AB1C7CD9A99A43F7EA0E77272C4E57E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0E17CADB4B1A6753ABAAE77272C5D89F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0E17CADB4B1A6753ABAAE77272C5D89F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails" xlink:type="extended">
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_AA4FF5F9C7399B9E123201A033E1EA9A" xlink:type="locator" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossTable" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_A99C21A4EE479667966701A033E0B540" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_AA4FF5F9C7399B9E123201A033E1EA9A" xlink:to="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_A99C21A4EE479667966701A033E0B540" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_57C906DF9889557E9FF901A033E052BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_A99C21A4EE479667966701A033E0B540" xlink:to="loc_srt_MajorCustomersAxis_57C906DF9889557E9FF901A033E052BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_57C906DF9889557E9FF901A033E052BF" xlink:to="loc_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_57C906DF9889557E9FF901A033E052BF" xlink:to="loc_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CustomerFeesDiscountsandOtherMember" xlink:label="loc_insm_CustomerFeesDiscountsandOtherMember_F4B1FF1B6900464E399401A033E13D74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2" xlink:to="loc_insm_CustomerFeesDiscountsandOtherMember_F4B1FF1B6900464E399401A033E13D74" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_RebatesChargebacksandCoPayAssistanceMember" xlink:label="loc_insm_RebatesChargebacksandCoPayAssistanceMember_B8983FA28B604D04700601A033E11DCC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2" xlink:to="loc_insm_RebatesChargebacksandCoPayAssistanceMember_B8983FA28B604D04700601A033E11DCC" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_AA4FF5F9C7399B9E123201A033E1EA9A" xlink:to="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_3D3BDA837EF005C6EB2E01A033E1DA1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1" xlink:to="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_3D3BDA837EF005C6EB2E01A033E1DA1E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales" xlink:label="loc_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_A8FE332F72CEA7FD823501A033E2DF06" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1" xlink:to="loc_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_A8FE332F72CEA7FD823501A033E2DF06" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" xlink:label="loc_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_A6350C01747F4242770901A033E272D9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1" xlink:to="loc_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_A6350C01747F4242770901A033E272D9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_7AD5DA608C165FF8FDC9C8B4E16D46D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_7AD5DA608C165FF8FDC9C8B4E16D46D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_84D6642761C512472EA2C8B4E16E9E2E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:to="loc_us-gaap_RestrictedStockMember_84D6642761C512472EA2C8B4E16E9E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_0ABFAF6C2817950EDCA5C8B4E16FAF53" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_0ABFAF6C2817950EDCA5C8B4E16FAF53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E137C8346391ED21946EC8B4E1709B09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E137C8346391ED21946EC8B4E1709B09" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_DFBE3B2A35CA937DAF8001482CAFF9A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_27064A71DB575E907A9A01482CABAF1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_DFBE3B2A35CA937DAF8001482CAFF9A1" xlink:to="loc_us-gaap_ConcentrationRiskTable_27064A71DB575E907A9A01482CABAF1E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_353F8579B7529BF3600A01482CAC9B5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_27064A71DB575E907A9A01482CABAF1E" xlink:to="loc_srt_MajorCustomersAxis_353F8579B7529BF3600A01482CAC9B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_054EC5A503A24B9998C201482CAC0E23_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_353F8579B7529BF3600A01482CAC9B5B" xlink:to="loc_srt_NameOfMajorCustomerDomain_054EC5A503A24B9998C201482CAC0E23_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_054EC5A503A24B9998C201482CAC0E23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_353F8579B7529BF3600A01482CAC9B5B" xlink:to="loc_srt_NameOfMajorCustomerDomain_054EC5A503A24B9998C201482CAC0E23" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CustomerAMember" xlink:label="loc_insm_CustomerAMember_E25144357E3D5A5513C101482CAC79C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_054EC5A503A24B9998C201482CAC0E23" xlink:to="loc_insm_CustomerAMember_E25144357E3D5A5513C101482CAC79C4" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CustomerBMember" xlink:label="loc_insm_CustomerBMember_0B8D743FE30F24C6BCE301482CAC57E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_054EC5A503A24B9998C201482CAC0E23" xlink:to="loc_insm_CustomerBMember_0B8D743FE30F24C6BCE301482CAC57E0" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CustomerCMember" xlink:label="loc_insm_CustomerCMember_1BCF617240E74973C32701482CAD8469" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_054EC5A503A24B9998C201482CAC0E23" xlink:to="loc_insm_CustomerCMember_1BCF617240E74973C32701482CAD8469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60FDA62B50D0C929B8FB01482CAD1B2E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_27064A71DB575E907A9A01482CABAF1E" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60FDA62B50D0C929B8FB01482CAD1B2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1E049EC3A75A355EDE0901482CAD4DE5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60FDA62B50D0C929B8FB01482CAD1B2E" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1E049EC3A75A355EDE0901482CAD4DE5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1E049EC3A75A355EDE0901482CAD4DE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60FDA62B50D0C929B8FB01482CAD1B2E" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1E049EC3A75A355EDE0901482CAD4DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_632E34A1F4A40BABBEA201482CADACFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1E049EC3A75A355EDE0901482CAD4DE5" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_632E34A1F4A40BABBEA201482CADACFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4563FAE63ADCFCC46A5201482CAE176E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_27064A71DB575E907A9A01482CABAF1E" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4563FAE63ADCFCC46A5201482CAE176E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D2A00228D3F65D247D7401482CAEA84E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4563FAE63ADCFCC46A5201482CAE176E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_D2A00228D3F65D247D7401482CAEA84E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D2A00228D3F65D247D7401482CAEA84E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4563FAE63ADCFCC46A5201482CAE176E" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_D2A00228D3F65D247D7401482CAEA84E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_C14D2A2BED77C3C743B701482CAE6123" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D2A00228D3F65D247D7401482CAEA84E" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_C14D2A2BED77C3C743B701482CAE6123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_55085B87629AF28D09C201482CAF3DEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_DFBE3B2A35CA937DAF8001482CAFF9A1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_55085B87629AF28D09C201482CAF3DEF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9F9F7978841007810417DD83939D2C0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9F9F7978841007810417DD83939D2C0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_62F2F1010C13DD274E18DD8D02AB63B3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_62F2F1010C13DD274E18DD8D02AB63B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_C44896F749BD245E63A9DD40960B5432" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_C44896F749BD245E63A9DD40960B5432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_E88DF0C18F588D94F583DD40960CC8E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_E88DF0C18F588D94F583DD40960CC8E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_BABB7C98F7E20566C2C3DD40960C9287" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_BABB7C98F7E20566C2C3DD40960C9287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_74A303BFD025BF031D49DD7DEB1D4083" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_74A303BFD025BF031D49DD7DEB1D4083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_D39B9843D14C79669D1ADD40960DACE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_D39B9843D14C79669D1ADD40960DACE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:to="loc_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77F8925089EF6DF7AC30DD4096131244" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77F8925089EF6DF7AC30DD4096131244" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_FairValueLevel1Level2Level3TransfersAmount" xlink:label="loc_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_70E698286CDF29AB1B60DD4096145671" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_70E698286CDF29AB1B60DD4096145671" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_BD07198EA2C43D950116DD4096149B27" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_BD07198EA2C43D950116DD4096149B27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_47128F6328719D0E3892DD4096144A3A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_47128F6328719D0E3892DD4096144A3A" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" xlink:label="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_154CCBB4BDA23C98FE72DD4096156DE3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_154CCBB4BDA23C98FE72DD4096156DE3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10236377179A2556917DC80C906CF0D7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B7522BCA0BB0E8ABD403C80C9069F417" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10236377179A2556917DC80C906CF0D7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B7522BCA0BB0E8ABD403C80C9069F417" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2B9F38124E3E2BB32427C80C906968A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B7522BCA0BB0E8ABD403C80C9069F417" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2B9F38124E3E2BB32427C80C906968A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60869E667C6E97897F2C80C90691CA4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2B9F38124E3E2BB32427C80C906968A1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60869E667C6E97897F2C80C90691CA4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60869E667C6E97897F2C80C90691CA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2B9F38124E3E2BB32427C80C906968A1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60869E667C6E97897F2C80C90691CA4" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ComputerHardwareAndSoftwareMember" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_4ACE69658385BA1C23F0C80C906ABD3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60869E667C6E97897F2C80C90691CA4" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember_4ACE69658385BA1C23F0C80C906ABD3A" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EquipmentFurnitureAndFixturesMember" xlink:label="loc_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60869E667C6E97897F2C80C90691CA4" xlink:to="loc_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E9EC0DA8B5D40A366FADC80C906BCD2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B7522BCA0BB0E8ABD403C80C9069F417" xlink:to="loc_srt_RangeAxis_E9EC0DA8B5D40A366FADC80C906BCD2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4CD4629D721CFCC933D8C80C906BE887_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_E9EC0DA8B5D40A366FADC80C906BCD2A" xlink:to="loc_srt_RangeMember_4CD4629D721CFCC933D8C80C906BE887_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4CD4629D721CFCC933D8C80C906BE887" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_E9EC0DA8B5D40A366FADC80C906BCD2A" xlink:to="loc_srt_RangeMember_4CD4629D721CFCC933D8C80C906BE887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D90DC3C12E72E93D3283C80C906B861B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4CD4629D721CFCC933D8C80C906BE887" xlink:to="loc_srt_MinimumMember_D90DC3C12E72E93D3283C80C906B861B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_690FC15EB0D971AD5BC3C80C906B07B5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4CD4629D721CFCC933D8C80C906BE887" xlink:to="loc_srt_MaximumMember_690FC15EB0D971AD5BC3C80C906B07B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA12F71346DF94270121C80C906CC416" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10236377179A2556917DC80C906CF0D7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA12F71346DF94270121C80C906CC416" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="insm-20181231.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:type="locator" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6CF73C360A47CCF2F16F5752D556DC42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:to="loc_us-gaap_AwardTypeAxis_6CF73C360A47CCF2F16F5752D556DC42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35D0632A670522D787FF5752D5569DE6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6CF73C360A47CCF2F16F5752D556DC42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35D0632A670522D787FF5752D5569DE6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35D0632A670522D787FF5752D5569DE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6CF73C360A47CCF2F16F5752D556DC42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35D0632A670522D787FF5752D5569DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_75C5DAFDD91F4836277E5752D5561017" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35D0632A670522D787FF5752D5569DE6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_75C5DAFDD91F4836277E5752D5561017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_CEAD3EF3F0DA580A7ED05752D55775C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35D0632A670522D787FF5752D5569DE6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_CEAD3EF3F0DA580A7ED05752D55775C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15A5E41A6A248CA4EAC95752D55738A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199" xlink:to="loc_us-gaap_NetIncomeLoss_15A5E41A6A248CA4EAC95752D55738A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCA14F2D6CF02213E5765752D558B0C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCA14F2D6CF02213E5765752D558B0C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0681DD05ED2C2DBD48955752D5587833" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0681DD05ED2C2DBD48955752D5587833" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F6062952D28D94127D4E5752D5592AA0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F6062952D28D94127D4E5752D5592AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_271830F523EB5086E3CB5752D559CD7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_271830F523EB5086E3CB5752D559CD7C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:href="insm-20181231.xsd#insm_SummaryOfSignificantPoliciesLineItems" xlink:label="loc_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:type="locator" />
    <link:loc xlink:href="insm-20181231.xsd#insm_SummaryOfSignificantPoliciesTable" xlink:label="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:to="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:to="loc_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_3A5EE3C3B2435403E4EE0DE740E64AE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9" xlink:to="loc_us-gaap_ScenarioForecastMember_3A5EE3C3B2435403E4EE0DE740E64AE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_233DF23FC48E151FFB1D0DE740EDCC2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_233DF23FC48E151FFB1D0DE740EDCC2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3A52140B7BF90524D7010DE740EE8660" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:to="loc_srt_RangeAxis_3A52140B7BF90524D7010DE740EE8660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_157A26414A36EC55B2800DE740EEA724_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3A52140B7BF90524D7010DE740EE8660" xlink:to="loc_srt_RangeMember_157A26414A36EC55B2800DE740EEA724_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_157A26414A36EC55B2800DE740EEA724" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3A52140B7BF90524D7010DE740EE8660" xlink:to="loc_srt_RangeMember_157A26414A36EC55B2800DE740EEA724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2CEEF7677CB737EB95E50DE740EE45A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_157A26414A36EC55B2800DE740EEA724" xlink:to="loc_srt_MinimumMember_2CEEF7677CB737EB95E50DE740EE45A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_70DDB0DF8F04B8882AF40DE740EEEDE6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_157A26414A36EC55B2800DE740EEA724" xlink:to="loc_srt_MaximumMember_70DDB0DF8F04B8882AF40DE740EEEDE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5049B4FB9CF779D960A20DE77F1732C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5049B4FB9CF779D960A20DE77F1732C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_F6884D4CEE189073D5A50DE740EFEF08" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:to="loc_us-gaap_OperatingLeaseLiability_F6884D4CEE189073D5A50DE740EFEF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_71A0810C3CB77F3F559A0DE740EFE182" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_71A0810C3CB77F3F559A0DE740EFE182" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>insm-20181231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_207FBCF1336C7BFE934BC80C922A608C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_207FBCF1336C7BFE934BC80C922A608C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_207FBCF1336C7BFE934BC80C922A608C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_207FBCF1336C7BFE934BC80C922A608C" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_207FBCF1336C7BFE934BC80C922A608C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_B4F9A607E9FDFA283DB6C80C922A166F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_B4F9A607E9FDFA283DB6C80C922A166F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_B4F9A607E9FDFA283DB6C80C922A166F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_B4F9A607E9FDFA283DB6C80C922A166F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_B4F9A607E9FDFA283DB6C80C922A166F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_B4F9A607E9FDFA283DB6C80C922A166F" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_B4F9A607E9FDFA283DB6C80C922A166F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_C8F25EDA06216266A412C8B4E23C054A_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_C8F25EDA06216266A412C8B4E23C054A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_C8F25EDA06216266A412C8B4E23C054A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C8F25EDA06216266A412C8B4E23C054A" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_C8F25EDA06216266A412C8B4E23C054A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F" xlink:to="lab_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2" xlink:to="lab_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9532C6FC5738EB74D9AAC8B4E23D8EE9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9532C6FC5738EB74D9AAC8B4E23D8EE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9532C6FC5738EB74D9AAC8B4E23D8EE9_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9532C6FC5738EB74D9AAC8B4E23D8EE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9532C6FC5738EB74D9AAC8B4E23D8EE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9532C6FC5738EB74D9AAC8B4E23D8EE9" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9532C6FC5738EB74D9AAC8B4E23D8EE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7FB3D6F5BB36380A993CC8B4E23EB726_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_7FB3D6F5BB36380A993CC8B4E23EB726" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7FB3D6F5BB36380A993CC8B4E23EB726_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_7FB3D6F5BB36380A993CC8B4E23EB726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7FB3D6F5BB36380A993CC8B4E23EB726" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_7FB3D6F5BB36380A993CC8B4E23EB726" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_7FB3D6F5BB36380A993CC8B4E23EB726" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_F72071759F44E23099D1C8B4E23ED4DD_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_F72071759F44E23099D1C8B4E23ED4DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_F72071759F44E23099D1C8B4E23ED4DD_label_en-US" xlink:label="lab_us-gaap_InventoryNet_F72071759F44E23099D1C8B4E23ED4DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_F72071759F44E23099D1C8B4E23ED4DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_F72071759F44E23099D1C8B4E23ED4DD" xlink:to="lab_us-gaap_InventoryNet_F72071759F44E23099D1C8B4E23ED4DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6756BDC42BAB476DF7B5C8B4E23E901F_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6756BDC42BAB476DF7B5C8B4E23E901F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6756BDC42BAB476DF7B5C8B4E23E901F_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6756BDC42BAB476DF7B5C8B4E23E901F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6756BDC42BAB476DF7B5C8B4E23E901F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6756BDC42BAB476DF7B5C8B4E23E901F" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6756BDC42BAB476DF7B5C8B4E23E901F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_CEEFC18E1543E2AAFD23C8B4E23E6D5F_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_CEEFC18E1543E2AAFD23C8B4E23E6D5F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_CEEFC18E1543E2AAFD23C8B4E23E6D5F_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_CEEFC18E1543E2AAFD23C8B4E23E6D5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_CEEFC18E1543E2AAFD23C8B4E23E6D5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_CEEFC18E1543E2AAFD23C8B4E23E6D5F" xlink:to="lab_us-gaap_AssetsCurrent_CEEFC18E1543E2AAFD23C8B4E23E6D5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_EDD298878BE12D8036C2C8B4E23F9992_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_EDD298878BE12D8036C2C8B4E23F9992" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_EDD298878BE12D8036C2C8B4E23F9992_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_EDD298878BE12D8036C2C8B4E23F9992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_EDD298878BE12D8036C2C8B4E23F9992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_EDD298878BE12D8036C2C8B4E23F9992" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_EDD298878BE12D8036C2C8B4E23F9992" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4971B01FD5ECF9390BB3C8B4E23F17EB_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_4971B01FD5ECF9390BB3C8B4E23F17EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4971B01FD5ECF9390BB3C8B4E23F17EB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_4971B01FD5ECF9390BB3C8B4E23F17EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4971B01FD5ECF9390BB3C8B4E23F17EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4971B01FD5ECF9390BB3C8B4E23F17EB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_4971B01FD5ECF9390BB3C8B4E23F17EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssets_C2875DE9FB86E5E392C2C8B4E23F5976_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets_C2875DE9FB86E5E392C2C8B4E23F5976" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_C2875DE9FB86E5E392C2C8B4E23F5976_label_en-US" xlink:label="lab_us-gaap_OtherAssets_C2875DE9FB86E5E392C2C8B4E23F5976" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_C2875DE9FB86E5E392C2C8B4E23F5976" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets_C2875DE9FB86E5E392C2C8B4E23F5976" xlink:to="lab_us-gaap_OtherAssets_C2875DE9FB86E5E392C2C8B4E23F5976" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_9A556A6E5B31BD4B47B7C8B4E23FA607_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_9A556A6E5B31BD4B47B7C8B4E23FA607" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_9A556A6E5B31BD4B47B7C8B4E23FA607_label_en-US" xlink:label="lab_us-gaap_Assets_9A556A6E5B31BD4B47B7C8B4E23FA607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_9A556A6E5B31BD4B47B7C8B4E23FA607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_9A556A6E5B31BD4B47B7C8B4E23FA607" xlink:to="lab_us-gaap_Assets_9A556A6E5B31BD4B47B7C8B4E23FA607" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2075AA8A5163FFEB4F4AC8B4E240097F_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_2075AA8A5163FFEB4F4AC8B4E240097F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2075AA8A5163FFEB4F4AC8B4E240097F_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_2075AA8A5163FFEB4F4AC8B4E240097F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2075AA8A5163FFEB4F4AC8B4E240097F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_2075AA8A5163FFEB4F4AC8B4E240097F" xlink:to="lab_us-gaap_AccountsPayableCurrent_2075AA8A5163FFEB4F4AC8B4E240097F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1F9B8D77B6520F2F1F7FC8B4E240BF29_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_1F9B8D77B6520F2F1F7FC8B4E240BF29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1F9B8D77B6520F2F1F7FC8B4E240BF29_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_1F9B8D77B6520F2F1F7FC8B4E240BF29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1F9B8D77B6520F2F1F7FC8B4E240BF29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1F9B8D77B6520F2F1F7FC8B4E240BF29" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_1F9B8D77B6520F2F1F7FC8B4E240BF29" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_38E38D02876EA99896E5C8B4E240C59C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_38E38D02876EA99896E5C8B4E240C59C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_38E38D02876EA99896E5C8B4E240C59C_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_38E38D02876EA99896E5C8B4E240C59C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_38E38D02876EA99896E5C8B4E240C59C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_38E38D02876EA99896E5C8B4E240C59C" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_38E38D02876EA99896E5C8B4E240C59C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0B9D2E011050E55BE5BBC8B4E24024F6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_0B9D2E011050E55BE5BBC8B4E24024F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0B9D2E011050E55BE5BBC8B4E24024F6_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_0B9D2E011050E55BE5BBC8B4E24024F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0B9D2E011050E55BE5BBC8B4E24024F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0B9D2E011050E55BE5BBC8B4E24024F6" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_0B9D2E011050E55BE5BBC8B4E24024F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4E297F2D5A1B59EEB80BC8B4E24173A1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_4E297F2D5A1B59EEB80BC8B4E24173A1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4E297F2D5A1B59EEB80BC8B4E24173A1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_4E297F2D5A1B59EEB80BC8B4E24173A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_4E297F2D5A1B59EEB80BC8B4E24173A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_4E297F2D5A1B59EEB80BC8B4E24173A1" xlink:to="lab_us-gaap_LiabilitiesCurrent_4E297F2D5A1B59EEB80BC8B4E24173A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_B9533764B2AF5CDF5069C8B4E243039A_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_B9533764B2AF5CDF5069C8B4E243039A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, long-term</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_B9533764B2AF5CDF5069C8B4E243039A_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_B9533764B2AF5CDF5069C8B4E243039A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_B9533764B2AF5CDF5069C8B4E243039A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_B9533764B2AF5CDF5069C8B4E243039A" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_B9533764B2AF5CDF5069C8B4E243039A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_874310B4639FBA4E9BB7C8B4E2438491_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_874310B4639FBA4E9BB7C8B4E2438491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_874310B4639FBA4E9BB7C8B4E2438491_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_874310B4639FBA4E9BB7C8B4E2438491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_874310B4639FBA4E9BB7C8B4E2438491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_874310B4639FBA4E9BB7C8B4E2438491" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_874310B4639FBA4E9BB7C8B4E2438491" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_3BF5CE271B2C54E65858C8B4E2449CDD_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_3BF5CE271B2C54E65858C8B4E2449CDD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_3BF5CE271B2C54E65858C8B4E2449CDD_label_en-US" xlink:label="lab_us-gaap_Liabilities_3BF5CE271B2C54E65858C8B4E2449CDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_3BF5CE271B2C54E65858C8B4E2449CDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_3BF5CE271B2C54E65858C8B4E2449CDD" xlink:to="lab_us-gaap_Liabilities_3BF5CE271B2C54E65858C8B4E2449CDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:to="lab_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_DDE371244FA35871DBD1C8B4E244E811_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_DDE371244FA35871DBD1C8B4E244E811" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value; 500,000,000 authorized shares, 77,307,521 and 76,610,508 issued and outstanding shares at December 31, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_DDE371244FA35871DBD1C8B4E244E811_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_DDE371244FA35871DBD1C8B4E244E811" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_DDE371244FA35871DBD1C8B4E244E811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_DDE371244FA35871DBD1C8B4E244E811" xlink:to="lab_us-gaap_CommonStockValue_DDE371244FA35871DBD1C8B4E244E811" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_512C09859AE9AC6B91B5C8B4E244623C_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_512C09859AE9AC6B91B5C8B4E244623C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_512C09859AE9AC6B91B5C8B4E244623C_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_512C09859AE9AC6B91B5C8B4E244623C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_512C09859AE9AC6B91B5C8B4E244623C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_512C09859AE9AC6B91B5C8B4E244623C" xlink:to="lab_us-gaap_AdditionalPaidInCapital_512C09859AE9AC6B91B5C8B4E244623C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DD489AE8C8AAF8601003C8B4E24643E9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DD489AE8C8AAF8601003C8B4E24643E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DD489AE8C8AAF8601003C8B4E24643E9_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DD489AE8C8AAF8601003C8B4E24643E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DD489AE8C8AAF8601003C8B4E24643E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DD489AE8C8AAF8601003C8B4E24643E9" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DD489AE8C8AAF8601003C8B4E24643E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5B12E063584509D21446C8B4E246F74C_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5B12E063584509D21446C8B4E246F74C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5B12E063584509D21446C8B4E246F74C_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5B12E063584509D21446C8B4E246F74C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5B12E063584509D21446C8B4E246F74C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5B12E063584509D21446C8B4E246F74C" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5B12E063584509D21446C8B4E246F74C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_B5E15F132C3F1136E8D3C8B4E2465A61_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B5E15F132C3F1136E8D3C8B4E2465A61" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_B5E15F132C3F1136E8D3C8B4E2465A61_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B5E15F132C3F1136E8D3C8B4E2465A61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B5E15F132C3F1136E8D3C8B4E2465A61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_B5E15F132C3F1136E8D3C8B4E2465A61" xlink:to="lab_us-gaap_StockholdersEquity_B5E15F132C3F1136E8D3C8B4E2465A61" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2D624528866E4BB13185C8B4E247DCD6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2D624528866E4BB13185C8B4E247DCD6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2D624528866E4BB13185C8B4E247DCD6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2D624528866E4BB13185C8B4E247DCD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2D624528866E4BB13185C8B4E247DCD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2D624528866E4BB13185C8B4E247DCD6" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_2D624528866E4BB13185C8B4E247DCD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E56230E125EBF0253F7A08DFA9DBD468_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E56230E125EBF0253F7A08DFA9DBD468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E56230E125EBF0253F7A08DFA9DBD468_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E56230E125EBF0253F7A08DFA9DBD468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E56230E125EBF0253F7A08DFA9DBD468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E56230E125EBF0253F7A08DFA9DBD468" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E56230E125EBF0253F7A08DFA9DBD468" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_809DF1EDA039D3FF7EC208DFA9DCDA66_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_809DF1EDA039D3FF7EC208DFA9DCDA66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General business credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_809DF1EDA039D3FF7EC208DFA9DCDA66_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_809DF1EDA039D3FF7EC208DFA9DCDA66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, General Business</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_809DF1EDA039D3FF7EC208DFA9DCDA66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_809DF1EDA039D3FF7EC208DFA9DCDA66" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_809DF1EDA039D3FF7EC208DFA9DCDA66" xlink:type="arc" />
    <link:label id="lab_insm_DeferredTaxAssetsLicensePayment_28B89DDC5432CD91BC6508DFA9DC0F62_terseLabel_en-US" xlink:label="lab_insm_DeferredTaxAssetsLicensePayment_28B89DDC5432CD91BC6508DFA9DC0F62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product license</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLicensePayment_28B89DDC5432CD91BC6508DFA9DC0F62_label_en-US" xlink:label="lab_insm_DeferredTaxAssetsLicensePayment_28B89DDC5432CD91BC6508DFA9DC0F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, License Payment</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLicensePayment_28B89DDC5432CD91BC6508DFA9DC0F62_documentation_en-US" xlink:label="lab_insm_DeferredTaxAssetsLicensePayment_28B89DDC5432CD91BC6508DFA9DC0F62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as License payment.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_DeferredTaxAssetsLicensePayment" xlink:label="loc_insm_DeferredTaxAssetsLicensePayment_28B89DDC5432CD91BC6508DFA9DC0F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DeferredTaxAssetsLicensePayment_28B89DDC5432CD91BC6508DFA9DC0F62" xlink:to="lab_insm_DeferredTaxAssetsLicensePayment_28B89DDC5432CD91BC6508DFA9DC0F62" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_08CB89E8F0F4B93B969708E5067FED4E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_08CB89E8F0F4B93B969708E5067FED4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_08CB89E8F0F4B93B969708E5067FED4E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_08CB89E8F0F4B93B969708E5067FED4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_08CB89E8F0F4B93B969708E5067FED4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory_08CB89E8F0F4B93B969708E5067FED4E" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory_08CB89E8F0F4B93B969708E5067FED4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_827EA899C8627B0621B108DFA9DCBABF_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_827EA899C8627B0621B108DFA9DCBABF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_827EA899C8627B0621B108DFA9DCBABF_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_827EA899C8627B0621B108DFA9DCBABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_827EA899C8627B0621B108DFA9DCBABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_827EA899C8627B0621B108DFA9DCBABF" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_827EA899C8627B0621B108DFA9DCBABF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_9AECEACE7F31D69E36BE08DFA9DDE685_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_9AECEACE7F31D69E36BE08DFA9DDE685" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_9AECEACE7F31D69E36BE08DFA9DDE685_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_9AECEACE7F31D69E36BE08DFA9DDE685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_9AECEACE7F31D69E36BE08DFA9DDE685" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9AECEACE7F31D69E36BE08DFA9DDE685" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_9AECEACE7F31D69E36BE08DFA9DDE685" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3DC2AEC49A61F0B99DBB08DFA9DD2655_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3DC2AEC49A61F0B99DBB08DFA9DD2655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3DC2AEC49A61F0B99DBB08DFA9DD2655_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3DC2AEC49A61F0B99DBB08DFA9DD2655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3DC2AEC49A61F0B99DBB08DFA9DD2655" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3DC2AEC49A61F0B99DBB08DFA9DD2655" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3DC2AEC49A61F0B99DBB08DFA9DD2655" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2D65D844498073F93D8B08DFA9DDFB9B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2D65D844498073F93D8B08DFA9DDFB9B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2D65D844498073F93D8B08DFA9DDFB9B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2D65D844498073F93D8B08DFA9DDFB9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2D65D844498073F93D8B08DFA9DDFB9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2D65D844498073F93D8B08DFA9DDFB9B" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2D65D844498073F93D8B08DFA9DDFB9B" xlink:type="arc" />
    <link:label id="lab_insm_DeferredTaxLiabilitiesConvertibleDebt_750A03B5944635B3911008DFA9DDD91A_negatedTerseLabel_en-US" xlink:label="lab_insm_DeferredTaxLiabilitiesConvertibleDebt_750A03B5944635B3911008DFA9DDD91A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_insm_DeferredTaxLiabilitiesConvertibleDebt_750A03B5944635B3911008DFA9DDD91A_label_en-US" xlink:label="lab_insm_DeferredTaxLiabilitiesConvertibleDebt_750A03B5944635B3911008DFA9DDD91A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Convertible Debt</link:label>
    <link:label id="lab_insm_DeferredTaxLiabilitiesConvertibleDebt_750A03B5944635B3911008DFA9DDD91A_documentation_en-US" xlink:label="lab_insm_DeferredTaxLiabilitiesConvertibleDebt_750A03B5944635B3911008DFA9DDD91A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Convertible Debt</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_DeferredTaxLiabilitiesConvertibleDebt" xlink:label="loc_insm_DeferredTaxLiabilitiesConvertibleDebt_750A03B5944635B3911008DFA9DDD91A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DeferredTaxLiabilitiesConvertibleDebt_750A03B5944635B3911008DFA9DDD91A" xlink:to="lab_insm_DeferredTaxLiabilitiesConvertibleDebt_750A03B5944635B3911008DFA9DDD91A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_541114E613DA1BC1382E08DFA9DDAFFE_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_541114E613DA1BC1382E08DFA9DDAFFE" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_541114E613DA1BC1382E08DFA9DDAFFE_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_541114E613DA1BC1382E08DFA9DDAFFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_541114E613DA1BC1382E08DFA9DDAFFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_541114E613DA1BC1382E08DFA9DDAFFE" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_541114E613DA1BC1382E08DFA9DDAFFE" xlink:type="arc" />
    <link:label id="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_C46B32F791E5318EAB4008DFA9DEC3C4_totalLabel_en-US" xlink:label="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_C46B32F791E5318EAB4008DFA9DEC3C4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_C46B32F791E5318EAB4008DFA9DEC3C4_label_en-US" xlink:label="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_C46B32F791E5318EAB4008DFA9DEC3C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets (Liabilities) Net before Valuation Allowances</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_C46B32F791E5318EAB4008DFA9DEC3C4_documentation_en-US" xlink:label="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_C46B32F791E5318EAB4008DFA9DEC3C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_C46B32F791E5318EAB4008DFA9DEC3C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_C46B32F791E5318EAB4008DFA9DEC3C4" xlink:to="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_C46B32F791E5318EAB4008DFA9DEC3C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7C5D972EB55E2D6245BB08DFA9DEBF37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7C5D972EB55E2D6245BB08DFA9DEBF37" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7C5D972EB55E2D6245BB08DFA9DEBF37_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7C5D972EB55E2D6245BB08DFA9DEBF37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7C5D972EB55E2D6245BB08DFA9DEBF37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7C5D972EB55E2D6245BB08DFA9DEBF37" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7C5D972EB55E2D6245BB08DFA9DEBF37" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7F4A61DA42BCF8FA9E2808DFA9DE604B_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7F4A61DA42BCF8FA9E2808DFA9DE604B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7F4A61DA42BCF8FA9E2808DFA9DE604B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7F4A61DA42BCF8FA9E2808DFA9DE604B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7F4A61DA42BCF8FA9E2808DFA9DE604B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7F4A61DA42BCF8FA9E2808DFA9DE604B" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7F4A61DA42BCF8FA9E2808DFA9DE604B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_52A0B22DEB4AC591838DDD409608ECE4_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_52A0B22DEB4AC591838DDD409608ECE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_52A0B22DEB4AC591838DDD409608ECE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_52A0B22DEB4AC591838DDD409608ECE4" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_52A0B22DEB4AC591838DDD409608ECE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9F9F7978841007810417DD83939D2C0C_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9F9F7978841007810417DD83939D2C0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reported Value Measurement</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9F9F7978841007810417DD83939D2C0C_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9F9F7978841007810417DD83939D2C0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9F9F7978841007810417DD83939D2C0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9F9F7978841007810417DD83939D2C0C" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9F9F7978841007810417DD83939D2C0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_62F2F1010C13DD274E18DD8D02AB63B3_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_62F2F1010C13DD274E18DD8D02AB63B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_62F2F1010C13DD274E18DD8D02AB63B3_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_62F2F1010C13DD274E18DD8D02AB63B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_62F2F1010C13DD274E18DD8D02AB63B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_62F2F1010C13DD274E18DD8D02AB63B3" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_62F2F1010C13DD274E18DD8D02AB63B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_C44896F749BD245E63A9DD40960B5432_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_C44896F749BD245E63A9DD40960B5432" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_C44896F749BD245E63A9DD40960B5432_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_C44896F749BD245E63A9DD40960B5432" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_C44896F749BD245E63A9DD40960B5432" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_C44896F749BD245E63A9DD40960B5432" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_C44896F749BD245E63A9DD40960B5432" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_E88DF0C18F588D94F583DD40960CC8E8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_E88DF0C18F588D94F583DD40960CC8E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_E88DF0C18F588D94F583DD40960CC8E8_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_E88DF0C18F588D94F583DD40960CC8E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_E88DF0C18F588D94F583DD40960CC8E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_E88DF0C18F588D94F583DD40960CC8E8" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_E88DF0C18F588D94F583DD40960CC8E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_BABB7C98F7E20566C2C3DD40960C9287_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_BABB7C98F7E20566C2C3DD40960C9287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_BABB7C98F7E20566C2C3DD40960C9287_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_BABB7C98F7E20566C2C3DD40960C9287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_BABB7C98F7E20566C2C3DD40960C9287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_BABB7C98F7E20566C2C3DD40960C9287" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_BABB7C98F7E20566C2C3DD40960C9287" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_74A303BFD025BF031D49DD7DEB1D4083_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_74A303BFD025BF031D49DD7DEB1D4083" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_74A303BFD025BF031D49DD7DEB1D4083_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_74A303BFD025BF031D49DD7DEB1D4083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_74A303BFD025BF031D49DD7DEB1D4083" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_74A303BFD025BF031D49DD7DEB1D4083" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_74A303BFD025BF031D49DD7DEB1D4083" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_D39B9843D14C79669D1ADD40960DACE7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_D39B9843D14C79669D1ADD40960DACE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_D39B9843D14C79669D1ADD40960DACE7_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_D39B9843D14C79669D1ADD40960DACE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_D39B9843D14C79669D1ADD40960DACE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_D39B9843D14C79669D1ADD40960DACE7" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_D39B9843D14C79669D1ADD40960DACE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028" xlink:to="lab_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37" xlink:type="arc" />
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4_terseLabel_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.75% Convertible Senior Note Due 2025</link:label>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4_label_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]</link:label>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4_documentation_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4" xlink:to="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77F8925089EF6DF7AC30DD4096131244_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77F8925089EF6DF7AC30DD4096131244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77F8925089EF6DF7AC30DD4096131244_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77F8925089EF6DF7AC30DD4096131244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77F8925089EF6DF7AC30DD4096131244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77F8925089EF6DF7AC30DD4096131244" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77F8925089EF6DF7AC30DD4096131244" xlink:type="arc" />
    <link:label id="lab_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A_terseLabel_en-US" xlink:label="lab_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value transfers in or out of Level 1, Level 2 or Level 3</link:label>
    <link:label id="lab_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A_label_en-US" xlink:label="lab_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Level 1, Level 2, Level 3 Transfers, Amount</link:label>
    <link:label id="lab_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A_documentation_en-US" xlink:label="lab_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Level 1, Level 2, Level 3 Transfers, Amount</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_FairValueLevel1Level2Level3TransfersAmount" xlink:label="loc_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A" xlink:to="lab_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_70E698286CDF29AB1B60DD4096145671_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_70E698286CDF29AB1B60DD4096145671" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of 1.75% convertible senior notes due 2025</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_70E698286CDF29AB1B60DD4096145671_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_70E698286CDF29AB1B60DD4096145671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_70E698286CDF29AB1B60DD4096145671" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_70E698286CDF29AB1B60DD4096145671" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_70E698286CDF29AB1B60DD4096145671" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_BD07198EA2C43D950116DD4096149B27_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_BD07198EA2C43D950116DD4096149B27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes ($450.0 face value)</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_BD07198EA2C43D950116DD4096149B27_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_BD07198EA2C43D950116DD4096149B27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_BD07198EA2C43D950116DD4096149B27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures_BD07198EA2C43D950116DD4096149B27" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures_BD07198EA2C43D950116DD4096149B27" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_47128F6328719D0E3892DD4096144A3A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_47128F6328719D0E3892DD4096144A3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized portion of debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_47128F6328719D0E3892DD4096144A3A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_47128F6328719D0E3892DD4096144A3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_47128F6328719D0E3892DD4096144A3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_47128F6328719D0E3892DD4096144A3A" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_47128F6328719D0E3892DD4096144A3A" xlink:type="arc" />
    <link:label id="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99_verboseLabel_en-US" xlink:label="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Securities in an unrealized gain or loss position</link:label>
    <link:label id="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99_label_en-US" xlink:label="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities</link:label>
    <link:label id="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99_documentation_en-US" xlink:label="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" xlink:label="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99" xlink:to="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_154CCBB4BDA23C98FE72DD4096156DE3_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_154CCBB4BDA23C98FE72DD4096156DE3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_154CCBB4BDA23C98FE72DD4096156DE3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_154CCBB4BDA23C98FE72DD4096156DE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_154CCBB4BDA23C98FE72DD4096156DE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_154CCBB4BDA23C98FE72DD4096156DE3" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_154CCBB4BDA23C98FE72DD4096156DE3" xlink:type="arc" />
    <link:label id="lab_insm_LicenseAndOtherAgreementsAbstract_5972C46D1716240205D7E772720F0704_label_en-US" xlink:label="lab_insm_LicenseAndOtherAgreementsAbstract_5972C46D1716240205D7E772720F0704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Other Agreements</link:label>
    <link:label id="lab_insm_LicenseAndOtherAgreementsAbstract_5972C46D1716240205D7E772720F0704_documentation_en-US" xlink:label="lab_insm_LicenseAndOtherAgreementsAbstract_5972C46D1716240205D7E772720F0704" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_LicenseAndOtherAgreementsAbstract" xlink:label="loc_insm_LicenseAndOtherAgreementsAbstract_5972C46D1716240205D7E772720F0704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LicenseAndOtherAgreementsAbstract_5972C46D1716240205D7E772720F0704" xlink:to="lab_insm_LicenseAndOtherAgreementsAbstract_5972C46D1716240205D7E772720F0704" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:type="arc" />
    <link:label id="lab_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74_terseLabel_en-US" xlink:label="lab_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment [Axis]</link:label>
    <link:label id="lab_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74_label_en-US" xlink:label="lab_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment [Axis]</link:label>
    <link:label id="lab_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74_documentation_en-US" xlink:label="lab_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment [Axis]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestonePaymentAxis" xlink:label="loc_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:to="lab_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:type="arc" />
    <link:label id="lab_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53_terseLabel_en-US" xlink:label="lab_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment [Domain]</link:label>
    <link:label id="lab_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53_label_en-US" xlink:label="lab_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment [Domain]</link:label>
    <link:label id="lab_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53_documentation_en-US" xlink:label="lab_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Milestone Payment [Axis]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestonePaymentDomain" xlink:label="loc_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:to="lab_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:type="arc" />
    <link:label id="lab_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F_terseLabel_en-US" xlink:label="lab_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone, New Drug Application</link:label>
    <link:label id="lab_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F_label_en-US" xlink:label="lab_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone, New Drug Application [Member]</link:label>
    <link:label id="lab_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F_documentation_en-US" xlink:label="lab_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone, New Drug Application [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestoneNewDrugApplicationMember" xlink:label="loc_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F" xlink:to="lab_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F" xlink:type="arc" />
    <link:label id="lab_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B_terseLabel_en-US" xlink:label="lab_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone, FDA Approval</link:label>
    <link:label id="lab_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B_label_en-US" xlink:label="lab_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone, FDA Approval [Member]</link:label>
    <link:label id="lab_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B_documentation_en-US" xlink:label="lab_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone, FDA Approval [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestoneFDAApprovalMember" xlink:label="loc_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B" xlink:to="lab_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17" xlink:to="lab_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314" xlink:to="lab_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseAndServiceMember_A6C7B632FCC827DD2C3CE7727212F85B_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember_A6C7B632FCC827DD2C3CE7727212F85B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Service</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_A6C7B632FCC827DD2C3CE7727212F85B_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember_A6C7B632FCC827DD2C3CE7727212F85B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_A6C7B632FCC827DD2C3CE7727212F85B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember_A6C7B632FCC827DD2C3CE7727212F85B" xlink:to="lab_us-gaap_LicenseAndServiceMember_A6C7B632FCC827DD2C3CE7727212F85B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8" xlink:to="lab_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:type="arc" />
    <link:label id="lab_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF_terseLabel_en-US" xlink:label="lab_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PARI Agreement</link:label>
    <link:label id="lab_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF_label_en-US" xlink:label="lab_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">P R I Pharma Gmbh Commercialization Agreement [Member]</link:label>
    <link:label id="lab_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF_documentation_en-US" xlink:label="lab_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the agreement with PARI Pharma GmbH, for the manufacture and supply of eFlow nebulizer systems and related accessories, liposomal amikacin for inhalation.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_PRIPharmaGmbhCommercializationAgreementMember" xlink:label="loc_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF" xlink:to="lab_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF" xlink:type="arc" />
    <link:label id="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272_terseLabel_en-US" xlink:label="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CFFT</link:label>
    <link:label id="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272_label_en-US" xlink:label="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cystic Fibrosis Foundation Therapeutics Inc Collaboration Agreements [Member]</link:label>
    <link:label id="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272_documentation_en-US" xlink:label="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the agreement with Cystic Fibrosis Foundation Therapeutics, Inc., for research funding for the development of ARIKAYCE product.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:label="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272" xlink:to="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272" xlink:type="arc" />
    <link:label id="lab_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072_terseLabel_en-US" xlink:label="lab_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Therapure</link:label>
    <link:label id="lab_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072_label_en-US" xlink:label="lab_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Therapure Biopharma Inc Contract Manufacturing Agreement [Member]</link:label>
    <link:label id="lab_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072_documentation_en-US" xlink:label="lab_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the agreement with Therapure Biopharma Inc., for manufacture of the entity product ARIKAYCE, liposomal amikacin for inhalation.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:label="loc_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072" xlink:to="lab_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072" xlink:type="arc" />
    <link:label id="lab_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5_terseLabel_en-US" xlink:label="lab_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement with SynteractHCR, Inc. for 212 Study</link:label>
    <link:label id="lab_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5_label_en-US" xlink:label="lab_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement With SynteractHCR, Inc. For 212 Study [Member]</link:label>
    <link:label id="lab_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5_documentation_en-US" xlink:label="lab_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement With SynteractHCR, Inc. For 212 Study [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_AgreementWithSynteractHCRInc.For212StudyMember" xlink:label="loc_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5" xlink:to="lab_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5" xlink:type="arc" />
    <link:label id="lab_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F_terseLabel_en-US" xlink:label="lab_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fill/Finish Agreement</link:label>
    <link:label id="lab_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F_label_en-US" xlink:label="lab_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Fil V Finish Services Agreement [Member]</link:label>
    <link:label id="lab_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F_documentation_en-US" xlink:label="lab_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the Commercial Fill/Finish Services Agreement (the "Fill/Finish Agreement") with Ajinomoto Althea, Inc., a Delaware corporation ("Althea"), for Althea to produce, on a non-exclusive basis, ARIKAYCE in finished dosage form.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CommercialFilVFinishServicesAgreementMember" xlink:label="loc_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F" xlink:to="lab_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F" xlink:type="arc" />
    <link:label id="lab_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097_terseLabel_en-US" xlink:label="lab_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement with AstraZeneca</link:label>
    <link:label id="lab_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097_label_en-US" xlink:label="lab_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement With Astrazeneca [Member]</link:label>
    <link:label id="lab_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097_documentation_en-US" xlink:label="lab_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to license agreement with AstraZeneca AB, a Swedish corporation (AstraZeneca).</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_LicenseAgreementWithAstrazenecaMember" xlink:label="loc_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097" xlink:to="lab_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097" xlink:type="arc" />
    <link:label id="lab_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1_terseLabel_en-US" xlink:label="lab_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply Agreement with Patheon UK Limited</link:label>
    <link:label id="lab_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1_label_en-US" xlink:label="lab_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supply Agreement With Patheon UK Limited [Member]</link:label>
    <link:label id="lab_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1_documentation_en-US" xlink:label="lab_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supply Agreement With Patheon UK Limited [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_SupplyAgreementWithPatheonUKLimitedMember" xlink:label="loc_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1" xlink:to="lab_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1" xlink:type="arc" />
    <link:label id="lab_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6_terseLabel_en-US" xlink:label="lab_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement With Syneos Health For Willow Study</link:label>
    <link:label id="lab_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6_label_en-US" xlink:label="lab_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement With Syneos Health For Willow Study [Member]</link:label>
    <link:label id="lab_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6_documentation_en-US" xlink:label="lab_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement With Syneos Health For Willow Study [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_AgreementWithSyneosHealthForWillowStudyMember" xlink:label="loc_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6" xlink:to="lab_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5_label_en-US" xlink:label="lab_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5" xlink:to="lab_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954_terseLabel_en-US" xlink:label="lab_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954_label_en-US" xlink:label="lab_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:to="lab_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_F0C432D4F2BCEA52FF55E772721794FD_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_F0C432D4F2BCEA52FF55E772721794FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_F0C432D4F2BCEA52FF55E772721794FD_label_en-US" xlink:label="lab_srt_MaximumMember_F0C432D4F2BCEA52FF55E772721794FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_F0C432D4F2BCEA52FF55E772721794FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_F0C432D4F2BCEA52FF55E772721794FD" xlink:to="lab_srt_MaximumMember_F0C432D4F2BCEA52FF55E772721794FD" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_4051280A8F29AA36FD62E772721709B4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_4051280A8F29AA36FD62E772721709B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_4051280A8F29AA36FD62E772721709B4_label_en-US" xlink:label="lab_srt_MinimumMember_4051280A8F29AA36FD62E772721709B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4051280A8F29AA36FD62E772721709B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_4051280A8F29AA36FD62E772721709B4" xlink:to="lab_srt_MinimumMember_4051280A8F29AA36FD62E772721709B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_65D55831FEE0DDDF322FE7727219101F_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_65D55831FEE0DDDF322FE7727219101F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_65D55831FEE0DDDF322FE7727219101F_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_65D55831FEE0DDDF322FE7727219101F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65D55831FEE0DDDF322FE7727219101F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65D55831FEE0DDDF322FE7727219101F" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_65D55831FEE0DDDF322FE7727219101F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:type="arc" />
    <link:label id="lab_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A_terseLabel_en-US" xlink:label="lab_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PARI milestone upon FDA approval</link:label>
    <link:label id="lab_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A_label_en-US" xlink:label="lab_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:label id="lab_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A_documentation_en-US" xlink:label="lab_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CollaborativeArrangementMilestonePayment" xlink:label="loc_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A" xlink:to="lab_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A" xlink:type="arc" />
    <link:label id="lab_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01_terseLabel_en-US" xlink:label="lab_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future milestone payments</link:label>
    <link:label id="lab_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01_label_en-US" xlink:label="lab_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Milestone Payments</link:label>
    <link:label id="lab_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01_documentation_en-US" xlink:label="lab_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Milestone Payments</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_FutureMilestonePayments" xlink:label="loc_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01" xlink:to="lab_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_345B317E624013DD1771E772721ACFD8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_345B317E624013DD1771E772721ACFD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation earned under research funding agreements with CFFT</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_345B317E624013DD1771E772721ACFD8_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_345B317E624013DD1771E772721ACFD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_345B317E624013DD1771E772721ACFD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_345B317E624013DD1771E772721ACFD8" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_345B317E624013DD1771E772721ACFD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_AC21BF1DF3C6F0C9FFCAE772721AE9A2_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_AC21BF1DF3C6F0C9FFCAE772721AE9A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payable on approval of ARIKAYCE as commercialized drug</link:label>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_AC21BF1DF3C6F0C9FFCAE772721AE9A2_label_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_AC21BF1DF3C6F0C9FFCAE772721AE9A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_AC21BF1DF3C6F0C9FFCAE772721AE9A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_AC21BF1DF3C6F0C9FFCAE772721AE9A2" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_AC21BF1DF3C6F0C9FFCAE772721AE9A2" xlink:type="arc" />
    <link:label id="lab_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB_terseLabel_en-US" xlink:label="lab_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment period</link:label>
    <link:label id="lab_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB_label_en-US" xlink:label="lab_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Payment Period</link:label>
    <link:label id="lab_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB_documentation_en-US" xlink:label="lab_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period for royalty payments under a research and development agreement.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_RoyaltyPaymentPeriod" xlink:label="loc_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB" xlink:to="lab_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB" xlink:type="arc" />
    <link:label id="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E_terseLabel_en-US" xlink:label="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period for meeting sales milestones for additional royalty payments</link:label>
    <link:label id="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E_label_en-US" xlink:label="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period for Meeting Sales Milestones for Additional Royalty Payments</link:label>
    <link:label id="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E_documentation_en-US" xlink:label="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period for meeting sales milestones for additional royalty payments after the drug is commercialized.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:label="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E" xlink:to="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E" xlink:type="arc" />
    <link:label id="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C_terseLabel_en-US" xlink:label="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payable on meeting certain sales milestones</link:label>
    <link:label id="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C_label_en-US" xlink:label="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Royalty Guarantees Commitments Amount</link:label>
    <link:label id="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C_documentation_en-US" xlink:label="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of royalty payments if entity meets certain milestones under a research and development agreement.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C" xlink:to="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C" xlink:type="arc" />
    <link:label id="lab_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033_terseLabel_en-US" xlink:label="lab_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial term of contract manufacturing agreement</link:label>
    <link:label id="lab_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033_label_en-US" xlink:label="lab_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Term of Contract Manufacturing Agreement</link:label>
    <link:label id="lab_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033_documentation_en-US" xlink:label="lab_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the initial period of contract manufacturing agreement.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_InitialTermOfContractManufacturingAgreement" xlink:label="loc_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033" xlink:to="lab_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033" xlink:type="arc" />
    <link:label id="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E_terseLabel_en-US" xlink:label="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of each automatic renewal of contract manufacturing agreement</link:label>
    <link:label id="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E_label_en-US" xlink:label="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period of Each Automatic Renewal of Contract Manufacturing Agreement</link:label>
    <link:label id="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E_documentation_en-US" xlink:label="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the period of each automatic renewal of contract manufacturing agreement.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:label="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E" xlink:to="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E" xlink:type="arc" />
    <link:label id="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B_terseLabel_en-US" xlink:label="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written notice period required for termination of contract manufacturing agreement</link:label>
    <link:label id="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B_label_en-US" xlink:label="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Notice Period for Termination of Contract Manufacturing Agreement</link:label>
    <link:label id="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B_documentation_en-US" xlink:label="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the written notice period required for termination of contract manufacturing agreement by either party.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:label="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B" xlink:to="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B" xlink:type="arc" />
    <link:label id="lab_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74_terseLabel_en-US" xlink:label="lab_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional term of contract manufacturing agreement</link:label>
    <link:label id="lab_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74_label_en-US" xlink:label="lab_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Term Of Contract Manufacturing Agreement</link:label>
    <link:label id="lab_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74_documentation_en-US" xlink:label="lab_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the additional extension period of contract manufacturing agreement.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_AdditionalTermOfContractManufacturingAgreement" xlink:label="loc_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74" xlink:to="lab_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74" xlink:type="arc" />
    <link:label id="lab_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383_terseLabel_en-US" xlink:label="lab_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment To Pay Aggregate Costs From Agreement</link:label>
    <link:label id="lab_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383_label_en-US" xlink:label="lab_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Implementation And Management Services Agreement, Aggregate Costs</link:label>
    <link:label id="lab_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383_documentation_en-US" xlink:label="lab_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Implementation And Management Services Agreement, Aggregate Costs</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ImplementationAndManagementServicesAgreementAggregateCosts" xlink:label="loc_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383" xlink:to="lab_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383" xlink:type="arc" />
    <link:label id="lab_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD_terseLabel_en-US" xlink:label="lab_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum obligation</link:label>
    <link:label id="lab_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD_label_en-US" xlink:label="lab_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Services Agreement, Minimum Obligation</link:label>
    <link:label id="lab_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD_documentation_en-US" xlink:label="lab_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the minimum obligation due under the terms of the agreement.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CommercialServicesAgreementMinimumObligation" xlink:label="loc_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD" xlink:to="lab_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD" xlink:type="arc" />
    <link:label id="lab_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9_terseLabel_en-US" xlink:label="lab_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension period</link:label>
    <link:label id="lab_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9_label_en-US" xlink:label="lab_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Services Agreement, Extension Period</link:label>
    <link:label id="lab_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9_documentation_en-US" xlink:label="lab_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the extension period under the terms of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CommercialServicesAgreementExtensionPeriod" xlink:label="loc_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9" xlink:to="lab_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9" xlink:type="arc" />
    <link:label id="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615_terseLabel_en-US" xlink:label="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period prior to expiration for extension</link:label>
    <link:label id="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615_label_en-US" xlink:label="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Services Agreement, Extension Period, Period Prior To Expiration For Extension Agreement</link:label>
    <link:label id="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615_documentation_en-US" xlink:label="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the period prior to the expiration of the agreement in which an agreement for extension may be entered into upon mutual agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" xlink:label="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615" xlink:to="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615" xlink:type="arc" />
    <link:label id="lab_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4_terseLabel_en-US" xlink:label="lab_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4_label_en-US" xlink:label="lab_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Upfront Payment</link:label>
    <link:label id="lab_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4_documentation_en-US" xlink:label="lab_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of upfront payment paid during the period under collaborative arrangement.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CollaborativeArrangementUpfrontPayment" xlink:label="loc_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4" xlink:to="lab_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4" xlink:type="arc" />
    <link:label id="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68_terseLabel_en-US" xlink:label="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate payment upon the achievement of certain clinical milestones</link:label>
    <link:label id="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68_label_en-US" xlink:label="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Upon Achievement Of Clinical Milestones Amount</link:label>
    <link:label id="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68_documentation_en-US" xlink:label="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate payment upon the achievement of certain clinical milestones.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_PaymentsUponAchievementOfClinicalMilestonesAmount" xlink:label="loc_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68" xlink:to="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68" xlink:type="arc" />
    <link:label id="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777_terseLabel_en-US" xlink:label="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional contingent payments upon second indication to develop INS1007</link:label>
    <link:label id="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777_label_en-US" xlink:label="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Additional Contingent Payments Upon Second Indication</link:label>
    <link:label id="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777_documentation_en-US" xlink:label="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate additional series of contingent milestone payments if selects to develop for second indication.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" xlink:label="loc_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777" xlink:to="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRoyalties_DB3B3DBB67A283258C55E772721EB91C_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties_DB3B3DBB67A283258C55E772721EB91C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_DB3B3DBB67A283258C55E772721EB91C_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties_DB3B3DBB67A283258C55E772721EB91C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_DB3B3DBB67A283258C55E772721EB91C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties_DB3B3DBB67A283258C55E772721EB91C" xlink:to="lab_us-gaap_PaymentsForRoyalties_DB3B3DBB67A283258C55E772721EB91C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_235EF3FBB079B767271CE772721E25B5_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_235EF3FBB079B767271CE772721E25B5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Annual net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_235EF3FBB079B767271CE772721E25B5_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_235EF3FBB079B767271CE772721E25B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_235EF3FBB079B767271CE772721E25B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_235EF3FBB079B767271CE772721E25B5" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_235EF3FBB079B767271CE772721E25B5" xlink:type="arc" />
    <link:label id="lab_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F_terseLabel_en-US" xlink:label="lab_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement to purchase raw materials and fixed assets</link:label>
    <link:label id="lab_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F_label_en-US" xlink:label="lab_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacture And Supply Agreement, Estimated Costs</link:label>
    <link:label id="lab_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F_documentation_en-US" xlink:label="lab_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacture And Supply Agreement, Estimated Costs</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ManufactureAndSupplyAgreementEstimatedCosts" xlink:label="loc_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F" xlink:to="lab_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_4341779971AB53FE78B6BE8FADA037C2_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_4341779971AB53FE78B6BE8FADA037C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4341779971AB53FE78B6BE8FADA037C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4341779971AB53FE78B6BE8FADA037C2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_4341779971AB53FE78B6BE8FADA037C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquipmentMember_4C7332D7EC1F48419932BE8FADA00622_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember_4C7332D7EC1F48419932BE8FADA00622" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_4C7332D7EC1F48419932BE8FADA00622_label_en-US" xlink:label="lab_us-gaap_EquipmentMember_4C7332D7EC1F48419932BE8FADA00622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_4C7332D7EC1F48419932BE8FADA00622" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_4C7332D7EC1F48419932BE8FADA00622" xlink:to="lab_us-gaap_EquipmentMember_4C7332D7EC1F48419932BE8FADA00622" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_2A05F085882D53907B75BE8FADA2EE5E_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_2A05F085882D53907B75BE8FADA2EE5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_2A05F085882D53907B75BE8FADA2EE5E_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_2A05F085882D53907B75BE8FADA2EE5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2A05F085882D53907B75BE8FADA2EE5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_2A05F085882D53907B75BE8FADA2EE5E" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_2A05F085882D53907B75BE8FADA2EE5E" xlink:type="arc" />
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381_terseLabel_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer hardware and software</link:label>
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381_label_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Hardware And Software [Member]</link:label>
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381_documentation_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchased computer hardware and software applications.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ComputerHardwareAndSoftwareMember" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381" xlink:to="lab_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381" xlink:type="arc" />
    <link:label id="lab_us-gaap_OfficeEquipmentMember_1E827B8596318CDABE4EBE8FADA2BE83_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember_1E827B8596318CDABE4EBE8FADA2BE83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_1E827B8596318CDABE4EBE8FADA2BE83_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember_1E827B8596318CDABE4EBE8FADA2BE83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_1E827B8596318CDABE4EBE8FADA2BE83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember_1E827B8596318CDABE4EBE8FADA2BE83" xlink:to="lab_us-gaap_OfficeEquipmentMember_1E827B8596318CDABE4EBE8FADA2BE83" xlink:type="arc" />
    <link:label id="lab_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226_terseLabel_en-US" xlink:label="lab_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226_label_en-US" xlink:label="lab_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226_documentation_en-US" xlink:label="lab_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents manufacturing equipment used to produce goods and services.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ManufacturingEquipmentMember" xlink:label="loc_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226" xlink:to="lab_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_7B6280AB4C7E913004C8BE8FADA2AD30_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_7B6280AB4C7E913004C8BE8FADA2AD30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_7B6280AB4C7E913004C8BE8FADA2AD30_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_7B6280AB4C7E913004C8BE8FADA2AD30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7B6280AB4C7E913004C8BE8FADA2AD30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_7B6280AB4C7E913004C8BE8FADA2AD30" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_7B6280AB4C7E913004C8BE8FADA2AD30" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_6583E3435A7335AB2B8BBE8FADA25308_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_6583E3435A7335AB2B8BBE8FADA25308" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress (CIP)</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_6583E3435A7335AB2B8BBE8FADA25308_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_6583E3435A7335AB2B8BBE8FADA25308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_6583E3435A7335AB2B8BBE8FADA25308" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_6583E3435A7335AB2B8BBE8FADA25308" xlink:to="lab_us-gaap_ConstructionInProgressMember_6583E3435A7335AB2B8BBE8FADA25308" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_587209B7F92301EA665BBE8FADA2C11B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_587209B7F92301EA665BBE8FADA2C11B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_587209B7F92301EA665BBE8FADA2C11B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_587209B7F92301EA665BBE8FADA2C11B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_587209B7F92301EA665BBE8FADA2C11B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_587209B7F92301EA665BBE8FADA2C11B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_587209B7F92301EA665BBE8FADA2C11B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EA4F08417D911622DDC6BE8FADA558B5_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EA4F08417D911622DDC6BE8FADA558B5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EA4F08417D911622DDC6BE8FADA558B5_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EA4F08417D911622DDC6BE8FADA558B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EA4F08417D911622DDC6BE8FADA558B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EA4F08417D911622DDC6BE8FADA558B5" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EA4F08417D911622DDC6BE8FADA558B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_47989EA0008F9131FC32BE8FADA56D92_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_47989EA0008F9131FC32BE8FADA56D92" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_47989EA0008F9131FC32BE8FADA56D92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_47989EA0008F9131FC32BE8FADA56D92" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_47989EA0008F9131FC32BE8FADA56D92" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_07EB0C2E0E79B33D9DEDBE8FADA5827E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_07EB0C2E0E79B33D9DEDBE8FADA5827E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Life (years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_07EB0C2E0E79B33D9DEDBE8FADA5827E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_07EB0C2E0E79B33D9DEDBE8FADA5827E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_07EB0C2E0E79B33D9DEDBE8FADA5827E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_07EB0C2E0E79B33D9DEDBE8FADA5827E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_07EB0C2E0E79B33D9DEDBE8FADA5827E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_A8015064194583E59421BE8FADA5D26A_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_A8015064194583E59421BE8FADA5D26A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_A8015064194583E59421BE8FADA5D26A_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_A8015064194583E59421BE8FADA5D26A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_A8015064194583E59421BE8FADA5D26A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_A8015064194583E59421BE8FADA5D26A" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_A8015064194583E59421BE8FADA5D26A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_4629103785249527514BBE8FADA52FB6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_4629103785249527514BBE8FADA52FB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation increase (decrease)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_4629103785249527514BBE8FADA52FB6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_4629103785249527514BBE8FADA52FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_4629103785249527514BBE8FADA52FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_4629103785249527514BBE8FADA52FB6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_4629103785249527514BBE8FADA52FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_3FBC4FB4A0C2D61D13E7A61648644BA0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_3FBC4FB4A0C2D61D13E7A61648644BA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_3FBC4FB4A0C2D61D13E7A61648644BA0_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_3FBC4FB4A0C2D61D13E7A61648644BA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3FBC4FB4A0C2D61D13E7A61648644BA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3FBC4FB4A0C2D61D13E7A61648644BA0" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_3FBC4FB4A0C2D61D13E7A61648644BA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6ED60FBAD3E39D1F8DE0A61648642097_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6ED60FBAD3E39D1F8DE0A61648642097" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6ED60FBAD3E39D1F8DE0A61648642097_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6ED60FBAD3E39D1F8DE0A61648642097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6ED60FBAD3E39D1F8DE0A61648642097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6ED60FBAD3E39D1F8DE0A61648642097" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6ED60FBAD3E39D1F8DE0A61648642097" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_3ABADC30CB2963C9C79BA61648643C9B_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_3ABADC30CB2963C9C79BA61648643C9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_3ABADC30CB2963C9C79BA61648643C9B_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_3ABADC30CB2963C9C79BA61648643C9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3ABADC30CB2963C9C79BA61648643C9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3ABADC30CB2963C9C79BA61648643C9B" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_3ABADC30CB2963C9C79BA61648643C9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_8E1216FCC33AF3D0C702A6164864FF4D_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_8E1216FCC33AF3D0C702A6164864FF4D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_8E1216FCC33AF3D0C702A6164864FF4D_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_8E1216FCC33AF3D0C702A6164864FF4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8E1216FCC33AF3D0C702A6164864FF4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8E1216FCC33AF3D0C702A6164864FF4D" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_8E1216FCC33AF3D0C702A6164864FF4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_A6D87B1B886FD33E63CDA6164865F635_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_A6D87B1B886FD33E63CDA6164865F635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_A6D87B1B886FD33E63CDA6164865F635_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_A6D87B1B886FD33E63CDA6164865F635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_A6D87B1B886FD33E63CDA6164865F635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_A6D87B1B886FD33E63CDA6164865F635" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_A6D87B1B886FD33E63CDA6164865F635" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EA99D662071C925E82EFA6164865B2EE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EA99D662071C925E82EFA6164865B2EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EA99D662071C925E82EFA6164865B2EE_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EA99D662071C925E82EFA6164865B2EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EA99D662071C925E82EFA6164865B2EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EA99D662071C925E82EFA6164865B2EE" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EA99D662071C925E82EFA6164865B2EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_24DF79010E2ADF8EDC12A6164865693F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_24DF79010E2ADF8EDC12A6164865693F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_24DF79010E2ADF8EDC12A6164865693F_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_24DF79010E2ADF8EDC12A6164865693F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_24DF79010E2ADF8EDC12A6164865693F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_24DF79010E2ADF8EDC12A6164865693F" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_24DF79010E2ADF8EDC12A6164865693F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_6C55E6228CA974EA0C38A6164865A509_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_6C55E6228CA974EA0C38A6164865A509" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_6C55E6228CA974EA0C38A6164865A509_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_6C55E6228CA974EA0C38A6164865A509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6C55E6228CA974EA0C38A6164865A509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6C55E6228CA974EA0C38A6164865A509" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_6C55E6228CA974EA0C38A6164865A509" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_B277C7F63598907FD402A6164865BB87_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_B277C7F63598907FD402A6164865BB87" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_B277C7F63598907FD402A6164865BB87_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_B277C7F63598907FD402A6164865BB87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B277C7F63598907FD402A6164865BB87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_B277C7F63598907FD402A6164865BB87" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_B277C7F63598907FD402A6164865BB87" xlink:type="arc" />
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_A99C21A4EE479667966701A033E0B540_terseLabel_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_A99C21A4EE479667966701A033E0B540" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Table]</link:label>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_A99C21A4EE479667966701A033E0B540_label_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_A99C21A4EE479667966701A033E0B540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Table]</link:label>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_A99C21A4EE479667966701A033E0B540_documentation_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_A99C21A4EE479667966701A033E0B540" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Table]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossTable" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_A99C21A4EE479667966701A033E0B540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_A99C21A4EE479667966701A033E0B540" xlink:to="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_A99C21A4EE479667966701A033E0B540" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_57C906DF9889557E9FF901A033E052BF_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_57C906DF9889557E9FF901A033E052BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_57C906DF9889557E9FF901A033E052BF_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_57C906DF9889557E9FF901A033E052BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_57C906DF9889557E9FF901A033E052BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_57C906DF9889557E9FF901A033E052BF" xlink:to="lab_srt_MajorCustomersAxis_57C906DF9889557E9FF901A033E052BF" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2" xlink:to="lab_srt_NameOfMajorCustomerDomain_553CD76638516AA849B101A033E0F3D2" xlink:type="arc" />
    <link:label id="lab_insm_CustomerFeesDiscountsandOtherMember_F4B1FF1B6900464E399401A033E13D74_terseLabel_en-US" xlink:label="lab_insm_CustomerFeesDiscountsandOtherMember_F4B1FF1B6900464E399401A033E13D74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Fees, Discounts and Other</link:label>
    <link:label id="lab_insm_CustomerFeesDiscountsandOtherMember_F4B1FF1B6900464E399401A033E13D74_label_en-US" xlink:label="lab_insm_CustomerFeesDiscountsandOtherMember_F4B1FF1B6900464E399401A033E13D74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Fees, Discounts and Other [Member]</link:label>
    <link:label id="lab_insm_CustomerFeesDiscountsandOtherMember_F4B1FF1B6900464E399401A033E13D74_documentation_en-US" xlink:label="lab_insm_CustomerFeesDiscountsandOtherMember_F4B1FF1B6900464E399401A033E13D74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer Fees, Discounts and Other [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CustomerFeesDiscountsandOtherMember" xlink:label="loc_insm_CustomerFeesDiscountsandOtherMember_F4B1FF1B6900464E399401A033E13D74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerFeesDiscountsandOtherMember_F4B1FF1B6900464E399401A033E13D74" xlink:to="lab_insm_CustomerFeesDiscountsandOtherMember_F4B1FF1B6900464E399401A033E13D74" xlink:type="arc" />
    <link:label id="lab_insm_RebatesChargebacksandCoPayAssistanceMember_B8983FA28B604D04700601A033E11DCC_terseLabel_en-US" xlink:label="lab_insm_RebatesChargebacksandCoPayAssistanceMember_B8983FA28B604D04700601A033E11DCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates, Chargebacks, and Co-Pay Assistance</link:label>
    <link:label id="lab_insm_RebatesChargebacksandCoPayAssistanceMember_B8983FA28B604D04700601A033E11DCC_label_en-US" xlink:label="lab_insm_RebatesChargebacksandCoPayAssistanceMember_B8983FA28B604D04700601A033E11DCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rebates, Chargebacks, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_insm_RebatesChargebacksandCoPayAssistanceMember_B8983FA28B604D04700601A033E11DCC_documentation_en-US" xlink:label="lab_insm_RebatesChargebacksandCoPayAssistanceMember_B8983FA28B604D04700601A033E11DCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rebates, Chargebacks, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_RebatesChargebacksandCoPayAssistanceMember" xlink:label="loc_insm_RebatesChargebacksandCoPayAssistanceMember_B8983FA28B604D04700601A033E11DCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_RebatesChargebacksandCoPayAssistanceMember_B8983FA28B604D04700601A033E11DCC" xlink:to="lab_insm_RebatesChargebacksandCoPayAssistanceMember_B8983FA28B604D04700601A033E11DCC" xlink:type="arc" />
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_AA4FF5F9C7399B9E123201A033E1EA9A_terseLabel_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_AA4FF5F9C7399B9E123201A033E1EA9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Line Items]</link:label>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_AA4FF5F9C7399B9E123201A033E1EA9A_label_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_AA4FF5F9C7399B9E123201A033E1EA9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Line Items]</link:label>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_AA4FF5F9C7399B9E123201A033E1EA9A_documentation_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_AA4FF5F9C7399B9E123201A033E1EA9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Contract with Customer, Asset, Allowance for Credit Loss [Table]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_AA4FF5F9C7399B9E123201A033E1EA9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_AA4FF5F9C7399B9E123201A033E1EA9A" xlink:to="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_AA4FF5F9C7399B9E123201A033E1EA9A" xlink:type="arc" />
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1_terseLabel_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1_label_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1_documentation_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1" xlink:to="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_2F74AAFAFDF884A2E18B01A033E1D9C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_3D3BDA837EF005C6EB2E01A033E1DA1E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_3D3BDA837EF005C6EB2E01A033E1DA1E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_3D3BDA837EF005C6EB2E01A033E1DA1E_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_3D3BDA837EF005C6EB2E01A033E1DA1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Accumulated Allowance for Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_3D3BDA837EF005C6EB2E01A033E1DA1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_3D3BDA837EF005C6EB2E01A033E1DA1E" xlink:to="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_3D3BDA837EF005C6EB2E01A033E1DA1E" xlink:type="arc" />
    <link:label id="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_A8FE332F72CEA7FD823501A033E2DF06_terseLabel_en-US" xlink:label="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_A8FE332F72CEA7FD823501A033E2DF06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowances for current period sales</link:label>
    <link:label id="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_A8FE332F72CEA7FD823501A033E2DF06_label_en-US" xlink:label="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_A8FE332F72CEA7FD823501A033E2DF06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Allowance For Current Period Sales</link:label>
    <link:label id="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_A8FE332F72CEA7FD823501A033E2DF06_documentation_en-US" xlink:label="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_A8FE332F72CEA7FD823501A033E2DF06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Allowance For Current Period Sales</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales" xlink:label="loc_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_A8FE332F72CEA7FD823501A033E2DF06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_A8FE332F72CEA7FD823501A033E2DF06" xlink:to="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_A8FE332F72CEA7FD823501A033E2DF06" xlink:type="arc" />
    <link:label id="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_A6350C01747F4242770901A033E272D9_negatedTerseLabel_en-US" xlink:label="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_A6350C01747F4242770901A033E272D9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments and credits</link:label>
    <link:label id="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_A6350C01747F4242770901A033E272D9_label_en-US" xlink:label="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_A6350C01747F4242770901A033E272D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Assets, Allowance For Credit Loss, Payments and Credits</link:label>
    <link:label id="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_A6350C01747F4242770901A033E272D9_documentation_en-US" xlink:label="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_A6350C01747F4242770901A033E272D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Assets, Allowance For Credit Loss, Payments and Credits</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" xlink:label="loc_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_A6350C01747F4242770901A033E272D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_A6350C01747F4242770901A033E272D9" xlink:to="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_A6350C01747F4242770901A033E272D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_AD0DDB99AC3ED35F2C3601A033E2FD53_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_AD0DDB99AC3ED35F2C3601A033E2FD53" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_AD0DDB99AC3ED35F2C3601A033E2FD53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_AD0DDB99AC3ED35F2C3601A033E2FD53" xlink:to="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_AD0DDB99AC3ED35F2C3601A033E2FD53" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_0EA0FC69F881263DF350E77272B8046E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract_0EA0FC69F881263DF350E77272B8046E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_0EA0FC69F881263DF350E77272B8046E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_0EA0FC69F881263DF350E77272B8046E" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract_0EA0FC69F881263DF350E77272B8046E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615" xlink:to="lab_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:type="arc" />
    <link:label id="lab_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E_terseLabel_en-US" xlink:label="lab_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E_label_en-US" xlink:label="lab_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee And Directors Stock Options [Member]</link:label>
    <link:label id="lab_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E_documentation_en-US" xlink:label="lab_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E" xlink:to="lab_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_93143804113477315143E77272BA2DE6_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_93143804113477315143E77272BA2DE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance-condition options</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_93143804113477315143E77272BA2DE6_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_93143804113477315143E77272BA2DE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_93143804113477315143E77272BA2DE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_93143804113477315143E77272BA2DE6" xlink:to="lab_us-gaap_PerformanceSharesMember_93143804113477315143E77272BA2DE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Option disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockOptionPlanExpense_E168FB0F2BD5509DF3ADE77272BC685C_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionPlanExpense_E168FB0F2BD5509DF3ADE77272BC685C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash compensation expense</link:label>
    <link:label id="lab_us-gaap_StockOptionPlanExpense_E168FB0F2BD5509DF3ADE77272BC685C_label_en-US" xlink:label="lab_us-gaap_StockOptionPlanExpense_E168FB0F2BD5509DF3ADE77272BC685C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock or Unit Option Plan Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_E168FB0F2BD5509DF3ADE77272BC685C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense_E168FB0F2BD5509DF3ADE77272BC685C" xlink:to="lab_us-gaap_StockOptionPlanExpense_E168FB0F2BD5509DF3ADE77272BC685C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value and assumptions used in determining fair value of stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_25580AEF3C2AE9516666E77272BD1A33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_25580AEF3C2AE9516666E77272BD1A33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_25580AEF3C2AE9516666E77272BD1A33_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_25580AEF3C2AE9516666E77272BD1A33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_25580AEF3C2AE9516666E77272BD1A33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_25580AEF3C2AE9516666E77272BD1A33" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_25580AEF3C2AE9516666E77272BD1A33" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1A21D0C912989D988B1FE77272BD6CDE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1A21D0C912989D988B1FE77272BD6CDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1A21D0C912989D988B1FE77272BD6CDE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1A21D0C912989D988B1FE77272BD6CDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1A21D0C912989D988B1FE77272BD6CDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1A21D0C912989D988B1FE77272BD6CDE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1A21D0C912989D988B1FE77272BD6CDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0A69ABEDD4B65D2088B5E77272BECE49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0A69ABEDD4B65D2088B5E77272BECE49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0A69ABEDD4B65D2088B5E77272BECE49_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0A69ABEDD4B65D2088B5E77272BECE49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0A69ABEDD4B65D2088B5E77272BECE49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0A69ABEDD4B65D2088B5E77272BECE49" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0A69ABEDD4B65D2088B5E77272BECE49" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C05DF76708E272D7F60AE77272BE5A4F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C05DF76708E272D7F60AE77272BE5A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected option term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C05DF76708E272D7F60AE77272BE5A4F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C05DF76708E272D7F60AE77272BE5A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C05DF76708E272D7F60AE77272BE5A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C05DF76708E272D7F60AE77272BE5A4F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C05DF76708E272D7F60AE77272BE5A4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E3738B1180BA0246407E77272BF1B98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E3738B1180BA0246407E77272BF1B98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E3738B1180BA0246407E77272BF1B98_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E3738B1180BA0246407E77272BF1B98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E3738B1180BA0246407E77272BF1B98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E3738B1180BA0246407E77272BF1B98" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E3738B1180BA0246407E77272BF1B98" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB30005DF10EF06D7023E77272BFC171_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB30005DF10EF06D7023E77272BFC171" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding beginning of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB30005DF10EF06D7023E77272BFC171_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB30005DF10EF06D7023E77272BFC171" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB30005DF10EF06D7023E77272BFC171" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB30005DF10EF06D7023E77272BFC171" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB30005DF10EF06D7023E77272BFC171" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6787B0B84DC880EC80A3E77272BF0F36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6787B0B84DC880EC80A3E77272BF0F36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6787B0B84DC880EC80A3E77272BF0F36_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6787B0B84DC880EC80A3E77272BF0F36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6787B0B84DC880EC80A3E77272BF0F36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6787B0B84DC880EC80A3E77272BF0F36" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6787B0B84DC880EC80A3E77272BF0F36" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8CFDE7D31EAF7F8D62C2E77272C08033_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8CFDE7D31EAF7F8D62C2E77272C08033" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8CFDE7D31EAF7F8D62C2E77272C08033_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8CFDE7D31EAF7F8D62C2E77272C08033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8CFDE7D31EAF7F8D62C2E77272C08033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8CFDE7D31EAF7F8D62C2E77272C08033" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8CFDE7D31EAF7F8D62C2E77272C08033" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2377ECDEF2C1EDB20BD2E77272C0DA44_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2377ECDEF2C1EDB20BD2E77272C0DA44" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited and expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2377ECDEF2C1EDB20BD2E77272C0DA44_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2377ECDEF2C1EDB20BD2E77272C0DA44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2377ECDEF2C1EDB20BD2E77272C0DA44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2377ECDEF2C1EDB20BD2E77272C0DA44" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2377ECDEF2C1EDB20BD2E77272C0DA44" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_406E01970BFB2B8A7D47E77272C05BAA_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_406E01970BFB2B8A7D47E77272C05BAA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding end of the year (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_406E01970BFB2B8A7D47E77272C05BAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_406E01970BFB2B8A7D47E77272C05BAA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_406E01970BFB2B8A7D47E77272C05BAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_C1F476D824D0C536CC0FE77272C082AE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_C1F476D824D0C536CC0FE77272C082AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_C1F476D824D0C536CC0FE77272C082AE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_C1F476D824D0C536CC0FE77272C082AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_C1F476D824D0C536CC0FE77272C082AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_C1F476D824D0C536CC0FE77272C082AE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_C1F476D824D0C536CC0FE77272C082AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CB299E2D56BD3A14A236E77272C17C8B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CB299E2D56BD3A14A236E77272C17C8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CB299E2D56BD3A14A236E77272C17C8B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CB299E2D56BD3A14A236E77272C17C8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CB299E2D56BD3A14A236E77272C17C8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CB299E2D56BD3A14A236E77272C17C8B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CB299E2D56BD3A14A236E77272C17C8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20D3B83726BABC840BECE77272C1CD59_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20D3B83726BABC840BECE77272C1CD59" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding beginning of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20D3B83726BABC840BECE77272C1CD59_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20D3B83726BABC840BECE77272C1CD59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20D3B83726BABC840BECE77272C1CD59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20D3B83726BABC840BECE77272C1CD59" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20D3B83726BABC840BECE77272C1CD59" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41069C08A98916666F53E77272C2E6CA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41069C08A98916666F53E77272C2E6CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41069C08A98916666F53E77272C2E6CA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41069C08A98916666F53E77272C2E6CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41069C08A98916666F53E77272C2E6CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41069C08A98916666F53E77272C2E6CA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41069C08A98916666F53E77272C2E6CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3AE07D4DBD5FA8DF4FAEE77272C228A2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3AE07D4DBD5FA8DF4FAEE77272C228A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3AE07D4DBD5FA8DF4FAEE77272C228A2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3AE07D4DBD5FA8DF4FAEE77272C228A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3AE07D4DBD5FA8DF4FAEE77272C228A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3AE07D4DBD5FA8DF4FAEE77272C228A2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3AE07D4DBD5FA8DF4FAEE77272C228A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9933D2D57EA3A4725152E77272C24B99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9933D2D57EA3A4725152E77272C24B99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited and expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9933D2D57EA3A4725152E77272C24B99_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9933D2D57EA3A4725152E77272C24B99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9933D2D57EA3A4725152E77272C24B99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9933D2D57EA3A4725152E77272C24B99" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9933D2D57EA3A4725152E77272C24B99" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AAE95532DD6968E0773EE77272C22DE6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AAE95532DD6968E0773EE77272C22DE6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding end of the year (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AAE95532DD6968E0773EE77272C22DE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AAE95532DD6968E0773EE77272C22DE6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AAE95532DD6968E0773EE77272C22DE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_742BE4942D8DAD60A332E77272C24662_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_742BE4942D8DAD60A332E77272C24662" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_742BE4942D8DAD60A332E77272C24662_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_742BE4942D8DAD60A332E77272C24662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_742BE4942D8DAD60A332E77272C24662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_742BE4942D8DAD60A332E77272C24662" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_742BE4942D8DAD60A332E77272C24662" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0B959100D54AE32B7E6FE77272C3C740_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0B959100D54AE32B7E6FE77272C3C740" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0B959100D54AE32B7E6FE77272C3C740_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0B959100D54AE32B7E6FE77272C3C740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0B959100D54AE32B7E6FE77272C3C740" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0B959100D54AE32B7E6FE77272C3C740" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0B959100D54AE32B7E6FE77272C3C740" xlink:type="arc" />
    <link:label id="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC_terseLabel_en-US" xlink:label="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</link:label>
    <link:label id="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC_label_en-US" xlink:label="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years [Abstract]</link:label>
    <link:label id="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC_documentation_en-US" xlink:label="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="insm-20181231.xsd#insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:label="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:to="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30536A72E0E12DE8D4FDE77272C35973_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30536A72E0E12DE8D4FDE77272C35973" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30536A72E0E12DE8D4FDE77272C35973_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30536A72E0E12DE8D4FDE77272C35973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30536A72E0E12DE8D4FDE77272C35973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30536A72E0E12DE8D4FDE77272C35973" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30536A72E0E12DE8D4FDE77272C35973" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_D62DD0F1E495148D4789E77272C39274_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_D62DD0F1E495148D4789E77272C39274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_D62DD0F1E495148D4789E77272C39274_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_D62DD0F1E495148D4789E77272C39274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_D62DD0F1E495148D4789E77272C39274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_D62DD0F1E495148D4789E77272C39274" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_D62DD0F1E495148D4789E77272C39274" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_280E2970552DC1BC4A21E77272C44090_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_280E2970552DC1BC4A21E77272C44090" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_280E2970552DC1BC4A21E77272C44090_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_280E2970552DC1BC4A21E77272C44090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_280E2970552DC1BC4A21E77272C44090" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_280E2970552DC1BC4A21E77272C44090" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_280E2970552DC1BC4A21E77272C44090" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3C6A701DE883405CF1ACE77272C417C3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3C6A701DE883405CF1ACE77272C417C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3C6A701DE883405CF1ACE77272C417C3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3C6A701DE883405CF1ACE77272C417C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3C6A701DE883405CF1ACE77272C417C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3C6A701DE883405CF1ACE77272C417C3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3C6A701DE883405CF1ACE77272C417C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5AB1C7CD9A99A43F7EA0E77272C4E57E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5AB1C7CD9A99A43F7EA0E77272C4E57E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5AB1C7CD9A99A43F7EA0E77272C4E57E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5AB1C7CD9A99A43F7EA0E77272C4E57E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5AB1C7CD9A99A43F7EA0E77272C4E57E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5AB1C7CD9A99A43F7EA0E77272C4E57E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5AB1C7CD9A99A43F7EA0E77272C4E57E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0E17CADB4B1A6753ABAAE77272C5D89F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0E17CADB4B1A6753ABAAE77272C5D89F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0E17CADB4B1A6753ABAAE77272C5D89F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0E17CADB4B1A6753ABAAE77272C5D89F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0E17CADB4B1A6753ABAAE77272C5D89F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0E17CADB4B1A6753ABAAE77272C5D89F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0E17CADB4B1A6753ABAAE77272C5D89F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF8EA262DDB77E5B2B22C80C92770DE8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF8EA262DDB77E5B2B22C80C92770DE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Value Assumptions for Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF8EA262DDB77E5B2B22C80C92770DE8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF8EA262DDB77E5B2B22C80C92770DE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF8EA262DDB77E5B2B22C80C92770DE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF8EA262DDB77E5B2B22C80C92770DE8" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF8EA262DDB77E5B2B22C80C92770DE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_47000C8108A86C27631FC80C9277FE64_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_47000C8108A86C27631FC80C9277FE64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_47000C8108A86C27631FC80C9277FE64_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_47000C8108A86C27631FC80C9277FE64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_47000C8108A86C27631FC80C9277FE64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_47000C8108A86C27631FC80C9277FE64" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_47000C8108A86C27631FC80C9277FE64" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_EA6A7EBAB9F7C5D28CE1C80C92785549_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_EA6A7EBAB9F7C5D28CE1C80C92785549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Exercise Price and Number of Stock Options Exercisable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_EA6A7EBAB9F7C5D28CE1C80C92785549_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_EA6A7EBAB9F7C5D28CE1C80C92785549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_EA6A7EBAB9F7C5D28CE1C80C92785549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_EA6A7EBAB9F7C5D28CE1C80C92785549" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_EA6A7EBAB9F7C5D28CE1C80C92785549" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_95FDC16E7E2810C12D5BC80C9278ED5A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_95FDC16E7E2810C12D5BC80C9278ED5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_95FDC16E7E2810C12D5BC80C9278ED5A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_95FDC16E7E2810C12D5BC80C9278ED5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_95FDC16E7E2810C12D5BC80C9278ED5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_95FDC16E7E2810C12D5BC80C9278ED5A" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_95FDC16E7E2810C12D5BC80C9278ED5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ABC2AEF7319AD07D0067C80C927862D0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ABC2AEF7319AD07D0067C80C927862D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Allocation of Employee Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ABC2AEF7319AD07D0067C80C927862D0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ABC2AEF7319AD07D0067C80C927862D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ABC2AEF7319AD07D0067C80C927862D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ABC2AEF7319AD07D0067C80C927862D0" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ABC2AEF7319AD07D0067C80C927862D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_451FE41644E6D839C5800DE7EBDC3AEC_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_451FE41644E6D839C5800DE7EBDC3AEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_451FE41644E6D839C5800DE7EBDC3AEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_451FE41644E6D839C5800DE7EBDC3AEC" xlink:to="lab_us-gaap_DebtDisclosureAbstract_451FE41644E6D839C5800DE7EBDC3AEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:to="lab_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:type="arc" />
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentConversionTermAxis" xlink:label="loc_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:to="lab_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:type="arc" />
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Domain]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Domain]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Debt Instrument Conversion Term [Axis]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentConversionTermDomain" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:to="lab_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:type="arc" />
    <link:label id="lab_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC_terseLabel_en-US" xlink:label="lab_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Term (i)</link:label>
    <link:label id="lab_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC_label_en-US" xlink:label="lab_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Term (i) [Member]</link:label>
    <link:label id="lab_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC_documentation_en-US" xlink:label="lab_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Term (i) [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ConversionTermiMember" xlink:label="loc_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC" xlink:to="lab_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC" xlink:type="arc" />
    <link:label id="lab_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF_terseLabel_en-US" xlink:label="lab_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Term (ii)</link:label>
    <link:label id="lab_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF_label_en-US" xlink:label="lab_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Term (ii) [Member]</link:label>
    <link:label id="lab_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF_documentation_en-US" xlink:label="lab_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Term (ii) [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ConversionTermiiMember" xlink:label="loc_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF" xlink:to="lab_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF" xlink:type="arc" />
    <link:label id="lab_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB_terseLabel_en-US" xlink:label="lab_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Term (iii)</link:label>
    <link:label id="lab_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB_label_en-US" xlink:label="lab_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Term (iii) [Member]</link:label>
    <link:label id="lab_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB_documentation_en-US" xlink:label="lab_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Term (iii) [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ConversionTermiiiMember" xlink:label="loc_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB" xlink:to="lab_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB" xlink:type="arc" />
    <link:label id="lab_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81_terseLabel_en-US" xlink:label="lab_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Term (iv)</link:label>
    <link:label id="lab_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81_label_en-US" xlink:label="lab_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Term (iv) [Member]</link:label>
    <link:label id="lab_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81_documentation_en-US" xlink:label="lab_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Term (iv) [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ConversionTermivMember" xlink:label="loc_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81" xlink:to="lab_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditMember_FD4B8CCEFB7D11145B700DE7EBE15D9F_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_FD4B8CCEFB7D11145B700DE7EBE15D9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">A&amp;R Loan Agreement</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_FD4B8CCEFB7D11145B700DE7EBE15D9F_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_FD4B8CCEFB7D11145B700DE7EBE15D9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_FD4B8CCEFB7D11145B700DE7EBE15D9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember_FD4B8CCEFB7D11145B700DE7EBE15D9F" xlink:to="lab_us-gaap_LineOfCreditMember_FD4B8CCEFB7D11145B700DE7EBE15D9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="lab_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_B930345FD856C65255920DE7EBE1B352_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_B930345FD856C65255920DE7EBE1B352" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_B930345FD856C65255920DE7EBE1B352" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_B930345FD856C65255920DE7EBE1B352" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_B930345FD856C65255920DE7EBE1B352" xlink:type="arc" />
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to purchase additional debt</link:label>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7_label_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Option To Purchase Additional Debt</link:label>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7_documentation_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Option To Purchase Additional Debt</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7" xlink:to="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_593BFDEED0B60A9C203E0DE7EBE297FB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_593BFDEED0B60A9C203E0DE7EBE297FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriting discounts and commissions and other offering expenses</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_593BFDEED0B60A9C203E0DE7EBE297FB_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_593BFDEED0B60A9C203E0DE7EBE297FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_593BFDEED0B60A9C203E0DE7EBE297FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_593BFDEED0B60A9C203E0DE7EBE297FB" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_593BFDEED0B60A9C203E0DE7EBE297FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_95E6B2B2D6E2CBC420FC0DE7EBE24AA3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_95E6B2B2D6E2CBC420FC0DE7EBE24AA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of 1.75% convertible senior notes due 2025</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_95E6B2B2D6E2CBC420FC0DE7EBE24AA3_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_95E6B2B2D6E2CBC420FC0DE7EBE24AA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_95E6B2B2D6E2CBC420FC0DE7EBE24AA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_95E6B2B2D6E2CBC420FC0DE7EBE24AA3" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_95E6B2B2D6E2CBC420FC0DE7EBE24AA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_0A387B9BEAC401AB49990DE7EBE28840_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_0A387B9BEAC401AB49990DE7EBE28840" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial conversion rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_0A387B9BEAC401AB49990DE7EBE28840_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_0A387B9BEAC401AB49990DE7EBE28840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_0A387B9BEAC401AB49990DE7EBE28840" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_0A387B9BEAC401AB49990DE7EBE28840" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_0A387B9BEAC401AB49990DE7EBE28840" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0472DAC8E0394D63DEEA0DE7EBE266C3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0472DAC8E0394D63DEEA0DE7EBE266C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0472DAC8E0394D63DEEA0DE7EBE266C3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0472DAC8E0394D63DEEA0DE7EBE266C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0472DAC8E0394D63DEEA0DE7EBE266C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0472DAC8E0394D63DEEA0DE7EBE266C3" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0472DAC8E0394D63DEEA0DE7EBE266C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A905463F2AC3CE0FD43E0DE7EBE2E7CA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A905463F2AC3CE0FD43E0DE7EBE2E7CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A905463F2AC3CE0FD43E0DE7EBE2E7CA_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A905463F2AC3CE0FD43E0DE7EBE2E7CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A905463F2AC3CE0FD43E0DE7EBE2E7CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A905463F2AC3CE0FD43E0DE7EBE2E7CA" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A905463F2AC3CE0FD43E0DE7EBE2E7CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_AA528A012E1CA591C4C50DE7EBE2468B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_AA528A012E1CA591C4C50DE7EBE2468B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_AA528A012E1CA591C4C50DE7EBE2468B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_AA528A012E1CA591C4C50DE7EBE2468B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_AA528A012E1CA591C4C50DE7EBE2468B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_AA528A012E1CA591C4C50DE7EBE2468B" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_AA528A012E1CA591C4C50DE7EBE2468B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90756108AE32198A68010DE7EBE32827_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90756108AE32198A68010DE7EBE32827" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90756108AE32198A68010DE7EBE32827_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90756108AE32198A68010DE7EBE32827" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90756108AE32198A68010DE7EBE32827" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90756108AE32198A68010DE7EBE32827" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90756108AE32198A68010DE7EBE32827" xlink:type="arc" />
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days following fundamental change</link:label>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC_label_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change</link:label>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC" xlink:to="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_D89957ED619FE909EEB30DE7EBE3CB9D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_D89957ED619FE909EEB30DE7EBE3CB9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_D89957ED619FE909EEB30DE7EBE3CB9D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_D89957ED619FE909EEB30DE7EBE3CB9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_D89957ED619FE909EEB30DE7EBE3CB9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_D89957ED619FE909EEB30DE7EBE3CB9D" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_D89957ED619FE909EEB30DE7EBE3CB9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5A9DC37622DC5BE416CC0DE7EBE3C70A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5A9DC37622DC5BE416CC0DE7EBE3C70A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5A9DC37622DC5BE416CC0DE7EBE3C70A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5A9DC37622DC5BE416CC0DE7EBE3C70A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5A9DC37622DC5BE416CC0DE7EBE3C70A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5A9DC37622DC5BE416CC0DE7EBE3C70A" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5A9DC37622DC5BE416CC0DE7EBE3C70A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_22FB3873BCC12411166C0DE7EBE38C22_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_22FB3873BCC12411166C0DE7EBE38C22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining discount amortization period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_22FB3873BCC12411166C0DE7EBE38C22_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_22FB3873BCC12411166C0DE7EBE38C22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_22FB3873BCC12411166C0DE7EBE38C22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_22FB3873BCC12411166C0DE7EBE38C22" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_22FB3873BCC12411166C0DE7EBE38C22" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_D80187B1C148611107C70DE7EBE4166B_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_D80187B1C148611107C70DE7EBE4166B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_D80187B1C148611107C70DE7EBE4166B_label_en-US" xlink:label="lab_us-gaap_InterestExpense_D80187B1C148611107C70DE7EBE4166B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D80187B1C148611107C70DE7EBE4166B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_D80187B1C148611107C70DE7EBE4166B" xlink:to="lab_us-gaap_InterestExpense_D80187B1C148611107C70DE7EBE4166B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_7E5A8894AB7E324DCCE60DE7EBE49923_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_7E5A8894AB7E324DCCE60DE7EBE49923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_7E5A8894AB7E324DCCE60DE7EBE49923_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_7E5A8894AB7E324DCCE60DE7EBE49923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_7E5A8894AB7E324DCCE60DE7EBE49923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_7E5A8894AB7E324DCCE60DE7EBE49923" xlink:to="lab_us-gaap_RepaymentsOfDebt_7E5A8894AB7E324DCCE60DE7EBE49923" xlink:type="arc" />
    <link:label id="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA_terseLabel_en-US" xlink:label="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of debt, back end fees, outstanding interest, and prepayment penalty fees</link:label>
    <link:label id="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA_label_en-US" xlink:label="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments Of Debt Fees And Outstanding Interest</link:label>
    <link:label id="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA_documentation_en-US" xlink:label="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayments Of Debt Fees And Outstanding Interest</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_RepaymentsOfDebtFeesAndOutstandingInterest" xlink:label="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA" xlink:to="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5AEF1A5F5AA5AEE12570DE7EBE41583_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5AEF1A5F5AA5AEE12570DE7EBE41583" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5AEF1A5F5AA5AEE12570DE7EBE41583_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5AEF1A5F5AA5AEE12570DE7EBE41583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5AEF1A5F5AA5AEE12570DE7EBE41583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5AEF1A5F5AA5AEE12570DE7EBE41583" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5AEF1A5F5AA5AEE12570DE7EBE41583" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8CD8F44F7D1615B18D30971953EA5272_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8CD8F44F7D1615B18D30971953EA5272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8CD8F44F7D1615B18D30971953EA5272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8CD8F44F7D1615B18D30971953EA5272" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8CD8F44F7D1615B18D30971953EA5272" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C83C390AB4BD3F5247F1971953EAFC0A_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C83C390AB4BD3F5247F1971953EAFC0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C83C390AB4BD3F5247F1971953EAFC0A_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C83C390AB4BD3F5247F1971953EAFC0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C83C390AB4BD3F5247F1971953EAFC0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C83C390AB4BD3F5247F1971953EAFC0A" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_C83C390AB4BD3F5247F1971953EAFC0A" xlink:type="arc" />
    <link:label id="lab_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F_label_en-US" xlink:label="lab_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information</link:label>
    <link:label id="lab_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F_documentation_en-US" xlink:label="lab_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DocumentAndEntityInformationAbstract" xlink:label="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="lab_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_4DCF2357ABDAE7D6AC3A807F95BBD3EC_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_4DCF2357ABDAE7D6AC3A807F95BBD3EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_4DCF2357ABDAE7D6AC3A807F95BBD3EC_label_en-US" xlink:label="lab_dei_EntityRegistrantName_4DCF2357ABDAE7D6AC3A807F95BBD3EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_4DCF2357ABDAE7D6AC3A807F95BBD3EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_4DCF2357ABDAE7D6AC3A807F95BBD3EC" xlink:to="lab_dei_EntityRegistrantName_4DCF2357ABDAE7D6AC3A807F95BBD3EC" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_7BFE28010E88E604B529807F95BBA1C6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7BFE28010E88E604B529807F95BBA1C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_7BFE28010E88E604B529807F95BBA1C6_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7BFE28010E88E604B529807F95BBA1C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7BFE28010E88E604B529807F95BBA1C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7BFE28010E88E604B529807F95BBA1C6" xlink:to="lab_dei_EntityCentralIndexKey_7BFE28010E88E604B529807F95BBA1C6" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_CAF490BA49C667ECFA27807F95BC6C8E_terseLabel_en-US" xlink:label="lab_dei_DocumentType_CAF490BA49C667ECFA27807F95BC6C8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_CAF490BA49C667ECFA27807F95BC6C8E_label_en-US" xlink:label="lab_dei_DocumentType_CAF490BA49C667ECFA27807F95BC6C8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_CAF490BA49C667ECFA27807F95BC6C8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_CAF490BA49C667ECFA27807F95BC6C8E" xlink:to="lab_dei_DocumentType_CAF490BA49C667ECFA27807F95BC6C8E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_475B8EEE1505922FB97A807F95BC5351_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_475B8EEE1505922FB97A807F95BC5351" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_475B8EEE1505922FB97A807F95BC5351_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_475B8EEE1505922FB97A807F95BC5351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_475B8EEE1505922FB97A807F95BC5351" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_475B8EEE1505922FB97A807F95BC5351" xlink:to="lab_dei_DocumentPeriodEndDate_475B8EEE1505922FB97A807F95BC5351" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_F897787393018F95CA75807F95BC8A51_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_F897787393018F95CA75807F95BC8A51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_F897787393018F95CA75807F95BC8A51_label_en-US" xlink:label="lab_dei_AmendmentFlag_F897787393018F95CA75807F95BC8A51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_F897787393018F95CA75807F95BC8A51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_F897787393018F95CA75807F95BC8A51" xlink:to="lab_dei_AmendmentFlag_F897787393018F95CA75807F95BC8A51" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_B127AF8DBE9AE1A14F2E807F95BC7CFA_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_B127AF8DBE9AE1A14F2E807F95BC7CFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_B127AF8DBE9AE1A14F2E807F95BC7CFA_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_B127AF8DBE9AE1A14F2E807F95BC7CFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_B127AF8DBE9AE1A14F2E807F95BC7CFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_B127AF8DBE9AE1A14F2E807F95BC7CFA" xlink:to="lab_dei_CurrentFiscalYearEndDate_B127AF8DBE9AE1A14F2E807F95BC7CFA" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_79427ABF3F802F537770807F95BC7913_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_79427ABF3F802F537770807F95BC7913" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_79427ABF3F802F537770807F95BC7913_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_79427ABF3F802F537770807F95BC7913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_79427ABF3F802F537770807F95BC7913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_79427ABF3F802F537770807F95BC7913" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_79427ABF3F802F537770807F95BC7913" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_6576C9524D20F5DC2E66807F95BDBD96_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_6576C9524D20F5DC2E66807F95BDBD96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_6576C9524D20F5DC2E66807F95BDBD96_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_6576C9524D20F5DC2E66807F95BDBD96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_6576C9524D20F5DC2E66807F95BDBD96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_6576C9524D20F5DC2E66807F95BDBD96" xlink:to="lab_dei_EntityVoluntaryFilers_6576C9524D20F5DC2E66807F95BDBD96" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_98CF39862ADC4876789E807F95BDE306_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_98CF39862ADC4876789E807F95BDE306" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_98CF39862ADC4876789E807F95BDE306_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_98CF39862ADC4876789E807F95BDE306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_98CF39862ADC4876789E807F95BDE306" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_98CF39862ADC4876789E807F95BDE306" xlink:to="lab_dei_EntityCurrentReportingStatus_98CF39862ADC4876789E807F95BDE306" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_FAFEFA1DC2357628CED6807F95BD4627_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_FAFEFA1DC2357628CED6807F95BD4627" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_FAFEFA1DC2357628CED6807F95BD4627_label_en-US" xlink:label="lab_dei_EntityFilerCategory_FAFEFA1DC2357628CED6807F95BD4627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_FAFEFA1DC2357628CED6807F95BD4627" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_FAFEFA1DC2357628CED6807F95BD4627" xlink:to="lab_dei_EntityFilerCategory_FAFEFA1DC2357628CED6807F95BD4627" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_8A2B2A822CC86D86A0E9807F95BD3FCB_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_8A2B2A822CC86D86A0E9807F95BD3FCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_8A2B2A822CC86D86A0E9807F95BD3FCB_label_en-US" xlink:label="lab_dei_EntityPublicFloat_8A2B2A822CC86D86A0E9807F95BD3FCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_8A2B2A822CC86D86A0E9807F95BD3FCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_8A2B2A822CC86D86A0E9807F95BD3FCB" xlink:to="lab_dei_EntityPublicFloat_8A2B2A822CC86D86A0E9807F95BD3FCB" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8C8B4DC178BBE6D29B24807F95BD8178_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_8C8B4DC178BBE6D29B24807F95BD8178" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8C8B4DC178BBE6D29B24807F95BD8178_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_8C8B4DC178BBE6D29B24807F95BD8178" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8C8B4DC178BBE6D29B24807F95BD8178" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_8C8B4DC178BBE6D29B24807F95BD8178" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_8C8B4DC178BBE6D29B24807F95BD8178" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_DB9FF77B2AA919E6F1FD807F95BDE830_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_DB9FF77B2AA919E6F1FD807F95BDE830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_DB9FF77B2AA919E6F1FD807F95BDE830_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_DB9FF77B2AA919E6F1FD807F95BDE830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_DB9FF77B2AA919E6F1FD807F95BDE830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_DB9FF77B2AA919E6F1FD807F95BDE830" xlink:to="lab_dei_DocumentFiscalYearFocus_DB9FF77B2AA919E6F1FD807F95BDE830" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5FC3EBBA16378342C577807F95BEFAEC_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_5FC3EBBA16378342C577807F95BEFAEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5FC3EBBA16378342C577807F95BEFAEC_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_5FC3EBBA16378342C577807F95BEFAEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5FC3EBBA16378342C577807F95BEFAEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_5FC3EBBA16378342C577807F95BEFAEC" xlink:to="lab_dei_DocumentFiscalPeriodFocus_5FC3EBBA16378342C577807F95BEFAEC" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_8B86FFF9360690E979CA807F95BE762B_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_8B86FFF9360690E979CA807F95BE762B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_8B86FFF9360690E979CA807F95BE762B_label_en-US" xlink:label="lab_dei_EntityShellCompany_8B86FFF9360690E979CA807F95BE762B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_8B86FFF9360690E979CA807F95BE762B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_8B86FFF9360690E979CA807F95BE762B" xlink:to="lab_dei_EntityShellCompany_8B86FFF9360690E979CA807F95BE762B" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_279839D27E3656FC9BC9807F95BE287D_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_279839D27E3656FC9BC9807F95BE287D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_279839D27E3656FC9BC9807F95BE287D_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_279839D27E3656FC9BC9807F95BE287D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_279839D27E3656FC9BC9807F95BE287D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_279839D27E3656FC9BC9807F95BE287D" xlink:to="lab_dei_EntityEmergingGrowthCompany_279839D27E3656FC9BC9807F95BE287D" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_6AF35B70E1C33505BA56807F95BE842A_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_6AF35B70E1C33505BA56807F95BE842A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_6AF35B70E1C33505BA56807F95BE842A_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_6AF35B70E1C33505BA56807F95BE842A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_6AF35B70E1C33505BA56807F95BE842A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_6AF35B70E1C33505BA56807F95BE842A" xlink:to="lab_dei_EntitySmallBusiness_6AF35B70E1C33505BA56807F95BE842A" xlink:type="arc" />
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1_terseLabel_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1_label_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1_documentation_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:to="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_75C5DAFDD91F4836277E5752D5561017_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_75C5DAFDD91F4836277E5752D5561017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_75C5DAFDD91F4836277E5752D5561017_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_75C5DAFDD91F4836277E5752D5561017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_75C5DAFDD91F4836277E5752D5561017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_75C5DAFDD91F4836277E5752D5561017" xlink:to="lab_us-gaap_EmployeeStockOptionMember_75C5DAFDD91F4836277E5752D5561017" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_CEAD3EF3F0DA580A7ED05752D55775C4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_CEAD3EF3F0DA580A7ED05752D55775C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock and restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_CEAD3EF3F0DA580A7ED05752D55775C4_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_CEAD3EF3F0DA580A7ED05752D55775C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_CEAD3EF3F0DA580A7ED05752D55775C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_CEAD3EF3F0DA580A7ED05752D55775C4" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_CEAD3EF3F0DA580A7ED05752D55775C4" xlink:type="arc" />
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA_terseLabel_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Line Items]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA_label_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Line Items]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA_documentation_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:to="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_15A5E41A6A248CA4EAC95752D55738A5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_15A5E41A6A248CA4EAC95752D55738A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_15A5E41A6A248CA4EAC95752D55738A5_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_15A5E41A6A248CA4EAC95752D55738A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15A5E41A6A248CA4EAC95752D55738A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_15A5E41A6A248CA4EAC95752D55738A5" xlink:to="lab_us-gaap_NetIncomeLoss_15A5E41A6A248CA4EAC95752D55738A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCA14F2D6CF02213E5765752D558B0C5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCA14F2D6CF02213E5765752D558B0C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares used in calculation of basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCA14F2D6CF02213E5765752D558B0C5_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCA14F2D6CF02213E5765752D558B0C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCA14F2D6CF02213E5765752D558B0C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCA14F2D6CF02213E5765752D558B0C5" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCA14F2D6CF02213E5765752D558B0C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0681DD05ED2C2DBD48955752D5587833_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0681DD05ED2C2DBD48955752D5587833" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0681DD05ED2C2DBD48955752D5587833_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0681DD05ED2C2DBD48955752D5587833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0681DD05ED2C2DBD48955752D5587833" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0681DD05ED2C2DBD48955752D5587833" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0681DD05ED2C2DBD48955752D5587833" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F6062952D28D94127D4E5752D5592AA0_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F6062952D28D94127D4E5752D5592AA0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F6062952D28D94127D4E5752D5592AA0_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F6062952D28D94127D4E5752D5592AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F6062952D28D94127D4E5752D5592AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F6062952D28D94127D4E5752D5592AA0" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F6062952D28D94127D4E5752D5592AA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_271830F523EB5086E3CB5752D559CD7C_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_271830F523EB5086E3CB5752D559CD7C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_271830F523EB5086E3CB5752D559CD7C_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_271830F523EB5086E3CB5752D559CD7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_271830F523EB5086E3CB5752D559CD7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_271830F523EB5086E3CB5752D559CD7C" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_271830F523EB5086E3CB5752D559CD7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_A14527FD60B1C0722DC4C9F686C28A3D_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember_A14527FD60B1C0722DC4C9F686C28A3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Jersey Division of Taxation</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_A14527FD60B1C0722DC4C9F686C28A3D_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember_A14527FD60B1C0722DC4C9F686C28A3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_A14527FD60B1C0722DC4C9F686C28A3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember_A14527FD60B1C0722DC4C9F686C28A3D" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember_A14527FD60B1C0722DC4C9F686C28A3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_7AF31B5C1F84467478DCC8B4E01BB0BE_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_7AF31B5C1F84467478DCC8B4E01BB0BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_7AF31B5C1F84467478DCC8B4E01BB0BE_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_7AF31B5C1F84467478DCC8B4E01BB0BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_7AF31B5C1F84467478DCC8B4E01BB0BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_7AF31B5C1F84467478DCC8B4E01BB0BE" xlink:to="lab_us-gaap_DomesticCountryMember_7AF31B5C1F84467478DCC8B4E01BB0BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_695DDE5874EF3DA06159C8B4E01A15EC_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_695DDE5874EF3DA06159C8B4E01A15EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_695DDE5874EF3DA06159C8B4E01A15EC_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_695DDE5874EF3DA06159C8B4E01A15EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_695DDE5874EF3DA06159C8B4E01A15EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_695DDE5874EF3DA06159C8B4E01A15EC" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_695DDE5874EF3DA06159C8B4E01A15EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E239B7FE07B9B2728AFFC8B4E01C955E_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E239B7FE07B9B2728AFFC8B4E01C955E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision (benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E239B7FE07B9B2728AFFC8B4E01C955E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_E239B7FE07B9B2728AFFC8B4E01C955E" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_E239B7FE07B9B2728AFFC8B4E01C955E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58605D08494716690590C8B4E01CE3E2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58605D08494716690590C8B4E01CE3E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58605D08494716690590C8B4E01CE3E2_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58605D08494716690590C8B4E01CE3E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58605D08494716690590C8B4E01CE3E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58605D08494716690590C8B4E01CE3E2" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58605D08494716690590C8B4E01CE3E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6431F38A5374FBD770ADC8B4E01CDB21_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6431F38A5374FBD770ADC8B4E01CDB21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6431F38A5374FBD770ADC8B4E01CDB21_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6431F38A5374FBD770ADC8B4E01CDB21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6431F38A5374FBD770ADC8B4E01CDB21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6431F38A5374FBD770ADC8B4E01CDB21" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6431F38A5374FBD770ADC8B4E01CDB21" xlink:type="arc" />
    <link:label id="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_614D554622436A55EE8BC8B4E01DE022_terseLabel_en-US" xlink:label="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_614D554622436A55EE8BC8B4E01DE022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets (prior to applying the valuation allowance)</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_614D554622436A55EE8BC8B4E01DE022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_614D554622436A55EE8BC8B4E01DE022" xlink:to="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_614D554622436A55EE8BC8B4E01DE022" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B0527100D9A8BD081AF0C8B4E01D3BBB_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B0527100D9A8BD081AF0C8B4E01D3BBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B0527100D9A8BD081AF0C8B4E01D3BBB_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B0527100D9A8BD081AF0C8B4E01D3BBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B0527100D9A8BD081AF0C8B4E01D3BBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B0527100D9A8BD081AF0C8B4E01D3BBB" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B0527100D9A8BD081AF0C8B4E01D3BBB" xlink:type="arc" />
    <link:label id="lab_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE_terseLabel_en-US" xlink:label="lab_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards for income tax purposes</link:label>
    <link:label id="lab_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE_label_en-US" xlink:label="lab_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards Total</link:label>
    <link:label id="lab_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE_documentation_en-US" xlink:label="lab_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of operating loss carryforward, before tax effects, for income tax purposes.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_OperatingLossCarryforwardsTotal" xlink:label="loc_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE" xlink:to="lab_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2F4984D5DF26F5326317C8B4E01FD7F1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_2F4984D5DF26F5326317C8B4E01FD7F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards available to offset future taxable income</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2F4984D5DF26F5326317C8B4E01FD7F1_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_2F4984D5DF26F5326317C8B4E01FD7F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2F4984D5DF26F5326317C8B4E01FD7F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_2F4984D5DF26F5326317C8B4E01FD7F1" xlink:to="lab_us-gaap_OperatingLossCarryforwards_2F4984D5DF26F5326317C8B4E01FD7F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_7CF3F360C8E4899485B6527256F600C1_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_7CF3F360C8E4899485B6527256F600C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7CF3F360C8E4899485B6527256F600C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7CF3F360C8E4899485B6527256F600C1" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_7CF3F360C8E4899485B6527256F600C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_6EAEB43F0D2D2A61E23A527256F6117F_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_6EAEB43F0D2D2A61E23A527256F6117F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_6EAEB43F0D2D2A61E23A527256F6117F_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_6EAEB43F0D2D2A61E23A527256F6117F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_6EAEB43F0D2D2A61E23A527256F6117F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_6EAEB43F0D2D2A61E23A527256F6117F" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_6EAEB43F0D2D2A61E23A527256F6117F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2D27AADEC72F5CF722BCC8B4E0268851_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2D27AADEC72F5CF722BCC8B4E0268851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Loss Before Income Taxes in the US and Globally</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2D27AADEC72F5CF722BCC8B4E0268851_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2D27AADEC72F5CF722BCC8B4E0268851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2D27AADEC72F5CF722BCC8B4E0268851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2D27AADEC72F5CF722BCC8B4E0268851" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2D27AADEC72F5CF722BCC8B4E0268851" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0F8ED6FF0E752F23852DC8B4E02604A7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0F8ED6FF0E752F23852DC8B4E02604A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components Income Tax (Benefit) Provision</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0F8ED6FF0E752F23852DC8B4E02604A7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0F8ED6FF0E752F23852DC8B4E02604A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0F8ED6FF0E752F23852DC8B4E02604A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0F8ED6FF0E752F23852DC8B4E02604A7" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0F8ED6FF0E752F23852DC8B4E02604A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9C08F7F5382EF0D2CE53C8B4E02607E7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9C08F7F5382EF0D2CE53C8B4E02607E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9C08F7F5382EF0D2CE53C8B4E02607E7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9C08F7F5382EF0D2CE53C8B4E02607E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9C08F7F5382EF0D2CE53C8B4E02607E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9C08F7F5382EF0D2CE53C8B4E02607E7" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9C08F7F5382EF0D2CE53C8B4E02607E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2C0AE5183E58D9715031C8B4E02783A4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2C0AE5183E58D9715031C8B4E02783A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2C0AE5183E58D9715031C8B4E02783A4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2C0AE5183E58D9715031C8B4E02783A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2C0AE5183E58D9715031C8B4E02783A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2C0AE5183E58D9715031C8B4E02783A4" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2C0AE5183E58D9715031C8B4E02783A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_319F3ADCD1E25DEFD19EC9CED8C18CC5_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_319F3ADCD1E25DEFD19EC9CED8C18CC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_319F3ADCD1E25DEFD19EC9CED8C18CC5_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_319F3ADCD1E25DEFD19EC9CED8C18CC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_319F3ADCD1E25DEFD19EC9CED8C18CC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_319F3ADCD1E25DEFD19EC9CED8C18CC5" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_319F3ADCD1E25DEFD19EC9CED8C18CC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_84D6642761C512472EA2C8B4E16E9E2E_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_84D6642761C512472EA2C8B4E16E9E2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_84D6642761C512472EA2C8B4E16E9E2E_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_84D6642761C512472EA2C8B4E16E9E2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_84D6642761C512472EA2C8B4E16E9E2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_84D6642761C512472EA2C8B4E16E9E2E" xlink:to="lab_us-gaap_RestrictedStockMember_84D6642761C512472EA2C8B4E16E9E2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_0ABFAF6C2817950EDCA5C8B4E16FAF53_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_0ABFAF6C2817950EDCA5C8B4E16FAF53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_0ABFAF6C2817950EDCA5C8B4E16FAF53_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_0ABFAF6C2817950EDCA5C8B4E16FAF53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_0ABFAF6C2817950EDCA5C8B4E16FAF53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_0ABFAF6C2817950EDCA5C8B4E16FAF53" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_0ABFAF6C2817950EDCA5C8B4E16FAF53" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E137C8346391ED21946EC8B4E1709B09_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E137C8346391ED21946EC8B4E1709B09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E137C8346391ED21946EC8B4E1709B09_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E137C8346391ED21946EC8B4E1709B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E137C8346391ED21946EC8B4E1709B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E137C8346391ED21946EC8B4E1709B09" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E137C8346391ED21946EC8B4E1709B09" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_116BB636411BD3DD6D74C80C91F50CF7_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_116BB636411BD3DD6D74C80C91F50CF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_116BB636411BD3DD6D74C80C91F50CF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_116BB636411BD3DD6D74C80C91F50CF7" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_116BB636411BD3DD6D74C80C91F50CF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_DDB8B1F414C8F6261807C80C91F58491_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_DDB8B1F414C8F6261807C80C91F58491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_DDB8B1F414C8F6261807C80C91F58491_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_DDB8B1F414C8F6261807C80C91F58491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_DDB8B1F414C8F6261807C80C91F58491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_DDB8B1F414C8F6261807C80C91F58491" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_DDB8B1F414C8F6261807C80C91F58491" xlink:type="arc" />
    <link:label id="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1_terseLabel_en-US" xlink:label="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1_label_en-US" xlink:label="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1_documentation_en-US" xlink:label="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares and stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1" xlink:to="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1" xlink:type="arc" />
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560_terseLabel_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and RSUs</link:label>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560_label_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560_documentation_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_StockOptionsAndRestrictedStockUnitsMember" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560" xlink:to="lab_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_DAB0218FDEF783E8F8B9FDBA302BB56F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_DAB0218FDEF783E8F8B9FDBA302BB56F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_DAB0218FDEF783E8F8B9FDBA302BB56F_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_DAB0218FDEF783E8F8B9FDBA302BB56F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_DAB0218FDEF783E8F8B9FDBA302BB56F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_DAB0218FDEF783E8F8B9FDBA302BB56F" xlink:to="lab_us-gaap_EmployeeStockMember_DAB0218FDEF783E8F8B9FDBA302BB56F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_883AE2A18A017815EBC8FDBA302C0BB4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_883AE2A18A017815EBC8FDBA302C0BB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_883AE2A18A017815EBC8FDBA302C0BB4_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_883AE2A18A017815EBC8FDBA302C0BB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_883AE2A18A017815EBC8FDBA302C0BB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_883AE2A18A017815EBC8FDBA302C0BB4" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_883AE2A18A017815EBC8FDBA302C0BB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Based Compensation disclosures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:type="arc" />
    <link:label id="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5_terseLabel_en-US" xlink:label="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares each award holder is entitled to receive</link:label>
    <link:label id="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5_label_en-US" xlink:label="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Common Shares To Be Received In Lieu Of Per Restricted Stock And Restricted Stock Unit</link:label>
    <link:label id="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5_documentation_en-US" xlink:label="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of common stock each restricted stock award entitles the holder to receive upon completion of a specific period of service or achievement of a specified milestone.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" xlink:label="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5" xlink:to="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE11B65043AFE7948EA7FE160FA281F7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE11B65043AFE7948EA7FE160FA281F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to unvested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE11B65043AFE7948EA7FE160FA281F7_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE11B65043AFE7948EA7FE160FA281F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE11B65043AFE7948EA7FE160FA281F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE11B65043AFE7948EA7FE160FA281F7" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE11B65043AFE7948EA7FE160FA281F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_115EABBD059AEBC2D6BAFDBA302D748C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_115EABBD059AEBC2D6BAFDBA302D748C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected weighted average period for recognized and unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_115EABBD059AEBC2D6BAFDBA302D748C_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_115EABBD059AEBC2D6BAFDBA302D748C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_115EABBD059AEBC2D6BAFDBA302D748C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_115EABBD059AEBC2D6BAFDBA302D748C" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_115EABBD059AEBC2D6BAFDBA302D748C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58C53ED28DE3E178CC23FDBA302D29B7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58C53ED28DE3E178CC23FDBA302D29B7" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58C53ED28DE3E178CC23FDBA302D29B7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58C53ED28DE3E178CC23FDBA302D29B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58C53ED28DE3E178CC23FDBA302D29B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58C53ED28DE3E178CC23FDBA302D29B7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58C53ED28DE3E178CC23FDBA302D29B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31827335BB384557A61BFDBA302E4E59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31827335BB384557A61BFDBA302E4E59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31827335BB384557A61BFDBA302E4E59_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31827335BB384557A61BFDBA302E4E59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31827335BB384557A61BFDBA302E4E59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31827335BB384557A61BFDBA302E4E59" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31827335BB384557A61BFDBA302E4E59" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ED180B981B2D96F2A45AFDBA302E3186_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ED180B981B2D96F2A45AFDBA302E3186" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ED180B981B2D96F2A45AFDBA302E3186_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ED180B981B2D96F2A45AFDBA302E3186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ED180B981B2D96F2A45AFDBA302E3186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ED180B981B2D96F2A45AFDBA302E3186" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ED180B981B2D96F2A45AFDBA302E3186" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2C7A0BD2975F81D07790FDBA302E5E46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2C7A0BD2975F81D07790FDBA302E5E46" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2C7A0BD2975F81D07790FDBA302E5E46_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2C7A0BD2975F81D07790FDBA302E5E46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2C7A0BD2975F81D07790FDBA302E5E46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2C7A0BD2975F81D07790FDBA302E5E46" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2C7A0BD2975F81D07790FDBA302E5E46" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FAA0850A068B9701582BFDBA302F7C23_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FAA0850A068B9701582BFDBA302F7C23" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FAA0850A068B9701582BFDBA302F7C23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FAA0850A068B9701582BFDBA302F7C23" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FAA0850A068B9701582BFDBA302F7C23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_69EC712A65F6E69A23CCFDBA302F39F6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_69EC712A65F6E69A23CCFDBA302F39F6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding Weighted Average Grant Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_69EC712A65F6E69A23CCFDBA302F39F6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_69EC712A65F6E69A23CCFDBA302F39F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_69EC712A65F6E69A23CCFDBA302F39F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_69EC712A65F6E69A23CCFDBA302F39F6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_69EC712A65F6E69A23CCFDBA302F39F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D692A23C5C1BF119D6B1FDBA302F8BAA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D692A23C5C1BF119D6B1FDBA302F8BAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D692A23C5C1BF119D6B1FDBA302F8BAA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D692A23C5C1BF119D6B1FDBA302F8BAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D692A23C5C1BF119D6B1FDBA302F8BAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D692A23C5C1BF119D6B1FDBA302F8BAA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D692A23C5C1BF119D6B1FDBA302F8BAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_33F845ABBB4721BB8F4FFDBA302F555A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_33F845ABBB4721BB8F4FFDBA302F555A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_33F845ABBB4721BB8F4FFDBA302F555A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_33F845ABBB4721BB8F4FFDBA302F555A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_33F845ABBB4721BB8F4FFDBA302F555A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_33F845ABBB4721BB8F4FFDBA302F555A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_33F845ABBB4721BB8F4FFDBA302F555A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6AB13B6D9DC3449917D8FDBA3030C657_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6AB13B6D9DC3449917D8FDBA3030C657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6AB13B6D9DC3449917D8FDBA3030C657_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6AB13B6D9DC3449917D8FDBA3030C657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6AB13B6D9DC3449917D8FDBA3030C657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6AB13B6D9DC3449917D8FDBA3030C657" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6AB13B6D9DC3449917D8FDBA3030C657" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_059BF76EA37F97A7D7D7FDBA30309D57_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_059BF76EA37F97A7D7D7FDBA30309D57" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding Weighted Average Grant Price (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_059BF76EA37F97A7D7D7FDBA30309D57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_059BF76EA37F97A7D7D7FDBA30309D57" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_059BF76EA37F97A7D7D7FDBA30309D57" xlink:type="arc" />
    <link:label id="lab_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047_terseLabel_en-US" xlink:label="lab_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense that resulted from the remeasurement of awards</link:label>
    <link:label id="lab_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047_label_en-US" xlink:label="lab_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share Based Compensation Expense, Due to Remeasurement of Awards</link:label>
    <link:label id="lab_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047_documentation_en-US" xlink:label="lab_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of stock-based compensation expense that resulted from the remeasurement of awards.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:label="loc_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047" xlink:to="lab_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_41F1C33E78C70B8535A8FDBA3030E30D_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_41F1C33E78C70B8535A8FDBA3030E30D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_41F1C33E78C70B8535A8FDBA3030E30D_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_41F1C33E78C70B8535A8FDBA3030E30D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_41F1C33E78C70B8535A8FDBA3030E30D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_41F1C33E78C70B8535A8FDBA3030E30D" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_41F1C33E78C70B8535A8FDBA3030E30D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1E3AC1F1AEE60B619DF70C93D4A81603_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_1E3AC1F1AEE60B619DF70C93D4A81603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1E3AC1F1AEE60B619DF70C93D4A81603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1E3AC1F1AEE60B619DF70C93D4A81603" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_1E3AC1F1AEE60B619DF70C93D4A81603" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C_label_en-US" xlink:label="lab_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:to="lab_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="lab_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_278DBCDD33E18A74FDA80C93D4AC939E_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_278DBCDD33E18A74FDA80C93D4AC939E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_278DBCDD33E18A74FDA80C93D4AC939E_label_en-US" xlink:label="lab_us-gaap_Depreciation_278DBCDD33E18A74FDA80C93D4AC939E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_278DBCDD33E18A74FDA80C93D4AC939E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_278DBCDD33E18A74FDA80C93D4AC939E" xlink:to="lab_us-gaap_Depreciation_278DBCDD33E18A74FDA80C93D4AC939E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_78E277EE2B7B5F29BE570C93D4ACA1FE_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_78E277EE2B7B5F29BE570C93D4ACA1FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_78E277EE2B7B5F29BE570C93D4ACA1FE_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_78E277EE2B7B5F29BE570C93D4ACA1FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_78E277EE2B7B5F29BE570C93D4ACA1FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_78E277EE2B7B5F29BE570C93D4ACA1FE" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_78E277EE2B7B5F29BE570C93D4ACA1FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_A8B568EAA8A4F87DA1780C93D4AD711A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A8B568EAA8A4F87DA1780C93D4AD711A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_A8B568EAA8A4F87DA1780C93D4AD711A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A8B568EAA8A4F87DA1780C93D4AD711A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A8B568EAA8A4F87DA1780C93D4AD711A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_A8B568EAA8A4F87DA1780C93D4AD711A" xlink:to="lab_us-gaap_ShareBasedCompensation_A8B568EAA8A4F87DA1780C93D4AD711A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_24E20B141B8689034A9F0C93D4AD1FFC_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_24E20B141B8689034A9F0C93D4AD1FFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_24E20B141B8689034A9F0C93D4AD1FFC_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_24E20B141B8689034A9F0C93D4AD1FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_24E20B141B8689034A9F0C93D4AD1FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_24E20B141B8689034A9F0C93D4AD1FFC" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_24E20B141B8689034A9F0C93D4AD1FFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_E7F518F7AEBE3F821F4F0C93D4ADD922_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_E7F518F7AEBE3F821F4F0C93D4ADD922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_E7F518F7AEBE3F821F4F0C93D4ADD922_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_E7F518F7AEBE3F821F4F0C93D4ADD922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_E7F518F7AEBE3F821F4F0C93D4ADD922" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_E7F518F7AEBE3F821F4F0C93D4ADD922" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_E7F518F7AEBE3F821F4F0C93D4ADD922" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionExpense_09B6785031A2A146FE110C93D4ADE9A3_terseLabel_en-US" xlink:label="lab_us-gaap_AccretionExpense_09B6785031A2A146FE110C93D4ADE9A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of back-end fee on debt</link:label>
    <link:label id="lab_us-gaap_AccretionExpense_09B6785031A2A146FE110C93D4ADE9A3_label_en-US" xlink:label="lab_us-gaap_AccretionExpense_09B6785031A2A146FE110C93D4ADE9A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_09B6785031A2A146FE110C93D4ADE9A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionExpense_09B6785031A2A146FE110C93D4ADE9A3" xlink:to="lab_us-gaap_AccretionExpense_09B6785031A2A146FE110C93D4ADE9A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_CE03F10ECB5D81C0C2880C93D4AEC369_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_CE03F10ECB5D81C0C2880C93D4AEC369" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_CE03F10ECB5D81C0C2880C93D4AEC369_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_CE03F10ECB5D81C0C2880C93D4AEC369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_CE03F10ECB5D81C0C2880C93D4AEC369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_CE03F10ECB5D81C0C2880C93D4AEC369" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_CE03F10ECB5D81C0C2880C93D4AEC369" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_14E5B153496501427D810C93D4AE8C06_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_14E5B153496501427D810C93D4AE8C06" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_14E5B153496501427D810C93D4AE8C06_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_14E5B153496501427D810C93D4AE8C06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_14E5B153496501427D810C93D4AE8C06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_14E5B153496501427D810C93D4AE8C06" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_14E5B153496501427D810C93D4AE8C06" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B7AAF1DA83F0F445571F0C93D4AE15D0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B7AAF1DA83F0F445571F0C93D4AE15D0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B7AAF1DA83F0F445571F0C93D4AE15D0_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B7AAF1DA83F0F445571F0C93D4AE15D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B7AAF1DA83F0F445571F0C93D4AE15D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B7AAF1DA83F0F445571F0C93D4AE15D0" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B7AAF1DA83F0F445571F0C93D4AE15D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9ED0A30F626F314FCD010C93D4AE673E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9ED0A30F626F314FCD010C93D4AE673E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9ED0A30F626F314FCD010C93D4AE673E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9ED0A30F626F314FCD010C93D4AE673E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9ED0A30F626F314FCD010C93D4AE673E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9ED0A30F626F314FCD010C93D4AE673E" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9ED0A30F626F314FCD010C93D4AE673E" xlink:type="arc" />
    <link:label id="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9_terseLabel_en-US" xlink:label="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9_label_en-US" xlink:label="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Current Liabilities</link:label>
    <link:label id="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9_documentation_en-US" xlink:label="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the sum of accrued expenses and Other Current Liabilities.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9" xlink:to="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3195AFCBD8C639CBC4FF0C93D4AF98A7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3195AFCBD8C639CBC4FF0C93D4AF98A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3195AFCBD8C639CBC4FF0C93D4AF98A7_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3195AFCBD8C639CBC4FF0C93D4AF98A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3195AFCBD8C639CBC4FF0C93D4AF98A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3195AFCBD8C639CBC4FF0C93D4AF98A7" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3195AFCBD8C639CBC4FF0C93D4AF98A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0A48BB7215B317E5F1BE0C93D4AFDF8D_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0A48BB7215B317E5F1BE0C93D4AFDF8D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0A48BB7215B317E5F1BE0C93D4AFDF8D_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0A48BB7215B317E5F1BE0C93D4AFDF8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0A48BB7215B317E5F1BE0C93D4AFDF8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0A48BB7215B317E5F1BE0C93D4AFDF8D" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0A48BB7215B317E5F1BE0C93D4AFDF8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45E41025C777BB78F7420C93D4AF26BE_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45E41025C777BB78F7420C93D4AF26BE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45E41025C777BB78F7420C93D4AF26BE_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45E41025C777BB78F7420C93D4AF26BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45E41025C777BB78F7420C93D4AF26BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45E41025C777BB78F7420C93D4AF26BE" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45E41025C777BB78F7420C93D4AF26BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_09CAA61361022BB04E590C93D4B01D77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_09CAA61361022BB04E590C93D4B01D77" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">PARI milestone upon FDA approval</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_09CAA61361022BB04E590C93D4B01D77_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_09CAA61361022BB04E590C93D4B01D77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_09CAA61361022BB04E590C93D4B01D77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_09CAA61361022BB04E590C93D4B01D77" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_09CAA61361022BB04E590C93D4B01D77" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_330E2CF10306994C6D590C93D4B0B480_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_330E2CF10306994C6D590C93D4B0B480" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_330E2CF10306994C6D590C93D4B0B480_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_330E2CF10306994C6D590C93D4B0B480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_330E2CF10306994C6D590C93D4B0B480" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_330E2CF10306994C6D590C93D4B0B480" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_330E2CF10306994C6D590C93D4B0B480" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_7E4D9DF066D68AE2483F0C93D4B12FD6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_7E4D9DF066D68AE2483F0C93D4B12FD6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_7E4D9DF066D68AE2483F0C93D4B12FD6_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_7E4D9DF066D68AE2483F0C93D4B12FD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7E4D9DF066D68AE2483F0C93D4B12FD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7E4D9DF066D68AE2483F0C93D4B12FD6" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_7E4D9DF066D68AE2483F0C93D4B12FD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_618F08679033118676350C93D4B195F2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_618F08679033118676350C93D4B195F2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_618F08679033118676350C93D4B195F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_618F08679033118676350C93D4B195F2" xlink:to="lab_us-gaap_RepaymentsOfDebt_618F08679033118676350C93D4B195F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_DDD448DE9E856CA08B7D0C93D4B18361_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_DDD448DE9E856CA08B7D0C93D4B18361" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_DDD448DE9E856CA08B7D0C93D4B18361_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_DDD448DE9E856CA08B7D0C93D4B18361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_DDD448DE9E856CA08B7D0C93D4B18361" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_DDD448DE9E856CA08B7D0C93D4B18361" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_DDD448DE9E856CA08B7D0C93D4B18361" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_860366CE10231D15EBF20C93D4B10B3E_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_860366CE10231D15EBF20C93D4B10B3E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_860366CE10231D15EBF20C93D4B10B3E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_860366CE10231D15EBF20C93D4B10B3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_860366CE10231D15EBF20C93D4B10B3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_860366CE10231D15EBF20C93D4B10B3E" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_860366CE10231D15EBF20C93D4B10B3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_7DD5C5382DD48011C6C80C93D4B12181_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_7DD5C5382DD48011C6C80C93D4B12181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options and ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_7DD5C5382DD48011C6C80C93D4B12181_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_7DD5C5382DD48011C6C80C93D4B12181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7DD5C5382DD48011C6C80C93D4B12181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_7DD5C5382DD48011C6C80C93D4B12181" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_7DD5C5382DD48011C6C80C93D4B12181" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_C86021248EB400E181280C93D4B2A1FC_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_C86021248EB400E181280C93D4B2A1FC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_C86021248EB400E181280C93D4B2A1FC_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_C86021248EB400E181280C93D4B2A1FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_C86021248EB400E181280C93D4B2A1FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_C86021248EB400E181280C93D4B2A1FC" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_C86021248EB400E181280C93D4B2A1FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2CDA63217499ED916F9A0C93D4B29F78_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2CDA63217499ED916F9A0C93D4B29F78" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2CDA63217499ED916F9A0C93D4B29F78_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2CDA63217499ED916F9A0C93D4B29F78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2CDA63217499ED916F9A0C93D4B29F78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2CDA63217499ED916F9A0C93D4B29F78" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2CDA63217499ED916F9A0C93D4B29F78" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8E010265053963D520D90C93D4B25D9E_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8E010265053963D520D90C93D4B25D9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8E010265053963D520D90C93D4B25D9E_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8E010265053963D520D90C93D4B25D9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8E010265053963D520D90C93D4B25D9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8E010265053963D520D90C93D4B25D9E" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8E010265053963D520D90C93D4B25D9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E1A695987984950FB6060C93D4B2C1AA_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E1A695987984950FB6060C93D4B2C1AA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E1A695987984950FB6060C93D4B2C1AA_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E1A695987984950FB6060C93D4B2C1AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E1A695987984950FB6060C93D4B2C1AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E1A695987984950FB6060C93D4B2C1AA" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E1A695987984950FB6060C93D4B2C1AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AFEBCC5EBDDBE0EBDE7B0C93D4B2AA4D_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AFEBCC5EBDDBE0EBDE7B0C93D4B2AA4D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AFEBCC5EBDDBE0EBDE7B0C93D4B2AA4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AFEBCC5EBDDBE0EBDE7B0C93D4B2AA4D" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AFEBCC5EBDDBE0EBDE7B0C93D4B2AA4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F38740DC1C763E95EFAD0C93D4B80CFB_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F38740DC1C763E95EFAD0C93D4B80CFB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F38740DC1C763E95EFAD0C93D4B80CFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F38740DC1C763E95EFAD0C93D4B80CFB" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F38740DC1C763E95EFAD0C93D4B80CFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_17623CE87AB346DBCD2F0C93D4B8A3B9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_17623CE87AB346DBCD2F0C93D4B8A3B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_17623CE87AB346DBCD2F0C93D4B8A3B9_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_17623CE87AB346DBCD2F0C93D4B8A3B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_17623CE87AB346DBCD2F0C93D4B8A3B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_17623CE87AB346DBCD2F0C93D4B8A3B9" xlink:to="lab_us-gaap_InterestPaidNet_17623CE87AB346DBCD2F0C93D4B8A3B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_436EBEC3FF37467E6E8A0C93D4B8223F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_436EBEC3FF37467E6E8A0C93D4B8223F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for taxes, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_436EBEC3FF37467E6E8A0C93D4B8223F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_436EBEC3FF37467E6E8A0C93D4B8223F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_436EBEC3FF37467E6E8A0C93D4B8223F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_436EBEC3FF37467E6E8A0C93D4B8223F" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_436EBEC3FF37467E6E8A0C93D4B8223F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7B3D48EBC10C0ABE6650C80C915B8F52_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7B3D48EBC10C0ABE6650C80C915B8F52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7B3D48EBC10C0ABE6650C80C915B8F52_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7B3D48EBC10C0ABE6650C80C915B8F52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7B3D48EBC10C0ABE6650C80C915B8F52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7B3D48EBC10C0ABE6650C80C915B8F52" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7B3D48EBC10C0ABE6650C80C915B8F52" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D3006A21824311B9E355C80C91DE229C_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D3006A21824311B9E355C80C91DE229C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D3006A21824311B9E355C80C91DE229C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D3006A21824311B9E355C80C91DE229C" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D3006A21824311B9E355C80C91DE229C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E9A2636C25AB22745B4DC80C91DEAC68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E9A2636C25AB22745B4DC80C91DEAC68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E9A2636C25AB22745B4DC80C91DEAC68_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E9A2636C25AB22745B4DC80C91DEAC68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E9A2636C25AB22745B4DC80C91DEAC68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E9A2636C25AB22745B4DC80C91DEAC68" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E9A2636C25AB22745B4DC80C91DEAC68" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DFF1C38EF516AFE492D3033D3B3D7DFC_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DFF1C38EF516AFE492D3033D3B3D7DFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DFF1C38EF516AFE492D3033D3B3D7DFC_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DFF1C38EF516AFE492D3033D3B3D7DFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DFF1C38EF516AFE492D3033D3B3D7DFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DFF1C38EF516AFE492D3033D3B3D7DFC" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DFF1C38EF516AFE492D3033D3B3D7DFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_6881D7337C1C0BBC2621033F646C4486_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_6881D7337C1C0BBC2621033F646C4486" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of product revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_6881D7337C1C0BBC2621033F646C4486_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_6881D7337C1C0BBC2621033F646C4486" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6881D7337C1C0BBC2621033F646C4486" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_6881D7337C1C0BBC2621033F646C4486" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_6881D7337C1C0BBC2621033F646C4486" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_CC00629090801D21DDF1033D3B3DEDBD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_CC00629090801D21DDF1033D3B3DEDBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_CC00629090801D21DDF1033D3B3DEDBD_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_CC00629090801D21DDF1033D3B3DEDBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_CC00629090801D21DDF1033D3B3DEDBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_CC00629090801D21DDF1033D3B3DEDBD" xlink:to="lab_us-gaap_OperatingIncomeLoss_CC00629090801D21DDF1033D3B3DEDBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_F2C9AEBC1A88CD5C16D8033D3B4338F1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_F2C9AEBC1A88CD5C16D8033D3B4338F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_F2C9AEBC1A88CD5C16D8033D3B4338F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_F2C9AEBC1A88CD5C16D8033D3B4338F1" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_F2C9AEBC1A88CD5C16D8033D3B4338F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_04F0F1B1C2BFDA49BBD2ECB41A6FC94B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_04F0F1B1C2BFDA49BBD2ECB41A6FC94B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Value and Fair Value of Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_04F0F1B1C2BFDA49BBD2ECB41A6FC94B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_04F0F1B1C2BFDA49BBD2ECB41A6FC94B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_04F0F1B1C2BFDA49BBD2ECB41A6FC94B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_04F0F1B1C2BFDA49BBD2ECB41A6FC94B" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_04F0F1B1C2BFDA49BBD2ECB41A6FC94B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1EA6AC898F3218744E63ECB41A6FC421_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1EA6AC898F3218744E63ECB41A6FC421" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1EA6AC898F3218744E63ECB41A6FC421_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1EA6AC898F3218744E63ECB41A6FC421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1EA6AC898F3218744E63ECB41A6FC421" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1EA6AC898F3218744E63ECB41A6FC421" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1EA6AC898F3218744E63ECB41A6FC421" xlink:type="arc" />
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock_EC97CBEF569373C1B18FECBB9472C27B_terseLabel_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock_EC97CBEF569373C1B18FECBB9472C27B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss</link:label>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock_EC97CBEF569373C1B18FECBB9472C27B_label_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock_EC97CBEF569373C1B18FECBB9472C27B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock_EC97CBEF569373C1B18FECBB9472C27B_documentation_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock_EC97CBEF569373C1B18FECBB9472C27B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock_EC97CBEF569373C1B18FECBB9472C27B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock_EC97CBEF569373C1B18FECBB9472C27B" xlink:to="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock_EC97CBEF569373C1B18FECBB9472C27B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3D575D107FFCDCD93F73ECB41A6F38D8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3D575D107FFCDCD93F73ECB41A6F38D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3D575D107FFCDCD93F73ECB41A6F38D8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3D575D107FFCDCD93F73ECB41A6F38D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3D575D107FFCDCD93F73ECB41A6F38D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3D575D107FFCDCD93F73ECB41A6F38D8" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3D575D107FFCDCD93F73ECB41A6F38D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6054CCEB35E445A02DA8ECB41A703B01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6054CCEB35E445A02DA8ECB41A703B01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6054CCEB35E445A02DA8ECB41A703B01_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6054CCEB35E445A02DA8ECB41A703B01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6054CCEB35E445A02DA8ECB41A703B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6054CCEB35E445A02DA8ECB41A703B01" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6054CCEB35E445A02DA8ECB41A703B01" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_0A7799E0A83B4AAB1B4CC80C9255C85D_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_0A7799E0A83B4AAB1B4CC80C9255C85D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0A7799E0A83B4AAB1B4CC80C9255C85D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0A7799E0A83B4AAB1B4CC80C9255C85D" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_0A7799E0A83B4AAB1B4CC80C9255C85D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7273CAA3908668FE849EC80C9255C150_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7273CAA3908668FE849EC80C9255C150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7273CAA3908668FE849EC80C9255C150_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7273CAA3908668FE849EC80C9255C150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7273CAA3908668FE849EC80C9255C150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7273CAA3908668FE849EC80C9255C150" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7273CAA3908668FE849EC80C9255C150" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_772439D169D11D19F24DC80C915E2864_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_772439D169D11D19F24DC80C915E2864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_772439D169D11D19F24DC80C915E2864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_772439D169D11D19F24DC80C915E2864" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_772439D169D11D19F24DC80C915E2864" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2DDA62FEC63866B45F94C80C915EBE74_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2DDA62FEC63866B45F94C80C915EBE74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2DDA62FEC63866B45F94C80C915EBE74_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2DDA62FEC63866B45F94C80C915EBE74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2DDA62FEC63866B45F94C80C915EBE74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2DDA62FEC63866B45F94C80C915EBE74" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2DDA62FEC63866B45F94C80C915EBE74" xlink:type="arc" />
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_4ACE69658385BA1C23F0C80C906ABD3A_verboseLabel_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember_4ACE69658385BA1C23F0C80C906ABD3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ComputerHardwareAndSoftwareMember" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_4ACE69658385BA1C23F0C80C906ABD3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ComputerHardwareAndSoftwareMember_4ACE69658385BA1C23F0C80C906ABD3A" xlink:to="lab_insm_ComputerHardwareAndSoftwareMember_4ACE69658385BA1C23F0C80C906ABD3A" xlink:type="arc" />
    <link:label id="lab_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6_terseLabel_en-US" xlink:label="lab_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures</link:label>
    <link:label id="lab_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6_label_en-US" xlink:label="lab_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment Furniture And Fixtures [Member]</link:label>
    <link:label id="lab_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6_documentation_en-US" xlink:label="lab_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to equipment, furniture and fixtures.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_EquipmentFurnitureAndFixturesMember" xlink:label="loc_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6" xlink:to="lab_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_10236377179A2556917DC80C906CF0D7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_10236377179A2556917DC80C906CF0D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10236377179A2556917DC80C906CF0D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10236377179A2556917DC80C906CF0D7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_10236377179A2556917DC80C906CF0D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA12F71346DF94270121C80C906CC416_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA12F71346DF94270121C80C906CC416" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful live of fixed assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA12F71346DF94270121C80C906CC416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA12F71346DF94270121C80C906CC416" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA12F71346DF94270121C80C906CC416" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B7F02BDA1C1ECAD1851AC80C91E162BC_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B7F02BDA1C1ECAD1851AC80C91E162BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B7F02BDA1C1ECAD1851AC80C91E162BC_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B7F02BDA1C1ECAD1851AC80C91E162BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B7F02BDA1C1ECAD1851AC80C91E162BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B7F02BDA1C1ECAD1851AC80C91E162BC" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B7F02BDA1C1ECAD1851AC80C91E162BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_60525AC641B42109544AC80C92281A3C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_60525AC641B42109544AC80C92281A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_60525AC641B42109544AC80C92281A3C_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_60525AC641B42109544AC80C92281A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_60525AC641B42109544AC80C92281A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_60525AC641B42109544AC80C92281A3C" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_60525AC641B42109544AC80C92281A3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_D8A3A7CDA5F8DC13B39D5752D433D153_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_D8A3A7CDA5F8DC13B39D5752D433D153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer matching contribution, percent of match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_D8A3A7CDA5F8DC13B39D5752D433D153_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_D8A3A7CDA5F8DC13B39D5752D433D153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_D8A3A7CDA5F8DC13B39D5752D433D153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_D8A3A7CDA5F8DC13B39D5752D433D153" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_D8A3A7CDA5F8DC13B39D5752D433D153" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1F904B270F9C4FA9BFEA5752D4336020_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1F904B270F9C4FA9BFEA5752D4336020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer matching contribution, percent of employees' gross pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1F904B270F9C4FA9BFEA5752D4336020_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1F904B270F9C4FA9BFEA5752D4336020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1F904B270F9C4FA9BFEA5752D4336020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1F904B270F9C4FA9BFEA5752D4336020" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1F904B270F9C4FA9BFEA5752D4336020" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_50552EFCF2CA985199115752D4332A5E_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_50552EFCF2CA985199115752D4332A5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_50552EFCF2CA985199115752D4332A5E_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_50552EFCF2CA985199115752D4332A5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_50552EFCF2CA985199115752D4332A5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_50552EFCF2CA985199115752D4332A5E" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_50552EFCF2CA985199115752D4332A5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C68E0E5BDDD4D55E38B3BAA235F73F3D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C68E0E5BDDD4D55E38B3BAA235F73F3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C68E0E5BDDD4D55E38B3BAA235F73F3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C68E0E5BDDD4D55E38B3BAA235F73F3D" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C68E0E5BDDD4D55E38B3BAA235F73F3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93" xlink:to="lab_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC" xlink:to="lab_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC" xlink:type="arc" />
    <link:label id="lab_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3_terseLabel_en-US" xlink:label="lab_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridgewater, NJ Facility</link:label>
    <link:label id="lab_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3_label_en-US" xlink:label="lab_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridgewater New Jersey Facility [Member]</link:label>
    <link:label id="lab_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3_documentation_en-US" xlink:label="lab_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent the Bridgewater location in New Jersey where the entity has leased office and laboratory space.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_BridgewaterNewJerseyFacilityMember" xlink:label="loc_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3" xlink:to="lab_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:type="arc" />
    <link:label id="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D_terseLabel_en-US" xlink:label="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum rental payments for additional laboratory space</link:label>
    <link:label id="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D_label_en-US" xlink:label="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Laboratory Space Operating Leases Future Minimum Payments Due</link:label>
    <link:label id="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D_documentation_en-US" xlink:label="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D" xlink:to="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_DC3B3ADE5A08C1BC27FBBAA235FAAEB4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_DC3B3ADE5A08C1BC27FBBAA235FAAEB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense charged to operations</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_DC3B3ADE5A08C1BC27FBBAA235FAAEB4_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_DC3B3ADE5A08C1BC27FBBAA235FAAEB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_DC3B3ADE5A08C1BC27FBBAA235FAAEB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_DC3B3ADE5A08C1BC27FBBAA235FAAEB4" xlink:to="lab_us-gaap_LeaseAndRentalExpense_DC3B3ADE5A08C1BC27FBBAA235FAAEB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligation_A716BF0AA9AC8098DEA1BAB566C3334E_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation_A716BF0AA9AC8098DEA1BAB566C3334E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum commitments due for firm purchase</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_A716BF0AA9AC8098DEA1BAB566C3334E_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation_A716BF0AA9AC8098DEA1BAB566C3334E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_A716BF0AA9AC8098DEA1BAB566C3334E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation_A716BF0AA9AC8098DEA1BAB566C3334E" xlink:to="lab_us-gaap_PurchaseObligation_A716BF0AA9AC8098DEA1BAB566C3334E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0E77313F69933601EF0DBAA235FA564F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0E77313F69933601EF0DBAA235FA564F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum rental payments under leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0E77313F69933601EF0DBAA235FA564F_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0E77313F69933601EF0DBAA235FA564F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0E77313F69933601EF0DBAA235FA564F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0E77313F69933601EF0DBAA235FA564F" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0E77313F69933601EF0DBAA235FA564F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2E40B4B39E34A68AE0C714C88A61D653_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_2E40B4B39E34A68AE0C714C88A61D653" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2E40B4B39E34A68AE0C714C88A61D653_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_2E40B4B39E34A68AE0C714C88A61D653" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2E40B4B39E34A68AE0C714C88A61D653" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_2E40B4B39E34A68AE0C714C88A61D653" xlink:to="lab_us-gaap_NumberOfOperatingSegments_2E40B4B39E34A68AE0C714C88A61D653" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_3201369409F6EC7911A414C88A62433A_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_3201369409F6EC7911A414C88A62433A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_3201369409F6EC7911A414C88A62433A_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_3201369409F6EC7911A414C88A62433A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_3201369409F6EC7911A414C88A62433A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_3201369409F6EC7911A414C88A62433A" xlink:to="lab_us-gaap_NumberOfReportableSegments_3201369409F6EC7911A414C88A62433A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_DFA176E4D1BB92C1A8C8A56D3C7476F5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_DFA176E4D1BB92C1A8C8A56D3C7476F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_DFA176E4D1BB92C1A8C8A56D3C7476F5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_DFA176E4D1BB92C1A8C8A56D3C7476F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_DFA176E4D1BB92C1A8C8A56D3C7476F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_DFA176E4D1BB92C1A8C8A56D3C7476F5" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_DFA176E4D1BB92C1A8C8A56D3C7476F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_A8B371E2B4B9252FCCB7C9E1B604554D_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_A8B371E2B4B9252FCCB7C9E1B604554D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_A8B371E2B4B9252FCCB7C9E1B604554D_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_A8B371E2B4B9252FCCB7C9E1B604554D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_A8B371E2B4B9252FCCB7C9E1B604554D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_A8B371E2B4B9252FCCB7C9E1B604554D" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_A8B371E2B4B9252FCCB7C9E1B604554D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_B47DAAC5F855665E5237C9D309E75662_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_B47DAAC5F855665E5237C9D309E75662" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets as of January 1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_B47DAAC5F855665E5237C9D309E75662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_B47DAAC5F855665E5237C9D309E75662" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_B47DAAC5F855665E5237C9D309E75662" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_71DF053D4C17C3AAC32CC9DE77B83013_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_71DF053D4C17C3AAC32CC9DE77B83013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions related to prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_71DF053D4C17C3AAC32CC9DE77B83013_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_71DF053D4C17C3AAC32CC9DE77B83013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_71DF053D4C17C3AAC32CC9DE77B83013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_71DF053D4C17C3AAC32CC9DE77B83013" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_71DF053D4C17C3AAC32CC9DE77B83013" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_AC18AE13656EEB031569C9DF1FE69C08_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_AC18AE13656EEB031569C9DF1FE69C08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions related to current period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_AC18AE13656EEB031569C9DF1FE69C08_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_AC18AE13656EEB031569C9DF1FE69C08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_AC18AE13656EEB031569C9DF1FE69C08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_AC18AE13656EEB031569C9DF1FE69C08" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_AC18AE13656EEB031569C9DF1FE69C08" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_08AAAAF64C004A474B60C9DB0EA8A00E_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_08AAAAF64C004A474B60C9DB0EA8A00E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets as of December 31</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_08AAAAF64C004A474B60C9DB0EA8A00E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_08AAAAF64C004A474B60C9DB0EA8A00E" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_08AAAAF64C004A474B60C9DB0EA8A00E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C47448B54C52059E29A1C80C927A1CB1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C47448B54C52059E29A1C80C927A1CB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments Required Under Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C47448B54C52059E29A1C80C927A1CB1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C47448B54C52059E29A1C80C927A1CB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C47448B54C52059E29A1C80C927A1CB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C47448B54C52059E29A1C80C927A1CB1" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C47448B54C52059E29A1C80C927A1CB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2F9D41C474346407C8D6807FFBA9692D_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2F9D41C474346407C8D6807FFBA9692D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory federal tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2F9D41C474346407C8D6807FFBA9692D_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2F9D41C474346407C8D6807FFBA9692D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2F9D41C474346407C8D6807FFBA9692D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2F9D41C474346407C8D6807FFBA9692D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2F9D41C474346407C8D6807FFBA9692D" xlink:type="arc" />
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_B67CB241108E6D9D2C77807FFBAA8831_terseLabel_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_B67CB241108E6D9D2C77807FFBAA8831" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_B67CB241108E6D9D2C77807FFBAA8831_label_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_B67CB241108E6D9D2C77807FFBAA8831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_B67CB241108E6D9D2C77807FFBAA8831_documentation_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_B67CB241108E6D9D2C77807FFBAA8831" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to permanent items.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_B67CB241108E6D9D2C77807FFBAA8831" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_B67CB241108E6D9D2C77807FFBAA8831" xlink:to="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_B67CB241108E6D9D2C77807FFBAA8831" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4064DE8C98B31E547671807FFBAA0BE2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4064DE8C98B31E547671807FFBAA0BE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4064DE8C98B31E547671807FFBAA0BE2_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4064DE8C98B31E547671807FFBAA0BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4064DE8C98B31E547671807FFBAA0BE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4064DE8C98B31E547671807FFBAA0BE2" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4064DE8C98B31E547671807FFBAA0BE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_FEF0F6A6541B6DE535FB807FFBAAA581_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_FEF0F6A6541B6DE535FB807FFBAAA581" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D and other tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_FEF0F6A6541B6DE535FB807FFBAAA581_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_FEF0F6A6541B6DE535FB807FFBAAA581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_FEF0F6A6541B6DE535FB807FFBAAA581" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_FEF0F6A6541B6DE535FB807FFBAAA581" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_FEF0F6A6541B6DE535FB807FFBAAA581" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_07D9D05F68F2C2896A90807FFBAA5616_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_07D9D05F68F2C2896A90807FFBAA5616" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_07D9D05F68F2C2896A90807FFBAA5616_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_07D9D05F68F2C2896A90807FFBAA5616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_07D9D05F68F2C2896A90807FFBAA5616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_07D9D05F68F2C2896A90807FFBAA5616" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_07D9D05F68F2C2896A90807FFBAA5616" xlink:type="arc" />
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_66D7CC7600AC8133389E807FFBAA231F_terseLabel_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_66D7CC7600AC8133389E807FFBAA231F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of Tax Act</link:label>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_66D7CC7600AC8133389E807FFBAA231F_label_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_66D7CC7600AC8133389E807FFBAA231F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Percent</link:label>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_66D7CC7600AC8133389E807FFBAA231F_documentation_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_66D7CC7600AC8133389E807FFBAA231F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Percent</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_66D7CC7600AC8133389E807FFBAA231F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_66D7CC7600AC8133389E807FFBAA231F" xlink:to="lab_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_66D7CC7600AC8133389E807FFBAA231F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2264BE4C5CFFDE361694807FFBAAA57E_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2264BE4C5CFFDE361694807FFBAAA57E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2264BE4C5CFFDE361694807FFBAAA57E_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2264BE4C5CFFDE361694807FFBAAA57E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2264BE4C5CFFDE361694807FFBAAA57E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2264BE4C5CFFDE361694807FFBAAA57E" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2264BE4C5CFFDE361694807FFBAAA57E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_221DA52B740ED0D5068A807FFBAB1447_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_221DA52B740ED0D5068A807FFBAB1447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_221DA52B740ED0D5068A807FFBAB1447_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_221DA52B740ED0D5068A807FFBAB1447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_221DA52B740ED0D5068A807FFBAB1447" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_221DA52B740ED0D5068A807FFBAB1447" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_221DA52B740ED0D5068A807FFBAB1447" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_A4239D4982B28AC78CCF807FFBAB985A_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_A4239D4982B28AC78CCF807FFBAB985A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_A4239D4982B28AC78CCF807FFBAB985A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_A4239D4982B28AC78CCF807FFBAB985A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_A4239D4982B28AC78CCF807FFBAB985A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_C8DBB076C9C35CB1AA05C80C91DBCE07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_C8DBB076C9C35CB1AA05C80C91DBCE07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Debt Balance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_C8DBB076C9C35CB1AA05C80C91DBCE07_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_C8DBB076C9C35CB1AA05C80C91DBCE07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_C8DBB076C9C35CB1AA05C80C91DBCE07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_C8DBB076C9C35CB1AA05C80C91DBCE07" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_C8DBB076C9C35CB1AA05C80C91DBCE07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_84C2A67F66BC39D22AAEC80C91DC4ADB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_84C2A67F66BC39D22AAEC80C91DC4ADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Principal Repayments of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_84C2A67F66BC39D22AAEC80C91DC4ADB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_84C2A67F66BC39D22AAEC80C91DC4ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_84C2A67F66BC39D22AAEC80C91DC4ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_84C2A67F66BC39D22AAEC80C91DC4ADB" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_84C2A67F66BC39D22AAEC80C91DC4ADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_56034A0BD38284C70B1CC80C91D692D9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_56034A0BD38284C70B1CC80C91D692D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_56034A0BD38284C70B1CC80C91D692D9_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_56034A0BD38284C70B1CC80C91D692D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_56034A0BD38284C70B1CC80C91D692D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_56034A0BD38284C70B1CC80C91D692D9" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_56034A0BD38284C70B1CC80C91D692D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_D44C624171062BE52CE4C80C91D603FC_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_D44C624171062BE52CE4C80C91D603FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_D44C624171062BE52CE4C80C91D603FC_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_D44C624171062BE52CE4C80C91D603FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_D44C624171062BE52CE4C80C91D603FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_D44C624171062BE52CE4C80C91D603FC" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_D44C624171062BE52CE4C80C91D603FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7CB348C1E137795A9499C80C91D61186_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_7CB348C1E137795A9499C80C91D61186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7CB348C1E137795A9499C80C91D61186_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_7CB348C1E137795A9499C80C91D61186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7CB348C1E137795A9499C80C91D61186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_7CB348C1E137795A9499C80C91D61186" xlink:to="lab_us-gaap_CommonStockSharesIssued_7CB348C1E137795A9499C80C91D61186" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8FE0593F7608891FDCCAC80C91D64EF7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_8FE0593F7608891FDCCAC80C91D64EF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8FE0593F7608891FDCCAC80C91D64EF7_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_8FE0593F7608891FDCCAC80C91D64EF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8FE0593F7608891FDCCAC80C91D64EF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_8FE0593F7608891FDCCAC80C91D64EF7" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_8FE0593F7608891FDCCAC80C91D64EF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_A82BC48EEC53118B3AC152BD402E84BC_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_A82BC48EEC53118B3AC152BD402E84BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_A82BC48EEC53118B3AC152BD402E84BC_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_A82BC48EEC53118B3AC152BD402E84BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_A82BC48EEC53118B3AC152BD402E84BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_A82BC48EEC53118B3AC152BD402E84BC" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_A82BC48EEC53118B3AC152BD402E84BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FD26DD458C88FABFC75F52BD402E52AD_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FD26DD458C88FABFC75F52BD402E52AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FD26DD458C88FABFC75F52BD402E52AD_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FD26DD458C88FABFC75F52BD402E52AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FD26DD458C88FABFC75F52BD402E52AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FD26DD458C88FABFC75F52BD402E52AD" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FD26DD458C88FABFC75F52BD402E52AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_63809881AD437F2BF03D52BD402E4106_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_63809881AD437F2BF03D52BD402E4106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_63809881AD437F2BF03D52BD402E4106_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_63809881AD437F2BF03D52BD402E4106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_63809881AD437F2BF03D52BD402E4106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_63809881AD437F2BF03D52BD402E4106" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_63809881AD437F2BF03D52BD402E4106" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5565DBE55BDBF0B734F52BD402FD307_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5565DBE55BDBF0B734F52BD402FD307" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5565DBE55BDBF0B734F52BD402FD307_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5565DBE55BDBF0B734F52BD402FD307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5565DBE55BDBF0B734F52BD402FD307" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5565DBE55BDBF0B734F52BD402FD307" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5565DBE55BDBF0B734F52BD402FD307" xlink:type="arc" />
    <link:label id="lab_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_5D139AF894728F9BB77952CA8EB1E4BE_terseLabel_en-US" xlink:label="lab_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_5D139AF894728F9BB77952CA8EB1E4BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 and thereafter</link:label>
    <link:label id="lab_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_5D139AF894728F9BB77952CA8EB1E4BE_label_en-US" xlink:label="lab_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_5D139AF894728F9BB77952CA8EB1E4BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturities, Repayments Of Principal In Year Five And Thereafter</link:label>
    <link:label id="lab_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_5D139AF894728F9BB77952CA8EB1E4BE_documentation_en-US" xlink:label="lab_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_5D139AF894728F9BB77952CA8EB1E4BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturities, Repayments Of Principal In Year Five And Thereafter</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="loc_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_5D139AF894728F9BB77952CA8EB1E4BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_5D139AF894728F9BB77952CA8EB1E4BE" xlink:to="lab_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_5D139AF894728F9BB77952CA8EB1E4BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_88361A35ABA9A288CC0A52BD402F3CD5_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_88361A35ABA9A288CC0A52BD402F3CD5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_88361A35ABA9A288CC0A52BD402F3CD5_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_88361A35ABA9A288CC0A52BD402F3CD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_88361A35ABA9A288CC0A52BD402F3CD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_88361A35ABA9A288CC0A52BD402F3CD5" xlink:to="lab_us-gaap_LongTermDebt_88361A35ABA9A288CC0A52BD402F3CD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_27064A71DB575E907A9A01482CABAF1E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_27064A71DB575E907A9A01482CABAF1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_27064A71DB575E907A9A01482CABAF1E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_27064A71DB575E907A9A01482CABAF1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_27064A71DB575E907A9A01482CABAF1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_27064A71DB575E907A9A01482CABAF1E" xlink:to="lab_us-gaap_ConcentrationRiskTable_27064A71DB575E907A9A01482CABAF1E" xlink:type="arc" />
    <link:label id="lab_insm_CustomerAMember_E25144357E3D5A5513C101482CAC79C4_terseLabel_en-US" xlink:label="lab_insm_CustomerAMember_E25144357E3D5A5513C101482CAC79C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_insm_CustomerAMember_E25144357E3D5A5513C101482CAC79C4_label_en-US" xlink:label="lab_insm_CustomerAMember_E25144357E3D5A5513C101482CAC79C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_insm_CustomerAMember_E25144357E3D5A5513C101482CAC79C4_documentation_en-US" xlink:label="lab_insm_CustomerAMember_E25144357E3D5A5513C101482CAC79C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CustomerAMember" xlink:label="loc_insm_CustomerAMember_E25144357E3D5A5513C101482CAC79C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerAMember_E25144357E3D5A5513C101482CAC79C4" xlink:to="lab_insm_CustomerAMember_E25144357E3D5A5513C101482CAC79C4" xlink:type="arc" />
    <link:label id="lab_insm_CustomerBMember_0B8D743FE30F24C6BCE301482CAC57E0_terseLabel_en-US" xlink:label="lab_insm_CustomerBMember_0B8D743FE30F24C6BCE301482CAC57E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_insm_CustomerBMember_0B8D743FE30F24C6BCE301482CAC57E0_label_en-US" xlink:label="lab_insm_CustomerBMember_0B8D743FE30F24C6BCE301482CAC57E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_insm_CustomerBMember_0B8D743FE30F24C6BCE301482CAC57E0_documentation_en-US" xlink:label="lab_insm_CustomerBMember_0B8D743FE30F24C6BCE301482CAC57E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CustomerBMember" xlink:label="loc_insm_CustomerBMember_0B8D743FE30F24C6BCE301482CAC57E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerBMember_0B8D743FE30F24C6BCE301482CAC57E0" xlink:to="lab_insm_CustomerBMember_0B8D743FE30F24C6BCE301482CAC57E0" xlink:type="arc" />
    <link:label id="lab_insm_CustomerCMember_1BCF617240E74973C32701482CAD8469_terseLabel_en-US" xlink:label="lab_insm_CustomerCMember_1BCF617240E74973C32701482CAD8469" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_insm_CustomerCMember_1BCF617240E74973C32701482CAD8469_label_en-US" xlink:label="lab_insm_CustomerCMember_1BCF617240E74973C32701482CAD8469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_insm_CustomerCMember_1BCF617240E74973C32701482CAD8469_documentation_en-US" xlink:label="lab_insm_CustomerCMember_1BCF617240E74973C32701482CAD8469" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CustomerCMember" xlink:label="loc_insm_CustomerCMember_1BCF617240E74973C32701482CAD8469" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerCMember_1BCF617240E74973C32701482CAD8469" xlink:to="lab_insm_CustomerCMember_1BCF617240E74973C32701482CAD8469" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_60FDA62B50D0C929B8FB01482CAD1B2E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_60FDA62B50D0C929B8FB01482CAD1B2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_60FDA62B50D0C929B8FB01482CAD1B2E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_60FDA62B50D0C929B8FB01482CAD1B2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60FDA62B50D0C929B8FB01482CAD1B2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60FDA62B50D0C929B8FB01482CAD1B2E" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_60FDA62B50D0C929B8FB01482CAD1B2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_1E049EC3A75A355EDE0901482CAD4DE5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_1E049EC3A75A355EDE0901482CAD4DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_1E049EC3A75A355EDE0901482CAD4DE5_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_1E049EC3A75A355EDE0901482CAD4DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1E049EC3A75A355EDE0901482CAD4DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1E049EC3A75A355EDE0901482CAD4DE5" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_1E049EC3A75A355EDE0901482CAD4DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_632E34A1F4A40BABBEA201482CADACFE_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember_632E34A1F4A40BABBEA201482CADACFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_632E34A1F4A40BABBEA201482CADACFE_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember_632E34A1F4A40BABBEA201482CADACFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_632E34A1F4A40BABBEA201482CADACFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember_632E34A1F4A40BABBEA201482CADACFE" xlink:to="lab_us-gaap_SalesRevenueProductLineMember_632E34A1F4A40BABBEA201482CADACFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_4563FAE63ADCFCC46A5201482CAE176E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_4563FAE63ADCFCC46A5201482CAE176E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_4563FAE63ADCFCC46A5201482CAE176E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_4563FAE63ADCFCC46A5201482CAE176E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4563FAE63ADCFCC46A5201482CAE176E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4563FAE63ADCFCC46A5201482CAE176E" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_4563FAE63ADCFCC46A5201482CAE176E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_D2A00228D3F65D247D7401482CAEA84E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_D2A00228D3F65D247D7401482CAEA84E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_D2A00228D3F65D247D7401482CAEA84E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_D2A00228D3F65D247D7401482CAEA84E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D2A00228D3F65D247D7401482CAEA84E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D2A00228D3F65D247D7401482CAEA84E" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_D2A00228D3F65D247D7401482CAEA84E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_C14D2A2BED77C3C743B701482CAE6123_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_C14D2A2BED77C3C743B701482CAE6123" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_C14D2A2BED77C3C743B701482CAE6123_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_C14D2A2BED77C3C743B701482CAE6123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_C14D2A2BED77C3C743B701482CAE6123" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_C14D2A2BED77C3C743B701482CAE6123" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_C14D2A2BED77C3C743B701482CAE6123" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_DFBE3B2A35CA937DAF8001482CAFF9A1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_DFBE3B2A35CA937DAF8001482CAFF9A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_DFBE3B2A35CA937DAF8001482CAFF9A1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_DFBE3B2A35CA937DAF8001482CAFF9A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_DFBE3B2A35CA937DAF8001482CAFF9A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_DFBE3B2A35CA937DAF8001482CAFF9A1" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_DFBE3B2A35CA937DAF8001482CAFF9A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_55085B87629AF28D09C201482CAF3DEF_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_55085B87629AF28D09C201482CAF3DEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_55085B87629AF28D09C201482CAF3DEF_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_55085B87629AF28D09C201482CAF3DEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_55085B87629AF28D09C201482CAF3DEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_55085B87629AF28D09C201482CAF3DEF" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_55085B87629AF28D09C201482CAF3DEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158FC8B42156092AB9B1C80C90944B4F_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158FC8B42156092AB9B1C80C90944B4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158FC8B42156092AB9B1C80C90944B4F_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158FC8B42156092AB9B1C80C90944B4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158FC8B42156092AB9B1C80C90944B4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158FC8B42156092AB9B1C80C90944B4F" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158FC8B42156092AB9B1C80C90944B4F" xlink:type="arc" />
    <link:label id="lab_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E_terseLabel_en-US" xlink:label="lab_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E_label_en-US" xlink:label="lab_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E_documentation_en-US" xlink:label="lab_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_SummaryOfSignificantPoliciesTable" xlink:label="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:to="lab_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C" xlink:to="lab_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_3A5EE3C3B2435403E4EE0DE740E64AE0_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_3A5EE3C3B2435403E4EE0DE740E64AE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_3A5EE3C3B2435403E4EE0DE740E64AE0_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_3A5EE3C3B2435403E4EE0DE740E64AE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_3A5EE3C3B2435403E4EE0DE740E64AE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_3A5EE3C3B2435403E4EE0DE740E64AE0" xlink:to="lab_us-gaap_ScenarioForecastMember_3A5EE3C3B2435403E4EE0DE740E64AE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D" xlink:to="lab_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_233DF23FC48E151FFB1D0DE740EDCC2B_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_233DF23FC48E151FFB1D0DE740EDCC2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_233DF23FC48E151FFB1D0DE740EDCC2B_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_233DF23FC48E151FFB1D0DE740EDCC2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_233DF23FC48E151FFB1D0DE740EDCC2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_233DF23FC48E151FFB1D0DE740EDCC2B" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_233DF23FC48E151FFB1D0DE740EDCC2B" xlink:type="arc" />
    <link:label id="lab_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010_terseLabel_en-US" xlink:label="lab_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010_label_en-US" xlink:label="lab_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010_documentation_en-US" xlink:label="lab_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_SummaryOfSignificantPoliciesLineItems" xlink:label="loc_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:to="lab_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_F6884D4CEE189073D5A50DE740EFEF08_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_F6884D4CEE189073D5A50DE740EFEF08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_F6884D4CEE189073D5A50DE740EFEF08_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_F6884D4CEE189073D5A50DE740EFEF08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_F6884D4CEE189073D5A50DE740EFEF08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_F6884D4CEE189073D5A50DE740EFEF08" xlink:to="lab_us-gaap_OperatingLeaseLiability_F6884D4CEE189073D5A50DE740EFEF08" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_71A0810C3CB77F3F559A0DE740EFE182_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_71A0810C3CB77F3F559A0DE740EFE182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_71A0810C3CB77F3F559A0DE740EFE182_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_71A0810C3CB77F3F559A0DE740EFE182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_71A0810C3CB77F3F559A0DE740EFE182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_71A0810C3CB77F3F559A0DE740EFE182" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_71A0810C3CB77F3F559A0DE740EFE182" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:to="lab_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebt_2CDE5A6BB150DF9309555752D4FB708C_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt_2CDE5A6BB150DF9309555752D4FB708C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.75% convertible senior notes due 2025</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_2CDE5A6BB150DF9309555752D4FB708C_label_en-US" xlink:label="lab_us-gaap_SecuredDebt_2CDE5A6BB150DF9309555752D4FB708C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_2CDE5A6BB150DF9309555752D4FB708C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebt_2CDE5A6BB150DF9309555752D4FB708C" xlink:to="lab_us-gaap_SecuredDebt_2CDE5A6BB150DF9309555752D4FB708C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_21674C05B821831D380D5752D4FC47D9_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_21674C05B821831D380D5752D4FC47D9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, unamortized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_21674C05B821831D380D5752D4FC47D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_21674C05B821831D380D5752D4FC47D9" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_21674C05B821831D380D5752D4FC47D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_9ED95C30CC5CB642D6FA5752D4FCA444_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_9ED95C30CC5CB642D6FA5752D4FCA444" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Discount on debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9ED95C30CC5CB642D6FA5752D4FCA444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9ED95C30CC5CB642D6FA5752D4FCA444" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_9ED95C30CC5CB642D6FA5752D4FCA444" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_372A143DA394CCC803E25752D4FCCF10_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_372A143DA394CCC803E25752D4FCCF10" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_372A143DA394CCC803E25752D4FCCF10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_372A143DA394CCC803E25752D4FCCF10" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_372A143DA394CCC803E25752D4FCCF10" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C3C814E30028C84E5678C80C927C12F7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C3C814E30028C84E5678C80C927C12F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C3C814E30028C84E5678C80C927C12F7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C3C814E30028C84E5678C80C927C12F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C3C814E30028C84E5678C80C927C12F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C3C814E30028C84E5678C80C927C12F7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C3C814E30028C84E5678C80C927C12F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E91AAED35E99C0E720AA0751EA5D4DC9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E91AAED35E99C0E720AA0751EA5D4DC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E91AAED35E99C0E720AA0751EA5D4DC9_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E91AAED35E99C0E720AA0751EA5D4DC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E91AAED35E99C0E720AA0751EA5D4DC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E91AAED35E99C0E720AA0751EA5D4DC9" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E91AAED35E99C0E720AA0751EA5D4DC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_AB8E8017EF4FE9E1B63B0751EA5EE0FF_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_AB8E8017EF4FE9E1B63B0751EA5EE0FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_AB8E8017EF4FE9E1B63B0751EA5EE0FF_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_AB8E8017EF4FE9E1B63B0751EA5EE0FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_AB8E8017EF4FE9E1B63B0751EA5EE0FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_AB8E8017EF4FE9E1B63B0751EA5EE0FF" xlink:to="lab_us-gaap_UseOfEstimates_AB8E8017EF4FE9E1B63B0751EA5EE0FF" xlink:type="arc" />
    <link:label id="lab_insm_InvestmentIncomeExpensePolicyTextBlock_3E8705E54C848D5045550751EA5ECF7C_terseLabel_en-US" xlink:label="lab_insm_InvestmentIncomeExpensePolicyTextBlock_3E8705E54C848D5045550751EA5ECF7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Income and Interest Expense</link:label>
    <link:label id="lab_insm_InvestmentIncomeExpensePolicyTextBlock_3E8705E54C848D5045550751EA5ECF7C_label_en-US" xlink:label="lab_insm_InvestmentIncomeExpensePolicyTextBlock_3E8705E54C848D5045550751EA5ECF7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income (Expense) [Policy Text Block]</link:label>
    <link:label id="lab_insm_InvestmentIncomeExpensePolicyTextBlock_3E8705E54C848D5045550751EA5ECF7C_documentation_en-US" xlink:label="lab_insm_InvestmentIncomeExpensePolicyTextBlock_3E8705E54C848D5045550751EA5ECF7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for components of investment income and interest expense.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_InvestmentIncomeExpensePolicyTextBlock" xlink:label="loc_insm_InvestmentIncomeExpensePolicyTextBlock_3E8705E54C848D5045550751EA5ECF7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_InvestmentIncomeExpensePolicyTextBlock_3E8705E54C848D5045550751EA5ECF7C" xlink:to="lab_insm_InvestmentIncomeExpensePolicyTextBlock_3E8705E54C848D5045550751EA5ECF7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5FB1C90CC0F878CEE09A0751EA5E45D6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5FB1C90CC0F878CEE09A0751EA5E45D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5FB1C90CC0F878CEE09A0751EA5E45D6_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5FB1C90CC0F878CEE09A0751EA5E45D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5FB1C90CC0F878CEE09A0751EA5E45D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5FB1C90CC0F878CEE09A0751EA5E45D6" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5FB1C90CC0F878CEE09A0751EA5E45D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_207DED513CF983AC320C0751EA5E5996_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_207DED513CF983AC320C0751EA5E5996" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_207DED513CF983AC320C0751EA5E5996_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_207DED513CF983AC320C0751EA5E5996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_207DED513CF983AC320C0751EA5E5996" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_207DED513CF983AC320C0751EA5E5996" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_207DED513CF983AC320C0751EA5E5996" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_54681352B3AF754F56780751EA5ED835_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_54681352B3AF754F56780751EA5ED835" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identifiable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_54681352B3AF754F56780751EA5ED835_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_54681352B3AF754F56780751EA5ED835" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_54681352B3AF754F56780751EA5ED835" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_54681352B3AF754F56780751EA5ED835" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_54681352B3AF754F56780751EA5ED835" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_1094FB4701FDD9803F930751EA5F8B0E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock_1094FB4701FDD9803F930751EA5F8B0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_1094FB4701FDD9803F930751EA5F8B0E_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock_1094FB4701FDD9803F930751EA5F8B0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_1094FB4701FDD9803F930751EA5F8B0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_1094FB4701FDD9803F930751EA5F8B0E" xlink:to="lab_us-gaap_DebtPolicyTextBlock_1094FB4701FDD9803F930751EA5F8B0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BBFD35965AB04C166C70751EA5F5CA6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BBFD35965AB04C166C70751EA5F5CA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BBFD35965AB04C166C70751EA5F5CA6_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BBFD35965AB04C166C70751EA5F5CA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BBFD35965AB04C166C70751EA5F5CA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BBFD35965AB04C166C70751EA5F5CA6" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BBFD35965AB04C166C70751EA5F5CA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1014184C6C3E32DD39AD0751EA5F3BCF_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1014184C6C3E32DD39AD0751EA5F3BCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1014184C6C3E32DD39AD0751EA5F3BCF_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1014184C6C3E32DD39AD0751EA5F3BCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1014184C6C3E32DD39AD0751EA5F3BCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1014184C6C3E32DD39AD0751EA5F3BCF" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1014184C6C3E32DD39AD0751EA5F3BCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_76ED54AA37CF6002A48E0751EA5FFD02_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_76ED54AA37CF6002A48E0751EA5FFD02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_76ED54AA37CF6002A48E0751EA5FFD02_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_76ED54AA37CF6002A48E0751EA5FFD02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_76ED54AA37CF6002A48E0751EA5FFD02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_76ED54AA37CF6002A48E0751EA5FFD02" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_76ED54AA37CF6002A48E0751EA5FFD02" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_85D61A7347B85E7534380751EA60A1BB_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_85D61A7347B85E7534380751EA60A1BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_85D61A7347B85E7534380751EA60A1BB_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_85D61A7347B85E7534380751EA60A1BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_85D61A7347B85E7534380751EA60A1BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_85D61A7347B85E7534380751EA60A1BB" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_85D61A7347B85E7534380751EA60A1BB" xlink:type="arc" />
    <link:label id="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_A59C6F07ADE4EE498CB50751EA603A6A_terseLabel_en-US" xlink:label="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_A59C6F07ADE4EE498CB50751EA603A6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory and cost of product revenues (excluding amortization of intangible assets)</link:label>
    <link:label id="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_A59C6F07ADE4EE498CB50751EA603A6A_label_en-US" xlink:label="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_A59C6F07ADE4EE498CB50751EA603A6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]</link:label>
    <link:label id="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_A59C6F07ADE4EE498CB50751EA603A6A_documentation_en-US" xlink:label="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_A59C6F07ADE4EE498CB50751EA603A6A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" xlink:label="loc_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_A59C6F07ADE4EE498CB50751EA603A6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_A59C6F07ADE4EE498CB50751EA603A6A" xlink:to="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_A59C6F07ADE4EE498CB50751EA603A6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_EADC04810E349BF4848C0751EA6073B1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_EADC04810E349BF4848C0751EA6073B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_EADC04810E349BF4848C0751EA6073B1_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_EADC04810E349BF4848C0751EA6073B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_EADC04810E349BF4848C0751EA6073B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_EADC04810E349BF4848C0751EA6073B1" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_EADC04810E349BF4848C0751EA6073B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8902914B7775EDD5C3F30751EA607981_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8902914B7775EDD5C3F30751EA607981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8902914B7775EDD5C3F30751EA607981_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8902914B7775EDD5C3F30751EA607981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8902914B7775EDD5C3F30751EA607981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8902914B7775EDD5C3F30751EA607981" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8902914B7775EDD5C3F30751EA607981" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_BC3BBAEF6D4B4A8BD2710751EA6049A6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_BC3BBAEF6D4B4A8BD2710751EA6049A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_BC3BBAEF6D4B4A8BD2710751EA6049A6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_BC3BBAEF6D4B4A8BD2710751EA6049A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_BC3BBAEF6D4B4A8BD2710751EA6049A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_BC3BBAEF6D4B4A8BD2710751EA6049A6" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_BC3BBAEF6D4B4A8BD2710751EA6049A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_FAF539D5C8856E1DAAC10751EA614160_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_FAF539D5C8856E1DAAC10751EA614160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_FAF539D5C8856E1DAAC10751EA614160_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_FAF539D5C8856E1DAAC10751EA614160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_FAF539D5C8856E1DAAC10751EA614160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_FAF539D5C8856E1DAAC10751EA614160" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_FAF539D5C8856E1DAAC10751EA614160" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_A415E7BC45DCAF335BF10751EA612391_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_A415E7BC45DCAF335BF10751EA612391" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_A415E7BC45DCAF335BF10751EA612391_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_A415E7BC45DCAF335BF10751EA612391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_A415E7BC45DCAF335BF10751EA612391" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_A415E7BC45DCAF335BF10751EA612391" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_A415E7BC45DCAF335BF10751EA612391" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5629DD7FE9D949995FC80751EA610051_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5629DD7FE9D949995FC80751EA610051" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5629DD7FE9D949995FC80751EA610051_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5629DD7FE9D949995FC80751EA610051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5629DD7FE9D949995FC80751EA610051" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5629DD7FE9D949995FC80751EA610051" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5629DD7FE9D949995FC80751EA610051" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D5979F8E630CA50B8F81A60239209544_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D5979F8E630CA50B8F81A60239209544" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">New drug milestone payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_D5979F8E630CA50B8F81A60239209544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_D5979F8E630CA50B8F81A60239209544" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D5979F8E630CA50B8F81A60239209544" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_72FC26C1AD090E546751A606A7192BD4_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_72FC26C1AD090E546751A606A7192BD4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72FC26C1AD090E546751A606A7192BD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72FC26C1AD090E546751A606A7192BD4" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_72FC26C1AD090E546751A606A7192BD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_FBAA5098BBB44B24ED78A60239209F08_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_FBAA5098BBB44B24ED78A60239209F08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_FBAA5098BBB44B24ED78A60239209F08_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_FBAA5098BBB44B24ED78A60239209F08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_FBAA5098BBB44B24ED78A60239209F08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_FBAA5098BBB44B24ED78A60239209F08" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_FBAA5098BBB44B24ED78A60239209F08" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D80F964AFB4FCDD365C0A6023920B446_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D80F964AFB4FCDD365C0A6023920B446" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, 2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D80F964AFB4FCDD365C0A6023920B446_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D80F964AFB4FCDD365C0A6023920B446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D80F964AFB4FCDD365C0A6023920B446" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D80F964AFB4FCDD365C0A6023920B446" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D80F964AFB4FCDD365C0A6023920B446" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25F50A02B19134590442A60239205A90_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25F50A02B19134590442A60239205A90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25F50A02B19134590442A60239205A90_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25F50A02B19134590442A60239205A90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25F50A02B19134590442A60239205A90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25F50A02B19134590442A60239205A90" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25F50A02B19134590442A60239205A90" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_124AA088C7E7B215BEFFA602392655E9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_124AA088C7E7B215BEFFA602392655E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_124AA088C7E7B215BEFFA602392655E9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_124AA088C7E7B215BEFFA602392655E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_124AA088C7E7B215BEFFA602392655E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_124AA088C7E7B215BEFFA602392655E9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_124AA088C7E7B215BEFFA602392655E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_066A748513C177AADF4AA60239263F96_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_066A748513C177AADF4AA60239263F96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_066A748513C177AADF4AA60239263F96_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_066A748513C177AADF4AA60239263F96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_066A748513C177AADF4AA60239263F96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_066A748513C177AADF4AA60239263F96" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_066A748513C177AADF4AA60239263F96" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_06F66B4EEF7C75B52D1AA60239267B32_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_06F66B4EEF7C75B52D1AA60239267B32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_06F66B4EEF7C75B52D1AA60239267B32_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_06F66B4EEF7C75B52D1AA60239267B32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_06F66B4EEF7C75B52D1AA60239267B32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_06F66B4EEF7C75B52D1AA60239267B32" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_06F66B4EEF7C75B52D1AA60239267B32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_68E405F80C4835C8B654A60239273A83_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_68E405F80C4835C8B654A60239273A83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_68E405F80C4835C8B654A60239273A83_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_68E405F80C4835C8B654A60239273A83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_68E405F80C4835C8B654A60239273A83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_68E405F80C4835C8B654A60239273A83" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_68E405F80C4835C8B654A60239273A83" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensingAgreementsMember_F949594D428D4C158DE9A6023927A01B_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_F949594D428D4C158DE9A6023927A01B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_F949594D428D4C158DE9A6023927A01B_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_F949594D428D4C158DE9A6023927A01B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_F949594D428D4C158DE9A6023927A01B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember_F949594D428D4C158DE9A6023927A01B" xlink:to="lab_us-gaap_LicensingAgreementsMember_F949594D428D4C158DE9A6023927A01B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_39C7FC2A76D867A90629A602392865D5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_39C7FC2A76D867A90629A602392865D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_39C7FC2A76D867A90629A602392865D5_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_39C7FC2A76D867A90629A602392865D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_39C7FC2A76D867A90629A602392865D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_39C7FC2A76D867A90629A602392865D5" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_39C7FC2A76D867A90629A602392865D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_76FB13C030901290F05EA6023928F335_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_76FB13C030901290F05EA6023928F335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_76FB13C030901290F05EA6023928F335_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_76FB13C030901290F05EA6023928F335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_76FB13C030901290F05EA6023928F335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_76FB13C030901290F05EA6023928F335" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_76FB13C030901290F05EA6023928F335" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_F96120BC1E736882B457A60239291D93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_F96120BC1E736882B457A60239291D93" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_F96120BC1E736882B457A60239291D93_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_F96120BC1E736882B457A60239291D93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_F96120BC1E736882B457A60239291D93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_F96120BC1E736882B457A60239291D93" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_F96120BC1E736882B457A60239291D93" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_A33C85872955814F9A73A56D3C898E5F_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_A33C85872955814F9A73A56D3C898E5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_A33C85872955814F9A73A56D3C898E5F_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_A33C85872955814F9A73A56D3C898E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_A33C85872955814F9A73A56D3C898E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_A33C85872955814F9A73A56D3C898E5F" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_A33C85872955814F9A73A56D3C898E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_C306E0269CD90819C55FA56D3C89E369_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_C306E0269CD90819C55FA56D3C89E369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_C306E0269CD90819C55FA56D3C89E369_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_C306E0269CD90819C55FA56D3C89E369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_C306E0269CD90819C55FA56D3C89E369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_C306E0269CD90819C55FA56D3C89E369" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_C306E0269CD90819C55FA56D3C89E369" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2F49C4254E8B51B3A30AA56D3C899B49_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2F49C4254E8B51B3A30AA56D3C899B49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2F49C4254E8B51B3A30AA56D3C899B49_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2F49C4254E8B51B3A30AA56D3C899B49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2F49C4254E8B51B3A30AA56D3C899B49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2F49C4254E8B51B3A30AA56D3C899B49" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2F49C4254E8B51B3A30AA56D3C899B49" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_76EBAE2AC2FC3F771E0EA56D3C89F153_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_76EBAE2AC2FC3F771E0EA56D3C89F153" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_76EBAE2AC2FC3F771E0EA56D3C89F153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_76EBAE2AC2FC3F771E0EA56D3C89F153" xlink:to="lab_us-gaap_InventoryNet_76EBAE2AC2FC3F771E0EA56D3C89F153" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_82D2A7554BECFC60BF37527256F3289F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_82D2A7554BECFC60BF37527256F3289F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_82D2A7554BECFC60BF37527256F3289F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_82D2A7554BECFC60BF37527256F3289F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_82D2A7554BECFC60BF37527256F3289F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_82D2A7554BECFC60BF37527256F3289F" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_82D2A7554BECFC60BF37527256F3289F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_89FE62B22CE288A1BA3519E1DE785EE7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_89FE62B22CE288A1BA3519E1DE785EE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock, maximum authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_89FE62B22CE288A1BA3519E1DE785EE7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_89FE62B22CE288A1BA3519E1DE785EE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_89FE62B22CE288A1BA3519E1DE785EE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_89FE62B22CE288A1BA3519E1DE785EE7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_89FE62B22CE288A1BA3519E1DE785EE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FA7F24C331027D70CABE19E1DE787DD9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FA7F24C331027D70CABE19E1DE787DD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FA7F24C331027D70CABE19E1DE787DD9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FA7F24C331027D70CABE19E1DE787DD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FA7F24C331027D70CABE19E1DE787DD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FA7F24C331027D70CABE19E1DE787DD9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FA7F24C331027D70CABE19E1DE787DD9" xlink:type="arc" />
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_5CA02F84DABBDFDFADAE19E1DE78BEA6_terseLabel_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_5CA02F84DABBDFDFADAE19E1DE78BEA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement stock option granted to new employees (in shares)</link:label>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_5CA02F84DABBDFDFADAE19E1DE78BEA6_label_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_5CA02F84DABBDFDFADAE19E1DE78BEA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross</link:label>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_5CA02F84DABBDFDFADAE19E1DE78BEA6_documentation_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_5CA02F84DABBDFDFADAE19E1DE78BEA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross number of inducement share options (or share units) granted during the period.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_5CA02F84DABBDFDFADAE19E1DE78BEA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_5CA02F84DABBDFDFADAE19E1DE78BEA6" xlink:to="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_5CA02F84DABBDFDFADAE19E1DE78BEA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9E673F6C48C3F596AF2BC80C91D93D1C_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9E673F6C48C3F596AF2BC80C91D93D1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9E673F6C48C3F596AF2BC80C91D93D1C_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9E673F6C48C3F596AF2BC80C91D93D1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9E673F6C48C3F596AF2BC80C91D93D1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9E673F6C48C3F596AF2BC80C91D93D1C" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9E673F6C48C3F596AF2BC80C91D93D1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:type="arc" />
    <link:label id="lab_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0_terseLabel_en-US" xlink:label="lab_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$3.03 to $4.55</link:label>
    <link:label id="lab_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0_label_en-US" xlink:label="lab_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range1 [Member]</link:label>
    <link:label id="lab_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0_documentation_en-US" xlink:label="lab_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_Range1Member" xlink:label="loc_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0" xlink:to="lab_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0" xlink:type="arc" />
    <link:label id="lab_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41_terseLabel_en-US" xlink:label="lab_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$6.90 to $6.90</link:label>
    <link:label id="lab_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41_label_en-US" xlink:label="lab_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range2 [Member]</link:label>
    <link:label id="lab_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41_documentation_en-US" xlink:label="lab_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_Range2Member" xlink:label="loc_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41" xlink:to="lab_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41" xlink:type="arc" />
    <link:label id="lab_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09_terseLabel_en-US" xlink:label="lab_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$6.96 to $10.85</link:label>
    <link:label id="lab_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09_label_en-US" xlink:label="lab_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range3 [Member]</link:label>
    <link:label id="lab_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09_documentation_en-US" xlink:label="lab_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_Range3Member" xlink:label="loc_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09" xlink:to="lab_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09" xlink:type="arc" />
    <link:label id="lab_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154_terseLabel_en-US" xlink:label="lab_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$11.14 to $12.58</link:label>
    <link:label id="lab_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154_label_en-US" xlink:label="lab_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range4 [Member]</link:label>
    <link:label id="lab_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154_documentation_en-US" xlink:label="lab_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_Range4Member" xlink:label="loc_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154" xlink:to="lab_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154" xlink:type="arc" />
    <link:label id="lab_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329_terseLabel_en-US" xlink:label="lab_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$12.66 to $13.94</link:label>
    <link:label id="lab_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329_label_en-US" xlink:label="lab_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range5 [Member]</link:label>
    <link:label id="lab_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329_documentation_en-US" xlink:label="lab_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_Range5Member" xlink:label="loc_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329" xlink:to="lab_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329" xlink:type="arc" />
    <link:label id="lab_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C_terseLabel_en-US" xlink:label="lab_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$14.24 to $16.07</link:label>
    <link:label id="lab_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C_label_en-US" xlink:label="lab_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range6 [Member]</link:label>
    <link:label id="lab_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C_documentation_en-US" xlink:label="lab_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_Range6Member" xlink:label="loc_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C" xlink:to="lab_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C" xlink:type="arc" />
    <link:label id="lab_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD_terseLabel_en-US" xlink:label="lab_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$16.09 to $17.16</link:label>
    <link:label id="lab_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD_label_en-US" xlink:label="lab_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range7 [Member]</link:label>
    <link:label id="lab_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD_documentation_en-US" xlink:label="lab_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_Range7Member" xlink:label="loc_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD" xlink:to="lab_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD" xlink:type="arc" />
    <link:label id="lab_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C_terseLabel_en-US" xlink:label="lab_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$17.24 to $22.76</link:label>
    <link:label id="lab_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C_label_en-US" xlink:label="lab_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range8 [Member]</link:label>
    <link:label id="lab_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C_documentation_en-US" xlink:label="lab_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_Range8Member" xlink:label="loc_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C" xlink:to="lab_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C" xlink:type="arc" />
    <link:label id="lab_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5_terseLabel_en-US" xlink:label="lab_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$22.84 to $30.46</link:label>
    <link:label id="lab_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5_label_en-US" xlink:label="lab_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range9 [Member]</link:label>
    <link:label id="lab_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5_documentation_en-US" xlink:label="lab_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_Range9Member" xlink:label="loc_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5" xlink:to="lab_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5" xlink:type="arc" />
    <link:label id="lab_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A_terseLabel_en-US" xlink:label="lab_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$30.86 to $32.46</link:label>
    <link:label id="lab_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A_label_en-US" xlink:label="lab_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range10 [Member]</link:label>
    <link:label id="lab_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A_documentation_en-US" xlink:label="lab_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_Range10Member" xlink:label="loc_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A" xlink:to="lab_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05A46263CC6617C6CD51807FFC3E3B06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05A46263CC6617C6CD51807FFC3E3B06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of stock options exercised during the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05A46263CC6617C6CD51807FFC3E3B06_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05A46263CC6617C6CD51807FFC3E3B06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05A46263CC6617C6CD51807FFC3E3B06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05A46263CC6617C6CD51807FFC3E3B06" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05A46263CC6617C6CD51807FFC3E3B06" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26FFC6253D453629FA35807FFC3EE6E7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26FFC6253D453629FA35807FFC3EE6E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26FFC6253D453629FA35807FFC3EE6E7_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26FFC6253D453629FA35807FFC3EE6E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26FFC6253D453629FA35807FFC3EE6E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26FFC6253D453629FA35807FFC3EE6E7" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26FFC6253D453629FA35807FFC3EE6E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_FE2ADA979ABACB5F13F3807FFC3FCFCB_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_FE2ADA979ABACB5F13F3807FFC3FCFCB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected weighted average period for recognizing unrecognized compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_FE2ADA979ABACB5F13F3807FFC3FCFCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_FE2ADA979ABACB5F13F3807FFC3FCFCB" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_FE2ADA979ABACB5F13F3807FFC3FCFCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_06AAC493F366650B4D97807FFC3F86BA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_06AAC493F366650B4D97807FFC3F86BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices lower range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_06AAC493F366650B4D97807FFC3F86BA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_06AAC493F366650B4D97807FFC3F86BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_06AAC493F366650B4D97807FFC3F86BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_06AAC493F366650B4D97807FFC3F86BA" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_06AAC493F366650B4D97807FFC3F86BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_6D831E308E75F43DC7F4807FFC3F3F2F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_6D831E308E75F43DC7F4807FFC3F3F2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices upper range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_6D831E308E75F43DC7F4807FFC3F3F2F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_6D831E308E75F43DC7F4807FFC3F3F2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_6D831E308E75F43DC7F4807FFC3F3F2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_6D831E308E75F43DC7F4807FFC3F3F2F" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_6D831E308E75F43DC7F4807FFC3F3F2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_68B9FFBBCFC17B4013ED807FFC3F4BCD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_68B9FFBBCFC17B4013ED807FFC3F4BCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_68B9FFBBCFC17B4013ED807FFC3F4BCD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_68B9FFBBCFC17B4013ED807FFC3F4BCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_68B9FFBBCFC17B4013ED807FFC3F4BCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_68B9FFBBCFC17B4013ED807FFC3F4BCD" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_68B9FFBBCFC17B4013ED807FFC3F4BCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1721D092FE5AD253B646807FFC3F0B0C_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1721D092FE5AD253B646807FFC3F0B0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1721D092FE5AD253B646807FFC3F0B0C_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1721D092FE5AD253B646807FFC3F0B0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1721D092FE5AD253B646807FFC3F0B0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1721D092FE5AD253B646807FFC3F0B0C" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1721D092FE5AD253B646807FFC3F0B0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_F4F469D51DC68C77F8DF807FFC40E57F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_F4F469D51DC68C77F8DF807FFC40E57F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_F4F469D51DC68C77F8DF807FFC40E57F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_F4F469D51DC68C77F8DF807FFC40E57F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_F4F469D51DC68C77F8DF807FFC40E57F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_F4F469D51DC68C77F8DF807FFC40E57F" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_F4F469D51DC68C77F8DF807FFC40E57F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_D015E674FD509EEA55D3807FFC40E967_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_D015E674FD509EEA55D3807FFC40E967" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_D015E674FD509EEA55D3807FFC40E967_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_D015E674FD509EEA55D3807FFC40E967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_D015E674FD509EEA55D3807FFC40E967" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_D015E674FD509EEA55D3807FFC40E967" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_D015E674FD509EEA55D3807FFC40E967" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2AB4AC4AB96508B70EE7807FFC403A98_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2AB4AC4AB96508B70EE7807FFC403A98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2AB4AC4AB96508B70EE7807FFC403A98_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2AB4AC4AB96508B70EE7807FFC403A98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2AB4AC4AB96508B70EE7807FFC403A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2AB4AC4AB96508B70EE7807FFC403A98" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2AB4AC4AB96508B70EE7807FFC403A98" xlink:type="arc" />
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_E81CBE3089831C9558B8807FFCF76592_terseLabel_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses_E81CBE3089831C9558B8807FFCF76592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_E81CBE3089831C9558B8807FFCF76592_label_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses_E81CBE3089831C9558B8807FFCF76592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_E81CBE3089831C9558B8807FFCF76592_documentation_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses_E81CBE3089831C9558B8807FFCF76592" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_AccruedClinicalTrialExpenses" xlink:label="loc_insm_AccruedClinicalTrialExpenses_E81CBE3089831C9558B8807FFCF76592" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedClinicalTrialExpenses_E81CBE3089831C9558B8807FFCF76592" xlink:to="lab_insm_AccruedClinicalTrialExpenses_E81CBE3089831C9558B8807FFCF76592" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_CFE2AAB9DE2FB6E8D55E807FFCF8B79C_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_CFE2AAB9DE2FB6E8D55E807FFCF8B79C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_CFE2AAB9DE2FB6E8D55E807FFCF8B79C_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_CFE2AAB9DE2FB6E8D55E807FFCF8B79C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_CFE2AAB9DE2FB6E8D55E807FFCF8B79C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_CFE2AAB9DE2FB6E8D55E807FFCF8B79C" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_CFE2AAB9DE2FB6E8D55E807FFCF8B79C" xlink:type="arc" />
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_D92018D072DF573E87FB807FFCF8C134_terseLabel_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses_D92018D072DF573E87FB807FFCF8C134" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued technical operation expenses</link:label>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_D92018D072DF573E87FB807FFCF8C134_label_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses_D92018D072DF573E87FB807FFCF8C134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Technical Operation Expenses</link:label>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_D92018D072DF573E87FB807FFCF8C134_documentation_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses_D92018D072DF573E87FB807FFCF8C134" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_AccruedTechnicalOperationExpenses" xlink:label="loc_insm_AccruedTechnicalOperationExpenses_D92018D072DF573E87FB807FFCF8C134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedTechnicalOperationExpenses_D92018D072DF573E87FB807FFCF8C134" xlink:to="lab_insm_AccruedTechnicalOperationExpenses_D92018D072DF573E87FB807FFCF8C134" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_8CA19513F81FDDF93441807FFCF87707_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_8CA19513F81FDDF93441807FFCF87707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_8CA19513F81FDDF93441807FFCF87707_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_8CA19513F81FDDF93441807FFCF87707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_8CA19513F81FDDF93441807FFCF87707" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_8CA19513F81FDDF93441807FFCF87707" xlink:to="lab_us-gaap_InterestPayableCurrent_8CA19513F81FDDF93441807FFCF87707" xlink:type="arc" />
    <link:label id="lab_insm_AccruedSalesAllowancesandRelatedCosts_9C4970F84CA40F84906C80A06F1B20EC_terseLabel_en-US" xlink:label="lab_insm_AccruedSalesAllowancesandRelatedCosts_9C4970F84CA40F84906C80A06F1B20EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued sales allowances and related costs</link:label>
    <link:label id="lab_insm_AccruedSalesAllowancesandRelatedCosts_9C4970F84CA40F84906C80A06F1B20EC_label_en-US" xlink:label="lab_insm_AccruedSalesAllowancesandRelatedCosts_9C4970F84CA40F84906C80A06F1B20EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Sales Allowances and Related Costs</link:label>
    <link:label id="lab_insm_AccruedSalesAllowancesandRelatedCosts_9C4970F84CA40F84906C80A06F1B20EC_documentation_en-US" xlink:label="lab_insm_AccruedSalesAllowancesandRelatedCosts_9C4970F84CA40F84906C80A06F1B20EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Sales Allowances and Related Costs</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_AccruedSalesAllowancesandRelatedCosts" xlink:label="loc_insm_AccruedSalesAllowancesandRelatedCosts_9C4970F84CA40F84906C80A06F1B20EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedSalesAllowancesandRelatedCosts_9C4970F84CA40F84906C80A06F1B20EC" xlink:to="lab_insm_AccruedSalesAllowancesandRelatedCosts_9C4970F84CA40F84906C80A06F1B20EC" xlink:type="arc" />
    <link:label id="lab_insm_AccruedConstructionLiabilitiesCurrent_C7986251FDAFB5F61F0B807FFCF9923E_terseLabel_en-US" xlink:label="lab_insm_AccruedConstructionLiabilitiesCurrent_C7986251FDAFB5F61F0B807FFCF9923E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued construction costs</link:label>
    <link:label id="lab_insm_AccruedConstructionLiabilitiesCurrent_C7986251FDAFB5F61F0B807FFCF9923E_label_en-US" xlink:label="lab_insm_AccruedConstructionLiabilitiesCurrent_C7986251FDAFB5F61F0B807FFCF9923E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Construction Liabilities, Current</link:label>
    <link:label id="lab_insm_AccruedConstructionLiabilitiesCurrent_C7986251FDAFB5F61F0B807FFCF9923E_documentation_en-US" xlink:label="lab_insm_AccruedConstructionLiabilitiesCurrent_C7986251FDAFB5F61F0B807FFCF9923E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Construction Liabilities, Current</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_AccruedConstructionLiabilitiesCurrent" xlink:label="loc_insm_AccruedConstructionLiabilitiesCurrent_C7986251FDAFB5F61F0B807FFCF9923E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedConstructionLiabilitiesCurrent_C7986251FDAFB5F61F0B807FFCF9923E" xlink:to="lab_insm_AccruedConstructionLiabilitiesCurrent_C7986251FDAFB5F61F0B807FFCF9923E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AE3EE05AADF7B046053E807FFCF99201_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AE3EE05AADF7B046053E807FFCF99201" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AE3EE05AADF7B046053E807FFCF99201_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AE3EE05AADF7B046053E807FFCF99201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AE3EE05AADF7B046053E807FFCF99201" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AE3EE05AADF7B046053E807FFCF99201" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AE3EE05AADF7B046053E807FFCF99201" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_F8A030BB69BE78F1CD96807FFCF95242_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_F8A030BB69BE78F1CD96807FFCF95242" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_F8A030BB69BE78F1CD96807FFCF95242" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_F8A030BB69BE78F1CD96807FFCF95242" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_F8A030BB69BE78F1CD96807FFCF95242" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="lab_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E7210374FEFFC6CBF42E153C73BF5EC0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E7210374FEFFC6CBF42E153C73BF5EC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E7210374FEFFC6CBF42E153C73BF5EC0_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E7210374FEFFC6CBF42E153C73BF5EC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E7210374FEFFC6CBF42E153C73BF5EC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E7210374FEFFC6CBF42E153C73BF5EC0" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E7210374FEFFC6CBF42E153C73BF5EC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C4E8328BA862C3280452153C73BFA02D_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C4E8328BA862C3280452153C73BFA02D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under underwritten public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C4E8328BA862C3280452153C73BFA02D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C4E8328BA862C3280452153C73BFA02D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C4E8328BA862C3280452153C73BFA02D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C4E8328BA862C3280452153C73BFA02D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C4E8328BA862C3280452153C73BFA02D" xlink:type="arc" />
    <link:label id="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07_terseLabel_en-US" xlink:label="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares exercised in full of over-allotment option by underwriter (in shares)</link:label>
    <link:label id="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07_label_en-US" xlink:label="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option</link:label>
    <link:label id="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07_documentation_en-US" xlink:label="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:label="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07" xlink:to="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_3AE64906F275F91388DB153C73C04B8C_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_3AE64906F275F91388DB153C73C04B8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_3AE64906F275F91388DB153C73C04B8C_label_en-US" xlink:label="lab_us-gaap_SharePrice_3AE64906F275F91388DB153C73C04B8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_3AE64906F275F91388DB153C73C04B8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_3AE64906F275F91388DB153C73C04B8C" xlink:to="lab_us-gaap_SharePrice_3AE64906F275F91388DB153C73C04B8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_E2B3A7C43FD664F514FF153C73C00395_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_E2B3A7C43FD664F514FF153C73C00395" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Underwriter's discount and offering expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_E2B3A7C43FD664F514FF153C73C00395_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_E2B3A7C43FD664F514FF153C73C00395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_E2B3A7C43FD664F514FF153C73C00395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_E2B3A7C43FD664F514FF153C73C00395" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_E2B3A7C43FD664F514FF153C73C00395" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_DC2D3096C50B5DC7A63A153C73C5DF16_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_DC2D3096C50B5DC7A63A153C73C5DF16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from the sale of shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DC2D3096C50B5DC7A63A153C73C5DF16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DC2D3096C50B5DC7A63A153C73C5DF16" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_DC2D3096C50B5DC7A63A153C73C5DF16" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_49189DC7B80A686CD952153C73C591F0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_49189DC7B80A686CD952153C73C591F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_49189DC7B80A686CD952153C73C591F0_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_49189DC7B80A686CD952153C73C591F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_49189DC7B80A686CD952153C73C591F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_49189DC7B80A686CD952153C73C591F0" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_49189DC7B80A686CD952153C73C591F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2BB3F608D01625B7102A153C73C5A57A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2BB3F608D01625B7102A153C73C5A57A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2BB3F608D01625B7102A153C73C5A57A_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2BB3F608D01625B7102A153C73C5A57A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BB3F608D01625B7102A153C73C5A57A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BB3F608D01625B7102A153C73C5A57A" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2BB3F608D01625B7102A153C73C5A57A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1F51066B83EA75F3863D153C73C6CAEE_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1F51066B83EA75F3863D153C73C6CAEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1F51066B83EA75F3863D153C73C6CAEE_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1F51066B83EA75F3863D153C73C6CAEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1F51066B83EA75F3863D153C73C6CAEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_1F51066B83EA75F3863D153C73C6CAEE" xlink:to="lab_us-gaap_PreferredStockSharesIssued_1F51066B83EA75F3863D153C73C6CAEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_719708F3B3DD32710132153C73C63813_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_719708F3B3DD32710132153C73C63813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_719708F3B3DD32710132153C73C63813_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_719708F3B3DD32710132153C73C63813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_719708F3B3DD32710132153C73C63813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_719708F3B3DD32710132153C73C63813" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_719708F3B3DD32710132153C73C63813" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B6D3DAAA20656053FC1EC80C907B3F41_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B6D3DAAA20656053FC1EC80C907B3F41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B6D3DAAA20656053FC1EC80C907B3F41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B6D3DAAA20656053FC1EC80C907B3F41" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B6D3DAAA20656053FC1EC80C907B3F41" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_80CF65D4F51173BB6902C80C907B4A2F_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_80CF65D4F51173BB6902C80C907B4A2F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_80CF65D4F51173BB6902C80C907B4A2F_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_80CF65D4F51173BB6902C80C907B4A2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_80CF65D4F51173BB6902C80C907B4A2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_80CF65D4F51173BB6902C80C907B4A2F" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_80CF65D4F51173BB6902C80C907B4A2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7E397218938090DE83C6807FFD76542E_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_7E397218938090DE83C6807FFD76542E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7E397218938090DE83C6807FFD76542E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7E397218938090DE83C6807FFD76542E" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_7E397218938090DE83C6807FFD76542E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:to="lab_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_67D9812FA89DE4BEA295807FFD77A807_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_67D9812FA89DE4BEA295807FFD77A807" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_67D9812FA89DE4BEA295807FFD77A807_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_67D9812FA89DE4BEA295807FFD77A807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_67D9812FA89DE4BEA295807FFD77A807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_67D9812FA89DE4BEA295807FFD77A807" xlink:to="lab_us-gaap_CommonStockMember_67D9812FA89DE4BEA295807FFD77A807" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_AD15C0334D055B9B1C55807FFD77F114_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_AD15C0334D055B9B1C55807FFD77F114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_AD15C0334D055B9B1C55807FFD77F114_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_AD15C0334D055B9B1C55807FFD77F114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_AD15C0334D055B9B1C55807FFD77F114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_AD15C0334D055B9B1C55807FFD77F114" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_AD15C0334D055B9B1C55807FFD77F114" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_F38403F16A203911FD90807FFD77E481_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_F38403F16A203911FD90807FFD77E481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_F38403F16A203911FD90807FFD77E481_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_F38403F16A203911FD90807FFD77E481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_F38403F16A203911FD90807FFD77E481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_F38403F16A203911FD90807FFD77E481" xlink:to="lab_us-gaap_RetainedEarningsMember_F38403F16A203911FD90807FFD77E481" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CCF39A1FD996CE103504807FFD77373E_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CCF39A1FD996CE103504807FFD77373E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CCF39A1FD996CE103504807FFD77373E_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CCF39A1FD996CE103504807FFD77373E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CCF39A1FD996CE103504807FFD77373E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CCF39A1FD996CE103504807FFD77373E" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CCF39A1FD996CE103504807FFD77373E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_DC2D59A97C6440B58B16807FFD78A421_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_DC2D59A97C6440B58B16807FFD78A421" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_DC2D59A97C6440B58B16807FFD78A421" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_DC2D59A97C6440B58B16807FFD78A421" xlink:to="lab_us-gaap_StockholdersEquity_DC2D59A97C6440B58B16807FFD78A421" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_7513838A60039BE2F41E807FFD781491_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_7513838A60039BE2F41E807FFD781491" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_7513838A60039BE2F41E807FFD781491_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_7513838A60039BE2F41E807FFD781491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_7513838A60039BE2F41E807FFD781491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_7513838A60039BE2F41E807FFD781491" xlink:to="lab_us-gaap_SharesOutstanding_7513838A60039BE2F41E807FFD781491" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3C9707AA3B39D6764C8F807FFD797CC6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3C9707AA3B39D6764C8F807FFD797CC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3C9707AA3B39D6764C8F807FFD797CC6_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3C9707AA3B39D6764C8F807FFD797CC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3C9707AA3B39D6764C8F807FFD797CC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3C9707AA3B39D6764C8F807FFD797CC6" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3C9707AA3B39D6764C8F807FFD797CC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_D09A8257BF8A0BCCFC8F807FFD79D7DC_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_D09A8257BF8A0BCCFC8F807FFD79D7DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_D09A8257BF8A0BCCFC8F807FFD79D7DC_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_D09A8257BF8A0BCCFC8F807FFD79D7DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_D09A8257BF8A0BCCFC8F807FFD79D7DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_D09A8257BF8A0BCCFC8F807FFD79D7DC" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_D09A8257BF8A0BCCFC8F807FFD79D7DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9F7A74B301B690A78220807FFD79604A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9F7A74B301B690A78220807FFD79604A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9F7A74B301B690A78220807FFD79604A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9F7A74B301B690A78220807FFD79604A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9F7A74B301B690A78220807FFD79604A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0E869170F73862C35F92807FFD799821_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0E869170F73862C35F92807FFD799821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0E869170F73862C35F92807FFD799821_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0E869170F73862C35F92807FFD799821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0E869170F73862C35F92807FFD799821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0E869170F73862C35F92807FFD799821" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0E869170F73862C35F92807FFD799821" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89E9B6272B28E465714E807FFD7A4A87_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89E9B6272B28E465714E807FFD7A4A87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89E9B6272B28E465714E807FFD7A4A87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89E9B6272B28E465714E807FFD7A4A87" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89E9B6272B28E465714E807FFD7A4A87" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9272184B92AF89EE0967807FFD7A929B_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9272184B92AF89EE0967807FFD7A929B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of convertible debt issuance</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9272184B92AF89EE0967807FFD7A929B_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9272184B92AF89EE0967807FFD7A929B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9272184B92AF89EE0967807FFD7A929B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9272184B92AF89EE0967807FFD7A929B" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9272184B92AF89EE0967807FFD7A929B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_94F0E1F24A5F8D9CF128807FFD7AA4D2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_94F0E1F24A5F8D9CF128807FFD7AA4D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for vesting of RSUs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_94F0E1F24A5F8D9CF128807FFD7AA4D2_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_94F0E1F24A5F8D9CF128807FFD7AA4D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_94F0E1F24A5F8D9CF128807FFD7AA4D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_94F0E1F24A5F8D9CF128807FFD7AA4D2" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_94F0E1F24A5F8D9CF128807FFD7AA4D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16D109FD69DC56659FDA807FFD7A8F16_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16D109FD69DC56659FDA807FFD7A8F16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for vesting of RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16D109FD69DC56659FDA807FFD7A8F16_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16D109FD69DC56659FDA807FFD7A8F16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16D109FD69DC56659FDA807FFD7A8F16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16D109FD69DC56659FDA807FFD7A8F16" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16D109FD69DC56659FDA807FFD7A8F16" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0A9EB13863865C36730F807FFD7A4AE0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0A9EB13863865C36730F807FFD7A4AE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0A9EB13863865C36730F807FFD7A4AE0_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0A9EB13863865C36730F807FFD7A4AE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0A9EB13863865C36730F807FFD7A4AE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0A9EB13863865C36730F807FFD7A4AE0" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0A9EB13863865C36730F807FFD7A4AE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_075A2309A29CD96156B0807FFD7B4320_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_075A2309A29CD96156B0807FFD7B4320" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_075A2309A29CD96156B0807FFD7B4320" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_075A2309A29CD96156B0807FFD7B4320" xlink:to="lab_us-gaap_StockholdersEquity_075A2309A29CD96156B0807FFD7B4320" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_1F87D593D6C7E76B0C7A807FFD7B5C65_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_1F87D593D6C7E76B0C7A807FFD7B5C65" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_1F87D593D6C7E76B0C7A807FFD7B5C65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_1F87D593D6C7E76B0C7A807FFD7B5C65" xlink:to="lab_us-gaap_SharesOutstanding_1F87D593D6C7E76B0C7A807FFD7B5C65" xlink:type="arc" />
    <link:label id="lab_insm_LicenseAndOtherAgreementsTextBlock_083E1AD4C358F6066D1AC80C9158691E_terseLabel_en-US" xlink:label="lab_insm_LicenseAndOtherAgreementsTextBlock_083E1AD4C358F6066D1AC80C9158691E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Other Agreements</link:label>
    <link:label id="lab_insm_LicenseAndOtherAgreementsTextBlock_083E1AD4C358F6066D1AC80C9158691E_label_en-US" xlink:label="lab_insm_LicenseAndOtherAgreementsTextBlock_083E1AD4C358F6066D1AC80C9158691E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Other Agreements [Text Block]</link:label>
    <link:label id="lab_insm_LicenseAndOtherAgreementsTextBlock_083E1AD4C358F6066D1AC80C9158691E_documentation_en-US" xlink:label="lab_insm_LicenseAndOtherAgreementsTextBlock_083E1AD4C358F6066D1AC80C9158691E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This entire text block refers to License and Other Agreement.</link:label>
    <link:loc xlink:href="insm-20181231.xsd#insm_LicenseAndOtherAgreementsTextBlock" xlink:label="loc_insm_LicenseAndOtherAgreementsTextBlock_083E1AD4C358F6066D1AC80C9158691E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LicenseAndOtherAgreementsTextBlock_083E1AD4C358F6066D1AC80C9158691E" xlink:to="lab_insm_LicenseAndOtherAgreementsTextBlock_083E1AD4C358F6066D1AC80C9158691E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_FB96A0CBFFCCE75A9825A63064D67F4B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_FB96A0CBFFCCE75A9825A63064D67F4B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FB96A0CBFFCCE75A9825A63064D67F4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_FB96A0CBFFCCE75A9825A63064D67F4B" xlink:to="lab_us-gaap_NetIncomeLoss_FB96A0CBFFCCE75A9825A63064D67F4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A924279659A91FF50991C80C91960E2F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A924279659A91FF50991C80C91960E2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A924279659A91FF50991C80C91960E2F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A924279659A91FF50991C80C91960E2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A924279659A91FF50991C80C91960E2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A924279659A91FF50991C80C91960E2F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A924279659A91FF50991C80C91960E2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_51289E594A85507C9868C8B4E21F8A58_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_51289E594A85507C9868C8B4E21F8A58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_51289E594A85507C9868C8B4E21F8A58_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_51289E594A85507C9868C8B4E21F8A58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_51289E594A85507C9868C8B4E21F8A58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_51289E594A85507C9868C8B4E21F8A58" xlink:to="lab_us-gaap_RevenuesAbstract_51289E594A85507C9868C8B4E21F8A58" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360" xlink:to="lab_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_CBFBF5CA03052936A401C8B4E21FD165_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_CBFBF5CA03052936A401C8B4E21FD165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product revenues (excluding amortization of intangible assets)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_CBFBF5CA03052936A401C8B4E21FD165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_CBFBF5CA03052936A401C8B4E21FD165" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_CBFBF5CA03052936A401C8B4E21FD165" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_18D1C61DE1ED77F2E379C8B4E2222036_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_18D1C61DE1ED77F2E379C8B4E2222036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_18D1C61DE1ED77F2E379C8B4E2222036_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_18D1C61DE1ED77F2E379C8B4E2222036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_18D1C61DE1ED77F2E379C8B4E2222036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_18D1C61DE1ED77F2E379C8B4E2222036" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_18D1C61DE1ED77F2E379C8B4E2222036" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8EDD060FAD8DE3F431B4C8B4E2226F0A_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_8EDD060FAD8DE3F431B4C8B4E2226F0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8EDD060FAD8DE3F431B4C8B4E2226F0A_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_8EDD060FAD8DE3F431B4C8B4E2226F0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8EDD060FAD8DE3F431B4C8B4E2226F0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_8EDD060FAD8DE3F431B4C8B4E2226F0A" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_8EDD060FAD8DE3F431B4C8B4E2226F0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_43E7413FE2945302DA59C8B4E2239742_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_43E7413FE2945302DA59C8B4E2239742" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_43E7413FE2945302DA59C8B4E2239742_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_43E7413FE2945302DA59C8B4E2239742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_43E7413FE2945302DA59C8B4E2239742" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_43E7413FE2945302DA59C8B4E2239742" xlink:to="lab_us-gaap_CostsAndExpenses_43E7413FE2945302DA59C8B4E2239742" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_88424FE4820EABF1C499C8B4E223A073_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_88424FE4820EABF1C499C8B4E223A073" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_88424FE4820EABF1C499C8B4E223A073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_88424FE4820EABF1C499C8B4E223A073" xlink:to="lab_us-gaap_OperatingIncomeLoss_88424FE4820EABF1C499C8B4E223A073" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_9B2D803BF66B528E4C37C8B4E2234619_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating_9B2D803BF66B528E4C37C8B4E2234619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_9B2D803BF66B528E4C37C8B4E2234619_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating_9B2D803BF66B528E4C37C8B4E2234619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_9B2D803BF66B528E4C37C8B4E2234619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating_9B2D803BF66B528E4C37C8B4E2234619" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating_9B2D803BF66B528E4C37C8B4E2234619" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_3064C6CD0C9C4F794CFEC8B4E2239BF3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_3064C6CD0C9C4F794CFEC8B4E2239BF3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_3064C6CD0C9C4F794CFEC8B4E2239BF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_3064C6CD0C9C4F794CFEC8B4E2239BF3" xlink:to="lab_us-gaap_InterestExpense_3064C6CD0C9C4F794CFEC8B4E2239BF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_17EF090C8381BE40DEE3C8B4E223F77E_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_17EF090C8381BE40DEE3C8B4E223F77E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_17EF090C8381BE40DEE3C8B4E223F77E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_17EF090C8381BE40DEE3C8B4E223F77E" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_17EF090C8381BE40DEE3C8B4E223F77E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_BBCA43DA9E8B57901892C8B4E224ED3C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_BBCA43DA9E8B57901892C8B4E224ED3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_BBCA43DA9E8B57901892C8B4E224ED3C_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_BBCA43DA9E8B57901892C8B4E224ED3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_BBCA43DA9E8B57901892C8B4E224ED3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_BBCA43DA9E8B57901892C8B4E224ED3C" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_BBCA43DA9E8B57901892C8B4E224ED3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_DCBA61DCE5D853143FAAC8B4E224A63A_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_DCBA61DCE5D853143FAAC8B4E224A63A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_DCBA61DCE5D853143FAAC8B4E224A63A_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_DCBA61DCE5D853143FAAC8B4E224A63A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_DCBA61DCE5D853143FAAC8B4E224A63A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_DCBA61DCE5D853143FAAC8B4E224A63A" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_DCBA61DCE5D853143FAAC8B4E224A63A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_22377C9EA98DAA2BBC84C8B4E2245840_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_22377C9EA98DAA2BBC84C8B4E2245840" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision (benefit) for income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_22377C9EA98DAA2BBC84C8B4E2245840" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_22377C9EA98DAA2BBC84C8B4E2245840" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_22377C9EA98DAA2BBC84C8B4E2245840" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_523214CF46CAF97806A8C8B4E225F018_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_523214CF46CAF97806A8C8B4E225F018" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_523214CF46CAF97806A8C8B4E225F018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_523214CF46CAF97806A8C8B4E225F018" xlink:to="lab_us-gaap_NetIncomeLoss_523214CF46CAF97806A8C8B4E225F018" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9F84CD3BB7CB92BF6C7AC8B4E2254E4A_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9F84CD3BB7CB92BF6C7AC8B4E2254E4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average basic and diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9F84CD3BB7CB92BF6C7AC8B4E2254E4A_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9F84CD3BB7CB92BF6C7AC8B4E2254E4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9F84CD3BB7CB92BF6C7AC8B4E2254E4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9F84CD3BB7CB92BF6C7AC8B4E2254E4A" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9F84CD3BB7CB92BF6C7AC8B4E2254E4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_A9FD56F56232DFEE76EAC8B4E225C1DF_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_A9FD56F56232DFEE76EAC8B4E225C1DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_A9FD56F56232DFEE76EAC8B4E225C1DF_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_A9FD56F56232DFEE76EAC8B4E225C1DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_A9FD56F56232DFEE76EAC8B4E225C1DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_A9FD56F56232DFEE76EAC8B4E225C1DF" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_A9FD56F56232DFEE76EAC8B4E225C1DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74FE404ECDB19FE88676C8B4E226CBA0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74FE404ECDB19FE88676C8B4E226CBA0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74FE404ECDB19FE88676C8B4E226CBA0_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74FE404ECDB19FE88676C8B4E226CBA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74FE404ECDB19FE88676C8B4E226CBA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74FE404ECDB19FE88676C8B4E226CBA0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74FE404ECDB19FE88676C8B4E226CBA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0F375B94650F49090A1CC8B4E22600A3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0F375B94650F49090A1CC8B4E22600A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation (losses) gains</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0F375B94650F49090A1CC8B4E22600A3_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0F375B94650F49090A1CC8B4E22600A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0F375B94650F49090A1CC8B4E22600A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0F375B94650F49090A1CC8B4E22600A3" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0F375B94650F49090A1CC8B4E22600A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_EB13DAC902DB22DB3532C8B4E226D96D_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_EB13DAC902DB22DB3532C8B4E226D96D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_EB13DAC902DB22DB3532C8B4E226D96D_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_EB13DAC902DB22DB3532C8B4E226D96D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_EB13DAC902DB22DB3532C8B4E226D96D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_EB13DAC902DB22DB3532C8B4E226D96D" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_EB13DAC902DB22DB3532C8B4E226D96D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_E06615121AAA9182D20EDD4093D7D970_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_E06615121AAA9182D20EDD4093D7D970" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_E06615121AAA9182D20EDD4093D7D970_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_E06615121AAA9182D20EDD4093D7D970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_E06615121AAA9182D20EDD4093D7D970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_E06615121AAA9182D20EDD4093D7D970" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_E06615121AAA9182D20EDD4093D7D970" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CFC0E61670C4A6766393DD4093D8A104_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CFC0E61670C4A6766393DD4093D8A104" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CFC0E61670C4A6766393DD4093D8A104_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CFC0E61670C4A6766393DD4093D8A104" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CFC0E61670C4A6766393DD4093D8A104" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CFC0E61670C4A6766393DD4093D8A104" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CFC0E61670C4A6766393DD4093D8A104" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_7C54F67702E04352B69BDD4093D8DFC9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_7C54F67702E04352B69BDD4093D8DFC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_7C54F67702E04352B69BDD4093D8DFC9_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_7C54F67702E04352B69BDD4093D8DFC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_7C54F67702E04352B69BDD4093D8DFC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_7C54F67702E04352B69BDD4093D8DFC9" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_7C54F67702E04352B69BDD4093D8DFC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E99424F854EBA307D914DD4093D86FC6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E99424F854EBA307D914DD4093D86FC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E99424F854EBA307D914DD4093D86FC6_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E99424F854EBA307D914DD4093D86FC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E99424F854EBA307D914DD4093D86FC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E99424F854EBA307D914DD4093D86FC6" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E99424F854EBA307D914DD4093D86FC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1C0F75C6F2E042B46A44DD4093D82577_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1C0F75C6F2E042B46A44DD4093D82577" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1C0F75C6F2E042B46A44DD4093D82577_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1C0F75C6F2E042B46A44DD4093D82577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1C0F75C6F2E042B46A44DD4093D82577" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1C0F75C6F2E042B46A44DD4093D82577" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1C0F75C6F2E042B46A44DD4093D82577" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D5A58C0F9D7E4D7864E6DD4093D8B7F2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D5A58C0F9D7E4D7864E6DD4093D8B7F2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D5A58C0F9D7E4D7864E6DD4093D8B7F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D5A58C0F9D7E4D7864E6DD4093D8B7F2" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D5A58C0F9D7E4D7864E6DD4093D8B7F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_26EF0D3CBC1237EB39C8C80C91569F23_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_26EF0D3CBC1237EB39C8C80C91569F23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_26EF0D3CBC1237EB39C8C80C91569F23_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_26EF0D3CBC1237EB39C8C80C91569F23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_26EF0D3CBC1237EB39C8C80C91569F23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_26EF0D3CBC1237EB39C8C80C91569F23" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_26EF0D3CBC1237EB39C8C80C91569F23" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_99240A7514E1119E3A68C80C91B14BB7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_99240A7514E1119E3A68C80C91B14BB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_99240A7514E1119E3A68C80C91B14BB7_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_99240A7514E1119E3A68C80C91B14BB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_99240A7514E1119E3A68C80C91B14BB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_99240A7514E1119E3A68C80C91B14BB7" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_99240A7514E1119E3A68C80C91B14BB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A1F9D34A0950AFC64C0BC80C91B1CEDA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A1F9D34A0950AFC64C0BC80C91B1CEDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A1F9D34A0950AFC64C0BC80C91B1CEDA_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A1F9D34A0950AFC64C0BC80C91B1CEDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A1F9D34A0950AFC64C0BC80C91B1CEDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A1F9D34A0950AFC64C0BC80C91B1CEDA" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A1F9D34A0950AFC64C0BC80C91B1CEDA" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>insm-20181231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpenses" xlink:href="insm-20181231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesDetails" xlink:href="insm-20181231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesTables" xlink:href="insm-20181231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingencies" xlink:href="insm-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:href="insm-20181231.xsd#CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="insm-20181231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesTables" xlink:href="insm-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:href="insm-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="insm-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="insm-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="insm-20181231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity" xlink:href="insm-20181231.xsd#ConsolidatedStatementsOfShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/Debt" xlink:href="insm-20181231.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtComponentsOfDebtDetails" xlink:href="insm-20181231.xsd#DebtComponentsOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtDetails" xlink:href="insm-20181231.xsd#DebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:href="insm-20181231.xsd#DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtTables" xlink:href="insm-20181231.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="insm-20181231.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails" xlink:href="insm-20181231.xsd#DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:href="insm-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNet" xlink:href="insm-20181231.xsd#FixedAssetsNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:href="insm-20181231.xsd#FixedAssetsNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetTables" xlink:href="insm-20181231.xsd#FixedAssetsNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxes" xlink:href="insm-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="insm-20181231.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:href="insm-20181231.xsd#IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails" xlink:href="insm-20181231.xsd#IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesNarrativeDetails" xlink:href="insm-20181231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:href="insm-20181231.xsd#IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="insm-20181231.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesTables" xlink:href="insm-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNet" xlink:href="insm-20181231.xsd#IntangiblesNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetDetails" xlink:href="insm-20181231.xsd#IntangiblesNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetTables" xlink:href="insm-20181231.xsd#IntangiblesNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/Inventory" xlink:href="insm-20181231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails" xlink:href="insm-20181231.xsd#InventoryScheduleOfInventoryCurrentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryTables" xlink:href="insm-20181231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/LicenseAndOtherAgreements" xlink:href="insm-20181231.xsd#LicenseAndOtherAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/LicenseAndOtherAgreementsDetails" xlink:href="insm-20181231.xsd#LicenseAndOtherAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/QuarterlyFinancialDataUnaudited" xlink:href="insm-20181231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="insm-20181231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="insm-20181231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/RetirementPlan" xlink:href="insm-20181231.xsd#RetirementPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/RetirementPlanDetails" xlink:href="insm-20181231.xsd#RetirementPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquity" xlink:href="insm-20181231.xsd#ShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:href="insm-20181231.xsd#ShareholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensation" xlink:href="insm-20181231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:href="insm-20181231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails" xlink:href="insm-20181231.xsd#StockBasedCompensationRangeOfExercisePricesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:href="insm-20181231.xsd#StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:href="insm-20181231.xsd#StockBasedCompensationStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationTables" xlink:href="insm-20181231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="insm-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_73AC2E827FD0409CAE14C80C91E13858" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B7F02BDA1C1ECAD1851AC80C91E162BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_73AC2E827FD0409CAE14C80C91E13858" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B7F02BDA1C1ECAD1851AC80C91E162BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_C790468E578F34B14D05807FFCF75DEF" xlink:type="locator" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AccruedClinicalTrialExpenses" xlink:label="loc_insm_AccruedClinicalTrialExpenses_E81CBE3089831C9558B8807FFCF76592" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C790468E578F34B14D05807FFCF75DEF" xlink:to="loc_insm_AccruedClinicalTrialExpenses_E81CBE3089831C9558B8807FFCF76592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_CFE2AAB9DE2FB6E8D55E807FFCF8B79C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C790468E578F34B14D05807FFCF75DEF" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_CFE2AAB9DE2FB6E8D55E807FFCF8B79C" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AccruedTechnicalOperationExpenses" xlink:label="loc_insm_AccruedTechnicalOperationExpenses_D92018D072DF573E87FB807FFCF8C134" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C790468E578F34B14D05807FFCF75DEF" xlink:to="loc_insm_AccruedTechnicalOperationExpenses_D92018D072DF573E87FB807FFCF8C134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_8CA19513F81FDDF93441807FFCF87707" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C790468E578F34B14D05807FFCF75DEF" xlink:to="loc_us-gaap_InterestPayableCurrent_8CA19513F81FDDF93441807FFCF87707" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AccruedSalesAllowancesandRelatedCosts" xlink:label="loc_insm_AccruedSalesAllowancesandRelatedCosts_9C4970F84CA40F84906C80A06F1B20EC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C790468E578F34B14D05807FFCF75DEF" xlink:to="loc_insm_AccruedSalesAllowancesandRelatedCosts_9C4970F84CA40F84906C80A06F1B20EC" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AccruedConstructionLiabilitiesCurrent" xlink:label="loc_insm_AccruedConstructionLiabilitiesCurrent_C7986251FDAFB5F61F0B807FFCF9923E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C790468E578F34B14D05807FFCF75DEF" xlink:to="loc_insm_AccruedConstructionLiabilitiesCurrent_C7986251FDAFB5F61F0B807FFCF9923E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AE3EE05AADF7B046053E807FFCF99201" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C790468E578F34B14D05807FFCF75DEF" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AE3EE05AADF7B046053E807FFCF99201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_F8A030BB69BE78F1CD96807FFCF95242" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C790468E578F34B14D05807FFCF75DEF" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_F8A030BB69BE78F1CD96807FFCF95242" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0A7799E0A83B4AAB1B4CC80C9255C85D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7273CAA3908668FE849EC80C9255C150" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0A7799E0A83B4AAB1B4CC80C9255C85D" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7273CAA3908668FE849EC80C9255C150" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_AC776581F80168D83D6AC80C91D99277" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9E673F6C48C3F596AF2BC80C91D93D1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_AC776581F80168D83D6AC80C91D99277" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9E673F6C48C3F596AF2BC80C91D93D1C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3B2176BBCA549D403527DD4093D70CEA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_E06615121AAA9182D20EDD4093D7D970" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3B2176BBCA549D403527DD4093D70CEA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_E06615121AAA9182D20EDD4093D7D970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CFC0E61670C4A6766393DD4093D8A104" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3B2176BBCA549D403527DD4093D70CEA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_CFC0E61670C4A6766393DD4093D8A104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_7C54F67702E04352B69BDD4093D8DFC9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3B2176BBCA549D403527DD4093D70CEA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_7C54F67702E04352B69BDD4093D8DFC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E99424F854EBA307D914DD4093D86FC6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3B2176BBCA549D403527DD4093D70CEA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_E99424F854EBA307D914DD4093D86FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1C0F75C6F2E042B46A44DD4093D82577" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3B2176BBCA549D403527DD4093D70CEA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1C0F75C6F2E042B46A44DD4093D82577" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D5A58C0F9D7E4D7864E6DD4093D8B7F2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3B2176BBCA549D403527DD4093D70CEA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_D5A58C0F9D7E4D7864E6DD4093D8B7F2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C68E0E5BDDD4D55E38B3BAA235F73F3D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C68E0E5BDDD4D55E38B3BAA235F73F3D" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7" xlink:to="loc_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_92A24232E7FEB44E9BCDBAA235F8FB93" xlink:to="loc_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_BridgewaterNewJerseyFacilityMember" xlink:label="loc_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7B2283F3072A40AC8D25BAA235F8EFEC" xlink:to="loc_insm_BridgewaterNewJerseyFacilityMember_899FBDC4B17720EE1A50BAA235F93BC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_C3A99566C4E100F04C79BAA235F85EC7" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:to="loc_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7646ACF5F9E816121B8ABAA235F9A58D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_DC3B3ADE5A08C1BC27FBBAA235FAAEB4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:to="loc_us-gaap_LeaseAndRentalExpense_DC3B3ADE5A08C1BC27FBBAA235FAAEB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_A716BF0AA9AC8098DEA1BAB566C3334E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:to="loc_us-gaap_PurchaseObligation_A716BF0AA9AC8098DEA1BAB566C3334E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0E77313F69933601EF0DBAA235FA564F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_F5F8E3A3FB680034EB63BAA235F90FFA" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0E77313F69933601EF0DBAA235FA564F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_62FD63EC7BECACDD4C5EC80C927A9A6C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C47448B54C52059E29A1C80C927A1CB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_62FD63EC7BECACDD4C5EC80C927A9A6C" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_C47448B54C52059E29A1C80C927A1CB1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_C8F25EDA06216266A412C8B4E23C054A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C8F25EDA06216266A412C8B4E23C054A" xlink:to="loc_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F" xlink:to="loc_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9532C6FC5738EB74D9AAC8B4E23D8EE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9532C6FC5738EB74D9AAC8B4E23D8EE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7FB3D6F5BB36380A993CC8B4E23EB726" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7FB3D6F5BB36380A993CC8B4E23EB726" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_F72071759F44E23099D1C8B4E23ED4DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2" xlink:to="loc_us-gaap_InventoryNet_F72071759F44E23099D1C8B4E23ED4DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6756BDC42BAB476DF7B5C8B4E23E901F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6756BDC42BAB476DF7B5C8B4E23E901F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_CEEFC18E1543E2AAFD23C8B4E23E6D5F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F7ACD6482C5191350EA0C8B4E23D41E2" xlink:to="loc_us-gaap_AssetsCurrent_CEEFC18E1543E2AAFD23C8B4E23E6D5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_EDD298878BE12D8036C2C8B4E23F9992" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_EDD298878BE12D8036C2C8B4E23F9992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4971B01FD5ECF9390BB3C8B4E23F17EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4971B01FD5ECF9390BB3C8B4E23F17EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_C2875DE9FB86E5E392C2C8B4E23F5976" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F" xlink:to="loc_us-gaap_OtherAssets_C2875DE9FB86E5E392C2C8B4E23F5976" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_9A556A6E5B31BD4B47B7C8B4E23FA607" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_FF576FF88E582A6756BDC8B4E23DD09F" xlink:to="loc_us-gaap_Assets_9A556A6E5B31BD4B47B7C8B4E23FA607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C8F25EDA06216266A412C8B4E23C054A" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2075AA8A5163FFEB4F4AC8B4E240097F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45" xlink:to="loc_us-gaap_AccountsPayableCurrent_2075AA8A5163FFEB4F4AC8B4E240097F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1F9B8D77B6520F2F1F7FC8B4E240BF29" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1F9B8D77B6520F2F1F7FC8B4E240BF29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_38E38D02876EA99896E5C8B4E240C59C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_38E38D02876EA99896E5C8B4E240C59C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0B9D2E011050E55BE5BBC8B4E24024F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0B9D2E011050E55BE5BBC8B4E24024F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_4E297F2D5A1B59EEB80BC8B4E24173A1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_360DDE27A840ACA5DA50C8B4E23FCE45" xlink:to="loc_us-gaap_LiabilitiesCurrent_4E297F2D5A1B59EEB80BC8B4E24173A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_B9533764B2AF5CDF5069C8B4E243039A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_B9533764B2AF5CDF5069C8B4E243039A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_874310B4639FBA4E9BB7C8B4E2438491" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_874310B4639FBA4E9BB7C8B4E2438491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_3BF5CE271B2C54E65858C8B4E2449CDD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7" xlink:to="loc_us-gaap_Liabilities_3BF5CE271B2C54E65858C8B4E2449CDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_DA9163A78E97C5526B52C8B4E23F42D7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_DDE371244FA35871DBD1C8B4E244E811" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:to="loc_us-gaap_CommonStockValue_DDE371244FA35871DBD1C8B4E244E811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_512C09859AE9AC6B91B5C8B4E244623C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:to="loc_us-gaap_AdditionalPaidInCapital_512C09859AE9AC6B91B5C8B4E244623C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DD489AE8C8AAF8601003C8B4E24643E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DD489AE8C8AAF8601003C8B4E24643E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5B12E063584509D21446C8B4E246F74C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5B12E063584509D21446C8B4E246F74C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B5E15F132C3F1136E8D3C8B4E2465A61" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:to="loc_us-gaap_StockholdersEquity_B5E15F132C3F1136E8D3C8B4E2465A61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2D624528866E4BB13185C8B4E247DCD6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_B481903731B56E0D4C64C8B4E24450BB" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2D624528866E4BB13185C8B4E247DCD6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_93787890C97098D9A2C4C80C91D522D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_56034A0BD38284C70B1CC80C91D692D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93787890C97098D9A2C4C80C91D522D3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_56034A0BD38284C70B1CC80C91D692D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_D44C624171062BE52CE4C80C91D603FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93787890C97098D9A2C4C80C91D522D3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_D44C624171062BE52CE4C80C91D603FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7CB348C1E137795A9499C80C91D61186" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93787890C97098D9A2C4C80C91D522D3" xlink:to="loc_us-gaap_CommonStockSharesIssued_7CB348C1E137795A9499C80C91D61186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8FE0593F7608891FDCCAC80C91D64EF7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93787890C97098D9A2C4C80C91D522D3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8FE0593F7608891FDCCAC80C91D64EF7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1E3AC1F1AEE60B619DF70C93D4A81603" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1E3AC1F1AEE60B619DF70C93D4A81603" xlink:to="loc_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C5188F092562072457410C93D4A91068" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:to="loc_us-gaap_DebtInstrumentAxis_C5188F092562072457410C93D4A91068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44C923B0813BB715A8470C93D4A975C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_C5188F092562072457410C93D4A91068" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44C923B0813BB715A8470C93D4A975C5" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_0D4AC9018D779B2E0D440C93D4AAFE4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44C923B0813BB715A8470C93D4A975C5" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_0D4AC9018D779B2E0D440C93D4AAFE4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2E51DFDCCFC2ABF65DC10C93D4AA1C61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2E51DFDCCFC2ABF65DC10C93D4AA1C61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_69886BC5417EE938B3D40C93D4AAF1D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2E51DFDCCFC2ABF65DC10C93D4AA1C61" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_69886BC5417EE938B3D40C93D4AAF1D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_3E2DAC133DCEA887C8830C93D4AA5C67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_69886BC5417EE938B3D40C93D4AAF1D3" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_3E2DAC133DCEA887C8830C93D4AA5C67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0CCAF7EDE49C3FF13F250C93D4A83D4C" xlink:to="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A4AFAEF73DFABD21AFE80C93D4AB1546" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:to="loc_us-gaap_NetIncomeLoss_A4AFAEF73DFABD21AFE80C93D4AB1546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5D99DA04E2D6A4FEEC4F0C93D4AB0306" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_278DBCDD33E18A74FDA80C93D4AC939E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_Depreciation_278DBCDD33E18A74FDA80C93D4AC939E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_78E277EE2B7B5F29BE570C93D4ACA1FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_78E277EE2B7B5F29BE570C93D4ACA1FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A8B568EAA8A4F87DA1780C93D4AD711A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_ShareBasedCompensation_A8B568EAA8A4F87DA1780C93D4AD711A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_24E20B141B8689034A9F0C93D4AD1FFC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_24E20B141B8689034A9F0C93D4AD1FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_663151FA7AF44821EC940C9678A432B4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_663151FA7AF44821EC940C9678A432B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_E7F518F7AEBE3F821F4F0C93D4ADD922" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_E7F518F7AEBE3F821F4F0C93D4ADD922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_09B6785031A2A146FE110C93D4ADE9A3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_AccretionExpense_09B6785031A2A146FE110C93D4ADE9A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_742FCCB762EC48E5AD340C93D4ACC0F3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_CE03F10ECB5D81C0C2880C93D4AEC369" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_CE03F10ECB5D81C0C2880C93D4AEC369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_14E5B153496501427D810C93D4AE8C06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_14E5B153496501427D810C93D4AE8C06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B7AAF1DA83F0F445571F0C93D4AE15D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_B7AAF1DA83F0F445571F0C93D4AE15D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9ED0A30F626F314FCD010C93D4AE673E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9ED0A30F626F314FCD010C93D4AE673E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_D44CF73A1FF9CE2738570C93D4AF4FD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3195AFCBD8C639CBC4FF0C93D4AF98A7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3195AFCBD8C639CBC4FF0C93D4AF98A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0A48BB7215B317E5F1BE0C93D4AFDF8D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_382F8F2DABD753200B1C0C93D4ADF8C4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0A48BB7215B317E5F1BE0C93D4AFDF8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45E41025C777BB78F7420C93D4AF26BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45E41025C777BB78F7420C93D4AF26BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_09CAA61361022BB04E590C93D4B01D77" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_09CAA61361022BB04E590C93D4B01D77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_330E2CF10306994C6D590C93D4B0B480" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C1E719B28E8262EBC5780C93D4AF8E2B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_330E2CF10306994C6D590C93D4B0B480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_4EEE6D6E06433A445B2D0C93D4B0C87B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_4EEE6D6E06433A445B2D0C93D4B0C87B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7E4D9DF066D68AE2483F0C93D4B12FD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7E4D9DF066D68AE2483F0C93D4B12FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_618F08679033118676350C93D4B195F2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_RepaymentsOfDebt_618F08679033118676350C93D4B195F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_DDD448DE9E856CA08B7D0C93D4B18361" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_DDD448DE9E856CA08B7D0C93D4B18361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_860366CE10231D15EBF20C93D4B10B3E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_860366CE10231D15EBF20C93D4B10B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7DD5C5382DD48011C6C80C93D4B12181" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7DD5C5382DD48011C6C80C93D4B12181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_C86021248EB400E181280C93D4B2A1FC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_C86021248EB400E181280C93D4B2A1FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2CDA63217499ED916F9A0C93D4B29F78" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49D65D3F5355E73581180C93D4B06D92" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2CDA63217499ED916F9A0C93D4B29F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8E010265053963D520D90C93D4B25D9E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8E010265053963D520D90C93D4B25D9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E1A695987984950FB6060C93D4B2C1AA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_E1A695987984950FB6060C93D4B2C1AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AFEBCC5EBDDBE0EBDE7B0C93D4B2AA4D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AFEBCC5EBDDBE0EBDE7B0C93D4B2AA4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F38740DC1C763E95EFAD0C93D4B80CFB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F38740DC1C763E95EFAD0C93D4B80CFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B5DE2E85924497BB8D180C93D4ABC079" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_17623CE87AB346DBCD2F0C93D4B8A3B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:to="loc_us-gaap_InterestPaidNet_17623CE87AB346DBCD2F0C93D4B8A3B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_436EBEC3FF37467E6E8A0C93D4B8223F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B964330B17410BF18380C93D4B88688" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_436EBEC3FF37467E6E8A0C93D4B8223F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DB36252F03E4015F22650C93D4B86373" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1E3AC1F1AEE60B619DF70C93D4A81603" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DB36252F03E4015F22650C93D4B86373" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_51289E594A85507C9868C8B4E21F8A58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_RevenuesAbstract_51289E594A85507C9868C8B4E21F8A58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EFD352602F47986778FEC8B4E21FBBF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_51289E594A85507C9868C8B4E21F8A58" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EFD352602F47986778FEC8B4E21FBBF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_CBFBF5CA03052936A401C8B4E21FD165" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_CBFBF5CA03052936A401C8B4E21FD165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_18D1C61DE1ED77F2E379C8B4E2222036" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_18D1C61DE1ED77F2E379C8B4E2222036" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8EDD060FAD8DE3F431B4C8B4E2226F0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8EDD060FAD8DE3F431B4C8B4E2226F0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_BD7B095313CD13434F28C8B4E222B430" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_BD7B095313CD13434F28C8B4E222B430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_43E7413FE2945302DA59C8B4E2239742" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5071EA073A7848128AC6C8B4E21F4360" xlink:to="loc_us-gaap_CostsAndExpenses_43E7413FE2945302DA59C8B4E2239742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_88424FE4820EABF1C499C8B4E223A073" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_OperatingIncomeLoss_88424FE4820EABF1C499C8B4E223A073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_9B2D803BF66B528E4C37C8B4E2234619" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_9B2D803BF66B528E4C37C8B4E2234619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_3064C6CD0C9C4F794CFEC8B4E2239BF3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_InterestExpense_3064C6CD0C9C4F794CFEC8B4E2239BF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_17EF090C8381BE40DEE3C8B4E223F77E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_17EF090C8381BE40DEE3C8B4E223F77E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_BBCA43DA9E8B57901892C8B4E224ED3C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_BBCA43DA9E8B57901892C8B4E224ED3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_DCBA61DCE5D853143FAAC8B4E224A63A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_DCBA61DCE5D853143FAAC8B4E224A63A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_22377C9EA98DAA2BBC84C8B4E2245840" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_22377C9EA98DAA2BBC84C8B4E2245840" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_523214CF46CAF97806A8C8B4E225F018" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_NetIncomeLoss_523214CF46CAF97806A8C8B4E225F018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_304E34679C97D951803AC8B4E22532DB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_304E34679C97D951803AC8B4E22532DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9F84CD3BB7CB92BF6C7AC8B4E2254E4A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9F84CD3BB7CB92BF6C7AC8B4E2254E4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_A9FD56F56232DFEE76EAC8B4E225C1DF" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_A9FD56F56232DFEE76EAC8B4E225C1DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74FE404ECDB19FE88676C8B4E226CBA0" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74FE404ECDB19FE88676C8B4E226CBA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0F375B94650F49090A1CC8B4E22600A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_74FE404ECDB19FE88676C8B4E226CBA0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0F375B94650F49090A1CC8B4E22600A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_EB13DAC902DB22DB3532C8B4E226D96D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A03EA2C47F4B91C1E8C3C8B4E21E349E" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_EB13DAC902DB22DB3532C8B4E226D96D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7E397218938090DE83C6807FFD76542E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_6BB5DA2E69D3EDDB758D807FFD767843" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7E397218938090DE83C6807FFD76542E" xlink:to="loc_us-gaap_StatementTable_6BB5DA2E69D3EDDB758D807FFD767843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6BB5DA2E69D3EDDB758D807FFD767843" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_960373BA8E23DA3F7073807FFD76F7A3" xlink:to="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_67D9812FA89DE4BEA295807FFD77A807" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:to="loc_us-gaap_CommonStockMember_67D9812FA89DE4BEA295807FFD77A807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_AD15C0334D055B9B1C55807FFD77F114" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_AD15C0334D055B9B1C55807FFD77F114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_F38403F16A203911FD90807FFD77E481" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:to="loc_us-gaap_RetainedEarningsMember_F38403F16A203911FD90807FFD77E481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CCF39A1FD996CE103504807FFD77373E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_FEE1A188B5C53E47F659807FFD7631FE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CCF39A1FD996CE103504807FFD77373E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1C94F51B79F6C9117D8B807FFD78B34A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6BB5DA2E69D3EDDB758D807FFD767843" xlink:to="loc_us-gaap_StatementLineItems_1C94F51B79F6C9117D8B807FFD78B34A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1C94F51B79F6C9117D8B807FFD78B34A" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_DC2D59A97C6440B58B16807FFD78A421" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockholdersEquity_DC2D59A97C6440B58B16807FFD78A421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_7513838A60039BE2F41E807FFD781491" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_SharesOutstanding_7513838A60039BE2F41E807FFD781491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DE5EB00C127FE19A65BE807FFD79FD58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:to="loc_us-gaap_NetIncomeLoss_DE5EB00C127FE19A65BE807FFD79FD58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3C9707AA3B39D6764C8F807FFD797CC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2053019FA6C7DA1358E2807FFD786D65" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3C9707AA3B39D6764C8F807FFD797CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_D09A8257BF8A0BCCFC8F807FFD79D7DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_D09A8257BF8A0BCCFC8F807FFD79D7DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9F7A74B301B690A78220807FFD79604A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9F7A74B301B690A78220807FFD79604A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0E869170F73862C35F92807FFD799821" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0E869170F73862C35F92807FFD799821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89E9B6272B28E465714E807FFD7A4A87" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89E9B6272B28E465714E807FFD7A4A87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9272184B92AF89EE0967807FFD7A929B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9272184B92AF89EE0967807FFD7A929B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_94F0E1F24A5F8D9CF128807FFD7AA4D2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_94F0E1F24A5F8D9CF128807FFD7AA4D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16D109FD69DC56659FDA807FFD7A8F16" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16D109FD69DC56659FDA807FFD7A8F16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0A9EB13863865C36730F807FFD7A4AE0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0A9EB13863865C36730F807FFD7A4AE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_075A2309A29CD96156B0807FFD7B4320" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_StockholdersEquity_075A2309A29CD96156B0807FFD7B4320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_1F87D593D6C7E76B0C7A807FFD7B5C65" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_FA8B09850FC1A26AFB4D807FFD789ABA" xlink:to="loc_us-gaap_SharesOutstanding_1F87D593D6C7E76B0C7A807FFD7B5C65" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_DE29461E3314321F5E8CC80C92289DB4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_60525AC641B42109544AC80C92281A3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_DE29461E3314321F5E8CC80C92289DB4" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_60525AC641B42109544AC80C92281A3C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtComponentsOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F2DBE86A4B89783749F55752D4F860BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_59BCE71C25EDBB3901DB5752D4F8FC72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F2DBE86A4B89783749F55752D4F860BB" xlink:to="loc_us-gaap_DebtInstrumentTable_59BCE71C25EDBB3901DB5752D4F8FC72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_800F0F745D6021F07EAF5752D4F93E67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59BCE71C25EDBB3901DB5752D4F8FC72" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_800F0F745D6021F07EAF5752D4F93E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A9B64D2A5873C12F8BE55752D4F9F7DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_800F0F745D6021F07EAF5752D4F93E67" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_A9B64D2A5873C12F8BE55752D4F9F7DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_F179802E54B5771361AF5752D4F9558E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_A9B64D2A5873C12F8BE55752D4F9F7DA" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_F179802E54B5771361AF5752D4F9558E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8FD6F48BB1A773098FC45752D4FAF6EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59BCE71C25EDBB3901DB5752D4F8FC72" xlink:to="loc_us-gaap_DebtInstrumentAxis_8FD6F48BB1A773098FC45752D4FAF6EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_532E311E0BA197BA13FC5752D4FA061E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8FD6F48BB1A773098FC45752D4FAF6EF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_532E311E0BA197BA13FC5752D4FA061E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_D5BD3D701075837BEC035752D4FB10E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_532E311E0BA197BA13FC5752D4FA061E" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_D5BD3D701075837BEC035752D4FB10E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_59BCE71C25EDBB3901DB5752D4F8FC72" xlink:to="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_2CDE5A6BB150DF9309555752D4FB708C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:to="loc_us-gaap_SecuredDebt_2CDE5A6BB150DF9309555752D4FB708C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_21674C05B821831D380D5752D4FC47D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_21674C05B821831D380D5752D4FC47D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9ED95C30CC5CB642D6FA5752D4FCA444" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9ED95C30CC5CB642D6FA5752D4FCA444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_372A143DA394CCC803E25752D4FCCF10" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_372A143DA394CCC803E25752D4FCCF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9B6B3F24B665BFC3F9455752D4FC349D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE836AB5819B3E5BD9B25752D4FBB95F" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9B6B3F24B665BFC3F9455752D4FC349D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_451FE41644E6D839C5800DE7EBDC3AEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_451FE41644E6D839C5800DE7EBDC3AEC" xlink:to="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentConversionTermAxis" xlink:label="loc_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:to="loc_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentConversionTermDomain" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_E8FA5A2DFF0756FAE9DE0DE7EBDCD286" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ConversionTermiMember" xlink:label="loc_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:to="loc_insm_ConversionTermiMember_82770A2297D9873386520DE7EBDDCFDC" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ConversionTermiiMember" xlink:label="loc_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:to="loc_insm_ConversionTermiiMember_72CA7494FA364E59DD9C0DE7EBDE91CF" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ConversionTermiiiMember" xlink:label="loc_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:to="loc_insm_ConversionTermiiiMember_319F5A307627AEA7C96F0DE7EBDECDFB" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ConversionTermivMember" xlink:label="loc_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_023855A8094DC57584D90DE7EBDD77B6" xlink:to="loc_insm_ConversionTermivMember_5BD1AE8B637BFC9181EA0DE7EBDEDA81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FACC58C95A3CEFB6C4560DE7EBDE82AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_FACC58C95A3CEFB6C4560DE7EBDE82AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_44E72205592D48E71A7C0DE7EBDEA147" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FACC58C95A3CEFB6C4560DE7EBDE82AF" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_44E72205592D48E71A7C0DE7EBDEA147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_A473FBAF9B02DC9FC3B40DE7EBDF7ED3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_44E72205592D48E71A7C0DE7EBDEA147" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_A473FBAF9B02DC9FC3B40DE7EBDF7ED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C1F21E5ACD55CB1EE3380DE7EBDFAAC6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:to="loc_us-gaap_DebtInstrumentAxis_C1F21E5ACD55CB1EE3380DE7EBDFAAC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A08936F2E8D37E6B01410DE7EBDFB24D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_C1F21E5ACD55CB1EE3380DE7EBDFAAC6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A08936F2E8D37E6B01410DE7EBDFB24D" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_F34FC0089A584E94114A0DE7EBE0DD38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A08936F2E8D37E6B01410DE7EBDFB24D" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_F34FC0089A584E94114A0DE7EBE0DD38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_FD4B8CCEFB7D11145B700DE7EBE15D9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A08936F2E8D37E6B01410DE7EBDFB24D" xlink:to="loc_us-gaap_LineOfCreditMember_FD4B8CCEFB7D11145B700DE7EBE15D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9C772F6D9D7E230B369F0DE7EBDCCD53" xlink:to="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_B930345FD856C65255920DE7EBE1B352" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_B930345FD856C65255920DE7EBE1B352" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_5B0520456AF5E021D41A0DE7EBE18ED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_593BFDEED0B60A9C203E0DE7EBE297FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_593BFDEED0B60A9C203E0DE7EBE297FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_95E6B2B2D6E2CBC420FC0DE7EBE24AA3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_95E6B2B2D6E2CBC420FC0DE7EBE24AA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_0A387B9BEAC401AB49990DE7EBE28840" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_0A387B9BEAC401AB49990DE7EBE28840" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0472DAC8E0394D63DEEA0DE7EBE266C3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0472DAC8E0394D63DEEA0DE7EBE266C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A905463F2AC3CE0FD43E0DE7EBE2E7CA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A905463F2AC3CE0FD43E0DE7EBE2E7CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_AA528A012E1CA591C4C50DE7EBE2468B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_AA528A012E1CA591C4C50DE7EBE2468B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90756108AE32198A68010DE7EBE32827" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_90756108AE32198A68010DE7EBE32827" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_B67ECBBE38DE5EC6CAED0DE7EBE3FDCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_ACE70DB48BA7899683440DE7EBE396B4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_ACE70DB48BA7899683440DE7EBE396B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_D89957ED619FE909EEB30DE7EBE3CB9D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_D89957ED619FE909EEB30DE7EBE3CB9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5A9DC37622DC5BE416CC0DE7EBE3C70A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_5A9DC37622DC5BE416CC0DE7EBE3C70A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_22FB3873BCC12411166C0DE7EBE38C22" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_22FB3873BCC12411166C0DE7EBE38C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_D80187B1C148611107C70DE7EBE4166B" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_InterestExpense_D80187B1C148611107C70DE7EBE4166B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_7E5A8894AB7E324DCCE60DE7EBE49923" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_RepaymentsOfDebt_7E5A8894AB7E324DCCE60DE7EBE49923" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_RepaymentsOfDebtFeesAndOutstandingInterest" xlink:label="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_92A5733DCAAA257B4D4E0DE7EBE40EBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5AEF1A5F5AA5AEE12570DE7EBE41583" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_D7E1187CFF1A1E43D5C70DE7EBE1BB46" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_B5AEF1A5F5AA5AEE12570DE7EBE41583" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_05037883280C063E6E0352BD402EF9E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_A82BC48EEC53118B3AC152BD402E84BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_05037883280C063E6E0352BD402EF9E5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_A82BC48EEC53118B3AC152BD402E84BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FD26DD458C88FABFC75F52BD402E52AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_05037883280C063E6E0352BD402EF9E5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_FD26DD458C88FABFC75F52BD402E52AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_63809881AD437F2BF03D52BD402E4106" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_05037883280C063E6E0352BD402EF9E5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_63809881AD437F2BF03D52BD402E4106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5565DBE55BDBF0B734F52BD402FD307" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_05037883280C063E6E0352BD402EF9E5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_C5565DBE55BDBF0B734F52BD402FD307" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="loc_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_5D139AF894728F9BB77952CA8EB1E4BE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_05037883280C063E6E0352BD402EF9E5" xlink:to="loc_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_5D139AF894728F9BB77952CA8EB1E4BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_88361A35ABA9A288CC0A52BD402F3CD5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_05037883280C063E6E0352BD402EF9E5" xlink:to="loc_us-gaap_LongTermDebt_88361A35ABA9A288CC0A52BD402F3CD5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5FCD4226B05CA15FC02FC80C91DB547F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_C8DBB076C9C35CB1AA05C80C91DBCE07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5FCD4226B05CA15FC02FC80C91DB547F" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_C8DBB076C9C35CB1AA05C80C91DBCE07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_84C2A67F66BC39D22AAEC80C91DC4ADB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5FCD4226B05CA15FC02FC80C91DB547F" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_84C2A67F66BC39D22AAEC80C91DC4ADB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B6D3DAAA20656053FC1EC80C907B3F41" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_80CF65D4F51173BB6902C80C907B4A2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B6D3DAAA20656053FC1EC80C907B3F41" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_80CF65D4F51173BB6902C80C907B4A2F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C0907769E9AEC8E20D99A63064D6EA12" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E72E6BB0D142F485B144A63064D6B624" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C0907769E9AEC8E20D99A63064D6EA12" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E72E6BB0D142F485B144A63064D6B624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FB96A0CBFFCCE75A9825A63064D67F4B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C0907769E9AEC8E20D99A63064D6EA12" xlink:to="loc_us-gaap_NetIncomeLoss_FB96A0CBFFCCE75A9825A63064D67F4B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="insm-20181231.xsd#insm_DocumentAndEntityInformationAbstract" xlink:label="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_4DCF2357ABDAE7D6AC3A807F95BBD3EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_EntityRegistrantName_4DCF2357ABDAE7D6AC3A807F95BBD3EC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7BFE28010E88E604B529807F95BBA1C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_EntityCentralIndexKey_7BFE28010E88E604B529807F95BBA1C6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_CAF490BA49C667ECFA27807F95BC6C8E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_DocumentType_CAF490BA49C667ECFA27807F95BC6C8E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_475B8EEE1505922FB97A807F95BC5351" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_DocumentPeriodEndDate_475B8EEE1505922FB97A807F95BC5351" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_F897787393018F95CA75807F95BC8A51" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_AmendmentFlag_F897787393018F95CA75807F95BC8A51" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_B127AF8DBE9AE1A14F2E807F95BC7CFA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_CurrentFiscalYearEndDate_B127AF8DBE9AE1A14F2E807F95BC7CFA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_79427ABF3F802F537770807F95BC7913" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_79427ABF3F802F537770807F95BC7913" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_6576C9524D20F5DC2E66807F95BDBD96" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_EntityVoluntaryFilers_6576C9524D20F5DC2E66807F95BDBD96" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_98CF39862ADC4876789E807F95BDE306" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_EntityCurrentReportingStatus_98CF39862ADC4876789E807F95BDE306" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_FAFEFA1DC2357628CED6807F95BD4627" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_EntityFilerCategory_FAFEFA1DC2357628CED6807F95BD4627" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_8A2B2A822CC86D86A0E9807F95BD3FCB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_EntityPublicFloat_8A2B2A822CC86D86A0E9807F95BD3FCB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8C8B4DC178BBE6D29B24807F95BD8178" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8C8B4DC178BBE6D29B24807F95BD8178" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_DB9FF77B2AA919E6F1FD807F95BDE830" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_DocumentFiscalYearFocus_DB9FF77B2AA919E6F1FD807F95BDE830" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5FC3EBBA16378342C577807F95BEFAEC" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5FC3EBBA16378342C577807F95BEFAEC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_8B86FFF9360690E979CA807F95BE762B" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_EntityShellCompany_8B86FFF9360690E979CA807F95BE762B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_279839D27E3656FC9BC9807F95BE287D" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_EntityEmergingGrowthCompany_279839D27E3656FC9BC9807F95BE287D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_6AF35B70E1C33505BA56807F95BE842A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_B5486EB80F7DBD62DF72807F95B7161F" xlink:to="loc_dei_EntitySmallBusiness_6AF35B70E1C33505BA56807F95BE842A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FixedAssetsNet" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E6C7B789D7B8BE3ECD41C80C927CA13F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C3C814E30028C84E5678C80C927C12F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E6C7B789D7B8BE3ECD41C80C927CA13F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C3C814E30028C84E5678C80C927C12F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4341779971AB53FE78B6BE8FADA037C2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4341779971AB53FE78B6BE8FADA037C2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60BD17664D2A90FEA96CBE8FADA0836B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_4C7332D7EC1F48419932BE8FADA00622" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_us-gaap_EquipmentMember_4C7332D7EC1F48419932BE8FADA00622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2A05F085882D53907B75BE8FADA2EE5E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2A05F085882D53907B75BE8FADA2EE5E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ComputerHardwareAndSoftwareMember" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember_E27782C42029BE46B9ABBE8FADA27381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_1E827B8596318CDABE4EBE8FADA2BE83" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_us-gaap_OfficeEquipmentMember_1E827B8596318CDABE4EBE8FADA2BE83" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ManufacturingEquipmentMember" xlink:label="loc_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_insm_ManufacturingEquipmentMember_7F43D1512FE3F0BCFEE8BE8FADA22226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7B6280AB4C7E913004C8BE8FADA2AD30" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7B6280AB4C7E913004C8BE8FADA2AD30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_6583E3435A7335AB2B8BBE8FADA25308" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F87305A408A48B9D416CBE8FADA0D584" xlink:to="loc_us-gaap_ConstructionInProgressMember_6583E3435A7335AB2B8BBE8FADA25308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14577A462730A64EA0A1BE8FADA25F89" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:to="loc_srt_RangeAxis_14577A462730A64EA0A1BE8FADA25F89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_E44AB9372E851821008BBE8FADA25A39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14577A462730A64EA0A1BE8FADA25F89" xlink:to="loc_srt_RangeMember_E44AB9372E851821008BBE8FADA25A39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C9A7730FA0E4E2E11932BE8FADA2F428" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_E44AB9372E851821008BBE8FADA25A39" xlink:to="loc_srt_MinimumMember_C9A7730FA0E4E2E11932BE8FADA2F428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_33476AB3684A1F246385BE8FADA27704" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_E44AB9372E851821008BBE8FADA25A39" xlink:to="loc_srt_MaximumMember_33476AB3684A1F246385BE8FADA27704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_C70F7F06E92F75FACFE4BE8FADA0A608" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_587209B7F92301EA665BBE8FADA2C11B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_587209B7F92301EA665BBE8FADA2C11B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EA4F08417D911622DDC6BE8FADA558B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EA4F08417D911622DDC6BE8FADA558B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_47989EA0008F9131FC32BE8FADA56D92" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_47989EA0008F9131FC32BE8FADA56D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_07EB0C2E0E79B33D9DEDBE8FADA5827E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_07EB0C2E0E79B33D9DEDBE8FADA5827E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_A8015064194583E59421BE8FADA5D26A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_A8015064194583E59421BE8FADA5D26A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_4629103785249527514BBE8FADA52FB6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_C24DC8EBE2A8D3DBBA0EBE8FADA2AC1A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_4629103785249527514BBE8FADA52FB6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FixedAssetsNetTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_AF6ECF97CB9102A390F1C80C9196E6EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A924279659A91FF50991C80C91960E2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_AF6ECF97CB9102A390F1C80C9196E6EE" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A924279659A91FF50991C80C91960E2F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_207FBCF1336C7BFE934BC80C922A608C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_B4F9A607E9FDFA283DB6C80C922A166F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_207FBCF1336C7BFE934BC80C922A608C" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_B4F9A607E9FDFA283DB6C80C922A166F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C10BDA71270C7D8EA8E208DFA9DB434F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C10BDA71270C7D8EA8E208DFA9DB434F" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E56230E125EBF0253F7A08DFA9DBD468" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_E56230E125EBF0253F7A08DFA9DBD468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_809DF1EDA039D3FF7EC208DFA9DCDA66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_809DF1EDA039D3FF7EC208DFA9DCDA66" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DeferredTaxAssetsLicensePayment" xlink:label="loc_insm_DeferredTaxAssetsLicensePayment_28B89DDC5432CD91BC6508DFA9DC0F62" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:to="loc_insm_DeferredTaxAssetsLicensePayment_28B89DDC5432CD91BC6508DFA9DC0F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_08CB89E8F0F4B93B969708E5067FED4E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_08CB89E8F0F4B93B969708E5067FED4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_827EA899C8627B0621B108DFA9DCBABF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_827EA899C8627B0621B108DFA9DCBABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_9AECEACE7F31D69E36BE08DFA9DDE685" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_DD79E186AE73B9153BC808DFA9DB8922" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_9AECEACE7F31D69E36BE08DFA9DDE685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3DC2AEC49A61F0B99DBB08DFA9DD2655" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C10BDA71270C7D8EA8E208DFA9DB434F" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3DC2AEC49A61F0B99DBB08DFA9DD2655" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2D65D844498073F93D8B08DFA9DDFB9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3DC2AEC49A61F0B99DBB08DFA9DD2655" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2D65D844498073F93D8B08DFA9DDFB9B" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DeferredTaxLiabilitiesConvertibleDebt" xlink:label="loc_insm_DeferredTaxLiabilitiesConvertibleDebt_750A03B5944635B3911008DFA9DDD91A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3DC2AEC49A61F0B99DBB08DFA9DD2655" xlink:to="loc_insm_DeferredTaxLiabilitiesConvertibleDebt_750A03B5944635B3911008DFA9DDD91A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_541114E613DA1BC1382E08DFA9DDAFFE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_3DC2AEC49A61F0B99DBB08DFA9DD2655" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_541114E613DA1BC1382E08DFA9DDAFFE" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_C46B32F791E5318EAB4008DFA9DEC3C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C10BDA71270C7D8EA8E208DFA9DB434F" xlink:to="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_C46B32F791E5318EAB4008DFA9DEC3C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7C5D972EB55E2D6245BB08DFA9DEBF37" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C10BDA71270C7D8EA8E208DFA9DB434F" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7C5D972EB55E2D6245BB08DFA9DEBF37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7F4A61DA42BCF8FA9E2808DFA9DE604B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C10BDA71270C7D8EA8E208DFA9DB434F" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7F4A61DA42BCF8FA9E2808DFA9DE604B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_85671A9A718563300CE0A616486329AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_85671A9A718563300CE0A616486329AA" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3FBC4FB4A0C2D61D13E7A61648644BA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3FBC4FB4A0C2D61D13E7A61648644BA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6ED60FBAD3E39D1F8DE0A61648642097" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6ED60FBAD3E39D1F8DE0A61648642097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3ABADC30CB2963C9C79BA61648643C9B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3ABADC30CB2963C9C79BA61648643C9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8E1216FCC33AF3D0C702A6164864FF4D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_BD9E8345B84EAA9CA548A6164863269E" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8E1216FCC33AF3D0C702A6164864FF4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_85671A9A718563300CE0A616486329AA" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_A6D87B1B886FD33E63CDA6164865F635" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_A6D87B1B886FD33E63CDA6164865F635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EA99D662071C925E82EFA6164865B2EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EA99D662071C925E82EFA6164865B2EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_24DF79010E2ADF8EDC12A6164865693F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_24DF79010E2ADF8EDC12A6164865693F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6C55E6228CA974EA0C38A6164865A509" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_99C694E33ECBF12B5795A6164864AA90" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6C55E6228CA974EA0C38A6164865A509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B277C7F63598907FD402A6164865BB87" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_85671A9A718563300CE0A616486329AA" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_B277C7F63598907FD402A6164865BB87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_07B4E642C1C3CD2B0409C80C91B16BA2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_99240A7514E1119E3A68C80C91B14BB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_07B4E642C1C3CD2B0409C80C91B16BA2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_99240A7514E1119E3A68C80C91B14BB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A1F9D34A0950AFC64C0BC80C91B1CEDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_07B4E642C1C3CD2B0409C80C91B16BA2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_A1F9D34A0950AFC64C0BC80C91B1CEDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6B48D886CBA5B7661C16C80C91B1ADCF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_07B4E642C1C3CD2B0409C80C91B16BA2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6B48D886CBA5B7661C16C80C91B1ADCF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_951D9C2B0EC965AD25B7C8B4E0193D65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_951D9C2B0EC965AD25B7C8B4E0193D65" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_A23941377E65DD5F8042C9F5EAD23ACA" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_A14527FD60B1C0722DC4C9F686C28A3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_72D2CE718EB40176614DC9F64B344E5B" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_A14527FD60B1C0722DC4C9F686C28A3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CDB8663433B843A3DC10C8B4E0190D84" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_7AF31B5C1F84467478DCC8B4E01BB0BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:to="loc_us-gaap_DomesticCountryMember_7AF31B5C1F84467478DCC8B4E01BB0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_695DDE5874EF3DA06159C8B4E01A15EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3DA8493F3D54120DAF53C8B4E01A4B1F" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_695DDE5874EF3DA06159C8B4E01A15EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_24D673E29F12AC36EBA3C8B4E0191DA6" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E239B7FE07B9B2728AFFC8B4E01C955E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E239B7FE07B9B2728AFFC8B4E01C955E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58605D08494716690590C8B4E01CE3E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58605D08494716690590C8B4E01CE3E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6431F38A5374FBD770ADC8B4E01CDB21" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6431F38A5374FBD770ADC8B4E01CDB21" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_614D554622436A55EE8BC8B4E01DE022" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_614D554622436A55EE8BC8B4E01DE022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B0527100D9A8BD081AF0C8B4E01D3BBB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_B0527100D9A8BD081AF0C8B4E01D3BBB" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_OperatingLossCarryforwardsTotal" xlink:label="loc_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_insm_OperatingLossCarryforwardsTotal_B202A1EFE7D0B2BD0779C8B4E01EBBCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2F4984D5DF26F5326317C8B4E01FD7F1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_99D4BD065FE8438F0CB1C8B4E01B7B1F" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2F4984D5DF26F5326317C8B4E01FD7F1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_47B3C8067709E39D9E42807FFBA996E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2F9D41C474346407C8D6807FFBA9692D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47B3C8067709E39D9E42807FFBA996E0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2F9D41C474346407C8D6807FFBA9692D" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_B67CB241108E6D9D2C77807FFBAA8831" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47B3C8067709E39D9E42807FFBA996E0" xlink:to="loc_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_B67CB241108E6D9D2C77807FFBAA8831" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4064DE8C98B31E547671807FFBAA0BE2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47B3C8067709E39D9E42807FFBA996E0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4064DE8C98B31E547671807FFBAA0BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_FEF0F6A6541B6DE535FB807FFBAAA581" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47B3C8067709E39D9E42807FFBA996E0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_FEF0F6A6541B6DE535FB807FFBAAA581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_07D9D05F68F2C2896A90807FFBAA5616" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47B3C8067709E39D9E42807FFBA996E0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_07D9D05F68F2C2896A90807FFBAA5616" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_66D7CC7600AC8133389E807FFBAA231F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47B3C8067709E39D9E42807FFBA996E0" xlink:to="loc_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_66D7CC7600AC8133389E807FFBAA231F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2264BE4C5CFFDE361694807FFBAAA57E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47B3C8067709E39D9E42807FFBA996E0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2264BE4C5CFFDE361694807FFBAAA57E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_221DA52B740ED0D5068A807FFBAB1447" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47B3C8067709E39D9E42807FFBA996E0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_221DA52B740ED0D5068A807FFBAB1447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_A4239D4982B28AC78CCF807FFBAB985A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_47B3C8067709E39D9E42807FFBA996E0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_A4239D4982B28AC78CCF807FFBAB985A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0CCA99A76639B54AF95BC9D21C734A23" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_A8B371E2B4B9252FCCB7C9E1B604554D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0CCA99A76639B54AF95BC9D21C734A23" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_A8B371E2B4B9252FCCB7C9E1B604554D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0CCA99A76639B54AF95BC9D21C734A23" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_B47DAAC5F855665E5237C9D309E75662" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_B47DAAC5F855665E5237C9D309E75662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_71DF053D4C17C3AAC32CC9DE77B83013" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_71DF053D4C17C3AAC32CC9DE77B83013" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_AC18AE13656EEB031569C9DF1FE69C08" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_AC18AE13656EEB031569C9DF1FE69C08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_08AAAAF64C004A474B60C9DB0EA8A00E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A72999A4872D99901D89C9E0463450D7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_08AAAAF64C004A474B60C9DB0EA8A00E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3A2EB43236143878BD99C8B4E02673A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2D27AADEC72F5CF722BCC8B4E0268851" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3A2EB43236143878BD99C8B4E02673A1" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2D27AADEC72F5CF722BCC8B4E0268851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0F8ED6FF0E752F23852DC8B4E02604A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3A2EB43236143878BD99C8B4E02673A1" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0F8ED6FF0E752F23852DC8B4E02604A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9C08F7F5382EF0D2CE53C8B4E02607E7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3A2EB43236143878BD99C8B4E02673A1" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9C08F7F5382EF0D2CE53C8B4E02607E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2C0AE5183E58D9715031C8B4E02783A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3A2EB43236143878BD99C8B4E02673A1" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2C0AE5183E58D9715031C8B4E02783A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_319F3ADCD1E25DEFD19EC9CED8C18CC5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3A2EB43236143878BD99C8B4E02673A1" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_319F3ADCD1E25DEFD19EC9CED8C18CC5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangiblesNet" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8CD8F44F7D1615B18D30971953EA5272" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C83C390AB4BD3F5247F1971953EAFC0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8CD8F44F7D1615B18D30971953EA5272" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_C83C390AB4BD3F5247F1971953EAFC0A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangiblesNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42EC802AF416069CFFE7A602391F22FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_D5979F8E630CA50B8F81A60239209544" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42EC802AF416069CFFE7A602391F22FB" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_D5979F8E630CA50B8F81A60239209544" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72FC26C1AD090E546751A606A7192BD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42EC802AF416069CFFE7A602391F22FB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72FC26C1AD090E546751A606A7192BD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_FBAA5098BBB44B24ED78A60239209F08" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42EC802AF416069CFFE7A602391F22FB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_FBAA5098BBB44B24ED78A60239209F08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D80F964AFB4FCDD365C0A6023920B446" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42EC802AF416069CFFE7A602391F22FB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_D80F964AFB4FCDD365C0A6023920B446" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25F50A02B19134590442A60239205A90" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42EC802AF416069CFFE7A602391F22FB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_25F50A02B19134590442A60239205A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_124AA088C7E7B215BEFFA602392655E9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42EC802AF416069CFFE7A602391F22FB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_124AA088C7E7B215BEFFA602392655E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_066A748513C177AADF4AA60239263F96" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42EC802AF416069CFFE7A602391F22FB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_066A748513C177AADF4AA60239263F96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_06F66B4EEF7C75B52D1AA60239267B32" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42EC802AF416069CFFE7A602391F22FB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_06F66B4EEF7C75B52D1AA60239267B32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42EC802AF416069CFFE7A602391F22FB" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_21E5556D1AE96F510B1EA6023926E0A7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_68E405F80C4835C8B654A60239273A83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_68E405F80C4835C8B654A60239273A83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_F949594D428D4C158DE9A6023927A01B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_476E7561B5684CA3A4BEA60239273004" xlink:to="loc_us-gaap_LicensingAgreementsMember_F949594D428D4C158DE9A6023927A01B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_137BDBB9A1B3A52EBA77A60239260D05" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3CDEE9846BE49D4E5F30A602392708C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_39C7FC2A76D867A90629A602392865D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_39C7FC2A76D867A90629A602392865D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_76FB13C030901290F05EA6023928F335" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_76FB13C030901290F05EA6023928F335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_F96120BC1E736882B457A60239291D93" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_F96120BC1E736882B457A60239291D93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_836A0949B9B037E2F171A6023929208D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_2D62BDCAC560A4F4310AA6023928D8A5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_836A0949B9B037E2F171A6023929208D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangiblesNetTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EB24A0AAA3D53BDA0D5FA56D3C74104F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_DFA176E4D1BB92C1A8C8A56D3C7476F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EB24A0AAA3D53BDA0D5FA56D3C74104F" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_DFA176E4D1BB92C1A8C8A56D3C7476F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7CF3F360C8E4899485B6527256F600C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_6EAEB43F0D2D2A61E23A527256F6117F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7CF3F360C8E4899485B6527256F600C1" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_6EAEB43F0D2D2A61E23A527256F6117F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1C2993EBE460A74114A5A56D3C8929D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_A33C85872955814F9A73A56D3C898E5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1C2993EBE460A74114A5A56D3C8929D6" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_A33C85872955814F9A73A56D3C898E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_C306E0269CD90819C55FA56D3C89E369" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1C2993EBE460A74114A5A56D3C8929D6" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_C306E0269CD90819C55FA56D3C89E369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2F49C4254E8B51B3A30AA56D3C899B49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1C2993EBE460A74114A5A56D3C8929D6" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2F49C4254E8B51B3A30AA56D3C899B49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_76EBAE2AC2FC3F771E0EA56D3C89F153" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1C2993EBE460A74114A5A56D3C8929D6" xlink:to="loc_us-gaap_InventoryNet_76EBAE2AC2FC3F771E0EA56D3C89F153" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_BB276347BF72FB38CDDE527256F330FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_82D2A7554BECFC60BF37527256F3289F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_BB276347BF72FB38CDDE527256F330FE" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_82D2A7554BECFC60BF37527256F3289F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LicenseAndOtherAgreements" xlink:type="extended">
    <link:loc xlink:href="insm-20181231.xsd#insm_LicenseAndOtherAgreementsAbstract" xlink:label="loc_insm_LicenseAndOtherAgreementsAbstract_ABDC69C2BFE803455CB3C80C91580A0C" xlink:type="locator" />
    <link:loc xlink:href="insm-20181231.xsd#insm_LicenseAndOtherAgreementsTextBlock" xlink:label="loc_insm_LicenseAndOtherAgreementsTextBlock_083E1AD4C358F6066D1AC80C9158691E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_LicenseAndOtherAgreementsAbstract_ABDC69C2BFE803455CB3C80C91580A0C" xlink:to="loc_insm_LicenseAndOtherAgreementsTextBlock_083E1AD4C358F6066D1AC80C9158691E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LicenseAndOtherAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="insm-20181231.xsd#insm_LicenseAndOtherAgreementsAbstract" xlink:label="loc_insm_LicenseAndOtherAgreementsAbstract_5972C46D1716240205D7E772720F0704" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_LicenseAndOtherAgreementsAbstract_5972C46D1716240205D7E772720F0704" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestonePaymentAxis" xlink:label="loc_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:to="loc_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestonePaymentDomain" xlink:label="loc_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_MilestonePaymentAxis_A031B7266CC85DDABEF7E77272104E74" xlink:to="loc_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestoneNewDrugApplicationMember" xlink:label="loc_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:to="loc_insm_MilestoneNewDrugApplicationMember_9D3E7F812572DB2AEEDBE7727211FD9F" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_MilestoneFDAApprovalMember" xlink:label="loc_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_MilestonePaymentDomain_7D2DF7A41BEA2753FD20E77272106B53" xlink:to="loc_insm_MilestoneFDAApprovalMember_5A1BD5E7D9BFD1F6CBDCE77272113F0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:to="loc_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9948428FF4B9754840C4E77272128F17" xlink:to="loc_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_A6C7B632FCC827DD2C3CE7727212F85B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A823E13041C249BE8412E77272123314" xlink:to="loc_us-gaap_LicenseAndServiceMember_A6C7B632FCC827DD2C3CE7727212F85B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_36E0F47F7095851B23D3E7727212FAC8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_PRIPharmaGmbhCommercializationAgreementMember" xlink:label="loc_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_PRIPharmaGmbhCommercializationAgreementMember_D53D0CC582CCAE7D8080E7727213A2AF" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:label="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_3165B48636F3326D2888E77272149272" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_TherapureBiopharmaIncContractManufacturingAgreementMember" xlink:label="loc_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_TherapureBiopharmaIncContractManufacturingAgreementMember_22350E57D0D9FF6DC01AE77272148072" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AgreementWithSynteractHCRInc.For212StudyMember" xlink:label="loc_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_AgreementWithSynteractHCRInc.For212StudyMember_D59960A50ED6513B7FFFE77272149EF5" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CommercialFilVFinishServicesAgreementMember" xlink:label="loc_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_CommercialFilVFinishServicesAgreementMember_8D5DAE038EDB8FB587DCE7727214172F" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_LicenseAgreementWithAstrazenecaMember" xlink:label="loc_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_LicenseAgreementWithAstrazenecaMember_D93D40D2F390C5F65214E77272159097" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_SupplyAgreementWithPatheonUKLimitedMember" xlink:label="loc_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_SupplyAgreementWithPatheonUKLimitedMember_9D63DC3B90AD1B6B6A16E77272154FA1" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AgreementWithSyneosHealthForWillowStudyMember" xlink:label="loc_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_AF79B95F28DCA9A4D526E7727213E6D1" xlink:to="loc_insm_AgreementWithSyneosHealthForWillowStudyMember_813BF2E0EDD935D837CCE77272154BB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:to="loc_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_99BDC22B209B8DC94013E772721644B5" xlink:to="loc_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_F0C432D4F2BCEA52FF55E772721794FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:to="loc_srt_MaximumMember_F0C432D4F2BCEA52FF55E772721794FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4051280A8F29AA36FD62E772721709B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9B14A1A1EC52A7A392D2E77272163954" xlink:to="loc_srt_MinimumMember_4051280A8F29AA36FD62E772721709B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_87641EFE55005AE78DE8E772721875B7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65D55831FEE0DDDF322FE7727219101F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_21852CBEBFCF985882FDE77272188278" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_65D55831FEE0DDDF322FE7727219101F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ECBCAEE1208E3A6405B9E772720F5DF8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CollaborativeArrangementMilestonePayment" xlink:label="loc_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_CollaborativeArrangementMilestonePayment_6F398D647CEB4E1ED1FBE77272198E5A" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_FutureMilestonePayments" xlink:label="loc_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_FutureMilestonePayments_1D4C62D5DA8DE5FAA3ADE772721A8C01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_345B317E624013DD1771E772721ACFD8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_345B317E624013DD1771E772721ACFD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_AC21BF1DF3C6F0C9FFCAE772721AE9A2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_AC21BF1DF3C6F0C9FFCAE772721AE9A2" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_RoyaltyPaymentPeriod" xlink:label="loc_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_RoyaltyPaymentPeriod_0476F51BF86F99C85434E772721A03BB" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:label="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_DA92141C87753A18A801E772721A8D1E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_1A918CFA734D7095F88FE772721B424C" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_InitialTermOfContractManufacturingAgreement" xlink:label="loc_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_InitialTermOfContractManufacturingAgreement_E967E4A9FC5EFF86821CE772721BB033" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:label="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_CC391F89872EEC6A535CE772721BB92E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:label="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_9554C5CC4608CE3334E6E772721B546B" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AdditionalTermOfContractManufacturingAgreement" xlink:label="loc_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_AdditionalTermOfContractManufacturingAgreement_A11FDD31FF0E114DE50FE772721CAE74" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ImplementationAndManagementServicesAgreementAggregateCosts" xlink:label="loc_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_ImplementationAndManagementServicesAgreementAggregateCosts_4526B61F52940439DA3FE772721C3383" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CommercialServicesAgreementMinimumObligation" xlink:label="loc_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_CommercialServicesAgreementMinimumObligation_C2B935631590E5CF8C86E772721C25DD" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CommercialServicesAgreementExtensionPeriod" xlink:label="loc_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_CommercialServicesAgreementExtensionPeriod_1076461DD286C7F50DC3E772721C31B9" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" xlink:label="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_F4CA2F73699E4893CCBCE772721D3615" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CollaborativeArrangementUpfrontPayment" xlink:label="loc_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_CollaborativeArrangementUpfrontPayment_DFF99344F5629CF1240EE772721DBDE4" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_PaymentsUponAchievementOfClinicalMilestonesAmount" xlink:label="loc_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_BE4028A5929DF5AD8F44E772721DBC68" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" xlink:label="loc_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_005F81ED9AE3870BA826E772721D3777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaap_PaymentsForRoyalties_DB3B3DBB67A283258C55E772721EB91C" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_us-gaap_PaymentsForRoyalties_DB3B3DBB67A283258C55E772721EB91C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_235EF3FBB079B767271CE772721E25B5" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_235EF3FBB079B767271CE772721E25B5" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ManufactureAndSupplyAgreementEstimatedCosts" xlink:label="loc_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_87B23B93437908F0FECCE7727219EE70" xlink:to="loc_insm_ManufactureAndSupplyAgreementEstimatedCosts_EB6C3A8FFDC6CA1C930FE772721EFF6F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_30FDB692F07736DB9DEAC80C91563941" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_26EF0D3CBC1237EB39C8C80C91569F23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_30FDB692F07736DB9DEAC80C91563941" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_26EF0D3CBC1237EB39C8C80C91569F23" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_320604CAC3702D0E7EAC033D3B3DEB07" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DFF1C38EF516AFE492D3033D3B3D7DFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_320604CAC3702D0E7EAC033D3B3DEB07" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DFF1C38EF516AFE492D3033D3B3D7DFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6881D7337C1C0BBC2621033F646C4486" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_320604CAC3702D0E7EAC033D3B3DEB07" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6881D7337C1C0BBC2621033F646C4486" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_CC00629090801D21DDF1033D3B3DEDBD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_320604CAC3702D0E7EAC033D3B3DEB07" xlink:to="loc_us-gaap_OperatingIncomeLoss_CC00629090801D21DDF1033D3B3DEDBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1FE3D3E5C0C804D6D6E3033D3B43716B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_320604CAC3702D0E7EAC033D3B3DEB07" xlink:to="loc_us-gaap_NetIncomeLoss_1FE3D3E5C0C804D6D6E3033D3B43716B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_F2C9AEBC1A88CD5C16D8033D3B4338F1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_320604CAC3702D0E7EAC033D3B3DEB07" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_F2C9AEBC1A88CD5C16D8033D3B4338F1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D3006A21824311B9E355C80C91DE229C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E9A2636C25AB22745B4DC80C91DEAC68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_D3006A21824311B9E355C80C91DE229C" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E9A2636C25AB22745B4DC80C91DEAC68" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/RetirementPlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_116BB636411BD3DD6D74C80C91F50CF7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_DDB8B1F414C8F6261807C80C91F58491" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_116BB636411BD3DD6D74C80C91F50CF7" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_DDB8B1F414C8F6261807C80C91F58491" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/RetirementPlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_47A4CA10B1C7C2DC64915752D43304B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_D8A3A7CDA5F8DC13B39D5752D433D153" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_47A4CA10B1C7C2DC64915752D43304B4" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_D8A3A7CDA5F8DC13B39D5752D433D153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1F904B270F9C4FA9BFEA5752D4336020" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_47A4CA10B1C7C2DC64915752D43304B4" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_1F904B270F9C4FA9BFEA5752D4336020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_50552EFCF2CA985199115752D4332A5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_47A4CA10B1C7C2DC64915752D43304B4" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_50552EFCF2CA985199115752D4332A5E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_772439D169D11D19F24DC80C915E2864" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2DDA62FEC63866B45F94C80C915EBE74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_772439D169D11D19F24DC80C915E2864" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2DDA62FEC63866B45F94C80C915EBE74" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_2DE7671847CD7AAFD3CE153C73BB5E63" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_2DE7671847CD7AAFD3CE153C73BB5E63" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4FAF5906DBC1EA5F5C7B153C73BC8230" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143" xlink:to="loc_us-gaap_AwardTypeAxis_4FAF5906DBC1EA5F5C7B153C73BC8230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CF682F6AE73168B10A5153C73BC8F88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4FAF5906DBC1EA5F5C7B153C73BC8230" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CF682F6AE73168B10A5153C73BC8F88" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_D1DF21346C606A5F33EA153C73BC4C8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CF682F6AE73168B10A5153C73BC8F88" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_D1DF21346C606A5F33EA153C73BC4C8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_00A143F8396E9AD4549B153C73BDB744" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CF682F6AE73168B10A5153C73BC8F88" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_00A143F8396E9AD4549B153C73BDB744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D7F2D0B39D73FCDE9AB2153C73BB6143" xlink:to="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_450C2C95AE705214EFFD153C73BD33BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_450C2C95AE705214EFFD153C73BD33BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_85B7D6097D6A51E1DB87153C73BEE6A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_85B7D6097D6A51E1DB87153C73BEE6A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A11C7C9721CBF3762408153C73BE4BD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_CommonStockSharesIssued_A11C7C9721CBF3762408153C73BE4BD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_F8F307570067ECD69E5D153C73BFB27C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_F8F307570067ECD69E5D153C73BFB27C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E7210374FEFFC6CBF42E153C73BF5EC0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E7210374FEFFC6CBF42E153C73BF5EC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C4E8328BA862C3280452153C73BFA02D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C4E8328BA862C3280452153C73BFA02D" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:label="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_30E03C5CB7500506EDA1153C73BFDA07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_3AE64906F275F91388DB153C73C04B8C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_SharePrice_3AE64906F275F91388DB153C73C04B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_E2B3A7C43FD664F514FF153C73C00395" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_E2B3A7C43FD664F514FF153C73C00395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DC2D3096C50B5DC7A63A153C73C5DF16" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DC2D3096C50B5DC7A63A153C73C5DF16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_49189DC7B80A686CD952153C73C591F0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_49189DC7B80A686CD952153C73C591F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BB3F608D01625B7102A153C73C5A57A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BB3F608D01625B7102A153C73C5A57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1F51066B83EA75F3863D153C73C6CAEE" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1F51066B83EA75F3863D153C73C6CAEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_719708F3B3DD32710132153C73C63813" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E37FCE45FC5E522B5035153C73BD4BA8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_719708F3B3DD32710132153C73C63813" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_81F0D4D46D275A71A6C3C80C90949BBD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158FC8B42156092AB9B1C80C90944B4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_81F0D4D46D275A71A6C3C80C90949BBD" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158FC8B42156092AB9B1C80C90944B4F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_C4188A092296A5D8B66A19E1DE78F475" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_89FE62B22CE288A1BA3519E1DE785EE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_C4188A092296A5D8B66A19E1DE78F475" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_89FE62B22CE288A1BA3519E1DE785EE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FA7F24C331027D70CABE19E1DE787DD9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_C4188A092296A5D8B66A19E1DE78F475" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FA7F24C331027D70CABE19E1DE787DD9" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_5CA02F84DABBDFDFADAE19E1DE78BEA6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_C4188A092296A5D8B66A19E1DE78F475" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_5CA02F84DABBDFDFADAE19E1DE78BEA6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_C92814D2511866759AD1807FFC3AD90E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_C92814D2511866759AD1807FFC3AD90E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_44C0022AF2251C5737D2807FFC3B79A5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range1Member" xlink:label="loc_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range1Member_996CC16BCB4C67702CEF807FFC3B71A0" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range2Member" xlink:label="loc_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range2Member_CD98A113F558AB37A1D0807FFC3B9E41" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range3Member" xlink:label="loc_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range3Member_9A7F3BC501A1D4C70CA3807FFC3C2B09" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range4Member" xlink:label="loc_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range4Member_39F995BD0C27CBED56D2807FFC3CE154" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range5Member" xlink:label="loc_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range5Member_506A3D9CE9C8424CE7E2807FFC3C6329" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range6Member" xlink:label="loc_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range6Member_AE6C4D1A0195C8871AE9807FFC3C558C" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range7Member" xlink:label="loc_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range7Member_AB03F3491B7A997FBD6A807FFC3CFDCD" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range8Member" xlink:label="loc_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range8Member_759CE514EF4F6366998D807FFC3C978C" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range9Member" xlink:label="loc_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range9Member_9AA9C5525FE72D58E492807FFC3DFCF5" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_Range10Member" xlink:label="loc_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1D6F500CF7D24B32FF5A807FFC3BEE41" xlink:to="loc_insm_Range10Member_F9AD85914CA4491A9C7D807FFC3D6D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C506716EAFB080FE77E4807FFC3D068C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:to="loc_us-gaap_AwardTypeAxis_C506716EAFB080FE77E4807FFC3D068C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC7874DCFE62BC7FD4DB807FFC3D41F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_C506716EAFB080FE77E4807FFC3D068C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC7874DCFE62BC7FD4DB807FFC3D41F5" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_8ADC80B5CA792CFFC1D7807FFC3D5509" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC7874DCFE62BC7FD4DB807FFC3D41F5" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_8ADC80B5CA792CFFC1D7807FFC3D5509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_ED678AD332AE941AD365807FFC3E3441" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CC7874DCFE62BC7FD4DB807FFC3D41F5" xlink:to="loc_us-gaap_PerformanceSharesMember_ED678AD332AE941AD365807FFC3E3441" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_24350BA10F31DB2096C6807FFC3A97D6" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05A46263CC6617C6CD51807FFC3E3B06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_05A46263CC6617C6CD51807FFC3E3B06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26FFC6253D453629FA35807FFC3EE6E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26FFC6253D453629FA35807FFC3EE6E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_FE2ADA979ABACB5F13F3807FFC3FCFCB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_FE2ADA979ABACB5F13F3807FFC3FCFCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_06AAC493F366650B4D97807FFC3F86BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_06AAC493F366650B4D97807FFC3F86BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_6D831E308E75F43DC7F4807FFC3F3F2F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_6D831E308E75F43DC7F4807FFC3F3F2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_68B9FFBBCFC17B4013ED807FFC3F4BCD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_68B9FFBBCFC17B4013ED807FFC3F4BCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1721D092FE5AD253B646807FFC3F0B0C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1721D092FE5AD253B646807FFC3F0B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_F4F469D51DC68C77F8DF807FFC40E57F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_F4F469D51DC68C77F8DF807FFC40E57F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_D015E674FD509EEA55D3807FFC40E967" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_D015E674FD509EEA55D3807FFC40E967" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2AB4AC4AB96508B70EE7807FFC403A98" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_16A2E095CEC18A868D6E807FFC3E1505" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2AB4AC4AB96508B70EE7807FFC403A98" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_7FD3A876CB116C0EB1FAFDBA30298491" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AEBDE45EB5BD268EBACEFDBA3029AB33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_7FD3A876CB116C0EB1FAFDBA30298491" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AEBDE45EB5BD268EBACEFDBA3029AB33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8FB8C0ABF38D3A1071ABFDBA3029BCB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AEBDE45EB5BD268EBACEFDBA3029AB33" xlink:to="loc_us-gaap_AwardTypeAxis_8FB8C0ABF38D3A1071ABFDBA3029BCB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8FB8C0ABF38D3A1071ABFDBA3029BCB7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD" xlink:to="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_A4C8426D5BD13E9C4F2CFDBA302A2BD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B30BAC965F0B79ED2009FDBA302A8E11" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_B30BAC965F0B79ED2009FDBA302A8E11" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_StockOptionsAndRestrictedStockUnitsMember" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember_B099C34A806E5C237CC2FDBA302B3560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_DAB0218FDEF783E8F8B9FDBA302BB56F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDA3B32057A48BF5BAEAFDBA302A59FD" xlink:to="loc_us-gaap_EmployeeStockMember_DAB0218FDEF783E8F8B9FDBA302BB56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D715A7212E8D8466FC04FDBA302B8ABE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AEBDE45EB5BD268EBACEFDBA3029AB33" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_D715A7212E8D8466FC04FDBA302B8ABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73F60B7F7078EDAC0533FDBA302BD08E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D715A7212E8D8466FC04FDBA302B8ABE" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73F60B7F7078EDAC0533FDBA302BD08E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F6AA64ECF99607B477E8FDBA302CF928" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73F60B7F7078EDAC0533FDBA302BD08E" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F6AA64ECF99607B477E8FDBA302CF928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_883AE2A18A017815EBC8FDBA302C0BB4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73F60B7F7078EDAC0533FDBA302BD08E" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_883AE2A18A017815EBC8FDBA302C0BB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AEBDE45EB5BD268EBACEFDBA3029AB33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" xlink:label="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_06DC0885B3B700C150A0FDBA302D7BA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE11B65043AFE7948EA7FE160FA281F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_BE11B65043AFE7948EA7FE160FA281F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_115EABBD059AEBC2D6BAFDBA302D748C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_115EABBD059AEBC2D6BAFDBA302D748C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58C53ED28DE3E178CC23FDBA302D29B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58C53ED28DE3E178CC23FDBA302D29B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31827335BB384557A61BFDBA302E4E59" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_31827335BB384557A61BFDBA302E4E59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ED180B981B2D96F2A45AFDBA302E3186" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ED180B981B2D96F2A45AFDBA302E3186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2C7A0BD2975F81D07790FDBA302E5E46" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2C7A0BD2975F81D07790FDBA302E5E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FAA0850A068B9701582BFDBA302F7C23" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1D5F297E207C7A37F649FDBA302D4273" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_FAA0850A068B9701582BFDBA302F7C23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_69EC712A65F6E69A23CCFDBA302F39F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_69EC712A65F6E69A23CCFDBA302F39F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D692A23C5C1BF119D6B1FDBA302F8BAA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D692A23C5C1BF119D6B1FDBA302F8BAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_33F845ABBB4721BB8F4FFDBA302F555A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_33F845ABBB4721BB8F4FFDBA302F555A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6AB13B6D9DC3449917D8FDBA3030C657" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6AB13B6D9DC3449917D8FDBA3030C657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_059BF76EA37F97A7D7D7FDBA30309D57" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0D741E9D0115A95C46F2FDBA302FF437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_059BF76EA37F97A7D7D7FDBA30309D57" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards" xlink:label="loc_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards_5379CDBD2336944717F8FDBA3030C047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_41F1C33E78C70B8535A8FDBA3030E30D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8F328584F9E59E732DF9FDBA302CDA49" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_41F1C33E78C70B8535A8FDBA3030E30D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_0EA0FC69F881263DF350E77272B8046E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_0EA0FC69F881263DF350E77272B8046E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:to="loc_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6E6B1F49E0FF779EAA12E77272B90615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_1971B0245E1792950E2FE77272BAC74E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_93143804113477315143E77272BA2DE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C953D758F5B789E460A1E77272B93885" xlink:to="loc_us-gaap_PerformanceSharesMember_93143804113477315143E77272BA2DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_0DFAFC59279A54B57880E77272BA50B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:to="loc_srt_RangeAxis_0DFAFC59279A54B57880E77272BA50B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FDE2ECBFA973CC683761E77272BA339A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0DFAFC59279A54B57880E77272BA50B8" xlink:to="loc_srt_RangeMember_FDE2ECBFA973CC683761E77272BA339A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_104B8AE4D4A815133BB5E77272BB2BF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_FDE2ECBFA973CC683761E77272BA339A" xlink:to="loc_srt_MinimumMember_104B8AE4D4A815133BB5E77272BB2BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_4553DDB2DD083C3D907AE77272BBCF04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_FDE2ECBFA973CC683761E77272BA339A" xlink:to="loc_srt_MaximumMember_4553DDB2DD083C3D907AE77272BBCF04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6A7DDC6FBCA3FB4B3537E77272B96AA2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_E168FB0F2BD5509DF3ADE77272BC685C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_StockOptionPlanExpense_E168FB0F2BD5509DF3ADE77272BC685C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_25580AEF3C2AE9516666E77272BD1A33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_25580AEF3C2AE9516666E77272BD1A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1A21D0C912989D988B1FE77272BD6CDE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1A21D0C912989D988B1FE77272BD6CDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0A69ABEDD4B65D2088B5E77272BECE49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0A69ABEDD4B65D2088B5E77272BECE49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C05DF76708E272D7F60AE77272BE5A4F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C05DF76708E272D7F60AE77272BE5A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E3738B1180BA0246407E77272BF1B98" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_4BB59D8B5BD31EAEB70AE77272BCB274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3E3738B1180BA0246407E77272BF1B98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB30005DF10EF06D7023E77272BFC171" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_BB30005DF10EF06D7023E77272BFC171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6787B0B84DC880EC80A3E77272BF0F36" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6787B0B84DC880EC80A3E77272BF0F36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8CFDE7D31EAF7F8D62C2E77272C08033" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8CFDE7D31EAF7F8D62C2E77272C08033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2377ECDEF2C1EDB20BD2E77272C0DA44" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2377ECDEF2C1EDB20BD2E77272C0DA44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_406E01970BFB2B8A7D47E77272C05BAA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_BC5CE887E7FA9A418706E77272BF5D86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_406E01970BFB2B8A7D47E77272C05BAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_C1F476D824D0C536CC0FE77272C082AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_C1F476D824D0C536CC0FE77272C082AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CB299E2D56BD3A14A236E77272C17C8B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_CB299E2D56BD3A14A236E77272C17C8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20D3B83726BABC840BECE77272C1CD59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20D3B83726BABC840BECE77272C1CD59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41069C08A98916666F53E77272C2E6CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_41069C08A98916666F53E77272C2E6CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3AE07D4DBD5FA8DF4FAEE77272C228A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3AE07D4DBD5FA8DF4FAEE77272C228A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9933D2D57EA3A4725152E77272C24B99" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9933D2D57EA3A4725152E77272C24B99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AAE95532DD6968E0773EE77272C22DE6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_C22C772008C58671A8FBE77272C1F4E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_AAE95532DD6968E0773EE77272C22DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_742BE4942D8DAD60A332E77272C24662" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_742BE4942D8DAD60A332E77272C24662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0B959100D54AE32B7E6FE77272C3C740" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0B959100D54AE32B7E6FE77272C3C740" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:label="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30536A72E0E12DE8D4FDE77272C35973" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30536A72E0E12DE8D4FDE77272C35973" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_D62DD0F1E495148D4789E77272C39274" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_D62DD0F1E495148D4789E77272C39274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_280E2970552DC1BC4A21E77272C44090" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_141F0ACE5030E0E6250BE77272C3B4BC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_280E2970552DC1BC4A21E77272C44090" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BB1553440D156A749ADEE77272BB8761" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3C6A701DE883405CF1ACE77272C417C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3C6A701DE883405CF1ACE77272C417C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5AB1C7CD9A99A43F7EA0E77272C4E57E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5AB1C7CD9A99A43F7EA0E77272C4E57E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0E17CADB4B1A6753ABAAE77272C5D89F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3AC0C1361C0E4E999E5DE77272C49CBC" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0E17CADB4B1A6753ABAAE77272C5D89F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_5C8F6E8AE4B711F4C269C80C9277DF3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF8EA262DDB77E5B2B22C80C92770DE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_5C8F6E8AE4B711F4C269C80C9277DF3E" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF8EA262DDB77E5B2B22C80C92770DE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_47000C8108A86C27631FC80C9277FE64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_5C8F6E8AE4B711F4C269C80C9277DF3E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_47000C8108A86C27631FC80C9277FE64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_EA6A7EBAB9F7C5D28CE1C80C92785549" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_5C8F6E8AE4B711F4C269C80C9277DF3E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_EA6A7EBAB9F7C5D28CE1C80C92785549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_95FDC16E7E2810C12D5BC80C9278ED5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_5C8F6E8AE4B711F4C269C80C9277DF3E" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_95FDC16E7E2810C12D5BC80C9278ED5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ABC2AEF7319AD07D0067C80C927862D0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_5C8F6E8AE4B711F4C269C80C9277DF3E" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ABC2AEF7319AD07D0067C80C927862D0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8378ABA878415C6228D0C80C915B649A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7B3D48EBC10C0ABE6650C80C915B8F52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8378ABA878415C6228D0C80C915B649A" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7B3D48EBC10C0ABE6650C80C915B8F52" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E80DA5A5C5B6ACAFAD7101A033DA87EB" xlink:type="locator" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossTable" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_75BE502553057FE69503015E4C862F02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E80DA5A5C5B6ACAFAD7101A033DA87EB" xlink:to="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_75BE502553057FE69503015E4C862F02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_C072D7B36DDE1C60D322015E4C864896" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_75BE502553057FE69503015E4C862F02" xlink:to="loc_srt_MajorCustomersAxis_C072D7B36DDE1C60D322015E4C864896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_DDE5DC271577E077B50C015E4C878570" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_C072D7B36DDE1C60D322015E4C864896" xlink:to="loc_srt_NameOfMajorCustomerDomain_DDE5DC271577E077B50C015E4C878570" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CustomerFeesDiscountsandOtherMember" xlink:label="loc_insm_CustomerFeesDiscountsandOtherMember_C7B3D9AF613F6F18FAA8015E4C8708A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DDE5DC271577E077B50C015E4C878570" xlink:to="loc_insm_CustomerFeesDiscountsandOtherMember_C7B3D9AF613F6F18FAA8015E4C8708A5" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_RebatesChargebacksandCoPayAssistanceMember" xlink:label="loc_insm_RebatesChargebacksandCoPayAssistanceMember_4C8A4ADA89F44F32B761015E4C87BBD8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DDE5DC271577E077B50C015E4C878570" xlink:to="loc_insm_RebatesChargebacksandCoPayAssistanceMember_4C8A4ADA89F44F32B761015E4C87BBD8" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_2A2707ED1613CF4476AC015E4C88EBCD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_75BE502553057FE69503015E4C862F02" xlink:to="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_2A2707ED1613CF4476AC015E4C88EBCD" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_F6AEEA43C95DB1EF2BB9015E4C8807A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_2A2707ED1613CF4476AC015E4C88EBCD" xlink:to="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_F6AEEA43C95DB1EF2BB9015E4C8807A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_A01C5BD5452D1E42FE5F015E4C88F042" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_F6AEEA43C95DB1EF2BB9015E4C8807A4" xlink:to="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_A01C5BD5452D1E42FE5F015E4C88F042" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales" xlink:label="loc_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_1CFD3168A84058D0CD65015E4C88955E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_F6AEEA43C95DB1EF2BB9015E4C8807A4" xlink:to="loc_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_1CFD3168A84058D0CD65015E4C88955E" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" xlink:label="loc_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_4D5D3C9FC062D8E392C5015E4C88576D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_F6AEEA43C95DB1EF2BB9015E4C8807A4" xlink:to="loc_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_4D5D3C9FC062D8E392C5015E4C88576D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_4822DD777861C603650B015E4C89EA5C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward_F6AEEA43C95DB1EF2BB9015E4C8807A4" xlink:to="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_4822DD777861C603650B015E4C89EA5C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_67BFB489C3CB03341E82C8B4E16A186B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67BFB489C3CB03341E82C8B4E16A186B" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0B3C8002AF807F7976CDC8B4E16BE02B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_7AD5DA608C165FF8FDC9C8B4E16D46D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_7AD5DA608C165FF8FDC9C8B4E16D46D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_84D6642761C512472EA2C8B4E16E9E2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:to="loc_us-gaap_RestrictedStockMember_84D6642761C512472EA2C8B4E16E9E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_0ABFAF6C2817950EDCA5C8B4E16FAF53" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_493899997CBAD22CD108C8B4E16C6BA7" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_0ABFAF6C2817950EDCA5C8B4E16FAF53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_06D070F24BC08B72FC6CC8B4E16B54AC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E137C8346391ED21946EC8B4E1709B09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_70BCBB3D3B4433023023C8B4E16FC505" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_E137C8346391ED21946EC8B4E1709B09" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7281B4245019639E7CF801482CA9E8C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_CB80520863A7B9F7993C01316E3335BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7281B4245019639E7CF801482CA9E8C9" xlink:to="loc_us-gaap_ConcentrationRiskTable_CB80520863A7B9F7993C01316E3335BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_030669F35B3A37ACF9EB01316E339CD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_CB80520863A7B9F7993C01316E3335BB" xlink:to="loc_srt_MajorCustomersAxis_030669F35B3A37ACF9EB01316E339CD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_DF0C2AB7663CA0B4738E01316E347BB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_030669F35B3A37ACF9EB01316E339CD5" xlink:to="loc_srt_NameOfMajorCustomerDomain_DF0C2AB7663CA0B4738E01316E347BB8" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CustomerAMember" xlink:label="loc_insm_CustomerAMember_7CD685A098D672618B5B01316E348707" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DF0C2AB7663CA0B4738E01316E347BB8" xlink:to="loc_insm_CustomerAMember_7CD685A098D672618B5B01316E348707" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CustomerBMember" xlink:label="loc_insm_CustomerBMember_26AEB7E4D5D1AD08225201316E355361" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DF0C2AB7663CA0B4738E01316E347BB8" xlink:to="loc_insm_CustomerBMember_26AEB7E4D5D1AD08225201316E355361" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_CustomerCMember" xlink:label="loc_insm_CustomerCMember_43210E7A159D4D3C14E501316E350B79" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DF0C2AB7663CA0B4738E01316E347BB8" xlink:to="loc_insm_CustomerCMember_43210E7A159D4D3C14E501316E350B79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6A9AA243CD3AC320138701316E3643DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_CB80520863A7B9F7993C01316E3335BB" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6A9AA243CD3AC320138701316E3643DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_426637FF522F6177A15001316E363D95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6A9AA243CD3AC320138701316E3643DA" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_426637FF522F6177A15001316E363D95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_91912F5EB5D622A0527B01316E368EE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_426637FF522F6177A15001316E363D95" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_91912F5EB5D622A0527B01316E368EE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_25B9736E50E66AF9F23101316E377B63" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_CB80520863A7B9F7993C01316E3335BB" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_25B9736E50E66AF9F23101316E377B63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_C18310C5A7BD4D3689C701316E375A14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_25B9736E50E66AF9F23101316E377B63" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_C18310C5A7BD4D3689C701316E375A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5CB7D86F3612682AAA2E01316E38023A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_C18310C5A7BD4D3689C701316E375A14" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5CB7D86F3612682AAA2E01316E38023A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5BA7D073D7ACA3C55E5C01316E39508B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_CB80520863A7B9F7993C01316E3335BB" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_5BA7D073D7ACA3C55E5C01316E39508B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_E3A3644D5C41222D7B9601316E3955EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5BA7D073D7ACA3C55E5C01316E39508B" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_E3A3644D5C41222D7B9601316E3955EC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_52A0B22DEB4AC591838DDD409608ECE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_52A0B22DEB4AC591838DDD409608ECE4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_DBC6202CA8FDAAEE5E11DD4096093902" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_F10FBB07609915884CC2DD4096090A14" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9F9F7978841007810417DD83939D2C0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9F9F7978841007810417DD83939D2C0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_62F2F1010C13DD274E18DD8D02AB63B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_68A44E87D1D2BAB9013BDD89D03036F0" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_62F2F1010C13DD274E18DD8D02AB63B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888DE212E20714CA8DF3DD40960AB56A" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_C44896F749BD245E63A9DD40960B5432" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_F664EE29506FAD0487FDDD40960B215B" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_C44896F749BD245E63A9DD40960B5432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_991F87F53C0945007003DD40960BE47C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_E88DF0C18F588D94F583DD40960CC8E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_E88DF0C18F588D94F583DD40960CC8E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_BABB7C98F7E20566C2C3DD40960C9287" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_BABB7C98F7E20566C2C3DD40960C9287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_74A303BFD025BF031D49DD7DEB1D4083" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B58759FE3D82BA475AFDD40960B7A2A" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_74A303BFD025BF031D49DD7DEB1D4083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C5423CFC36A4EFFB8386DD40960C4B66" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_D39B9843D14C79669D1ADD40960DACE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_EDC5DBEA53ACEA29022FDD40960CC9A9" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_D39B9843D14C79669D1ADD40960DACE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:to="loc_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_E3E83C1863A952329147DD4096124028" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ED53151C8C2613FAB02DD4096123A37" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2FA39334833042A29E45DD40961312E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FA1D973100096F45FA5CDD4096091067" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77F8925089EF6DF7AC30DD4096131244" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_77F8925089EF6DF7AC30DD4096131244" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_FairValueLevel1Level2Level3TransfersAmount" xlink:label="loc_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_insm_FairValueLevel1Level2Level3TransfersAmount_0F37EBEBE3A54B1A3DEEDD409614867A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_70E698286CDF29AB1B60DD4096145671" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_70E698286CDF29AB1B60DD4096145671" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_BD07198EA2C43D950116DD4096149B27" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_BD07198EA2C43D950116DD4096149B27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_47128F6328719D0E3892DD4096144A3A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_47128F6328719D0E3892DD4096144A3A" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" xlink:label="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_021B91EE05E91426FEDEDD4096156A99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_154CCBB4BDA23C98FE72DD4096156DE3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C05CA6CEA93B7551BBDD40961350D3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_154CCBB4BDA23C98FE72DD4096156DE3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_DE8DF40E9F381E55FD4AC80C9069C217" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B7522BCA0BB0E8ABD403C80C9069F417" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DE8DF40E9F381E55FD4AC80C9069C217" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B7522BCA0BB0E8ABD403C80C9069F417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2B9F38124E3E2BB32427C80C906968A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B7522BCA0BB0E8ABD403C80C9069F417" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2B9F38124E3E2BB32427C80C906968A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60869E667C6E97897F2C80C90691CA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2B9F38124E3E2BB32427C80C906968A1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60869E667C6E97897F2C80C90691CA4" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ComputerHardwareAndSoftwareMember" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_4ACE69658385BA1C23F0C80C906ABD3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60869E667C6E97897F2C80C90691CA4" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember_4ACE69658385BA1C23F0C80C906ABD3A" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_EquipmentFurnitureAndFixturesMember" xlink:label="loc_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_E60869E667C6E97897F2C80C90691CA4" xlink:to="loc_insm_EquipmentFurnitureAndFixturesMember_675D91E0AD41696C09FAC80C906AB5B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E9EC0DA8B5D40A366FADC80C906BCD2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B7522BCA0BB0E8ABD403C80C9069F417" xlink:to="loc_srt_RangeAxis_E9EC0DA8B5D40A366FADC80C906BCD2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4CD4629D721CFCC933D8C80C906BE887" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_E9EC0DA8B5D40A366FADC80C906BCD2A" xlink:to="loc_srt_RangeMember_4CD4629D721CFCC933D8C80C906BE887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D90DC3C12E72E93D3283C80C906B861B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4CD4629D721CFCC933D8C80C906BE887" xlink:to="loc_srt_MinimumMember_D90DC3C12E72E93D3283C80C906B861B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_690FC15EB0D971AD5BC3C80C906B07B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4CD4629D721CFCC933D8C80C906BE887" xlink:to="loc_srt_MaximumMember_690FC15EB0D971AD5BC3C80C906B07B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10236377179A2556917DC80C906CF0D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B7522BCA0BB0E8ABD403C80C9069F417" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10236377179A2556917DC80C906CF0D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA12F71346DF94270121C80C906CC416" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10236377179A2556917DC80C906CF0D7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_EA12F71346DF94270121C80C906CC416" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0C34A66F763C9F11D4655752D5558A6A" xlink:type="locator" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0C34A66F763C9F11D4655752D5558A6A" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6CF73C360A47CCF2F16F5752D556DC42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:to="loc_us-gaap_AwardTypeAxis_6CF73C360A47CCF2F16F5752D556DC42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35D0632A670522D787FF5752D5569DE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6CF73C360A47CCF2F16F5752D556DC42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35D0632A670522D787FF5752D5569DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_75C5DAFDD91F4836277E5752D5561017" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35D0632A670522D787FF5752D5569DE6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_75C5DAFDD91F4836277E5752D5561017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_CEAD3EF3F0DA580A7ED05752D55775C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35D0632A670522D787FF5752D5569DE6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_CEAD3EF3F0DA580A7ED05752D55775C4" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_545FFBE7700D2062C84F5752D556ADE1" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15A5E41A6A248CA4EAC95752D55738A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_06CF2E962EA0FD9EFC585752D5575199" xlink:to="loc_us-gaap_NetIncomeLoss_15A5E41A6A248CA4EAC95752D55738A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCA14F2D6CF02213E5765752D558B0C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCA14F2D6CF02213E5765752D558B0C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0681DD05ED2C2DBD48955752D5587833" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_F081FEDE1712A3313AEB5752D558CCFB" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0681DD05ED2C2DBD48955752D5587833" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F6062952D28D94127D4E5752D5592AA0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9ED819168390E66DB2105752D5582890" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F6062952D28D94127D4E5752D5592AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_3F3EDFC3F5B42768059A5752D5575AAA" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_271830F523EB5086E3CB5752D559CD7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_AF408A555C3027E8D2DB5752D5590436" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_271830F523EB5086E3CB5752D559CD7C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_427B87427797948DC36C0DE740DFCAB4" xlink:type="locator" />
    <link:loc xlink:href="insm-20181231.xsd#insm_SummaryOfSignificantPoliciesTable" xlink:label="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_427B87427797948DC36C0DE740DFCAB4" xlink:to="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:to="loc_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_41CDE1E631B9F809070A0DE740E56F5C" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_3A5EE3C3B2435403E4EE0DE740E64AE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_2E61FD0BC97CF27A40CE0DE740E551D9" xlink:to="loc_us-gaap_ScenarioForecastMember_3A5EE3C3B2435403E4EE0DE740E64AE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82658B1366E9A59DD29D0DE740E7D8BD" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_233DF23FC48E151FFB1D0DE740EDCC2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D7A765014CF817DD25540DE740E81A9D" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_233DF23FC48E151FFB1D0DE740EDCC2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3A52140B7BF90524D7010DE740EE8660" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:to="loc_srt_RangeAxis_3A52140B7BF90524D7010DE740EE8660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_157A26414A36EC55B2800DE740EEA724" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3A52140B7BF90524D7010DE740EE8660" xlink:to="loc_srt_RangeMember_157A26414A36EC55B2800DE740EEA724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2CEEF7677CB737EB95E50DE740EE45A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_157A26414A36EC55B2800DE740EEA724" xlink:to="loc_srt_MinimumMember_2CEEF7677CB737EB95E50DE740EE45A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_70DDB0DF8F04B8882AF40DE740EEEDE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_157A26414A36EC55B2800DE740EEA724" xlink:to="loc_srt_MaximumMember_70DDB0DF8F04B8882AF40DE740EEEDE6" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_SummaryOfSignificantPoliciesLineItems" xlink:label="loc_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_SummaryOfSignificantPoliciesTable_2304A9A8A4EF005A0C460DE740E2EA9E" xlink:to="loc_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5049B4FB9CF779D960A20DE77F1732C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5049B4FB9CF779D960A20DE77F1732C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_F6884D4CEE189073D5A50DE740EFEF08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:to="loc_us-gaap_OperatingLeaseLiability_F6884D4CEE189073D5A50DE740EFEF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_71A0810C3CB77F3F559A0DE740EFE182" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_SummaryOfSignificantPoliciesLineItems_A73982FF7C2BE64754DF0DE740EF2010" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_71A0810C3CB77F3F559A0DE740EFE182" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E91AAED35E99C0E720AA0751EA5D4DC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_E91AAED35E99C0E720AA0751EA5D4DC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_AB8E8017EF4FE9E1B63B0751EA5EE0FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_UseOfEstimates_AB8E8017EF4FE9E1B63B0751EA5EE0FF" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_InvestmentIncomeExpensePolicyTextBlock" xlink:label="loc_insm_InvestmentIncomeExpensePolicyTextBlock_3E8705E54C848D5045550751EA5ECF7C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_insm_InvestmentIncomeExpensePolicyTextBlock_3E8705E54C848D5045550751EA5ECF7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5FB1C90CC0F878CEE09A0751EA5E45D6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5FB1C90CC0F878CEE09A0751EA5E45D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_207DED513CF983AC320C0751EA5E5996" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_207DED513CF983AC320C0751EA5E5996" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_54681352B3AF754F56780751EA5ED835" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_54681352B3AF754F56780751EA5ED835" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_1094FB4701FDD9803F930751EA5F8B0E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_DebtPolicyTextBlock_1094FB4701FDD9803F930751EA5F8B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BBFD35965AB04C166C70751EA5F5CA6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BBFD35965AB04C166C70751EA5F5CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1014184C6C3E32DD39AD0751EA5F3BCF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1014184C6C3E32DD39AD0751EA5F3BCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_76ED54AA37CF6002A48E0751EA5FFD02" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_76ED54AA37CF6002A48E0751EA5FFD02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_85D61A7347B85E7534380751EA60A1BB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_85D61A7347B85E7534380751EA60A1BB" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" xlink:label="loc_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_A59C6F07ADE4EE498CB50751EA603A6A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_A59C6F07ADE4EE498CB50751EA603A6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_EADC04810E349BF4848C0751EA6073B1" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_EADC04810E349BF4848C0751EA6073B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8902914B7775EDD5C3F30751EA607981" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8902914B7775EDD5C3F30751EA607981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_BC3BBAEF6D4B4A8BD2710751EA6049A6" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_BC3BBAEF6D4B4A8BD2710751EA6049A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_FAF539D5C8856E1DAAC10751EA614160" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_FAF539D5C8856E1DAAC10751EA614160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_A415E7BC45DCAF335BF10751EA612391" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_A415E7BC45DCAF335BF10751EA612391" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5629DD7FE9D949995FC80751EA610051" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4E354BC85AF657F511350751EA5D20DB" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5629DD7FE9D949995FC80751EA610051" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_08FC8835E49DF5F6B6E714C88A61F177" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2E40B4B39E34A68AE0C714C88A61D653" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_08FC8835E49DF5F6B6E714C88A61F177" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2E40B4B39E34A68AE0C714C88A61D653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_3201369409F6EC7911A414C88A62433A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_08FC8835E49DF5F6B6E714C88A61F177" xlink:to="loc_us-gaap_NumberOfReportableSegments_3201369409F6EC7911A414C88A62433A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CFAF868926028742A747ECB41A6E6242" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_04F0F1B1C2BFDA49BBD2ECB41A6FC94B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CFAF868926028742A747ECB41A6E6242" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_04F0F1B1C2BFDA49BBD2ECB41A6FC94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1EA6AC898F3218744E63ECB41A6FC421" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CFAF868926028742A747ECB41A6E6242" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1EA6AC898F3218744E63ECB41A6FC421" xlink:type="arc" />
    <link:loc xlink:href="insm-20181231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock_EC97CBEF569373C1B18FECBB9472C27B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CFAF868926028742A747ECB41A6E6242" xlink:to="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock_EC97CBEF569373C1B18FECBB9472C27B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3D575D107FFCDCD93F73ECB41A6F38D8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CFAF868926028742A747ECB41A6E6242" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3D575D107FFCDCD93F73ECB41A6F38D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6054CCEB35E445A02DA8ECB41A703B01" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CFAF868926028742A747ECB41A6E6242" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6054CCEB35E445A02DA8ECB41A703B01" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>chart-803421e59edbca9d8b7.jpg
<TEXT>
begin 644 chart-803421e59edbca9d8b7.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &8 F4# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M76O#GB/2-4TW4;B&Y81>KT %%)D>_P"1_P *6@ HHHH **** "BBB@ HHHH
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M_P#_ "AO_P""@G_9 =4_]2;PO7ZG_#+_ ))UX$_[$SPI_P"H]IE?BI_P7O\
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MQ5XBO?[7O]6E\1?#K4;W7=52+4+7^@P$$ CH?8@_B#@@CH00"#P1F@!:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,#KCGUHKYTU#]J3X
M4V'Q3O/A*DWBG5M<T77=(\(>+-=T#P=X@UWP;X)\;^(HOA]=>'?!7B_Q)I=G
M<VVB^(M9T[XI^ =6$3Q3:=HFE>*="OO%.I:!#K6D&^ /HK !)  )ZG R?J>M
M  '0 9ZX'6O,_#WQ@^'_ (I^)WQ(^#VB:S=7/Q"^$NB_#[Q#X\T2?0?$.G1:
M3H_Q2C\52>![VSUC4M+M-$\00ZR/!7B:-F\.ZCJHTVYTJ:RU0V5Z4MCQ<G[4
M'P4B\ >+/BS)XP0?"GPA=RZ;>?$A-+U6?PAK>JQ>(8_"*Z7X(U*WM)7^(%[>
M>+9K?PIHZ^"K;78/$/BBXA\.^'KC5=8<6= 'T" !P!@>@HKS;X9?%CP7\6M-
MUZ_\'W]U+<^$O$]_X)\9Z#JVFWVB>)/!OC+3+'2]4OO#'BC0M3A@OM)U:/2=
M<T36K>.5&MM3T'6]%U[2KF^T;5].OKGTF@#\=_\ @O\ _P#*&_\ X*"?]D!U
M7_U)O"]?J?\ #+_DG7@3_L3/"G_J/:97Y7?\%_W3_ASA_P %!!O7/_"@=5&-
MPSG_ (2;POQC.<U^J/PR_P"2=>!/^Q,\*?\ J/:90!W-%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1103@9YX] 2?R&2?P%
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M\%I)88&D<* !N=T+,%7 &20J@ 8  H _ ']EKQ+XF_X+7?\ !+J\T7XP:_\
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M2S+/<RZW\+_B!8QGQG\(?&UO<7VF>*_!M["8=2NM2TO6$@_0+ /4=.1['UH
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M >O_ !A_8;^#OPI^"WQ;U;3-9T'PA'\5K#0_VO-->ZT;Q;:PRL+OP-J_Q1\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?C1KWC/Q-X5FU&&>>&[MO!5QX8TPVTTEG#I\-D1;#L/VGO\ @G]^Q7^VA?\
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M??5'DM([2\T=89I)@#Z>H_SZ?RKQGX%7'[05QX(8_M*Z1\'=(^(L6LWL"1_
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MB2_$%O$DVHS.9)7_ &X^&/'PY\!]_P#BC/"?)ZG_ (I[3.M '<T444 %%%%
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MT_9^)[<26\$\HMYO"BWD$K65K?VUE)>!H@#]'J*_-JQ^//\ P4N\5HZ>'?V
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MW7])_LWRM,,#7<D\0![I;P6UM&([6"*")#(P2"%(H\S2-/*R+&BH3+*[RR%
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M&OF+]L/]DOX3?MM? 'QO^SY\8K"_;P]XJ@M+_0O%'AZ[.D^.?AIX\T"X75/
MWQ3^&_B.)3=>&?B#X \0PVFO>&=9M6VBXMY=,U*&]T34M4TZ\^,O^"<O[6GQ
M7O\ Q-XZ_P""?7[;FHV$7[>'[,&@:=J>I>+(+5='\/\ [7?[/MY?MHWP^_:W
M^&=BVV)[?Q"8[?P[\9?#>G277_"O?BK#?6%\NG6VNZ7IMF ?K71110 4444
M%! (P>1110!^>UA_P2C_ ."=>F?M*']KNP_9&^#]M^T$?%4WCU?',>BWWV2'
MX@W#":?XC6O@9M3/PZM/B1+>#^TI/B#:^$8?&+:L3JQUK^TR;P_H2!C@444
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M =5_]2;PO7ZG_#+_ ))UX$_[$SPI_P"H]IE?EA_P7_\ ^4-__!03_L@.J_\
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M$/B;3-,LHIM1MIX[>PL=4M[:*WDMK::WCC6&6WMVC\M?]8S]D+_@@-_P2_\
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MQC^&W[37[-?A3XL^%-/N++1=7U+]FG]K?Q3<_$3X*_$;P[IT*6>B6WPG\=_
MOQ=X8L;2.TTZUM(H((XOK/X+?'C]J+X0?#7P?XFU#]A3]G?]JW]G75="\4:Y
MX3^.'_!+/5_".G_;O"'Q!UM]?\2ZW%^R9\:YO!FK_9?'?B!I/%?BBR^$7QK^
M+UUXJU*XFU:32]7U##R@'ZFW7[3'P>BFUVWTS7M<\6W/AO5_A)H^M6OP_P#
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M,4/BWX*_$RZ\.WEU%K_P+^.VA01^$_B!I/VEULUETOQ78I)<:-);WWZ1>+?
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MP1^QUX:\5/\ &#]O#XQ7.FZOH?PR^.O[2'@GQ5\(K+6=/U'1;C7]!\$_LM_
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M],O+3P)I7A]TMK>"+PYXA7QCIUO#'Y<8"':/VJ\;_&+X2?#'3_$NJ?$3XF>
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MI]UX42+3/$7BJPM/#&MVVK0>J?%3]EC_ (*$^.=1\-V?A+_@H[;?#SPY8O\
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M1H-4N_%.MZ)?ZM9:Y>V&L^(=;U35M7U:.ZU;3;"_GDU"\N)Y+BTMV:;;$J@
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MXSFZ"RB+]OWX2?LT?&_]C/\ :/\ AQ^V!/HNE_LX:Q\*/%M[\5/%&MQ6IA\
M>']!TV;7O^%FZ9=7=AJ<6E>)/AM?Z?:^./#&N+87<^C>(-#T_4H8)7@\MP#^
M/;]F_P"+?[3?QO\ V@/^";_@3]J3]JKQQ\'OV=_#7[0'P)\7?L37GAOX*?\
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MUS]J#Q!\%/">H"50;BVN?"/[).B_L[:)-IKS#>FGW4-U"B 0%G@WH_7> _\
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M#OB2+X>>!_#/@6TU;2I;0P:1X<TJ60/'-/86_N.@?&?]NSX6VEOX:@_X)<^
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M375Y>WCS7-U<2R3SRR2NSG=WJ3C#_C'(!^97'ZT>8@."Z@^A8 ^G0G/7CZT
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M?($O-*^)/[5_Q)\"^#;Q0.8[WX9_LU3_  #^&E[;D_?M;[PG=P2K\DZRJ2&
M/L#XK?M$_ 'X$V1U+XV_&[X1_!_3A&LQOOBC\2?!G@"U\MPWEL)?%>MZ2'\S
M8XC"!VD92L89ABOD%_\ @JW^QYKK7MI\&==^+7[4.K6N1;V?[*O[.WQW^/VD
M:@RG:_V7XA> _A]??"B&*-BJRW>H^/["QA\Q&FNHU8&O8/A5_P $^OV'?@C>
MV>K_  L_9+_9Y\&^([%FDA\8Z=\)?!=SXZ>1MNZ6Z\>:MI&I>,KV4[$/FWFN
MSRY&=^:^ODAC10B*%15"+&,B-44!518\^6JA0 %50 !@ "@#\WC^U[^V-X[^
MR/\ !?\ X)I?%VPTZ_7%KXF_:K^./P'_ &=M$![SWGAKP-XA_:+^+MA  T;I
M#J'PUL+]QYD<MK:R(-WR!_P4 ^%'_!6[]H7]AO\ ;*^'TS_L<^$$\=_LU_&7
MPWI7P:^#/@SXT_M!_%3XA7>N> M<TZW^'/ASXH^/O%7P \(>'M9\5/<IHUKX
MH/PCUQ]*N[N.\LM)EEMHWD_>,*JC"@*/0  ?D*" 000"#P01D$>A!ZT ?R ?
M&[2O^"GOQ@G_ &</"WPQ\0?MT?&+5-(_:R_8[^*>K^!_VU/V#OA%\$?@5X8U
M'X,?%KP7XI'BQ?B]\!O$>A^,_AE\.] _L"+6_'&B7N@_'#7-<L+>^3P]<PZS
M<&[G_:E?^"B?Q;^!Y>S_ &[?V'?CK\#=-LV<W?QS_9WM=1_;9_9H:QMT1)]:
MU#Q!\(/"]C\?/A_I_G^9)<2_$S]GCPUI.FP%6F\17,:M.?U4$40((CC!!R"$
M4$$="#C@BG%0>HYQC()#8SG 888#(!X(H \(^ ?[4/[.G[4OA5_&O[.?QN^&
M'QL\,P2);:AJ?PT\::'XM&B7SKN.E^(K+2KR?4O#6L1#BYT?Q!9:9JEJV4N+
M2)P5KW<$,,@@CU!!'YBOB'X]?\$Y/V-OVC/%B_$OQ[\%M'T3XSV^Y]/^/_PC
MUGQ/\"?V@]-N%B$=K-;_ !O^#6M>!_B3<QV+K'-;:=J_B'5-'\Q )]-GB>2)
M_!$_9O\ ^"DG[/ )_9M_;+\*?M1^![0PQV7P@_X*#>#Y9_&EM8JYGN+'0OVN
MO@%IOASQ?'(7WV]IJ'Q5^"GQCU-8)5%]JURT/FL ?JU17Y3K_P %.-2^#8>R
M_;T_9#_:)_9"%H9OMOQ:T/P]=?M5?LK21!PMM>I\=?@!I.OZUX,TR4;GEOOC
M?\*/A!'9*"UVR(CR#] ?@]\=_@I^T+X.M/B%\!_BU\-_C-X$OF$=MXP^%WC7
MP[X\\./.$#26LFK^&=1U*SM[VWY2ZLKJ6"\M95>&X@BE1T4 ]7HI 00"""#T
M(.0?H12T %%%% !2%0<9'(S@]QD8.#U&1QP1QQ2T4 ?@C_P7N_X)-+_P4]_9
MDT7P+\(OA7\%W_:='Q2^&\/A?X_?$#RO#6K?"GP#;ZE<R_$#4;[Q5HFGW?B_
MQ-X?NO#T)T0^ DM/$5MJ&I:GIVK6VD6NH:-:ZYI7Q/\ \$6/^#<CX=_L01_M
M">'OVZ_V?OV3/VJ_$\_Q#\*^(?@;\=M5\+P?$>.Z\ S>&+NPU+PJ_@#XFZ)*
MOP]UK0=<M9-3U4VVG:C!KZ^*88%\2ZU;Z#;1:?\ UC44 <)X#^%_PV^%NBQ>
M'/AGX \%?#KP] H2#0O ?A30/!VCP(OW4ATWPWI^F6<2+@85(0HP.*Z#Q%KW
MA_PEH.M>*O%.L:3X=\-^&M(U+7O$'B'7[^UTO1="T+1K.;4M7UG6-6U"6&ST
MS2=*T^VN+_4M0O)XK6RL[>>ZN98XHG<;1( )/0>Q)_ #))/0  DG@#-?@1^T
M!K6J_P#!7S]IGQ)^Q!\.-4U*V_X)Y?LN^-;*W_X*#_$W0;J>TM?VE/C%H4UE
MK6A_L(>!?$=E-$9/!GAJ=;+Q+^U5KFB337 6/1_A1'>Z/=7^HR:D 3_LR>'M
M;_X*S_M+>#_^"AWQ7T/5=-_8:_9R\3:M/_P36^#_ (IL+S3A\8?'=JUUH>K_
M /!0;X@^%=12)PMQ +[0?V4M&\069O/#WA:>]^*$6G:-K^M:??7W[X !0 !@
M#@?Y_F3R>]9VC:-I/AW2=,T'0=,T_1=$T73[+2M(T?2;*WT[2M*TO3K:*RT_
M3=,T^SCBM+#3M/LX(+.QLK6**VM+6&&W@C2*-%&E0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'Q]^W'^QE\-_VY_@-K'P9\>W^L^$M:L=:T/X
M@_"'XN>$)#9_$7X$_&OP3<MJGPX^,GPWU:*6VNM,\6>#-9Q,$M[RTBU[0[G6
M?"VIRG2=;O4/SO\ \$X?VS/B+\7E^)'[)?[7FG:3X)_;_P#V3I=,T#XX^'M-
MB%CX9^,W@?42T'PZ_:O^#".D":Q\*/C%I\,=WJ,%C#%-\._B =;\#:]I^CNF
MAQ7OZDU^6W_!1W]C7XC_ !;/PS_:V_9#O]%\&_M]_LF3ZIK_ ,$];U9VL?#'
MQJ\":DIE^(O[)_QCEAGM5U/X6_&&QC:VTVZOIEE^'WC]=$\:Z)?:1(FL7-P
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MJQ>9)Y0D9A$)'$84.P,NT8QSTQU)./KG.??.>!SP* /SZ_8NL=9OOC'^W_\
M$;2XYD^"WQ0_:B\*:_\ !N]6.6+1?%</A[]E[X!^!/BAX[\)AHD@NO#?B#XJ
M^%_$VFIK5D[Z?XEUWPWKVOV;W<-^-3U#]!J,8_4\DGJ<]_T'0#@<44 ?@1_P
M7H\"?&.S_P""4/\ P4"UK4_CG_:?A-?@OX@O'\&_\*J\'6GF:7-XHT(VVC_\
M))#?MJD7V5);>'^TDA-U+Y'VAT$K;:_;[X8Y_P"%<^ \G)_X0OPGD],G_A'=
M,YQVK\L/^"__ /RAO_X*"?\ 9 =5_P#4F\+U^I_PR_Y)UX$_[$SPI_ZCVF4
M=S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!;A>Y632;/[#+'>?:=06VA^R.MSO\ ((DK\&?!FL>,/@;\;OB-X#_9EOO
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MKOH\GBG03::6/%K_ !4OEBN[>.2VBEU8>&W%PT,DXTV%I$BC_;GX8_\ ).?
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MN:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ*HED# 'Y]_L2-?W/QB_X*#:GX;\O_A1.I?M6>'9O@W+I_DGPO?7MO\ LQ?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.O\ XJXT+_Z+2OV4HH _&O\ X90_X+/_ /27']G7_P 5<:%_]%I1_P ,H?\
M!9__ *2X_LZ_^*N-"_\ HM*_92B@#\:_^&4/^"S_ /TEQ_9U_P#%7&A?_1:4
M?\,H?\%G_P#I+C^SK_XJXT+_ .BTK]E** /QK_X90_X+/_\ 27']G7_Q5QH7
M_P!%I7AWC[X<?\%F_ OQ@^!'PF;_ (*G_LZZFWQNO/B7:+KW_#L_1+,>&/\
MA7/@=O&;2-I@_:@N_P"V!JZJ-.VB_P!-^P;A=AKTYM1_0+7">(?AIX*\4^,O
M 7C_ %W1A?>+/AC-XGN/!.J_;M1MSHLOC+0CX:\1N+.UNX;&_P#[1T4FRVZE
M;7:VV?/M!!<@34 ?E-_PRA_P6?\ ^DN/[.O_ (JXT+_Z+2C_ (90_P""S_\
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M%G_^DN/[.O\ XJXT+_Z+2C_AE#_@L_\ ])<?V=?_ !5QH7_T6E?LI10!_/\
M_#GX9_\ !9OX@_$WX_?#=?\ @JA^SKI+? KQAX'\)OK/_#L[0[X>*3XT^%'@
MWXH+J"V!_:AL_P"QAIR^+QHGV4WFIF[_ +..I&>U-T+"#VS_ (90_P""S_\
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ME>BQTNQM;7[7?W=U>W'E>;=7$T[O(P!^3/\ PRA_P6?_ .DN/[.O_BKC0O\
MZ+2C_AE#_@L__P!)<?V=?_%7&A?_ $6E?LI10!^-?_#*'_!9_P#Z2X_LZ_\
MBKC0O_HM*/\ AE#_ (+/_P#27']G7_Q5QH7_ -%I7[*44 ?C7_PRA_P6?_Z2
MX_LZ_P#BKC0O_HM*/^&4/^"S_P#TEQ_9U_\ %7&A?_1:5^RE% 'XU_\ #*'_
M  6?_P"DN/[.O_BKC0O_ *+2C_AE#_@L_P#])<?V=?\ Q5QH7_T6E?LI10!^
M-?\ PRA_P6?_ .DN/[.O_BKC0O\ Z+2C_AE#_@L__P!)<?V=?_%7&A?_ $6E
M?LI10!^-?_#*'_!9_P#Z2X_LZ_\ BKC0O_HM*\3^.'PT_P""SGP7TSX=ZB__
M  5/_9U\2?\ "??&KX1_!U8!_P $SM#T@Z4_Q5\96/A%?$1D_P"&HM2%Z-"-
M[_:']E;;3^T_)-J=1L-XN!_0!7#>._AOX-^)5KX<L_&FCC6;?PGXW\'_ !&T
M",WVH6/V#QCX"UJ#Q#X4U?=IUU:/<'2]7MH;L65TTVGWA3R;ZUN;=FB(!^4:
M_LH_\%GF56_X>X_LZ?,H/'_!+G0\<C/&?VLP<?4 ^H'2E_X90_X+/_\ 27']
MG7_Q5QH7_P!%I7[)@!0% P%  'H , <\]/6EH _&O_AE#_@L_P#])<?V=?\
MQ5QH7_T6E'_#*'_!9_\ Z2X_LZ_^*N-"_P#HM*_92B@#\:_^&4/^"S__ $EQ
M_9U_\5<:%_\ 1:4?\,H?\%G_ /I+C^SK_P"*N-"_^BTK]E** /QK_P"&4/\
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M/AGQ):_\?7A_Q"- U+4#HFN6PYN-)U,6M_".9+=<'&MIOC3PCJ\^CVFE^)]
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M\"WU>W\4:@#I5C:/.U[\:O%7Q.T=Y9-\=QIW@[0)(B8HH@@!]G4444 %%%%
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M @.P+WL+*6ZCO9+.UDO(5"Q73V\+W,2J)0JQSLAF0*)I@ K@ 2R #$CYMT4
M0PVUO;F5H((86GF:XG,4:1F:=PJO-+L5?-F9456E?=(54 L0 *FHHH ****
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M1@M9[*&_DM8)+V*SNGBDN;2*[>,W$=K<20Q/<6Z2+#.\2-*CLJD>.^+?V?\
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MGB;Q=:ZE8:['X9M?$.E^']>\1ZL+&;P5J?PK\5-HVAI:>/=.MM3O_P!*+_X
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MU_9+JTMC+J46F&[MQJ,FG07$-I/?)8F7[4]G#<W$%O+=+";>.>>&%Y%DE16
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M+'6/"5M^S2Z)H\;7+1Z5IT;7AOFNV2QM$:Z;4S;G43<LL(,YO_LEK]N\TO\
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M_"W/^$JTO^T/^&H?^%H?\*Y_X0G^S]8_MG['_P *E_XJ?_A*?[4_L#^S//\
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>insmed10k2018_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31"
  xmlns:insm="http://www.insmed.com/20181231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="insm-20181231.xsd" xlink:type="simple"/>
    <context id="FD2018Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermivMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermivMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Feb2018_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiiiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermiiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="FI2017Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="FI2015Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="D2017Q3Sept17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="I2017Q2May18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2017-05-18</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_NewJerseyDivisionOfTaxationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_insm_CommercialFilVFinishServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CommercialFilVFinishServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2016Q4OCT01-OCT31_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="D2014Q3JUL01-JUL31_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-01</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2004Q4JAN01-DEC31_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2004-01-01</startDate>
            <endDate>2004-12-31</endDate>
        </period>
    </context>
    <context id="D2008Q2APR01-APR30_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-04-01</startDate>
            <endDate>2008-04-30</endDate>
        </period>
    </context>
    <context id="I2017Q4Oct31_us-gaap_TypeOfArrangementAxis_insm_SupplyAgreementWithPatheonUKLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:SupplyAgreementWithPatheonUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="D2014Q1FEB01-FEB28_us-gaap_TypeOfArrangementAxis_insm_TherapureBiopharmaIncContractManufacturingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:TherapureBiopharmaIncContractManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-02-01</startDate>
            <endDate>2014-02-28</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="D2014Q3JUL01-JUL31_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-01</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="D2008Q2APR01-APR30_insm_MilestonePaymentAxis_insm_MilestoneNewDrugApplicationMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:MilestonePaymentAxis">insm:MilestoneNewDrugApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-04-01</startDate>
            <endDate>2008-04-30</endDate>
        </period>
    </context>
    <context id="D2008Q2APR01-APR30_insm_MilestonePaymentAxis_insm_MilestoneFDAApprovalMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:MilestonePaymentAxis">insm:MilestoneFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-04-01</startDate>
            <endDate>2008-04-30</endDate>
        </period>
    </context>
    <context id="D2014Q4DEC01-DEC31_us-gaap_TypeOfArrangementAxis_insm_AgreementWithSynteractHCRInc.For212StudyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:AgreementWithSynteractHCRInc.For212StudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="D2016Q4OCT01-OCT31_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="I2016Q4OCT31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="FI2015Q3_us-gaap_TypeOfArrangementAxis_insm_CommercialFilVFinishServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CommercialFilVFinishServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2014Q4DEC01-DEC31_us-gaap_TypeOfArrangementAxis_insm_AgreementWithSyneosHealthForWillowStudyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:AgreementWithSyneosHealthForWillowStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="D2009Q4JAN01-DEC31_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-01-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_StatementGeographicalAxis_insm_BridgewaterNewJerseyFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:BridgewaterNewJerseyFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_insm_BridgewaterNewJerseyFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:BridgewaterNewJerseyFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FD2017Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q1Q1Feb19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_EquipmentFurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q1Jan01_srt_RangeAxis_srt_MaximumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="I2019Q1Jan01_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q1YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2017Q1Jan01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="I2017Q1Jan01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q3Sep28-Sep28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2018-09-28</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <unit id="segment">
        <measure>insm:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>insm:security</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="day">
        <measure>insm:day</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2018Q4YTD"
      id="Fact-71B44FD80380B850FBBCC80C6441BC57-wk-Fact-71B44FD80380B850FBBCC80C6441BC57">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2018Q4YTD"
      id="Fact-B3AEA95179E72A7590D7C80C643D0015-wk-Fact-B3AEA95179E72A7590D7C80C643D0015">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2018Q4YTD"
      id="Fact-3DE9432CE88B341DF268C80C643BD716-wk-Fact-3DE9432CE88B341DF268C80C643BD716">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2018Q4YTD"
      id="Fact-DF1273AA09DD43B84916C80C643948E9-wk-Fact-DF1273AA09DD43B84916C80C643948E9">2018</dei:DocumentFiscalYearFocus>
    <dei:DocumentPeriodEndDate
      contextRef="FD2018Q4YTD"
      id="Fact-F14876D9F917A568E917C80C64380136-wk-Fact-F14876D9F917A568E917C80C64380136">2018-12-31</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey
      contextRef="FD2018Q4YTD"
      id="Fact-4EBC7A90C76AD19367E0C80C64379DB5-wk-Fact-4EBC7A90C76AD19367E0C80C64379DB5">0001104506</dei:EntityCentralIndexKey>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2018Q4YTD"
      id="Fact-90C38765419BBE187289C80C6441BB81-wk-Fact-90C38765419BBE187289C80C6441BB81">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2018Q4YTD"
      id="Fact-9AC056370091BF7DF909579A2E4C2FF4-wk-Fact-9AC056370091BF7DF909579A2E4C2FF4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityFilerCategory
      contextRef="FD2018Q4YTD"
      id="Fact-085F5561A3E0DEAE00F6C80C643AD701-wk-Fact-085F5561A3E0DEAE00F6C80C643AD701">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityRegistrantName
      contextRef="FD2018Q4YTD"
      id="Fact-77167C5A14C2A331A2A9C80C643F8C97-wk-Fact-77167C5A14C2A331A2A9C80C643F8C97">INSMED INC</dei:EntityRegistrantName>
    <dei:EntityShellCompany
      contextRef="FD2018Q4YTD"
      id="Fact-8F9D4B1BDF3B7EF37A27579984C98E2C-wk-Fact-8F9D4B1BDF3B7EF37A27579984C98E2C">false</dei:EntityShellCompany>
    <dei:EntitySmallBusiness
      contextRef="FD2018Q4YTD"
      id="Fact-1DF37062A1AE6765ABBE579BAAF43366-wk-Fact-1DF37062A1AE6765ABBE579BAAF43366">false</dei:EntitySmallBusiness>
    <dei:EntityVoluntaryFilers
      contextRef="FD2018Q4YTD"
      id="Fact-5EA7374172D3AB3E6B94C80C643A8F8A-wk-Fact-5EA7374172D3AB3E6B94C80C643A8F8A">No</dei:EntityVoluntaryFilers>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="FD2018Q4YTD"
      id="Fact-3C79888DFD224ADC672CC80C643FEEF0-wk-Fact-3C79888DFD224ADC672CC80C643FEEF0">Yes</dei:EntityWellKnownSeasonedIssuer>
    <insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-EBDE1BCD170547E68FA3C80C645ABDC1-wk-Fact-EBDE1BCD170547E68FA3C80C645ABDC1"
      unitRef="security">0</insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities>
    <insm:CommercialServicesAgreementExtensionPeriod
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_insm_CommercialFilVFinishServicesAgreementMember"
      id="Fact-C46CB54EB96BEDD97F5CC80C64668C1D-wk-Fact-C46CB54EB96BEDD97F5CC80C64668C1D">P2Y</insm:CommercialServicesAgreementExtensionPeriod>
    <insm:FairValueLevel1Level2Level3TransfersAmount
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="Fact-D605ED0AA3131C8588101A5D1C01B53A-wk-Fact-D605ED0AA3131C8588101A5D1C01B53A"
      unitRef="usd">0</insm:FairValueLevel1Level2Level3TransfersAmount>
    <insm:RoyaltyPaymentPeriod
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember"
      id="Fact-4E1C65EC05A16A8D124CC80C645CA355-wk-Fact-4E1C65EC05A16A8D124CC80C645CA355">P3Y</insm:RoyaltyPaymentPeriod>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-C79848154B3F91BF6D0FC80C64370C29-wk-Fact-C79848154B3F91BF6D0FC80C64370C29"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-87C6E35A778346618DE0C80C643CF194-wk-Fact-87C6E35A778346618DE0C80C643CF194"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-BF16B39EEE35C8798604C80C643602E5-wk-Fact-BF16B39EEE35C8798604C80C643602E5"
      unitRef="shares">76610508</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-B3B7BC8015CB98624A84C80C6438E103-wk-Fact-B3B7BC8015CB98624A84C80C6438E103"
      unitRef="shares">77307521</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-E6427A52FCF99DB6B849C80C64365386-wk-Fact-E6427A52FCF99DB6B849C80C64365386"
      unitRef="shares">76610508</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"
      decimals="7"
      id="Fact-299BA43F9CB8E34560291B3DB68932ED-wk-Fact-299BA43F9CB8E34560291B3DB68932ED"
      unitRef="number">0.0255384</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="Fact-E63E78ADC6EFA5AD48A41A6250CAA0CA-wk-Fact-E63E78ADC6EFA5AD48A41A6250CAA0CA"
      unitRef="usd">450000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-65FFEE9714E2E152417E9AF2D7AD9689-wk-Fact-65FFEE9714E2E152417E9AF2D7AD9689"
      unitRef="usd">5000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-23E234C2FC5ACE1BB6559B651D197C72-wk-Fact-23E234C2FC5ACE1BB6559B651D197C72"
      unitRef="usd">5000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-44C99EC6AE03A17CD2E89B64D5603258-wk-Fact-44C99EC6AE03A17CD2E89B64D5603258"
      unitRef="usd">5000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-770E1A9E4786CF973F939B5F7CF2B9D4-wk-Fact-770E1A9E4786CF973F939B5F7CF2B9D4"
      unitRef="usd">5000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-8B785C65401E140F93F99B5F28BB3348-wk-Fact-8B785C65401E140F93F99B5F28BB3348"
      unitRef="usd">5000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Jan01_srt_RangeAxis_srt_MaximumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember"
      decimals="-6"
      id="Fact-FC61AEFA0E3CCD784E740143187DB0DC-wk-Fact-FC61AEFA0E3CCD784E740143187DB0DC"
      unitRef="usd">49000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Jan01_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember"
      decimals="-6"
      id="Fact-CDB0F6D9FF18FD0C2DA60142910BE80C-wk-Fact-CDB0F6D9FF18FD0C2DA60142910BE80C"
      unitRef="usd">44000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact-E173BD8A7EDFF80D7912C9F1A4D61825-wk-Fact-E173BD8A7EDFF80D7912C9F1A4D61825"
      unitRef="usd">1300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-EEE1340DDAE87B3653E4C80C6470758C-wk-Fact-EEE1340DDAE87B3653E4C80C6470758C"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-97D2A27B46C907460981C80C6477E39C-wk-Fact-97D2A27B46C907460981C80C6477E39C"
      unitRef="shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-89FD8E03353A0A8D3154C80C6471417F-wk-Fact-89FD8E03353A0A8D3154C80C6471417F"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-506CBBC8F10EF5C02F42C80C64748D22-wk-Fact-506CBBC8F10EF5C02F42C80C64748D22"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-BE3D088BF4060383673AC80C6471B68C-wk-Fact-BE3D088BF4060383673AC80C6471B68C"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2016Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="Fact-50055C2BCF80B1099135C80C645E2D3D-wk-Fact-50055C2BCF80B1099135C80C645E2D3D"
      unitRef="number">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2016Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="Fact-EA50553AA123930B10F0C80C642532B4-wk-Fact-EA50553AA123930B10F0C80C642532B4"
      unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="Fact-CA420385469BF20C75FCC80C64230B0C-wk-Fact-CA420385469BF20C75FCC80C64230B0C"
      unitRef="number">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="Fact-120B2E5818E39AB19F9DC80C642D5AC1-wk-Fact-120B2E5818E39AB19F9DC80C642D5AC1"
      unitRef="number">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="Fact-087413CE40C4B1F4C4F6C80C642C8975-wk-Fact-087413CE40C4B1F4C4F6C80C642C8975"
      unitRef="number">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="Fact-F82F610FB923C5E5843EC80C64206428-wk-Fact-F82F610FB923C5E5843EC80C64206428"
      unitRef="number">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2016Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="4"
      id="Fact-878CD1D2358B154C5899C80C64253B43-wk-Fact-878CD1D2358B154C5899C80C64253B43"
      unitRef="number">0.0190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2016Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="4"
      id="Fact-2E9F381BAE854BA2D3A0C80C641FA10A-wk-Fact-2E9F381BAE854BA2D3A0C80C641FA10A"
      unitRef="number">0.0100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="4"
      id="Fact-438EB0D98E61B9CECC1EC80C641ADC84-wk-Fact-438EB0D98E61B9CECC1EC80C641ADC84"
      unitRef="number">0.0213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="4"
      id="Fact-538C3E4B02CA52BAF7C0C80C6462C9A0-wk-Fact-538C3E4B02CA52BAF7C0C80C6462C9A0"
      unitRef="number">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="4"
      id="Fact-904CF5813BC517DBAB96C80C645BF1A3-wk-Fact-904CF5813BC517DBAB96C80C645BF1A3"
      unitRef="number">0.0296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="4"
      id="Fact-E06CE7DFBD2BEEBC2AE8C80C641F1C18-wk-Fact-E06CE7DFBD2BEEBC2AE8C80C641F1C18"
      unitRef="number">0.0225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-0BF8A6AB06D738699331C80C64292726-wk-Fact-0BF8A6AB06D738699331C80C64292726"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <dei:DocumentType
      contextRef="FD2018Q4YTD"
      id="d14995944e864-wk-Fact-A16B48F0E7D8DA5A6F6B1455D059E3A9">10-K</dei:DocumentType>
    <dei:EntityPublicFloat
      contextRef="FI2018Q2"
      decimals="-6"
      id="d14995944e1166-wk-Fact-5AF76CB0F12A94E87B3F807EEDCE4AF5"
      unitRef="usd">1803000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2019Q1Q1Feb19"
      decimals="INF"
      id="d14995944e1177-wk-Fact-18668FFCB01F9FF05913145B7CF118B6"
      unitRef="shares">77538562</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1068-wk-Fact-427FBC64188DA71D9DF1C80C64763291"
      unitRef="usd">495072000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1087-wk-Fact-51D76EC3E2C2D919A799C80C64749C4F"
      unitRef="usd">381165000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1107-wk-Fact-90EB21BBF15DD6EB987D199A58854276"
      unitRef="usd">5515000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1126-wk-Fact-B2B07187A8162BD0FE53199A5894A613"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1151-wk-Fact-1DBCE8064A0BCB536A421995AF92293F"
      unitRef="usd">7032000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1170-wk-Fact-D1A7F3048148B1BBDA191995AF96F5A1"
      unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1195-wk-Fact-92C077B8EB60ED9317CEC80C6464B0B4"
      unitRef="usd">11327000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1214-wk-Fact-80D353DD6BFF5C89D38CC80C6471C8F0"
      unitRef="usd">8279000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1239-wk-Fact-BE68755F148F352A7BAEC80C646F97AD"
      unitRef="usd">518946000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1258-wk-Fact-BE449DFA902D22237F15C80C64783F9D"
      unitRef="usd">389444000</us-gaap:AssetsCurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1329-wk-Fact-37DB01866B7D3BE6F66CC80C6466A9B9"
      unitRef="usd">58675000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1348-wk-Fact-5F4E1E308F165E3B6678C80C64771C5C"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1374-wk-Fact-E1B09700CAF1045121D4C80C647C57EB"
      unitRef="usd">22636000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1393-wk-Fact-00C9FAFCE2A161EA3686C80C646A5ED4"
      unitRef="usd">12432000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1418-wk-Fact-1AB2611DDB602C70DC48C80C6462E308"
      unitRef="usd">4299000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1437-wk-Fact-218F5300BC5DFB8E7ABCC80C64748E9A"
      unitRef="usd">1971000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1467-wk-Fact-0DF9EE5DDB5713B5CE18C80C64762419"
      unitRef="usd">604556000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1486-wk-Fact-E22C8E2E35242923225DC80C646A359E"
      unitRef="usd">462047000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1645-wk-Fact-897AAECFE4E1F2FAA531C80C6477EEBC"
      unitRef="usd">17741000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1664-wk-Fact-0C8D758F4BE6405901AEC80C647ADAB6"
      unitRef="usd">14671000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1684-wk-Fact-5D090E567899D78AEC44C80C647E734C"
      unitRef="usd">38254000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1703-wk-Fact-71F7BB0080BFEB1A3989C80C646A1E6C"
      unitRef="usd">17142000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1728-wk-Fact-614E126349829E5B91438084237C8E1A"
      unitRef="usd">22208000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1747-wk-Fact-2CFE5BAD035C11BCEE7780843B6C9A06"
      unitRef="usd">12197000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1772-wk-Fact-412E17813E194C04EBD6C80C6474FFD7"
      unitRef="usd">1529000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1791-wk-Fact-423F823D1F0D339C5853C80C647130CE"
      unitRef="usd">646000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1816-wk-Fact-D8FA475AFB5E0ED3F1F4C80C64787E52"
      unitRef="usd">79732000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1835-wk-Fact-2292CFA9A88FE5A04550C80C64795D93"
      unitRef="usd">44656000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1905-wk-Fact-2E25EFE980C3474A3F0EC80C647C1254"
      unitRef="usd">316558000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1924-wk-Fact-0889BF9A7343EB1D9B84C80C64658185"
      unitRef="usd">55567000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1949-wk-Fact-85F46ACE66FEB53C250EC80C64727493"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e1968-wk-Fact-E2FCD139D76F330845BDC80C646FFF1C"
      unitRef="usd">765000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e1993-wk-Fact-4DB683B889EFAE225C05C80C646CB94A"
      unitRef="usd">396290000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e2012-wk-Fact-0717CFE7A8E4FC72A1ADC80C6465FDAD"
      unitRef="usd">100988000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e2129-wk-Fact-588C55B7879C279BCC66C80C647B81F0"
      unitRef="usd">773000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e2148-wk-Fact-0B457D664EDC98483331C80C6467622A"
      unitRef="usd">766000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e2173-wk-Fact-46184AD89A7A2C616164C80C6472FB44"
      unitRef="usd">1489664000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e2192-wk-Fact-A9FD4D51BE263DDC9E38C80C64696533"
      unitRef="usd">1318181000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e2217-wk-Fact-CC574BBE44F93BDBCC14C80C647DF7FD"
      unitRef="usd">-1282162000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e2237-wk-Fact-A50145461DBF576017F6C80C647EEAC9"
      unitRef="usd">-957885000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e2263-wk-Fact-917152A732ABC720BDA0C80C647BA7A0"
      unitRef="usd">-9000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e2283-wk-Fact-4824CB9301E839D4FA7CC80C6468AE6B"
      unitRef="usd">-3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e2309-wk-Fact-B75D79B791B3584126F9C80C647031BB"
      unitRef="usd">208266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e2328-wk-Fact-DCE7F8BE5E46B6FEC90DC80C6465F0C6"
      unitRef="usd">361059000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15032183e2359-wk-Fact-A334E7D7BF3172A5CF5DC80C6472FC6A"
      unitRef="usd">604556000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15032183e2378-wk-Fact-498BC1AB2095D286A15EC80C64796EF1"
      unitRef="usd">462047000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e1067-wk-Fact-0CE9CA24C5A1FC8486371AD4F405D7F5"
      unitRef="usd">9835000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e1086-wk-Fact-386BA215910B5BD7882B19A235C5AC3A"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e1105-wk-Fact-7FD3E4DB733DAA82E07119A24A457D43"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e1121-wk-Fact-0CE9CA24C5A1FC8486371AD4F405D7F5"
      unitRef="usd">9835000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e1140-wk-Fact-386BA215910B5BD7882B19A235C5AC3A"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e1159-wk-Fact-7FD3E4DB733DAA82E07119A24A457D43"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e1301-wk-Fact-5ABE2B07153213A344EC1ADE1929033C"
      unitRef="usd">2423000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e1320-wk-Fact-4000BD3A37997FB14A771ADE19229D92"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e1339-wk-Fact-7F3DDBA768CE9677928A1ADE1926AE4F"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e1360-wk-Fact-319DC661D7F4FFE6C715C80C6442BD89"
      unitRef="usd">145283000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e1379-wk-Fact-43281E1F2620A921EBFAC80C6432DE5C"
      unitRef="usd">109749000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e1398-wk-Fact-A326D7B0541A8BC8C541C80C64334850"
      unitRef="usd">122721000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e1419-wk-Fact-92EB997E01FEB1B1410DC80C643BADD9"
      unitRef="usd">168218000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e1438-wk-Fact-F0FE99C8725DC17858CDC80C643F751B"
      unitRef="usd">79171000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e1457-wk-Fact-FE401B3B74530F86F764C80C643BD76B"
      unitRef="usd">50679000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e1478-wk-Fact-E12E542CC2BAF2409A4719A92EAC878F"
      unitRef="usd">1249000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e1497-wk-Fact-8C100FA5E0B9F66560EA19A96A097229"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e1516-wk-Fact-D7A9152B906156D1403F19A9A330A7AF"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e1538-wk-Fact-CF4283EBC4B7F77CED65C80C642E37D6"
      unitRef="usd">317173000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e1557-wk-Fact-DED48228298CB04EB1DEC80C6430F5BA"
      unitRef="usd">188920000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e1576-wk-Fact-6A265CAB491AE29E3243C80C64324C3B"
      unitRef="usd">173400000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e1659-wk-Fact-94636DE7E0B2D950EF3EC80C64407EF0"
      unitRef="usd">-307338000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e1679-wk-Fact-9A1B732379CE71D1D61EC80C643B8C9A"
      unitRef="usd">-188920000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e1699-wk-Fact-D235A19CD8A61BD5CBDCC80C643BDD41"
      unitRef="usd">-173400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e1783-wk-Fact-CBCAC97E51EDCE9CB62EC80C643D4DF1"
      unitRef="usd">10341000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e1802-wk-Fact-2C237DDB03100D8B0A1EC80C642CAAF4"
      unitRef="usd">1624000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e1821-wk-Fact-4BCDFC5F765DD74505D0C80C6441F2B4"
      unitRef="usd">604000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e1842-wk-Fact-BEE70880F81C17F6C423C80C6433566B"
      unitRef="usd">25472000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e1862-wk-Fact-321A472A693B36955FECC80C64408854"
      unitRef="usd">5925000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e1882-wk-Fact-9AAEF84C59D4D4710955C80C643BB756"
      unitRef="usd">3498000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e1904-wk-Fact-79144B5414C6CFB1FC8E808979A5D4CF"
      unitRef="usd">-2209000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e1924-wk-Fact-8EFABA5FA4D897D3438180899DAEBDFC"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e1943-wk-Fact-EEC990E7E9A002C1F1EB8089B090FE9E"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e1964-wk-Fact-E9AB1DB6A2349186701DC80C643CCD8F"
      unitRef="usd">602000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e1983-wk-Fact-2DACF4031849687CDE2FC80C643C0A49"
      unitRef="usd">300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e2002-wk-Fact-5947E43724AC6F68A3E4C80C64467F52"
      unitRef="usd">119000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e2023-wk-Fact-12A725180DFC88524CFCC80C64387A24"
      unitRef="usd">-324076000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e2043-wk-Fact-A15D7F28ADF1B4BED74EC80C642BF891"
      unitRef="usd">-192921000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e2063-wk-Fact-885B0511759F68EBB430C80C642DAEE3"
      unitRef="usd">-176175000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e2147-wk-Fact-8D74C5FB87F23963EC01C80C64442BB1"
      unitRef="usd">201000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e2166-wk-Fact-DE237BCC7B9D2B1576DAC80C64408AF8"
      unitRef="usd">-272000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e2186-wk-Fact-EEB607607F1CA43AAEDDC80C6430DE13"
      unitRef="usd">98000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e2275-wk-Fact-B42634276C7A9632D85AC80C6434F487"
      unitRef="usd">-324277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e2295-wk-Fact-04977BE1C74AC80F3F04C80C643AC548"
      unitRef="usd">-192649000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e2315-wk-Fact-7F7EDEF8E2CD9E9CBE90C80C642F7957"
      unitRef="usd">-176273000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15023556e2399-wk-Fact-518DC39F637E8302275EC80C64362527"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15023556e2419-wk-Fact-E7AA589AA67B3269D3FEC80C6440E3D2"
      unitRef="usdPerShare">-2.89</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15023556e2439-wk-Fact-392E31090CD7F1536356C80C6432E7FF"
      unitRef="usdPerShare">-2.85</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e2518-wk-Fact-0731903F1DC62230D922C80C643EAD1F"
      unitRef="shares">76889000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e2537-wk-Fact-764806C4124A807A428DC80C64341125"
      unitRef="shares">66576000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e2556-wk-Fact-D2DB4889A1B537702B8AC80C642E3F3B"
      unitRef="shares">61892000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e2644-wk-Fact-3F5C1FF348013389AAF7C80C6446F8B4"
      unitRef="usd">-324277000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e2664-wk-Fact-B79973E21F1101F13969C80C6442F1A0"
      unitRef="usd">-192649000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e2684-wk-Fact-C4A58318AE76A8EB42A9C80C643E352C"
      unitRef="usd">-176273000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e2822-wk-Fact-D0E153C1F918FBA1591EC80C64436E77"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e2842-wk-Fact-F7E99A649F603644FBC8C80C6443594A"
      unitRef="usd">62000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e2861-wk-Fact-1F8186588345698F33F4C80C64378A3A"
      unitRef="usd">-65000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15023556e2889-wk-Fact-2757970DCC73604ECC65C80C6432A7C5"
      unitRef="usd">-324283000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15023556e2909-wk-Fact-6AD3D75DFD18420B9DECC80C642BCE66"
      unitRef="usd">-192587000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15023556e2929-wk-Fact-87105D960B6C6E07F00DC80C6442BEE4"
      unitRef="usd">-176338000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e1147-wk-Fact-2A48278BE08E5A353208C80C64579E1D"
      unitRef="shares">61814000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e1166-wk-Fact-2D4E63DEF1505751511EC80C6482A9C9"
      unitRef="usd">618000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d15024959e1185-wk-Fact-90DD0B89E39D08324E91C80C641B86C9"
      unitRef="usd">900043000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d15024959e1205-wk-Fact-7F67D23F831D540399DBC80C6463DB26"
      unitRef="usd">-588963000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d15024959e1225-wk-Fact-035BCFDE1B6C5D09DE50C80C646126F0"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2015Q4"
      decimals="-3"
      id="d15024959e1244-wk-Fact-D4243DFCEFD996E3A84AC80C6456C1E0"
      unitRef="usd">311698000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d15024959e1425-wk-Fact-2C8C5A1E224088205195C80C64600739"
      unitRef="usd">-176273000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15024959e1464-wk-Fact-7F7EDEF8E2CD9E9CBE90C80C642F7957"
      unitRef="usd">-176273000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d15024959e1562-wk-Fact-94D551901D0F50340504C80C64801F83"
      unitRef="usd">-65000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15024959e1582-wk-Fact-16E2AE0E7D92D53BFB88C80C6481CB49"
      unitRef="usd">-65000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e1604-wk-Fact-0B180CA73A935F4495DAC80C64598083"
      unitRef="shares">162000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e1618-wk-Fact-FB449EE2F5509E208AB2C80C646515A4"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d15024959e1637-wk-Fact-FBAB77BB0BC75D84F476C80C645A60DC"
      unitRef="usd">1082000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15024959e1695-wk-Fact-E92CB3DBCAF7788E359AC80C644F2117"
      unitRef="usd">1084000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e1716-wk-Fact-12C2EE9B3FE5BA583BD1C80C6454D8F9"
      unitRef="shares">44000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15024959e1807-wk-Fact-9AC3E442F5C216A45F761AB276B3FE6F"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d15024959e1861-wk-Fact-AB9F3919FBD0B790FDA0C80C6451BFBE"
      unitRef="usd">18039000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15024959e1919-wk-Fact-0B4317C6F86C0A4918B4C80C6460BCAF"
      unitRef="usd">18039000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e1940-wk-Fact-DFCC6AD42506B0AF030FC80C6457876E"
      unitRef="shares">62020000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e1959-wk-Fact-322011EB862A7EFF4B6AC80C645276D3"
      unitRef="usd">620000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d15024959e1978-wk-Fact-0928514A062F9114E36FC80C6462BABB"
      unitRef="usd">919164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d15024959e1998-wk-Fact-B60BE7B5940EE7FAD32EC80C6452F9D2"
      unitRef="usd">-765236000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d15024959e2018-wk-Fact-C573DD62C7EAE617C734C80C6455DE27"
      unitRef="usd">-65000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4"
      decimals="-3"
      id="d15024959e2038-wk-Fact-0F189D575FA156BA45AEC80C647FDEB3"
      unitRef="usd">154483000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d15024959e2220-wk-Fact-69831BBA751461425C49C80C645B7E87"
      unitRef="usd">-192649000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15024959e2259-wk-Fact-04977BE1C74AC80F3F04C80C643AC548"
      unitRef="usd">-192649000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d15024959e2353-wk-Fact-0556C473D8585607CB23C80C64594653"
      unitRef="usd">62000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15024959e2372-wk-Fact-6E512521CAF6A9EDA685C80C64676E53"
      unitRef="usd">62000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e2393-wk-Fact-6540229C63FAD94B307BC80C64581F41"
      unitRef="shares">379000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e2407-wk-Fact-DBD6CF17D4A927EB0B40C80C64617A0E"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d15024959e2426-wk-Fact-48861F50A2B9B0DD484CC80C6466D6CE"
      unitRef="usd">3429000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15024959e2484-wk-Fact-494D9FAE9B7DE261F15DC80C645C10F2"
      unitRef="usd">3433000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e2505-wk-Fact-1FC20A3278F68E3225C2C80C64539FC9"
      unitRef="shares">14123000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e2519-wk-Fact-AC1900DAF94DDDBF720AC80C645333BF"
      unitRef="usd">141000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d15024959e2538-wk-Fact-1614285A8D79FDC4EC99C80C645889BA"
      unitRef="usd">377515000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15024959e2598-wk-Fact-E586115F74F3C3AFDF3CC80C645E4ED1"
      unitRef="usd">377656000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e2619-wk-Fact-29C7C03E5317701C15B0C80C6451FD1F"
      unitRef="shares">89000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e2633-wk-Fact-DA5609AD22470FAF1875C80C645FB6D3"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15024959e2710-wk-Fact-F339702F0210C6B6027AC80C645E1F63"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d15024959e2764-wk-Fact-4FB4640A86A6AF5002B8C80C645FD4C9"
      unitRef="usd">18073000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15024959e2822-wk-Fact-66EC6A46829C86DF09CBC80C645C99AF"
      unitRef="usd">18073000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e2843-wk-Fact-6791043C668C8BA861F8C80C6450EF13"
      unitRef="shares">76611000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e2862-wk-Fact-0F875F4C57415C3DAB5EC80C6450305F"
      unitRef="usd">766000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d15024959e2881-wk-Fact-4FEDB1CF49C2B93EF437C80C644F4C54"
      unitRef="usd">1318181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d15024959e2901-wk-Fact-E97D6D08028DA32DD5ACC80C6455C360"
      unitRef="usd">-957885000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d15024959e2921-wk-Fact-2725C690BFC3960FB2A1C80C647FB71D"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15024959e2941-wk-Fact-DCE7F8BE5E46B6FEC90DC80C6465F0C6"
      unitRef="usd">361059000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d15024959e3122-wk-Fact-6AE169FF092815D59E6E808B0A3BB06E"
      unitRef="usd">-324277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15024959e3161-wk-Fact-B42634276C7A9632D85AC80C6434F487"
      unitRef="usd">-324277000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d15024959e3255-wk-Fact-A449FDA1F9AD2F6EF872808B0A155C5B"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15024959e3275-wk-Fact-9D3C7CC6F871F81281861AB42EC28D2E"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e3297-wk-Fact-6FE5149D1D01D1627CAC808B0A1EAE8D"
      unitRef="shares">645000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e3311-wk-Fact-E57A440615F1FB187C5E808B0A28C4E5"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d15024959e3330-wk-Fact-2BFF6C727DF10345DAB1808B0A0864CB"
      unitRef="usd">8809000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15024959e3388-wk-Fact-1FD3C95911E10A3B90741AB57945BA4D"
      unitRef="usd">8815000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d15024959e3443-wk-Fact-670A9875945AB16ADCC2808C8EAF051C"
      unitRef="usd">136434000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15024959e3503-wk-Fact-49A8158429DCCA93B6A41ABA4F701A28"
      unitRef="usd">136434000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e3524-wk-Fact-7D06EB53A4A425756C2F808B09FE8D6C"
      unitRef="shares">52000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e3538-wk-Fact-CE0AC1D804C19DDABBA3808B0A110EF0"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15024959e3615-wk-Fact-25860F8EDAE1011AACBA1AB63AA2569F"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d15024959e3669-wk-Fact-38CA5CF9A20C5C71AE7E808B0A3179AF"
      unitRef="usd">26240000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15024959e3727-wk-Fact-4ED8A016F97727C4BFFD1AB76C9FDCDA"
      unitRef="usd">26240000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e3748-wk-Fact-2BF28B55D7B73A55BC251AAE9CF3CB81"
      unitRef="shares">77308000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d15024959e3767-wk-Fact-469EC9E651EAD656274C1AAE2BB1387F"
      unitRef="usd">773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d15024959e3786-wk-Fact-A5339A35FCC6CAD6D35D1AAE427B1E4F"
      unitRef="usd">1489664000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d15024959e3806-wk-Fact-927C3C5E2A10798F58111AAE56C5F961"
      unitRef="usd">-1282162000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d15024959e3826-wk-Fact-5EC49E262E93DF8F2DD41AAE6D204E3E"
      unitRef="usd">-9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15024959e3846-wk-Fact-B75D79B791B3584126F9C80C647031BB"
      unitRef="usd">208266000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1068-wk-Fact-B42634276C7A9632D85AC80C6434F487"
      unitRef="usd">-324277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1088-wk-Fact-04977BE1C74AC80F3F04C80C643AC548"
      unitRef="usd">-192649000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1108-wk-Fact-7F7EDEF8E2CD9E9CBE90C80C642F7957"
      unitRef="usd">-176273000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1186-wk-Fact-A8731CDF0DE81CD6EFE4C80C6462AD43"
      unitRef="usd">3577000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1205-wk-Fact-2E01AFC1B8BC8A0F103FC80C646A89AE"
      unitRef="usd">2901000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1224-wk-Fact-05F194E562CA20D89096C80C646B74A2"
      unitRef="usd">2438000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1245-wk-Fact-E12E542CC2BAF2409A4719A92EAC878F"
      unitRef="usd">1249000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1264-wk-Fact-8C100FA5E0B9F66560EA19A96A097229"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1283-wk-Fact-D7A9152B906156D1403F19A9A330A7AF"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1304-wk-Fact-DD83F5BF9FA7C72A6ECCC80C64814481"
      unitRef="usd">26240000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1323-wk-Fact-058E77C5D7C04F6A3AA6C80C64715123"
      unitRef="usd">18073000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1342-wk-Fact-E5C58CC410A8DD17C537C80C6460D335"
      unitRef="usd">18039000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1363-wk-Fact-79144B5414C6CFB1FC8E808979A5D4CF"
      unitRef="usd">-2209000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1382-wk-Fact-8EFABA5FA4D897D3438180899DAEBDFC"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1401-wk-Fact-EEC990E7E9A002C1F1EB8089B090FE9E"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1422-wk-Fact-1951FFB1CE8756B9CCA2808E44B8513F"
      unitRef="usd">1350000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1441-wk-Fact-4D61271764D612683EEFC80C6468F59A"
      unitRef="usd">118000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1460-wk-Fact-80FDCF9EC974B8A7524FC80C647AD8E9"
      unitRef="usd">281000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1481-wk-Fact-42A6C5C1F47FF3A7E489813ECD4C0895"
      unitRef="usd">15889000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1500-wk-Fact-2A93B44B9EAA7AA79760813EE3E27930"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2016Q4YTD"
      id="d15031429e1519-wk-Fact-F847EBD8C5ABBA016F19813EF939958D"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccretionExpense
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1540-wk-Fact-5934124C5B657E4E1D5E808E44D46198"
      unitRef="usd">50000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1559-wk-Fact-E40DDB88F29A1B9F8A2AC80C64806C42"
      unitRef="usd">658000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1578-wk-Fact-712C68D6D0DCF4A68055C80C6476BA5A"
      unitRef="usd">171000</us-gaap:AccretionExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1660-wk-Fact-43D577DB8EEA36169FEC19AE178ECF17"
      unitRef="usd">5515000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1680-wk-Fact-AEAF72389CFC539722E919AE17B67EFD"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1699-wk-Fact-0AED4611C3466C720BC819AE17D057A7"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1720-wk-Fact-04F3A921FC18942281E019AE17D4DA26"
      unitRef="usd">7032000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1740-wk-Fact-7E1BE50DB5D7BFE8010219AE177B8615"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1759-wk-Fact-EA78196B325A1307F4E819AE17A2C2CE"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1780-wk-Fact-A59B0719E555014A5AD3C80C6477E0A7"
      unitRef="usd">5514000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1800-wk-Fact-D83234C91AEE15B8C5B9C80C647695E6"
      unitRef="usd">2783000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1820-wk-Fact-A4E0CFB65598A640E8D4C80C6472B857"
      unitRef="usd">-191000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1841-wk-Fact-FAE5D4C23B3978733B8DC80C646D7D4D"
      unitRef="usd">3870000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1860-wk-Fact-6430BE4F65D32C35B79EC80C6472F4F4"
      unitRef="usd">3604000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1879-wk-Fact-5364E074DE4C30C8A8C3C80C6475483F"
      unitRef="usd">2767000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1900-wk-Fact-66C52A8E4247A050367CC80C645D006A"
      unitRef="usd">19916000</insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities>
    <insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1919-wk-Fact-91AFCD62ED45C79A69C2C80C647FA7B2"
      unitRef="usd">5201000</insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities>
    <insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1938-wk-Fact-AF217592A82124D36955C80C645F5F2F"
      unitRef="usd">3043000</insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e1959-wk-Fact-8174BB42583C564346EC808FB5202712"
      unitRef="usd">10011000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e1978-wk-Fact-674A33198352EBF3D037808FF8C36ECA"
      unitRef="usd">5260000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e1997-wk-Fact-2D8B8442D6F22006419A809026263B6D"
      unitRef="usd">2635000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2018-wk-Fact-248A658F9B4C22946315C80C64603B60"
      unitRef="usd">-257977000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2038-wk-Fact-05630F79F07C1B84BB64C80C6477653D"
      unitRef="usd">-159617000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2058-wk-Fact-33D16192453658B23094C80C6479E698"
      unitRef="usd">-146708000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2139-wk-Fact-B2C8286A735E085860F8C80C647330FF"
      unitRef="usd">13090000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2159-wk-Fact-3F3B761EA115E95B2F79C80C64654010"
      unitRef="usd">3001000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2179-wk-Fact-8682D546DE4951E26778C80C6463C203"
      unitRef="usd">4200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2202-wk-Fact-A82209BD79A224E29E4081362E310250"
      unitRef="usd">1724000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2222-wk-Fact-BC9EDD34A0C5F9569664813671B82643"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2241-wk-Fact-A8271004D3B3E58E94EC81368E45D8CA"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2262-wk-Fact-C1505E7E82674544B888C80C647C03C9"
      unitRef="usd">-14814000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2282-wk-Fact-AEB940781367D8492D98C80C646FF319"
      unitRef="usd">-3001000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2302-wk-Fact-DB69BDE37C07D9FA9338C80C648133FB"
      unitRef="usd">-4200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2383-wk-Fact-4F3A950C29E99B92310819AE17CC9D08"
      unitRef="usd">450000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2402-wk-Fact-8EA276C7082E41A2DBD5808E44DDA825"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2421-wk-Fact-C48253AC3DADF4A7FCFD808E4501FEA2"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2442-wk-Fact-7AB1DAA83E8241368D5E19AE17B2ECF0"
      unitRef="usd">2835000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2462-wk-Fact-7A9F9FFDBCA4C0494E47808E45041363"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2481-wk-Fact-38692E432A2E3E2F6987808E44C0CF85"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:RepaymentsOfDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2502-wk-Fact-6ED1CD9175A3879BA5C719AE17AEA6ED"
      unitRef="usd">55000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2522-wk-Fact-D229255C5700BD4C66FB808E44E5C6F9"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2541-wk-Fact-464A105FC1CD7913D9EC808E44D1A8DA"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2562-wk-Fact-DBF9E021873F2273C5EFC80C647E694F"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2581-wk-Fact-07FCA54C51CE956AE1F7C80C645F2BC7"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2600-wk-Fact-AE9FFF6A56E203DC5936C80C64756E5F"
      unitRef="usd">30000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2621-wk-Fact-0B21BE595A6A300FB6FDC80C646B0C17"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2640-wk-Fact-8DFE884DBD577AADCCB6C80C647BEEB3"
      unitRef="usd">377656000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2659-wk-Fact-E2262C1C68C0A1DB42EDC80C6475C530"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2680-wk-Fact-FC1AD0C074A03149042719AE17A7DBFE"
      unitRef="usd">8815000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2699-wk-Fact-CDC9615D415D7E00C114C80C64680D6D"
      unitRef="usd">3433000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2718-wk-Fact-829507C24FD1A57B0DC8C80C6478D55C"
      unitRef="usd">1084000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2739-wk-Fact-F9C535027D38ECEE4632C80C64628BFE"
      unitRef="usd">14237000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2759-wk-Fact-1EFB301D2B93AA528122C80C6475EF43"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2778-wk-Fact-2E5CE69799AEF3B41ECBC80C64702267"
      unitRef="usd">411000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2800-wk-Fact-3C5E36D748A531FBCF1FC80C647FDA38"
      unitRef="usd">386743000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2819-wk-Fact-49505E0FB9782829059AC80C641D72F9"
      unitRef="usd">381089000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2838-wk-Fact-5DDABBA30404087F58FCC80C6463312B"
      unitRef="usd">30673000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2860-wk-Fact-EE7937103E6E7E183C39808E44F987C3"
      unitRef="usd">-45000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2880-wk-Fact-58A9DD44FA8930E466E0C80C647EEDAB"
      unitRef="usd">103000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2899-wk-Fact-04E110093DC64A054AA5C80C6479312E"
      unitRef="usd">-50000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e2921-wk-Fact-0D019ACA93FE46D78AF3C80C647D78E0"
      unitRef="usd">113907000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e2940-wk-Fact-A58C06CE392D89AC5A49C80C64740D69"
      unitRef="usd">218574000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e2959-wk-Fact-36EDF4FBF7199B4DAE04C80C646A57D8"
      unitRef="usd">-120285000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15031429e2981-wk-Fact-51D76EC3E2C2D919A799C80C64749C4F"
      unitRef="usd">381165000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q4"
      decimals="-3"
      id="d15031429e3000-wk-Fact-748B101BA8C6641AC63BC80C647FB856"
      unitRef="usd">162591000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2015Q4"
      decimals="-3"
      id="d15031429e3019-wk-Fact-06AF0A34E81C9BE262E9C80C645EA6BE"
      unitRef="usd">282876000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15031429e3045-wk-Fact-427FBC64188DA71D9DF1C80C64763291"
      unitRef="usd">495072000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15031429e3064-wk-Fact-51D76EC3E2C2D919A799C80C64749C4F"
      unitRef="usd">381165000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q4"
      decimals="-3"
      id="d15031429e3083-wk-Fact-748B101BA8C6641AC63BC80C647FB856"
      unitRef="usd">162591000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e3163-wk-Fact-D64AE895F2926B86D626C80C6469104A"
      unitRef="usd">6289000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e3182-wk-Fact-257C6BA4DE27B1070181C80C647ABC00"
      unitRef="usd">5165000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e3201-wk-Fact-0B115CFDB5EE74E23988C80C647FE320"
      unitRef="usd">3608000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15031429e3222-wk-Fact-02EA68BE7D72B0291327C80C6478EFF5"
      unitRef="usd">154000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15031429e3241-wk-Fact-661A37F26CDCB56C71BEC80C646E0083"
      unitRef="usd">166000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15031429e3260-wk-Fact-99BA2E9ABC6B675F3883C80C641B1060"
      unitRef="usd">85000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-D28F72440837709E1F5CC80C648A8421-0-wk-Fact-CE32415E24167246C9DEC80C645215E6">Description of Business and Basis of Presentation&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), received accelerated approval in the United States (US) on September 28, 2018 for the treatment of refractory &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Mycobacterium avium&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) with therapeutic potential in non-cystic fibrosis (non-CF) bronchiectasis and other inflammatory diseases. INS1009 is an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension (PAH).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, Ireland, Germany, France, the United Kingdom (UK), the Netherlands, Bermuda and Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$495.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash and cash equivalents as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and reported a net loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$324.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Historically, the Company has funded its operations through public offerings of equity securities and debt financings. To date, the Company has not generated significant revenue from ARIKAYCE. The Company commenced commercial shipments in October 2018. The Company expects to continue to incur operating losses while funding commercial launch efforts for ARIKAYCE, research and development (R&amp;amp;D) activities, regulatory submissions outside the US, and selling, general and administrative (SG&amp;amp;A) expenses. The Company expects its future cash requirements to be substantial, and it may need to raise additional capital to fund operations, including the commercialization of ARIKAYCE and additional clinical trials related to ARIKAYCE, to develop INS1007 and INS1009 and to develop, acquire, in-license or co-promote other products that address orphan or rare diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#x2019;s commercial, regulatory and development activities. Any equity or debt financing will also be contingent upon equity and debt market conditions and interest rates at the time. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts. The Company believes it currently has sufficient funds to meet its financial needs for at least the next 12&#160;months.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&#x2014;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Insmed Limited, Celtrix Pharmaceuticals,&#160;Inc., Insmed Holdings Limited, Insmed Ireland Limited, Insmed France SAS, Insmed Germany&#160;GmbH, Insmed Netherlands&#160;B.V., Insmed Bermuda Limited and Insmed Godo Kaisha. All intercompany transactions and balances have been eliminated in consolidation and certain prior year amounts have been restated to conform to the current year presentation. In the prior year, accrued compensation was presented within the accrued expense line in the consolidated balance sheet. In the current year, accrued compensation is presented as a discrete line on the face of the consolidated balance sheet.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-5"
      id="d15017886e874-wk-Fact-8B26CB98D40AB4553E27A617EA64BBC9"
      unitRef="usd">495100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d15017886e882-wk-Fact-21EC0C135BCC4F6D9251A5F4EDC890F4"
      unitRef="usd">-324300000</us-gaap:NetIncomeLoss>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-F1D1A71F3F73F2BFC0F1C80C648A7924-0-wk-Fact-4B569F02A324EA0EC6C1C80C6453182D">Basis of Presentation&#x2014;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Insmed Limited, Celtrix Pharmaceuticals,&#160;Inc., Insmed Holdings Limited, Insmed Ireland Limited, Insmed France SAS, Insmed Germany&#160;GmbH, Insmed Netherlands&#160;B.V., Insmed Bermuda Limited and Insmed Godo Kaisha. All intercompany transactions and balances have been eliminated in consolidation and certain prior year amounts have been restated to conform to the current year presentation.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-8662E0A15332C9838894C80C648C8906-0-wk-Fact-25DC1C8BDD52BA8BCD56C80C6481398F">Summary of Significant Accounting Policies&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, and accounting for research and development costs. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Investment Income and Interest Expense&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Investment income consists of interest income earned on the Company's cash and cash equivalents. Interest expense consists primarily of interest costs related to the Company's debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company considers cash equivalents to be highly liquid investments with maturities of three months or less from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fixed Assets, Net&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Fixed assets are recorded at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. Estimated useful lives of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are used for computer equipment. Estimated useful lives of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are used for laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Identifiable Intangible Assets&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Identifiable intangible assets are measured at their respective fair values and began amortizing over their estimated useful lives upon commercialization. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. Unanticipated events or circumstances may occur that may require the Company to review the assets for impairment. Events or circumstances that may require an impairment assessment include negative clinical trial results, the non-approval of a new drug application by a regulatory agency, material delays in the Company's development program or a sustained decline in market capitalization. The Company performs its annual impairment test as of October&#160;1 of each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company performed a qualitative assessment to evaluate whether there was an impairment of the assets. This assessment did not identify any indicators of impairment of the intangible assets as of that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Debt Issuance Costs&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:54px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 1 &#x2014; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2 &#x2014; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 3 &#x2014; Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's only financial assets and liabilities which were measured at fair value as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were Level 1 assets comprised of cash and cash equivalents. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.04873294346979%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;495.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;495.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; transfers in or out of Level&#160;1, Level&#160;2 or Level&#160;3 during &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company held &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; securities that were in an unrealized loss or gain position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the security was rated below investment grade; (3)&#160;how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated fair value of the liability component of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.75%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; convertible senior notes due 2025 (the Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$313.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the Convertible Notes. The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$316.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; carrying value of the Convertible Notes as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; excludes the $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;125.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the unamortized portion of the debt discount.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign Currency&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company has operations in the US, Ireland, Germany, France, the UK, the Netherlands and Japan. The results of its non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' equity, as a component of other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company realizes foreign currency transaction gains (losses) in the normal course of business based on movements in the applicable exchange rates. These gains (losses) are included as a component of other income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:17px;padding-top:17px;text-align:center;text-indent:0px;font-size:11pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:357px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:181px;"/&gt;&lt;td style="width:176px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Percentage of Total Gross Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;Customer A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;Customer B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;Customer C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company did not have product revenue prior to US FDA approval of ARIKAYCE in 2018. The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially impact future operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company did not incur or capitalize any incremental costs associated with obtaining contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Product revenues consist primarily of sales of ARIKAYCE in the US. Product revenues are recognized once the Company performs and satisfies all five steps mentioned above. In October 2018, the Company began shipping ARIKAYCE to its customers in the US, which include specialty pharmacies and specialty distributors.&#160;The Company recognizes revenues for product received by its customers net of allowances for customer credits, including estimated rebates, chargebacks, prompt pay discounts, returns, service fees, and government rebates, such as Medicaid rebates and Medicare Part D coverage gap reimbursements in the US.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Customer credits:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;The Company&#x2019;s customers are offered various forms of consideration, including service fees and prompt payment discounts. The Company anticipates that its customers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total gross product revenues when revenues are recognized. Service fees are also deducted from total gross product revenues as they are earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Rebates:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; The Company contracts with Medicaid, other government agencies and various private organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:17px;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Chargebacks:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price initially paid by the specialty distributor and the discounted price paid by the contracted customers. The Company estimates the chargebacks it provides to the specialty distributor and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:17px;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Co-payment assistance:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by a third-party administrator.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:54px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If any, or all, of the Company&#x2019;s actual experience vary from the estimates above, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides a summary roll-forward of our sales allowances and related accruals for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands), which have been deducted in arriving at net product revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:53px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Customer fees, discounts and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Rebates, chargebacks and co-pay assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Balance as of January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;Allowances for current period sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;849&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;&#160;&#160;&#160;&#160;Payments and credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;234&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition, upon US FDA approval of ARIKAYCE, the Company began recognizing revenue from sales to the French National Agency for Medicines and Health Products Safety (ANSM), which granted ARIKAYCE a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU). Pursuant to this program, the Company ships product to pharmacies after receiving requests from physicians for patients in France. The Company is initiating expanded access programs (EAPs) in Europe and other countries, some of which may be fully reimbursed. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventory and cost of product revenues (excluding amortization of intangible assets)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Inventory is stated at the lower of cost and net realizable value with cost determined on a standard costing method. The Company capitalized inventory costs following regulatory approval of ARIKAYCE from the FDA on September 28, 2018. Inventory is sold on a first-in, first out basis. Manufacturing variances, such as material usage variance and yield variance, are capitalized in inventory until the respective units are sold, at which point the variances are recognized in cost of product revenues. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, records a write-down accordingly. The Company also performs strict quality control throughout the manufacturing processes of products; however, certain batches or units of product may not meet quality specifications and result in a charge to cost of product revenues in the period incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred; therefore, inventory is not included in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consolidated balance sheet. Inventory that is used for clinical development purposes is expensed to research and development expense when consumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight-in, allocation of overhead costs, and inventory adjustment charges, in addition to royalty expenses due to PARI. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Research and development expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in the Company's research and development functions, and other internal operating expenses, the cost of manufacturing a drug candidate, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, research and development expenses include payments to third parties for the license rights to products in development (prior to marketing approval). The Company's expenses related to manufacturing its drug candidate and medical devices for clinical study are primarily related to activities at contract manufacturing organizations that manufacture ARIKAYCE, INS1007, and INS1009 and the medical devices for the Company's use. The Company's expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on the Company's behalf. These contracts set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company recognizes stock-based compensation expense for awards of equity instruments to employees and directors based on the grant-date fair value of those awards. The grant-date fair value of the award is recognized as compensation expense ratably over the requisite service period, which generally equals the vesting period of the award, and if applicable, is adjusted for expected forfeitures. The Company also grants performance-based stock options to employees. The grant-date fair value of the performance-based stock options is recognized as compensation expense over the implicit service period using the accelerated attribution method once it is probable that the performance condition will &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;be achieved. Stock-based compensation expense is included in both R&amp;amp;D and SG&amp;amp;A expenses in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A valuation allowance is recorded to reduce the deferred tax assets to the amount that is expected to be realized. In evaluating the need for a valuation allowance, the Company takes into account various factors, including the expected level of future taxable income and available tax planning strategies. If actual results differ from the assumptions made in the evaluation of a valuation allowance, the Company records a change in valuation allowance through income tax expense in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based solely on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; likelihood to be sustained upon ultimate settlement. As any adjustment to the Company&#x2019;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's policy for interest and penalties related to income tax exposures is to recognize interest and penalties as a component of the income tax provision (benefit) in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"/&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options and restricted stock units would be anti-dilutive as the Company incurred a net loss in all periods presented. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options would be determined based on the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(324,277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(192,649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(176,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares outstanding used in calculation of diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as their effect would have been anti-dilutive (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company currently operates in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business segment, which is the development and commercialization of therapies for patients with rare diseases. A single management team that reports to the Chief Executive Officer comprehensively manages the entire business. The Company does not operate separate lines of business with respect to its products or product candidates. Accordingly, the Company has &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements (Adopted)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-15, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which addressed eight specific cash flow issues with the objective of reducing the existing diversity in practice. Among the updates, the standard requires debt extinguishment costs to be classified as cash outflows for financing activities. This standard update became effective as of the first quarter of 2018. As a result of the adoption of the standard, in the first quarter of 2018, the Company reported a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; loss on extinguishment of debt in the operating activities section of its consolidated statement of cash flows. The Company had no material debt extinguishment costs prior to the first quarter of 2018. The impact of adopting this standard was not material to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU&#160;2014-09, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; which amended the existing accounting standards for revenue recognition. ASU 2014-09 establishes principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services. In July 2015, the FASB deferred the effective date for annual reporting periods beginning after December&#160;15, 2017. The Company adopted ASU 2014-09 in the first quarter of 2018.  The adoption did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements (Not Yet Adopted)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In February 2016, the FASB issued ASU 2016-02, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018 (including interim periods within those periods) and early adoption is permitted. In August 2018, the FASB issued ASU 2018-11, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Targeted Improvements to ASC 842&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which provides a new transition option in which an entity initially applies ASU 2016-02 at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will use the new transition option and will be also utilizing the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any expired or existing leases. The Company will also use the short-term lease exception for leases with a term of twelve months or less. Additionally, the Company expects to use the practical expedient that allows it to treat the lease and non-lease components of its leases as a single component. The Company has identified approximately ten leasing arrangements and estimates the impact on its consolidated balance sheet to be approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$44 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$49 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. There will be no adjustment recognized through retained earnings as a result of adoption. The Company will adopt ASU 2016-02 effective January 1, 2019, and is continuing to evaluate the impact of adoption on its consolidated financial statements and its internal control over financial reporting. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; which requires financial assets measured at an amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. ASU 2016-13 is effective for fiscal years effective for fiscal years after beginning after December 15, 2019. Different aspects of the guidance require modified &lt;/span&gt;&lt;/div&gt;retrospective or prospective adoption. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="FD2018Q4YTD"
      id="TextSelection-04C40125A79E2F4CD327C80C648BAA3B-0-wk-Fact-E205A0B067A866BE2694C80C6480B9F9">Use of Estimates&#x2014;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, and accounting for research and development costs. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <insm:InvestmentIncomeExpensePolicyTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-D788A6CD9AD5706BF99CC80C648C2314-0-wk-Fact-11F9E44CA88ED5541BE7C80C648269FD">Investment Income and Interest Expense&#x2014;Investment income consists of interest income earned on the Company's cash and cash equivalents. Interest expense consists primarily of interest costs related to the Company's debt.</insm:InvestmentIncomeExpensePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-81C008BBE735A3CF14E0C80C648B11A3-0-wk-Fact-C50C8F1F3DC69E975F92C80C6479FC7C">Cash and Cash Equivalents&#x2014;The Company considers cash equivalents to be highly liquid investments with maturities of three months or less from the date of purchase.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-09B1B28141E114FA8B29C80C648B12C5-0-wk-Fact-57047539A99E38A04168C80C641B326C">Fixed Assets, Net&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Fixed assets are recorded at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. Estimated useful lives of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are used for computer equipment. Estimated useful lives of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;seven years&lt;/span&gt;&lt;/span&gt; are used for laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember"
      id="d15037063e901-wk-Fact-18696D317CF507F8343BC80C641CABA3">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember"
      id="d15037063e905-wk-Fact-5478C22FCDC5D3B78B20C80C641B763D">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_EquipmentFurnitureAndFixturesMember"
      id="d15037063e909-wk-Fact-5A40D00E829A56BF6617C80C647A85F0">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="FD2018Q4YTD"
      id="TextSelection-D2124733E6CC0BE6607DC80C648BD7BB-0-wk-Fact-6A64E989C40D11977B91C80C6480A591">Identifiable Intangible Assets&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Identifiable intangible assets are measured at their respective fair values and began amortizing over their estimated useful lives upon commercialization. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. Unanticipated events or circumstances may occur that may require the Company to review the assets for impairment. Events or circumstances that may require an impairment assessment include negative clinical trial results, the non-approval of a new drug application by a regulatory agency, material delays in the Company's development program or a sustained decline in market capitalization. The Company performs its annual impairment test as of October&#160;1 of each year.&lt;/span&gt;The Company performed a qualitative assessment to evaluate whether there was an impairment of the assets. This assessment did not identify any indicators of impairment of the intangible assets as of that date.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:DebtPolicyTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-9BEFA7008D4AABE5762AC80C648B8AF4-0-wk-Fact-1F0B54FD8E1DF17628FEC80C6480D443">Debt Issuance Costs&#x2014;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</us-gaap:DebtPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="FD2018Q4YTD"
      id="TextSelection-29127A07CC357E975727C80C648C2DE1-0-wk-Fact-ECDF65B56C3081A24824C80C645217D3">Fair Value Measurements&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:&lt;/span&gt;&lt;div style="line-height:120%;padding-left:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 1 &#x2014; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2 &#x2014; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 3 &#x2014; Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's only financial assets and liabilities which were measured at fair value as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were Level 1 assets comprised of cash and cash equivalents. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.04873294346979%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;495.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;495.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; transfers in or out of Level&#160;1, Level&#160;2 or Level&#160;3 during &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company held &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; securities that were in an unrealized loss or gain position.&lt;/span&gt;&lt;/div&gt;The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the security was rated below investment grade; (3)&#160;how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-91C668D3D9FB55C5CD061A3A1537B434-0-wk-Fact-8C103EB212FCE424EA581A52E05B7D81">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.04873294346979%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;495.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;495.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d15037063e1281-wk-Fact-3660B12AE6C87FB744CEA5D94BC43AE7"
      unitRef="usd">495100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d15037063e1300-wk-Fact-40EF15115473A4FF91F4A5D94BD184BC"
      unitRef="usd">495100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d15037063e1319-wk-Fact-EC9E59385733F981F308DD8D0202FDFE"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d15037063e1339-wk-Fact-FB3CE297316D237D0B02DD7C184C1476"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d15037063e1685-wk-Fact-AC55023CF7CD5670D828A5FB876E5E05"
      unitRef="usd">381200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d15037063e1704-wk-Fact-A0B4C037EE05F54E65FBA5FB6B742BCD"
      unitRef="usd">381200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d15037063e1723-wk-Fact-3F175F37362471A78D42DD7C79901871"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d15037063e1743-wk-Fact-C7A0B2AAE3F516FC90AADD7C81648852"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <insm:FairValueLevel1Level2Level3TransfersAmount
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d15037063e1756-wk-Fact-BD10EA8EB7F5B75FD3B71A58A5DCC85D"
      unitRef="usd">0</insm:FairValueLevel1Level2Level3TransfersAmount>
    <insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities
      contextRef="FI2018Q4"
      decimals="INF"
      id="d15037063e1782-wk-Fact-7E06FF47992752D71913C80C647A9FDB"
      unitRef="security">0</insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15037063e1798-wk-Fact-5F5CB767749920DD4B8652FB10DFBDEE"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d15037063e1806-wk-Fact-B187C6EA398F5930DA8D1A881432964B"
      unitRef="usd">313000000.0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d15037063e1810-wk-Fact-9B1D719D13062A905A41DD82C476D281"
      unitRef="usd">316600000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d15037063e1819-wk-Fact-B6B4C3F17966D16FF7A11A4408B0DAE0"
      unitRef="usd">125000000.0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-97C740DA89EE6694C237C80C648CA85D-0-wk-Fact-9F47DCAD3C9E5DE50D95C80C647E9F4A">Foreign Currency&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company has operations in the US, Ireland, Germany, France, the UK, the Netherlands and Japan. The results of its non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' equity, as a component of other comprehensive loss.&lt;/span&gt;The Company realizes foreign currency transaction gains (losses) in the normal course of business based on movements in the applicable exchange rates. These gains (losses) are included as a component of other income, net.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="FD2018Q4YTD"
      id="TextSelection-6D61090D6B59C200C710C80C648C88D0-0-wk-Fact-76770CDF47BA9F166F6EC80C64786AA1">Concentration of Credit Risk&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:17px;padding-top:17px;text-align:center;text-indent:0px;font-size:11pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:357px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:181px;"/&gt;&lt;td style="width:176px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Percentage of Total Gross Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;Customer A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;Customer B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;Customer C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;The Company did not have product revenue prior to US FDA approval of ARIKAYCE in 2018. The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially impact future operating results.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-2C484BDA0748FBFB8026533381033D49-0-wk-Fact-25D5CD2401EEB51F8E7458D6303256EC">The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:357px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:181px;"/&gt;&lt;td style="width:176px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Percentage of Total Gross Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;Customer A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;Customer B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:inherit;font-size:11pt;"&gt;Customer C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d15037063e1883-wk-Fact-6E379A0BF5A1E8D1356258DBCE490518"
      unitRef="number">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d15037063e1894-wk-Fact-F4C2268BCF2C1D04F0D358DBCE51A1B5"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d15037063e1905-wk-Fact-7F2226FDC7DD3C3F426358DBCE42C443"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-37401FEE94FE8BC2AEBFC80C648A3968-0-wk-Fact-C2B2438678024AC9EF9AC80C647B22B6">Revenue Recognition&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company did not incur or capitalize any incremental costs associated with obtaining contracts with customers.&lt;/span&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Product revenues consist primarily of sales of ARIKAYCE in the US. Product revenues are recognized once the Company performs and satisfies all five steps mentioned above. In October 2018, the Company began shipping ARIKAYCE to its customers in the US, which include specialty pharmacies and specialty distributors.&#160;The Company recognizes revenues for product received by its customers net of allowances for customer credits, including estimated rebates, chargebacks, prompt pay discounts, returns, service fees, and government rebates, such as Medicaid rebates and Medicare Part D coverage gap reimbursements in the US.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Customer credits:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;The Company&#x2019;s customers are offered various forms of consideration, including service fees and prompt payment discounts. The Company anticipates that its customers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total gross product revenues when revenues are recognized. Service fees are also deducted from total gross product revenues as they are earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Rebates:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; The Company contracts with Medicaid, other government agencies and various private organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:17px;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Chargebacks:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price initially paid by the specialty distributor and the discounted price paid by the contracted customers. The Company estimates the chargebacks it provides to the specialty distributor and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:17px;text-align:justify;text-indent:52px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Co-payment assistance:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by a third-party administrator.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:54px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;If any, or all, of the Company&#x2019;s actual experience vary from the estimates above, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides a summary roll-forward of our sales allowances and related accruals for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands), which have been deducted in arriving at net product revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:53px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Customer fees, discounts and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Rebates, chargebacks and co-pay assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Balance as of January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;Allowances for current period sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;849&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;&#160;&#160;&#160;&#160;Payments and credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;234&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition, upon US FDA approval of ARIKAYCE, the Company began recognizing revenue from sales to the French National Agency for Medicines and Health Products Safety (ANSM), which granted ARIKAYCE a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU). Pursuant to this program, the Company ships product to pharmacies after receiving requests from physicians for patients in France. The Company is initiating expanded access programs (EAPs) in Europe and other countries, some of which may be fully reimbursed. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <insm:ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-F7D0DD45D85C53489B30ECB8A40925BD-0-wk-Fact-B027DEA30E215C168821ECBB948E7653">The following table provides a summary roll-forward of our sales allowances and related accruals for the year ended &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands), which have been deducted in arriving at net product revenue:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Customer fees, discounts and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Rebates, chargebacks and co-pay assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Balance as of January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;Allowances for current period sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;849&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;&#160;&#160;&#160;&#160;Payments and credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;234&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</insm:ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="FI2017Q4_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember"
      decimals="-3"
      id="d15037063e2064-wk-Fact-313A124974909A8BC3C5EDC5FFBD2218"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="FI2017Q4_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember"
      decimals="-3"
      id="d15037063e2083-wk-Fact-2DCE6178D599F6F20B6AEDC5FFB5128B"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15037063e2102-wk-Fact-C8EDF2FF7D1FC5504DF5EDC5FFAC4DBD"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember"
      decimals="-3"
      id="d15037063e2118-wk-Fact-4329A9ED75689934BA82EDCD6FD8BA17"
      unitRef="usd">335000</insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales>
    <insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember"
      decimals="-3"
      id="d15037063e2137-wk-Fact-3A5939A41A88B0900D29EDCD6FC69146"
      unitRef="usd">849000</insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales>
    <insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15037063e2156-wk-Fact-BBEBAB18619955AABFE0EDCD6FABD347"
      unitRef="usd">1184000</insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales>
    <insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember"
      decimals="-3"
      id="d15037063e2177-wk-Fact-2E78BBB246E4823FD521EDCFB3C95B5B"
      unitRef="usd">101000</insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits>
    <insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember"
      decimals="-3"
      id="d15037063e2197-wk-Fact-1E83B6E37D7006182669EDCFB3D4D286"
      unitRef="usd">161000</insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits>
    <insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15037063e2217-wk-Fact-540269A501C4BD0CC4D2EDCFB3CE6E89"
      unitRef="usd">262000</insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="FI2018Q4_srt_MajorCustomersAxis_insm_CustomerFeesDiscountsandOtherMember"
      decimals="-3"
      id="d15037063e2244-wk-Fact-19C8F1314930051CACC8EDC6F2194EF9"
      unitRef="usd">234000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="FI2018Q4_srt_MajorCustomersAxis_insm_RebatesChargebacksandCoPayAssistanceMember"
      decimals="-3"
      id="d15037063e2263-wk-Fact-122A5B16BD91E3E6E8C9EDC6F4B46B0A"
      unitRef="usd">688000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15037063e2282-wk-Fact-9604004A15D5F6D6F110EDC6F74D9EE4"
      unitRef="usd">922000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <insm:InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-3513FCE137D4C96EB9DA57B9A9F0CCAC-0-wk-Fact-2A67225DEFB0BE9AB1B157BA079E3049">Inventory and cost of product revenues (excluding amortization of intangible assets)&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Inventory is stated at the lower of cost and net realizable value with cost determined on a standard costing method. The Company capitalized inventory costs following regulatory approval of ARIKAYCE from the FDA on September 28, 2018. Inventory is sold on a first-in, first out basis. Manufacturing variances, such as material usage variance and yield variance, are capitalized in inventory until the respective units are sold, at which point the variances are recognized in cost of product revenues. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, records a write-down accordingly. The Company also performs strict quality control throughout the manufacturing processes of products; however, certain batches or units of product may not meet quality specifications and result in a charge to cost of product revenues in the period incurred.&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred; therefore, inventory is not included in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consolidated balance sheet. Inventory that is used for clinical development purposes is expensed to research and development expense when consumed.&lt;/span&gt;&lt;/div&gt;Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight-in, allocation of overhead costs, and inventory adjustment charges, in addition to royalty expenses due to PARI. </insm:InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="FD2018Q4YTD"
      id="TextSelection-BFE13860BF34B34F1177C80C648C2CAF-0-wk-Fact-AAFCDFDD06252FC4F14AC80C647C5820">Research and Development&#x2014;Research and development expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in the Company's research and development functions, and other internal operating expenses, the cost of manufacturing a drug candidate, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, research and development expenses include payments to third parties for the license rights to products in development (prior to marketing approval). The Company's expenses related to manufacturing its drug candidate and medical devices for clinical study are primarily related to activities at contract manufacturing organizations that manufacture ARIKAYCE, INS1007, and INS1009 and the medical devices for the Company's use. The Company's expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on the Company's behalf. These contracts set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="FD2018Q4YTD"
      id="TextSelection-CF2CB8B5750FF43B4228C80C648D53EA-0-wk-Fact-077CDA20B00E2ECB404BC80C6450EA4D">Stock-Based Compensation&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company recognizes stock-based compensation expense for awards of equity instruments to employees and directors based on the grant-date fair value of those awards. The grant-date fair value of the award is recognized as compensation expense ratably over the requisite service period, which generally equals the vesting period of the award, and if applicable, is adjusted for expected forfeitures. The Company also grants performance-based stock options to employees. The grant-date fair value of the performance-based stock options is recognized as compensation expense over the implicit service period using the accelerated attribution method once it is probable that the performance condition will &lt;/span&gt;be achieved. Stock-based compensation expense is included in both R&amp;amp;D and SG&amp;amp;A expenses in the consolidated statements of comprehensive loss.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-283D233C1041E7644AC2C80C648B3BF1-0-wk-Fact-3DE63C9C8A1B85293C05C80C647A26DA">Income Taxes&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A valuation allowance is recorded to reduce the deferred tax assets to the amount that is expected to be realized. In evaluating the need for a valuation allowance, the Company takes into account various factors, including the expected level of future taxable income and available tax planning strategies. If actual results differ from the assumptions made in the evaluation of a valuation allowance, the Company records a change in valuation allowance through income tax expense in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based solely on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; likelihood to be sustained upon ultimate settlement. As any adjustment to the Company&#x2019;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions.&lt;/span&gt;&lt;/div&gt;The Company's policy for interest and penalties related to income tax exposures is to recognize interest and penalties as a component of the income tax provision (benefit) in the consolidated statements of comprehensive loss.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-0DCF28C612DD2FC8E743C80C648C7128-0-wk-Fact-D761A6844E656F5996EEC80C647C948A">Net Loss Per Share&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options and restricted stock units would be anti-dilutive as the Company incurred a net loss in all periods presented. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options would be determined based on the treasury stock method.&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(324,277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(192,649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(176,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares outstanding used in calculation of diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as their effect would have been anti-dilutive (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-1E49B9DA74C690094DB8C80C648BF43F-0-wk-Fact-F40077E01F3ECAAA9D27C80C64596AA6">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended &lt;span style="font-family:inherit;font-size:10pt;"&gt;December 31,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(324,277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(192,649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(176,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares outstanding used in calculation of diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;61,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15037063e2690-wk-Fact-B42634276C7A9632D85AC80C6434F487"
      unitRef="usd">-324277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15037063e2710-wk-Fact-04977BE1C74AC80F3F04C80C643AC548"
      unitRef="usd">-192649000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15037063e2730-wk-Fact-7F7EDEF8E2CD9E9CBE90C80C642F7957"
      unitRef="usd">-176273000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15037063e2806-wk-Fact-31F42F46DB6574DFBE34C80C646871D8"
      unitRef="shares">76889000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15037063e2825-wk-Fact-A121841324E659209E0FC80C64630925"
      unitRef="shares">66576000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15037063e2844-wk-Fact-1DFD161E563E2CB5D32CC80C6461DA35"
      unitRef="shares">61892000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d15037063e2924-wk-Fact-A968F2037E484AB84156C80C646D98CF"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d15037063e2943-wk-Fact-3560213C156077375321C80C645D56E9"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d15037063e2962-wk-Fact-2C60FAAC50A0786CA216C80C646926F3"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d15037063e2983-wk-Fact-EEE971BE376A98B5BCEBC80C6465E9B8"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d15037063e3002-wk-Fact-E5FF182BD6F9C3880E45C80C645B1D97"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d15037063e3021-wk-Fact-A06265FAEBB412229A8AC80C64687797"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15037063e3042-wk-Fact-39E1AB39F73419995A39C80C64648E3D"
      unitRef="shares">76889000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15037063e3061-wk-Fact-470C3DD88378548D680BC80C6467F11C"
      unitRef="shares">66576000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15037063e3080-wk-Fact-FAFC75174D34AD128004C80C645DC4F0"
      unitRef="shares">61892000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15037063e3166-wk-Fact-518DC39F637E8302275EC80C64362527"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15037063e3186-wk-Fact-E7AA589AA67B3269D3FEC80C6440E3D2"
      unitRef="usdPerShare">-2.89</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15037063e3206-wk-Fact-392E31090CD7F1536356C80C6432E7FF"
      unitRef="usdPerShare">-2.85</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-B6EDC26957B1A62AF918C80C648A5F33-0-wk-Fact-686CF8AFA16695C7E4EAC80C648189D6">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as their effect would have been anti-dilutive (in thousands).&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-3"
      id="d15037063e3310-wk-Fact-30924E24C58F1DAE183CC80C64444C53"
      unitRef="shares">9382000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-3"
      id="d15037063e3324-wk-Fact-3C87C6EDEBB22DF7F120C80C64462DC1"
      unitRef="shares">8609000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-3"
      id="d15037063e3338-wk-Fact-600C33E1371052F59210C80C6447AFAB"
      unitRef="shares">7117000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember"
      decimals="-3"
      id="d15037063e3353-wk-Fact-17BB04D0B5F9A8F0087DC80C64473042"
      unitRef="shares">228000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember"
      decimals="-3"
      id="d15037063e3367-wk-Fact-DA79F9FFF5DE9D5F4DC4C80C6444FBAA"
      unitRef="shares">47000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember"
      decimals="-3"
      id="d15037063e3381-wk-Fact-52A86C847D3FE5AB5747C80C64469896"
      unitRef="shares">89000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="-3"
      id="d15037063e3396-wk-Fact-61E01799EE8083939FF39727AC78CFAF"
      unitRef="shares">11492000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="-3"
      id="d15037063e3410-wk-Fact-465679CC65A4E1CDF8D3972879C094C7"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="-3"
      id="d15037063e3424-wk-Fact-1A4CEE2EB8C0C0BE056097289A4FF66F"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-6591A9D56318745967D0C80C648AB2D2-0-wk-Fact-5EAC0197AAF6ADEC636BC80C647FAD37">Segment Information&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company currently operates in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business segment, which is the development and commercialization of therapies for patients with rare diseases. A single management team that reports to the Chief Executive Officer comprehensively manages the entire business. The Company does not operate separate lines of business with respect to its products or product candidates. Accordingly, the Company has &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt; reportable segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d15037063e3442-wk-Fact-4B1EC734327F927FFB3DC80C6481E70E"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d15037063e3446-wk-Fact-23CB31D02903EB5FB79314EA27D49F45"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-74C3521C8D799BFE2F09C80C648B8884-0-wk-Fact-2693E70D8DBFFDB78AC3C80C647BC9EA">New Accounting Pronouncements (Adopted)&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-15, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which addressed eight specific cash flow issues with the objective of reducing the existing diversity in practice. Among the updates, the standard requires debt extinguishment costs to be classified as cash outflows for financing activities. This standard update became effective as of the first quarter of 2018. As a result of the adoption of the standard, in the first quarter of 2018, the Company reported a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; loss on extinguishment of debt in the operating activities section of its consolidated statement of cash flows. The Company had no material debt extinguishment costs prior to the first quarter of 2018. The impact of adopting this standard was not material to the Company.&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU&#160;2014-09, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; which amended the existing accounting standards for revenue recognition. ASU 2014-09 establishes principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services. In July 2015, the FASB deferred the effective date for annual reporting periods beginning after December&#160;15, 2017. The Company adopted ASU 2014-09 in the first quarter of 2018.  The adoption did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements (Not Yet Adopted)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In February 2016, the FASB issued ASU 2016-02, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018 (including interim periods within those periods) and early adoption is permitted. In August 2018, the FASB issued ASU 2018-11, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Targeted Improvements to ASC 842&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which provides a new transition option in which an entity initially applies ASU 2016-02 at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will use the new transition option and will be also utilizing the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any expired or existing leases. The Company will also use the short-term lease exception for leases with a term of twelve months or less. Additionally, the Company expects to use the practical expedient that allows it to treat the lease and non-lease components of its leases as a single component. The Company has identified approximately ten leasing arrangements and estimates the impact on its consolidated balance sheet to be approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$44 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$49 million&lt;/span&gt;&lt;/span&gt;. There will be no adjustment recognized through retained earnings as a result of adoption. The Company will adopt ASU 2016-02 effective January 1, 2019, and is continuing to evaluate the impact of adoption on its consolidated financial statements and its internal control over financial reporting. </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q1YTD"
      decimals="-5"
      id="d15037063e3469-wk-Fact-056404937DC6727DB9B60DE84AE8EB8F"
      unitRef="usd">-2200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OperatingLeaseLiability
      contextRef="I2019Q1Jan01_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember"
      decimals="-6"
      id="d15037063e3495-wk-Fact-12022F5B785B309BED9CDD5B3F9DE0F3"
      unitRef="usd">44000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="I2019Q1Jan01_srt_RangeAxis_srt_MaximumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember"
      decimals="-6"
      id="d15037063e3499-wk-Fact-2AE7ED581DE8583427AADD6F425E850E"
      unitRef="usd">49000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-A38EF5728C23D73BF1291590E3359B85-0-wk-Fact-19F89575F02A8C424214159276639BE7">Inventory&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2018, the Company's inventory balance consists of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:407px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:274px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:119px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,567&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Inventory is stated at the lower of cost or net realizable value and consists of raw materials, work-in-process and finished goods. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE on September 28, 2018. The Company has not recorded any inventory write downs since that time. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-3114E0F93D1FE570D670159298175405-0-wk-Fact-1E4B59EA0F8021308C881595919F4A91">As of December 31, 2018, the Company's inventory balance consists of the following (in thousands): &lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:407px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:274px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:119px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,567&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,032&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15029005e929-wk-Fact-696332621182DB3735C115A64FC403E6"
      unitRef="usd">2145000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15029005e944-wk-Fact-D24B4AB3BEC14B3C8FD715A80F8ABC7F"
      unitRef="usd">4567000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15029005e964-wk-Fact-75B64BE58E68766F1B6F15AA1E7E3DB2"
      unitRef="usd">320000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15029005e989-wk-Fact-1DBCE8064A0BCB536A421995AF92293F"
      unitRef="usd">7032000</us-gaap:InventoryNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-0297DBE2657B18DD6168C80C648DE850-0-wk-Fact-5EAE7F125F859347C8C1C80C644357DC">Accrued Expenses&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,635&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued technical operation expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued interest payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,631&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued sales allowances and related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued construction costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-88E5DDC6CE60E979EAA2C80C648D9085-0-wk-Fact-C054CF22CB138893ADBBC80C6442B826">Accrued expenses consist of the following:&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,635&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued technical operation expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued interest payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,631&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued sales allowances and related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued construction costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <insm:AccruedClinicalTrialExpenses
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15038244e1016-wk-Fact-62D2BB9CEC6D33E73E3AC80C6422F559"
      unitRef="usd">6635000</insm:AccruedClinicalTrialExpenses>
    <insm:AccruedClinicalTrialExpenses
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15038244e1035-wk-Fact-EE6527851203C449ABF9C80C644A4863"
      unitRef="usd">7837000</insm:AccruedClinicalTrialExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15038244e1050-wk-Fact-E325643DC0D4A624ED0EC80C641DA9E3"
      unitRef="usd">13398000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15038244e1069-wk-Fact-132CE3A20CD2D1601EC5C80C641FCAEC"
      unitRef="usd">4500000</us-gaap:AccruedProfessionalFeesCurrent>
    <insm:AccruedTechnicalOperationExpenses
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15038244e1089-wk-Fact-6DB046C28350C7487A5AC80C64202A0B"
      unitRef="usd">9371000</insm:AccruedTechnicalOperationExpenses>
    <insm:AccruedTechnicalOperationExpenses
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15038244e1108-wk-Fact-C5BB6490508F042C0501C80C6422E27E"
      unitRef="usd">2182000</insm:AccruedTechnicalOperationExpenses>
    <us-gaap:InterestPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15038244e1128-wk-Fact-5DA24597D43D316660BEC80C641F6E13"
      unitRef="usd">3631000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15038244e1147-wk-Fact-51CA7067ABE99B843CDCC80C644D3EBE"
      unitRef="usd">423000</us-gaap:InterestPayableCurrent>
    <insm:AccruedSalesAllowancesandRelatedCosts
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15038244e1167-wk-Fact-1933ECD73B4169D6759780A06F2A1BF3"
      unitRef="usd">818000</insm:AccruedSalesAllowancesandRelatedCosts>
    <insm:AccruedSalesAllowancesandRelatedCosts
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15038244e1186-wk-Fact-6920CE1C08BA8CAD279080A06F2E8535"
      unitRef="usd">0</insm:AccruedSalesAllowancesandRelatedCosts>
    <insm:AccruedConstructionLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15038244e1206-wk-Fact-ACD570A65F3B6FD67FADC80C641E0267"
      unitRef="usd">2946000</insm:AccruedConstructionLiabilitiesCurrent>
    <insm:AccruedConstructionLiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15038244e1225-wk-Fact-71AAA0674EEF87358E8414C8F85A9244"
      unitRef="usd">1719000</insm:AccruedConstructionLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15038244e1245-wk-Fact-1D80F81920A4F2BE567FC80C644B12CF"
      unitRef="usd">1455000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15038244e1264-wk-Fact-9A0C0F33C31ED7C01DD5C80C644C02DE"
      unitRef="usd">481000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15038244e1289-wk-Fact-5D090E567899D78AEC44C80C647E734C"
      unitRef="usd">38254000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15038244e1308-wk-Fact-71F7BB0080BFEB1A3989C80C646A1E6C"
      unitRef="usd">17142000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-7A5C10C763A25C74E45FC80C648D93DB-0-wk-Fact-B2D4ACBCBB29DD1B8DCAC80C6480D115">Intangibles, net&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company's identifiable intangible assets consisted of acquired ARIKAYCE R&amp;amp;D, formerly referred to as in-process research and development, and a milestone paid to PARI Pharma GmbH (PARI) for the license to use PARI's Lamira&#xae; Nebulizer System for the delivery of ARIKAYCE to patients. The Company's only identifiable intangible asset was in-process research and development (IPRD) related to ARIKAYCE as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which resulted from the initial amount recorded at the time of the Company's merger with Transave in 2010 and subsequent adjustments in the value. On September 28, 2018, as a result of the FDA approval of ARIKAYCE, the Company recorded a milestone payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; due to PARI. Total intangible assets, net was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$58.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$58.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the Acquired ARIKAYCE milestone, at the date of subsequent adjustments of fair value. The Company began amortizing its &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;intangible assets October 1, 2018, over ARIKAYCE's initial regulatory exclusivity period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Amortization of intangible assets during each of the next five years is estimated to be approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per year. The Company performed its annual impairment test as of October&#160;1, 2018. The Company performed a qualitative assessment to evaluate whether there was an impairment of the assets. This assessment did not identify any indicators of impairment of the intangible assets as of that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A rollforward of the Company's intangible assets for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Intangible Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;January 1,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56,988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;PARI milestone upon FDA approval&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,724&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,724&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;"&gt;Intangible Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;"&gt;January 1,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Acquired ARIKAYCE IPRD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D2018Q3Sep28-Sep28"
      decimals="-5"
      id="d15039921e871-wk-Fact-B86CBA3438C421D79685812E9FF53FF2"
      unitRef="usd">1700000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d15039921e875-wk-Fact-B9FB144BBC30B53A00D5A6061E762BCE"
      unitRef="usd">58700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q4"
      decimals="-5"
      id="d15039921e879-wk-Fact-0C06D2B0EC2B98F0B963A6061E8516DC"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2018Q4YTD"
      id="d15039921e899-wk-Fact-9E7EB770EB48C59ADD281AC1F87114F1">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-4DD6628C4DA2EC2B39D815746850693F-0-wk-Fact-FAC48973C1AC6B25D8A41575B9090159">A rollforward of the Company's intangible assets for the years ended &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; follows:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Intangible Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;January 1,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56,988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;PARI milestone upon FDA approval&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,724&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,724&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;"&gt;Intangible Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;"&gt;January 1,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Acquired ARIKAYCE IPRD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="I2018Q1Jan01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-3"
      id="d15039921e1088-wk-Fact-5FD0B3B197962CEEA384585607225507"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-3"
      id="d15039921e1102-wk-Fact-DACB9F8B2CDD3872584858C794DFE600"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-3"
      id="d15039921e1116-wk-Fact-35F16FD06CBFCE6FD4085869108697CB"
      unitRef="usd">1212000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-3"
      id="d15039921e1132-wk-Fact-061C64DAE5159570E8DA5855B6B064F3"
      unitRef="usd">56988000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="I2018Q1Jan01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-3"
      id="d15039921e1147-wk-Fact-875C6A7FCF33DD1ECCF058C7222485B7"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-3"
      id="d15039921e1161-wk-Fact-9207CE9CC8717B9E58E158517995E003"
      unitRef="usd">1724000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-3"
      id="d15039921e1175-wk-Fact-D5AB01DBCC50AD173705586E537E3092"
      unitRef="usd">37000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-3"
      id="d15039921e1190-wk-Fact-B0A918F4505115A60135585AF004CA57"
      unitRef="usd">1687000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="I2018Q1Jan01"
      decimals="-3"
      id="d15039921e1216-wk-Fact-271023C74E3197BFC69A5856969A542E"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15039921e1230-wk-Fact-974A9E0C63F9C015A7415860463A9419"
      unitRef="usd">1724000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15039921e1244-wk-Fact-772A6D335720DB6DEBB9586E9AC2D4D7"
      unitRef="usd">1249000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15039921e1260-wk-Fact-37DB01866B7D3BE6F66CC80C6466A9B9"
      unitRef="usd">58675000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="I2017Q1Jan01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-3"
      id="d15039921e1480-wk-Fact-3D14D4306A488705CF6F1ACA2BCAFA40"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-3"
      id="d15039921e1494-wk-Fact-9F76A1D15548D179DDC958C812B012E2"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-3"
      id="d15039921e1508-wk-Fact-67B476CC35D975C6630158C853BE5BEA"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-3"
      id="d15039921e1523-wk-Fact-27365AF1525A7BF6A1DA1ACBB4AC2AF7"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="I2017Q1Jan01"
      decimals="-3"
      id="d15039921e1543-wk-Fact-253F5CCF3814CFBB78EB5853E166D344"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15039921e1557-wk-Fact-CEE342E594AD76AE6DAF58C7F4DD2079"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15039921e1571-wk-Fact-56B79B5AEB9D1073654058C86BA5C5C4"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15039921e1586-wk-Fact-5F4E1E308F165E3B6678C80C64771C5C"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-5C6A1CB3776DB60DB6CBC80C648D0EE8-0-wk-Fact-FC198E993C4DA695C83AC80C6455E544">Fixed Assets, net&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Useful Life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Asset Description&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lab equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,055&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,937&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer hardware and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;3&#160;-&#160;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Office equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Manufacturing equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,939&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Construction in progress (CIP)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,077&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14,173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10,645&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fixed assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fixed assets, net of depreciation, increased to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$22.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during the year ended December 31, 2018 from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in 2017. The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; increase was primarily due to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.0 million&lt;/span&gt;&lt;/span&gt; in construction in progress related to the long-term capacity build-out at the Patheon manufacturing facility.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-A26C5405FC82FCA80637C80C648D674B-0-wk-Fact-B83CA8B1E621A3E12705C80C6453AD9B">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows:&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Useful Life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Asset Description&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Lab equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,055&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,937&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Computer hardware and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;3&#160;-&#160;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Office equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Manufacturing equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;lease term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,939&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Construction in progress (CIP)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,077&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14,173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10,645&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fixed assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      id="d15038311e1046-wk-Fact-75A139B863A10C01C429C80C644484B4">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      decimals="-3"
      id="d15038311e1061-wk-Fact-B1ABE8FE6F32333DD8BCC80C644D7041"
      unitRef="usd">7935000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember"
      decimals="-3"
      id="d15038311e1080-wk-Fact-0494A4A1D33F564EA2DFC80C644BC688"
      unitRef="usd">7055000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      id="d15038311e1095-wk-Fact-6A0BB7EB8FECFDD16CE1C80C6448EBA4">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d15038311e1105-wk-Fact-4D6910A4BFDCB9442906C80C6447ADFD"
      unitRef="usd">2320000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d15038311e1124-wk-Fact-4B34B6AFF56F207C1C94C80C644A53DE"
      unitRef="usd">1937000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember"
      decimals="-3"
      id="d15038311e1154-wk-Fact-EF2661335317D97020A2C80C644DD11B"
      unitRef="usd">3796000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember"
      decimals="-3"
      id="d15038311e1173-wk-Fact-FB3024F46C836D8BD029C80C64459D14"
      unitRef="usd">2325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember"
      id="d15038311e1193-wk-Fact-0B67097D6B333141AC45C80C64516649">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember"
      decimals="-3"
      id="d15038311e1203-wk-Fact-35BCF4411ADE355A01B1C80C644AFC3B"
      unitRef="usd">65000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember"
      decimals="-3"
      id="d15038311e1222-wk-Fact-7C3F3C21D93907A189BCC80C645095FD"
      unitRef="usd">65000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ManufacturingEquipmentMember"
      id="d15038311e1242-wk-Fact-A5C8C6804B215E031CCBC80C64518807">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ManufacturingEquipmentMember"
      decimals="-3"
      id="d15038311e1252-wk-Fact-8FCAB3E9E10EAF8D1238C80C644860D2"
      unitRef="usd">1166000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ManufacturingEquipmentMember"
      decimals="-3"
      id="d15038311e1271-wk-Fact-9D0C733FCBF4DDDD3BCEC80C644D4499"
      unitRef="usd">1436000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d15038311e1301-wk-Fact-5E0F5C4314D51A71E726C80C644C45D3"
      unitRef="usd">7202000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d15038311e1320-wk-Fact-1D773ED475237B6F72B9C80C644C13B1"
      unitRef="usd">6939000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d15038311e1349-wk-Fact-331EE2FDBFF3850D2585C80C644F3B28"
      unitRef="usd">14325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d15038311e1367-wk-Fact-AEA37E3641777897DD61C80C644947C5"
      unitRef="usd">3320000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15038311e1397-wk-Fact-F7175FB2A6F4E393BE50C80C644C9A68"
      unitRef="usd">36809000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15038311e1416-wk-Fact-2F7BAD73F2BD9CB7C104C80C6446281D"
      unitRef="usd">23077000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15038311e1447-wk-Fact-284681DCCA49F683DAFEC80C644526D6"
      unitRef="usd">14173000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15038311e1467-wk-Fact-B135541307F17185E66CC80C6448CB01"
      unitRef="usd">10645000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15038311e1503-wk-Fact-E1B09700CAF1045121D4C80C647C57EB"
      unitRef="usd">22636000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15038311e1522-wk-Fact-00C9FAFCE2A161EA3686C80C646A5ED4"
      unitRef="usd">12432000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d15038311e1535-wk-Fact-827C823920930786AB28C80C64532E54"
      unitRef="usd">3600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d15038311e1539-wk-Fact-83F098927BCA82323818C80C64540DAE"
      unitRef="usd">2900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2016Q4YTD"
      decimals="-5"
      id="d15038311e1543-wk-Fact-7B94A07CC816EB375CFBC80C64532B92"
      unitRef="usd">2400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-5"
      id="d15038311e1564-wk-Fact-0B05CD40AA31471DAF64BEBB795C6DF4"
      unitRef="usd">22600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2017Q4"
      decimals="-5"
      id="d15038311e1568-wk-Fact-C371E2C10E6623B57D3853980882C3AD"
      unitRef="usd">12400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d15038311e1572-wk-Fact-95438133956EDD862C86A57530A3226A"
      unitRef="usd">10200000</us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease>
    <us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease
      contextRef="FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-5"
      id="d15038311e1576-wk-Fact-8424EF6A3E337A035578A57579905CF0"
      unitRef="usd">11000000.0</us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-103FB603671155CB790FC80C648DEF02-0-wk-Fact-0EDB22428745C778BDE5C80C642DB674">Debt&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2018, the Company completed an underwritten public offering of the Convertible Notes, in which the Company sold &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$450.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; aggregate principal amount of Convertible Notes, including the exercise in full of the underwriters' option to purchase additional Convertible Notes of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, were approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$435.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On or after October&#160;15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their Convertible Notes at any time. Upon conversion, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The initial conversion rate is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;25.5384&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$39.16&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Holders may convert their Convertible Notes prior to October 15, 2024, only under the following circumstances, subject to the conditions set forth in an indenture, dated as of January 26, 2018, between the Company and Wells Fargo Bank, National Association (Wells Fargo), as trustee, as supplemented by the first supplemental indenture, dated January 26, 2018, between the Company and Wells Fargo (as supplemented, the Indenture): (i) during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business day period immediately after any &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of convertible notes, as determined following a request by a holder of the convertible notes, for each trading day of the measurement period was less than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company&#x2019;s assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the Convertible Notes may be surrendered by a holder for conversion at any time from or after the date that is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2018 (and only during such calendar quarter), the last reported sale price of the common stock for at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; trading days (whether or not consecutive) during the period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the conversion price on each applicable trading day, or, (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its Convertible Notes, to which the notice of redemption relates, for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Convertible Notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in the convertible notes are not required to be separately accounted for as a derivative. However, since the Convertible Notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated equity component. The fair value was based on data from readily available pricing &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option was determined by deducting the fair value of the liability component from the gross proceeds of the Convertible Notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity&#x2019;s own equity.  The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$309.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; using an effective interest rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.6%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and accordingly, the residual equity component on the date of issuance was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$140.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The discount is being amortized to interest expense over the term of the Convertible Notes and has a remaining period of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.04 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;twelve months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, total interest expense related to the Convertible Notes was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$25.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount, as described in the table below. The following table presents the carrying value of the Company&#x2019;s debt balance as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.8635477582846%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;&#160;1.75% convertible senior notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;450,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;Debt issuance costs, unamortized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;&#160;Discount on debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(125,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term debt, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;316,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:38.01169590643275%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;450,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;450,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2018, the Company used part of the net proceeds from the issuance of the Convertible Notes to pay off its outstanding debt to Hercules Capital (Hercules). The payments to Hercules consisted of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$55.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the principal amount and an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in back-end fees, outstanding interest, and prepayment penalty fees, which resulted in a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; loss on extinguishment of debt in the quarter ended March 31, 2018.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated fair value of the debt (categorized as a Level&#160;2 liability for fair value measurement purposes) is determined using current market factors and the ability of the Company to obtain debt at comparable terms to those that are currently in place. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;, the fair value of the Company's debt approximated the carrying amount.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15041894e864-wk-Fact-F211D101D4C839E09BF11AF90DB30CC0"
      unitRef="usd">450000000.0</us-gaap:DebtInstrumentFaceAmount>
    <insm:DebtInstrumentOptionToPurchaseAdditionalDebt
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15041894e868-wk-Fact-50AB1379B0E54D9EEF951AFAE7D8FBEC"
      unitRef="usd">50000000.0</insm:DebtInstrumentOptionToPurchaseAdditionalDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d15041894e872-wk-Fact-47386DFF1571BEF1483B1AFDF158478F"
      unitRef="usd">14200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d15041894e876-wk-Fact-49FA42A3709FB47568F91AFF1B8FACCC"
      unitRef="usd">435800000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="2"
      id="d15041894e890-wk-Fact-D051B4A03AA995BCBDF41B07A384814B"
      unitRef="usdPerShare">39.16</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15041894e900-wk-Fact-BF2E44937DDCE1EF25511B2CE999C218"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15041894e904-wk-Fact-9605E65D0F0943D931CB1B2E199DFAC5"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15041894e908-wk-Fact-B5DE4F9741E6AFF91D5C1B09678E118B"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15041894e912-wk-Fact-7CBFCFCEFB96C0D77EC21B1348369E67"
      unitRef="day">45</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15041894e916-wk-Fact-64B3F0BB3172903537A91B16DEC21A74"
      unitRef="day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15041894e921-wk-Fact-328BBC28FCB7D2CB6EC41B178875AEAB"
      unitRef="number">0.10</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermiiiMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15041894e925-wk-Fact-A606FFEFBD521043C30E1B29462C4990"
      unitRef="day">30</insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermivMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15041894e929-wk-Fact-70D5CBF78B106571F5241B1A00CC77A0"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermivMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15041894e933-wk-Fact-8928303EC80241D145DC1B1B81782441"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_ConversionTermivMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d15041894e937-wk-Fact-F504BA15BD15EA2A8B671B1E86F69160"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d15041894e951-wk-Fact-EE09E77FE418FBDA938E1B1F99D08864"
      unitRef="usd">309100000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="3"
      id="d15041894e955-wk-Fact-8D50076BDBD0A8C94DE81B206FD55583"
      unitRef="number">0.076</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d15041894e959-wk-Fact-B876F1813E8A832E74C31B229B6180AC"
      unitRef="usd">140900000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      id="d15041894e963-wk-Fact-93814DF0E67AAB8D2C911B2357DD4234">P6Y14D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:InterestExpense
      contextRef="FD2018Q4YTD_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d15041894e980-wk-Fact-6E7B9482E78867E2E5A01B24C21B8E85"
      unitRef="usd">25500000</us-gaap:InterestExpense>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-7B2C1ED90B6C9A155ED8C80C648EBF87-0-wk-Fact-DB752A450454A8327A02C80C64358089">The following table presents the carrying value of the Company&#x2019;s debt balance as of &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.8635477582846%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;&#160;1.75% convertible senior notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;450,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;Debt issuance costs, unamortized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;&#160;Discount on debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(125,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term debt, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;316,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:SecuredDebt
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15041894e1040-wk-Fact-06EA1C2E0904D5B52C841B5A158195DB"
      unitRef="usd">450000000</us-gaap:SecuredDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15041894e1055-wk-Fact-117C7C74F0CAF4EDF53F1B5B90FA17B3"
      unitRef="usd">8440000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15041894e1076-wk-Fact-BB55628CC86E222401E91B5CD1F6B13D"
      unitRef="usd">125002000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15041894e1102-wk-Fact-2E25EFE980C3474A3F0EC80C647C1254"
      unitRef="usd">316558000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-D9DB53D8EFE0912AF2E5C80C648E1C8A-0-wk-Fact-D0A5A8338B54F94B68BEC80C642E3ECD">As of &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):&#160;&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:38.01169590643275%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;450,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;450,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15041894e1164-wk-Fact-DEA74D1848ABCCCD54EA1B61E025D9D1"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15041894e1179-wk-Fact-F31EAA0294F68157E2441B62AA7BABA0"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15041894e1199-wk-Fact-0CC7A965F62261F6567F1B6330F3CA17"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15041894e1219-wk-Fact-26DA41463126013F996D1B637FDACA42"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <insm:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15041894e1239-wk-Fact-5546CFFB008262F62C281B66C65175BF"
      unitRef="usd">450000000</insm:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15041894e1264-wk-Fact-63F1332BCB2F0215DCAA1B67700FE48F"
      unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="D2018Q1Feb2018_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d15041894e1279-wk-Fact-486750B118C6F4F2C31F1B4343C30ACC"
      unitRef="usd">55000000.0</us-gaap:RepaymentsOfDebt>
    <insm:RepaymentsOfDebtFeesAndOutstandingInterest
      contextRef="D2018Q1Feb2018_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d15041894e1283-wk-Fact-5E5FBB3BADAA991903441B474677B347"
      unitRef="usd">3200000</insm:RepaymentsOfDebtFeesAndOutstandingInterest>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q1YTD"
      decimals="-5"
      id="d15041894e1287-wk-Fact-056404937DC6727DB9B60DE84AE8EB8F"
      unitRef="usd">-2200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-7F53B3DBC7A25B1307ADC80C648E0FE1-0-wk-Fact-47D38DD2C09A72E8E8AFC80C6464F807">Shareholders' Equity&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;500,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock authorized with a par value of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.01&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,307,521&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock issued and outstanding. In addition, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had reserved &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,381,730&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock for issuance upon the exercise of outstanding common stock options and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;227,826&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock for issuance upon the vesting of restricted stock units.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In&#160;September&#160;2017, the Company completed an underwritten public offering of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,123,150&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares of the Company&#x2019;s common stock, which included the underwriter&#x2019;s exercise in full of its over-allotment option of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,842,150&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares, at a price to the public of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$28.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;per share.&#160; The Company&#x2019;s net proceeds from the sale of the shares, after deducting underwriting discounts and offering expenses of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$24.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, were approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$377.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;200,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of preferred stock authorized with a par value of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.01&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt; shares of preferred stock were issued and outstanding.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="d15036687e869-wk-Fact-80A4FEC10D98CBD51703C80C643AE1DA"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="d15036687e873-wk-Fact-8EC0BAB1272807ACB403C80C643DF6C6"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="d15036687e877-wk-Fact-D035E33264095F31F5C2C80C6435D784"
      unitRef="shares">77307521</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="INF"
      id="d15036687e886-wk-Fact-C9693E8DE38C3CB3181B1545D2652E62"
      unitRef="shares">9381730</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15036687e890-wk-Fact-9CB974F409E8156A48031547760D7E4E"
      unitRef="shares">227826</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2017Q3Sept17"
      decimals="INF"
      id="d15036687e898-wk-Fact-F7502527BF35B35FDE96C80C6469BF10"
      unitRef="shares">14123150</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <insm:CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption
      contextRef="FI2017Q3"
      decimals="INF"
      id="d15036687e902-wk-Fact-2B44191BA82B4660F1B4C80C646CE271"
      unitRef="shares">1842150</insm:CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption>
    <us-gaap:SharePrice
      contextRef="FI2017Q3"
      decimals="INF"
      id="d15036687e906-wk-Fact-6ADD3F9E97CC500BBA71C80C6470397F"
      unitRef="usdPerShare">28.50</us-gaap:SharePrice>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="D2017Q3Sept17"
      decimals="-5"
      id="d15036687e910-wk-Fact-BCB24E75C0894DAF0673C80C647D8E1F"
      unitRef="usd">24800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D2017Q3Sept17"
      decimals="-5"
      id="d15036687e914-wk-Fact-4AF3DD5EB7216BA8216BC80C646B0243"
      unitRef="usd">377700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="d15036687e931-wk-Fact-AF49F5A6715E5F0E1F4BC80C646C8211"
      unitRef="shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="d15036687e935-wk-Fact-E2147C6D81463875DF97C80C646D07D2"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="d15036687e939-wk-Fact-BBE601BC38AE6F43A753C80C6466B224"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-8789C1AA69EEFFA054B9C80C648E24C3-0-wk-Fact-E722C60268F12E1A92DBC80C6466F7D8">Stock-Based Compensation&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s current equity compensation plan, the 2017 Incentive Plan, was approved by shareholders at the Company&#x2019;s Annual Meeting of Shareholders on May&#160;18, 2017.&#160;The 2017 Incentive Plan is administered by the Compensation Committee and the Board of Directors of the Company.&#160;Under the terms of the 2017 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards, as well as pay incentive bonuses to eligible employees and non-employee directors.&#160;On May&#160;18, 2017, upon the approval of the 2017 Incentive Plan by shareholders,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. As of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,622,830&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;shares remained for future issuance under the 2017 Incentive Plan. The 2017 Incentive Plan will terminate on April&#160;3, 2027 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options.&#160;These awards are made pursuant to the Nasdaq inducement grant exception as a component of new hires&#x2019; employment compensation in connection with the Company&#x2019;s equity grant program. During the&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;twelve months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company granted inducement stock options covering &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;295,720&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;266,230&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively,&#160;shares of the Company's common stock to new employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company calculates the fair value of stock options granted using the Black-Scholes valuation model. The following table summarizes the grant date fair value and assumptions used in determining the fair value of all stock options granted, including grants of inducement options, during the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:373px;"/&gt;&lt;td style="width:100px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:100px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:100px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;66% - 68%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;71% - 79%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;74% - 77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.25% - 2.96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.73% - 2.13%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.00% - 1.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected option term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average fair value of stock options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$16.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the volatility factor was based on the Company&#x2019;s historical volatility during the expected option term.&#160;Estimated forfeitures were based on the actual percentage of option forfeitures since the closing of the Company&#x2019;s merger with Transave, Inc. in December&#160;2010 for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Beginning with the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, estimated forfeitures were based on the actual percentage of option forfeitures over the expected option term.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time, the Company grants performance-condition options to certain employees. Vesting of these options is subject to the Company achieving certain performance criteria established at the date of grant and the individuals fulfilling a service condition (continued employment). As a result of the FDA approval of ARIKAYCE in September 2018, the vesting of performance options totaling &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was recorded as non-cash compensation expense in the third quarter of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock option activity for stock options granted for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:321px;"/&gt;&lt;td style="width:82px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:72px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:86px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:72px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Life in Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in '000)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at January 1, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,273,722&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,532,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(162,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited and expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(527,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,116,706&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,850,658&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,113,998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Options outstanding at December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,116,706&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,284,710&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(378,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited and expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(414,220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Options outstanding at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,608,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,325,255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Exercisable at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,229,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,608,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,755,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(494,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited and expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(488,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,381,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,052&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,693,635&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,926&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,649,698&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The total intrinsic value of stock options exercised during the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$29.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.4 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="23"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Outstanding as of December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercisable as of&lt;br/&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Range of&lt;br/&gt;Exercise Prices&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;960,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;960,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;120,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;120,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;953,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;604,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;947,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;887,207&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;967,420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;455,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,142,513&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;782,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,380,220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;687,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22.76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,387,909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.04&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,081,677&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;166,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,069&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Stock and Restricted Stock Units&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;The Company may grant Restricted Stock (RS) and Restricted Stock Units (RSUs) to employees and non-employee directors. Each share of RS vests upon and each RSU represents a right to receive &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; share of the Company's common stock upon the completion of a specific period of continued service.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;RS and RSU awards granted are valued at the market price of the Company's common stock on the date of grant. The Company recognizes noncash compensation expense for the fair values of these RS and RSUs on a straight-line basis over the requisite service period of these awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes RSU awards granted during the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Grant Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at January&#160;1, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89,194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(43,554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89,194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(89,194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;253,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(51,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(20,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;227,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation expense related to unvested awards, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.8 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the stock-based compensation recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.66861598440545%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;_________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Includes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, for the remeasurement of certain stock options and RSUs that occurred during May 2013.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:inherit;font-size:10pt;"/&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;- On May 15, 2018, the Company's shareholders approved the Company&#x2019;s 2018 Employee Stock Purchase Plan (ESPP). As part of the ESPP, eligible employees may acquire an ownership interest in the Company by purchasing common stock, at a discount, through payroll deductions. The ESPP is compensatory under GAAP and the Company recorded stock compensation expense of $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.9 million&lt;/span&gt;&lt;/span&gt; in 2018.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="I2017Q2May18"
      decimals="INF"
      id="d15052227e864-wk-Fact-094E8843A5928BF88E3E19E9993CBBB7"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2018Q4"
      decimals="INF"
      id="d15052227e872-wk-Fact-45B1800B5CFDFDC2FD54C80C6471F7A7"
      unitRef="shares">3622830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d15052227e889-wk-Fact-A9A26E9B3A1C5AB9B47D19EA78D12AB6"
      unitRef="shares">295720</insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross>
    <insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="d15052227e893-wk-Fact-E6DEAA00AFCD55862D6DC80C646D64D1"
      unitRef="shares">266230</insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-D62B3AE82DDDC53AEF03C80C648F6E42-0-wk-Fact-2A861480819F7B9AF91EC80C646C6170">The following table summarizes the grant date fair value and assumptions used in determining the fair value of all stock options granted, including grants of inducement options, during the years ended &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:373px;"/&gt;&lt;td style="width:100px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:100px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:100px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;66% - 68%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;71% - 79%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;74% - 77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.25% - 2.96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.73% - 2.13%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.00% - 1.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected option term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average fair value of stock options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$16.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="3"
      id="d15052227e1033-wk-Fact-B3DDF340CB19749C511DC80C643E3C16"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="3"
      id="d15052227e1043-wk-Fact-8ED64EEF5C94C0331CFBC80C643F65EA"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="3"
      id="d15052227e1053-wk-Fact-B5AF6AD6F1E6785F4206C80C6434A44B"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      id="d15052227e1064-wk-Fact-DE392918EFAB1F1C8764C80C64317B0C">P5Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      id="d15052227e1074-wk-Fact-5AA3A3794E7F990AB1A3C80C643EB1C7">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      id="d15052227e1084-wk-Fact-2C40BE615D20B01A9164C80C64521295">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d15052227e1095-wk-Fact-B3D8DB6C2D17BB00539AC80C643237EC"
      unitRef="usdPerShare">16.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d15052227e1105-wk-Fact-3D02420747F04D1C9E93C80C643DFACF"
      unitRef="usdPerShare">10.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d15052227e1115-wk-Fact-2DA1248E8185B0CDF8C6C80C643A67CB"
      unitRef="usdPerShare">8.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockOptionPlanExpense
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d15052227e1147-wk-Fact-54AE505F2E13BE9B66A1E778BDB70D29"
      unitRef="usd">1100000</us-gaap:StockOptionPlanExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-8770D801F4A2FC152B7DC80C648E8005-0-wk-Fact-16285284548C40D125F1C80C646DE78C">The following table summarizes stock option activity for stock options granted for the years ended &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as follows:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:321px;"/&gt;&lt;td style="width:82px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:72px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:86px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:72px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Life in Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in '000)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at January 1, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,273,722&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,532,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(162,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited and expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(527,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,116,706&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,850,658&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,113,998&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Options outstanding at December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,116,706&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,284,710&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(378,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited and expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(414,220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Options outstanding at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,608,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,325,255&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Exercisable at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,229,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,608,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,755,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(494,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited and expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(488,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,381,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,052&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,693,635&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,926&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,649,698&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2015Q4"
      decimals="INF"
      id="d15052227e1303-wk-Fact-161E08C3188729AC7468C80C6430638A"
      unitRef="shares">5273722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2015Q4"
      decimals="2"
      id="d15052227e1322-wk-Fact-69C6D32ED0430EDA244AC80C644E285B"
      unitRef="usdPerShare">13.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2016Q4YTD"
      decimals="INF"
      id="d15052227e1367-wk-Fact-EC7CFF85E92E4BADDB69C80C64388D1D"
      unitRef="shares">2532675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15052227e1386-wk-Fact-3330D7E27289BF7B31DBC80C643FDD3D"
      unitRef="usdPerShare">12.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2016Q4YTD"
      decimals="INF"
      id="d15052227e1431-wk-Fact-97296609BE495D0C4804C80C6455AA3B"
      unitRef="shares">162340</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15052227e1451-wk-Fact-3905FEB55C245F7D5F53C80C64297145"
      unitRef="usdPerShare">6.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="FD2016Q4YTD"
      decimals="INF"
      id="d15052227e1496-wk-Fact-35BF8E4B8D98A31D08FDC80C64526E5F"
      unitRef="shares">527351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15052227e1516-wk-Fact-A8B7853DDFE8FD799DA6C80C6457D0A0"
      unitRef="usdPerShare">17.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2016Q4"
      decimals="INF"
      id="d15052227e1561-wk-Fact-4BC402C542CFABAB3826C80C6431A894"
      unitRef="shares">7116706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2016Q4"
      decimals="2"
      id="d15052227e1580-wk-Fact-45E8B83E2C73059C2EA9C80C64307855"
      unitRef="usdPerShare">13.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="FI2016Q4"
      decimals="INF"
      id="d15052227e1625-wk-Fact-2531CB4CC7A5E9F108C0C80C644C9768"
      unitRef="shares">6850658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="FI2016Q4"
      decimals="2"
      id="d15052227e1644-wk-Fact-B7CEE3CB4D2E044D39B3C80C644375B5"
      unitRef="usdPerShare">13.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2016Q4"
      decimals="INF"
      id="d15052227e1689-wk-Fact-1F95604930822DDFD65DC80C6442F78E"
      unitRef="shares">3113998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2016Q4"
      decimals="2"
      id="d15052227e1708-wk-Fact-A6BD123F9F3612609F1CC80C644737C8"
      unitRef="usdPerShare">11.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2016Q4"
      decimals="INF"
      id="d15052227e1753-wk-Fact-4BC402C542CFABAB3826C80C6431A894"
      unitRef="shares">7116706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2016Q4"
      decimals="2"
      id="d15052227e1772-wk-Fact-45E8B83E2C73059C2EA9C80C64307855"
      unitRef="usdPerShare">13.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="d15052227e1817-wk-Fact-BBD550BCE5723CB064D6C80C6454C6CA"
      unitRef="shares">2284710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15052227e1836-wk-Fact-D46E3D3CE40E3BE93985C80C645096C2"
      unitRef="usdPerShare">15.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="d15052227e1881-wk-Fact-CB8B12EAEF80E23FA288C80C64432F5C"
      unitRef="shares">378275</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15052227e1901-wk-Fact-BB72E26E957CEB7A3158C80C6453AF81"
      unitRef="usdPerShare">9.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="d15052227e1947-wk-Fact-DED3BEBB684236E3BBBBC80C64417F48"
      unitRef="shares">414220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15052227e1967-wk-Fact-3285560EA94272B948A3C80C6461B0BF"
      unitRef="usdPerShare">15.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2017Q4"
      decimals="INF"
      id="d15052227e2012-wk-Fact-2548D07248FDB369B30EC80C645786EC"
      unitRef="shares">8608921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2017Q4"
      decimals="2"
      id="d15052227e2031-wk-Fact-98C55E17F67CBB9770FCC80C642B6F6E"
      unitRef="usdPerShare">14.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="FI2017Q4"
      decimals="INF"
      id="d15052227e2077-wk-Fact-6CFC694D32F377A37050C80C6454CE12"
      unitRef="shares">8325255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="FI2017Q4"
      decimals="2"
      id="d15052227e2096-wk-Fact-542016ADE819C157E74EC80C64563782"
      unitRef="usdPerShare">14.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2017Q4"
      decimals="INF"
      id="d15052227e2142-wk-Fact-8B226CBA722228E5D079C80C645572A5"
      unitRef="shares">4229478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2017Q4"
      decimals="2"
      id="d15052227e2161-wk-Fact-C3C04A270DBA2878A368C80C6455D2F7"
      unitRef="usdPerShare">12.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2017Q4"
      decimals="INF"
      id="d15052227e2207-wk-Fact-2548D07248FDB369B30EC80C645786EC"
      unitRef="shares">8608921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2017Q4"
      decimals="2"
      id="d15052227e2226-wk-Fact-98C55E17F67CBB9770FCC80C642B6F6E"
      unitRef="usdPerShare">14.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d15052227e2272-wk-Fact-96DBCF2B85776D0C958080ACF300441A"
      unitRef="shares">1755600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15052227e2291-wk-Fact-EF1F7DDD293F2DAAC98A80ACF30DB4E0"
      unitRef="usdPerShare">27.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d15052227e2336-wk-Fact-2F6B8D9F5F240FCCE7D680ACF37A260F"
      unitRef="shares">494351</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15052227e2356-wk-Fact-0ADB8F432E85981350BB80ACF35281A0"
      unitRef="usdPerShare">14.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d15052227e2401-wk-Fact-66124EB6F41637606F6380ACF3270916"
      unitRef="shares">488440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15052227e2421-wk-Fact-F2E22BED237E0BD2E4B180ACF3345A30"
      unitRef="usdPerShare">19.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q4"
      decimals="INF"
      id="d15052227e2467-wk-Fact-68C0F294EDC2D689494180ACF32B69A8"
      unitRef="shares">9381730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q4"
      decimals="2"
      id="d15052227e2486-wk-Fact-2321B2B386A67526D95A80ACF35BD50B"
      unitRef="usdPerShare">16.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD"
      id="d15052227e2500-wk-Fact-7CF20C80E5B371C2248A80ACF3167200">P6Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15052227e2516-wk-Fact-E55E268DACD77657C35180ACF347CBBE"
      unitRef="usd">13052000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="FI2018Q4"
      decimals="INF"
      id="d15052227e2531-wk-Fact-C320315AB325EEF647E380ACF2F25860"
      unitRef="shares">8693635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q4"
      decimals="2"
      id="d15052227e2550-wk-Fact-8C23D0B40AEF86B4C0E480ACF364B9D7"
      unitRef="usdPerShare">15.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="FD2018Q4YTD"
      id="d15052227e2564-wk-Fact-8EA509F9B1F8B11784C980ACF304DB87">P6Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15052227e2580-wk-Fact-F4B2C44BA9B9BA23447F80ACF377EEB9"
      unitRef="usd">12926000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2018Q4"
      decimals="INF"
      id="d15052227e2595-wk-Fact-DA15BC444C01A67D0E1380ACF34F0C6B"
      unitRef="shares">5649698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2018Q4"
      decimals="2"
      id="d15052227e2614-wk-Fact-184728B800D03F076F7580ACF36D346D"
      unitRef="usdPerShare">13.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2018Q4YTD"
      id="d15052227e2628-wk-Fact-A713C5EA0C1288084F0980ACF33EAAB3">P5Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15052227e2644-wk-Fact-3A0CF8984C13544AE08A80ACF31F23A8"
      unitRef="usd">12181000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d15052227e2669-wk-Fact-343DC27FDAEB3C25AAAAC80C647BACD9"
      unitRef="usd">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d15052227e2673-wk-Fact-712C9C08C78D51962EBFC80C64666327"
      unitRef="usd">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d15052227e2678-wk-Fact-EB092BCE4F98D95C673DC80C6475E3C1"
      unitRef="usd">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d15052227e2689-wk-Fact-E6A177084DE77F5FF1BDC80C64688CCF"
      unitRef="usd">29700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      id="d15052227e2693-wk-Fact-11D20D14EA8935B33E3BC80C6463B99E">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-B3FA912AB64DBB167B4FC80C648ED503-0-wk-Fact-0732CB45FFD07446A86BC80C6476DAE2">The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable as of &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="23"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Outstanding as of December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercisable as of&lt;br/&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Range of&lt;br/&gt;Exercise Prices&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;960,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;960,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;120,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;120,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;953,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;604,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;947,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;887,207&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;967,420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;455,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,142,513&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;782,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,380,220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;687,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22.76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,387,909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.04&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,081,677&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,355,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;166,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,069&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      decimals="2"
      id="d15052227e2979-wk-Fact-7086D2D616172EE40EDF19E0DAD0F226"
      unitRef="usdPerShare">3.03</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      decimals="2"
      id="d15052227e2998-wk-Fact-9F4910E7FF73D7C39B5619E0DAD4B956"
      unitRef="usdPerShare">4.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      decimals="INF"
      id="d15052227e3012-wk-Fact-B18E8C7B2F5090295C9DA5EA8C5BE205"
      unitRef="shares">960038</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      id="d15052227e3027-wk-Fact-F1015617348758F15FFC19E0DAE2B66B">P3Y7M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      decimals="2"
      id="d15052227e3042-wk-Fact-3EA1E46BE0FF684E97A219E0DAD9ABBD"
      unitRef="usdPerShare">3.60</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      decimals="INF"
      id="d15052227e3056-wk-Fact-5493FDCE547F030904F119E0DAC8DC50"
      unitRef="shares">960038</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      decimals="2"
      id="d15052227e3075-wk-Fact-64A266F244DC8EB9B43019E0DADDB8E4"
      unitRef="usdPerShare">3.60</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      decimals="2"
      id="d15052227e3091-wk-Fact-F1F5E644DC96CB1C3FCEA5EA8CA3B90D"
      unitRef="usdPerShare">6.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      decimals="2"
      id="d15052227e3110-wk-Fact-8E6796E1F8CC54519E3EA5EA8C354F8B"
      unitRef="usdPerShare">6.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      decimals="INF"
      id="d15052227e3124-wk-Fact-F0FE3EB46A07EF692BB3A5EA8CB4DB7D"
      unitRef="shares">120403</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      id="d15052227e3139-wk-Fact-C8BB3E1D681EF746880CA5EA8C0A2938">P4Y1M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      decimals="2"
      id="d15052227e3154-wk-Fact-4EEF2F82C9B30BF5218BA5EA8D025431"
      unitRef="usdPerShare">6.90</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      decimals="INF"
      id="d15052227e3168-wk-Fact-6AFDAA479BFEF6326C07A5EA8D27D287"
      unitRef="shares">120403</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      decimals="2"
      id="d15052227e3187-wk-Fact-158790FA9EC3D390456FA5EA8C9243B4"
      unitRef="usdPerShare">6.90</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      decimals="2"
      id="d15052227e3203-wk-Fact-8F6F8298C5ECF6CEFFDDA5EA8CCA2800"
      unitRef="usdPerShare">6.96</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      decimals="2"
      id="d15052227e3222-wk-Fact-50A84D1903175B9CC933A5EA8C8E53AE"
      unitRef="usdPerShare">10.85</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      decimals="INF"
      id="d15052227e3236-wk-Fact-436296D126AB0D523CD4A5EA8C3F1DDA"
      unitRef="shares">953089</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      id="d15052227e3251-wk-Fact-6532508C577F3016BD04A5EA8D1A125A">P6Y10M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      decimals="2"
      id="d15052227e3266-wk-Fact-3FB3806D91166DC10DB5A5EA8C26BC4B"
      unitRef="usdPerShare">10.76</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      decimals="INF"
      id="d15052227e3280-wk-Fact-7BCC67056911C7B3D4F4A5EA8C04E440"
      unitRef="shares">604037</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      decimals="2"
      id="d15052227e3299-wk-Fact-8E8AFA8E31594F9B2F79A5EA8C9B5632"
      unitRef="usdPerShare">10.71</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      decimals="2"
      id="d15052227e3315-wk-Fact-BCEF0B133CB3F73F84DEA5EA8C16E4F2"
      unitRef="usdPerShare">11.14</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      decimals="2"
      id="d15052227e3334-wk-Fact-92841C356234A69E1869A5EA8CF7920E"
      unitRef="usdPerShare">12.58</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      decimals="INF"
      id="d15052227e3348-wk-Fact-5978FBC5AE78B8A8466CA5EA8CFCD868"
      unitRef="shares">947839</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      id="d15052227e3363-wk-Fact-937235DD233FD3218092A5EA8C1B93C9">P4Y8M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      decimals="2"
      id="d15052227e3378-wk-Fact-910277BC54C522310B50A5EA8C9F753A"
      unitRef="usdPerShare">12.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      decimals="INF"
      id="d15052227e3392-wk-Fact-2EA732A5F529DC4447D0A5EA8C8923CE"
      unitRef="shares">887207</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      decimals="2"
      id="d15052227e3411-wk-Fact-C955605FBFA2D419D847A5EA8CCF3184"
      unitRef="usdPerShare">12.18</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      decimals="2"
      id="d15052227e3427-wk-Fact-621B4CA3EB919207966AA5EA8C214331"
      unitRef="usdPerShare">12.66</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      decimals="2"
      id="d15052227e3446-wk-Fact-170C91F49801A5822DC2A5EA8D1F4DB2"
      unitRef="usdPerShare">13.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      decimals="INF"
      id="d15052227e3460-wk-Fact-845E7424934E449374C2A5EA8C96D1DF"
      unitRef="shares">967420</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      id="d15052227e3475-wk-Fact-C5D6FE4A9DDC9F22C2FCA5EA8BE85EAE">P7Y3M21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      decimals="2"
      id="d15052227e3490-wk-Fact-2E83FF07646EADC4592AA5EA8C72C20C"
      unitRef="usdPerShare">13.62</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      decimals="INF"
      id="d15052227e3504-wk-Fact-10CE20AF6F4DCA073627A5EA8CAD726E"
      unitRef="shares">455114</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      decimals="2"
      id="d15052227e3523-wk-Fact-7DD354A0FC3027F36C5BA5EA8C6A0FB1"
      unitRef="usdPerShare">13.59</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      decimals="2"
      id="d15052227e3539-wk-Fact-7AD5476D4BB8E1F0B20FA5EA8C50E582"
      unitRef="usdPerShare">14.24</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      decimals="2"
      id="d15052227e3558-wk-Fact-715E8FA08E262CEAF887A5EA8C4BBD64"
      unitRef="usdPerShare">16.07</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      decimals="INF"
      id="d15052227e3572-wk-Fact-6DA4B92290252AF5A465A5EA8D2CA494"
      unitRef="shares">1142513</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      id="d15052227e3587-wk-Fact-C0F118A498CCC5338901A5EA8CBF6376">P5Y9M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      decimals="2"
      id="d15052227e3602-wk-Fact-4B93846543D6330C2DD2A5EA8CC5DF79"
      unitRef="usdPerShare">15.31</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      decimals="INF"
      id="d15052227e3616-wk-Fact-7DFB56AAA181CDED4CDAA5EA8D0DD779"
      unitRef="shares">782818</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      decimals="2"
      id="d15052227e3635-wk-Fact-B3D167AA856A0A00D510A5EA8C6EA4F6"
      unitRef="usdPerShare">15.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      decimals="2"
      id="d15052227e3651-wk-Fact-3D7DF9B1C1567C4E1583A5EA8C6058D0"
      unitRef="usdPerShare">16.09</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      decimals="2"
      id="d15052227e3670-wk-Fact-558BD7D223E38F31BE00A5EA8CD4C895"
      unitRef="usdPerShare">17.16</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      decimals="INF"
      id="d15052227e3684-wk-Fact-58E5F6FA1DA6164DE9D7A5EA8CE64E04"
      unitRef="shares">1380220</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      id="d15052227e3699-wk-Fact-071584CD2A9346FDBC38A5EA8C459593">P7Y6M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      decimals="2"
      id="d15052227e3714-wk-Fact-C5E8D8F015EC014DEF17A5EA8BFF4885"
      unitRef="usdPerShare">16.69</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      decimals="INF"
      id="d15052227e3728-wk-Fact-134BF850D0321F2FD310A5EA8C55583B"
      unitRef="shares">687691</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      decimals="2"
      id="d15052227e3747-wk-Fact-E6FDC6683C2B1A0BDB79A5EA8BEF281C"
      unitRef="usdPerShare">16.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      decimals="2"
      id="d15052227e3763-wk-Fact-C42C6CCE114365ACA39CA5EA8CF13364"
      unitRef="usdPerShare">17.24</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      decimals="2"
      id="d15052227e3782-wk-Fact-1AE9007B76398B2A7C61A5EA8CA8DE68"
      unitRef="usdPerShare">22.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      decimals="INF"
      id="d15052227e3796-wk-Fact-09F2C32915F16F61E78BA5EA8D082EE5"
      unitRef="shares">1387909</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      id="d15052227e3811-wk-Fact-713A96BF54D15A09A776A5EA8CB991BE">P6Y6M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      decimals="2"
      id="d15052227e3826-wk-Fact-672A5A7176FE9B971424A5EA8BFAAB22"
      unitRef="usdPerShare">21.04</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      decimals="INF"
      id="d15052227e3840-wk-Fact-E8A704923E6087E9BEF7A5EA8C30F2FD"
      unitRef="shares">1081677</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      decimals="2"
      id="d15052227e3859-wk-Fact-97EF5BC07C603D9D0761A5EA8D239755"
      unitRef="usdPerShare">21.31</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      decimals="2"
      id="d15052227e3875-wk-Fact-340BEA265E2A9CAAC984A5EA8CEC7FB2"
      unitRef="usdPerShare">22.84</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      decimals="2"
      id="d15052227e3894-wk-Fact-982FD23F22E69972A725A5EA8BF40946"
      unitRef="usdPerShare">30.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      decimals="INF"
      id="d15052227e3908-wk-Fact-EFC77A2E8FFF61B13BA9A5EA8C39CE5D"
      unitRef="shares">1355366</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      id="d15052227e3923-wk-Fact-8D50D0D31C569E2C159CA5EA8C6545F1">P8Y4M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      decimals="2"
      id="d15052227e3938-wk-Fact-813F8C186DAB44819DE1A5EA8C2BDA07"
      unitRef="usdPerShare">28.54</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      decimals="INF"
      id="d15052227e3952-wk-Fact-05A187AC3E4DB73F8F27A5EA8D137B08"
      unitRef="shares">57644</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      decimals="2"
      id="d15052227e3971-wk-Fact-275420F121A62914003CA5EA8C800B7E"
      unitRef="usdPerShare">25.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      decimals="2"
      id="d15052227e3988-wk-Fact-75CB0D9D573BC3159B1FA5EA8C858939"
      unitRef="usdPerShare">30.86</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      decimals="2"
      id="d15052227e4007-wk-Fact-D04973ACFA9703850719A5EA8D3198DA"
      unitRef="usdPerShare">32.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      decimals="INF"
      id="d15052227e4021-wk-Fact-19EC138C96C15FDD1C02A5EA8C77E9DC"
      unitRef="shares">166933</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      id="d15052227e4036-wk-Fact-69E0B9149C161F769853A5EA8CDF9F93">P8Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      decimals="2"
      id="d15052227e4051-wk-Fact-37344ACABCC94AE9E7FDA5EA8CD938AD"
      unitRef="usdPerShare">31.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      decimals="INF"
      id="d15052227e4065-wk-Fact-146D596637D0C5659E31A5EA8C112F96"
      unitRef="shares">13069</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      decimals="2"
      id="d15052227e4084-wk-Fact-A0106F4DB1F046F92A3FA5EA8C7B35A3"
      unitRef="usdPerShare">31.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember"
      decimals="INF"
      id="d15052227e4101-wk-Fact-89BB2BEC84816D85A2B6C80C6473DA8F"
      unitRef="shares">1</insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-5A380E0844CDAC758722C80C648E22B8-0-wk-Fact-64F19B8F7653D2CA0DE7C80C646DE0C2">The following table summarizes RSU awards granted during the years ended &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Grant Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at January&#160;1, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89,194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(43,554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;89,194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(89,194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;253,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(51,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(20,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;227,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4205-wk-Fact-39D95FD868CC2DE1CBA6C80C642A4D3F"
      unitRef="shares">43554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4224-wk-Fact-B8EB4AB9C635204AEC7CC80C642CAAF3"
      unitRef="usdPerShare">19.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4244-wk-Fact-0D52EDBB77882286A069C80C6433899F"
      unitRef="shares">89194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4263-wk-Fact-61C7197BE23EEF0ED71EC80C64256BC5"
      unitRef="usdPerShare">10.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4283-wk-Fact-AC1AE797C261406CA4E1C80C64303E82"
      unitRef="shares">43554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4303-wk-Fact-85D5D9FAC2E0A8C5E78DC80C64343724"
      unitRef="usdPerShare">16.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4323-wk-Fact-3A73BC4224F2E1048C32C80C6439EEFD"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4342-wk-Fact-2B14D5BA635E0F6B4EFFC80C64269489"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4362-wk-Fact-427C97FC2259D829915FC80C6435519A"
      unitRef="shares">89194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4381-wk-Fact-6D0D3251DADE72CE6BC4C80C64260E68"
      unitRef="usdPerShare">10.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4401-wk-Fact-00F68B21F189A111B8F4C80C6428C33E"
      unitRef="shares">46914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4420-wk-Fact-5E507C0C7EEDBC077670C80C6430F95F"
      unitRef="usdPerShare">17.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4440-wk-Fact-85D6B46E3BCEE85AB993C80C641E5421"
      unitRef="shares">89194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4460-wk-Fact-CC08D9F9A2980A893CEBC80C6425A5ED"
      unitRef="usdPerShare">10.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4480-wk-Fact-8E4816B3BD5D773A6601C80C6422EBB8"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4499-wk-Fact-D7C89B4EEAE0BCC69A67C80C6420270E"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4519-wk-Fact-A8220C05DB110A06C4C7C80C642801A9"
      unitRef="shares">46914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4538-wk-Fact-4F34018F807F95AAA4C5C80C642FD6A4"
      unitRef="usdPerShare">17.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4558-wk-Fact-63EA2FA97A4E26C307D019CF12877BC2"
      unitRef="shares">253586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4577-wk-Fact-3AFA0AE7EC3D4FA452CA19CF30552A15"
      unitRef="usdPerShare">29.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4598-wk-Fact-5234E5381931D8D9C5F119CF54FC7030"
      unitRef="shares">51992</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4618-wk-Fact-A8369C222FFDDB2E409F19CF6E3EEDCE"
      unitRef="usdPerShare">18.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4638-wk-Fact-88EBF3167A02D60006AF19CF89EFF461"
      unitRef="shares">20682</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4658-wk-Fact-BCEC1495BC0C449C894619CFA6E49758"
      unitRef="usdPerShare">29.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d15052227e4678-wk-Fact-95C6DE3F1236D237799819CFC3ABD308"
      unitRef="shares">227826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d15052227e4697-wk-Fact-B6BCFAF093487D18025419CFDE4B5836"
      unitRef="usdPerShare">29.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d15052227e4714-wk-Fact-1C70732A039DF6D6990EC8D419CF5BF5"
      unitRef="usd">3400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember"
      id="d15052227e4718-wk-Fact-276FB24AFBC1DE2E7325DD9499B141CB">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-B08E1E746F54BCC5052CC80C648ED6AA-0-wk-Fact-156A989A32E2E7673C21C80C647DF4B1">The following table summarizes the stock-based compensation recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the years ended &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in millions):&lt;/span&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.66861598440545%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;_________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Includes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;, respectively, for the remeasurement of certain stock options and RSUs that occurred during May 2013.</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d15052227e4837-wk-Fact-A7BD853BB6ED63E4F4E2C80C64497A04"
      unitRef="usd">9400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d15052227e4856-wk-Fact-A8974F69FD4714B348E1C80C6449FB98"
      unitRef="usd">6500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d15052227e4875-wk-Fact-9A40E94A96B8C31FBDB7C80C64461153"
      unitRef="usd">6200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="d15052227e4891-wk-Fact-D04820307BBD8C094D80C80C644A6650"
      unitRef="usd">16800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="d15052227e4910-wk-Fact-2590CBF49F4E33758029C80C644AD22E"
      unitRef="usd">11600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="d15052227e4929-wk-Fact-EC5506F4B1D1C8F0F141C80C6446EC01"
      unitRef="usd">11800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d15052227e4955-wk-Fact-B1F45FE0CAE8B7D4D274C80C6448CC43"
      unitRef="usd">26200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d15052227e4974-wk-Fact-6FE92E7BB57A27EBF2DCC80C6448DA3F"
      unitRef="usd">18100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d15052227e4993-wk-Fact-D580FB950E4FE1A79246C80C64469606"
      unitRef="usd">18000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <insm:AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d15052227e5015-wk-Fact-513523D05905B525A16BC80C647373A8"
      unitRef="usd">0.0</insm:AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards>
    <insm:AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d15052227e5019-wk-Fact-DE54EB387B755AD07599C80C647661F8"
      unitRef="usd">0.0</insm:AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards>
    <insm:AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards
      contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d15052227e5023-wk-Fact-9E1F88E3D7EA7F1491E0C80C646E070D"
      unitRef="usd">1700000</insm:AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="-5"
      id="d15052227e5051-wk-Fact-28A355BAB5DFE79224F6A64E932E7850"
      unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-F5E181F0BABCCB3493C6C80C648F98BE-0-wk-Fact-89A565CACC434697B772C80C6443F169">Income Taxes&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The income tax provision (benefit) was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$(0.3) million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and the effective rates were approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. The income tax (benefit) for the year ended December 31, 2017 reflects the reversal of the valuation allowance related to alternative minimum tax (AMT) that the Company paid in 2009. As a result of the Tax Cuts and Jobs Act (the Tax Act), the Company recorded a noncurrent receivable to reflect the refund due to the Company in future periods relating to the previously paid AMT. In addition, the income tax provision (benefit) for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflected current income tax expense recorded as a result of the taxable income in certain of the Company's non-US subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company was also subject to foreign income taxes as a result of legal entities established for activities in Europe and Japan. The Company's loss before income taxes in the US and globally was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;US&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(286,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(136,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(140,354&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(37,865&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(56,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(35,821&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(324,076&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(192,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(176,175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's income tax (benefit) provision consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(272&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The reconciliation between the federal statutory tax rates and the Company's effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Statutory federal tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;R&amp;amp;D and other tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Impact of Tax Act&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:505px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:72px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:72px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;231,918&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;186,342&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General business credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;109,502&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Product license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,651&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,855&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;380,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;277,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangibles&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(15,424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(48,223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;332,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;261,300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(332,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(261,300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The net deferred tax assets (prior to applying the valuation allowance) of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$332.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$261.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, primarily consist of net operating loss carryforwards for income tax purposes. Due to the Company's history of operating losses, the Company recorded a full valuation allowance on its net deferred tax assets by increasing the valuation allowance by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$71.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and decreasing by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$23.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, as it was more likely than not that such tax benefits will not be realized. As of December 31, 2017, the Company's gross deferred tax assets were also impacted by the Tax Act which required the change to a 21% US tax rate (see below for further discussion on the Tax Act).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:54px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had federal net operating loss carryforwards for income tax purposes of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$880.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Due to the limitation on NOLs as more fully discussed below, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$709.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the NOLs are available to offset future taxable income, if any. The NOL carryovers and general business tax credits expire in various years beginning in 2018. For state tax purposes, the Company has approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$515.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of New Jersey NOLs available to offset against future taxable income. The Company also has California and Virginia NOLs that are entirely limited due to Section&#160;382 (as discussed below).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From 2014 through 2017, the Company completed an Internal Revenue Code Section&#160;382 (Section&#160;382) analysis in order to determine the amount of losses that are currently available for potential offset against future taxable income, if any. It was determined that the utilization of the Company's NOL and general business tax credit carryforwards generated in tax periods up to and including December 2010 were subject to substantial limitations under Section&#160;382 due to ownership changes that occurred at various points from the Company's original organization through December 2010. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of shareholders that own, directly or indirectly, 5% or more of a corporation's stock, in the stock of a corporation by more than 50 percentage points over a testing period (usually &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years). Since the Company's formation, it has raised capital through the issuance of common stock on several occasions which, combined with the purchasing shareholders' subsequent disposition of those shares, have resulted in multiple changes in ownership, as defined by Section&#160;382, since the Company's formation in 1999. These ownership changes resulted in substantial limitations on the use of the Company's NOLs and general business tax credit carryforwards up to and including December 2010. The Company continues to track all of its NOLs and tax credit carryforwards but has provided a full valuation allowance to offset those amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2017, the US government enacted the Tax Act. The Tax Act significantly revises US tax law by, among other provisions, lowering the US federal statutory income tax rate from 35% to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"/&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;The Tax Act&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"/&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;ASC&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; 740, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the Tax Act&#x2019;s provisions, the SEC staff issued SAB 118, which allowed companies to record the tax effects of the Tax Act on a provisional basis based on a reasonable estimate, and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Tax Act did not have a material impact on the Company's financial statements because its deferred temporary differences are fully offset by a valuation allowance and the Company does not have any significant offshore earnings from which to record the mandatory transition tax. The Company completed its analysis during the fourth quarter of 2018 and no additional tax effects of the Act were required to be recorded for the year ended December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement. If such unrecognized tax benefits were realized and not subject to valuation allowances, we would recognize a tax benefit of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.16764132553607%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Deferred Tax Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Balance as of January 1,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additions related to prior period tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Additions related to current period tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,087&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is subject to US federal and state income taxes and the statute of limitations for tax audit is open for the federal tax returns for the years ended 2014 and later, and is generally open for certain states for the years 2013 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company's policy is to recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense. The Company has recorded no such expense. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company has recorded reserves for unrecognized income tax benefits of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.0 million&lt;/span&gt;&lt;/span&gt;, respectively. As any adjustment to the Company&#x2019;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12&#160;months.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d15047081e863-wk-Fact-C3F87DAFF7AA94E53AE3C80C64246AEE"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d15047081e867-wk-Fact-7E1F90F7742924259264C80C64230364"
      unitRef="usd">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2016Q4YTD"
      decimals="-5"
      id="d15047081e871-wk-Fact-56863E29648D69FCF493C80C646A2585"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15047081e875-wk-Fact-3B7DFACEB29ACC01298FC80C6464968B"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15047081e879-wk-Fact-236A89997E0688536A4FC80C6428BB52"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15047081e884-wk-Fact-ABDA33B72E601F9F5BE2C80C641ED71E"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-43B6722E62DD3ED8A4C3C80C648F63F1-0-wk-Fact-891235CF56B36C621149C80C643DF042">The Company's loss before income taxes in the US and globally was as follows (in thousands):&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;US&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(286,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(136,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(140,354&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(37,865&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(56,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(35,821&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(324,076&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(192,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(176,175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e1086-wk-Fact-61DC0E78F82C35C6E3A0C80C64260A03"
      unitRef="usd">-286211000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e1106-wk-Fact-CA01ECBCBF8D16BFECE4C80C642B4539"
      unitRef="usd">-136682000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15047081e1126-wk-Fact-966CC710101385BC1F90C80C642A4135"
      unitRef="usd">-140354000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e1143-wk-Fact-4B743C503381BD50DE98C80C64287460"
      unitRef="usd">-37865000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e1163-wk-Fact-3E1029C7E5770D584FB6C80C64340FD4"
      unitRef="usd">-56239000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15047081e1183-wk-Fact-EFA2DE983037115AEE6FC80C6428CBF0"
      unitRef="usd">-35821000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e1210-wk-Fact-12A725180DFC88524CFCC80C64387A24"
      unitRef="usd">-324076000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e1230-wk-Fact-A15D7F28ADF1B4BED74EC80C642BF891"
      unitRef="usd">-192921000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15047081e1250-wk-Fact-885B0511759F68EBB430C80C642DAEE3"
      unitRef="usd">-176175000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-1ADD89DFCB5743E228C9C80C648FBB43-0-wk-Fact-4C0E765CB16E42AA3942C80C6434EA52">The Company's income tax (benefit) provision consisted of the following (in thousands):&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(272&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e1484-wk-Fact-A69FCCA0A07B35BB49FEC80C643AE0DB"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e1503-wk-Fact-4B0D2D3CC0FEE792F547C80C642F200A"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15047081e1522-wk-Fact-0F814CD227253A3F5E96C80C642FA3A5"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e1538-wk-Fact-086B17D2D8BD21C4C735C80C643E7718"
      unitRef="usd">4000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e1557-wk-Fact-A9D6C1E9DE02A92C4905C80C64364DBD"
      unitRef="usd">3000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15047081e1576-wk-Fact-91FF67D5542C2085FEABC80C642352D0"
      unitRef="usd">3000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e1597-wk-Fact-819CD01056B8B5A0FD29C80C643AAD08"
      unitRef="usd">197000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e1616-wk-Fact-CFD0009881ACDC8053ABC80C6435B444"
      unitRef="usd">142000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15047081e1635-wk-Fact-72202E0738E9774B6B0FC80C64417454"
      unitRef="usd">95000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e1656-wk-Fact-5F65043746EF9BCBAC70C80C64272452"
      unitRef="usd">201000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e1675-wk-Fact-52B298E5B4F6AB95CA41C80C642EA44D"
      unitRef="usd">145000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15047081e1694-wk-Fact-E34E0154E537E198454DC80C64320BC8"
      unitRef="usd">98000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e1774-wk-Fact-E88DCF00FEBE02231317C80C643BC869"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e1793-wk-Fact-236BA9508C636AE4BE7AC80C64310221"
      unitRef="usd">-417000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15047081e1813-wk-Fact-1B14F6BDD248A2FCEDBFC80C6432092D"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e1834-wk-Fact-832D3D036C1C8878D284C80C6431351D"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e1853-wk-Fact-CC2170961ECEDC858A40C80C642D8493"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15047081e1872-wk-Fact-A0E28B75C7BD125C0BC9C80C6429DDB7"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e1893-wk-Fact-864706EE3974C621ECE0C80C642A6A26"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e1912-wk-Fact-66168C8531D13EC3A538C80C642269B9"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15047081e1931-wk-Fact-4AADE11964E7E417BF06C80C643E4994"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e1953-wk-Fact-F1576C4EB8F3B584E9A4C80C64243781"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e1972-wk-Fact-9AF8ADAC622F8102F74DC80C6435BC1B"
      unitRef="usd">-417000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15047081e1992-wk-Fact-F39159D1EE512192EED1C80C642D2503"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e2018-wk-Fact-8D74C5FB87F23963EC01C80C64442BB1"
      unitRef="usd">201000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e2037-wk-Fact-DE237BCC7B9D2B1576DAC80C64408AF8"
      unitRef="usd">-272000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2016Q4YTD"
      decimals="-3"
      id="d15047081e2057-wk-Fact-EEB607607F1CA43AAEDDC80C6430DE13"
      unitRef="usd">98000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-CD3EB6A201BE0DFF44EDC80C648FBBC6-0-wk-Fact-B000843DB077C273385CC80C641EC891">The reconciliation between the federal statutory tax rates and the Company's effective tax rate is as follows:&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Statutory federal tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;R&amp;amp;D and other tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Impact of Tax Act&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d15047081e2190-wk-Fact-34AA558ECF55E318B993C80C64583FAB"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="d15047081e2205-wk-Fact-F7EC8209732F7268224BC80C645D5ADF"
      unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2016Q4YTD"
      decimals="INF"
      id="d15047081e2220-wk-Fact-E2A9E0BD738A1C735FDEC80C644F68CF"
      unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <insm:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15047081e2236-wk-Fact-5E0C7A37AC176C07E3E9C80C644F1F5B"
      unitRef="number">0</insm:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <insm:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15047081e2251-wk-Fact-E68C650E06A111B8C2A1C80C645F5249"
      unitRef="number">-0.03</insm:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <insm:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15047081e2266-wk-Fact-F5644B75AF752CB9B1C6C80C64507050"
      unitRef="number">-0.03</insm:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15047081e2282-wk-Fact-F82B6FBCE6C8533838B2C80C6456E814"
      unitRef="number">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15047081e2297-wk-Fact-6F51F4FF9874B4B6E76AC80C644ED824"
      unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15047081e2312-wk-Fact-40BB822038C14204A818C80C6456AF4B"
      unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15047081e2328-wk-Fact-53B379BF4B31541A0E5CC80C645AB9B9"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15047081e2343-wk-Fact-52AD47A6E81F0E31899DC80C64614E7F"
      unitRef="number">0.08</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15047081e2358-wk-Fact-91B6A85F9F271C3C452CC80C644742BA"
      unitRef="number">0.08</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15047081e2374-wk-Fact-03BC6D6DB24B2D903B8BC80C64646F95"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15047081e2389-wk-Fact-5FCEC425DAB3B56C66C5C80C64573980"
      unitRef="number">-0.06</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15047081e2404-wk-Fact-AA73FEC1AC867FE08126C80C6460951C"
      unitRef="number">-0.04</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <insm:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15047081e2420-wk-Fact-A5F168E383FA3BC305EFC80C64592A0B"
      unitRef="number">0</insm:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <insm:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15047081e2435-wk-Fact-7E96E7B7293E419FD5FAC80C645BA9C7"
      unitRef="number">-0.49</insm:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <insm:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15047081e2450-wk-Fact-88B9322A9C6A49CBCB05C80C645F4720"
      unitRef="number">0</insm:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15047081e2466-wk-Fact-20947D400ED1596C22AAC80C64443685"
      unitRef="number">-0.27</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15047081e2481-wk-Fact-69FC26FEB0D37F7C2F48C80C645EFCAB"
      unitRef="number">0.12</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15047081e2496-wk-Fact-B4A0A90C466896899957C80C645963CE"
      unitRef="number">-0.39</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15047081e2512-wk-Fact-F606B7D34BF4AA84A773C80C64583860"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15047081e2527-wk-Fact-0EBFA375433C8F44E9ECC80C6453019C"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15047081e2542-wk-Fact-ECEA60BA25EA08B281F2C80C64632E97"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15047081e2558-wk-Fact-3B7DFACEB29ACC01298FC80C6464968B"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15047081e2573-wk-Fact-236A89997E0688536A4FC80C6428BB52"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2016Q4YTD"
      decimals="2"
      id="d15047081e2588-wk-Fact-ABDA33B72E601F9F5BE2C80C641ED71E"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-94FC5732E76D79344F34C80C648F3AA1-0-wk-Fact-4ABE3189AF0C78C70475C80C642650CF">The components of the deferred tax assets and liabilities consist of the following:&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:505px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:72px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;td style="width:5px;"/&gt;&lt;td style="width:9px;"/&gt;&lt;td style="width:72px;"/&gt;&lt;td style="width:4px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;231,918&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;186,342&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General business credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;109,502&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;66,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Product license&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,651&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,855&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;380,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;277,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangibles&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(15,424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(32,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(48,223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(16,360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;332,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;261,300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(332,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(261,300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e2756-wk-Fact-0852B35D91E1B1E138B6C80C6426E71E"
      unitRef="usd">231918000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e2775-wk-Fact-0803D5AD9B5EE8123A43C80C642361E7"
      unitRef="usd">186342000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e2790-wk-Fact-DC1E08A0BE0FC576213DC80C64235818"
      unitRef="usd">109502000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e2809-wk-Fact-46EC64DBFEBEA95EBB91C80C642B1644"
      unitRef="usd">66371000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <insm:DeferredTaxAssetsLicensePayment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e2829-wk-Fact-DF6502F55C3E81B05B9DC80C6424DFC9"
      unitRef="usd">6902000</insm:DeferredTaxAssetsLicensePayment>
    <insm:DeferredTaxAssetsLicensePayment
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e2848-wk-Fact-CB3BA8ABDE663E298E93C80C6420811E"
      unitRef="usd">7730000</insm:DeferredTaxAssetsLicensePayment>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e2868-wk-Fact-BEBDF563816F1A9A8541C80C641D455C"
      unitRef="usd">7651000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e2887-wk-Fact-DEC2A79F8D229C5F0602C80C641FBF5A"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e2907-wk-Fact-184CD5F7D8D5C501A88FC80C64274FF3"
      unitRef="usd">24855000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e2926-wk-Fact-1DD99689A50CE3A88DC5C80C6422342B"
      unitRef="usd">17217000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e2951-wk-Fact-92F20D5513008B95D752C80C642257D5"
      unitRef="usd">380828000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e2970-wk-Fact-2E13664352C48A323A46C80C6421892A"
      unitRef="usd">277660000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e3029-wk-Fact-313562BBA3D0E51929D1C80C642207B0"
      unitRef="usd">15424000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e3049-wk-Fact-4DF323C0F3C55206B23DC80C641B5AAB"
      unitRef="usd">16360000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <insm:DeferredTaxLiabilitiesConvertibleDebt
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e3066-wk-Fact-6657853B95396708C257C8EA246B1540"
      unitRef="usd">32799000</insm:DeferredTaxLiabilitiesConvertibleDebt>
    <insm:DeferredTaxLiabilitiesConvertibleDebt
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e3086-wk-Fact-1853D89DA3104BB16C3DC8EA2477F132"
      unitRef="usd">0</insm:DeferredTaxLiabilitiesConvertibleDebt>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e3111-wk-Fact-514AD791057418AB0672C80C64201460"
      unitRef="usd">48223000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e3131-wk-Fact-407D538243D5829BC180C80C642AB6CD"
      unitRef="usd">16360000</us-gaap:DeferredIncomeTaxLiabilities>
    <insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e3152-wk-Fact-793796E126568FC7EBD2C80C64246C01"
      unitRef="usd">332605000</insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e3171-wk-Fact-3FC14764B63E7E61839AC80C6429EDEB"
      unitRef="usd">261300000</insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e3186-wk-Fact-1D9764BF435197B25AB4C80C64210D68"
      unitRef="usd">332605000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e3206-wk-Fact-ED60CE990B171D099794C80C64213A7A"
      unitRef="usd">261300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e3232-wk-Fact-7E900776B0DA90B0E647C80C6420E9CB"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e3251-wk-Fact-AC3E332B849E10CBCCCDC80C641C352B"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="FI2018Q4"
      decimals="-5"
      id="d15047081e3264-wk-Fact-E00AF5165694AFE6D0FBC80C6427BB41"
      unitRef="usd">332600000</insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="FI2017Q4"
      decimals="-5"
      id="d15047081e3268-wk-Fact-CBD7AF784A388E0C6F5AC80C642A32E2"
      unitRef="usd">261300000</insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d15047081e3280-wk-Fact-B5FC6619220F6EDE6E2FC80C642B205C"
      unitRef="usd">71300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d15047081e3289-wk-Fact-2B48299538494B42CB96C80C645A1AAE"
      unitRef="usd">-23300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <insm:OperatingLossCarryforwardsTotal
      contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="d15047081e3305-wk-Fact-F4D9FDF6247B8E57102AC80C6426D61D"
      unitRef="usd">880600000</insm:OperatingLossCarryforwardsTotal>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="d15047081e3309-wk-Fact-4BD92C0A251534E7F45FC80C64252A6F"
      unitRef="usd">709700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_NewJerseyDivisionOfTaxationMember"
      decimals="-5"
      id="d15047081e3313-wk-Fact-D0A84670CB9D6FCA13ECC80C642A45B4"
      unitRef="usd">515300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-5"
      id="d15047081e3360-wk-Fact-1319FE027A070B55B99DC9DA22FFFBFC"
      unitRef="usd">4100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-6221D242344CF6ECBFE1C9C9CB2B55CB-0-wk-Fact-A58A5AC61A3D4AD0365AC9CED91D4EB3">The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.16764132553607%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Deferred Tax Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Balance as of January 1,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additions related to prior period tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Additions related to current period tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance as of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,087&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e3438-wk-Fact-7BF5F60932B76FF804E9C9D30A1ECFF5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2016Q4"
      decimals="-3"
      id="d15047081e3457-wk-Fact-64737D1460153AD34E87C9D32084BE49"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e3472-wk-Fact-13791593F502046BBC8BC9D7BC631F7F"
      unitRef="usd">3345000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e3491-wk-Fact-6719058237196ADCF0D0C9D7BF249AEA"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15047081e3511-wk-Fact-BE862A3844FA5BDC3556C9D7E84B749E"
      unitRef="usd">742000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15047081e3530-wk-Fact-A7F2AD1ACB5CFDBC463DC9D7EAEE309E"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15047081e3555-wk-Fact-E52AE06A245B587220E2C9D38C740627"
      unitRef="usd">4087000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-3"
      id="d15047081e3574-wk-Fact-7BF5F60932B76FF804E9C9D30A1ECFF5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-5"
      id="d15047081e3598-wk-Fact-1319FE027A070B55B99DC9DA22FFFBFC"
      unitRef="usd">4100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-5"
      id="d15047081e3602-wk-Fact-853BE8B2C94102D66F3AC9F9B326EDCE"
      unitRef="usd">0.0</us-gaap:UnrecognizedTaxBenefits>
    <insm:LicenseAndOtherAgreementsTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-841EF0395AE2C6CA1B2CC80C648F6221-0-wk-Fact-F0657875F19786A9BFD8C80C6473BFF7">License and Other Agreements&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;In-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;PARI Pharma&#160;GmbH&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In April 2008, the Company entered into a licensing agreement with PARI Pharma&#160;GmbH (PARI) for use of the optimized Lamira Nebulizer System for delivery of ARIKAYCE in treating patients with NTM lung infections, CF and bronchiectasis. Under the licensing agreement, the Company has rights under several US and foreign issued patents and patent applications involving improvements to the optimized Lamira Nebulizer System, to exploit such system with ARIKAYCE for the treatment of such indications, but the Company cannot manufacture such nebulizers except as permitted under the Commercialization Agreement with PARI. Under the licensing agreement, the Company paid PARI an upfront license fee and certain milestone payments. Upon FDA acceptance of the Company's New Drug Application and the subsequent FDA approval of ARIKAYCE, the Company paid PARI additional milestone payments of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x20ac;1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x20ac;1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. In addition, PARI is entitled to receive a future milestone payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x20ac;0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash based on achievement of first receipt of marketing approval in a major EU country for ARIKAYCE and the device. PARI is entitled to receive royalty payments in the mid-single digits on the annual global net sales of ARIKAYCE, pursuant to the licensing agreement, subject to certain specified annual minimum royalties. In October 2017, the Company exercised an option to buy-down the royalties that will be paid to PARI on ARIKAYCE net sales. The payment to PARI was included as a component of SG&amp;amp;A expenses in the fourth quarter of 2017. See below for information related to the commercialization agreement with PARI. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cystic Fibrosis Foundation Therapeutics,&#160;Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In 2004 and 2009, the Company entered into research funding agreements with Cystic Fibrosis Foundation Therapeutics,&#160;Inc. (CFFT) whereby it received &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for each respective agreement in research funding for the development of ARIKAYCE. If ARIKAYCE becomes an approved product for certain infections in CF patients or such infections in human pulmonary disease in the US, the Company will owe a payment to CFFT of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; that is payable over a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year period after regulatory approval in the US. Furthermore, if certain global sales milestones are met within &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the drug's commercialization, the Company would owe an additional payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Because there is significant development and regulatory risk associated with ARIKAYCE, including with respect to the CF indication, the Company has not accrued these obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Therapure Biopharma&#160;Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In February 2014, the Company entered into a contract manufacturing agreement with Therapure Biopharma&#160;Inc. (Therapure) for the manufacture of ARIKAYCE, on a non-exclusive basis, at a 200 kg scale. Pursuant to the agreement, the Company and Therapure collaborated to construct a production area for the manufacture of ARIKAYCE in Therapure's existing manufacturing facility in Canada. The agreement has an initial term of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which began in October 2018, and will renew automatically for successive periods of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; each, unless terminated by either party by providing the required &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; prior written notice to the other party. Notwithstanding the foregoing, the parties have rights and obligations under the agreement prior to the commencement of the initial term. Under the agreement, the Company is obligated to pay certain minimum amounts for the batches of ARIKAYCE produced each calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;PARI Pharma&#160;GmbH&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In July 2014, the Company entered into a Commercialization Agreement with PARI for the manufacture and supply of Lamira Nebulizer Systems and related accessories (the Device) as optimized for use with ARIKAYCE. Under the Commercialization Agreement, PARI manufactures the Device except in the case of certain defined supply failures, when the Company will have the right to make the Device and have it made by third parties (but not certain third parties deemed under the Commercialization Agreement to compete with PARI). The Commercialization Agreement has an initial term of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;fifteen years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the first commercial sale of ARIKAYCE in October 2018 (the Initial Term). The term of the agreement may be extended by the Company for an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; by providing written notice to PARI at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; prior to the expiration of the Initial Term. Notwithstanding the foregoing, the parties have certain rights and obligations under the agreement prior to the commencement of the Initial Term. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;SynteractHCR,&#160;Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In December 2014, the Company entered into a services agreement with SynteractHCR,&#160;Inc. (Synteract) pursuant to which the Company retained Synteract to perform implementation and management services in connection with the CONVERT study. The Company anticipates that aggregate costs relating to all work orders for the CONVERT study will be approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$48 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; over the period of the study. In April 2015, the Company entered into a work order with Synteract to perform implementation and management services for the completed 312 study. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Ajinomoto Althea,&#160;Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In September 2015, the Company entered into a Commercial Fill/Finish Services Agreement (the Fill/Finish Agreement) with Ajinomoto Althea,&#160;Inc., a Delaware corporation (Althea), for Althea to produce, on a non-&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;exclusive basis, ARIKAYCE in finished dosage form at a 50 kg scale. Under the Fill/Finish Agreement, the Company is obligated to pay a minimum of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the batches of ARIKAYCE produced by Althea each calendar year during the term of the Fill/Finish Agreement. The Fill/Finish Agreement became effective as of January&#160;1, 2015, and following an extension in 2018, is expected to remain in effect through December 31, 2021. The Fill/Finish Agreement may be extended for additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;two&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year periods upon mutual written agreement of the Company and Althea at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; prior to the expiration of its then-current term. The Company has expensed at least the required minimum in each year of the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;AstraZeneca AB&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In October 2016, the Company entered into a license agreement (AZ License Agreement) with AstraZeneca AB, a Swedish corporation (AstraZeneca). Pursuant to the terms of the AZ License Agreement, AstraZeneca granted the Company exclusive global rights for the purpose of developing and commercializing AZD7986 (renamed INS 1007). In consideration of the licenses and other rights granted by AstraZeneca, the Company made an upfront payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$30.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was included as research and development expense in the fourth quarter of 2016. The Company is also obligated to make a series of contingent milestone payments totaling up to an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$85.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of clinical development and regulatory filing milestones. If the Company elects to develop INS1007 for a second indication, the Company will be obligated to make an additional series of contingent milestone payments to AstraZeneca totaling up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$42.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company is not obligated to make any additional milestone payments for additional indications. In addition, the Company will pay AstraZeneca tiered royalties ranging from a high single-digit to mid-teens on net sales of any approved product based on INS1007 and one additional payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upon the first achievement of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in annual net sales. The AZ License Agreement provides AstraZeneca with the option to negotiate a future agreement with the Company for commercialization of INS1007 in chronic obstructive pulmonary disease or asthma.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Patheon UK Limited&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In October 2017, the Company entered into certain agreements with Patheon UK Limited (Patheon) related to the increase of its long-term production capacity for ARIKAYCE commercial inventory. The agreements provide for Patheon to manufacture and supply ARIKAYCE for its anticipated commercial needs.&#160;Under these agreements, the Company is required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.&#160;Patheon's supply obligations will commence once certain technology transfer and construction services are completed. The Company's manufacturing and supply agreement with Patheon will remain in effect for a fixed initial term, after which it will continue for successive renewal terms unless either party has given written notice of termination. The technology transfer agreement will expire when the parties agree that the technology transfer services have been completed. The agreements may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party&#x2019;s insolvency. These early termination clauses may reduce the amounts due to the relevant parties. The investment in our long-term production capacity build-out, including under the Patheon agreements and related agreements or purchase orders with third parties for raw materials and fixed assets, is estimated to be approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$60 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Syneos Health&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;We entered into a services agreement with Syneos Health (Syneos) pursuant to which we retained Syneos to perform implementation and management services in connection with the WILLOW study. We may terminate the services agreement or any work order for any reason and without cause with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;30&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;days' written notice. Either party may terminate the agreement in the event of a material breach or bankruptcy petition by the other party or, if any approval from a regulatory authority is revoked, suspended or expires without renewal. We anticipate that aggregate costs relating to all work orders for the WILLOW study will be approximately $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21 million&lt;/span&gt;&lt;/span&gt; over the period of the study.</insm:LicenseAndOtherAgreementsTextBlock>
    <insm:CollaborativeArrangementMilestonePayment
      contextRef="D2008Q2APR01-APR30_insm_MilestonePaymentAxis_insm_MilestoneNewDrugApplicationMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember"
      decimals="-5"
      id="d15041899e867-wk-Fact-8231AF3BFC2D1767D64B3DB34ED45698"
      unitRef="eur">1000000.0</insm:CollaborativeArrangementMilestonePayment>
    <insm:CollaborativeArrangementMilestonePayment
      contextRef="D2008Q2APR01-APR30_insm_MilestonePaymentAxis_insm_MilestoneFDAApprovalMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember"
      decimals="-5"
      id="d15041899e871-wk-Fact-2AFF5A23580BA099B95A3DB5A8652A00"
      unitRef="eur">1500000</insm:CollaborativeArrangementMilestonePayment>
    <insm:FutureMilestonePayments
      contextRef="D2008Q2APR01-APR30_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember"
      decimals="-5"
      id="d15041899e875-wk-Fact-91D8CA90EB8DD074F8A4C80C6469D566"
      unitRef="eur">500000</insm:FutureMilestonePayments>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="D2004Q4JAN01-DEC31_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember"
      decimals="-5"
      id="d15041899e887-wk-Fact-449532D80D6940A58C16C80C645FB992"
      unitRef="usd">1700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="D2009Q4JAN01-DEC31_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember"
      decimals="-5"
      id="d15041899e891-wk-Fact-C2F10591422A8589C84BC80C64657FC6"
      unitRef="usd">2200000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember"
      decimals="-5"
      id="d15041899e895-wk-Fact-24930568D6F37823638EC80C64625B18"
      unitRef="usd">13400000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <insm:PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember"
      id="d15041899e903-wk-Fact-ABDAE9E69617627AB77DC80C646C8B6F">P5Y</insm:PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments>
    <insm:AdditionalRoyaltyGuaranteesCommitmentsAmount
      contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember"
      decimals="-5"
      id="d15041899e908-wk-Fact-A6BFCF0D300C69C57772C80C64720C47"
      unitRef="usd">3900000</insm:AdditionalRoyaltyGuaranteesCommitmentsAmount>
    <insm:InitialTermOfContractManufacturingAgreement
      contextRef="D2014Q1FEB01-FEB28_us-gaap_TypeOfArrangementAxis_insm_TherapureBiopharmaIncContractManufacturingAgreementMember"
      id="d15041899e917-wk-Fact-B0E85922C30ADA064F21C80C6468A8A1">P5Y</insm:InitialTermOfContractManufacturingAgreement>
    <insm:PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement
      contextRef="D2014Q1FEB01-FEB28_us-gaap_TypeOfArrangementAxis_insm_TherapureBiopharmaIncContractManufacturingAgreementMember"
      id="d15041899e921-wk-Fact-11534175543AA7149C83C80C645E16DA">P2Y</insm:PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement>
    <insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement
      contextRef="D2014Q1FEB01-FEB28_us-gaap_TypeOfArrangementAxis_insm_TherapureBiopharmaIncContractManufacturingAgreementMember"
      id="d15041899e925-wk-Fact-B02853FA6B35B9A35D6AC80C6479EB6C">P2Y</insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement>
    <insm:InitialTermOfContractManufacturingAgreement
      contextRef="D2014Q3JUL01-JUL31_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember"
      id="d15041899e934-wk-Fact-94EF42EA00544446BA28C80C646CE818">P15Y</insm:InitialTermOfContractManufacturingAgreement>
    <insm:AdditionalTermOfContractManufacturingAgreement
      contextRef="D2014Q3JUL01-JUL31_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember"
      id="d15041899e938-wk-Fact-467BF003E34E70CBFFF8C80C646E3B17">P5Y</insm:AdditionalTermOfContractManufacturingAgreement>
    <insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement
      contextRef="D2014Q3JUL01-JUL31_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember"
      id="d15041899e942-wk-Fact-AF168650A8EAF29D9261C80C646DDE39">P1Y</insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement>
    <insm:ImplementationAndManagementServicesAgreementAggregateCosts
      contextRef="D2014Q4DEC01-DEC31_us-gaap_TypeOfArrangementAxis_insm_AgreementWithSynteractHCRInc.For212StudyMember"
      decimals="-6"
      id="d15041899e951-wk-Fact-F5B43375E96A940E3210C8ABE2CE8E31"
      unitRef="usd">48000000</insm:ImplementationAndManagementServicesAgreementAggregateCosts>
    <insm:CommercialServicesAgreementMinimumObligation
      contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_insm_CommercialFilVFinishServicesAgreementMember"
      decimals="-5"
      id="d15041899e963-wk-Fact-9004DB6DFC94A95D118CC80C64639A51"
      unitRef="usd">2700000</insm:CommercialServicesAgreementMinimumObligation>
    <insm:CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_insm_CommercialFilVFinishServicesAgreementMember"
      id="d15041899e971-wk-Fact-819E348014904F3272FEC80C64255773">P1Y</insm:CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement>
    <insm:CollaborativeArrangementUpfrontPayment
      contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember"
      decimals="-5"
      id="d15041899e980-wk-Fact-2A0C43EC1621B4671C43C80C646BC396"
      unitRef="usd">30000000.0</insm:CollaborativeArrangementUpfrontPayment>
    <insm:PaymentsUponAchievementOfClinicalMilestonesAmount
      contextRef="I2016Q4OCT31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember"
      decimals="-5"
      id="d15041899e984-wk-Fact-42F520FC9C0BA5FE308EC80C6470FE22"
      unitRef="usd">85000000.0</insm:PaymentsUponAchievementOfClinicalMilestonesAmount>
    <insm:CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication
      contextRef="I2016Q4OCT31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember"
      decimals="-5"
      id="d15041899e988-wk-Fact-C572ECD5B03DF56C3826C80C6464378B"
      unitRef="usd">42500000</insm:CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication>
    <us-gaap:PaymentsForRoyalties
      contextRef="D2016Q4OCT01-OCT31_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember"
      decimals="-5"
      id="d15041899e992-wk-Fact-B046254C37B3AAFC226FC80C64674628"
      unitRef="usd">35000000.0</us-gaap:PaymentsForRoyalties>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="D2016Q4OCT01-OCT31_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_insm_LicenseAgreementWithAstrazenecaMember"
      decimals="-8"
      id="d15041899e996-wk-Fact-04A9B9406BDE7AA25D25C80C64656F7C"
      unitRef="usd">1000000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <insm:ManufactureAndSupplyAgreementEstimatedCosts
      contextRef="I2017Q4Oct31_us-gaap_TypeOfArrangementAxis_insm_SupplyAgreementWithPatheonUKLimitedMember"
      decimals="-6"
      id="d15041899e1008-wk-Fact-A2292B807609BAD04D44C80C645C5691"
      unitRef="usd">60000000</insm:ManufactureAndSupplyAgreementEstimatedCosts>
    <insm:ImplementationAndManagementServicesAgreementAggregateCosts
      contextRef="D2014Q4DEC01-DEC31_us-gaap_TypeOfArrangementAxis_insm_AgreementWithSyneosHealthForWillowStudyMember"
      decimals="-6"
      id="d15041899e1021-wk-Fact-DEF136E62D8AEC8A9CB19BCCBAB0838B"
      unitRef="usd">21000000</insm:ImplementationAndManagementServicesAgreementAggregateCosts>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-7F4957570EDEAE041985C80C648F8A81-0-wk-Fact-A0623F012E15BF946845C80C647D832F">Commitments and Contingencies&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has an operating lease for office and laboratory space located in Bridgewater, NJ for which the initial lease term expires in November 2019. Future minimum rental payments under this lease are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In July 2016, the Company signed an operating lease for additional laboratory space located in Bridgewater, NJ for which the initial lease term expires in September 2021. In October 2018, the Company expanded its lease for additional laboratory space located in Bridgewater, NJ. Future minimum rental payments under this, and the initial lease, are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In September 2018, the Company entered into a new lease for its new corporate headquarters in Bridgewater, NJ for which the initial lease term expires in June 2030. Future minimum rental payments under this lease are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$32.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Rent expense charged to operations was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Rent expense is recorded on a straight-line basis over the term of the applicable leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under the Company's lease obligations as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,568&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition to rent, the Company has several firm purchase commitments, primarily related to the manufacturing of ARIKAYCE and annual minimum royalties on global net sales of ARIKAYCE. Future firm purchase commitments under these agreements, the last of which ends in 2034, total &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$86.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. These amounts do not represent our entire anticipated purchases in the future, but instead represent only purchases that are the subject of contractually obligated minimum purchases. The minimum commitments disclosed are determined based on noncancelable minimum spend amounts or termination amounts.  Additionally, we purchase products and services as needed with no firm commitment. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#x2019;s consolidated financial position, results of operations or cash flows.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_insm_BridgewaterNewJerseyFacilityMember"
      decimals="-5"
      id="d15040144e865-wk-Fact-B25CD4D8F2F0902D75EBC80C647C5D8F"
      unitRef="usd">1000000.0</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <insm:AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_insm_BridgewaterNewJerseyFacilityMember"
      decimals="-5"
      id="d15040144e869-wk-Fact-093EF3BAE16B48448E9514F1D9A076AA"
      unitRef="usd">3300000</insm:AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue>
    <insm:AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2017Q4_srt_StatementGeographicalAxis_insm_BridgewaterNewJerseyFacilityMember"
      decimals="-5"
      id="d15040144e873-wk-Fact-F494A5C5C33D014644A5C80C646A20E2"
      unitRef="usd">32300000</insm:AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:LeaseAndRentalExpense
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d15040144e880-wk-Fact-E0A86B482BD89E3E25FBC80C646A085F"
      unitRef="usd">2100000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d15040144e884-wk-Fact-ECCB17DF577AB547E9CBC80C647C8F22"
      unitRef="usd">1500000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="FD2016Q4YTD"
      decimals="-5"
      id="d15040144e888-wk-Fact-60EDD9920E9A1C2D8171C80C647E2795"
      unitRef="usd">1200000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-E377FC6D37F457A784BCC80C64907244-0-wk-Fact-009D289585101805A8F8C80C647D95D2">Future minimum lease payments under the Company's lease obligations as of &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,568&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15040144e961-wk-Fact-E65AD37091A1E99DCCB7C80C6470AFE2"
      unitRef="usd">3125000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15040144e976-wk-Fact-AA357D7C336BE01AD569C80C646FDC33"
      unitRef="usd">4919000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15040144e996-wk-Fact-A177FE240A0487679743C80C648008CC"
      unitRef="usd">4568000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15040144e1016-wk-Fact-D4B789D3C5792A692BA4C80C645C35D0"
      unitRef="usd">2027000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15040144e1036-wk-Fact-86C797892F13D13EDC27C80C6478AB76"
      unitRef="usd">24036000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d15040144e1061-wk-Fact-4468B71805DBFC045FA6C80C646740C3"
      unitRef="usd">38675000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:PurchaseObligation
      contextRef="FI2018Q4"
      decimals="-5"
      id="d15040144e1074-wk-Fact-5260BE62EE8523E88878810C8021F3F4"
      unitRef="usd">86400000</us-gaap:PurchaseObligation>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-93D1F321A267523A7D48C80C6490AD8B-0-wk-Fact-8D66CDD70BF60BCA6D39C80C6480B4F8">Quarterly Financial Data (Unaudited)&lt;div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes unaudited quarterly financial data for the years ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands, except per share data).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,835&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,835&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of product revenues*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(62,751&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(72,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(87,722&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(307,338&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(68,524&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(76,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(87,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(91,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(324,277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of product revenues*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(35,969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(43,515&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(44,083&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(65,353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(188,920&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(37,414&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(44,672&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(45,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(65,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(192,649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:81px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*   Excludes amortization of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:81px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;** Includes a one-time payment in October 2017 related to the buy-down of royalties payable to PARI on the global net sales of ARIKAYCE.&lt;/span&gt;&lt;/div&gt;Basic and diluted net loss per share amounts included in the above table were computed independently for each of the quarters presented. Accordingly, the sum of the quarterly basic and diluted net loss per share amounts may not agree to the total for the year.</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-FB55405ED03A56D04676C80C649091A9-0-wk-Fact-E67687394E8C1112B840C80C6428EE45">The following table summarizes unaudited quarterly financial data for the years ended &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands, except per share data).&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,835&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,835&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of product revenues*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(62,751&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(72,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(83,983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(87,722&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(307,338&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(68,524&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(76,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(87,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(91,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(324,277&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarter**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of product revenues*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(35,969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(43,515&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(44,083&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(65,353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(188,920&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(37,414&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(44,672&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(45,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(65,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(192,649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:81px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*   Excludes amortization of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;text-indent:81px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;** Includes a one-time payment in October 2017 related to the buy-down of royalties payable to PARI on the global net sales of ARIKAYCE.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q1YTD"
      decimals="-3"
      id="d15044529e1130-wk-Fact-B4BA31C3951C92EF2542C80C64376E80"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d15044529e1149-wk-Fact-4B60665E9AF306818D4FC80C647AAB5F"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d15044529e1168-wk-Fact-897DC7D226AA5D8DEE4CC80C646E98D1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4QTD"
      decimals="-3"
      id="d15044529e1188-wk-Fact-82571F1E6C67BFD384C0C80C647AFE67"
      unitRef="usd">9835000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15044529e1207-wk-Fact-0CE9CA24C5A1FC8486371AD4F405D7F5"
      unitRef="usd">9835000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q1YTD"
      decimals="-3"
      id="d15044529e1227-wk-Fact-E8312B778B1F1B49E7A3033F6114A3C7"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d15044529e1246-wk-Fact-07CB1B59188C52F91543033F610CFC28"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d15044529e1265-wk-Fact-7D1AD6291EEAF40173C9033F61189A6E"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q4QTD"
      decimals="-3"
      id="d15044529e1285-wk-Fact-12EAE753A99C06FC09AF033F611097CB"
      unitRef="usd">2423000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15044529e1304-wk-Fact-5ABE2B07153213A344EC1ADE1929033C"
      unitRef="usd">2423000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q1YTD"
      decimals="-3"
      id="d15044529e1324-wk-Fact-5984FC3E94A5368EDF9BC80C641B3794"
      unitRef="usd">-62751000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d15044529e1344-wk-Fact-0CC5FA57DFCCCA2D75B6C80C6456516B"
      unitRef="usd">-72882000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d15044529e1364-wk-Fact-F8742BA27F81ACA66BE7C80C6476507D"
      unitRef="usd">-83983000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q4QTD"
      decimals="-3"
      id="d15044529e1385-wk-Fact-61FAE81285CFC56321CEC80C645D2464"
      unitRef="usd">-87722000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15044529e1405-wk-Fact-94636DE7E0B2D950EF3EC80C64407EF0"
      unitRef="usd">-307338000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q1YTD"
      decimals="-3"
      id="d15044529e1426-wk-Fact-D7752B30B2EC5C85A0A2C80C647B0D04"
      unitRef="usd">-68524000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d15044529e1446-wk-Fact-6B67474644AAAFF8B931C80C6472D5B7"
      unitRef="usd">-76437000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d15044529e1466-wk-Fact-82C2127E1AFBA750992AC80C6478C7AE"
      unitRef="usd">-87743000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4QTD"
      decimals="-3"
      id="d15044529e1487-wk-Fact-1205D822AEF71B9B8696C80C64736800"
      unitRef="usd">-91573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-3"
      id="d15044529e1507-wk-Fact-B42634276C7A9632D85AC80C6434F487"
      unitRef="usd">-324277000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q1YTD"
      decimals="2"
      id="d15044529e1528-wk-Fact-6BEC1180FE51BDEE37CBC80C646D16F8"
      unitRef="usdPerShare">-0.89</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q2QTD"
      decimals="2"
      id="d15044529e1548-wk-Fact-E458D441137EB9E087A3C80C6474017A"
      unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d15044529e1568-wk-Fact-60D1AB8879185E217254C80C64777C0B"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q4QTD"
      decimals="2"
      id="d15044529e1589-wk-Fact-F95353F7DF17A5E24908C80C64766C5A"
      unitRef="usdPerShare">-1.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d15044529e1609-wk-Fact-518DC39F637E8302275EC80C64362527"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q1QTD"
      decimals="-3"
      id="d15044529e1876-wk-Fact-2B073775EFD4A5559189C80C647518FF"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d15044529e1895-wk-Fact-FF66C5371B44947F9E0FC80C642ECC29"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d15044529e1914-wk-Fact-0074733BCA80AE23D651C80C64274A9F"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4QTD"
      decimals="-3"
      id="d15044529e1934-wk-Fact-66B5E4B8462B10A1CA16C80C647F3603"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15044529e1953-wk-Fact-386BA215910B5BD7882B19A235C5AC3A"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2017Q1QTD"
      decimals="-3"
      id="d15044529e1973-wk-Fact-7EDAECB07C8958FE6A32033FC8E5EB5B"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d15044529e1992-wk-Fact-FC3804240BE948B653CD033FC8EFABB8"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d15044529e2011-wk-Fact-1DB4208886274C4135F7033FC8F84A78"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2017Q4QTD"
      decimals="-3"
      id="d15044529e2031-wk-Fact-A2597345888D2BFFE8AB033FC8FFB51C"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15044529e2050-wk-Fact-4000BD3A37997FB14A771ADE19229D92"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q1QTD"
      decimals="-3"
      id="d15044529e2070-wk-Fact-1FC400B5269F5C274F78C80C648236F7"
      unitRef="usd">-35969000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d15044529e2090-wk-Fact-AF5E0BEBAD94C5918662C80C641C2F0F"
      unitRef="usd">-43515000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d15044529e2110-wk-Fact-BECC6E022579AC17CCE6C80C641D2718"
      unitRef="usd">-44083000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q4QTD"
      decimals="-3"
      id="d15044529e2131-wk-Fact-828EE623C8C8E9F81104C80C64746053"
      unitRef="usd">-65353000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15044529e2151-wk-Fact-9A1B732379CE71D1D61EC80C643B8C9A"
      unitRef="usd">-188920000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q1QTD"
      decimals="-3"
      id="d15044529e2172-wk-Fact-73DB1B2B31E889CB9F7FC80C641CB1E3"
      unitRef="usd">-37414000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d15044529e2192-wk-Fact-67DFD485E06F4B50E280C80C6426CB29"
      unitRef="usd">-44672000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d15044529e2212-wk-Fact-3ECF88A8B83601E96EA2C80C641FF407"
      unitRef="usd">-45179000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4QTD"
      decimals="-3"
      id="d15044529e2233-wk-Fact-7803669ADFA032789AF2C80C6420DD15"
      unitRef="usd">-65384000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-3"
      id="d15044529e2253-wk-Fact-04977BE1C74AC80F3F04C80C643AC548"
      unitRef="usd">-192649000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q1QTD"
      decimals="2"
      id="d15044529e2274-wk-Fact-28EDEAF9096D752F5A68C80C641B8ED2"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q2QTD"
      decimals="2"
      id="d15044529e2294-wk-Fact-B24D055AF08493BCB1BDC80C6424067A"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q3QTD"
      decimals="2"
      id="d15044529e2314-wk-Fact-8BA0CF5B87696B11287AC80C647E8F92"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q4QTD"
      decimals="2"
      id="d15044529e2335-wk-Fact-053B7678166B7C5E831EC80C6422B48B"
      unitRef="usdPerShare">-0.85</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d15044529e2355-wk-Fact-E7AA589AA67B3269D3FEC80C6440E3D2"
      unitRef="usdPerShare">-2.89</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="FD2018Q4YTD"
      id="TextSelection-C8CC996C14031CF8CDC0C80C6490964F-0-wk-Fact-A08E10B3EDCD266A7362C80C643806B7">Retirement Plan&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has a 401(k) defined contribution plan for the benefit for all US employees and permits voluntary contributions by employees subject to IRS-imposed limitations. Effective January 1, 2018, the Company matched &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of eligible employee contributions on the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of employee salary (up to the IRS maximum). Employer contributions for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Prior to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company matched &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of eligible employee contributions on the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt; of employee salary (up to the IRS maximum).</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d15040134e862-wk-Fact-04A6AB6EFE21CFA63F9C57AFC44D068C"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d15040134e866-wk-Fact-2E55E68E9075B72EA718C80C6459F505"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="FD2018Q4YTD"
      decimals="-5"
      id="d15040134e883-wk-Fact-4661A070C3B56EF1E9FFC80C643B9A22"
      unitRef="usd">2200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="FD2017Q4YTD"
      decimals="-5"
      id="d15040134e887-wk-Fact-9011045E5301EC83A0E0C80C645FBAEF"
      unitRef="usd">800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="FD2016Q4YTD"
      decimals="-5"
      id="d15040134e891-wk-Fact-638E3DB25EF62068AC40C80C6444D131"
      unitRef="usd">600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="d15040134e901-wk-Fact-68B3F419D7E0D7BFCB8BC80C64452930"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="d15040134e905-wk-Fact-6241C33430D64BB595E0C80C643C072D"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797568464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 15, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSMED INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001104506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,538,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795673840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 495,072<span></span>
</td>
<td class="nump">$ 381,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">5,515<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">7,032<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,327<span></span>
</td>
<td class="nump">8,279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">518,946<span></span>
</td>
<td class="nump">389,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">58,675<span></span>
</td>
<td class="nump">58,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">22,636<span></span>
</td>
<td class="nump">12,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">4,299<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">604,556<span></span>
</td>
<td class="nump">462,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">17,741<span></span>
</td>
<td class="nump">14,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">38,254<span></span>
</td>
<td class="nump">17,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">22,208<span></span>
</td>
<td class="nump">12,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,529<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">79,732<span></span>
</td>
<td class="nump">44,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, long-term</a></td>
<td class="nump">316,558<span></span>
</td>
<td class="nump">55,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">396,290<span></span>
</td>
<td class="nump">100,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 500,000,000 authorized shares, 77,307,521 and 76,610,508 issued and outstanding shares at December 31, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">773<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,489,664<span></span>
</td>
<td class="nump">1,318,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,282,162)<span></span>
</td>
<td class="num">(957,885)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">208,266<span></span>
</td>
<td class="nump">361,059<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 604,556<span></span>
</td>
<td class="nump">$ 462,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6950989952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="nump">77,307,521<span></span>
</td>
<td class="nump">76,610,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="nump">77,307,521<span></span>
</td>
<td class="nump">76,610,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797481552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 9,835<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product revenues (excluding amortization of intangible assets)</a></td>
<td class="nump">2,423<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">145,283<span></span>
</td>
<td class="nump">109,749<span></span>
</td>
<td class="nump">122,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">168,218<span></span>
</td>
<td class="nump">79,171<span></span>
</td>
<td class="nump">50,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,249<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">317,173<span></span>
</td>
<td class="nump">188,920<span></span>
</td>
<td class="nump">173,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(307,338)<span></span>
</td>
<td class="num">(188,920)<span></span>
</td>
<td class="num">(173,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Investment income</a></td>
<td class="nump">10,341<span></span>
</td>
<td class="nump">1,624<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(25,472)<span></span>
</td>
<td class="num">(5,925)<span></span>
</td>
<td class="num">(3,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(2,209)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(324,076)<span></span>
</td>
<td class="num">(192,921)<span></span>
</td>
<td class="num">(176,175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">201<span></span>
</td>
<td class="num">(272)<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (324,277)<span></span>
</td>
<td class="num">$ (192,649)<span></span>
</td>
<td class="num">$ (176,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss (in dollars per share)</a></td>
<td class="num">$ (4.22)<span></span>
</td>
<td class="num">$ (2.89)<span></span>
</td>
<td class="num">$ (2.85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average basic and diluted common shares outstanding (in shares)</a></td>
<td class="nump">76,889<span></span>
</td>
<td class="nump">66,576<span></span>
</td>
<td class="nump">61,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (324,277)<span></span>
</td>
<td class="num">$ (192,649)<span></span>
</td>
<td class="num">$ (176,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation (losses) gains</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (324,283)<span></span>
</td>
<td class="num">$ (192,587)<span></span>
</td>
<td class="num">$ (176,338)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797989712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 311,698<span></span>
</td>
<td class="nump">$ 618<span></span>
</td>
<td class="nump">$ 900,043<span></span>
</td>
<td class="num">$ (588,963)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(176,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1,084<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">162,340<span></span>
</td>
<td class="nump">162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">18,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">154,483<span></span>
</td>
<td class="nump">$ 620<span></span>
</td>
<td class="nump">919,164<span></span>
</td>
<td class="num">(765,236)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,020,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(192,649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192,649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 3,433<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">3,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">378,275<span></span>
</td>
<td class="nump">379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 377,656<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">377,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">18,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">361,059<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">1,318,181<span></span>
</td>
<td class="num">(957,885)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,611,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(324,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(324,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 8,815<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">8,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">494,351<span></span>
</td>
<td class="nump">645,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible debt issuance</a></td>
<td class="nump">$ 136,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">26,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 208,266<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">$ 1,489,664<span></span>
</td>
<td class="num">$ (1,282,162)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797930032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (324,277)<span></span>
</td>
<td class="num">$ (192,649)<span></span>
</td>
<td class="num">$ (176,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,577<span></span>
</td>
<td class="nump">2,901<span></span>
</td>
<td class="nump">2,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,249<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">26,240<span></span>
</td>
<td class="nump">18,073<span></span>
</td>
<td class="nump">18,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">2,209<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of debt discount</a></td>
<td class="nump">15,889<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion of back-end fee on debt</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(5,515)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(7,032)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(5,514)<span></span>
</td>
<td class="num">(2,783)<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,870<span></span>
</td>
<td class="nump">3,604<span></span>
</td>
<td class="nump">2,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities', window );">Accrued expenses and other</a></td>
<td class="nump">19,916<span></span>
</td>
<td class="nump">5,201<span></span>
</td>
<td class="nump">3,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">10,011<span></span>
</td>
<td class="nump">5,260<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(257,977)<span></span>
</td>
<td class="num">(159,617)<span></span>
</td>
<td class="num">(146,708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(13,090)<span></span>
</td>
<td class="num">(3,001)<span></span>
</td>
<td class="num">(4,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">PARI milestone upon FDA approval</a></td>
<td class="num">(1,724)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(14,814)<span></span>
</td>
<td class="num">(3,001)<span></span>
</td>
<td class="num">(4,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 1.75% convertible senior notes due 2025</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment on extinguishment of debt</a></td>
<td class="num">(2,835)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payment of debt</a></td>
<td class="num">(55,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">377,656<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options and ESPP</a></td>
<td class="nump">8,815<span></span>
</td>
<td class="nump">3,433<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(14,237)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(411)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">386,743<span></span>
</td>
<td class="nump">381,089<span></span>
</td>
<td class="nump">30,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rates on cash and cash equivalents</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">113,907<span></span>
</td>
<td class="nump">218,574<span></span>
</td>
<td class="num">(120,285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">381,165<span></span>
</td>
<td class="nump">162,591<span></span>
</td>
<td class="nump">282,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">495,072<span></span>
</td>
<td class="nump">381,165<span></span>
</td>
<td class="nump">162,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">6,289<span></span>
</td>
<td class="nump">5,165<span></span>
</td>
<td class="nump">3,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes, net</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75% Convertible Senior Note Due 2025 | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Proceeds from issuance of 1.75% convertible senior notes due 2025</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the sum of accrued expenses and Other Current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6933158016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text">Description of Business and Basis of Presentation<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Description of Business</span><span style="font-family:inherit;font-size:10pt;">&#8212;Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), received accelerated approval in the United States (US) on September 28, 2018 for the treatment of refractory </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Mycobacterium avium</span><span style="font-family:inherit;font-size:10pt;"> complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) with therapeutic potential in non-cystic fibrosis (non-CF) bronchiectasis and other inflammatory diseases. INS1009 is an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension (PAH).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, Ireland, Germany, France, the United Kingdom (UK), the Netherlands, Bermuda and Japan.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$495.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and reported a net loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$324.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Historically, the Company has funded its operations through public offerings of equity securities and debt financings. To date, the Company has not generated significant revenue from ARIKAYCE. The Company commenced commercial shipments in October 2018. The Company expects to continue to incur operating losses while funding commercial launch efforts for ARIKAYCE, research and development (R&amp;D) activities, regulatory submissions outside the US, and selling, general and administrative (SG&amp;A) expenses. The Company expects its future cash requirements to be substantial, and it may need to raise additional capital to fund operations, including the commercialization of ARIKAYCE and additional clinical trials related to ARIKAYCE, to develop INS1007 and INS1009 and to develop, acquire, in-license or co-promote other products that address orphan or rare diseases.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#8217;s commercial, regulatory and development activities. Any equity or debt financing will also be contingent upon equity and debt market conditions and interest rates at the time. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts. The Company believes it currently has sufficient funds to meet its financial needs for at least the next 12&#160;months.</span></div><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span>&#8212;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Insmed Limited, Celtrix Pharmaceuticals,&#160;Inc., Insmed Holdings Limited, Insmed Ireland Limited, Insmed France SAS, Insmed Germany&#160;GmbH, Insmed Netherlands&#160;B.V., Insmed Bermuda Limited and Insmed Godo Kaisha. All intercompany transactions and balances have been eliminated in consolidation and certain prior year amounts have been restated to conform to the current year presentation. In the prior year, accrued compensation was presented within the accrued expense line in the consolidated balance sheet. In the current year, accrued compensation is presented as a discrete line on the face of the consolidated balance sheet.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6661246192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span><span style="font-family:inherit;font-size:10pt;">&#8212;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, and accounting for research and development costs. Actual results could differ from those estimates.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investment Income and Interest Expense</span><span style="font-family:inherit;font-size:10pt;">&#8212;Investment income consists of interest income earned on the Company's cash and cash equivalents. Interest expense consists primarily of interest costs related to the Company's debt.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span><span style="font-family:inherit;font-size:10pt;">&#8212;The Company considers cash equivalents to be highly liquid investments with maturities of three months or less from the date of purchase.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fixed Assets, Net</span><span style="font-family:inherit;font-size:10pt;">&#8212;Fixed assets are recorded at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. Estimated useful lives of </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> are used for computer equipment. Estimated useful lives of </span><span style="font-family:inherit;font-size:10pt;"><span>seven years</span></span><span style="font-family:inherit;font-size:10pt;"> are used for laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Identifiable Intangible Assets</span><span style="font-family:inherit;font-size:10pt;">&#8212;Identifiable intangible assets are measured at their respective fair values and began amortizing over their estimated useful lives upon commercialization. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. Unanticipated events or circumstances may occur that may require the Company to review the assets for impairment. Events or circumstances that may require an impairment assessment include negative clinical trial results, the non-approval of a new drug application by a regulatory agency, material delays in the Company's development program or a sustained decline in market capitalization. The Company performs its annual impairment test as of October&#160;1 of each year.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company performed a qualitative assessment to evaluate whether there was an impairment of the assets. This assessment did not identify any indicators of impairment of the intangible assets as of that date.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Debt Issuance Costs</span><span style="font-family:inherit;font-size:10pt;">&#8212;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;">&#8212;The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's only financial assets and liabilities which were measured at fair value as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> were Level 1 assets comprised of cash and cash equivalents. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.04873294346979%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> transfers in or out of Level&#160;1, Level&#160;2 or Level&#160;3 during </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company held </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> securities that were in an unrealized loss or gain position.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the security was rated below investment grade; (3)&#160;how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of the liability component of the </span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2025 (the Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$313.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the Convertible Notes. The </span><span style="font-family:inherit;font-size:10pt;"><span>$316.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> carrying value of the Convertible Notes as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> excludes the $</span><span style="font-family:inherit;font-size:10pt;"><span>125.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the unamortized portion of the debt discount.  </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency</span><span style="font-family:inherit;font-size:10pt;">&#8212;The Company has operations in the US, Ireland, Germany, France, the UK, the Netherlands and Japan. The results of its non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' equity, as a component of other comprehensive loss.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company realizes foreign currency transaction gains (losses) in the normal course of business based on movements in the applicable exchange rates. These gains (losses) are included as a component of other income, net.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</span><span style="font-family:inherit;font-size:10pt;">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:17px;padding-top:17px;text-align:center;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:357px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:181px;"/><td style="width:176px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage of Total Gross Product Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company did not have product revenue prior to US FDA approval of ARIKAYCE in 2018. The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially impact future operating results.</span></div><div style="line-height:120%;text-align:left;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">&#8212;In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company did not incur or capitalize any incremental costs associated with obtaining contracts with customers.</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenues consist primarily of sales of ARIKAYCE in the US. Product revenues are recognized once the Company performs and satisfies all five steps mentioned above. In October 2018, the Company began shipping ARIKAYCE to its customers in the US, which include specialty pharmacies and specialty distributors.&#160;The Company recognizes revenues for product received by its customers net of allowances for customer credits, including estimated rebates, chargebacks, prompt pay discounts, returns, service fees, and government rebates, such as Medicaid rebates and Medicare Part D coverage gap reimbursements in the US.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Customer credits:</span><span style="font-family:inherit;font-size:10pt;">&#160;The Company&#8217;s customers are offered various forms of consideration, including service fees and prompt payment discounts. The Company anticipates that its customers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total gross product revenues when revenues are recognized. Service fees are also deducted from total gross product revenues as they are earned.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Rebates:</span><span style="font-family:inherit;font-size:10pt;"> The Company contracts with Medicaid, other government agencies and various private organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized.</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-bottom:17px;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Chargebacks:</span><span style="font-family:inherit;font-size:10pt;"> Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price initially paid by the specialty distributor and the discounted price paid by the contracted customers. The Company estimates the chargebacks it provides to the specialty distributor and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized.</span></div><div style="line-height:120%;padding-bottom:17px;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Co-payment assistance:</span><span style="font-family:inherit;font-size:10pt;"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by a third-party administrator.</span></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any, or all, of the Company&#8217;s actual experience vary from the estimates above, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a summary roll-forward of our sales allowances and related accruals for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands), which have been deducted in arriving at net product revenue:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:53px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Customer fees, discounts and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rebates, chargebacks and co-pay assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Balance as of January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Allowances for current period sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,184</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;&#160;&#160;Payments and credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(262</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>688</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, upon US FDA approval of ARIKAYCE, the Company began recognizing revenue from sales to the French National Agency for Medicines and Health Products Safety (ANSM), which granted ARIKAYCE a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU). Pursuant to this program, the Company ships product to pharmacies after receiving requests from physicians for patients in France. The Company is initiating expanded access programs (EAPs) in Europe and other countries, some of which may be fully reimbursed. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory and cost of product revenues (excluding amortization of intangible assets)</span><span style="font-family:inherit;font-size:10pt;">&#8212;Inventory is stated at the lower of cost and net realizable value with cost determined on a standard costing method. The Company capitalized inventory costs following regulatory approval of ARIKAYCE from the FDA on September 28, 2018. Inventory is sold on a first-in, first out basis. Manufacturing variances, such as material usage variance and yield variance, are capitalized in inventory until the respective units are sold, at which point the variances are recognized in cost of product revenues. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, records a write-down accordingly. The Company also performs strict quality control throughout the manufacturing processes of products; however, certain batches or units of product may not meet quality specifications and result in a charge to cost of product revenues in the period incurred.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred; therefore, inventory is not included in the </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> consolidated balance sheet. Inventory that is used for clinical development purposes is expensed to research and development expense when consumed.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight-in, allocation of overhead costs, and inventory adjustment charges, in addition to royalty expenses due to PARI. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</span><span style="font-family:inherit;font-size:10pt;">&#8212;Research and development expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in the Company's research and development functions, and other internal operating expenses, the cost of manufacturing a drug candidate, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, research and development expenses include payments to third parties for the license rights to products in development (prior to marketing approval). The Company's expenses related to manufacturing its drug candidate and medical devices for clinical study are primarily related to activities at contract manufacturing organizations that manufacture ARIKAYCE, INS1007, and INS1009 and the medical devices for the Company's use. The Company's expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on the Company's behalf. These contracts set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</span><span style="font-family:inherit;font-size:10pt;">&#8212;The Company recognizes stock-based compensation expense for awards of equity instruments to employees and directors based on the grant-date fair value of those awards. The grant-date fair value of the award is recognized as compensation expense ratably over the requisite service period, which generally equals the vesting period of the award, and if applicable, is adjusted for expected forfeitures. The Company also grants performance-based stock options to employees. The grant-date fair value of the performance-based stock options is recognized as compensation expense over the implicit service period using the accelerated attribution method once it is probable that the performance condition will </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">be achieved. Stock-based compensation expense is included in both R&amp;D and SG&amp;A expenses in the consolidated statements of comprehensive loss.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;">&#8212;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A valuation allowance is recorded to reduce the deferred tax assets to the amount that is expected to be realized. In evaluating the need for a valuation allowance, the Company takes into account various factors, including the expected level of future taxable income and available tax planning strategies. If actual results differ from the assumptions made in the evaluation of a valuation allowance, the Company records a change in valuation allowance through income tax expense in the period such determination is made.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based solely on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than </span><span style="font-family:inherit;font-size:10pt;">50%</span><span style="font-family:inherit;font-size:10pt;"> likelihood to be sustained upon ultimate settlement. As any adjustment to the Company&#8217;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's policy for interest and penalties related to income tax exposures is to recognize interest and penalties as a component of the income tax provision (benefit) in the consolidated statements of comprehensive loss.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</span><span style="font-family:inherit;font-size:10pt;">&#8212;Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options and restricted stock units would be anti-dilutive as the Company incurred a net loss in all periods presented. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options would be determined based on the treasury stock method.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31,</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(324,277</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(176,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares used in calculation of basic net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,889</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,576</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding used in calculation of diluted net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,889</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.22</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.89</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.85</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> as their effect would have been anti-dilutive (in thousands).</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,609</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,492</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</span><span style="font-family:inherit;font-size:10pt;">&#8212;The Company currently operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment, which is the development and commercialization of therapies for patients with rare diseases. A single management team that reports to the Chief Executive Officer comprehensively manages the entire business. The Company does not operate separate lines of business with respect to its products or product candidates. Accordingly, the Company has </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> reportable segment.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Pronouncements (Adopted)</span><span style="font-family:inherit;font-size:10pt;">&#8212;In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</span><span style="font-family:inherit;font-size:10pt;">, which addressed eight specific cash flow issues with the objective of reducing the existing diversity in practice. Among the updates, the standard requires debt extinguishment costs to be classified as cash outflows for financing activities. This standard update became effective as of the first quarter of 2018. As a result of the adoption of the standard, in the first quarter of 2018, the Company reported a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on extinguishment of debt in the operating activities section of its consolidated statement of cash flows. The Company had no material debt extinguishment costs prior to the first quarter of 2018. The impact of adopting this standard was not material to the Company.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU&#160;2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span><span style="font-family:inherit;font-size:10pt;"> which amended the existing accounting standards for revenue recognition. ASU 2014-09 establishes principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services. In July 2015, the FASB deferred the effective date for annual reporting periods beginning after December&#160;15, 2017. The Company adopted ASU 2014-09 in the first quarter of 2018.  The adoption did not have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Pronouncements (Not Yet Adopted)</span><span style="font-family:inherit;font-size:10pt;">&#8212;In February 2016, the FASB issued ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018 (including interim periods within those periods) and early adoption is permitted. In August 2018, the FASB issued ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements to ASC 842</span><span style="font-family:inherit;font-size:10pt;">, which provides a new transition option in which an entity initially applies ASU 2016-02 at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will use the new transition option and will be also utilizing the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any expired or existing leases. The Company will also use the short-term lease exception for leases with a term of twelve months or less. Additionally, the Company expects to use the practical expedient that allows it to treat the lease and non-lease components of its leases as a single component. The Company has identified approximately ten leasing arrangements and estimates the impact on its consolidated balance sheet to be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$44 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$49 million</span></span><span style="font-family:inherit;font-size:10pt;">. There will be no adjustment recognized through retained earnings as a result of adoption. The Company will adopt ASU 2016-02 effective January 1, 2019, and is continuing to evaluate the impact of adoption on its consolidated financial statements and its internal control over financial reporting. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses</span><span style="font-family:inherit;font-size:10pt;"> which requires financial assets measured at an amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. ASU 2016-13 is effective for fiscal years effective for fiscal years after beginning after December 15, 2019. Different aspects of the guidance require modified </span></div>retrospective or prospective adoption. The Company is currently evaluating the impact of adoption on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6930747152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Company's inventory balance consists of the following (in thousands): </span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:407px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:274px;"/><td style="width:9px;"/><td style="width:119px;"/><td style="width:4px;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,567</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,032</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Inventory is stated at the lower of cost or net realizable value and consists of raw materials, work-in-process and finished goods. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE on September 28, 2018. The Company has not recorded any inventory write downs since that time. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6661245904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following:</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trial expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,398</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued technical operation expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,631</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued sales allowances and related costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>818</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued construction costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,946</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,719</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,254</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,142</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931784544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangibles, net</a></td>
<td class="text">Intangibles, net<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company's identifiable intangible assets consisted of acquired ARIKAYCE R&amp;D, formerly referred to as in-process research and development, and a milestone paid to PARI Pharma GmbH (PARI) for the license to use PARI's Lamira&#174; Nebulizer System for the delivery of ARIKAYCE to patients. The Company's only identifiable intangible asset was in-process research and development (IPRD) related to ARIKAYCE as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, which resulted from the initial amount recorded at the time of the Company's merger with Transave in 2010 and subsequent adjustments in the value. On September 28, 2018, as a result of the FDA approval of ARIKAYCE, the Company recorded a milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> due to PARI. Total intangible assets, net was </span><span style="font-family:inherit;font-size:10pt;"><span>$58.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$58.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the Acquired ARIKAYCE milestone, at the date of subsequent adjustments of fair value. The Company began amortizing its </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">intangible assets October 1, 2018, over ARIKAYCE's initial regulatory exclusivity period of </span><span style="font-family:inherit;font-size:10pt;"><span>12 years</span></span><span style="font-family:inherit;font-size:10pt;">. Amortization of intangible assets during each of the next five years is estimated to be approximately </span><span style="font-family:inherit;font-size:10pt;">$5.0 million</span><span style="font-family:inherit;font-size:10pt;"> per year. The Company performed its annual impairment test as of October&#160;1, 2018. The Company performed a qualitative assessment to evaluate whether there was an impairment of the assets. This assessment did not identify any indicators of impairment of the intangible assets as of that date.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A rollforward of the Company's intangible assets for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> follows:</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Intangible Asset</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">January 1,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Additions</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Acquired ARIKAYCE R&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,988</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PARI milestone upon FDA approval</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,724</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,687</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,724</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Intangible Asset</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">January 1,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Additions</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired ARIKAYCE IPRD</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657614672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets, net</a></td>
<td class="text">Fixed Assets, net<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Useful Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Asset Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lab equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,055</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer hardware and software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3&#160;-&#160;5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,796</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,436</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lease term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,939</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress (CIP)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,077</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,645</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed assets, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><span style="font-family:inherit;font-size:10pt;">Fixed assets, net of depreciation, increased to </span><span style="font-family:inherit;font-size:10pt;"><span>$22.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended December 31, 2018 from </span><span style="font-family:inherit;font-size:10pt;"><span>$12.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2017. The </span><span style="font-family:inherit;font-size:10pt;"><span>$10.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> increase was primarily due to </span><span style="font-family:inherit;font-size:10pt;"><span>$11.0 million</span></span> in construction in progress related to the long-term capacity build-out at the Patheon manufacturing facility.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6655521776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, the Company completed an underwritten public offering of the Convertible Notes, in which the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>$450.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of Convertible Notes, including the exercise in full of the underwriters' option to purchase additional Convertible Notes of </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$435.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On or after October&#160;15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their Convertible Notes at any time. Upon conversion, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The initial conversion rate is </span><span style="font-family:inherit;font-size:10pt;">25.5384</span><span style="font-family:inherit;font-size:10pt;"> shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$39.16</span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Holders may convert their Convertible Notes prior to October 15, 2024, only under the following circumstances, subject to the conditions set forth in an indenture, dated as of January 26, 2018, between the Company and Wells Fargo Bank, National Association (Wells Fargo), as trustee, as supplemented by the first supplemental indenture, dated January 26, 2018, between the Company and Wells Fargo (as supplemented, the Indenture): (i) during the </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> business day period immediately after any </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of convertible notes, as determined following a request by a holder of the convertible notes, for each trading day of the measurement period was less than </span><span style="font-family:inherit;font-size:10pt;"><span>98%</span></span><span style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than </span><span style="font-family:inherit;font-size:10pt;"><span>45</span></span><span style="font-family:inherit;font-size:10pt;"> days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company&#8217;s assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the Convertible Notes may be surrendered by a holder for conversion at any time from or after the date that is </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2018 (and only during such calendar quarter), the last reported sale price of the common stock for at least </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during the period of </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price on each applicable trading day, or, (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its Convertible Notes, to which the notice of redemption relates, for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in the convertible notes are not required to be separately accounted for as a derivative. However, since the Convertible Notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated equity component. The fair value was based on data from readily available pricing </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option was determined by deducting the fair value of the liability component from the gross proceeds of the Convertible Notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity&#8217;s own equity.  The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at </span><span style="font-family:inherit;font-size:10pt;"><span>$309.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> using an effective interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>7.6%</span></span><span style="font-family:inherit;font-size:10pt;">, and accordingly, the residual equity component on the date of issuance was </span><span style="font-family:inherit;font-size:10pt;"><span>$140.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. The discount is being amortized to interest expense over the term of the Convertible Notes and has a remaining period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>6.04 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">twelve months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, total interest expense related to the Convertible Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>$25.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount, as described in the table below. The following table presents the carrying value of the Company&#8217;s debt balance as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.8635477582846%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;1.75% convertible senior notes due 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;Debt issuance costs, unamortized</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,440</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;Discount on debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(125,002</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316,558</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:38.01169590643275%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December&#160;31:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the Company used part of the net proceeds from the issuance of the Convertible Notes to pay off its outstanding debt to Hercules Capital (Hercules). The payments to Hercules consisted of </span><span style="font-family:inherit;font-size:10pt;"><span>$55.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the principal amount and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in back-end fees, outstanding interest, and prepayment penalty fees, which resulted in a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on extinguishment of debt in the quarter ended March 31, 2018.&#160;&#160;&#160;&#160;</span></div><span style="font-family:inherit;font-size:10pt;">The estimated fair value of the debt (categorized as a Level&#160;2 liability for fair value measurement purposes) is determined using current market factors and the ability of the Company to obtain debt at comparable terms to those that are currently in place. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span>, the fair value of the Company's debt approximated the carrying amount.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6943278960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders' Equity<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span style="font-family:inherit;font-size:10pt;">&#8212;As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>500,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock authorized with a par value of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>77,307,521</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock issued and outstanding. In addition, as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had reserved </span><span style="font-family:inherit;font-size:10pt;"><span>9,381,730</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock for issuance upon the exercise of outstanding common stock options and </span><span style="font-family:inherit;font-size:10pt;"><span>227,826</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock for issuance upon the vesting of restricted stock units.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In&#160;September&#160;2017, the Company completed an underwritten public offering of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>14,123,150</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares of the Company&#8217;s common stock, which included the underwriter&#8217;s exercise in full of its over-allotment option of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>1,842,150</span></span><span style="font-family:inherit;font-size:10pt;"> shares, at a price to the public of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$28.50</span></span><span style="font-family:inherit;font-size:10pt;">&#160;per share.&#160; The Company&#8217;s net proceeds from the sale of the shares, after deducting underwriting discounts and offering expenses of&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$24.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$377.7 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</span><span style="font-family:inherit;font-size:10pt;">&#8212;As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>200,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock authorized with a par value of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span> shares of preferred stock were issued and outstanding.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6651883712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s current equity compensation plan, the 2017 Incentive Plan, was approved by shareholders at the Company&#8217;s Annual Meeting of Shareholders on May&#160;18, 2017.&#160;The 2017 Incentive Plan is administered by the Compensation Committee and the Board of Directors of the Company.&#160;Under the terms of the 2017 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards, as well as pay incentive bonuses to eligible employees and non-employee directors.&#160;On May&#160;18, 2017, upon the approval of the 2017 Incentive Plan by shareholders,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>5,000,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. As of&#160;</span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">,&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>3,622,830</span></span><span style="font-family:inherit;font-size:10pt;">&#160;shares remained for future issuance under the 2017 Incentive Plan. The 2017 Incentive Plan will terminate on April&#160;3, 2027 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options.&#160;These awards are made pursuant to the Nasdaq inducement grant exception as a component of new hires&#8217; employment compensation in connection with the Company&#8217;s equity grant program. During the&#160;</span><span style="font-family:inherit;font-size:10pt;">twelve months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company granted inducement stock options covering </span><span style="font-family:inherit;font-size:10pt;"><span>295,720</span></span><span style="font-family:inherit;font-size:10pt;">&#160;and </span><span style="font-family:inherit;font-size:10pt;"><span>266,230</span></span><span style="font-family:inherit;font-size:10pt;">, respectively,&#160;shares of the Company's common stock to new employees.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</span><span style="font-family:inherit;font-size:10pt;">&#8212;The Company calculates the fair value of stock options granted using the Black-Scholes valuation model. The following table summarizes the grant date fair value and assumptions used in determining the fair value of all stock options granted, including grants of inducement options, during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:373px;"/><td style="width:100px;"/><td style="width:5px;"/><td style="width:100px;"/><td style="width:5px;"/><td style="width:100px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66% - 68%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71% - 79%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74% - 77%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25% - 2.96%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.73% - 2.13%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.00% - 1.90%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected option term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.09</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.25</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.25</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average fair value of stock options granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$10.52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.77</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, the volatility factor was based on the Company&#8217;s historical volatility during the expected option term.&#160;Estimated forfeitures were based on the actual percentage of option forfeitures since the closing of the Company&#8217;s merger with Transave, Inc. in December&#160;2010 for the year ended </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">. Beginning with the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, estimated forfeitures were based on the actual percentage of option forfeitures over the expected option term.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company grants performance-condition options to certain employees. Vesting of these options is subject to the Company achieving certain performance criteria established at the date of grant and the individuals fulfilling a service condition (continued employment). As a result of the FDA approval of ARIKAYCE in September 2018, the vesting of performance options totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded as non-cash compensation expense in the third quarter of </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity for stock options granted for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:321px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:72px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:86px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:72px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Life in Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in '000)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at January 1, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,273,722</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,532,675</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162,340</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited and expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(527,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,116,706</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,850,658</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,113,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Options outstanding at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,116,706</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,284,710</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(378,275</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited and expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(414,220</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Options outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,608,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,325,255</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Exercisable at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,229,478</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,608,921</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,755,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(494,351</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited and expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(488,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,381,730</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.69</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,052</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,693,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,926</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,649,698</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.58</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,181</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total intrinsic value of stock options exercised during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$29.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.4 years</span></span><span style="font-family:inherit;font-size:10pt;">. The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding as of December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable as of<br/>December&#160;31, 2018</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of<br/>Exercise Prices</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of<br/>Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted<br/>Average<br/>Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of<br/>Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>960,038</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>960,038</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.13</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>953,089</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>604,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>947,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.72</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>887,207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>967,420</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>455,114</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,142,513</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.76</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>782,818</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,380,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>687,691</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,387,909</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.51</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,081,677</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355,366</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,644</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.60</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,069</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock and Restricted Stock Units</span><span style="font-family:inherit;font-size:10pt;">&#8212;The Company may grant Restricted Stock (RS) and Restricted Stock Units (RSUs) to employees and non-employee directors. Each share of RS vests upon and each RSU represents a right to receive </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> share of the Company's common stock upon the completion of a specific period of continued service.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RS and RSU awards granted are valued at the market price of the Company's common stock on the date of grant. The Company recognizes noncash compensation expense for the fair values of these RS and RSUs on a straight-line basis over the requisite service period of these awards.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes RSU awards granted during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Price</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,914</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(89,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,914</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>253,586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(51,992</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to unvested awards, which is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.8 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the stock-based compensation recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total (1)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">_________________________________</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Includes </span><span style="font-family:inherit;font-size:10pt;"><span>$0.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively, for the remeasurement of certain stock options and RSUs that occurred during May 2013.</span></div></td></tr></table><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan </span><span style="font-family:inherit;font-size:10pt;">- On May 15, 2018, the Company's shareholders approved the Company&#8217;s 2018 Employee Stock Purchase Plan (ESPP). As part of the ESPP, eligible employees may acquire an ownership interest in the Company by purchasing common stock, at a discount, through payroll deductions. The ESPP is compensatory under GAAP and the Company recorded stock compensation expense of $</span><span style="font-family:inherit;font-size:10pt;"><span>0.9 million</span></span> in 2018.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6655537680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The income tax provision (benefit) was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$(0.3) million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and the effective rates were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>0%</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>0%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>0%</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively. The income tax (benefit) for the year ended December 31, 2017 reflects the reversal of the valuation allowance related to alternative minimum tax (AMT) that the Company paid in 2009. As a result of the Tax Cuts and Jobs Act (the Tax Act), the Company recorded a noncurrent receivable to reflect the refund due to the Company in future periods relating to the previously paid AMT. In addition, the income tax provision (benefit) for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> reflected current income tax expense recorded as a result of the taxable income in certain of the Company's non-US subsidiaries.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company was also subject to foreign income taxes as a result of legal entities established for activities in Europe and Japan. The Company's loss before income taxes in the US and globally was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(286,211</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(136,682</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(140,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35,821</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(324,076</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(176,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's income tax (benefit) provision consisted of the following (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(417</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(417</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The reconciliation between the federal statutory tax rates and the Company's effective tax rate is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory federal tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Permanent items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State income taxes, net of federal benefit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D and other tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of Tax Act</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities consist of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:505px;"/><td style="width:9px;"/><td style="width:72px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:72px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>231,918</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186,342</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General business credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,502</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product license</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,902</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,730</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,651</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,217</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>380,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,660</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangibles</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,424</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32,799</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48,223</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,360</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332,605</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>261,300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(332,605</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(261,300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The net deferred tax assets (prior to applying the valuation allowance) of </span><span style="font-family:inherit;font-size:10pt;"><span>$332.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$261.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, primarily consist of net operating loss carryforwards for income tax purposes. Due to the Company's history of operating losses, the Company recorded a full valuation allowance on its net deferred tax assets by increasing the valuation allowance by </span><span style="font-family:inherit;font-size:10pt;"><span>$71.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and decreasing by </span><span style="font-family:inherit;font-size:10pt;"><span>$23.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, as it was more likely than not that such tax benefits will not be realized. As of December 31, 2017, the Company's gross deferred tax assets were also impacted by the Tax Act which required the change to a 21% US tax rate (see below for further discussion on the Tax Act).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had federal net operating loss carryforwards for income tax purposes of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$880.6 million</span></span><span style="font-family:inherit;font-size:10pt;">. Due to the limitation on NOLs as more fully discussed below, </span><span style="font-family:inherit;font-size:10pt;"><span>$709.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the NOLs are available to offset future taxable income, if any. The NOL carryovers and general business tax credits expire in various years beginning in 2018. For state tax purposes, the Company has approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$515.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of New Jersey NOLs available to offset against future taxable income. The Company also has California and Virginia NOLs that are entirely limited due to Section&#160;382 (as discussed below).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From 2014 through 2017, the Company completed an Internal Revenue Code Section&#160;382 (Section&#160;382) analysis in order to determine the amount of losses that are currently available for potential offset against future taxable income, if any. It was determined that the utilization of the Company's NOL and general business tax credit carryforwards generated in tax periods up to and including December 2010 were subject to substantial limitations under Section&#160;382 due to ownership changes that occurred at various points from the Company's original organization through December 2010. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of shareholders that own, directly or indirectly, 5% or more of a corporation's stock, in the stock of a corporation by more than 50 percentage points over a testing period (usually </span><span style="font-family:inherit;font-size:10pt;">3</span><span style="font-family:inherit;font-size:10pt;"> years). Since the Company's formation, it has raised capital through the issuance of common stock on several occasions which, combined with the purchasing shareholders' subsequent disposition of those shares, have resulted in multiple changes in ownership, as defined by Section&#160;382, since the Company's formation in 1999. These ownership changes resulted in substantial limitations on the use of the Company's NOLs and general business tax credit carryforwards up to and including December 2010. The Company continues to track all of its NOLs and tax credit carryforwards but has provided a full valuation allowance to offset those amounts.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the US government enacted the Tax Act. The Tax Act significantly revises US tax law by, among other provisions, lowering the US federal statutory income tax rate from 35% to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;font-style:italic;">The Tax Act</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC</span><span style="font-family:inherit;font-size:10pt;"> 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the Tax Act&#8217;s provisions, the SEC staff issued SAB 118, which allowed companies to record the tax effects of the Tax Act on a provisional basis based on a reasonable estimate, and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Tax Act did not have a material impact on the Company's financial statements because its deferred temporary differences are fully offset by a valuation allowance and the Company does not have any significant offshore earnings from which to record the mandatory transition tax. The Company completed its analysis during the fourth quarter of 2018 and no additional tax effects of the Act were required to be recorded for the year ended December 31, 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement. If such unrecognized tax benefits were realized and not subject to valuation allowances, we would recognize a tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.16764132553607%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Deferred Tax Assets</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Balance as of January 1,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions related to prior period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Additions related to current period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>742</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31,</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,087</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to US federal and state income taxes and the statute of limitations for tax audit is open for the federal tax returns for the years ended 2014 and later, and is generally open for certain states for the years 2013 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin.</span></div><span style="font-family:inherit;font-size:10pt;">The Company's policy is to recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense. The Company has recorded no such expense. As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company has recorded reserves for unrecognized income tax benefits of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.0 million</span></span>, respectively. As any adjustment to the Company&#8217;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12&#160;months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6714860032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LicenseAndOtherAgreementsAbstract', window );"><strong>License and Other Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LicenseAndOtherAgreementsTextBlock', window );">License and Other Agreements</a></td>
<td class="text">License and Other Agreements<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">In-License Agreements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">PARI Pharma&#160;GmbH</span><span style="font-family:inherit;font-size:10pt;">&#8212;In April 2008, the Company entered into a licensing agreement with PARI Pharma&#160;GmbH (PARI) for use of the optimized Lamira Nebulizer System for delivery of ARIKAYCE in treating patients with NTM lung infections, CF and bronchiectasis. Under the licensing agreement, the Company has rights under several US and foreign issued patents and patent applications involving improvements to the optimized Lamira Nebulizer System, to exploit such system with ARIKAYCE for the treatment of such indications, but the Company cannot manufacture such nebulizers except as permitted under the Commercialization Agreement with PARI. Under the licensing agreement, the Company paid PARI an upfront license fee and certain milestone payments. Upon FDA acceptance of the Company's New Drug Application and the subsequent FDA approval of ARIKAYCE, the Company paid PARI additional milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. In addition, PARI is entitled to receive a future milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>&#8364;0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash based on achievement of first receipt of marketing approval in a major EU country for ARIKAYCE and the device. PARI is entitled to receive royalty payments in the mid-single digits on the annual global net sales of ARIKAYCE, pursuant to the licensing agreement, subject to certain specified annual minimum royalties. In October 2017, the Company exercised an option to buy-down the royalties that will be paid to PARI on ARIKAYCE net sales. The payment to PARI was included as a component of SG&amp;A expenses in the fourth quarter of 2017. See below for information related to the commercialization agreement with PARI. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Agreements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cystic Fibrosis Foundation Therapeutics,&#160;Inc.</span><span style="font-family:inherit;font-size:10pt;">&#8212;In 2004 and 2009, the Company entered into research funding agreements with Cystic Fibrosis Foundation Therapeutics,&#160;Inc. (CFFT) whereby it received </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for each respective agreement in research funding for the development of ARIKAYCE. If ARIKAYCE becomes an approved product for certain infections in CF patients or such infections in human pulmonary disease in the US, the Company will owe a payment to CFFT of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$13.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> that is payable over a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year period after regulatory approval in the US. Furthermore, if certain global sales milestones are met within </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> of the drug's commercialization, the Company would owe an additional payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. Because there is significant development and regulatory risk associated with ARIKAYCE, including with respect to the CF indication, the Company has not accrued these obligations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Therapure Biopharma&#160;Inc.</span><span style="font-family:inherit;font-size:10pt;">&#8212;In February 2014, the Company entered into a contract manufacturing agreement with Therapure Biopharma&#160;Inc. (Therapure) for the manufacture of ARIKAYCE, on a non-exclusive basis, at a 200 kg scale. Pursuant to the agreement, the Company and Therapure collaborated to construct a production area for the manufacture of ARIKAYCE in Therapure's existing manufacturing facility in Canada. The agreement has an initial term of </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;">, which began in October 2018, and will renew automatically for successive periods of </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> each, unless terminated by either party by providing the required </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> prior written notice to the other party. Notwithstanding the foregoing, the parties have rights and obligations under the agreement prior to the commencement of the initial term. Under the agreement, the Company is obligated to pay certain minimum amounts for the batches of ARIKAYCE produced each calendar year.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">PARI Pharma&#160;GmbH</span><span style="font-family:inherit;font-size:10pt;">&#8212;In July 2014, the Company entered into a Commercialization Agreement with PARI for the manufacture and supply of Lamira Nebulizer Systems and related accessories (the Device) as optimized for use with ARIKAYCE. Under the Commercialization Agreement, PARI manufactures the Device except in the case of certain defined supply failures, when the Company will have the right to make the Device and have it made by third parties (but not certain third parties deemed under the Commercialization Agreement to compete with PARI). The Commercialization Agreement has an initial term of </span><span style="font-family:inherit;font-size:10pt;"><span>fifteen years</span></span><span style="font-family:inherit;font-size:10pt;"> from the first commercial sale of ARIKAYCE in October 2018 (the Initial Term). The term of the agreement may be extended by the Company for an additional </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> by providing written notice to PARI at least </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> prior to the expiration of the Initial Term. Notwithstanding the foregoing, the parties have certain rights and obligations under the agreement prior to the commencement of the Initial Term. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">SynteractHCR,&#160;Inc.</span><span style="font-family:inherit;font-size:10pt;">&#8212;In December 2014, the Company entered into a services agreement with SynteractHCR,&#160;Inc. (Synteract) pursuant to which the Company retained Synteract to perform implementation and management services in connection with the CONVERT study. The Company anticipates that aggregate costs relating to all work orders for the CONVERT study will be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$48 million</span></span><span style="font-family:inherit;font-size:10pt;"> over the period of the study. In April 2015, the Company entered into a work order with Synteract to perform implementation and management services for the completed 312 study. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Ajinomoto Althea,&#160;Inc.</span><span style="font-family:inherit;font-size:10pt;">&#8212;In September 2015, the Company entered into a Commercial Fill/Finish Services Agreement (the Fill/Finish Agreement) with Ajinomoto Althea,&#160;Inc., a Delaware corporation (Althea), for Althea to produce, on a non-</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">exclusive basis, ARIKAYCE in finished dosage form at a 50 kg scale. Under the Fill/Finish Agreement, the Company is obligated to pay a minimum of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the batches of ARIKAYCE produced by Althea each calendar year during the term of the Fill/Finish Agreement. The Fill/Finish Agreement became effective as of January&#160;1, 2015, and following an extension in 2018, is expected to remain in effect through December 31, 2021. The Fill/Finish Agreement may be extended for additional </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;">-year periods upon mutual written agreement of the Company and Althea at least </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> prior to the expiration of its then-current term. The Company has expensed at least the required minimum in each year of the contract.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">AstraZeneca AB</span><span style="font-family:inherit;font-size:10pt;">&#8212;In October 2016, the Company entered into a license agreement (AZ License Agreement) with AstraZeneca AB, a Swedish corporation (AstraZeneca). Pursuant to the terms of the AZ License Agreement, AstraZeneca granted the Company exclusive global rights for the purpose of developing and commercializing AZD7986 (renamed INS 1007). In consideration of the licenses and other rights granted by AstraZeneca, the Company made an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was included as research and development expense in the fourth quarter of 2016. The Company is also obligated to make a series of contingent milestone payments totaling up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$85.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of clinical development and regulatory filing milestones. If the Company elects to develop INS1007 for a second indication, the Company will be obligated to make an additional series of contingent milestone payments to AstraZeneca totaling up to </span><span style="font-family:inherit;font-size:10pt;"><span>$42.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company is not obligated to make any additional milestone payments for additional indications. In addition, the Company will pay AstraZeneca tiered royalties ranging from a high single-digit to mid-teens on net sales of any approved product based on INS1007 and one additional payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$35.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the first achievement of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in annual net sales. The AZ License Agreement provides AstraZeneca with the option to negotiate a future agreement with the Company for commercialization of INS1007 in chronic obstructive pulmonary disease or asthma.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Patheon UK Limited</span><span style="font-family:inherit;font-size:10pt;">&#8212;In October 2017, the Company entered into certain agreements with Patheon UK Limited (Patheon) related to the increase of its long-term production capacity for ARIKAYCE commercial inventory. The agreements provide for Patheon to manufacture and supply ARIKAYCE for its anticipated commercial needs.&#160;Under these agreements, the Company is required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.&#160;Patheon's supply obligations will commence once certain technology transfer and construction services are completed. The Company's manufacturing and supply agreement with Patheon will remain in effect for a fixed initial term, after which it will continue for successive renewal terms unless either party has given written notice of termination. The technology transfer agreement will expire when the parties agree that the technology transfer services have been completed. The agreements may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party&#8217;s insolvency. These early termination clauses may reduce the amounts due to the relevant parties. The investment in our long-term production capacity build-out, including under the Patheon agreements and related agreements or purchase orders with third parties for raw materials and fixed assets, is estimated to be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$60 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><span style="font-family:inherit;font-size:10pt;font-style:italic;">Syneos Health</span><span style="font-family:inherit;font-size:10pt;">&#8212;We entered into a services agreement with Syneos Health (Syneos) pursuant to which we retained Syneos to perform implementation and management services in connection with the WILLOW study. We may terminate the services agreement or any work order for any reason and without cause with </span><span style="font-family:inherit;font-size:10pt;">30</span><span style="font-family:inherit;font-size:10pt;">&#160;days' written notice. Either party may terminate the agreement in the event of a material breach or bankruptcy petition by the other party or, if any approval from a regulatory authority is revoked, suspended or expires without renewal. We anticipate that aggregate costs relating to all work orders for the WILLOW study will be approximately $</span><span style="font-family:inherit;font-size:10pt;"><span>21 million</span></span> over the period of the study.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LicenseAndOtherAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LicenseAndOtherAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LicenseAndOtherAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This entire text block refers to License and Other Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LicenseAndOtherAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6655664672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has an operating lease for office and laboratory space located in Bridgewater, NJ for which the initial lease term expires in November 2019. Future minimum rental payments under this lease are </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. In July 2016, the Company signed an operating lease for additional laboratory space located in Bridgewater, NJ for which the initial lease term expires in September 2021. In October 2018, the Company expanded its lease for additional laboratory space located in Bridgewater, NJ. Future minimum rental payments under this, and the initial lease, are </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. In September 2018, the Company entered into a new lease for its new corporate headquarters in Bridgewater, NJ for which the initial lease term expires in June 2030. Future minimum rental payments under this lease are </span><span style="font-family:inherit;font-size:10pt;"><span>$32.3 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rent expense charged to operations was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively. Rent expense is recorded on a straight-line basis over the term of the applicable leases. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum lease payments under the Company's lease obligations as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Year Ending December&#160;31:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,036</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Total future minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to rent, the Company has several firm purchase commitments, primarily related to the manufacturing of ARIKAYCE and annual minimum royalties on global net sales of ARIKAYCE. Future firm purchase commitments under these agreements, the last of which ends in 2034, total </span><span style="font-family:inherit;font-size:10pt;"><span>$86.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. These amounts do not represent our entire anticipated purchases in the future, but instead represent only purchases that are the subject of contractually obligated minimum purchases. The minimum commitments disclosed are determined based on noncancelable minimum spend amounts or termination amounts.  Additionally, we purchase products and services as needed with no firm commitment. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</span></div>From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946400368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text">Quarterly Financial Data (Unaudited)<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes unaudited quarterly financial data for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data).</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenues*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(62,751</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(72,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87,722</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(307,338</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68,524</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(76,437</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87,743</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(91,573</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(324,277</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.00</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total**</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenues*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35,969</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43,515</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,353</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(188,920</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37,414</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44,672</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(45,179</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,384</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192,649</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">________________</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:81px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*   Excludes amortization of intangible assets.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:81px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">** Includes a one-time payment in October 2017 related to the buy-down of royalties payable to PARI on the global net sales of ARIKAYCE.</span></div>Basic and diluted net loss per share amounts included in the above table were computed independently for each of the quarters presented. Accordingly, the sum of the quarterly basic and diluted net loss per share amounts may not agree to the total for the year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931265424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text">Retirement Plan<span style="font-family:inherit;font-size:10pt;">The Company has a 401(k) defined contribution plan for the benefit for all US employees and permits voluntary contributions by employees subject to IRS-imposed limitations. Effective January 1, 2018, the Company matched </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of eligible employee contributions on the first </span><span style="font-family:inherit;font-size:10pt;"><span>4%</span></span><span style="font-family:inherit;font-size:10pt;"> of employee salary (up to the IRS maximum). Employer contributions for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Prior to </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company matched </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of eligible employee contributions on the first </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span> of employee salary (up to the IRS maximum).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6952699168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation&#8212;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Insmed Limited, Celtrix Pharmaceuticals,&#160;Inc., Insmed Holdings Limited, Insmed Ireland Limited, Insmed France SAS, Insmed Germany&#160;GmbH, Insmed Netherlands&#160;B.V., Insmed Bermuda Limited and Insmed Godo Kaisha. All intercompany transactions and balances have been eliminated in consolidation and certain prior year amounts have been restated to conform to the current year presentation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of Estimates&#8212;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, and accounting for research and development costs. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_InvestmentIncomeExpensePolicyTextBlock', window );">Investment Income and Interest Expense</a></td>
<td class="text">Investment Income and Interest Expense&#8212;Investment income consists of interest income earned on the Company's cash and cash equivalents. Interest expense consists primarily of interest costs related to the Company's debt.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash Equivalents&#8212;The Company considers cash equivalents to be highly liquid investments with maturities of three months or less from the date of purchase.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets, Net</a></td>
<td class="text">Fixed Assets, Net<span style="font-family:inherit;font-size:10pt;">&#8212;Fixed assets are recorded at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. Estimated useful lives of </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> are used for computer equipment. Estimated useful lives of </span><span style="font-family:inherit;font-size:10pt;"><span>seven years</span></span> are used for laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Identifiable Intangible Assets</a></td>
<td class="text">Identifiable Intangible Assets<span style="font-family:inherit;font-size:10pt;">&#8212;Identifiable intangible assets are measured at their respective fair values and began amortizing over their estimated useful lives upon commercialization. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. Unanticipated events or circumstances may occur that may require the Company to review the assets for impairment. Events or circumstances that may require an impairment assessment include negative clinical trial results, the non-approval of a new drug application by a regulatory agency, material delays in the Company's development program or a sustained decline in market capitalization. The Company performs its annual impairment test as of October&#160;1 of each year.</span>The Company performed a qualitative assessment to evaluate whether there was an impairment of the assets. This assessment did not identify any indicators of impairment of the intangible assets as of that date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text">Debt Issuance Costs&#8212;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<span style="font-family:inherit;font-size:10pt;">&#8212;The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's only financial assets and liabilities which were measured at fair value as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> were Level 1 assets comprised of cash and cash equivalents. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.04873294346979%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> transfers in or out of Level&#160;1, Level&#160;2 or Level&#160;3 during </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company held </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> securities that were in an unrealized loss or gain position.</span></div>The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the security was rated below investment grade; (3)&#160;how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">Foreign Currency<span style="font-family:inherit;font-size:10pt;">&#8212;The Company has operations in the US, Ireland, Germany, France, the UK, the Netherlands and Japan. The results of its non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' equity, as a component of other comprehensive loss.</span>The Company realizes foreign currency transaction gains (losses) in the normal course of business based on movements in the applicable exchange rates. These gains (losses) are included as a component of other income, net.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">Concentration of Credit Risk<span style="font-family:inherit;font-size:10pt;">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:17px;padding-top:17px;text-align:center;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:357px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:181px;"/><td style="width:176px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage of Total Gross Product Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company did not have product revenue prior to US FDA approval of ARIKAYCE in 2018. The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially impact future operating results.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<span style="font-family:inherit;font-size:10pt;">&#8212;In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company did not incur or capitalize any incremental costs associated with obtaining contracts with customers.</span><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenues consist primarily of sales of ARIKAYCE in the US. Product revenues are recognized once the Company performs and satisfies all five steps mentioned above. In October 2018, the Company began shipping ARIKAYCE to its customers in the US, which include specialty pharmacies and specialty distributors.&#160;The Company recognizes revenues for product received by its customers net of allowances for customer credits, including estimated rebates, chargebacks, prompt pay discounts, returns, service fees, and government rebates, such as Medicaid rebates and Medicare Part D coverage gap reimbursements in the US.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Customer credits:</span><span style="font-family:inherit;font-size:10pt;">&#160;The Company&#8217;s customers are offered various forms of consideration, including service fees and prompt payment discounts. The Company anticipates that its customers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total gross product revenues when revenues are recognized. Service fees are also deducted from total gross product revenues as they are earned.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Rebates:</span><span style="font-family:inherit;font-size:10pt;"> The Company contracts with Medicaid, other government agencies and various private organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized.</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-bottom:17px;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Chargebacks:</span><span style="font-family:inherit;font-size:10pt;"> Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price initially paid by the specialty distributor and the discounted price paid by the contracted customers. The Company estimates the chargebacks it provides to the specialty distributor and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized.</span></div><div style="line-height:120%;padding-bottom:17px;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Co-payment assistance:</span><span style="font-family:inherit;font-size:10pt;"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using data provided by a third-party administrator.</span></div><div style="line-height:120%;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any, or all, of the Company&#8217;s actual experience vary from the estimates above, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a summary roll-forward of our sales allowances and related accruals for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands), which have been deducted in arriving at net product revenue:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:53px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Customer fees, discounts and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rebates, chargebacks and co-pay assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Balance as of January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Allowances for current period sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,184</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;&#160;&#160;Payments and credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(262</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>688</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, upon US FDA approval of ARIKAYCE, the Company began recognizing revenue from sales to the French National Agency for Medicines and Health Products Safety (ANSM), which granted ARIKAYCE a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU). Pursuant to this program, the Company ships product to pharmacies after receiving requests from physicians for patients in France. The Company is initiating expanded access programs (EAPs) in Europe and other countries, some of which may be fully reimbursed. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock', window );">Inventory and cost of product revenues (excluding amortization of intangible assets)</a></td>
<td class="text">Inventory and cost of product revenues (excluding amortization of intangible assets)<span style="font-family:inherit;font-size:10pt;">&#8212;Inventory is stated at the lower of cost and net realizable value with cost determined on a standard costing method. The Company capitalized inventory costs following regulatory approval of ARIKAYCE from the FDA on September 28, 2018. Inventory is sold on a first-in, first out basis. Manufacturing variances, such as material usage variance and yield variance, are capitalized in inventory until the respective units are sold, at which point the variances are recognized in cost of product revenues. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, records a write-down accordingly. The Company also performs strict quality control throughout the manufacturing processes of products; however, certain batches or units of product may not meet quality specifications and result in a charge to cost of product revenues in the period incurred.</span><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred; therefore, inventory is not included in the </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> consolidated balance sheet. Inventory that is used for clinical development purposes is expensed to research and development expense when consumed.</span></div>Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight-in, allocation of overhead costs, and inventory adjustment charges, in addition to royalty expenses due to PARI. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">Research and Development&#8212;Research and development expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in the Company's research and development functions, and other internal operating expenses, the cost of manufacturing a drug candidate, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, research and development expenses include payments to third parties for the license rights to products in development (prior to marketing approval). The Company's expenses related to manufacturing its drug candidate and medical devices for clinical study are primarily related to activities at contract manufacturing organizations that manufacture ARIKAYCE, INS1007, and INS1009 and the medical devices for the Company's use. The Company's expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on the Company's behalf. These contracts set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<span style="font-family:inherit;font-size:10pt;">&#8212;The Company recognizes stock-based compensation expense for awards of equity instruments to employees and directors based on the grant-date fair value of those awards. The grant-date fair value of the award is recognized as compensation expense ratably over the requisite service period, which generally equals the vesting period of the award, and if applicable, is adjusted for expected forfeitures. The Company also grants performance-based stock options to employees. The grant-date fair value of the performance-based stock options is recognized as compensation expense over the implicit service period using the accelerated attribution method once it is probable that the performance condition will </span>be achieved. Stock-based compensation expense is included in both R&amp;D and SG&amp;A expenses in the consolidated statements of comprehensive loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<span style="font-family:inherit;font-size:10pt;">&#8212;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A valuation allowance is recorded to reduce the deferred tax assets to the amount that is expected to be realized. In evaluating the need for a valuation allowance, the Company takes into account various factors, including the expected level of future taxable income and available tax planning strategies. If actual results differ from the assumptions made in the evaluation of a valuation allowance, the Company records a change in valuation allowance through income tax expense in the period such determination is made.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based solely on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than </span><span style="font-family:inherit;font-size:10pt;">50%</span><span style="font-family:inherit;font-size:10pt;"> likelihood to be sustained upon ultimate settlement. As any adjustment to the Company&#8217;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions.</span></div>The Company's policy for interest and penalties related to income tax exposures is to recognize interest and penalties as a component of the income tax provision (benefit) in the consolidated statements of comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<span style="font-family:inherit;font-size:10pt;">&#8212;Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options and restricted stock units would be anti-dilutive as the Company incurred a net loss in all periods presented. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options would be determined based on the treasury stock method.</span><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31,</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(324,277</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(176,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares used in calculation of basic net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,889</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,576</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding used in calculation of diluted net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,889</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.22</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.89</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.85</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> as their effect would have been anti-dilutive (in thousands).</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,609</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,492</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<span style="font-family:inherit;font-size:10pt;">&#8212;The Company currently operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment, which is the development and commercialization of therapies for patients with rare diseases. A single management team that reports to the Chief Executive Officer comprehensively manages the entire business. The Company does not operate separate lines of business with respect to its products or product candidates. Accordingly, the Company has </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span> reportable segment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text">New Accounting Pronouncements (Adopted)<span style="font-family:inherit;font-size:10pt;">&#8212;In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</span><span style="font-family:inherit;font-size:10pt;">, which addressed eight specific cash flow issues with the objective of reducing the existing diversity in practice. Among the updates, the standard requires debt extinguishment costs to be classified as cash outflows for financing activities. This standard update became effective as of the first quarter of 2018. As a result of the adoption of the standard, in the first quarter of 2018, the Company reported a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on extinguishment of debt in the operating activities section of its consolidated statement of cash flows. The Company had no material debt extinguishment costs prior to the first quarter of 2018. The impact of adopting this standard was not material to the Company.</span><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU&#160;2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span><span style="font-family:inherit;font-size:10pt;"> which amended the existing accounting standards for revenue recognition. ASU 2014-09 establishes principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services. In July 2015, the FASB deferred the effective date for annual reporting periods beginning after December&#160;15, 2017. The Company adopted ASU 2014-09 in the first quarter of 2018.  The adoption did not have a material impact on the Company's consolidated financial statements.</span></div><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Pronouncements (Not Yet Adopted)</span><span style="font-family:inherit;font-size:10pt;">&#8212;In February 2016, the FASB issued ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018 (including interim periods within those periods) and early adoption is permitted. In August 2018, the FASB issued ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements to ASC 842</span><span style="font-family:inherit;font-size:10pt;">, which provides a new transition option in which an entity initially applies ASU 2016-02 at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will use the new transition option and will be also utilizing the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any expired or existing leases. The Company will also use the short-term lease exception for leases with a term of twelve months or less. Additionally, the Company expects to use the practical expedient that allows it to treat the lease and non-lease components of its leases as a single component. The Company has identified approximately ten leasing arrangements and estimates the impact on its consolidated balance sheet to be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$44 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$49 million</span></span>. There will be no adjustment recognized through retained earnings as a result of adoption. The Company will adopt ASU 2016-02 effective January 1, 2019, and is continuing to evaluate the impact of adoption on its consolidated financial statements and its internal control over financial reporting. <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_InvestmentIncomeExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for components of investment income and interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_InvestmentIncomeExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783718448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Carrying Value and Fair Value of Assets and Liabilities</a></td>
<td class="text">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.04873294346979%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><span style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor</a></td>
<td class="text">The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:357px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:181px;"/><td style="width:176px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage of Total Gross Product Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock', window );">Contract with Customer, Asset, Allowance for Credit Loss</a></td>
<td class="text">The following table provides a summary roll-forward of our sales allowances and related accruals for the year ended <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands), which have been deducted in arriving at net product revenue:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Customer fees, discounts and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rebates, chargebacks and co-pay assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Balance as of January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Allowances for current period sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>849</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,184</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;&#160;&#160;Payments and credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(262</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>688</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>922</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share</a></td>
<td class="text">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended <span style="font-family:inherit;font-size:10pt;">December 31,</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(324,277</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(176,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares used in calculation of basic net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,889</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,576</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding used in calculation of diluted net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,889</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.22</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.89</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.85</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding</a></td>
<td class="text">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> as their effect would have been anti-dilutive (in thousands).</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,609</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,492</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Asset, Allowance for Credit Loss [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797545680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text">As of December 31, 2018, the Company's inventory balance consists of the following (in thousands): <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:407px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:274px;"/><td style="width:9px;"/><td style="width:119px;"/><td style="width:4px;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,567</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,032</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6944557600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued expenses consist of the following:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trial expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,398</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued technical operation expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,631</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued sales allowances and related costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>818</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued construction costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,946</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,719</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,254</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,142</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6952810544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule Intangible Assets</a></td>
<td class="text">A rollforward of the Company's intangible assets for the years ended <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.54970760233918%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Intangible Asset</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">January 1,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Additions</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Acquired ARIKAYCE R&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,988</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PARI milestone upon FDA approval</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,724</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,687</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,724</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Intangible Asset</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">January 1,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Additions</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">Amortization</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;text-decoration:underline;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired ARIKAYCE IPRD</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6953976400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Fixed Assets</a></td>
<td class="text">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Useful Life (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Asset Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lab equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,055</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Computer hardware and software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3&#160;-&#160;5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,796</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,436</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lease term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,202</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,939</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Construction in progress (CIP)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,077</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,645</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed assets, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934180304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Components of Debt Balance</a></td>
<td class="text">The following table presents the carrying value of the Company&#8217;s debt balance as of <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.8635477582846%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;1.75% convertible senior notes due 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;Debt issuance costs, unamortized</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,440</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;Discount on debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(125,002</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316,558</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Repayments of Debt</a></td>
<td class="text">As of <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:38.01169590643275%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December&#160;31:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946118848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Value Assumptions for Stock Options</a></td>
<td class="text">The following table summarizes the grant date fair value and assumptions used in determining the fair value of all stock options granted, including grants of inducement options, during the years ended <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:373px;"/><td style="width:100px;"/><td style="width:5px;"/><td style="width:100px;"/><td style="width:5px;"/><td style="width:100px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66% - 68%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71% - 79%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74% - 77%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25% - 2.96%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.73% - 2.13%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.00% - 1.90%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected option term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.09</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.25</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.25</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average fair value of stock options granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$10.52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.77</span></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">The following table summarizes stock option activity for stock options granted for the years ended <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:321px;"/><td style="width:82px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:72px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:86px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:72px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Life in Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in '000)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at January 1, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,273,722</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,532,675</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162,340</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited and expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(527,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,116,706</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,850,658</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,113,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Options outstanding at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,116,706</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,284,710</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(378,275</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited and expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(414,220</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Options outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,608,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,325,255</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Exercisable at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,229,478</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,608,921</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,755,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(494,351</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited and expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(488,440</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,381,730</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.69</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,052</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,693,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,926</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,649,698</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.58</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,181</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Exercise Price and Number of Stock Options Exercisable</a></td>
<td class="text">The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable as of <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding as of December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable as of<br/>December&#160;31, 2018</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of<br/>Exercise Prices</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of<br/>Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted<br/>Average<br/>Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of<br/>Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>960,038</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>960,038</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.13</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>953,089</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>604,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>947,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.72</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>887,207</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>967,420</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>455,114</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,142,513</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.76</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>782,818</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,380,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>687,691</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,387,909</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.51</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,081,677</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,355,366</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,644</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166,933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.60</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,069</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text">The following table summarizes RSU awards granted during the years ended <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.47368421052632%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Price</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43,554</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,914</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(89,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,914</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>253,586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(51,992</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Allocation of Employee Stock-Based Compensation</a></td>
<td class="text">The following table summarizes the stock-based compensation recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the years ended <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> (in millions):</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total (1)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">_________________________________</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div><span style="font-family:inherit;font-size:10pt;">Includes </span><span style="font-family:inherit;font-size:10pt;"><span>$0.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the years ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span>, respectively, for the remeasurement of certain stock options and RSUs that occurred during May 2013.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6955253152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Income Taxes in the US and Globally</a></td>
<td class="text">The Company's loss before income taxes in the US and globally was as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">US</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(286,211</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(136,682</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(140,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35,821</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(324,076</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(176,175</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components Income Tax (Benefit) Provision</a></td>
<td class="text">The Company's income tax (benefit) provision consisted of the following (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(417</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(417</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate</a></td>
<td class="text">The reconciliation between the federal statutory tax rates and the Company's effective tax rate is as follows:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory federal tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Permanent items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State income taxes, net of federal benefit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D and other tax credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of Tax Act</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">The components of the deferred tax assets and liabilities consist of the following:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:505px;"/><td style="width:9px;"/><td style="width:72px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:72px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>231,918</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186,342</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General business credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,502</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product license</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,902</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,730</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,651</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,855</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,217</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>380,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,660</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangibles</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15,424</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32,799</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(48,223</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,360</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332,605</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>261,300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(332,605</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(261,300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net deferred tax assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.16764132553607%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Deferred Tax Assets</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Balance as of January 1,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions related to prior period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Additions related to current period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>742</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance as of December 31,</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,087</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6951415312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments Required Under Operating Leases</a></td>
<td class="text">Future minimum lease payments under the Company's lease obligations as of <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Year Ending December&#160;31:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,036</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Total future minimum lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782189568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of Quarterly Financial Data (Unaudited)</a></td>
<td class="text">The following table summarizes unaudited quarterly financial data for the years ended <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data).</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenues*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(62,751</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(72,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87,722</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(307,338</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68,524</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(76,437</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87,743</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(91,573</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(324,277</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.00</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total**</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of product revenues*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35,969</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43,515</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44,083</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,353</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(188,920</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37,414</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44,672</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(45,179</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65,384</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192,649</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.85</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">________________</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:81px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*   Excludes amortization of intangible assets.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:81px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">** Includes a one-time payment in October 2017 related to the buy-down of royalties payable to PARI on the global net sales of ARIKAYCE.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109225645&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781652832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation Description of Business and Basis of Presentation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 495,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 495,072<span></span>
</td>
<td class="nump">$ 381,165<span></span>
</td>
<td class="nump">$ 162,591<span></span>
</td>
<td class="nump">$ 282,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 91,573<span></span>
</td>
<td class="nump">$ 87,743<span></span>
</td>
<td class="nump">$ 76,437<span></span>
</td>
<td class="nump">$ 68,524<span></span>
</td>
<td class="nump">$ 65,384<span></span>
</td>
<td class="nump">$ 45,179<span></span>
</td>
<td class="nump">$ 44,672<span></span>
</td>
<td class="nump">$ 37,414<span></span>
</td>
<td class="nump">$ 324,277<span></span>
</td>
<td class="nump">$ 192,649<span></span>
</td>
<td class="nump">$ 176,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6946485440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fixed Assets, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful live of fixed assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful live of fixed assets</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_EquipmentFurnitureAndFixturesMember', window );">Laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful live of fixed assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_EquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_EquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797347392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair Value Measurements (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_FairValueLevel1Level2Level3TransfersAmount', window );">Fair value transfers in or out of Level 1, Level 2 or Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized portion of debt discount</a></td>
<td class="nump">$ 125,002,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities', window );">Securities in an unrealized gain or loss position | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized portion of debt discount</a></td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | 1.75% Convertible Senior Note Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Proceeds from issuance of 1.75% convertible senior notes due 2025</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes ($450.0 face value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Reported Value Measurement | Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 495,100,000<span></span>
</td>
<td class="nump">$ 381,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Reported Value Measurement | Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes ($450.0 face value)</a></td>
<td class="nump">316,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">495,100,000<span></span>
</td>
<td class="nump">381,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes ($450.0 face value)</a></td>
<td class="nump">313,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_FairValueLevel1Level2Level3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Level 1, Level 2, Level 3 Transfers, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_FairValueLevel1Level2Level3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781430080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration Risk (Details) - Sales Revenue, Product Line - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerAMember', window );">Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerBMember', window );">Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerCMember', window );">Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6954653856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward', window );"><strong>Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Balance at beginning</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales', window );">Allowances for current period sales</a></td>
<td class="nump">1,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits', window );">Payments and credits</a></td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Ending balance</a></td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerFeesDiscountsandOtherMember', window );">Customer Fees, Discounts and Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward', window );"><strong>Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Balance at beginning</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales', window );">Allowances for current period sales</a></td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits', window );">Payments and credits</a></td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Ending balance</a></td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_RebatesChargebacksandCoPayAssistanceMember', window );">Rebates, Chargebacks, and Co-Pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward', window );"><strong>Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Balance at beginning</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales', window );">Allowances for current period sales</a></td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits', window );">Payments and credits</a></td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Ending balance</a></td>
<td class="nump">$ 688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Allowance For Current Period Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Assets, Allowance For Credit Loss, Payments and Credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerFeesDiscountsandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerFeesDiscountsandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_RebatesChargebacksandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_RebatesChargebacksandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797477264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (91,573)<span></span>
</td>
<td class="num">$ (87,743)<span></span>
</td>
<td class="num">$ (76,437)<span></span>
</td>
<td class="num">$ (68,524)<span></span>
</td>
<td class="num">$ (65,384)<span></span>
</td>
<td class="num">$ (45,179)<span></span>
</td>
<td class="num">$ (44,672)<span></span>
</td>
<td class="num">$ (37,414)<span></span>
</td>
<td class="num">$ (324,277)<span></span>
</td>
<td class="num">$ (192,649)<span></span>
</td>
<td class="num">$ (176,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares used in calculation of basic net loss per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,889<span></span>
</td>
<td class="nump">66,576<span></span>
</td>
<td class="nump">61,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,889<span></span>
</td>
<td class="nump">66,576<span></span>
</td>
<td class="nump">61,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.19)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (4.22)<span></span>
</td>
<td class="num">$ (2.89)<span></span>
</td>
<td class="num">$ (2.85)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6953006992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">9,382<span></span>
</td>
<td class="nump">8,609<span></span>
</td>
<td class="nump">7,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">11,492<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=insm_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=insm_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6592724496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6954760032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - New Accounting Pronouncements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_SummaryOfSignificantPoliciesLineItems', window );"><strong>Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,209<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast | Accounting Standards Update 2016-02 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_SummaryOfSignificantPoliciesLineItems', window );"><strong>Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast | Accounting Standards Update 2016-02 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_SummaryOfSignificantPoliciesLineItems', window );"><strong>Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_SummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Summary Of Significant Policies [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_SummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784340800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">4,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="nump">$ 7,032<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6936723760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedClinicalTrialExpenses', window );">Accrued clinical trial expenses</a></td>
<td class="nump">$ 6,635<span></span>
</td>
<td class="nump">$ 7,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">13,398<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedTechnicalOperationExpenses', window );">Accrued technical operation expenses</a></td>
<td class="nump">9,371<span></span>
</td>
<td class="nump">2,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">3,631<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedSalesAllowancesandRelatedCosts', window );">Accrued sales allowances and related costs</a></td>
<td class="nump">818<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedConstructionLiabilitiesCurrent', window );">Accrued construction costs</a></td>
<td class="nump">2,946<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">1,455<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 38,254<span></span>
</td>
<td class="nump">$ 17,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedConstructionLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Construction Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedConstructionLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedSalesAllowancesandRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Allowances and Related Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedSalesAllowancesandRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedTechnicalOperationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedTechnicalOperationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799035072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Jan. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">New drug milestone payment</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,724<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,675<span></span>
</td>
<td class="nump">58,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization of intangible assets, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization of intangible assets, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization of intangible assets, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization of intangible assets, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Amortization of intangible assets, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,200<span></span>
</td>
<td class="nump">$ 58,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,724<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,249)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,675<span></span>
</td>
<td class="nump">58,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,988<span></span>
</td>
<td class="nump">58,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,200<span></span>
</td>
<td class="nump">$ 58,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,212)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,988<span></span>
</td>
<td class="nump">$ 58,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797889968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 36,809<span></span>
</td>
<td class="nump">$ 23,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(14,173)<span></span>
</td>
<td class="num">(10,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">22,636<span></span>
</td>
<td class="nump">12,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease', window );">Depreciation increase (decrease)</a></td>
<td class="nump">10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 7,935<span></span>
</td>
<td class="nump">7,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 2,320<span></span>
</td>
<td class="nump">1,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 3,796<span></span>
</td>
<td class="nump">2,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 1,166<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 7,202<span></span>
</td>
<td class="nump">6,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress (CIP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">14,325<span></span>
</td>
<td class="nump">$ 3,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease', window );">Depreciation increase (decrease)</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799084896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Underwriting discounts and commissions and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 1.75% convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,472,000<span></span>
</td>
<td class="nump">5,925,000<span></span>
</td>
<td class="nump">3,498,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">2,209,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75% Convertible Senior Note Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0255384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember', window );">A&amp;R Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_RepaymentsOfDebtFeesAndOutstandingInterest', window );">Repayments of debt, back end fees, outstanding interest, and prepayment penalty fees</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | 1.75% Convertible Senior Note Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentOptionToPurchaseAdditionalDebt', window );">Option to purchase additional debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Underwriting discounts and commissions and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 1.75% convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes ($450.0 face value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining discount amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiMember', window );">Conversion Term (i) | Convertible Notes Payable | 1.75% Convertible Senior Note Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiiMember', window );">Conversion Term (ii) | Convertible Notes Payable | 1.75% Convertible Senior Note Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiiiMember', window );">Conversion Term (iii) | Convertible Notes Payable | 1.75% Convertible Senior Note Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange', window );">Threshold trading days following fundamental change | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermivMember', window );">Conversion Term (iv) | Convertible Notes Payable | 1.75% Convertible Senior Note Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentOptionToPurchaseAdditionalDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Option To Purchase Additional Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentOptionToPurchaseAdditionalDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_RepaymentsOfDebtFeesAndOutstandingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Debt Fees And Outstanding Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_RepaymentsOfDebtFeesAndOutstandingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermivMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_ConversionTermivMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6943416640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Components of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">1.75% convertible senior notes due 2025</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, unamortized</a></td>
<td class="num">(8,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="num">(125,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">316,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="num">$ (125,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | 1.75% Convertible Senior Note Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, unamortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Proceeds from issuance of 1.75% convertible senior notes due 2025</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6956333744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Future Principal Repayments of Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2019</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2020</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter', window );">2023 and thereafter</a></td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturities, Repayments Of Principal In Year Five And Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6955673632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,307,521<span></span>
</td>
<td class="nump">76,610,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,307,521<span></span>
</td>
<td class="nump">76,610,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under underwritten public offering (in shares)</a></td>
<td class="nump">14,123,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption', window );">Shares exercised in full of over-allotment option by underwriter (in shares)</a></td>
<td class="nump">1,842,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares price (in dollars per share)</a></td>
<td class="nump">$ 28.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriter's discount and offering expenses</a></td>
<td class="nump">$ 24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from the sale of shares</a></td>
<td class="nump">$ 377,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 377,656<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,381,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6655610128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>May 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock, maximum authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">3,622,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross', window );">Inducement stock option granted to new employees (in shares)</a></td>
<td class="nump">295,720<span></span>
</td>
<td class="nump">266,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of inducement share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798404224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding beginning of the year (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,608,921<span></span>
</td>
<td class="nump">7,116,706<span></span>
</td>
<td class="nump">5,273,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,755,600<span></span>
</td>
<td class="nump">2,284,710<span></span>
</td>
<td class="nump">2,532,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(494,351)<span></span>
</td>
<td class="num">(378,275)<span></span>
</td>
<td class="num">(162,340)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(488,440)<span></span>
</td>
<td class="num">(414,220)<span></span>
</td>
<td class="num">(527,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding end of the year (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,381,730<span></span>
</td>
<td class="nump">8,608,921<span></span>
</td>
<td class="nump">7,116,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,693,635<span></span>
</td>
<td class="nump">8,325,255<span></span>
</td>
<td class="nump">6,850,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,649,698<span></span>
</td>
<td class="nump">4,229,478<span></span>
</td>
<td class="nump">3,113,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding beginning of the year (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.08<span></span>
</td>
<td class="nump">$ 13.30<span></span>
</td>
<td class="nump">$ 13.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.63<span></span>
</td>
<td class="nump">15.92<span></span>
</td>
<td class="nump">12.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.46<span></span>
</td>
<td class="nump">9.08<span></span>
</td>
<td class="nump">6.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.79<span></span>
</td>
<td class="nump">15.50<span></span>
</td>
<td class="nump">17.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding end of the year (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.30<span></span>
</td>
<td class="nump">14.08<span></span>
</td>
<td class="nump">13.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.90<span></span>
</td>
<td class="nump">14.03<span></span>
</td>
<td class="nump">13.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.45<span></span>
</td>
<td class="nump">$ 12.71<span></span>
</td>
<td class="nump">$ 11.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_WeightedAverageRemainingContractualLifeInYearsAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value and assumptions used in determining fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 1 month 2 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.03<span></span>
</td>
<td class="nump">$ 10.52<span></span>
</td>
<td class="nump">$ 8.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Stock options to purchase common stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value and assumptions used in determining fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">1.73%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Stock options to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value and assumptions used in determining fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.13%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-condition options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Non-cash compensation expense</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_WeightedAverageRemainingContractualLifeInYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_WeightedAverageRemainingContractualLifeInYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799751696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Range of Exercise Prices (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised during the period</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock options</a></td>
<td class="nump">$ 29.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period for recognizing unrecognized compensation expense</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range1Member', window );">$3.03 to $4.55</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="nump">$ 4.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
<td class="nump">960,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">3 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
<td class="nump">960,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range2Member', window );">$6.90 to $6.90</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="nump">6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
<td class="nump">120,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">4 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
<td class="nump">120,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range3Member', window );">$6.96 to $10.85</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="nump">6.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="nump">$ 10.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
<td class="nump">953,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">6 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 10.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
<td class="nump">604,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 10.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range4Member', window );">$11.14 to $12.58</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="nump">11.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="nump">$ 12.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
<td class="nump">947,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">4 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
<td class="nump">887,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range5Member', window );">$12.66 to $13.94</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="nump">12.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="nump">$ 13.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
<td class="nump">967,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">7 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 13.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
<td class="nump">455,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 13.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range6Member', window );">$14.24 to $16.07</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="nump">14.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="nump">$ 16.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
<td class="nump">1,142,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
<td class="nump">782,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range7Member', window );">$16.09 to $17.16</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="nump">16.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="nump">$ 17.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
<td class="nump">1,380,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">7 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 16.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
<td class="nump">687,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 16.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range8Member', window );">$17.24 to $22.76</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="nump">17.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="nump">$ 22.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
<td class="nump">1,387,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">6 years 6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 21.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
<td class="nump">1,081,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 21.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range9Member', window );">$22.84 to $30.46</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="nump">22.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="nump">$ 30.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
<td class="nump">1,355,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">8 years 4 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 28.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
<td class="nump">57,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 25.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range10Member', window );">$30.86 to $32.46</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="nump">30.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="nump">$ 32.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options outstanding (in shares)</a></td>
<td class="nump">166,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 31.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options exercisable (in shares)</a></td>
<td class="nump">13,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 31.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range8Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range8Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6955533824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_RestrictedStockAndRestrictedStockUnitsMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit', window );">Number of common shares each award holder is entitled to receive</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to unvested awards</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period for recognized and unrecognized compensation expense</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">46,914<span></span>
</td>
<td class="nump">89,194<span></span>
</td>
<td class="nump">43,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">253,586<span></span>
</td>
<td class="nump">46,914<span></span>
</td>
<td class="nump">89,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="num">(51,992)<span></span>
</td>
<td class="num">(89,194)<span></span>
</td>
<td class="num">(43,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(20,682)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">227,826<span></span>
</td>
<td class="nump">46,914<span></span>
</td>
<td class="nump">89,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding Weighted Average Grant Price (in dollars per share)</a></td>
<td class="nump">$ 17.16<span></span>
</td>
<td class="nump">$ 10.85<span></span>
</td>
<td class="nump">$ 19.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">29.16<span></span>
</td>
<td class="nump">17.16<span></span>
</td>
<td class="nump">10.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in dollars per share)</a></td>
<td class="nump">18.46<span></span>
</td>
<td class="nump">10.85<span></span>
</td>
<td class="nump">16.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">29.05<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding Weighted Average Grant Price (in dollars per share)</a></td>
<td class="nump">$ 29.14<span></span>
</td>
<td class="nump">$ 17.16<span></span>
</td>
<td class="nump">$ 10.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards', window );">Stock-based compensation expense that resulted from the remeasurement of awards</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">ESPP compensation expense</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs | Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">ESPP compensation expense</a></td>
<td class="nump">9.4<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs | Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">ESPP compensation expense</a></td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">ESPP compensation expense</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of stock-based compensation expense that resulted from the remeasurement of awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock each restricted stock award entitles the holder to receive upon completion of a specific period of service or achievement of a specified milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_RestrictedStockAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_RestrictedStockAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6951016256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>NOL carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">$ 201,000<span></span>
</td>
<td class="num">$ (272,000)<span></span>
</td>
<td class="nump">$ 98,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances', window );">Net deferred tax assets (prior to applying the valuation allowance)</a></td>
<td class="nump">$ 332,605,000<span></span>
</td>
<td class="nump">261,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">71,300,000<span></span>
</td>
<td class="num">(23,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>NOL carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_OperatingLossCarryforwardsTotal', window );">Net operating loss carryforwards for income tax purposes</a></td>
<td class="nump">880,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards available to offset future taxable income</a></td>
<td class="nump">709,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>NOL carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards available to offset future taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember', window );">New Jersey Division of Taxation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>NOL carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards available to offset future taxable income</a></td>
<td class="nump">$ 515,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_OperatingLossCarryforwardsTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, for income tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_OperatingLossCarryforwardsTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6954056624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Loss Before Income Taxes in the US and Globally (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">US</a></td>
<td class="num">$ (286,211)<span></span>
</td>
<td class="num">$ (136,682)<span></span>
</td>
<td class="num">$ (140,354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(37,865)<span></span>
</td>
<td class="num">(56,239)<span></span>
</td>
<td class="num">(35,821)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (324,076)<span></span>
</td>
<td class="num">$ (192,921)<span></span>
</td>
<td class="num">$ (176,175)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781908048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax (Benefit) Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax provision (benefit)</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(417)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax provision (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(417)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 201<span></span>
</td>
<td class="num">$ (272)<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6943994560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">R&amp;D and other tax credits</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income taxes</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent', window );">Impact of Tax Act</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(49.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(27.00%)<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="num">(39.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to permanent items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6936352416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 231,918<span></span>
</td>
<td class="nump">$ 186,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credits</a></td>
<td class="nump">109,502<span></span>
</td>
<td class="nump">66,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DeferredTaxAssetsLicensePayment', window );">Product license</a></td>
<td class="nump">6,902<span></span>
</td>
<td class="nump">7,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">7,651<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">24,855<span></span>
</td>
<td class="nump">17,217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">380,828<span></span>
</td>
<td class="nump">277,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(15,424)<span></span>
</td>
<td class="num">(16,360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DeferredTaxLiabilitiesConvertibleDebt', window );">Convertible debt</a></td>
<td class="num">(32,799)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(48,223)<span></span>
</td>
<td class="num">(16,360)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances', window );">Net deferred tax assets</a></td>
<td class="nump">332,605<span></span>
</td>
<td class="nump">261,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(332,605)<span></span>
</td>
<td class="num">(261,300)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DeferredTaxAssetsLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as License payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DeferredTaxAssetsLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DeferredTaxLiabilitiesConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DeferredTaxLiabilitiesConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784195616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Net deferred tax assets as of January 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions related to prior period tax positions</a></td>
<td class="nump">3,345<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions related to current period tax positions</a></td>
<td class="nump">742<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Net deferred tax assets as of December 31</a></td>
<td class="nump">$ 4,087<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798732832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Other Agreements (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2014</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
<th class="th">
<div>Apr. 30, 2008 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2009 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2004 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember', window );">PARI Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_InitialTermOfContractManufacturingAgreement', window );">Initial term of contract manufacturing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AdditionalTermOfContractManufacturingAgreement', window );">Additional term of contract manufacturing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember', window );">PARI Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_FutureMilestonePayments', window );">Future milestone payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember', window );">PARI Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement', window );">Written notice period required for termination of contract manufacturing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember', window );">CFFT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Compensation earned under research funding agreements with CFFT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Royalty payable on approval of ARIKAYCE as commercialized drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_RoyaltyPaymentPeriod', window );">Royalty payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments', window );">Period for meeting sales milestones for additional royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount', window );">Royalty payable on meeting certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_TherapureBiopharmaIncContractManufacturingAgreementMember', window );">Therapure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_InitialTermOfContractManufacturingAgreement', window );">Initial term of contract manufacturing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement', window );">Period of each automatic renewal of contract manufacturing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement', window );">Written notice period required for termination of contract manufacturing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_AgreementWithSynteractHCRInc.For212StudyMember', window );">Agreement with SynteractHCR, Inc. for 212 Study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ImplementationAndManagementServicesAgreementAggregateCosts', window );">Commitment To Pay Aggregate Costs From Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_CommercialFilVFinishServicesAgreementMember', window );">Fill/Finish Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CommercialServicesAgreementMinimumObligation', window );">Minimum obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CommercialServicesAgreementExtensionPeriod', window );">Extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement', window );">Period prior to expiration for extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember', window );">License Agreement with AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember', window );">License Agreement with AstraZeneca | Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CollaborativeArrangementUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember', window );">License Agreement with AstraZeneca | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_PaymentsUponAchievementOfClinicalMilestonesAmount', window );">Aggregate payment upon the achievement of certain clinical milestones</a></td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication', window );">Additional contingent payments upon second indication to develop INS1007</a></td>
<td class="nump">42.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_SupplyAgreementWithPatheonUKLimitedMember', window );">Supply Agreement with Patheon UK Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ManufactureAndSupplyAgreementEstimatedCosts', window );">Agreement to purchase raw materials and fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_AgreementWithSyneosHealthForWillowStudyMember', window );">Agreement With Syneos Health For Willow Study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ImplementationAndManagementServicesAgreementAggregateCosts', window );">Commitment To Pay Aggregate Costs From Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and Service | License Agreement with AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Annual net sales</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_MilestonePaymentAxis=insm_MilestoneNewDrugApplicationMember', window );">Milestone, New Drug Application | PARI Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CollaborativeArrangementMilestonePayment', window );">PARI milestone upon FDA approval | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_MilestonePaymentAxis=insm_MilestoneFDAApprovalMember', window );">Milestone, FDA Approval | PARI Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CollaborativeArrangementMilestonePayment', window );">PARI milestone upon FDA approval | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of royalty payments if entity meets certain milestones under a research and development agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AdditionalRoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AdditionalTermOfContractManufacturingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional extension period of contract manufacturing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AdditionalTermOfContractManufacturingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional series of contingent milestone payments if selects to develop for second indication.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CollaborativeArrangementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CollaborativeArrangementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CollaborativeArrangementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payment paid during the period under collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CollaborativeArrangementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CommercialServicesAgreementExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the extension period under the terms of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CommercialServicesAgreementExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period prior to the expiration of the agreement in which an agreement for extension may be entered into upon mutual agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CommercialServicesAgreementMinimumObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum obligation due under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CommercialServicesAgreementMinimumObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_FutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_FutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ImplementationAndManagementServicesAgreementAggregateCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Implementation And Management Services Agreement, Aggregate Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ImplementationAndManagementServicesAgreementAggregateCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_InitialTermOfContractManufacturingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the initial period of contract manufacturing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_InitialTermOfContractManufacturingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ManufactureAndSupplyAgreementEstimatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacture And Supply Agreement, Estimated Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ManufactureAndSupplyAgreementEstimatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_PaymentsUponAchievementOfClinicalMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate payment upon the achievement of certain clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_PaymentsUponAchievementOfClinicalMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for meeting sales milestones for additional royalty payments after the drug is commercialized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period of each automatic renewal of contract manufacturing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_RoyaltyPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for royalty payments under a research and development agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_RoyaltyPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the written notice period required for termination of contract manufacturing agreement by either party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_TherapureBiopharmaIncContractManufacturingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_TherapureBiopharmaIncContractManufacturingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_AgreementWithSynteractHCRInc.For212StudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_AgreementWithSynteractHCRInc.For212StudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_CommercialFilVFinishServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_CommercialFilVFinishServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_SupplyAgreementWithPatheonUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_SupplyAgreementWithPatheonUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_AgreementWithSyneosHealthForWillowStudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_AgreementWithSyneosHealthForWillowStudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_MilestonePaymentAxis=insm_MilestoneNewDrugApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_MilestonePaymentAxis=insm_MilestoneNewDrugApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_MilestonePaymentAxis=insm_MilestoneFDAApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_MilestonePaymentAxis=insm_MilestoneFDAApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6955809952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense charged to operations</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Future minimum commitments due for firm purchase</a></td>
<td class="nump">86,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum rental payments under leases</a></td>
<td class="nump">38,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=insm_BridgewaterNewJerseyFacilityMember', window );">Bridgewater, NJ Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum rental payments for additional laboratory space</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">$ 32,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum rental payments under leases</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=insm_BridgewaterNewJerseyFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=insm_BridgewaterNewJerseyFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6655599984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Minimum Rental Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">$ 3,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">4,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">4,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="nump">2,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">2023</a></td>
<td class="nump">24,036<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">$ 38,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6954719536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 9,835<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,835<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product revenues</a></td>
<td class="nump">2,423<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,423<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(87,722)<span></span>
</td>
<td class="num">(83,983)<span></span>
</td>
<td class="num">(72,882)<span></span>
</td>
<td class="num">(62,751)<span></span>
</td>
<td class="num">(65,353)<span></span>
</td>
<td class="num">(44,083)<span></span>
</td>
<td class="num">(43,515)<span></span>
</td>
<td class="num">(35,969)<span></span>
</td>
<td class="num">(307,338)<span></span>
</td>
<td class="num">(188,920)<span></span>
</td>
<td class="num">(173,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (91,573)<span></span>
</td>
<td class="num">$ (87,743)<span></span>
</td>
<td class="num">$ (76,437)<span></span>
</td>
<td class="num">$ (68,524)<span></span>
</td>
<td class="num">$ (65,384)<span></span>
</td>
<td class="num">$ (45,179)<span></span>
</td>
<td class="num">$ (44,672)<span></span>
</td>
<td class="num">$ (37,414)<span></span>
</td>
<td class="num">$ (324,277)<span></span>
</td>
<td class="num">$ (192,649)<span></span>
</td>
<td class="num">$ (176,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss (in dollars per share)</a></td>
<td class="num">$ (1.19)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (4.22)<span></span>
</td>
<td class="num">$ (2.89)<span></span>
</td>
<td class="num">$ (2.85)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934989632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent of match</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contributions</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M]8??5=AWUNW=/S:^"*H&?MV%^@)02P,$%     @ !CQ63IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M.?O?_9NO@WQT$OK8M74_?:]VK_W0-G,KP4I3_;P=3^?I>)W;?P^3 W .P'L
MZ/\-4'. (@'IS=F4ZI=JJ+;KKKVNNMML7:JQ*.!!A<'<C3>GL9M^"]GVX>[;
M5N$Z?1O;F26/-PDN)$11<H52=TD:^K^;0-$$3O%J&:_E>"7&JRE>+^,-2>(F
ML9/D/$ET83)',^$RE0-8([O1HAO-W5CBYB8QBVZ, 6*YY*),MF%$&X;;<,2&
M83VXC$Y_R441&U:T8;F-G-BPK < A<1LR54YND*VXD0KCELIB!7')P;R0I/Y
M*[E,!96.%&TNNLF9&YT1-SEWDUM'ZT12!8[+7@K12\&] /%2L%X0+2WLDJL
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M-_VGM[TT;56,O3@I1?9C^#Z5_?=U[/\SC ^ ,0!N 4(]#(C&@.AG@'P8(,<
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M2^VNZ^%-Q7#35N?Q+4QP>Q6T^A]02P,$%     @ !CQ63NHTAUF[!   NQ<
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M6N DL#F(^5-V>(:FA>!!T"6LR DB,"ZU['%'$,X '0([(4O*L0TK$USSLSH
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MT6>D"YX"8]\)])V CB<X@(<!O.JXM5[T_*1)+IQRHKJM1909*_H,1(Y3[#=
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M\6;C_!MC/*"4Y 97J,,'MC@2&A_,]VC;:<TFQYM^?D%L><;E;U!+ P04
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M,MXBBTK-)2C+M4(&F@+?)H=C%O 1\(?#:%=G%"HY:_T2C!]U@7<A(1!0N:#
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M'VPV)-0N'&_]V8QC-AH.N^D'L?D;%Q]02P,$%     @ !CQ63L&]>*6V 0
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M1SS;:<PFPYM^_D%L^<;%3U!+ P04    "  &/%9.@5_<#;0!  #2 P  &0
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MCR\;^U\;XP&E)%<X0BU^L-F04/MPO,&S'<=L-+SIIA_$YF]<_ %02P,$%
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M:<7X;G?'M) =+;+H.YLBP\$IV<'9$#MH+<RO$R@<<YK0-\>3;%H7'*S(>M'
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M_]H8#YC*[@9'J,4/MA@*:A^.G_!LIS&;#&_Z^0>QY1L7?P!02P,$%     @
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MN)_]V7B++"HUEZ LUPH9: I\MSN>LH"/@%\<1KLZHU#)1>OG8'RO"YR$A$!
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M4]MNW" 0_17$!X0UZZ;1RK:4314E4BNM4K5]9NVQC0+& ;Q._[X#=APW=5^
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M;6KW:FS]T3"RFZ8:G4=K^0=02P,$%     @ !CQ63B$>,9.W 0  T@,  !D
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M!H+8<<Q&PV,W_2 V?^/B+U!+ P04    "  &/%9.E@+:/+<!  #2 P  &0
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M>+;CF(V&-]WT@]C\C?,_4$L#!!0    (  8\5DY][AHZV0(  'T*   9
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M0>@4 8?". IFEPL\ >>.R>IX&TF#J:<KG.^O[,_>O#5S9!J>)/]5EZ;:!4E
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MM)\S O*'_.#RI;9^&>GM1&MJRY.1F([5%M<IM85JS>2:VDK];"9QJ5),J\$
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M8D2)8<6L41(T2H)$28THR0>BI&B4%$9)S#62?B *\7%<^4@<P"+_(X$L7"2
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M;X:7^>%"BEI_J/!.7TL6_P!02P,$%     @ !CQ63O6K5XW> P  81(  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULE5A=K^(V$/TK4=Z[L6<<)[D"
MI NH:J56NMIJV^=<,!!M$M/$7+;_OOE:-MCC%;R0Q)P9'X]]9FPOKKKYVIZ4
M,L&WJJS;97@RYOP21>WNI*J\_:3/JN[^.>BFRDWWV1RC]MRH?#\8564$C,FH
MRHLZ7"V&MK=FM= 74Q:U>FN"]E)5>?/?6I7ZN@QY^+WA<W$\F;XA6BW.^5']
MI<R7\UO3?44W+_NB4G5;Z#IHU&$9OO*7K6"]P8#XNU#7=O8>]$-YU_IK__'[
M?AFRGI$JU<[T+O+N\:$VJBQ[3QV/?R>GX:W/WG#^_MW[K\/@N\&\YZW:Z/*?
M8F].RS -@[TZY)?2?-;7W]0TH#@,IM'_H3Y4V<%[)ET?.UVVPV^PN[1&5Y.7
MCDJ5?QN?13T\K^,_,4YFM %,!G SX/*G!C@9X \#\5,#,1D(RR :AS+$9IN;
M?+5H]#5HQND]Y_TJXB^BB_ZN;QR"/?S7A:?M6C]6F*:+Z*-W-&'6(P9F&'Y#
M1)WW6Q= =;$&QQSN.]BX",1[R-:%R(0F@>0X<;#'NW%FM -!.A"# S%WD#$K
M4"-&#IAZQ,B49=9H710@2SRCB4DR,4&&6V1&3#SKYA<N>&(%=D/!F!0Q34>2
M=*1#1]ALI-,-@$1ID7%1' 0"S24AN21$:*SUMDZ<;E R:S(W+@@R&[1-W+D4
M,] =WY3DFQ)\K3E:IVY8&/BZR<AN,J(;03O@C,X4['$)<4^RX0^(: +-8YID
M&%NS,Z'F,4E8[%FUG$Q,KQP(.K%-QP5!YEF1G,X]'(E^I,<%G7VX>"+X=,[@
M5-)P@A\3R0EL:7 W:? ,/1F,TSF#NTF#"+X+\@>?S@><2@@^JK1$>?I$\&GY
M<4I_3O SMWXDF9TC)U1\/T6>E0^TEH$1=%*/"UK+P!\/"M#Z@T?T1X @]5&E
M]0>4_GQ4:?W!$_H#6G] Z<\9K0N"S)/H@186$-785RN U@PD3XR6U@Q0=<U>
M\!-HON"EG>C!+7[2M]AI[0&E/2?P+LB;:9 6%;JB$LRS4T9:5/B$J) 6%5*B
ML@,_@>:!YUS:F69"W:5Y@9["A9Y]-Z4]._@$R!]\6J#H[L\%\[F@!8KQ$\&G
MM8=447."+]T-#C#[3(3N7EAFZ*-#ZQC=VB<8>ES0.L8G:A_2^L-':A^Z5:U;
M:V!G R1*Y'Q_<G^0HW4JJ.)G;[DGT+U"F)-'H]DYNU+-<;C#:(.=OM2F/Z[.
M6F_W)*_0G].M]C5_V8ZW'3_<C)<O?^;-L:C;X%T;HZOAK'[0VJB.)?O4Q>ND
M\OWMHU0'T[\FW7LS7GJ,'T:?IPN=Z':KM/H?4$L#!!0    (  8\5DX'@SN>
M< 0   87   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;)58:X_B-A3]
M*X@?,(FOG1<"I(&9I95::;15NY\S8![:A+!)&+;_OGD-);['6> #).;<E^US
M;N+I)<N_%WNMR]'/-#D6L_&^+$\3QRG6>YW&Q5-VTL?JGVV6IW%9W>8[ISCE
M.MXT1FGBD.OZ3AH?CN/YM!E[R^?3[%PFAZ-^RT?%.4WC_-^%3K++;"S&GP-?
M#[M]60\X\^DIWNF_=/GWZ2VO[IRKE\TAU<?BD!U'N=[.QL]BLE)A;= @_CGH
M2W%S/:I+><^R[_7-[YO9V*TSTHE>E[6+N/KYT$N=)+6G*H\?G=/Q-69M>'O]
MZ?U+4WQ5S'M<Z&66?#MLROUL'(Y'&[V-STGY-;O\IKN"O/&HJ_X/_:&3"EYG
M4L589TG1?(_6YZ+,TLY+E4H:_VQ_#\?F]]+Y_S3#!M09T-6 Q*"![ SDU4"J
M00/5&:A[(WB=@7>O@=\9^/<:!)U!8!@X[>PVR_42E_%\FF>74=[NN%-<;VPQ
M":H-L:X'F_5O_JM6K*A&/^;*55/GHW;4818MAGH8KX]YX1@*PC[FE6/$%>%4
M65Y3)93J@D :?C_$$F$"(U6$,5/E&$EN'_,%^8GZF!7 "!<7+>'ZR,:!O)TS
M7V$'"CI0C0/5RT 8U;88O\$<&TRHE%M]<" /!O)8("'-0"W&NPFD/+?]&)/K
ML90,Q&H(T4O7A^GZ+%VV7WV6+7DJ()XL!WH1>0RWXCBIHM ZSP%,/  +2D;F
M 4_(@]/,@6;.0XA>MB',-N33;'#D)60+201R?0WY<I ;\9JX/[.F(42OI@C6
M%($5D-B!<+'JNO?36EB$6X L#.5>=J#PMM(GESQ/AK9H4'N?!8%HGL4%5C+Q
M@)0)K&4"B9FQ]Q>"JQG;_/U@6,\$%S0E?#,85R%)0[&P& FN1M*U-$>!94$$
M#TPOYJK@9%7"Z)ZO@M.0:W@_&F:1X#22KH5&A&E$#]"(,(T(T<BH>=F!_/MK
M)DPC0C0*S6C$U7LX&"8<R5^W_F4'N@TFU- .)DQ-XM1D[7])G)I*>N%0-,Q-
M0MR,S&@M*+CE9O1T0^%^),Q,0LPT9;8#]53 C<1079C$!)J[^=RYA"#;DS1F
M.@&F$YEQ>)L4JFFXUJHPTPDT3))F- 2R<%EB.9#NKY_I.DSO::-K#Y986#<D
MT VR-$2)Q4#2_>HE+6\'@.)DOA-)3G%;HIC;$K1=,C6R ]T3!7-: DZ3J8T0
M%%GB8$9+SF@E;8N/:2H?Z+42,U B!K*50[W6$@933R)6L:6+> ^P3(C"S%.<
M>7SM$$A:=$MAUBG .DD6%YAUZ@'6*<PZ!5@G33U3G'6V7:8L;^Z =M*6*>:4
M\AXH%M-% ;JPC:K J[*M6$PIA9J:N5$5?QFUSBFFG4*T8QL5@*3).^?FA"W5
M^:XY4"U&Z^Q\+.L9OQF]'MH^4WU"9XPOQ&0IP/BKF*S:$[W_W;<GQ'_&^>YP
M+$;O65EF:7-ZM\VR4E>YNT_5Y.QUO+G>)'I;UI=!=9VW)[/M39F=NE-GYWKT
M/?\/4$L#!!0    (  8\5DYW[4Z)3@(  *<'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;(U5VX[;(!3\%<OO78S!ET2.I291U4JMM-JJ[3-)2&PM
M-BZ0>/OW!>RU?"%M\A #GC-SYO@ 6<O%JRPH5=Y;Q6JY\0NEFC4 \EC0BL@G
MWM!:OSES41&EI^("9",H.=F@BH$P"&)0D;+V\\RN/8L\XU?%RIH^"T]>JXJ(
M/UO*>+OQH?^^\%)>"F460)XUY$*_4_6C>19Z!@:64UG16I:\]@0];_R/<+V'
MR 18Q,^2MG(T]HR5 ^>O9O+EM/$#DQ%E]*@,!=&/&]U1Q@R3SN-W3^H/FB9P
M/'YG_V3-:S,'(NF.LU_E214;/_6]$SV3*U,OO/U,>T.1[_7NO](;91IN,M$:
M1\ZD_?>.5ZEXU;/H5"KRUCW+VC[;[DV<]&'N@+ /"(< B/\9@/H ]&@ [@/P
M+ !T5FQM]D21/!.\]43W>1MBN@BNL:[^T2S:8MMWNCQ2K]YRC.(,W Q1C]EV
MF'"$":>(W1*!43+%[)<8A 8(T$D.F8;.3$,;CR8:J9L .0F0)< 3@M7,:H>)
M+:;N,%&@?VX=[-3!2QT<S'0Z3#32^9".41.9R"D3.63@3"9:RL!0&PK=0K%3
M*'8(S1I@&R^$$(RC*)WU0+PH;Q1%<>+.)G%FDRRR00%T$Z1.@O3Q/EHY"58/
M%'ZU,-H5_LX7AH%[<P8.LW<V#;RSO^'C=J%[X\'P_PV]ZT%3QSB\:]B]1>%R
MCT(TKZT+A.<]!$8'H+G"OA%Q*6OI';C29ZD]\<Z<*ZH)@R?=MX6^-8<)HV=E
MAHD>B^[JZ":*-_VU"(:[.?\+4$L#!!0    (  8\5D[4XAN^Z0$  %4%   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;'64VXZ;,!"&7P7Y =9@#J$1
M(#5;5:W42M%6;:\=& ):@ZGMA.W;US8LHN!P@4___-^,P<Y&+EYE Z"\MX[U
M,D>-4L,18UDVT%'YQ ?H]4K-14>5'HHKEH, 6MF@CF'B^PGN:-NC(K-S9U%D
M_*98V\-9>/+6=53\/0'C8XX"]#[QTEX;929PD0WT"C] _1S.0H_PXE*U'?2R
MY;TGH,[1Q^!X2HW>"GZU,,I5WS.57#A_-8.O58Y\DQ P*)5QH+JYPS,P9HQT
M&G]F3[0@3>"Z_^[^V=:N:[E0"<^<_6XKU>0H15X%-;TQ]<+'+S#7$R-O+OX;
MW(%IN<E$,TK.I'U[Y4TJWLTN.I6.ODUMV]MVG%:2= YS!Y Y@"P!9*IE MG,
M/U%%BTSPT1/3W@_4?.+@2/3>E&;2;H5=T\E+/7LOHBC,\-T8S9K3I"$K34C\
M18.U_P(A3@BQ!N'*($ABMT'H- BM06P->FM _.##)LU)E*Q$#Y*,G(S(P5B5
M.3'VH@>,V,F(78Q@P]B+'C 2)R-Q,<B&L1<]8!R<C(,-C_[[:Z(-XK!#1+&O
M'S<G=7)2!R?><-+=9W=R\.I$F OG.Q77MI?>A2M]N.P1J#E7H"W])YUUH^^X
M9<"@5J9[T'TQG?1IH/@P7V)XN4F+?U!+ P04    "  &/%9.=I%#/T$#  "%
M#0  &0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6R-5]%NFS 4_17$!P1L
M;$RJ)%)+.VW2)E6=MCW3Q$E0 6?@)-W?SQB7@'U)TX>"S;GWG&O,B>_B+.JW
M9L^Y]-[+HFJ6_E[*PUT0-.L]+[-F)@Z\4D^VHBXSJ8;U+F@.-<\V.J@L AR&
M<5!F>>6O%GKNN5XMQ%$6><6?:Z\YEF56_WO@A3@O?>1_3+SDN[UL)X+5XI#M
M^$\N?QV>:S4*^BR;O.15DXO*J_EVZ=^CNR>,VP"-^)WS<S.X]]I27H5X:P??
M-DL_;!7Q@J]EFR)3EQ-/>5&TF92.OR:IWW.V@</[C^Q?=/&JF->LX:DH_N0;
MN5_ZB>]M^#8[%O)%G+]R4Q#U/5/]=W[BA8*W2A3'6A2-_N^MCXT4I<FBI)39
M>W?-*WT]=T\8,V%P #8!N ]0W-<"(A,070+BJP'$!)!+ +D:0$T M0*"KG:]
MF(^9S%:+6IR]NML/AZS==NB.JM>U;B?UV]'/U'HV:O:T(B1>!*<VD<$\=!@\
MQ(1TC$E=#.H1@5+0R\"0C ?LA.,$610 9HQX=!%1-(8\N9"8P4(C<+TB'1^-
MUFLB 0$3$)V # 58&M,.0C6DTA :FC^KX%N0(TT4U$1=3=;2IAV$#9C"66B]
MH<=/0",E,:@D=I402TGLU,Q8%#**;34 ,(Y12,,$5L1 1<Q59.]]=JLB 'A5
M40(J2AQ%A"36)YLX3(@@'"$ZL2_F(-,<8)I;3'.7*2%XD@B%L V%+A4-;1\*
MG?V%DQF=()KP.P00(9NH \5#(I),?5,(M+1[A $F;#-AAREBC-D?>@K@;"^
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M2&&&I[ 1FK24\DF[1I0? 1N$W4; 5#5.7P+D+W_=:."<Y:H!U:KV(A)@,J+
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M,M&,>9MTI5#78;CIRSQGJ#77_P%02P,$%     @ !CQ63M#4;ZF= @  4@H
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MF?F>A72TK9(MZTS,.C;\W;2!94+]PPE!VFY)04C;+AD$.8\</_C2.X"$OAL
M:%[AST#9!]#4,7AP[!QW_B*%,\=S"'#\"2C[ .H<6Z.#M<;TK)H69N3DTG!Y
M/HUFA\9HI_HB;3Z1#9,ZL-]ENF[K!Z+GLF'&@7!Q[*O#^40(Q\*C_22^MH5H
M\(9!A4]<WH;BGG9=3C?@I.T[.&MH(^/_4$L#!!0    (  8\5DZL*E[@M@(
M #D*   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;'V6;6^;,!#'OPKB
M?8L?P$"51%HR39NT256G;:_=Q$E0 3/;2;IO/QL(2NTC;X)M_G?WNXLY>W&1
MZDT?A3#1>U.W>AD?C>F>DD1OCZ+A^E%VHK5O]E(UW-BI.B2Z4X+O>J.F3@A"
M+&EXU<:K1;_VK%8+>3)UU8IG%>E3TW#U;RUJ>5G&.+XNO%2'HW$+R6K1\8/X
M*<RO[EG963)YV56-:'4EVTB)_3+^A)\V.',&O>)W)2[Z9ARY5%ZE?'.3;[ME
MC!R1J,76.!?</LYB(^K:>;(<?T>G\133&=Z.K]Z_],G;9%ZY%AM9_ZEVYKB,
MBSC:B3T_U>9%7KZ*,:$LCL;LOXNSJ*W<D=@86UGK_C?:GK21S>C%HC3\?7A6
M;?^\C/ZO9K !&0W(9(#3NP9T-*">03*0]:E^YH:O%DI>(C7\6QUWFP(_45O,
MK5OL:]>_L]EJNWI>,4P6R=DY&C7K04-N-)YB$RHHG22)!9@H"$A!>GOZ@6+&
M 04=T-Y!^L%!ZJ4Q:%BO:8<T*"YQX>42RG#!:$I@G!3$20&<S,,9--EM'%1F
MR"]M*&.,YABFR4":#*!A'DT6ABD#EE"4YQ3!* Q$80$*S3T2%@9A&?9(0M$,
M1@YBY$!%O!#K/ A!TB+S_L5-J,(YP3D,4X P!0#C%Z4(PM "%<3?NZ&,Y#EC
M,[4I09P2^!8+V %&<$]!0$:EWU10P/J LY2D?FN!=(S.Y81GVAP.D0CRD7 8
MBI*\+'VD4#=' [<[3  :?_^-H@\T:4$(]6D W;T"P0T4 QV4! <!#;<A)0SY
M'P6@([:AHSDDN(EBH(OZV:]QV!\?8"9 >!<*[J48:*9AG;+@#$$^SCW) )+<
MG.'N4O6#JT/5ZNA5&GL=Z _MO91&6'?HT;H[VGO<-*G%WKAA;L=JN,P,$R.[
M\:*63+?%U7]02P,$%     @ !CQ63N3&KF V @  NP8  !D   !X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL?571CILP$/P5Q <<!!,@$2!=J*I6:J7HJEZ?
M';()Z RFMA.N?U_;$(X87U[ 7F9G9Q98ISUE;[P"$,Y[0UJ>N940W=;S>%E!
M@_D3[:"53TZ4-5C(+3M[O&. CSJI(5[@^Y'7X+IU\U3']BQ/Z460NH4]<_BE
M:3#[MP-"^\Q=N;? 2WVNA IX>=KA,_P"\;O;,[GS)I9CW4#+:]HZ#$Z9^[S:
M%AN%UX#7&GH^6SO*R8'2-[7Y?LQ<7PD" J50#%C>KE  (8I(RO@[<KI3294X
M7]_8OVKOTLL!<R@H^5,?196YB>L<X80O1+S0_AN,?M:N,YK_ 5<@$JZ4R!HE
M)5Q?G?+"!6U&%BFEP>_#O6[UO1_Y;VGVA&!,"*:$5?0P 8T)Z",AU.8'9=KJ
M%RQPGC+:.VQX61U6W\1JBV0S2Q74O=//I%LNH]<\"L+4NRJB$;,;,,$,LYH0
MGF2?2@2V$KM@D1[<%RB6"(3L%9#5!-+Y:"XP#NT$H94@U 3A71?61A<&3*0Q
MK<;XAHU'B#L1:ZN(]<)%%$1V@LA*$%E<Q(:+ ;-^X.(1XDY$;!416T0DAHAX
M40*AT.AWL01]HB.QZD@L.C:&CF11(@[-;W.)^43&QBICLY2!C([O-HOO)O03
MX\452Y"IPYO]\PVPLQZ/W"GII17J[YI%IPG\'*B98<1W<C(/@_2#9ACK/S$[
MURUW#E3(B:3GQHE2 5*@_R1[5,F39-H0. FUC.6:#?-TV C:C4>%-YU7^7]0
M2P,$%     @ !CQ63D'G#/V>!   +1D  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3DN>&ULE9G;<N(X$(9?A>(!L'6R30JH"DF8)).M2LW4[EX[( XU-F9M
M$V;??GT0'EON?];<!%OYNULMZ6L),;LDZ8]LKW4^^AE'QVP^WN?YZ<YQLO5>
MQV$V24[Z6/QGFZ1QF!>OZ<[)3JD.-Y51'#G<=3TG#@_'\6)6M;VGBUERSJ/#
M4;^GH^P<QV'Z[U)'R64^9N-KP[?#;I^7#<YB=@IW^KO._SR]I\6;TWC9'&)]
MS [)<93J[7Q\S^[>E%\:5(J_#OJ2M9Y'92H?2?*C?'G9S,=NV2,=Z75>N@B+
MCT_]H*.H]%3TXQ_C=-S$+ W;SU?OJRKY(IF/,-,/2?3W89/OY^-@/-KH;7B.
M\F_)Y5F;A-1X9+)_TY\Z*N1E3XH8ZR3*JK^C]3G+D]AX*;H2AS_KS\.Q^KP8
M_U<SVH ; ]X8</9; V$,Q% #:0QD8\#D;PV4,5!##3QCX WMDF\,_*$&@3$(
MAAI,C<%TJ %SKS/G#C9I)IL--KE.-[/GVZD75K52'\,\7,S2Y#)*:]A.8<DT
MNRNL"N=E:[7VJW\6JS4K6C\7GF SY[/T9#3+6L-;&NFJKN9+7_/+BU-TH>D'
M)_NQY#U[3_!NC =*([J:1THCNYHG2F/ELZ(TGI5S7R.XV]4\]S6269H7*I;?
MU;Q2FJ"K^4IIIEW-&Z&1+CU3@EXQHO(@.Q[ 7$O:@ZP\B(X'3GM0M =%],%>
M"91&TE$\.HI'>+#6R6-?PZ=@/'TZBD]$\6@/ >TA&#Z>4]K#E.B#M0)7M8;5
M2^=8B=R)HL.4Q8^L-BX1*  ^4,5BP]-E=+6Y9YSHAX7*(R528&X9@(41M"A
M"P.XL!MX80 81M"@K/KZ8D3E)#53S">6ZI52L8D/^@/08@1;2MA[BD=$$A,
M,0-\,0(P)>U0?1$/T,($&+* "-3;)_LB6# 8H)41N"I[<S*BSN")R92.Q &O
MG.!5@:GF@%=^ Z\<\,HI7JWE\D2(X-!RP"NG> WL0)0(C2R FLO_KT!/E @&
M N1S@GP/C0J@E7LW3"' D!,8>M9)\\&(O-::1=L#!Q1R@D(/]14 QJ?#\Q4
M'4&@XUE+]LV(K(H+ !, ,,&(2':!HT1H*0E H2 H].P"1XG0KBG0$9, S -G
M(@$ $S?LF@*P(RAVK'/1THC::U: 8Y$ ? EB-_3 NA> +^'?D"]@1U#L6$7I
MV8@Z^:+Y!7P)8@/S@0\)^)+N\'PE($<24/CVMU\C4JU\ S"_$H C"29\;L>I
M18RUBQ]')VP)T)$$.KX /M#WLQO0D0 =2:#C6T7IJ^RC@[8F"="1!#H^&C.
MCKP!'0G0D10Z]O8F^^AP]-49H",I=$!I5  ==0,Z"J"C*'3LTFA$[7R9ZX(9
M5@ >1<$#BJ,"5"AQ0\: "D4<QGRK.*Z,J%TLP 0K=+5!@!.@(0-0J!O.:PI
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MLT0L$$9FX7\&#&0\>S@!$SCPU8DNW]_\=!4<7/285*0LE_N"[Y%<'[93/*:
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MKNL:\!L!A9QS55P#'=VA+,D$7:AKQ608%E6BT 04$-2!2"EM*,E4!2BFB/7
MD%&]P,U\3K(M:]\G(O5P$ )\KX<@SZ(Y29Q*F.,^PDV'5>]12'<$<WMB+59Q
MF)C /:W,4V0\;1+N9C]4!MX!QM51U"-F+[I!9.&+#BL++S<O"\Z"\(27<8\#
MT++D+4<3=DGY"56P(N<C97*AFH"H5 !=$JQ Q@%^N0EH!K#-8ZXFWF)Y2-#$
M=416D=&J/:H@VN'%!>E%$'H=DA_$WR4QR54J&+%-3G1K ;M0V0-"BJ(4R$Z
MVUL4,8 &4RR0N*8 &2S,"/3)KF+TJ:.UT(CP#BYAAA2%9+A0$E"P9<IH=L5;
M@17N4M0@\;HZ'2%GY1F7!KP!<(^!EZ=?#M%@&.TH?J[W/$WE[@CR2DEH>6<H
ML<1>X&&_!]5EU6;+:S[2K;*T6[V>/WGTD0T$KT$\VA'&B.:"@-VC^:ITA(0I
MC#%M>LA57KO*Z *A$(;82M)@XN>5R[:%B83<PA&A#K$W@D]-;_CQYN;]E2)>
M!;B6@W1+2(+'F'Q*H]2MGLA"51UW>^6W2%_8X(!#)SL-&!)!0*9\>E\T\DIT
M-=P*&9%J&(CDBI J7-'?C^M[,0'GT8,3&XAKE%E*=F@D['GT.6%USAD)=2<\
MD2X?B5VK";*Q,:\=+,6277$ !)'N<$CGS[:N7S\B7HPT 1;,-HUHS^B/TA0J
M. 1DM@)UGD>,W!^9.+Q =D 8,XZ6QP,)+ZIK'0JF+@9O2/P6*09PIGC$K<!P
M58<%.@Z<MC%+>HZBKDA&T!,-INB0,L@"!M1[=3A2#$$%FB(.>-RN17-@X>KP
M4%0&'X'F>E^X.-R(?RJ5?LU0]O:"FN><$#.K^'P<;9??8*D8Q%G43[I3-NY%
M=<^['Q]N)M",;'L*9N)0 ",:A#,A(^I%S@Y&?[PVLK@A)E[0S%$$*ZNFY,[R
MT4-V_P"KV&;PRUJLQ#NOD -<53PFFE2FJ5!F9!5;Y-9R$BG)R60R$9MV+^+
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M.$A2EB>) #JR!0MD69J6Q?L";<J$5AC0 6)7+_J@'[P(R\N4FY!N.1"072;
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M*+70J$RA9)?SB[7V#[%-;C"U61"I+\:3OI$"DGM UWMN04 >G\26#FP=.0S
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M2SAYSL1/92D=]4DUYV)@@AMMC:,]CZ2ZC(B [+@4%=<QEL:\DJ9@;\C )OO
M]&XTH^K'WTCIT4]OV.CL?J2[(B4EVHL"V;\6\9SZ5_"_MP5?0K46EC+,OSTY
MSC >#T?NWU_#@BH7T>5T&,^DO\?E;!C/M:;??!0OYE(W:3ZC=C;T-_9C'HWF
M4N[(C3*/)UJY:3:-QZ.9?W,LHRP&\60F?V/AO^$,'WJ98/,,LM]GV^-!$HEH
M7'\"\$:_-U](%:=>OZ]_#<;N+_EUW*.5TL%^\V']V[_Q<<&_SSZPYE_??F@M
M5;X;!S>:Q(NI;GH43P83^1LSU03,TTD\FFCQJSFV?^G7#FXTB\<*1'AS*F4
M+\>3>#!;^%'F"NC%$'NC?-7!3>6X^CT=O=_3E5-Y<_IKR ?<*.3\;]'K+U+&
M&8AF>3#FXLR5#Q,K0B^"$W-5GQ.?+:^6\S 49U9GP"Y4'0;W_%5C=4U\.CY\
MEN?6*=^'%!D>K0&K)Y_Y^:7F5W63T=I@34TN&O<'EY^N7/P6<<$,&"D"#ML?
M>]^ZS>_=4OI/V,V!\V$J;,0'# MM[W8P"C'R+YBL@K<?[JZI@D&ZMLF-/5-M
M,'2?S^N^073ZK]$!^1U"ME%1NK:.P $RYE?T23@>G.>2W4T4,?3A#F;X@GSZ
MRA75+FM#/B>9NMFL!^.;@U!XJC?NPV(D3<YV\PE%^??J4&\ID/5/067T7:.E
M-K%5"E>\,_'8-RM*;4%J\QY3'2DN3_]J2 8O69W88)OR2DUASWK(]",)RN"W
M5@L0OZ_X3%<N0;D>J$ IU0\@/YRNL8;*.B@"C+$S%?JVQ8T31[?I%N#U14)&
MU0U1Q?_Z+X-I_P>.M)%W?BJV)$[YE^6'MTA&\G7C^S<EY67=W=RYKWZDVJ0G
M'AWC4]TO0)5!/<%Q*O[U9>^O?NZ7\-YQG3CW$TZG0Q8@8O\ER8#B@CBYW7(>
MZDI $I0;HJ1!SG*VYG6M!\)6 W\4BJZNPR)A)ET'%6O]()CY:N+!R3RJ,7L2
M_B'Q(AX!&F3R(_O-M)-G0W*M_VXP",;=)V%TPG.02M>*-D9N=N^1'_8+;^R1
MMONT:4ZX2UV]$FR&@[9A3IZ^Q'KR5[X0BK$&J^=:K=Q\'+8U+BLQ&@;D52C8
M&3 ^/^73^Z*15X(#N!50P53'T<O"956IF%RPHK\?U_=BW,]M*U:T+L =TB(;
MA2\]QW9=LQ-QT_@J AV%4^L;\S8$P5(0(U)]\1 .J=(45[31_"XWHDM DNA#
M03O1XAC($IO?=1ZNW$N9<M?B#1JM-3Y9"ZH<BMC2)$UEDN4%)1NZFH+$M3+$
MG/)N#;>Q.]%@BH[H%S)N][!:"!H,M/K8BI)VN*J*AB]C9)#;?^,VOO5>)2GS
MPV1'TMQ?,]"_[2WGFS>.*WI8BHY*6V?7&H)^XZ[QS?(RE-A)E K_P+OW&>,
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M2()OCIY+/#87(G@@UZO0=^9"&-=M4_G9X8)9G;9@ Y?/LGY6Y#.GV/MSUT
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M$/=;3XC[8<KO#P)OEL/_R=-W[7$I/2&GR8OHXVJVU"QKN),(H &W* Q%9DA
M\T(F)1A6$SVIP'N16.S9+S*I<%@=LN^W%(AP8O,&/%/0M=XI]$P&A:X%=!"P
M+\/DIGTRK2#N;K%Z6KD*T/>< 5=Y47*XA'WG=.=>AA)+>K/-YZPO[-:JA,],
M6D2P>0(779J(SQPDCH-^>1/,YQ]A@H@!;=<SSDT&O8'FX$^X+"4^%7E;]JEG
M Y7R/9_7&<3Z^WM7M]DV7K6V,SF_T>RDR<C7_^^NCO;9HF3<C^R:)_(D>)?
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MNK'NJ7'$@@H)E#YWFLXSGN+!ACT[,D>RT6&$"UG7MA7L][*9/@JT(P-(*.T
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M_IS/QG]=+=X 4$L! A0#%     @ !CQ63A\CSP/     $P(   L
M     ( !     %]R96QS+RYR96QS4$L! A0#%     @ !CQ63B?HAPZ"
ML0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  &/%9.;Q<:I^\    K @  $0              @ &9 0  9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  &/%9.F5R<(Q &  "<)P  $P
M        @ &W @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  8\
M5DXS2HG@O0(  ,\*   8              "  ?@(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  &/%9. 9M?!+L#  "4$   &
M        @ 'K"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ !CQ63LH!TPOU 0  AP4  !@              ( !W \  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (  8\5DZ?1N7;_0,  !82   8
M              "  0<2  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    "  &/%9.ZC2'6;L$  "[%P  &               @ $Z%@  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ !CQ63M4HM?M^!0
MWQP  !@              ( !*QL  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    (  8\5DZ\1=T[L0$  -(#   8              "  =\@
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  &/%9.XN=J
M\+,!  #2 P  &               @ '&(@  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ !CQ63FPE$4FU 0  T ,  !@
M ( !KR0  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  8\
M5D[T8@5_M $  -(#   9              "  9HF  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ !CQ63L&]>*6V 0  T ,  !D
M         ( !A2@  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    "  &/%9._QRMF[,!  #2 P  &0              @ %R*@  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (  8\5DZ!7]P-M $  -(#
M   9              "  5PL  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ !CQ63DBC4Y^T 0  T@,  !D              ( !1RX
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  &/%9.E5;$
MH[,!  #2 P  &0              @ $R,   >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    (  8\5DZ-YA!%M $  -(#   9
M  "  1PR  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M!CQ63DL)L(6T 0  T@,  !D              ( !!S0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    "  &/%9.:)3DXK8!  #2 P  &0
M            @ 'R-0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    (  8\5DXCQ/VMM $  -(#   9              "  =\W  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ !CQ63JID7H*T 0
MT@,  !D              ( !RCD  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    "  &/%9.IC;-ZYL"  "L"@  &0              @ &U
M.P  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  8\5DY/
M@K)'Z0$  &8%   9              "  8<^  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ !CQ63@4V#6:W 0  T@,  !D
M     ( !IT   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  8\5DX<%WTD[0$  &8%   9              "
M 5M*  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ !CQ6
M3H]\S\+N 0  9@4  !D              ( !?TP  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    "  &/%9.(1XQD[<!  #2 P  &0
M        @ &D3@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   (  8\5DZ6 MH\MP$  -(#   9              "  9)0  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ !CQ63GWN&CK9 @  ?0H
M !D              ( !@%(  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    "  &/%9.#+SC6?D!  #G!0  &0              @ &050
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (  8\5D[U1AEX
M-@,  (8.   9              "  <!7  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ !CQ63L1:/^GV 0  YP4  !D
M ( !+5L  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  &
M/%9.CB[1NX("  !*"0  &0              @ %:70  >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  8\5DX)F6]!B@,  )H/   9
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M970T,2YX;6Q02P$"% ,4    "  &/%9.I^'/35D"  "A!P  &0
M    @ $9;0  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M  8\5DXX\'7R@0,  #D1   9              "  :EO  !X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ !CQ63O6K5XW> P  81(  !D
M             ( !87,  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    "  &/%9.!X,[GG $   &%P  &0              @ %V=P  >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (  8\5DYW[4Z)3@(
M *<'   9              "  1U\  !X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ !CQ63M3B&[[I 0  504  !D              ( !
MHGX  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  &/%9.
M=I%#/T$#  "%#0  &0              @ '"@   >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    (  8\5DZOEZ/Q%0(  (\%   9
M      "  3J$  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ !CQ63@FR@\L'!0  7QD  !D              ( !AH8  'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  &/%9.ES,%I*4&   /*
M&0              @ '$BP  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    (  8\5D[#:N1U^@,  -H2   9              "  :"2  !X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ !CQ63OS+BX3&
M @  8PH  !D              ( !T98  'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    "  &/%9.)2N[,3P"  !4!@  &0
M@ '.F0  >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (  8\
M5DZ:H,YYL0(  '<*   9              "  4&<  !X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ !CQ63M#4;ZF= @  4@H  !D
M         ( !*9\  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
M    "  &/%9.K"I>X+8"   Y"@  &0              @ ']H0  >&PO=V]R
M:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (  8\5D[DQJY@-@(  +L&
M   9              "  >JD  !X;"]W;W)K<VAE971S+W-H965T-3@N>&UL
M4$L! A0#%     @ !CQ63D'G#/V>!   +1D  !D              ( !5Z<
M 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    "  &/%9.OJDY
MR$L"   C!P  &0              @ $LK   >&PO=V]R:W-H965T<R]S:&5E
M=#8P+GAM;%!+ 0(4 Q0    (  8\5DX C%<M\@$  & %   9
M  "  :ZN  !X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @
M!CQ63O_]9A*D P  7Q   !D              ( !U[   'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6Q02P$"% ,4    "  &/%9.IFKPT!0"  #O!0  &0
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9>&UL4$L%!@    !( $@ JA,  ')9 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>199</ContextCount>
  <ElementCount>344</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>75</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Intangibles, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangiblesNet</Role>
      <ShortName>Intangibles, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Fixed Assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FixedAssetsNet</Role>
      <ShortName>Fixed Assets, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - License and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LicenseAndOtherAgreements</Role>
      <ShortName>License and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Inventory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/AccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Intangibles, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangiblesNetTables</Role>
      <ShortName>Intangibles, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IntangiblesNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Fixed Assets, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FixedAssetsNetTables</Role>
      <ShortName>Fixed Assets, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/FixedAssetsNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Debt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/StockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Description of Business and Basis of Presentation Description of Business and Basis of Presentation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails</Role>
      <ShortName>Description of Business and Basis of Presentation Description of Business and Basis of Presentation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Fixed Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fixed Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2402408 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2402409 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2402410 - Disclosure - Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Inventory - Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails</Role>
      <ShortName>Inventory - Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/AccruedExpensesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Intangibles, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangiblesNetDetails</Role>
      <ShortName>Intangibles, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IntangiblesNetTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Fixed Assets, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FixedAssetsNetDetails</Role>
      <ShortName>Fixed Assets, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/FixedAssetsNetTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/DebtTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Debt - Components of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtComponentsOfDebtDetails</Role>
      <ShortName>Debt - Components of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Debt - Future Principal Repayments of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails</Role>
      <ShortName>Debt - Future Principal Repayments of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/ShareholdersEquity</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Stock-Based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Stock-Based Compensation - Range of Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails</Role>
      <ShortName>Stock-Based Compensation - Range of Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Income Taxes - Loss Before Income Taxes in the US and Globally (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails</Role>
      <ShortName>Income Taxes - Loss Before Income Taxes in the US and Globally (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Income Taxes - Income Tax (Benefit) Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails</Role>
      <ShortName>Income Taxes - Income Tax (Benefit) Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Income Taxes - Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2411401 - Disclosure - License and Other Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LicenseAndOtherAgreementsDetails</Role>
      <ShortName>License and Other Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/LicenseAndOtherAgreements</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Commitments and Contingencies - Minimum Rental Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Minimum Rental Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="insmed10k2018.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - Retirement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/RetirementPlanDetails</Role>
      <ShortName>Retirement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/RetirementPlan</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="insmed10k2018.htm">insmed10k2018.htm</File>
    <File>insm-20181231.xsd</File>
    <File>insm-20181231_cal.xml</File>
    <File>insm-20181231_def.xml</File>
    <File>insm-20181231_lab.xml</File>
    <File>insm-20181231_pre.xml</File>
    <File>insm-20181231xex10154.htm</File>
    <File>insm-20181231xex10292.htm</File>
    <File>insm-20181231xex211.htm</File>
    <File>insm-20181231xex231.htm</File>
    <File>insm-20181231xex311.htm</File>
    <File>insm-20181231xex312.htm</File>
    <File>insm-20181231xex321.htm</File>
    <File>insm-20181231xex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "insmed10k2018.htm": {
   "axisCustom": 2,
   "axisStandard": 23,
   "contextCount": 199,
   "dts": {
    "calculationLink": {
     "local": [
      "insm-20181231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "insm-20181231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "insmed10k2018.htm"
     ]
    },
    "labelLink": {
     "local": [
      "insm-20181231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "insm-20181231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "insm-20181231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd",
      "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 554,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 33,
    "http://www.insmed.com/20181231": 4,
    "http://xbrl.sec.gov/dei/2018-01-31": 14,
    "total": 51
   },
   "keyCustom": 45,
   "keyStandard": 299,
   "memberCustom": 37,
   "memberStandard": 37,
   "nsprefix": "insm",
   "nsuri": "http://www.insmed.com/20181231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Document and Entity Information",
     "role": "http://www.insmed.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Accrued Expenses",
     "role": "http://www.insmed.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Intangibles, net",
     "role": "http://www.insmed.com/role/IntangiblesNet",
     "shortName": "Intangibles, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Fixed Assets, net",
     "role": "http://www.insmed.com/role/FixedAssetsNet",
     "shortName": "Fixed Assets, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Debt",
     "role": "http://www.insmed.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Shareholders' Equity",
     "role": "http://www.insmed.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Stock-Based Compensation",
     "role": "http://www.insmed.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Income Taxes",
     "role": "http://www.insmed.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "insm:LicenseAndOtherAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - License and Other Agreements",
     "role": "http://www.insmed.com/role/LicenseAndOtherAgreements",
     "shortName": "License and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "insm:LicenseAndOtherAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Commitments and Contingencies",
     "role": "http://www.insmed.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - Quarterly Financial Data (Unaudited)",
     "role": "http://www.insmed.com/role/QuarterlyFinancialDataUnaudited",
     "shortName": "Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Consolidated Balance Sheets",
     "role": "http://www.insmed.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Retirement Plan",
     "role": "http://www.insmed.com/role/RetirementPlan",
     "shortName": "Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Inventory (Tables)",
     "role": "http://www.insmed.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.insmed.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Intangibles, net (Tables)",
     "role": "http://www.insmed.com/role/IntangiblesNetTables",
     "shortName": "Intangibles, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Fixed Assets, net (Tables)",
     "role": "http://www.insmed.com/role/FixedAssetsNetTables",
     "shortName": "Fixed Assets, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Debt (Tables)",
     "role": "http://www.insmed.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.insmed.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.insmed.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.insmed.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.insmed.com/role/QuarterlyFinancialDataUnauditedTables",
     "shortName": "Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401401 - Disclosure - Description of Business and Basis of Presentation Description of Business and Basis of Presentation - Narrative (Details)",
     "role": "http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails",
     "shortName": "Description of Business and Basis of Presentation Description of Business and Basis of Presentation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_ComputerHardwareAndSoftwareMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Summary of Significant Accounting Policies - Fixed Assets, Net (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails",
     "shortName": "Summary of Significant Accounting Policies - Fixed Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_insm_EquipmentFurnitureAndFixturesMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "insm:FairValueLevel1Level2Level3TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails",
     "shortName": "Summary of Significant Accounting Policies - Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "insm:FairValueLevel1Level2Level3TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD_srt_MajorCustomersAxis_insm_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402406 - Disclosure - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails",
     "shortName": "Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402407 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402408 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402409 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402410 - Disclosure - Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails",
     "shortName": "Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "I2019Q1Jan01_srt_RangeAxis_srt_MinimumMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Inventory - Schedule of Inventory, Current (Details)",
     "role": "http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails",
     "shortName": "Inventory - Schedule of Inventory, Current (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "insm:AccruedClinicalTrialExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.insmed.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "insm:AccruedClinicalTrialExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2018Q3Sep28-Sep28",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Intangibles, net (Details)",
     "role": "http://www.insmed.com/role/IntangiblesNetDetails",
     "shortName": "Intangibles, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2018Q3Sep28-Sep28",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Fixed Assets, net (Details)",
     "role": "http://www.insmed.com/role/FixedAssetsNetDetails",
     "shortName": "Fixed Assets, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Debt (Details)",
     "role": "http://www.insmed.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2018Q1Feb2018_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Debt - Components of Debt (Details)",
     "role": "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
     "shortName": "Debt - Components of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Debt - Future Principal Repayments of Debt (Details)",
     "role": "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails",
     "shortName": "Debt - Future Principal Repayments of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408401 - Disclosure - Shareholders' Equity (Details)",
     "role": "http://www.insmed.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2017Q3Sept17",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "I2017Q2May18",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "I2017Q2May18",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2015Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Consolidated Statements of Shareholders' Equity",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2015Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Stock-Based Compensation - Stock Options (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2015Q4",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Stock-Based Compensation - Range of Exercise Prices (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails",
     "shortName": "Stock-Based Compensation - Range of Exercise Prices (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Income Taxes - Loss Before Income Taxes in the US and Globally (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails",
     "shortName": "Income Taxes - Loss Before Income Taxes in the US and Globally (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Income Taxes - Income Tax (Benefit) Provision (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails",
     "shortName": "Income Taxes - Income Tax (Benefit) Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Income Taxes - Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410407 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2016Q4",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2014Q3JUL01-JUL31_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "insm:InitialTermOfContractManufacturingAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411401 - Disclosure - License and Other Agreements (Details)",
     "role": "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails",
     "shortName": "License and Other Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2014Q3JUL01-JUL31_us-gaap_TypeOfArrangementAxis_insm_PRIPharmaGmbhCommercializationAgreementMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "insm:InitialTermOfContractManufacturingAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Commitments and Contingencies - Minimum Rental Payments (Details)",
     "role": "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails",
     "shortName": "Commitments and Contingencies - Minimum Rental Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)",
     "role": "http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails",
     "shortName": "Quarterly Financial Data (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414401 - Disclosure - Retirement Plan (Details)",
     "role": "http://www.insmed.com/role/RetirementPlanDetails",
     "shortName": "Retirement Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Description of Business and Basis of Presentation",
     "role": "http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentation",
     "shortName": "Description of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Inventory",
     "role": "http://www.insmed.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 75,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "insm_AccruedClinicalTrialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.",
        "label": "Accrued Clinical Trial Expenses",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenses",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedConstructionLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Construction Liabilities, Current",
        "label": "Accrued Construction Liabilities, Current",
        "terseLabel": "Accrued construction costs"
       }
      }
     },
     "localname": "AccruedConstructionLiabilitiesCurrent",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedSalesAllowancesandRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Sales Allowances and Related Costs",
        "label": "Accrued Sales Allowances and Related Costs",
        "terseLabel": "Accrued sales allowances and related costs"
       }
      }
     },
     "localname": "AccruedSalesAllowancesandRelatedCosts",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedTechnicalOperationExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.",
        "label": "Accrued Technical Operation Expenses",
        "terseLabel": "Accrued technical operation expenses"
       }
      }
     },
     "localname": "AccruedTechnicalOperationExpenses",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Additional Laboratory Space Operating Leases Future Minimum Payments Due",
        "terseLabel": "Future minimum rental payments for additional laboratory space"
       }
      }
     },
     "localname": "AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AdditionalRoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of royalty payments if entity meets certain milestones under a research and development agreement.",
        "label": "Additional Royalty Guarantees Commitments Amount",
        "terseLabel": "Royalty payable on meeting certain sales milestones"
       }
      }
     },
     "localname": "AdditionalRoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AdditionalTermOfContractManufacturingAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the additional extension period of contract manufacturing agreement.",
        "label": "Additional Term Of Contract Manufacturing Agreement",
        "terseLabel": "Additional term of contract manufacturing agreement"
       }
      }
     },
     "localname": "AdditionalTermOfContractManufacturingAgreement",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_AgreementWithSyneosHealthForWillowStudyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement With Syneos Health For Willow Study [Member]",
        "label": "Agreement With Syneos Health For Willow Study [Member]",
        "terseLabel": "Agreement With Syneos Health For Willow Study"
       }
      }
     },
     "localname": "AgreementWithSyneosHealthForWillowStudyMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_AgreementWithSynteractHCRInc.For212StudyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement With SynteractHCR, Inc. For 212 Study [Member]",
        "label": "Agreement With SynteractHCR, Inc. For 212 Study [Member]",
        "terseLabel": "Agreement with SynteractHCR, Inc. for 212 Study"
       }
      }
     },
     "localname": "AgreementWithSynteractHCRInc.For212StudyMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of stock-based compensation expense that resulted from the remeasurement of awards.",
        "label": "Allocated Share Based Compensation Expense, Due to Remeasurement of Awards",
        "terseLabel": "Stock-based compensation expense that resulted from the remeasurement of awards"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseDueToRemeasurementOfAwards",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities",
        "label": "Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities",
        "verboseLabel": "Securities in an unrealized gain or loss position"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "insm_BridgewaterNewJerseyFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represent the Bridgewater location in New Jersey where the entity has leased office and laboratory space.",
        "label": "Bridgewater New Jersey Facility [Member]",
        "terseLabel": "Bridgewater, NJ Facility"
       }
      }
     },
     "localname": "BridgewaterNewJerseyFacilityMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate additional series of contingent milestone payments if selects to develop for second indication.",
        "label": "Collaborative Arrangement Additional Contingent Payments Upon Second Indication",
        "terseLabel": "Additional contingent payments upon second indication to develop INS1007"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_CollaborativeArrangementMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment",
        "label": "Collaborative Arrangement, Milestone Payment",
        "terseLabel": "PARI milestone upon FDA approval"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePayment",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_CollaborativeArrangementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of upfront payment paid during the period under collaborative arrangement.",
        "label": "Collaborative Arrangement, Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontPayment",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_CommercialFilVFinishServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to the Commercial Fill/Finish Services Agreement (the \"Fill/Finish Agreement\") with Ajinomoto Althea, Inc., a Delaware corporation (\"Althea\"), for Althea to produce, on a non-exclusive basis, ARIKAYCE in finished dosage form.",
        "label": "Commercial Fil V Finish Services Agreement [Member]",
        "terseLabel": "Fill/Finish Agreement"
       }
      }
     },
     "localname": "CommercialFilVFinishServicesAgreementMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CommercialServicesAgreementExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the extension period under the terms of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Commercial Services Agreement, Extension Period",
        "terseLabel": "Extension period"
       }
      }
     },
     "localname": "CommercialServicesAgreementExtensionPeriod",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the period prior to the expiration of the agreement in which an agreement for extension may be entered into upon mutual agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Commercial Services Agreement, Extension Period, Period Prior To Expiration For Extension Agreement",
        "terseLabel": "Period prior to expiration for extension"
       }
      }
     },
     "localname": "CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_CommercialServicesAgreementMinimumObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the minimum obligation due under the terms of the agreement.",
        "label": "Commercial Services Agreement, Minimum Obligation",
        "terseLabel": "Minimum obligation"
       }
      }
     },
     "localname": "CommercialServicesAgreementMinimumObligation",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option",
        "label": "Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option",
        "terseLabel": "Shares exercised in full of over-allotment option by underwriter (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "insm_ComputerHardwareAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased computer hardware and software applications.",
        "label": "Computer Hardware And Software [Member]",
        "terseLabel": "Computer hardware and software",
        "verboseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerHardwareAndSoftwareMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Asset, Allowance For Current Period Sales",
        "label": "Contract With Customer, Asset, Allowance For Current Period Sales",
        "terseLabel": "Allowances for current period sales"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAllowanceForCurrentPeriodSales",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Assets, Allowance For Credit Loss, Payments and Credits",
        "label": "Contract With Customer, Assets, Allowance For Credit Loss, Payments and Credits",
        "negatedTerseLabel": "Payments and credits"
       }
      }
     },
     "localname": "ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Contract with Customer, Asset, Allowance for Credit Loss [Table]",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss [Line Items]",
        "terseLabel": "Contract with Customer, Asset, Allowance for Credit Loss [Line Items]"
       }
      }
     },
     "localname": "ContractwithCustomerAssetAllowanceforCreditLossLineItems",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ContractwithCustomerAssetAllowanceforCreditLossRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "ContractwithCustomerAssetAllowanceforCreditLossRollForward",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ContractwithCustomerAssetAllowanceforCreditLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with Customer, Asset, Allowance for Credit Loss [Table]",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss [Table]",
        "terseLabel": "Contract with Customer, Asset, Allowance for Credit Loss [Table]"
       }
      }
     },
     "localname": "ContractwithCustomerAssetAllowanceforCreditLossTable",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with Customer, Asset, Allowance for Credit Loss [Table Text Block]",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Contract with Customer, Asset, Allowance for Credit Loss"
       }
      }
     },
     "localname": "ContractwithCustomerAssetAllowanceforCreditLossTableTextBlock",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "insm_ConversionTermiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Conversion Term (i) [Member]",
        "label": "Conversion Term (i) [Member]",
        "terseLabel": "Conversion Term (i)"
       }
      }
     },
     "localname": "ConversionTermiMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ConversionTermiiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Conversion Term (ii) [Member]",
        "label": "Conversion Term (ii) [Member]",
        "terseLabel": "Conversion Term (ii)"
       }
      }
     },
     "localname": "ConversionTermiiMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ConversionTermiiiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Conversion Term (iii) [Member]",
        "label": "Conversion Term (iii) [Member]",
        "terseLabel": "Conversion Term (iii)"
       }
      }
     },
     "localname": "ConversionTermiiiMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ConversionTermivMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Conversion Term (iv) [Member]",
        "label": "Conversion Term (iv) [Member]",
        "terseLabel": "Conversion Term (iv)"
       }
      }
     },
     "localname": "ConversionTermivMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer A [Member]",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer B [Member]",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer C [Member]",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CustomerFeesDiscountsandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer Fees, Discounts and Other [Member]",
        "label": "Customer Fees, Discounts and Other [Member]",
        "terseLabel": "Customer Fees, Discounts and Other"
       }
      }
     },
     "localname": "CustomerFeesDiscountsandOtherMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the agreement with Cystic Fibrosis Foundation Therapeutics, Inc., for research funding for the development of ARIKAYCE product.",
        "label": "Cystic Fibrosis Foundation Therapeutics Inc Collaboration Agreements [Member]",
        "terseLabel": "CFFT"
       }
      }
     },
     "localname": "CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConversionTermAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Conversion Term [Axis]",
        "label": "Debt Instrument Conversion Term [Axis]",
        "terseLabel": "Debt Instrument Conversion Term [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermAxis",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_DebtInstrumentConversionTermDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Debt Instrument Conversion Term [Axis]",
        "label": "Debt Instrument Conversion Term [Domain]",
        "terseLabel": "Debt Instrument Conversion Term [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermDomain",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change",
        "label": "Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change",
        "terseLabel": "Threshold trading days following fundamental change"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "insm_DebtInstrumentOptionToPurchaseAdditionalDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Option To Purchase Additional Debt",
        "label": "Debt Instrument, Option To Purchase Additional Debt",
        "terseLabel": "Option to purchase additional debt"
       }
      }
     },
     "localname": "DebtInstrumentOptionToPurchaseAdditionalDebt",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Assets (Liabilities) Net before Valuation Allowances",
        "terseLabel": "Net deferred tax assets (prior to applying the valuation allowance)",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_DeferredTaxAssetsLicensePayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as License payment.",
        "label": "Deferred Tax Assets, License Payment",
        "terseLabel": "Product license"
       }
      }
     },
     "localname": "DeferredTaxAssetsLicensePayment",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_DeferredTaxLiabilitiesConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Convertible Debt",
        "label": "Deferred Tax Liabilities, Convertible Debt",
        "negatedTerseLabel": "Convertible debt"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesConvertibleDebt",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.insmed.com/20181231",
     "xbrltype": "stringItemType"
    },
    "insm_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to permanent items.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "insm_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts And Jobs Act Of 2017, Percent",
        "terseLabel": "Impact of Tax Act"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "insm_EmployeeAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee And Directors Stock Options [Member]",
        "terseLabel": "Stock options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeAndDirectorsStockOptionsMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_EquipmentFurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to equipment, furniture and fixtures.",
        "label": "Equipment Furniture And Fixtures [Member]",
        "terseLabel": "Laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures"
       }
      }
     },
     "localname": "EquipmentFurnitureAndFixturesMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_FairValueLevel1Level2Level3TransfersAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value Level 1, Level 2, Level 3 Transfers, Amount",
        "label": "Fair Value Level 1, Level 2, Level 3 Transfers, Amount",
        "terseLabel": "Fair value transfers in or out of Level 1, Level 2 or Level 3"
       }
      }
     },
     "localname": "FairValueLevel1Level2Level3TransfersAmount",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_FutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future Milestone Payments",
        "label": "Future Milestone Payments",
        "terseLabel": "Future milestone payments"
       }
      }
     },
     "localname": "FutureMilestonePayments",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_ImplementationAndManagementServicesAgreementAggregateCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Implementation And Management Services Agreement, Aggregate Costs",
        "label": "Implementation And Management Services Agreement, Aggregate Costs",
        "terseLabel": "Commitment To Pay Aggregate Costs From Agreement"
       }
      }
     },
     "localname": "ImplementationAndManagementServicesAgreementAggregateCosts",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the sum of accrued expenses and Other Current Liabilities.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Current Liabilities",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_InitialTermOfContractManufacturingAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the initial period of contract manufacturing agreement.",
        "label": "Initial Term of Contract Manufacturing Agreement",
        "terseLabel": "Initial term of contract manufacturing agreement"
       }
      }
     },
     "localname": "InitialTermOfContractManufacturingAgreement",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]",
        "label": "Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]",
        "terseLabel": "Inventory and cost of product revenues (excluding amortization of intangible assets)"
       }
      }
     },
     "localname": "InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "insm_InvestmentIncomeExpensePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for components of investment income and interest expense.",
        "label": "Investment Income (Expense) [Policy Text Block]",
        "terseLabel": "Investment Income and Interest Expense"
       }
      }
     },
     "localname": "InvestmentIncomeExpensePolicyTextBlock",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "insm_LicenseAgreementWithAstrazenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to license agreement with AstraZeneca AB, a Swedish corporation (AstraZeneca).",
        "label": "License Agreement With Astrazeneca [Member]",
        "terseLabel": "License Agreement with AstraZeneca"
       }
      }
     },
     "localname": "LicenseAgreementWithAstrazenecaMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_LicenseAndOtherAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "No definition available.",
        "label": "License and Other Agreements"
       }
      }
     },
     "localname": "LicenseAndOtherAgreementsAbstract",
     "nsuri": "http://www.insmed.com/20181231",
     "xbrltype": "stringItemType"
    },
    "insm_LicenseAndOtherAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This entire text block refers to License and Other Agreement.",
        "label": "License and Other Agreements [Text Block]",
        "terseLabel": "License and Other Agreements"
       }
      }
     },
     "localname": "LicenseAndOtherAgreementsTextBlock",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "insm_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-Term Debt, Maturities, Repayments Of Principal In Year Five And Thereafter",
        "label": "Long-Term Debt, Maturities, Repayments Of Principal In Year Five And Thereafter",
        "terseLabel": "2023 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_ManufactureAndSupplyAgreementEstimatedCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacture And Supply Agreement, Estimated Costs",
        "label": "Manufacture And Supply Agreement, Estimated Costs",
        "terseLabel": "Agreement to purchase raw materials and fixed assets"
       }
      }
     },
     "localname": "ManufactureAndSupplyAgreementEstimatedCosts",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents manufacturing equipment used to produce goods and services.",
        "label": "Manufacturing Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_MilestoneFDAApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone, FDA Approval [Member]",
        "label": "Milestone, FDA Approval [Member]",
        "terseLabel": "Milestone, FDA Approval"
       }
      }
     },
     "localname": "MilestoneFDAApprovalMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_MilestoneNewDrugApplicationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone, New Drug Application [Member]",
        "label": "Milestone, New Drug Application [Member]",
        "terseLabel": "Milestone, New Drug Application"
       }
      }
     },
     "localname": "MilestoneNewDrugApplicationMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_MilestonePaymentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payment [Axis]",
        "label": "Milestone Payment [Axis]",
        "terseLabel": "Milestone Payment [Axis]"
       }
      }
     },
     "localname": "MilestonePaymentAxis",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_MilestonePaymentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Milestone Payment [Axis]",
        "label": "Milestone Payment [Domain]",
        "terseLabel": "Milestone Payment [Domain]"
       }
      }
     },
     "localname": "MilestonePaymentDomain",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock each restricted stock award entitles the holder to receive upon completion of a specific period of service or achievement of a specified milestone.",
        "label": "Number Of Common Shares To Be Received In Lieu Of Per Restricted Stock And Restricted Stock Unit",
        "terseLabel": "Number of common shares each award holder is entitled to receive"
       }
      }
     },
     "localname": "NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]",
        "label": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]",
        "terseLabel": "1.75% Convertible Senior Note Due 2025"
       }
      }
     },
     "localname": "OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_OperatingLossCarryforwardsTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, for income tax purposes.",
        "label": "Operating Loss Carryforwards Total",
        "terseLabel": "Net operating loss carryforwards for income tax purposes"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTotal",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_PRIPharmaGmbhCommercializationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the agreement with PARI Pharma GmbH, for the manufacture and supply of eFlow nebulizer systems and related accessories, liposomal amikacin for inhalation.",
        "label": "P R I Pharma Gmbh Commercialization Agreement [Member]",
        "terseLabel": "PARI Agreement"
       }
      }
     },
     "localname": "PRIPharmaGmbhCommercializationAgreementMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_PaymentsUponAchievementOfClinicalMilestonesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate payment upon the achievement of certain clinical milestones.",
        "label": "Payments Upon Achievement Of Clinical Milestones Amount",
        "terseLabel": "Aggregate payment upon the achievement of certain clinical milestones"
       }
      }
     },
     "localname": "PaymentsUponAchievementOfClinicalMilestonesAmount",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period for meeting sales milestones for additional royalty payments after the drug is commercialized.",
        "label": "Period for Meeting Sales Milestones for Additional Royalty Payments",
        "terseLabel": "Period for meeting sales milestones for additional royalty payments"
       }
      }
     },
     "localname": "PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the period of each automatic renewal of contract manufacturing agreement.",
        "label": "Period of Each Automatic Renewal of Contract Manufacturing Agreement",
        "terseLabel": "Period of each automatic renewal of contract manufacturing agreement"
       }
      }
     },
     "localname": "PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_Range10Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range10 [Member]",
        "terseLabel": "$30.86 to $32.46"
       }
      }
     },
     "localname": "Range10Member",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range1 [Member]",
        "terseLabel": "$3.03 to $4.55"
       }
      }
     },
     "localname": "Range1Member",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range2 [Member]",
        "terseLabel": "$6.90 to $6.90"
       }
      }
     },
     "localname": "Range2Member",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range3Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range3 [Member]",
        "terseLabel": "$6.96 to $10.85"
       }
      }
     },
     "localname": "Range3Member",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range4Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range4 [Member]",
        "terseLabel": "$11.14 to $12.58"
       }
      }
     },
     "localname": "Range4Member",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range5Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range5 [Member]",
        "terseLabel": "$12.66 to $13.94"
       }
      }
     },
     "localname": "Range5Member",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range6Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range6 [Member]",
        "terseLabel": "$14.24 to $16.07"
       }
      }
     },
     "localname": "Range6Member",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range7Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range7 [Member]",
        "terseLabel": "$16.09 to $17.16"
       }
      }
     },
     "localname": "Range7Member",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range8Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range8 [Member]",
        "terseLabel": "$17.24 to $22.76"
       }
      }
     },
     "localname": "Range8Member",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range9Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range9 [Member]",
        "terseLabel": "$22.84 to $30.46"
       }
      }
     },
     "localname": "Range9Member",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_RebatesChargebacksandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rebates, Chargebacks, and Co-Pay Assistance [Member]",
        "label": "Rebates, Chargebacks, and Co-Pay Assistance [Member]",
        "terseLabel": "Rebates, Chargebacks, and Co-Pay Assistance"
       }
      }
     },
     "localname": "RebatesChargebacksandCoPayAssistanceMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_RepaymentsOfDebtFeesAndOutstandingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Repayments Of Debt Fees And Outstanding Interest",
        "label": "Repayments Of Debt Fees And Outstanding Interest",
        "terseLabel": "Repayments of debt, back end fees, outstanding interest, and prepayment penalty fees"
       }
      }
     },
     "localname": "RepaymentsOfDebtFeesAndOutstandingInterest",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_RestrictedStockAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares and stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.",
        "label": "Restricted Stock And Restricted Stock Units [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockAndRestrictedStockUnitsMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_RoyaltyPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period for royalty payments under a research and development agreement.",
        "label": "Royalty Payment Period",
        "terseLabel": "Royalty payment period"
       }
      }
     },
     "localname": "RoyaltyPaymentPeriod",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_ScheduleofEarningsPerShareBasicandDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]"
       }
      }
     },
     "localname": "ScheduleofEarningsPerShareBasicandDilutedLineItems",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ScheduleofEarningsPerShareBasicandDilutedTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table]"
       }
      }
     },
     "localname": "ScheduleofEarningsPerShareBasicandDilutedTable",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of inducement share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross",
        "terseLabel": "Inducement stock option granted to new employees (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "insm_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock options and RSUs"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_SummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Summary Of Significant Policies [Table]",
        "label": "Summary Of Significant Policies [Line Items]",
        "terseLabel": "Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_SummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary Of Significant Policies [Table]",
        "label": "Summary Of Significant Policies [Table]",
        "terseLabel": "Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_SupplyAgreementWithPatheonUKLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supply Agreement With Patheon UK Limited [Member]",
        "label": "Supply Agreement With Patheon UK Limited [Member]",
        "terseLabel": "Supply Agreement with Patheon UK Limited"
       }
      }
     },
     "localname": "SupplyAgreementWithPatheonUKLimitedMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_TherapureBiopharmaIncContractManufacturingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the agreement with Therapure Biopharma Inc., for manufacture of the entity product ARIKAYCE, liposomal amikacin for inhalation.",
        "label": "Therapure Biopharma Inc Contract Manufacturing Agreement [Member]",
        "terseLabel": "Therapure"
       }
      }
     },
     "localname": "TherapureBiopharmaIncContractManufacturingAgreementMember",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_WeightedAverageRemainingContractualLifeInYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Weighted Average Remaining Contractual Life in Years [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life in Years"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeInYearsAbstract",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the written notice period required for termination of contract manufacturing agreement by either party.",
        "label": "Written Notice Period for Termination of Contract Manufacturing Agreement",
        "terseLabel": "Written notice period required for termination of contract manufacturing agreement"
       }
      }
     },
     "localname": "WrittenNoticePeriodForTerminationOfContractManufacturingAgreement",
     "nsuri": "http://www.insmed.com/20181231",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r136",
      "r191",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r134",
      "r191",
      "r193",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r135",
      "r191",
      "r194",
      "r348",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r21",
      "r192"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionExpense": {
     "auth_ref": [
      "r159",
      "r160"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.",
        "label": "Accretion Expense",
        "terseLabel": "Accretion of back-end fee on debt"
       }
      }
     },
     "localname": "AccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails",
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r43"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r155"
     ],
     "calculation": {
      "http://www.insmed.com/role/FixedAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r57",
      "r58",
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of convertible debt issuance"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r201",
      "r203",
      "r239",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r203",
      "r233",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "ESPP compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r74",
      "r89",
      "r307"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r69",
      "r89",
      "r309"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r89",
      "r142",
      "r149"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r133",
      "r325",
      "r338"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r53"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r204",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Reported Value Measurement"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r35",
      "r91"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r92",
      "r94",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r161",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; 500,000,000 authorized shares, 77,307,521 and 76,610,508 issued and outstanding shares at December 31, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r61",
      "r63",
      "r64"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r124",
      "r125",
      "r300",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r124",
      "r125",
      "r300",
      "r301",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r124",
      "r125",
      "r300",
      "r301",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r119",
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r124",
      "r125",
      "r300",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration Risk, Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r122",
      "r124",
      "r125",
      "r126",
      "r300",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r124",
      "r125",
      "r300",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress (CIP)"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Accumulated Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Balance at beginning"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAllowanceForCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Convertible notes ($450.0 face value)"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible debt securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r14",
      "r326",
      "r336",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product revenues (excluding amortization of intangible assets)",
        "verboseLabel": "Cost of product revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r271",
      "r275"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r273"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r271",
      "r275"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax provision (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r271",
      "r275"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r326",
      "r328",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Equity component of convertible debt"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Initial conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r46",
      "r178",
      "r181",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining discount amortization period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r308",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r45",
      "r170",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Proceeds from issuance of 1.75% convertible senior notes due 2025"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "verboseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r47",
      "r98",
      "r178",
      "r182",
      "r183",
      "r184",
      "r307",
      "r308",
      "r310",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r307",
      "r310"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Discount on debt",
        "terseLabel": "Unamortized portion of debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r272",
      "r275"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r39",
      "r309"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Debt issuance costs, unamortized",
        "terseLabel": "Underwriting discounts and commissions and other offering expenses"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r272",
      "r275"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r89",
      "r96",
      "r272",
      "r275"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income tax provision (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r17",
      "r18",
      "r262",
      "r327",
      "r335"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r272",
      "r275"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r246",
      "r269",
      "r270"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r245",
      "r269",
      "r270"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r246",
      "r269",
      "r270"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": {
     "auth_ref": [
      "r267",
      "r269",
      "r270"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, General Business",
        "terseLabel": "General business credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r246",
      "r269",
      "r270"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees' gross pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution, percent of match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r89",
      "r153"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r89",
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r186",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss (in dollars per share)",
        "verboseLabel": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r100",
      "r251",
      "r252"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails",
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r251",
      "r252",
      "r274"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory federal tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r251",
      "r252",
      "r274"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r251",
      "r252",
      "r274"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r251",
      "r252",
      "r274"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "R&amp;D and other tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r251",
      "r252",
      "r274"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r251",
      "r252",
      "r274"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted average period for recognized and unrecognized compensation expense",
        "verboseLabel": "Expected weighted average period for recognizing unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Unrecognized compensation expense related to unvested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested options awarded to employees as compensation.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Unrecognized compensation expense related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r288",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r287",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r288",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r288",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r288",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [
      "r286",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).",
        "label": "Fair Value, Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r286",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.",
        "label": "Fair Value, Measurements, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r94",
      "r294",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible assets estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "Amortization of intangible assets, 2019"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Amortization of intangible assets, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "Amortization of intangible assets, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "Amortization of intangible assets, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "Amortization of intangible assets, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r143",
      "r145",
      "r148",
      "r151",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r148",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangibles, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r143",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangibles, net",
        "verboseLabel": "Intangibles, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Finite-lived Intangible Assets [Roll Forward]",
        "terseLabel": "Finite-lived Intangible Assets [Roll Forward]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r303",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r89",
      "r171",
      "r172"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r94",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Identifiable Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "US"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r105",
      "r323",
      "r330",
      "r344"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesInUsAndGloballyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r132",
      "r276"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision (benefit) for income taxes",
        "totalLabel": "Total",
        "verboseLabel": "Income tax provision (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails",
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r249",
      "r250",
      "r260",
      "r261",
      "r266",
      "r277",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes, net"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r109",
      "r113"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r65",
      "r130",
      "r306",
      "r309",
      "r332"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "verboseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r83",
      "r85",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r43"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r140"
     ],
     "calculation": {
      "http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r52",
      "r139"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r140"
     ],
     "calculation": {
      "http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r28",
      "r140"
     ],
     "calculation": {
      "http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/InventoryScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense charged to operations"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r329",
      "r341"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "License and Service"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "A&amp;R Loan Agreement"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r167",
      "r328",
      "r339"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r102",
      "r163"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r102",
      "r163"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r102",
      "r163"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r102",
      "r163"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Debt, long-term",
        "totalLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r47",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r59",
      "r62",
      "r67",
      "r90",
      "r113",
      "r331",
      "r343"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTerseLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity",
      "http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentationDescriptionOfBusinessAndBasisOfPresentationNarrativeDetails",
      "http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r105",
      "r107"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New Jersey.",
        "label": "New Jersey Division of Taxation [Member]",
        "terseLabel": "New Jersey Division of Taxation"
       }
      }
     },
     "localname": "NewJerseyDivisionOfTaxationMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating loss",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease, right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "Future minimum rental payments under leases",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails",
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards available to offset future taxable income"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Description of Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DescriptionOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r43"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r13",
      "r324",
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r281",
      "r282",
      "r283"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation (losses) gains"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r60",
      "r63",
      "r281",
      "r282",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r43"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "terseLabel": "Royalty payment"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Payment on extinguishment of debt"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Underwriter's discount and offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "PARI milestone upon FDA approval",
        "verboseLabel": "New drug milestone payment"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Retirement Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/RetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares or units awarded to employees for meeting certain performance targets.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-condition options"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in shares)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r33",
      "r34"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of 1.75% convertible senior notes due 2025"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from the sale of shares",
        "verboseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r77",
      "r236"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options and ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r38",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Fixed Assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r37",
      "r154"
     ],
     "calculation": {
      "http://www.insmed.com/role/FixedAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Fixed assets, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Gross, Period Increase (Decrease)",
        "terseLabel": "Depreciation increase (decrease)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Fixed Assets, Net",
        "verboseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r156",
      "r342"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.insmed.com/role/FixedAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Fixed assets, net",
        "totalLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r36",
      "r94",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Fixed Assets, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Life (years)",
        "verboseLabel": "Estimated useful live of fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Future minimum commitments due for firm purchase"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/QuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Payment of debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Compensation earned under research funding agreements with CFFT"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r242",
      "r351"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r94",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock and restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r185",
      "r340"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r189",
      "r190",
      "r191"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://www.insmed.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r189",
      "r190",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "verboseLabel": "Annual net sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Royalty payable on approval of ARIKAYCE as commercialized drug"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue during the period derived from a specified product line, after deducting returns, allowances and discounts, when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Sales Revenue, Product Line [Member]",
        "terseLabel": "Sales Revenue, Product Line"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reporting scenario used to indicate financial results forecast for a future period.",
        "label": "Scenario, Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.",
        "label": "Scenario, Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components Income Tax (Benefit) Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Components of Debt Balance"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r203",
      "r232",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Summary of Allocation of Employee Stock-Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Carrying Value and Fair Value of Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r143",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r143",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments Required Under Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Loss Before Income Taxes in the US and Globally"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Principal Repayments of Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r38",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Summary of Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/QuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r204",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]",
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Exercise Price and Number of Stock Options Exercisable"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r208",
      "r220",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Fair Value Assumptions for Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r49",
      "r97",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r122",
      "r124",
      "r125",
      "r126",
      "r300",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of Concentration of Risk, by Risk Factor"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebt": {
     "auth_ref": [
      "r16",
      "r328",
      "r339"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "Secured Debt",
        "terseLabel": "1.75% convertible senior notes due 2025"
       }
      }
     },
     "localname": "SecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding Weighted Average Grant Price (in dollars per share)",
        "periodStartLabel": "Outstanding Weighted Average Grant Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Fair value and assumptions used in determining fair value of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock Based Compensation disclosures",
        "verboseLabel": "Stock Option disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares of common stock, maximum authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited and expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited and expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r210",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding end of the year (in shares)",
        "periodStartLabel": "Options outstanding beginning of the year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding end of the year (in dollars per share)",
        "periodStartLabel": "Options outstanding beginning of the year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r202",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r94",
      "r204",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Range of Exercise Prices lower range limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options",
        "terseLabel": "Number of Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options",
        "terseLabel": "Number of Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Range of Exercise Prices upper range limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Shares price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r227",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price",
        "terseLabel": "Exercisable Options, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price",
        "terseLabel": "Outstanding Options, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r51",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r177",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Net proceeds from issuance of common stock (in shares)",
        "verboseLabel": "Shares issued under underwritten public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r19",
      "r20",
      "r177",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock for vesting of RSUs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r177",
      "r185",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r177",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r177",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock for vesting of RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r51",
      "r177",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.",
        "label": "Stock or Unit Option Plan Expense",
        "terseLabel": "Non-cash compensation expense"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r24",
      "r25",
      "r138"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/ConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r254",
      "r259",
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseAndOtherAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r247",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Net deferred tax assets as of December 31",
        "periodStartLabel": "Net deferred tax assets as of January 1",
        "terseLabel": "Tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions related to current period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions related to prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r117",
      "r118",
      "r120",
      "r121",
      "r127",
      "r128",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r108",
      "r111"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average basic and diluted common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r106",
      "r111"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares used in calculation of basic net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109225645&loc=d3e1280-108306"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "305",
   "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=114001942&loc=d3e12317-112629"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=114001942&loc=d3e12355-112629"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL6742756-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13467-108611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13476-108611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r352": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  }
 },
 "version": "2.0"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001104506-19-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104506-19-000009-xbrl.zip
M4$L#!!0    (  8\5DY=] ?5T1,  !#7   1    :6YS;2TR,#$X,3(S,2YX
M<V3M/6MSVSB2W^=7\/SE9JM6L60[#Z<FV9+M*.-=Q_99]F;OTQ9$0A(J%* %
M0=N:7W_=X/O]D#QFCJI*.12);O0+C4;C]=O?GE>V\4BEPP3_=#!Z,SPP*#>%
MQ?CBT\'#=#">GE]>'OSM\R^__==@\*^SNROC0ICNBG)EG$M*%+6,)Z:6QG>+
M.C^,N10KX[N0/]@C&0P\($,_/#O61\=<TA4QB%*2S5Q%)T*N+NB<N+;Z=.#R
M_[C$9G-&+2#!IEA%HD#LLR)R0=4U65%G34SZZ6"IU/KCX>'3T],;QIT5M=Z8
M8G5X-!Q]&!T=CPX,8)(['_%3W;(VXS\299]GTGXCY )*#H\/\?.,.#0HS@7G
M[BH?P%+R4&W6]! *#: 4E<P,X:J!D@!8P%(A3)RJMX?>QWA15L(#<*\(-T,>
MGC,\/QWKTJ/3T]-#_34LZEAY!0'MZ/!?WZZF6M$'GW\Q#*UXMEH+J0R>4=B<
M.#,-Z4BE53 8C@:H!,]4KH1)E#;,.+L9H$-J*P=_#2(4;Z#> ^.P 0FN,U@0
MLFY.1AS0(\5_LRTY4MC4V1$]&M>V!*%![HH@C:L-066&7$!.%@1_#0*X ;X:
MC(ZVHR)R"<VH".!V0<7I(9$FJAK49JH!?5[;A!,EY&8"O^M19DN9P/(E0H(D
MGB*)HW=;D*@Q<[K SJ,^27&HG=+10"P!Q-;UYW<)=<B(0UY[@#NDIATE[<G(
M[[YJMI\  "M^VZQ*AYIO%N+QT!0N5W*#GNE]'9>6!Q?\&$1(6A+C2@FQ5PMJ
MXH#AKZWIL2BK]/5.$1 ^M/'N"63TV5PV)R&$TD];$\'X(W5TH''<1"DQ,/]Y
M$*%H1PDGS'0:6T<$Y3UN;1<.,Q'=J D1 0P^#"+@E@2HM6QN%B&4?BHQ"\*Y
M4!H3O@I>KM>,SX7W!MYAK_TQZ+KOZ-S0\?%'O^,LCZ(/UU*LJ50,@JG80$(C
M6$HZ_W2  Y-!,"3YMTGL-Q!W!T4R%22#"MU) 8CIVIJ)JXC(  .Z[4\'#DC;
MIC[G?SI3%ITW90I &&<=YLDFLZ8\ 0BU.\K.6M*F[ "( P/W5H:'".ZA@,%@
M<#DV3>E2"X)/RAWJ'!CX]>'NLFC\KFM/ P7X@QHB _I\-!J>C(9#8V!<,,>T
MA>-*"C]\#$: XK?#-& *I>M0ZX9_UL]IYGU@OT@)8*JUUH9+-HA<,/]E(-OZ
M$K^@BC"[G> #V#+YGPQ/3H9'5?(W?O5Q_:6_FK@G,[ME"_!!R_1P/#PY'HZJ
M]>"AZI,:SL5JQ13F(9TQM\X%5XPO(+)F=951AJ#4-8V.<EQ3#)M!N&4D\.W5
M@E+X!K6LW-4=,F??DHTNU,B1M45>ZNE&X.R.&ZD3OOO5&5Y]1E!A+QUBB5:N
MB91 W2/=E9HS""M5F^G$JE0;5K%79E+V37JZ:C2EO1X$N-E>KUQQO>P"N2-L
M9F'2]8S8F"R?+BE5M754!%ZB&^CZX!]V?U,0FYX'U*J)4!D^+L-#MM>'<FZ)
M!*Z65#&@<TOE)'%5:.JM;D4U-67\FL#=UY842LNYF9\39SFQQ5.+%I6/IEQ?
M)Q4M*\)IB+F!6 V-=J^I.70.P-@2AD/0<U\)9UN-9="5:^ZHF>;BV U$O]?@
M?+H$[[,4MD6E\^4_+E.;[528@Z]<A\>-=!A'_]^&5T&/M'A!9ZJ>?G3)\ES?
M^YP!-8+U3)[H%@3WK!=_-QHTE2$HS_2]SQG_(K07<OL(T>3URSX.BEHIH[;P
M,R/47LMYXBJ0PJUD,*Q;$_N.KOW<2LLV41-?I99."IJ(A]\(*S"B&GK?9IID
M#&+ERQ/B[W-2 YZ4^Y<!N*".*=D:L=W,SUR'<>I@PN6,. P,_#;&7%TMU$=8
MWJ>/<OOT$#NVC0"_SN;H&O!MO(Z]*O,DWZ!HNP3LGT1+N<\=G>2U\X8&U *B
M[QG@8 <!*/$+5S"JN>1S(5=-G$@9AA*E#\/<8KB+(?:(&O/0&3%\/5+,A#U3
M:^PX5#G7M.;@*P53[K+?Y;ALC<#P,/S5X+1/8[*D\!IYT'S0<H?W+F<HD!%_
M+UU24II-HLI<R/+X\EU.?)FCAOX%FY<<Q$KOR7-=X<<!RE=4#',\CP=M:/!^
M2CF9SIE3*:D%'SPSA,[UBI$9LQFN&&SDG+:KHGS&?0A^K$R3.4DEKU;\[+<P
MW=7':NZESXLI*7P\HQRJ4+=2/#)'!]_MM%Z)L%+'F6Q(2L?13^-7OY*_&&$U
M?5<HSOB<48AA:4(I#]CBOMIB1FQ[TU:W37!7JCF3%TZI&2LSO-J2GQ@WU)(:
M#U/=EH-Z^Z[W=J/Q,@25&LQ$E"D-]GNL&Q/M'34%-Z''T22=4?5$*9]0BTIB
MX\R?BULLH>0=410'MO,Y-5%N_JNV&MU1M95V\+;"#I)T&#XAAD^)$9*B73K6
M[(W' W*BUSTW(]Q<;[DVO9D_< DR77#VAPZI_%ZP=:16&W&E*;RO,(6@)HS.
MXG5I'0>U]5W/30:A6;#2$>AHF#,"3>BHEX-/1?B"(=NUDU\IF/+DU]O<(6B(
MH&^YKZ3L&CJM/-#RW-?;W$@E*?V>NIRX,)MYG1S(\M37VUS'D]9"'YW/(Q /
MT4]=R0?%RUW.<:[+\6'[*-XHQ@E?G>OS$IHZH-KXRKW2<:Y7\C&E(J7P_5\-
MOXZ>^BM?#,U<51*HW$L=YWJI0"L]=$]7S,1MH# \O%%+*L<+2;UUJO6D7PQ>
MGK3/6^'AX]*#0XW-B-#M-=)P]%>)I7RHE[> HDP_O?17_^,2J:BT-Q/&"3<9
ML2^((@^<N!;3)V#54505DO)VE!<&A!B-$*6!.(U?0ZQ[+86B:-2J:N(J;UMY
MD4$=G>W;6%;B32*%>JC*TRMY\4,]W?4OM+BCBDG=/=S:I.;RKQ1,N?/+.^8E
M0F @AMZ*NY%;RP<M]V(G.1%"2OB]=%AMMZ(UVW)V-!I^R+'^GF\LR\JP43,H
M!B\?ZG_(:0IYFNAG>U#"_'%& !K7[L  HL%BX +8\G9QFM<N$-% 8S+BJ'JO
MAW:K"FKB*F\UISEA<)&>>K_8(%_B=X0OZ,W\RS.5)G-PHYK9<#E?"[R56LVL
M[RK1JJX)4Z!!7897V5[)D3*HHT F>H<Z?!]S*_7F@3==&K"+BBK-(+-JI,P,
MPHJ\4CK'E'FIZ]];1B@X_?9&[T_:A?[ST%5J.;/*KT3+GA;]&O9Z#$73)(E1
MBJ%\[N,T)W=1J*T>YBNF[FI%Y.9F/F4+SN;,)%R-37T&/..+6V&S^@=$UL15
M'LGFG17I(]:GB$2HC0BW$2#?:RXE[;%MBR<\LVHBY+FD%E.X!+F9X]Q!1>4N
M]2AG#T1]G>/YKD'EQEQ(PZO>6VO=2X=;3V'PZX+9+@XOIM1T9?-],;NHJ-(R
M/FQG&?!F8/FU&U'U>\,HU->Y@(;$E?3B8^;\> &;**RCTARR$783<TC4:V#%
M>T,H5-*$,/E/8KOT&R4H[.83\CNHI](@LB/O)@:!=1NZ<B->^]XJBK75?I/W
M-A54VD%V4-;(#A(;EJ][NGBVGH) .AA;W5*))PS#&!K3_B]@"*7U5-I#9M=&
M(WM "] !)-1N>-5[TQM[NRC1UU/LI10<'LT7ZS5JU%9E(Z,M1IK:1IX27Q(T
M[.VD4',OD56HE5TX&L*_;#JHOLY_#9[V2DTK8$H7:/>QDX9>H,T75U+9'9QN
MU=3]BN,'*>T;>*&:&N5VFV LS_7BOVT:]__K[.]OAZE[__P7B=L!]=V _FWE
M6M^HK7_[MR>= U8\Y_Y>,F)'-YGA[8;A)4]%99AMHW _'2@H=6 X[LQ13+E8
M[U<IW/6G WV]]T>FZ.K \.Y5\]Y X 7-3&XNX0MR<V!X[V?>4?R?#DR=[0M>
MKZEDPKK7"+P+D57\,L1"W@24E:[IR34\2,7?F))FLJIPU[F=$CN6L'4(3GK:
M>&3WN7!46J65A;O.[3TUE]HH;P"!-O4"XRTMV%TN+4N[ V)?D9F0^F;K*=XV
MZG/!%U>4  _>N;O^/4SAA4_(BR^$[?'\!#*Z$QMBJ\U7ET@ HOI I_#BG17V
M"5EYU(+Y"7B_IW*%-S5@_M-4WPAW\4)T5X)JPTTM6>YK0K7GWW*]QI;F/\YH
M4":/4P(U(6E!U1'G 7G?F5I.-YP*YW<*FEQ.A/S.T*--E6MMOM'5C,J0\89
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MK%-/)\Z#TQU"AY9*^K4![%K8%$E!EY\(^8U2M%Z]J#MB #YD=HBGTX/;H>A
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M%.770C&3AGE8O0^6:^BZZ<M=(/H30T/O5&<'0I@5^?S+_P%02P,$%     @
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M]J<'$*0E*W86&D"L=G/)KC*]"/5RBA_3._=EORQ;'NU;A-N+84Y-DR+^80T
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MB&A)LEHK-&Q.?7?HI%C7!=H3(]T[5&F3RXO4=.?<][HJKH*BRE-4LV,"2Z(
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M^#W+^[W[;;8097?!*G(? R,!9) &E$^JA*:K D!2SNK,Z ^R9G12-7M':=Q
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MV+J22D5C,V,H1[DTD2O/( <7<8R7!,.*J*PZG/T?5\?OW/-W712'A/5H!#O
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M4*8R:",LL=FPU.56GB,Y#W3IY8=R4/0-X]A$NK70/IY.;:JI*'&.6!= $2_
M1V-P9N<>@I&>9Y)])OU<#O^#DVH@,$>?H]9+<8<Y:F<%E1$D..$84"D89!<9
M6,L""$)1.[3"\RXQ"^.>Y0PZ1_4-XY@[;N70^UY"PY?3]\4=^^^3F7>3R=?3
MV'S[WZN\3OCJM O\,%_LO)2S0ZU54AE-%IX@AZA HQ$*7G$!-D6A+2-6^@Y!
MX?_<EU:-VR_C9AT]J%6;>;Q?"F\JK9Q(6G"J('/J ?LD@!/E!$8HD6P,T;>+
M^CB^J?A3,/CQW3+FXCQ>I/:-E[Y)V#^AGJQC,)^EQ>>4IAL[K&C.R^*8@$^^
M62O1ZWO 4<;-5\=6%J[EN6Y2D6H;*78,]/:55)EZ4SQU(!?/0*Z8 .Z) TV8
MYLQJJ>@1[]3>WI#;77RVN-N[MQX^&*:#:J\DC=2@,07$L)(C4!"P0A-(UGO4
MFXV*7?R?QUG:AZ++[!3@?K2+81MQ7Z?FRI6(T-7:\)#7X>$U500;)3C:ZTFR
M!-Z)HIY0MG:JXTHYPT]^:W9@6HT'[5A*7YO&;-_\V1F2V*7:*C(>(Z<<LB0>
MI,VNW,B%XR_ZQ 336O*3O\WNA.:W'G$^)5:B5HSJT3*LHIXV&TC;+P_MR-/V
M+ZJ$2<1P&<J6)P$1$5M.K (KC:8B*!7#R=^V=T+,'13Y4^+RW?W0E5508\%R
M?ER[24<&[ZN^8E1:QPQJ-T9;,$H(H-9$M.E"3$0ER74'WH[C47Q"O!T [T%5
MRA)JLURE$_F_,S\_"XM7&2O2J,2$'8$MW6NNM-/8WB" $(<0I*B ,!:^Z47&
MF-AADU+]#+P['M2G-$&>?W#32WR@F\M\SV^JT""T@@54ZWEQ'"SWXSDK..@L
M-+=9D^@Z!&+HGX&^IP/]*=%Y%9ER%O][N;[ LZLE=;>ZBI#,M3*VK"H,:%"F
MC',/@B-%LJ&$=4FT8?[9B-D#OF/N@;\-'U!KGJ17^?VTP89<3LL5(]]#1/9D
M"NMW;WSXA&S?LJ ,F[KT]GM&0/#FZX8'\4Z0ZH"O^,[.ZZ\VCK+'/@>YEF=W
MMKJ;CU5*^1"U=>!HX!"8B."-%Z ="8EKCL:G;S/3#MRB-^[S;SBM-6A\%#Z]
MRL6,;C[MW,/;7[AR5MN0G <>M (G8O&3IA&"LX1%F8RT)W\MW..[<\N%W+WC
M-=[A_T;X?\R:/UZ6?+$AS0^GRL.E*X+:FE$J /$T@*19@DF1 V>:K=*QZRY1
MRV,=Y_?-E5X!&YTL+^II/<?IO&0I.YPL#Y>N HN1&$$ ;58-W' //B8+V3-F
M)6?"DE;W9AWS"*!_LO0*V @:Z4;LH;6737*0LVE<*^J734JWS*H17SFX8OCO
M2]?@VC+YNKYK$M>8"[=P[Z=N&9&.\6@O/G;#AR;9F[2HFU4?E]388[UG<%3'
MO$[Z_KN&;]YB%OYXYN8IED3:.&17-8S]OO&<TK:__TW95WN5GW])3:CGY8;-
ML"]=^'"RI/D"W[^ZU1S_CC/HG6_>3\?8H=@NW.K;5ZLK88XEPM#SV-NBO31?
M7^6W]>6TSG4H>?[#ZO+9>GKY>C:I0WW\]U]O]+Z8->LL<,57=?@N:2<<_G91
M3Y9E1*]N &^1?G\TX<YGTW+>L]X:?5//_S@1N5ZXNBG[^.FWY.;+9B1MJ:5L
M!UQ+-)I0*$GA_.O4X/1PA7-363V/O47VCY79A&!]2HV[3+\OKWQJ7N75:,#Y
MNX@X?[5<S!=N&K$M.ZS  VNJ& U)9):!6QU*^#T#H[@$':R@0CF"_S]J_,^:
MTFYRH[?F9PM<V?QR4>;T=[/5=ZL)?Y/'\ S5 ER9]QT!=:^\2I+YE'F&J+B#
M2)D%XY4#8:AE64:K?8=8BG$VZ@9ES/WXB/$A'VO[Y@$@[R%8+L+;%9YV4#T5
MB]$Z:R@D*2WB(2AD&AB(Z+7-FCJ=3C[+S)@4'!K=P?=_VBYSGV]\V<RF^#&<
ME'9P*CKQVW1YM<I4<WTAY(D M-=DV1"L_/ X7?[M7_X_4$L#!!0    (  8\
M5D[K1*4#N%H  #]N!  5    :6YS;2TR,#$X,3(S,5]D968N>&UL[+W9EALY
MDB9\/T^1?\YU5F)?^G3-'*S9ZE$J8B1EU\R5'Q?#0\$I!CW*24J*>OH?(.F,
ME:33=T96=K5$D0ZXV6<&P& PF/W[__QQ._OI6U8LIOG\KS_#OX"??\KFD_QJ
M.O_ZUY__^/2+^F3>O?OY?_Z/__;O_]\OO_P?_?']3S:?K&ZS^?(G4V3I,KOZ
MZ?MT>?/3WZZRQ=]_NB[RVY_^EA=_GWY+?_EET^BG]8?9=/[W?XM_?$D7V4\_
M%M-_6TQNLMOT?3Y)E^MWWRR7=__VZZ_?OW__RX\OQ>PO>?'U5P0 _G77:N\3
M\5^_E(_]$K_Z!:)?,/S+C\75SS\%#N>+];LKO*1\//YZM=PU>/PP_77SX^[1
M%UU_Q^MGH93RU_6ONT<7T]<>#)W"7__/[^\_K2'Y93I?+-/Y)/OY?_RWGW[:
M(%?DL^QC=OU3_/N/C^^>=!(>O\VN_C+);W^-/_^J)I-BE5VY'W?9?)$MPKO7
M7=P4V?5??XX/!X2@@&B#SW_?\_CR_B[[Z\^+Z>W=+(#R:RNDV&R93F>G4O2L
M51>$?4Z_S$Y&ZFFC5L@R^>WM=!E'UT+-KTP^7X9Q&,;C]#AQ%9IV3>+OT_GT
M=G7[,?R6SB[3^_5#%67>L-NN6?N0%D68I[YES=G9UU77+%33\<H=M$3N?)'/
MIE=Q'='I+$YZGVZR;%F!S",-NR7O,BT"0C?9<CI)9[5I?;67U@G_M Q_K@5Z
M<6W2Q8V?Y=]/PO=@!]V2F]_>%=E-F&W#<'F?+^J3O:^C3LG_=!,$?)//KH)Y
MY?ZQFB[OZ]*_OZ=6&+#9E^4QTAX_T]I+HUSR^8;'^.^*LVN%IJV1> ))79'@
M5\M5D5T6TS -WZ6SC]G==A$\&;33>FJ-@6I+S\LG6R)@,2FF=W&3<7&M5XOI
M/%O$M4VGBVG@^[+(%M&RB+\?I_#DKOIFX81'3[5I^J6B'>"V>]7P:A<LF>7]
MN_EU7MQ6$W:%MJT0Z:<_LBNU6 2+X$-V=!Y^_>D."*FH%0<;=4!6M;GD4)M6
MB'HW#Q^SS^F/X[2\\FC;)#Q=#*^SHLBNP@\; (("OY^F7Z:SZ7):>0_>2N=M
ML[G[J+-Y=CU=7A;YM^EB/=^<RE35KMIF(1J?.@L32?:$F#\BD+_-\B_I;'9_
M.C<U>FV;L5-7DPI-VR;Q8S;)@^$SFZ[G<)TMOV?9W&?!J$YGT=I>+?/B/CSY
M,1C><=:_OLXFD:SM5Z<SUNX+VX8C>ANO5K/LXOJ/>1$H_3J?_G,]LK=#HL94
M<6J7;;-4;7'8VZ E<I;I_.LT]EMA.7_]Z0X(J2S, XTZ(*NJQ/:W:8FH;V&!
M"Z/Q."7/'FSW]0\#:/>561713519?J?VU"X#5>7YZN.MD/)^.HGN^3"?7BQO
MLD)]+;*-&^4844<;=DM>10%7;=\*L?][E1;+K)C=^^D\#2M9.K/I,OUCGJZN
MILOLZABM%9OW06I%=$_KI0_"JPVHDSIIA>R/V7):K#7O<I8>W4R__G0'A%24
M\\%&K9!UNO.W8R?OR^XK8G6T83OD+?/)WW6ZR*[B?C-,<96<-(=;=4C8J=N=
MTWKID/"/P9 *1H'[D163Z2+Z@B>5G0+U>^R2H6RQ#*]<GYB$W\/"^.R;/^;5
M]S(MOJ)#EM??7JS=J\T8.]!1A^176]*JM&V'R-7M;5K<7UQ_FH;]ZO5TDLZ7
M:C+)5^NS[\M\-JT2?W%:+ST2KF:S_'L\=/9Y88HLV /16U15;=I[19\LAW_9
MZ6P59]9/V615G.+Y;/$5/;)L\@#_?%ELYJOIXN^M<GNL]QX9]>FT^*]TMLI^
MS]+%JCAI[]3>&_IDN,ZI3 M=]\AB>'F<,"ZS(H8?A64I6IRM<EKE#;TR_/W1
MET4^#Q\G':AR]??TR'R[*^J *^NG[&N$\M&Y<*O".]I]CZQ6--EJ]+67B;28
ME'QL/SYF91>0/9TO?[V:WOZZ?>;7=/8L(&]/R'<9Q1W#Q>F:^D<MVR8J?(ZQ
M9_G\EZOL.EW-EC5)W-M/AP3GM^ETWIS>)]VT3NZZ]U]NL]LO65&7UM?Z:)O0
MF]!?,5E]R7[905.3W ,][24Z*,TT[%3#H^_#/[=/1[KJW"?8O"7[L<SF5]&7
MV_9[7IWLNGO=:[-2BV^K')[?SSNKQ]3W0\]A1]B.ADA!2<,LG[PV<M:CYCI=
M?%D/G=7BEZ]I>O=K7*9^S6;+1?G->N'Z!<#M+:'_OOTZN0BC*HUTO<^BZV%C
M' <FLW?+['9'UBS]DLW^^G,@(:G6,/'4"X<5]IH) #!QFF&M%,+42^"]>LKP
M+-Z*RHLMYMUR_'!0^"H+ZW%Q@.\JS1.#E924,4,<!, #8KC<<B^H,[P*]P\Z
MIXK)3WEQE15__1F6+;<3[$GV0;RMUHT0\\XQ"NR$+]9KPK]-9GGHZZ\_+\-\
M]O!E&%YAW+C9VMP/R\'&FJRC4HMB^4B=PK^>JU+X*MF%J_^6Y5^+].XF7FI0
M/Z:OC9F#SR<2*4001HY[IPEQ4AM; N&UQ#TJRX%%]J7RM"OEO'VHUCK3E?@W
MZO680OO$Y'LN_GW/)UPC)+#'@"-%@#+"(EKRY+PSR:NF;Z=JL-?L?E""EN24
M=X?0VY#^,%)_PLLXA7ZJL%_NWN,WB2ZF5U^S[X&GXD/V_3^S8I'=^S3&,"[O
M?W^R-7HDTHHM$R&EU]80#3E'P#FH*"C73ZQ-GS/[J[N]9Y)M+HN\2WQJRUA=
M7:T!3&?OTR]YD:[#Q>[22?9TW5IL;@MMMPJ[3<+J-6NPE7X3S@A3)EA9T@G(
M(():J))_184=CWYT9# . 6/-=>'D?<::Z/71>=QS;K?=!S86KSZ?6(,U5M91
M!82!VB#N]98WI<(T6UM%T)FH2)OP]"7ZRU4QN0GD7GR93;\^B=!Y1>XO'TX4
MATQ[H)0,<RV0PCH%M=+1C,8X0%9;Z/C,A-X8F[XD7G\E.;&'!#C.,<2>28DQ
M ]!Y4%I9BC+B:^L&.3/=Z :P!X7Y]U]?<?UUZ!+LW"%;*8-$'V\\D >BH]=7
M2.G0H\]U1TT5/^O+AQ--K4-.4(D(D5QK8:$ 1F)+E#: RP%]JR6Q1[VH3QY,
M@#'*<V<=D09['T8KHEN.1/BCSUWP07]I$V$\]Y$V0:!/;^C)2A#S&KR;+P(]
MZ^ODK[M$]S^<& J%\$ BRE#8<1+*"=Q"(2%@8K3^T)H2S5M&I"^;YRFA']+;
M;*\/[%B3A! C$=9 0*PUAU0)PDL..35TG$[0-D1V4/J-$7J+NC JE^B85* E
M=]G%/+O, Q*?LF_9W$^_99=A#@R4!(/J6U8LXZW43]E\FA<?\F46+&P$$#WL
M*JW?8P("<T8&&BWG4B,7_DVV/"OO&FR%.W.1-1=?/@1TO;G%\OG795;<KK,?
MA3<?L0]>>SQ!CD+KK3'>(*4]H]:4(TM!PV!MI3C=*3:$A= ")D-)^^BJ\'J#
MA$DAF#:40.Z<Q$('OG:Z#"T>MWW03&!'I-\(H;>F!Z.T#<8@_F'$_FB5BNO3
MXC*]CS/?7FNA4KL$.V25@1A;XY00W B!2UZI87U&5U6T"9H*+>\.GKY4X4.V
MC)ZW==ZIJ^Q*W_^QR*[>S7=>7!4S :TOE:DOP7A*)\L#^G%Z9PFU4EH%2 "'
M*>*=,\27?AJ  1N?TK3H;.H<KQZU:)/-Z'%2V]<5Y.&Y1!'EE?,<6Z^T13"8
MOSO8("4CE'V7 GNI&[6AZDOLZNK_K1:;8Y//>9EE+'M"^>>\O>FEB]<EG"!O
MC.8,!<D(1Y7%Y61O#/#U39?.3O)[5,(1(-Z?J^RNR";38V$!CQ]+$!=6&VLQ
M=E H3KQ5Y:@,?\H1>D&&%>@+CUIM+'N;X6[S8-#],]VD$'[(_[8Y+3\T5QUL
MF'#A$ _6)=)<4X^D=K1T.AD%?7W-Z6S6&97FM(IN7[JTONR]-TG0:Z>QKS9(
ME-"4":>4"%.YX%9!7HX4RR&L=(>GWS"D4>E.*Z@.,_]LLZK-OYI\<<+L\[19
M@H(9 #0D4 LF),!$R=(8L-#[^J?ZG84JC4I_6L2V+RWZ+8"\3LZ<+2[F[D<$
M9#5=W$1 -Q47#JC2T;8)8QA2Z!57GA"!H#,R LEX&$D8-8B%I7\*?6H;X&&F
MIG7=CNEBG63ALLANIZO;RO/3*VT3QSV%PG/EM,,^,.UW.Q9K)4*UE8K]*92J
M;8![4ZK)I,@BT<<#\Y\_F@"IPY"@ $.%%"3,.UBZ[JV3JOY.GO\Y5*89GGUI
M2("FB)'%-MO\_0@,D]Y-E^FL@B>I>B<)%L@+CZS2EE.,0%C=38F"%Z;^ZB;^
M%%K5&=+#Z=LVE5 LJY!-OQV)J*W2/#$.8 ^!,YI:$9E&HMQ[.(-9I<CA?OU(
M78CUJ.8T1FXXG2DSS3_*LU))61ZU2R!Q5$.*B6040()XX+CD59@&1V6=^8P&
MT9+ZD VG'L$HNTNG5V59H^T*O$NN?\S96*_#1//U>;82V(.PLZ"4P]($=)!:
M,#Y'TB *U0&6PR]>V]B$6BO7MFTBG04* \\0\Q@2;RS8C2[&<7TG=F>.I$&7
MK7JPU8X7?I60F&KL4:&T4HFW)5D>_;(O9KA9KXDEQ'B.%?1>&H<X%CO/?-A_
MVOJ63F>^H@Y5IG] AYMWW.W=++_/LH_9+-[\.ZQI=;I),)14>:.M, Q+HPWQ
MY0SLI5#UP\\Z\Q@-,ANUAN#X(M1:B4Q+@")":XX@U1AR1SW4KD0A8%T_^T=G
M;J0>]*@S_ ;6HKA96+05YWB@L\1 QZ'42#B!&'+:T-WQHA<.Z?%MWKJ/<VP/
MK]XRB&P3&'S.U>0?JVFL89Z'(;"\C^6;UB6:P[=WFRN]>[6G>B<)H8Y @*CA
M/,#-A><$E2@@ID<88-2EJ)]G(>D*Q\&TZ83XHJ-M$R"-4@QB%AA'6@/BJ-SP
MK &TO+X]U'=@8R^ZTQ"^\2UCK2Q?"<; (>-A#!*5DAAF'U#01(S01=2C$G6&
MX\#:M(MI:<,H.M!90J1EU&)/,:6.8RI@:4]HP*RL?\C?F79U;Q2UAU=ORUB1
M3[+L:N$#6H^N0!V)*SK0*B'..6:9 XQ@K BA&MF23R-X?6.Y;[.G%6$^7[I:
M ZYO.V<3B/(TQ.E8)./1M@EWQ$KK 0N,"^40B2[X#<\0>3O"8[$^E:5E^/I2
MF8_9W1/*#VC(\T<3!H4'@G$), XP,<XP+3F2U(]P5>E1(1JB-<2:\FZQ6,4L
M=4<U87^CQ%I+B+!.AH6:&06$YN7$" 5ND)JBLZ.J@5:41K@-JQW;DGJQ7NO)
M2O*H;2(8P(P9%S9^&%I(G?:HY!GH!L>:G9U1#:XK]>$;0F4>EQLNRT5?5529
M5]LFW%IJ*!8H#!<!(#3,B-TB"D7]Z:6SLZ>!5*8-^(8Q6TME/\U@?=(J,6%L
M(!A,+*<) "Z>V)=\(@4;W+SI[&AI,%.U"7#C<Y^TXC9)D+&*800YD=)9"9F7
MJD1!>EX_ V=GH<@]JD]G./:E3>[Z.ILL+Z[=C\E-.O^:?4R7V<4\\A134H>_
MXG'&MW06Q\@!?3JEFT0X$)9I1@'%DF%+$;"E6Q)1V^ ">V=F<8L.N Z1ZDMG
M7B?V,BNF^=7SJ( #.G-*-XF#BDDJ!9>"2 J\9H"52!BHZE\_[LP\;E%G.D1J
M6)U18?8LBOLP4:YKSI^L+,_:)\H[;4PP_JW5#H2_'->[%5N1^E$TG5G$G6M)
M,XAZRU*PNKO;I"=/9V5._D>UORL<!%7L(>%:1C<UT#!FX-4>"ERN]$(P,4)S
MILT\\YV U%]\YS(KLL7R,IU>!</K8 CGDR<3R!G"Q@FN-"8L9GQ!I;M9**Q'
M>-6I=4F]"-%L@E"/$;WY;?8Y_1'3&AX7^O.'$X*9TR[FT\6<,.Z8$Z7-+1#"
M]>OC=!?_UKG<&X+T(/J.:N+L*=22W]X5V4U,LOKM2;Z_WDK%K#.XW.2S(/]%
M7%^7]WM(&'_-&&@D\11J+CTS$D)NA1: >V^Y",-_R'K<-6O&,!V61(4<DQ:[
M8-EP*NR6(\8%Z3,5\*DU8RH+XW#-F-,02,=<,V;'V6:8Q:&?S]>V[.'T\ ?;
M)9(!S+%6PB%L%?8<<%P"Y'F#1 W]5I*I+.=]ZM(".+TYIYZ2>C1/^*O/)S[6
MDH5"Z.CM=X1[%G;'6]XP]&[<Z>);DMMS+U2+2+TM;1A&"XXDC1^3$@SD/WHX
MZZV0,/[9LPGC5@J(O!+2.J*=0I)N>>(J?!C?_J^A;%[DB&^&2%]2?JC^'#<G
M[^;;BV1')7ZP7:(LI 9@3"R@5$L-#=WQZB$<8=GD=J7?)CK]A>(M \O9E4N+
M^73^=7%4!5YOD'@L2$S6PA0".%C7WDI0<N=(@QB)SL+RVI5]*[#T-OPGD]7M
M:GU#>'/S_/&F?^.Y.#X55.TC,<9CJ2+K<ATXA"D@)09XE(DD6IX6.D)JN.O^
MZP7NB8OF8SZ;^;SXGA:'0JU.["D)JZ8&4E#@#52(*:])N0<34NGZAY%]E@^I
MZW?H%JS>#IQ>T'S0L?#\X<0:9*E4DAM&"-!4:,A*KA1!]=>5'I.GM22W%XZ&
MAF#UI@+1H;NX6"T7RW1^%1;'0QKP_-F$4X@%%HJ!L(!JASR!KN0)$MEGV<&Q
M*4!#K'K<4CY?[SYDRXOKS^F/"N?-%5HG"% ,H/2*F9C:'=.P0R_Y9I;5+U[;
M8ZJS;G2D??1Z#+^L473*.NHT  8B[AV4BE%=C@#I+>VSC'E%36A50@>K3)V&
M35]RWF<21Y)+("YCNNL@CN6RF'Y9+:-__G-^F1:',W$T[#G!1G+ E<(:2\LX
M(T;X$B]NS BO'G:I2_VBV:MY&J/1LRN[*L(:N@GV6X=PG7J1Y.2^$@ND$HAR
M[84".E8E?<#$<CO"6AV]&K<=8CFP?FU,MY84[$!GB?1<<:+#B-=, L4%0J7_
M23)0+0)AZ(R,O6I8>V".80K[D'U?_W+X-+]"^P0XP23DP',L&#*8>EDN&U**
M!OOP'O,O]C]5U<5O%--3 ^5YUD$BI).:(8YB&A["*(>D-#T54:+^N6"/61<'
MF(;J MC?,>*C6A1[3K^>^=)CA&'5)#)M=)_( !H41$ND?$#1@5A9:8N<1+)^
MMIG.XM#[4KT!X!W#FO@Q"SNAZ60==1J>4A'#]08FX'F=39>KHO9R6:7K1!(/
M'/2(*.J%E<;#6-5B@Y@BMGX"$WGN"MDSM*-89+O1QNI])Y!9"*2W3%I#&:-R
M79IW@YGPL$&9=O!&];$S<,>T;*^9_/*\CNK'+("[F"ZS3UGQ;3K)-H#$*E1?
M-_(_=KVPZU<G0$FG8;"QP_^HP8QCX!\,)5<_I24\^P/#D6'?\067Q[9EZW=7
M8N</P:';$HPQ FBV[[Y,'R7NORS?S<.DM*IZ8V5/B\0Y@9G25$"IL:/:2HTH
MI\@2K[6DE6YS]<'CL;LKKSR=4*F-X] @ZJS66 )H]98WX0VO;WVU?(&EL6SR
MMK$8]566]_G\ZS(K;B.;GP.Y1VZPO/9X(@#PP'-";4Q'XP%WRF_AD-BQ/H.7
M3[JXTDBT>>O ]&7%/"?UZ#V%UQLD2FH6]@:*"HX-1%YH1TON/+=JW-=6F@GL
MB/0;(?36]& 8^1^YL#(&\0\55;1S1'W(EUE9?ZW"I94#[1(/N10 .4K"=,EC
M?8 'Z"@5(RS)T51H+P*&VH.G+U5XN@ >6?I?/IR(L$'WL:P15#SL6618(<F6
M*^69ZS-[P6 +?V-8AA'VA_3V^(2_KTE",7(80@>T@I*'/[ W)8> P9'?6&TB
MLH/2;XS06]2%42[_8U"!4T6_IZ#IQ3R[S ,2G[)OV=Q/OT4GTV2=QWZW('W*
MYM.\B,N2764((+IWL6_88V+#QAI;#B#@5&"NG0&XW&5#X$9XZZ"Y^/(AH.OM
M#":;K(KLZLB!\Z.G8AI11Q4+XX@"&^QF$ R<D@\.1/W8O)Y4H+G+J#X:_<W_
MFZ+=FS2PFVS"AW-7[6F1(,@X,8!J@:# T&(![)8_0WB#RL6=Q?JV[R!L YEA
M5OX_YNEM##W^9]#6Z6)=C[NR"?!*VUC#6U*#@3'4A&T4"BNJ*GE6A-2_R-[9
M?9)NW<7-,>K3&?1YNQO^D,\GFY+:1YQ!+QLDF",%2<SR(8DQ1@#L2MQ,+/0V
MOLCLMC6@%6"&F0[*G(LQY?/Z0N[5UGQ)OU8_+CK422(UT]@CHAFCVAOL)2F7
M0X.)K)__MK.PZFXGB!;!ZN%8^.V<U%KN(!3<> \5=&%84L.!==QI![4FE8)W
MQGI2*PWGR#,K Y,( XV9]!O>K#&6CB;58&/95#BI/0V+CDYJ]VS<G]*[V2%&
MYT5<//;X8BNU2YP(%H5"UONPE0S6A9/6E4Q;)!I$IO7OEJTLP+P[A&J[9@[1
ML=?A5K%E A 6E"H!)+'1,2&(E5L>+.>:C=,'V[)\JDJ]$6;G*?]1^5W'+?:6
MQ/WTW=/#3M97'TX$XAPHA&3,?L=QC =$):7&-[C8VKKSK'7L\Y;!:4N,I\FQ
MI)4CHSB1Q"O,B*/26FFVM#H)S8@2N_<IR'KHM";)$T594HNA]%1AP!GBRBEN
M)"MM$&>LKW\3JG6O5J^RK =/6\+\=I(LMT\G89\.E1.:81YVU#*\PZF25JL:
M9%MLW3W5IRCKH3-4G%J=$%6OC*'"R*"GQGG-#*&LY$P@=5:1*J=NB5H$YMQ"
M$PEQ'"% J426",=AF)U*[A0D?)Q[I'8$5BU&L1Y";TT/1K57&I/XAQ%[-R&J
MBG#LM?)2 V2-] 9KLN75<V?[](LV"U&M++230E1/@^=<0E0-] @ZJL+"2(V&
MSN%X#K_A2JD&N<A.M]T'6_@;PW*.88D*"(F91TY8S!W3 !)8<J@1L>->^IN(
MK&I\8CV$WJ(NC'+Y'X,*M+1U'U6(JL?$&Q 85V&O["2!D&PWN0Y8BT>8Z;2Y
M^%H*43T-NMXV"=-Y=G%MBNQJNCQJ(KY\./&QCJ2)UC2W,+!$-0?E>3.U<D2N
MVM85HC54AED5?#K)U.U)48L/31(M,<"$>BLH,XRB:$_OX@PP[?-&>\-8I'8B
M)FI#T]+YZ"9MY.?\<E5,;M)%]I!I8T_T^<E])%0#BD#8,BM/'4#0$EA.8% X
M6]\/T'NT\JDB[QJK\XM<IQ)K;YVS0#.@I$$ ;P^;'9)\3*<ZW0W_-I#I2_*7
M13[)LJN%#[A43X5XH%4B:5@BD4:6.62T(0AX4_))5(."J[W'*M?5@/;0&<8
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M 54R.?B8.HF0!"L'N"566^J5L)YXY4II(-$@X]4Y^'-'/ZRZE.5H1E931^!
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MSR[S@,2GF"O"3[]EV_M\CY:Q3]E\FA=Q,;.K#(6][N'<7_5[3)!76&),!,:
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M*)4CP'M$E&H,$+?"^%'7R@\([K_M/KJ!I2;[<1#,Q(+Z6TZ).!08.(JP7Q6
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M0EQQVW<[Y"1;] (?O?0V0/94A#:4@F]"9GC53!;V6R!=3W?-;2#UDWDH^7V
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MY+A*)6 3]BQ+10<1Y"W&NID]E (F6#ZJ"ZE)B1&FY11F;)+5A*?GMX/7T-L
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MO1"K94\G*:A79<\50?1&[7K$J@W([9%I."%,6*4]Q9'$T'D0M?,:%0]SY<R
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M/[U2IVE,8RV5U+!C61,;+,#55#T=WA0USC)E^A/=%M@5Z!B<>H+[G"<9^1K
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MR6YVT^5JL,#]4I5UO0CB"#HHB1B"GN-2'(;!7E53US5SG$'.E.UM+4<G]*_
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MQ><<%)OF%ZYWVUV57X%Z]^D_^"^(3WS.ZZU85A,KZ65S<Q 'N:V*94//%<C
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M3&LNHD.R[03MZAO)N%,PHYIU)XO>:)EW?[1&R@D/4R<B/DE(P'!,F,\P[9V
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M2M^B2UF"-9AV64=UW)$20VV>9!7M4]'LZG*U*]:?=]7JG_W=\EE,DB0.TR3
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MJ#IQ:YLNPQ?DUGK0W-!>^VY6$W<&A=<-SO;6VG'AR7?^$+O,_:HUY';C,"$
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MZNE_M\Q#L4TX4(9MKMW^U7,0:[S-5,AM.O+S9R-/"^K>]B^*6!8#B!"*TS!
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MEI8O;ZJ5/D/Z,G5=%P_+<DV*FZ*NBW4_EX;;=7L/7E]Z@5((64!@%C&?Q3$
M:3"LR-$ $'_0+UWI,@)"0]/4Y*Q'.11(=+/;JKVX6:>RRU8L=/5ONB"8%,8A
M*#W<-B;=9=ISU(?IL:HDHT;#Y*J^FG7R3>&UP.GXF?+U\K%-6'-*?!CY+ D3
M%@4QP\0_C 1)&BF5SHZW9G_CHINR/71X3$V)I<D<.Q^VP:/9R?#U&\Q./!/N
MX6A-@U7)=E7NM/V1G@#K,25U1?&+1NL]SZZ."_^#E.(]UU=QE\'A)PL2QYBE
M$0P8RS$-TR@[E/6RF!&I:TJFP#'!CBW'^D)RJ7!IK>U07!9'UZ)@2C;;N)R
M/,DQ>P].?^I0N!1N&'8H;'KW"W^Y*WBXAA"N#R%<[VNQ)=;=&/P@2D_XOW4/
M-(CPBN\W^_OV_N"7>N"K81Y[S_ XPE\8+:<,HP-W#$_E:35])QD[@:#W#YOJ
ML2@^%9MVD>,$0A3D #*,2(:3*,<(QVR8P[ \@TIOQ1DU/-'HNI(YJS$!S;JS
MC(D8-C)R#EB]'JS4(#G1Y.-U'I7F(0;"X>J4Q(1K;\Y.C/%G_I*SA0_C#*$T
M# "*@I0"%B Z " L(XM=M5MNY*32H%DEH3P@E.[+'V3NP+%UR]G;G,OIYDQT
MJZFFQJUFKEYE=D$S+83"#<6TX9CVE66*W(U4RW?M@U@O7RV# YH&.0HSFH5)
M2!$&AV.3+*,A,G EY!CSEM/, S338CF*\E&B.17;1L7S& <';O!2)U9=3TU$
MR6E=->*@G+Z:XU)69_OW")LO%5S]S[ZL"PZ)B_SN\9HW^AW<MH\4/HB/+&)
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M%X342CS<D%([KE43M&<U.7W9V'5[>]GY;2H+&L D!WF6YEF< Y^AQ$\&"#B
M4"4%-6IX@B3TI9O?2F-J:C8,<FHZ6P34U/15R;SR.JS>"[=#32NG*DQ>D%,K
M 7%#3NVX5DW0H$W(*>0Y<UT_\O3X[\O-OEA 1A'&@")"$/7Y/VB*#FL),":+
M[O;(S[MEO1NCIJIV53KQ.43U_GRNF-YRYWTM;LOM5LPP>?;4F7"A*Y\1J=R'
M=0/A<N?5]DFJUXYCS&QW95&6QC[! 4Z3B.: ,CC4EV0^9JCOKG0KN5-@QJIZ
M9QT FNFJXKG?OW0GE0W S]1)I7W2ZJ1JC,EVTL_[AX=-T=[7O!$ V*;Z_FY[
M4]7W[26KA^,I*<J3.(I\%*1QX",69-&P0I]E29:I+/:8LFEYG><4IK<NF]6F
M:O9UT>Y0M7WVAN/FTY0#<,7G<8U1+S<CF8-UM<G($\);>108O1.0LYVTDR3O
M@BR:IM\-833N566WT:K>S<UEHVAVU\MR_:'8+8(T"2-,LQ2B*$X(PB0<SJMD
M,$)2;UWH_FW+8M=VM_8E+G%RJ^S!J=ZQK4B7G'#99$I-H 8DGH!R)1:@-_OU
MR8O=Y;\*L6#2?>C*@3M@SZB[($^Z)+LA0]KHGUUQ/88%A2O_J_OBR_)'T0R&
MXBBAB.*(L2B-DY0F-!NV\[(PC)CBQ?ZJ?WY2<=D)9!IU[#JTR2J,5<9414:
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MU_ON@=B;LK[W'GKD:JJC0Z><Y%AF4DUO!C#>$<W$EQD]8^."PHR@S@UY&>/
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MKARO5",,!FE"8Q(@E(<X@!G.>&)&(IS&:<* WA$Z<_8M*]CAM-<19E]6HGN
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M::;A\+BFHZ;=>U5;K? HJ[<\&[H7!>+<PO6R_EBWI>)KL4977!?UY[ME72Q
MXD<Q]!&)LI"C2'T4X-ZR. Z;JTBL"7OV$T0.T6L$QBOO85FW>RJ%]TNY]=;5
M9K.L&W%2SFL$V+^IB:H1NN5T=&JFU:2S)_ES1S('R+MV=RIFW6YL%&*YRVM1
M3BN5$K1=4$>3I+LAB$8]JNPU46W9:\TT<+^[JVIQQ=B"Q#%.PCA( S\)$04A
MIO%@T8\8UI0[93N3RMSR@*O3M::5N^Y+?8U3YU99VZS2.D;3.F#>$=EL.G9.
MD9Q^:1/KG&[I>_*Z7HUD1UNGWC7-GEM+,8KB# <TB-(T!S"/\WRP%@29TD$%
M71N3ZE/98C*O3;)\:NJ2!2K':]*5U\&:69 Z$"IBI,BFHT*DZL5;(J3%BK8
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M^%9L]P7C[G'CW/)J]X]R=X?WS:ZZ+^ISY<P 20*81G&*,D!3$,51OVJ8^#!
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M(Y =:T1E='"I!ZY?EINB)IM-]4/XNYJ[KL]=LER1D:Q>8!KB&+!$U.41_\
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M#E/&5%9&H=;]@C/ML80 "-(4X32/$^;3#*.AO2@(@T4CTK8K72W0:$5)HPZ
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MC$"H='!JH?FY)%9J&W3Z.I"&IKB)'G%ZCALQ4*56I DN3811QYJ5($\0]F/
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M#!P.U(65X?#BSJ.=WG!CVEJS[OFJL198E*\S\KW8[HOZT$SD!PG.(QR2)(I
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MN*=0>*Z<=M@'H?UVQ6>M1"F7/)Q^,NGG(F33RNGP@.\LCX/>W*!SB'_/'LV
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M7L.,"HO_#2K>FJ14_J0[.X9-RI[UT$,N5A36CXK9ZC:$AY-TA[S*&JTS95P
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MN2T5%W;:J5$FU&79V6AWQ;+M2/_([[X<O 3MV9,9,1QC9+DST!-!H)085?(
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M)^_=:!;E^Y9?GB<G*;32! HX(\,ZS*( OA&!'@!*;%FM@'4[LNZOW[*JFGE
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M/F;W8SQ97@7KM$Y(F8=U2/BZI^$7GTOW8W173%>/?\P7R]ET_K&<3/QZ^_@
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M^;169-,_#-N65^,F\&%'(>TE3.-O=\JR)N)C<36?7;^;76^[[I]J)$]]?P"
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M'#@F!1+,6(^DTE"S4NL(93RGS>&0SQ=ZM8FMB:>'_;]$RRO6_$@KAF.C@[:
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M*ZR45!?7:0.WF"VWLELD9W_=_4/_?'CFP^3GNBPQ$?9 W>PZ+8:5JCS;^%S
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M>ME7E?W+9CX0I+,"2L@$ENF:>ZL1+#T2@83,N5SM;%?K?#O8BW"&!NTU5QM
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MBL4DS?9],8G<W]Y0\/, MO:,")X)02R)*RX4$G!LX_I:<BZJ;,[=VP-:KSJ
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M>)]>,_"I6+#*+YX;YS __4OQDX.?_^H,ZL"W]+E;<.B7!X+!1U!+ P04
M"  &/%9.=]DBFEP$   *%   %P   &EN<VTM,C Q.#$R,S%X97@R,S$N:'1M
MY5AM<^(V$/Z<_ J=.[VYFXGQ&P0PA)F$D#G:-,WDZ*3W4;8%:,Z6/)((X7Y]
M5[*=.@2:)B&7WG080*^[SSZ[VI7=?W?Z^W#RY7*$YBI+T>4?)^?C(;)LQ[D.
MAHYS.CE%GR:_G:-FP_701& FJ:*<X=1Q1A<6LN9*Y:'C+)?+QC)H<#%S)E>.
M%M5T4LXE:20JL0;[?3TTV-_KSPE.X'^O_\ZVT2F/%QEA"L6"8$42M)"4S=!U
M0N17Y"';OELYY/E*T-E<(=_UNNB:BZ_T!E<K%%4I&8QNYS2BJN\475#FE-KZ
M$4]62*I52HZL*6?*GN*,IJMP0C,BT059HBN>8=8S<Y)^(Z'GYJJG@2?T9M#'
MB.$,]LI6J^T>CX:M$W<T:IVUAR?=;A.Z(VBTCKW6L37H.QB^9E?U4VE.*2/V
MG&@S0L]W?WZHKJ]'-@&E;$X$51MV1 +4Z>%*:TVWF7L418Z3!&BW(ZX4ST+O
M,+_M*7*K;)S2&0L-[37%W:<BU1M,;UDHC7B:@(31GY_&)^,)\H.&]_XG[]#M
MW;=CAY!WR.X+4,40Z42\ I-#SJ0^17R*QBPA.8$?Z%Z1&96@$<[5Y2)*:8R.
MXY@OF-)G[(R*;,>L/[#O.]%>@Y"2Z4[\?DU07)*J.%)S@BB+N<BYP#K[H6B%
M!)D"M2S64V;%E*<I7VIN"^++I9\59#:=Y&3XIB8]Y%3A* 4[29J6CCVR7,OT
M98[CJO\OLB9ZJ$R!,I54FY<T4?,P:$.\Z 2I$CU9-ARS]-[R&R(4C7%:,J!X
M;CTICU9QJJD+O4+ID_GZX'U<RZL%[.T@>X^@? 6G;HXT!)TS+C+TV0[0!6^@
M( ALW^MX7J?($3*#G#"^BVB2'"#,D@WF&N<X)E#^CP';_*$"UO]A U;6(K8#
M$2N+D VZONL>F&:G#9^BZ?G=9KM;MMNM5N"7[4ZGTRK;OMMLN8%NZ[@_/.SH
M^"YF?-@0;#D&O?_\$?C. ( FOA!0ZX @\%)B+NEG)!(++%;(![;U=?P +:F:
MPRJ9D_BN8NH"RE-:[)E2AEE,<0KJ_W;Z1B<85VD!9#H%<?2&,"+-8JKO%_#H
MH44KP5/$(:9KH@N8N@)OD0Q%/%TDI@$:J$3'C"U@XY79B#Z8$/1<^]>/VR1,
MN3#85@0+I.]9"3HE,<DB !)XAHY.8V<WJC4W/NN^^((HVG:-KFV_E[G<"CTU
M%U#3K\MG0"].[XR&#*1%WK/8SO@WN]!K[3#AK]E0I7>M/.(B(<*.X?:&<TG"
MJO' #QD6,\H*2_%"\6K H W=6A$!$8"/'5F>M;UFU#'\P[*UK%T$ROV"X8.$
M.J?U?AE8]:$"KU^HK;E2'Z8IW&##.4W ?;W2:;X&N(-4LNEAX^V-?H6<Z4@'
MC023JK#X/<[R'OH"SUVS8N#\_/*Q,K/V(+^C]/%LB\:2@.H#<YY^(4*2U6ME
MN&=#K&I207%5F%X&\[4*^-I[F;=Z1;37=_1KL<%^W[RO&_P%4$L#!!0    (
M  8\5DZFQX; C@<  ',@   7    :6YS;2TR,#$X,3(S,7AE>#,Q,2YH=&WE
M6FUOV[86_MS^"L[%MABP8RF.F]5Q R1.B@;KMJ++T'L_4A)E$:%$C:3LN+]^
MSZ%DQX[=-5E=++DW0!R3.N1Y?\ZAF-%WY[^-K_[[_H)E+E?L_1]G[R['K-7M
M]3[VQ[W>^=4Y>WOURSMVN!^$[,KPPDHG=<%5KW?Q:XNU,N?*8:\WF\WV9_U]
M;2:]JP\]VNJPI[2V8C]Q2>OD^8BF3IX_&V6")_C[;/1=M\O.=5SEHG L-H([
MD;#*RF+"/B;"7K.0=;M+RK$NYT9.,L<.@O 5^ZC-M9SR!8633HF3BYM,1M*-
M>O40S'H-MU&DDSFS;J[$ZU:J"]=->2[5?'@E<V'9KV+&/NB<%\?^F96?Q# ,
M2G=,@B=R>C+BK. YUMKSEX<_!>%I<'IT& [&X_'9X-71X'00!$%X=/3FY5GK
M9-3C^/6K%A\+SDH6HIL)4F,8'@3?;[(;T<PV0661"2/=EA61 3N:7G!=X>V?
M?5&*DB<)S-Z-M',Z'_Y4WAP[<>.Z7,E),?16_WI)_7!6<XVT2K#%Q7_>7IY=
M7K%^N!_^\")\&1RO*_*OR[S-NO]<J!B!+LPWL>3O(J:DK(W8#P[86!@G4QGS
MV^G'IL9NC:M$NA.'7W;81ZF4Y#E[N\_>B9FT'3;.N#2 !\:+! ,I4G9Q(^+*
MR:E@OZ6PLS!,I^RRL#E [+*(M2FU(43KL-B[8LY<QMWPL:F[%[;9)<LX]#!B
M*L4,XKM,6FA:5%QA$GHXI@OV1IN\#J0PZ/[\&6UW%F0[T^^@S<ZXA9A0(9^S
MZT+/E$@FHE.KV>B7:%2!0J,.80,NR=%S5A7.5 +LH)DO4M"9LQPC(V&:E,>8
M@M]SZ9C3-=T&02%B82TW<R+)^;4 WY4]+>82" .6RE<W\"""6!I41I 56 Y)
M$@38+)-QQFQ%'[?K9\*(9A-2()=6H>91%9U)ET%!6P(<B#OM6T(TG4#-*98E
M+)JOFN'Q>:__-]X3+)4%[$.FOK5'Q^>HQF.S\EP6*<+7@R&^QZI*L"=LOJ)\
M!_Z21LU9"9.1MRD*E+IU9V-)>X<U(B;Q'5&'*"H% OA0P]">G?7RQ-QF+%5Z
M9A<.-F(BK4,[Y1BGR5IN2-E9\9-="+,A[>-SU6&;7:WI]:-MW-  ((6D;K"2
M=+UDW AO55A)1DJ0]DS E9&2-B-R(LN1CI22-$ZDC96V%=91HAJM:O.61L<B
MP;1E>[!F(N">VF07-W'&BXE@I\B!#Y42ML&P/N^&@SW1]NO#05*/ZJ&D E?4
MOB4FC+)EQ>6U"TB@AW%+U[BEX$8:WXT&4! >[[94+$AH,#PDBEWXG+?9N;!@
M O4]+GW901V"S)A7]OY+"+LB 3LWG&HTU)7!!LB3J;0^^T E"K\/5=K;O%W-
M?2,4]XYKX/#6[IT&%^BA1 Y#%JN53/RIQ%:1E8GD1I("L@9MCT8%[519 E(?
M[-:CKL]5G'T@$(XB?E')$3%QI3A!#-3R0MP",E;4\+Y:E? M$D0(%,#Z79?7
M;Q,3T=V8N'<V;83&_?/PWA&"J)K*A!S/+0ZQA#K<(FBHSE(T<),L/(-8D3R2
M2KHY@?8VMA2GWHG>/W6(K9&NU&D/;C>-0F6%CLDBM*G(Q.B?$B^ K]@34:!V
M*(0)GHB2XH](T(W4H8 XE26@Y2D$0]QF%U.N*I]%9"F1IG14F4)'NZ46HF;<
M P_JX?;"Z+V.A<AE6Y??2%?N\[SO@UA\22VHMTB_W$FQ:-&U^$ 6M0T@SS%M
M_@0<ER"+:\ML6IAZXZ;.^2=W'/B K"6<UG%<&;+@"BBN[9=KZS!#QT[L8F-L
M\6<%-,6F>QO$*=R/'+I#UXB)+DSX)KY8/]ZT:TDR;I=5@[+/APN=X)"Y7OL&
M,N9HU:^%:CKZ._2=KS#([H-C%Z$P>'ACY\^3R2)^.K?90,FYZL_;Q""_/*!2
M;-1O",51O9TV=@G+?@*;Y3BA.2&VPDVD ?GT))&0R2_?@[^1W9;0 W^I>U@$
MIOBSDA#9AV)5^'<NMOU$.K53'&:H/OK70EA/?6LL!4S;0.JR8YH)?DT86=<G
MCY*^LOK3[N)@\R"'-<U-W?!O22.>8*$5RRS:XMRF$H,8?D+![-00;8'/MLIS
M]&:?A%>C0:FMA[^G K]HHDZ!LJE!"'=@/.'S#>;W1_S&3YT:MF0QU6HJ"+L*
M/FG>5)@F145>*CT7>#K+=)V7?"T*X+6OA/']QX98Y[#/D+T1D0'\S^L3V,%!
MQU\<_$^_8-Z94#^\Z!\LV\L5>=:"/5@PE^BVBWJ\*G!!2:>6(CM=TO9K G=S
M_:E;2PTQG6_'8Z%4L^9U*VCYL2UYO!@__!)G)A.7#0?]_:,P>-4_&GQ_' $_
MA.G&6BE>6C%<?-F(1L#*1!:UOKQR>C'A91X&7FKXSU$?2%(6KULAW0"YA#[,
M\FDC="U)&,"3?T,UI;**]J41I/;U0N;&\V%YP_SYE+T(_,\Z$!W SJN&7QTW
M.ZQ.U>K03&O-W]\@.7NVM_&"_<[UU8/,\B34WG)C\W]G@];)?6Y1/@N%WZ*S
M?5^?I5',-N1H?\X?/8]2&U>MC_,N[<X%\+]U%_ULU*/[]Y/G(_^/ 2=_ 5!+
M P04    "  &/%9.^T!;.X<'  #W'P  %P   &EN<VTM,C Q.#$R,S%X97@S
M,3(N:'1MY5G_3^,X%O]YYJ_P=K5[(+6T:6&&*1TD**!%M[<[FNMI[GYT$K>Q
M<.*L[;1T_OK[/#NA+90=.$#':)%H:^?9[_OG/<>C'\Y^'T_^\^F<92Y7[-._
M3G^]'+-6I]O],AAWNV>3,_;+Y!^_LOV]7L0FAA=6.JD+KKK=\]]:K)4Y5PZ[
MW<5BL;<8[&DSZTX^=VFK_:[2VHJ]U*6MX[<CFCI^^V:4"9[B^\WHATZ'G>FD
MRD7A6&($=R)EE97%C'U)A;UB$>MT;BC'NEP:.<L<Z_>B#^R+-E=RSAL*)YT2
MQ^?7F8RE&W7#$,RZ-;=1K-,ELVZIQ,?65!>N,^6Y5,OA1.;"LM_$@GW6.2^.
M_#,KOXIAU"O=$0F>ROGQB+."YUAKHT'4>[\_>#^(#L<'I[WQZ?GA_FET>GAQ
M<C$^.XO&K>-1E^/?KVH^&LY*%J*3"5)C&/5[/]UE-Z*9;8+*(A-&NBTK8@-V
M--UP7>/MGWU3BI*G*<S>B;5S.A]&[\KK(R>N78<K.2N&WNQKC#\\5E):X$>+
MP#36*L4.Y__^Y?+T<L(&T5[_YQ^C=[VC33V>4>1GM.X3I$H0Z<*\@"7_*1+*
MR6#$0:_/QL(X.94)7TV_G!:OP[A*3)\<I*WCRS;[Q+72;*+S6%C99N-,BBF[
MD 4O$LD5^WT*NPK#])1=%C8'9ET6B3:E-@1@;99XTR^9R[@;OC+M=J)==LDR
M/A?,B+D4"TCO,FD9+XH*NAD!-1S3!;O0)@]Q$_4Z?[]'V>>+J6=2K[_+3KF%
ME- @7[*K0B^42&>B';2LU4LU(+_0*#I8SV4![9>L*IRI!+A!,5^1H#)G.4:&
MO#[E":;@]5PZYG2@NT-0B$18R\V22')^)<!W;4^+N13"@*7RI0P\B""1!F40
M9 660Y(4X;7(9)(Q6]'':OU"&%%O0@KDTBH4."J9"^DR*&A+0 %QIWU+B*93
MJ#G'LI3%RW4SO#KG#?[$>8)-;Q)P98XV/ =R/#9KSV4Q1?!ZY,/O1%4I]H3)
MUW1OPUW2J"4K83%R-@6!4BMOUH:TMU@C8%+?_;2)HE(@@ LU[.S962]/PFW&
MIDHO;.-?(V;2.K1.CG&:#')#RO::FVPCS!UI7YVG]G?99$.MO]G:"S7X44#J
M&B=)U4O&C?!&A9%DK 0ISP0\&2MI,R(GLAS)2 E)XU3:1&E;81VEJ=$J6+<T
M.A$IIBW;@3%3 >\$BYU?)QDO9H*=( ,^5TK8&L &O!,=[(A=OSXZ2,,H#"75
MLB*XEI@PRI4UCP</D$"/XS;=X#8%-]+X=C" @L#XF<M$0T.#X?XA*)[N<KX;
MU#M#39R1"3PR?=M);0+-A%?VX4L(O6(!6]>< A[JRF #I,I<6I^ H!*%WX<J
M[2IUU]/?",6]\VI 7-F^74,#/91(8\ABM9*I/X38*K8RE=Q(4D &V/: 5-!.
ME24H]0%O/>[Z=,51!P+AY.$7E1Q1DU2*$\I +2_$"I*Q(@#\>EW"KU@0(8
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M_J[GV!<#VSQ!#U\.BK?QX7]02P,$%     @ !CQ63G(2E(F?>0, =W,D !$
M  !I;G-M960Q,&LR,#$X+FAT;>R];7>C2+(@_/GNKV!]=_96W6.[  D!U=VU
M!R'H]G25[;9=W=/[G#US$*0LIA"H>;&M^?5/1":O$DB62K(EBSG3+DF9))F1
M\9X1D3_^GZ>)QSV0,'(#_Z<3X9P_X8AO!X[KW_]T\O7./%-._L^G__'C_SP[
M^T?_YC,W".QD0OR8TT-BQ<3A'MUXS/WAD.@;-PJ#"?='$'YS'ZRS,_;0].-
M,D2E*_>DSH"7NE)7%02UTQWTA([ \]V.=/KT<33JJI*BCB1)5KL6Z:A$5BU1
M[0FJT[7YD9 -5KS=3M^>1##/]/5<WDT/IK/0O1_'G,@+:C8EUCZ.8;VP9C_Z
MZ60<Q]./'SX\/CZ>/W;.@_#^@Z"JZH<G['/".GU\&H:>X^9]\2OM*?)\[P-K
MS+J&9%09L]H76K..ON7:477(B-CG]\'#!]H$#PCR&2^<=83LD20ZN[>LZ1DL
M/IQ=!ZX?GUF>EX\QLJ(A?55]/QQ0J0[HD[AQLNJ',/#(!^A2>KT5VOAK5/O.
MK+'F15$8+SX"/]9T=8A;#Q5HJ!O9M2M J#R2-N)C0O6Q,%F<C^-&'\*DYAWW
MB176=\>6^DDU3JAF,M!Z%I+Z-["VNG?88^($[IGK6E;#HZ4>-0.XOAU;3_6/
MLK::AS+46HIW]<@6.@T@=VHZVW9]9]NNZYR$(?"K63,BE'O4$-:3Y_K?FED!
MMF9= [=^8D$=<N:OC6)GQ<2@1\W$K&G]VZQI+4:,SES_H8;0XLF'M+%NDD&"
M?&+)'(L.-5,,";RB86<)XR4+$P6<G@1U+"'#>&RM>W T/7.&0<,*66,=IC\U
M<3FA Z@.VTM0KLU3UCCP&E"VW*/F?<2Q:^:(#V)+W1:$=C1LV&K65O/0*((-
MK>'$^!!KJ^/X*%I0,#1O=Z5+S8;3L6,2DJAA TL=:F7./4KMU7*'=BOOO.T!
M0C7O/6UNP+8HF3;"JFA?"J]&WE+ILD1JEP&^P#)34,\C;A1T14%NA!5@+^N1
M/;# QZJ]L7EH1:0,FH>_FL'R\%<SOUC**VK @%OD+J-=MY9VHT:Y6#LUQQVY
MMA6#'GLVM>HXS$*7)1QQZ;;/=:I9,6D0%;5Z3'FXE9RXF3@#>SIJP'/:5//F
M)V\)QOSC<TGV9:]?"9,&>#S9X^7K*_>HXZM_)6X\:P J;:NC(>N^@1EC2QU?
M#>PFQ@8M=2@:3\/Z]6!+W0-U2@0E@UHM K78I6 K=:C1+LFT 2&@H>9M<0/!
MQ74$YUI-^A"VU NM88-0I4VUE#&IAQ8T-.S&$HL@;<W^J]^=>L&:[E"#9(T;
MH!S7=2Y9:,OE0C,Q9#I(E$Q6*RIIIP:EL5FE8HVUQL,#B/?E'++:AVI;"U9A
MO2&1-M1;A\UTD#;6<8ZDB1<G=5@:NTWB(VNI5^*FPT8=;CJL6TV#6>G4<@V0
MD=$R 1K5[E2385EK5#ID&A(;%2]AE8)6=,T?MNUIT&"+LK9ZAM!L"J2-#7BP
ME">6.C3 ,K&7JI.TN>;1(!Y[KM6PT6ECLQ8Z;;!K\^8ZY$6IV$AE6>L2P;'4
M/U(BSWFW!#49';<&20N+$IKKWCPF=I.,PZ:&R2Z5</72+=OGQC66.M2\U0H;
ME -HJ.GND0;\AH:&30_)4LN#-B]A[T%@/R[G[=BCCNZ;7"AAO0\EM.^)W\B^
MH*U)UC9O6MJ:_=>$VLO5P?H' =X-0,66.BT7!G8;>1JZ :+8\FU2XDO#9JXT
MK-4#@2":&31KK'EL:C6HM-#0+'D;@5:TUTC<5*UHU#<:5E4G0[)%U<H1UZGS
M$5.]T*EW$".N+.=5I1Y+M#?W"=9.[,I.%Z#)7#T?XM#RHU$03J@AB.-(9[Q2
M)A_/;V(-M*F!VFW?&=4QS(S<67O-P\,H&(WJGZ--]4NM1^A5ZQ3/Q%Y9VXV&
MS?8(-M9C89./BS8U(NXRI*U!6*"UT=AKD+9IXS+'ZW)S>JY7G=>"ZOL@Y&KX
M?F$/8/LR%7T,2LPSE/2L6\U0XR9HCVMA#>0<SZ8-YS2TI8$9-S/BN@<F_ZKQ
M-E.U&EKJCX'JS9VTH59]O0\:/*.TJ=9@;))C09T0R[!@.8[4G1I$58&2GAF
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M[8N9U.[ZRWK 7U\OV( SM#KE'AR';IEC;(8*K>IP<)N\OKNDW>1#=)"T3/T
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M,WD@7@7=\CX7/NQ&1#L(<P=1I2&_$"M*0E8<WXK<*NH:4>Q.8"U7H_R)_,/
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M>L=1;B(GM%<H-/$B(3;MWN_EWN^/&?R]R)*WO6$,F5OC4:#%_!G&.CBA!\#
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MT4_HP[B6R 6TL4(.YA""-@D0C+AW,/]'XGFX#J9S/-(E!M5NF5Z)^S=*X@0
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M3R]YR],RTJP,.@/+'J=%E^>'+I^ L5")/%(C?9?/W8V#T+)=.[\(',^1+M)
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M=889 \@):D(C?.LP(Z)X\FQ^#KA>7P. =N9KXGQ>0;$)?MF$D-SAS/+9IV,
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M@2&@*<Y3ZVR"TFNYYY8"<F2<,S[']>ZKLIM V&Z=/3XP/T.0:[<BR.VL[D[
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MUU:&$ZY$C>HYQ8PK:;?K(NY\JXOXT]9%?(%QJ&41K-AI+(-R+#:6HA#2'39
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MU3]A67RNS_(R_3ZA"#TS>LK8FM0  N5G3<A<-L@E@UF#P;)<:R+(U1R(/@%
MQC0O9^ ) Z@1,XX92E]L^I<[AX^2R?HPY0F .6*L,M'\5\Z,W;;WV%+:/ V4
M<G&HQR<LV#TL(JAG8Q2@R6,*IT7O! -+7 G"/J8+30CH@?W@S%5)I<&LP^48
M9KU9$Z:IE6/%=@^D'1J&B:DI,T"208'XA=S<>K%660C/^O#<J\<L5WO'EB>\
MY@=Y9NA\H1"B/)%O;*GIL0)>NB<W'2>\-:NQ-U ZRJ5%=%+VQUHF>3 /NXI"
M4R&T9C0QJ8SFMIAQ;']"%Q-[EU',R@_LFHA+TJWX4>>[?XR#Z=V$EUK*Y>SI
M[3.L!UK&!6;K#^T8_YIN0]ETHU_*(%^7.W_7?I*#$.<%)RC\N/]A;X&^],5<
MA=^?_?KKR]^_>0J[[RGXG=KF*.CI^&2I/3G6P,)G/^)FK^06ZAT'F;CS6B?-
M1=WO&_@H8_E_(\5*<=7#?7WC)FXL*)O.&0-B44I&6P4T/(C@^FG?Y7[7^*^_
MW'&3_[_'#QX]O#_:"V>DH+)?N:_VX;PFV/!I\USIJ>KE]8ZG)0>Y1"6R:]!R
MG7%_N7-T>-1K0 )"F5_(X9I'5#]#L5><*6>;\0)5?/V^)RHS<DNZ;DC"*-H(
MOR"M_/W+PWOYN"Q7GC5$&>Q #GGB])8 L+KR??*:2#ARBU%Q.]DD[H([5?L6
M^.CF3 87(YG$QR],LA)_N7N2-879\I.M/?36ZP^TO64UE$E+_R![#BX9*Y9(
MMJW":8I]7\1X!#^5;XO+((XC;M\Z0/L6AEG-#M9E6:.5*VG<BA>.\U2M]\VC
MJ-*$^EX6"_%V86&/*!.9OQSSIR=1Y*7KR\;&T?0A5:%9Y2Y9%K,D8I]<75Z$
M&YV.4J'=@)GI(T7O/=\R@F4^@,%R&8XML <D\T39X)X-3UO<K2^7A<JV-K,@
M9W(=P;+Z93=#F/Q^<GN6&D@ T"BV7U]8=X^^[].P'VYT>W)!0*N.Y-:=)U9D
M'4@QT1(\LF27X*_?W"MF2G;W(;_.T/V!$['S5S,=ITG5N#P?P'[RHH89X<-4
M$I8A71+D9ZK3?,?%]_/P!8=\K']N%(5[24IE5LWG)4JUJ3:P<]DM%QY)7S\>
M&*!P1$Q1/\YE3E."DPO',4A9>.LF8J;N=I7$W6]5$G_:*HD_!CVBFU*(J>K0
MW(H+HEN&"X NF%9@\4G<J+/&SA,.#E4.!Y4_K\BEO@B__U]#B'0&]+HZD+#6
M.P[*\I?Y7QR![-"ST<1;,=SCSTD;L/G<^1=SI0,%S\*H.+[-N>BZJ*$<PN/"
MQ3B5,9(CSFQM&I*C@E=F*: Z4L(;DD+#&4^R<RZ P^&[ENY2KN $D)&@7#ED
M2O?TP]&94W#T?;TY#<62G6F*8]-CK*TG>.;%G%>?"S[0I4*K!U>E6&MAQ1I,
M3$W8*07\A%52ARNTHLJ8B&1-KX?ZO6#VKD3Y,IN4;]H-1AK^@$*0>AHF2)OO
MX.WT,3J50W0?H&GHBD:V$%"@@J$^'+APQ+R+&GN<B "P0%.IH15H@X2&I<$_
M,3M\\&W=7"W*V86AF1GB$U\?():8;F)-X4;L)'<Y\?YCZ\<B;L.WU!1FB)1W
M #HM7DE$]M:N-W5%9;$IVM,:ZQO!X K*<(#;2FQ=-C+Y8]Q&12198?RSZX/<
MR.Z2?) 55)MC@#];X(V$*Q[&L4"QNI?2ZZ:73</1;0ML#XGS4[;04'XS!A9U
MU3&KDBUD' <O<O!G@@KGWCP=OR]8,>3P")+-@.D&4GW[(B\#]E[.5Y:L&<6=
MWE7EU<Y;@L]8<'J3864XQH%@\!)_9A3M*[,8 =J66&U1PT<59\*_1@8;7GGK
M?D@AV8:!(-4+RX SX2BV$AWA\K)T $5R9BF>0"Y<> 87?\E]F&$G#HY@F&14
MP@+%5<'M+HE'#6SG9-ZJU^"915QJOC_G5/Y NG, (93I,PE X71).KL8"PP<
M+:4 /4ZHCBPEKS3J!M5?%5)JIV]>__#L\>O3@[;D^DN4*=ML"4]Z6<;4,,A\
M_K><[;Y/]C.=PQJ3>,4!J*_JG?UQRN=ENZ+>BL>4#7]<$I#'[9P:X5I5)/*O
MUW0?[;RZC/4"?@=.PZ6Z]_+QZ3ZW6!$X%EW!B *' XD/HG!A%K<*-S.LY:J6
MYFJ*?="AHS0/[O@83")-)5%!A<>@#K?!CSACP2HF*O>: B9IYWMT3HZ.QD='
M1Z-5V:P622$)T;(S(%ODQPXJ!)DM#SK#2:R7@A865B#82\8I2@N"Q>BVK<8X
M#M70QM3FLX$'4W6OVW?3$_Q^1GHK9\GRT@(2)WP<'(T"8%RK33!?IHM@AG%-
M-IB#BV#40(V_N8S8_OK <I8@^1,"EYN',6OKW; 7.XU-82/CB+$ (S3V9J4H
MIS3"%!_Z,Y-?@YU+7;F9-12J[#X_I5:48<Y5W72%80=1TA%E%[22RVK:-A-A
MP;IL+DH)R(09IU-N8MATA^>XM7ACUUO7[)+H:1ZT%\XKP>3I5F%NS$]O!.O>
M_@JV'GE-[TJKP0JGW-O[Z^)]4 GEK!(W1A_OX:U+-/>.A;_LJD#SE3SN_/%O
M3T\3&C,"*]S3WMG+,OE;5Y9O.Y<69YP:YZ.0_27VJ3EC6[3._N%HVQK!P2XH
M0#[KM.6502M<*MF3!ZN1**]R T+Z(^?!H!<>CEX[^V_L4B0O'MN":'JB8(3&
M;;>)5(U19?\TV#FM-JHMFZIDSA MI<JA&TWQ]I<2%&-1@>J[W6LSO,4"V/(U
MUPG&W&Q$1>2U"V[%G(HL@HU;MM*15Z1W@UO:<;R/9)4)? RWFMJD#N3TU-Q<
M\3@ZP[OORK ^3!N:3Z2+(:7>I^-0M&DB?U"2PGL<<6&V3,A6P1L+<!O84X#7
MP(HUYPJ2&!7.+:'&Q/M'?^.V3Q"\Q@YO:U$M86YE73>*F5H0W36097PNM]M@
MP*V0SR"OGJ_QEJFF!\RO@:''D7N"XE19#$Y=8B40:G3)@_YL!^V?Y ,FV?XY
M@X85$Y,[6+N%VB\$B49KTC+GNIX:E],F%XMP CSC3?@/F1<_)EH6(/M!&2YH
M62=A,T8E1; H\H6)VZ)K*#;NPCJH6_(9-T2V5$D][ZQ<H@?."J.*.9UWL,9I
MZ+$NNZ1^]O:%7[[[OX8;'_R%6Y)@LR$3FA9A5P31O-D*%I2L92.;F54:L[M
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M@;@#EA\?/;GJ=5LW"HQ'28N9HA=17I?D6;E>251P- L)O_ 3J;N3&VIDH>-
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M9!WDK2,VOG#ECM7IZA+L2"5P+GI >0PB6W)QM;"[1:#01$=-&HY95@-M2HA
M3@MC!DN^"5J\6!HZ1!PY'FCX&4O-?LXU.1X)N3*"Q8 :L#\;MHW49**@;PNA
MM8S:CY2]:JIWF%$@=!(T./F&$8/G-[EKF7U.[KJNM,Y^:97CG(W;#%(?37C<
MA2Z$+347$GK>[:[4_2IRFL8]Z^C1DJYVLPAVX5LHBEER+/2A5X58#;;M63=S
MKVX-7QFH=]U'8DSGEK[MIFE(=P0*JC4LOMIMQ(.3HV_U =_J [XJX@$=8N4@
MUB.I$3,*%97EV\IS:3>]4YN7*#&E4= 4I :A[+GOG5I719<=Q+X'K_>T.I\
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M;P8-ZXGXBCNX$GU@;PM"*J8/(-2D^P(=_";G&N+Q77UVDP.MA#KF*MJPB)_
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M//N+1M%3V6Z-3Z//.F9#]-0U5,E'51OH5D<W,?U^:#"CGPUB>+SCQ?/WLT#
MM^+Y;\7S7[9X'L4>."@SK/9/TIQ*R\X0R^$#3]:7U92="%2T,O\1((XX T?]
M=(L&M:))7#TRT8%X7.\H:%Y".!)\_I84?Q&)V:VZZL.#(DMNR<5><1! P9X*
M>"QZM9;49-AV6R^DW=?';U"-)'"DN.23^U0R$]G5T^J&<2$Q"BJE?8C&R.:)
M/9-*TXG_C@%!T(3J4JHH[91R<*Y!Y5Y&A_;F1C0>U<JS)>?7; D_Q+'6&JJ>
M%AXIA5U5W(Y3MJ5>X?+OFU*[;^H^!0DSUYG>'E,7^0X;N9<&@R;2U%G8I&?K
M4O=$J+'BK@K%2+*Y02+C5QZR?-RZO1[4]KMF1SSXY^V(8E3-_L]WW=U[CQZ<
MW7MP].#)HWOW[A\_?G3GZ.GIDSLG#QX_?'QR=GKZ'5_0;AF^&2"WU #Y&FKP
MV9LGST?'IX>?'H"Z(RD^4@/_WO__^1'%S_SFP#Z]>O;Z;Z.GIV=O7KYZ_=GZ
M-CP\5;CXQ4W<-G>_W/6+CT>.GI<.>"4CZQ)6-L SM%7WEMU- ]O@^/DI]PZA
M)GSX,]3-/6VK"9DP!#XS-K:KA1!6<;O[NKD \<!8.D4UNK"XEK0"D%S0R4#-
M.0EDS-C=Q@:&-)9V!G:&72(EV-/ AV1?^Z)MKM:7L<OD7;'8E$+KQ#1P,,VK
MVE"%&EKT9OHVZS23.,R65>!)30NT&4S%Q.3A$9D5^DS]G 6OC^)5Y7MTG'&L
MB@HG*H$#:EIJU#M8-(T@,UCEEC#,.82W0>MA1(;#:&\%?!B*%_$2G!4;M"&U
MUZ,7S;H4@@AZQ5-YY:_RRM?QE<5J)?T@@CX,XNS:FGUN',/^/Y&E_KCC]#6T
M]BOL-4(\L2/QS!)-TFW%Q94-PP#-1J>.&$,!F6_%W!/-,; :+[E_4([6_\_>
MVS:W<219HW\%L3N[*T6 7$E^?WQC(SAZ&6O'LG0E>73C?FL #;(MH!O3C2:%
M^?5/Y<F7RJIND+0MR:2)+S,6 ?1+55965N;)<QP-5"2WD\:\</2<EY$M":V_
M1I$MO2)3&QR%/UP472*N@X*9EX.>W/OYS7V'6?N1%:,FKZ*R\*MB>Z9\OR=A
M1F9A*6+%,<PV_&79U\0R_H05+']\=?*$&4CI4+<J.6B/Q/9\.>IK65+^DUZZ
MKY526EZ3-(-WKOX81I451ZHZ54K!0]E+_U;_)GTP-@^Y6\N]F#'?>(>;.5M'
M9O,I([P;LD^R*8.DEJ1V)^>5QV+S?B%&G5ETF.IDHDV#))W6/08?V<13^:G(
MH3"D*B5"QX3!.T3^+?BU=Y,7)X\GJSYRZ4)E2EK]T= \4QFN(ED*:%-G3OPZ
MZC .F,)Y<34MFIM7PJUSGCS<1IH5WY5* W/.,J[:A0YF-'#ST <)[42Y7')!
M@YB;S?J#R8<1G,>2.4M*I&.LR3M'P\;ER"UM<N<EW13[JQ'B8PW(E)Z5Q3F1
MDS?U_A6L"(Q(M0AE\#'Q"[^J:=<66!9?(6&7(J&:BA()$+/-Y.FV_6*7,OC3
M&RZ)?LAC&W@X> B(W/)2P]1Q0B?L!G9QO=>(%IEKA$(LA+;%X\GO6/A?_V&;
MV%LF?M#A=#O5J*W(\E^4IU*>DYYSVBTVD#2F*=]8G^;45M%TK!_36@S-O%/B
MA?6ZKXE#^>..[*?PH$]*XK+TK(?!6)XU(ID($'E&?'7OV9.3^XEL6%S06R?(
MI=+DIV'A(5L.BCC3RJ*/6NH9)3JJWS4937NMN7"&(4!F7I3ZO.;&SZN"PY(0
M4VCDX%2M:$FK4\T$,\] V5EU<73H384)<?B2J8(98A-[QD53LEA%,3\#H@-M
MN!:*U%$?$W1 V"KLRM/@4O@QWU-LH%5?9G^E*5$GZ_VX.ERB:F<*$*8;847@
MMU>LGL0,) Y4IY]LC2Q5(O]>-J1GI#@"N@A3NU7"$)A$I 4U&\_X:WJ:0S>,
MU$L]K=JA^?9&8= _^A[!&P 9='AEY?!!Q$6H"XN!G 8Z[7I])RP5H->VGGP6
M5.7D1SS.')I@[I EE80Y(^I;',I4#8;.5\$U%J=E&EE@)QL-I;N#U=PAJZ$
MFEMBP$?$&^8JVPQM6PJN9TW2*(V4I\.?*+2Q-BR8GO@MJ?\[  (R=<T'$JHI
M&!@0>2[L]N6<,X*=I!QPX*$#5 7$64=,07"&*IXE"%VB[:!W :=T" A;.50(
M*W?XBO)](,52QX_DUCX00KC!(80'+!210HSNPT*I?' 7=N*#Y[UC:XA!=U!_
MJD/P6:&J#DT@41TLDJ/'P2[NB%V0;]6<4"J0@^1]P_G=@[^XBW:A+&N'_>)N
MSK]/\8^<_YR?(%D;:KZEPUXSAZ@Y&%'3\@VT9#\4U.9.%>TC9:(_&-4=,:HW
M/9W]JES3JS*2'Y-:&I Z?S\Y&,G=,)*WD"EKR_IT>Q83H'H*,]6E"K6H#6 3
M2!@38\^IRYA6U ",LI*P55/7R):9N(W#&[^,&84#L\;=L3,6*I-><>T B'DG
MYH".^:EKF,_OXN+(WS"9C8]5@AK'']^X2AEA#;3639VM8;!!I/^1:X9:JC39
MPT%)4[GOT^*-E-L]1_&LG)Q"/Q1M#[5U50KR/1&2([#+FL22RH[L@KLLM\I"
MIT)1*-Q1NR\HO*UD?4MKR.]*P064B]%2NA_Y6, RZ:YZ#]:()*L[296A3&\?
M*8*'$16G4M=*2_].RJ"X#M+ :?!)NV=ZST3QBEB]F3\^O5;*V0O,!W4H2K<V
M$)$B\*[@(TL EH+RS+0!;_YZIBW]V9.36/>UN7;(-"H!7XDJNVRJ60\5#2>,
M 4,ZMN )L&\G\YPJ6!P3J>3PWI 1Z$R#I-A.[E7WG?S"@JK"S8:7^<UN[O@V
MVZ$.3:)WIT?CLVP&__8_"(=(;9T%[,DIYFKW!KYKV@C=Q,*^5X65I6*(!:F?
MT??)7;,"#.L;JF8F:H.0&*I4O]MH#69E]#8.M4^".NHF5':-F(\HO"CKQ::I
MF/:=U.+;MCE-_HZU7R4D @K[0%F;J-JC2Y&GG$Z".SG3N*"(G]ME52&0! <J
MV4>JEC B+:NQAV!A5BT86#/FH)*P!1?"L8@1\>&Y5B S#>YN46R+J'K_ZHSF
MX(O)XY<__>/IZ[>\RVE04Q(XEC'<9U9Z0KU R[?9ECT&B+P$>#F=]""K$<R-
M C>[3;_MUY-YN%;?2K&B19_OO448S5JI$0D< P%;(3(Q6:5UL$<"6*<7ZN[3
M4+R@SR9?*[FBDOCK1/P>O/WGW$DMJDRV,NQ@TRAB$F64>(^EEN>^ZZPB&?9C
M@'],3U86#:D +)IUN.=B.EDTX9 4MH3P_N%?FU4Q+V?-D7!K$5-(NH%"=;KK
M5"!&NURXMS=;%[G]I):3FPNCHO@F3(LC]LF*1Q(8>=R 7VMA$)PKT?D&/[3(
M5;%*]P!["DDHB4>M.WH$\#* ' ^?_Y6C40%ZIEJ7G$I@Q:Y)O]&IV7*XQ!@_
MK$J:I6TSIX?I(*X6%IM-&2&!Z5 1!KPW\1$&W)T5JZ5 O;Z;RL7;*NVSF2E1
M"ON+1P\>?:E*3<"U;;<K"-/.RX6J,-M<2NAC6A,NM"\_$-C>"3.1S+=0SF"+
M& Y1HGQUP=C%L@:-%8G'A9=9E9#=8S%,?E62-F;3CZ T>2S-&5%-'50NQHN4
MC+,> Y.YS[UT)TPU_HE\-]BB7)&J#8G4U+0V]-X.VKQ5"YXJA92",VG=28,$
M_]K_-/Z.E8W615T#B$"<"N)=Q:;P,JWJ[:B533:T%2^BWQ N]/!M "&E\SYS
M)33Y]&SNR$27SALZ<,S1.X$H9>P^4WL\]'R-PS/HL1=M<<$(BI'-[7CRAN2]
M:7YL$QOS@0ZQF!P%PBV;:!-S]HYR#J0P(:PT%;V3ACIY:I/%$M]U)&B48K7K
MJDA/8^C2$WL XO;R '6'"\_.A?X82#N;1#7A]8T7N(BGU1%%&\UKS$7&=D4L
MJ1Y9STT,8;^,8'?X:KKT-#?6):%%0<'*@T(-";3^JR6% 6AC6(?QS>@6R4+/
MJ_!?VC#!773!TYT1X9D[0,-N+AD""#\5=)!.9M/<2_0&'_G\^]GR(6U)&.,]
MW:53,]9$LM2E#F*6I(W-=FF_QS(.-ZP\$H]U&?D*=V*NT.Q(/BA8]%Q4\B1_
MGJ0V8E<4"?S<MFS$GO68ZL-[8E'*-L[?%Z?X3Z*P*HAM;%40 R"P9@LDM#O^
M:O T#?>BB9]IVL71>Y&:]J/N=ZQD-K;- 4C]IRPY*"<1Y..F667+&4Z'&BDE
MG$,8Q6QYX8^;LGA?MDZ[B_C1N&D@!.J>_XP3YNPSPW<A$LL_$MK7S:I"O17^
M8$3VN+CH#@77NV*53Y@,J\P/<QH[,5AV9ZF53$AN6>)429R'HH!HGS9.8!-L
ME,R:F$C[4DZ"4C('@[LS!O?"Z2[ST9-]$K5<==-8[CBW&DE5=^A]0HENF4>1
MTE5&W=THTD5N[8-%W0V+>NS"6R7!)8[EC"!>*%^)%F'^MQ>OF,5 R9'U**.:
M[$E(!HWB\IREJ->;IF;5]X]9\/_\Y?W/$6P_N^P,,G+&:<(&<2H;QCQ60WT!
MWG*]2 #_LP<CH1=9^.TC\&GFX.!E_AQ>YGE'&5SNP-7.H%7);*%@A]]66TK+
MZM]F.ZYZ=UW92@:0NX.9R')R7C4Q?\S$#1<'+.Q=,::PBW25SGY5_Z*B(*B*
M0OAT';:9+56H-F4(KT&918K45$BHMLR/*7Z3Q8WP(_JUJA<2Y0TJ9'HP7")!
M6Q!/0+>=<'66V2ZZ#>4<N43.F@ '2[PCEOBF[XA.7=)\FH7GU/L(5NM@%W?2
M+@@HH=Q(1)DEH5N:,X!#:<MEWU&A-W%0E&%E0 :Y,R0]7?YKLUGIP8TN00B&
ME65#(Y+#?^]@AW?%#LOJ7W2$H"*[ *^GL<BHIW]JR%ZE!DB60]@]VNA0UJ"B
M+;1R8%]2M2KF:2K^%.H/:VD-U\]I!314B@--(\&.\%_Z0!D?Z\$D_^0FZ5SC
M<BH<I"Z<2Y0M*:,/BCO'MQK-C1KE5@3UOLB2%4G^0>!4(##TA;Y#ENL.6=U/
MFOC8:.M*:DBN_$_$Q5VO$@DQANNW9PVK,RE4C),LFE-9&8<6  UE2ZQ38M1\
M7/"\?;$)P[=FC/.&79>Y[= U\UL?\YUA01PY9-$1DB06^YI^>]0LCY(N733P
M"GJ-\4=,(^9(_V3F8J<FP4N(T#"A>Z874A:Q9=/7"[%%(&KP(&,/$1_6)?\8
M\)<R$W1Y10FP6P$+Q_?TKU-U*;'9LN?0$WB@, =$*[2:6$./X++F10WNMKZ@
MXFDI&G_ Z>H%M.G D:YL,Z(X<O-+_'E%;3NO!#;HGC26<B_.0/2MK[,0<2J"
M*^_<OB"9)E?X=<,\Y50I^.08\\D@)Q_1=/.V#Q'WSK/S+@@3!^ '55;R3"UA
M>(B9"45ADXS50-U=^K2O%M'.W%[%,^?>M12G,TMX,GV*E_,4E.S0S,<05W*C
M&BN^&T/G'QHK#HT5GQ+'5#O'*,527E@M 4#*JZ@CT[8(^0UG T%/.37**D%:
M=@FOMBC-1CYN%-- YA\BA;1C<M-O%8^R*-: 3WD$J"_DT)X"UT2<6H0TP[,1
M8VJYGWF7+_-+")R[1:7\61>E@) %Y9SXFC44Z,<*4&@X").K\%5S@.&F8=;K
M/?'4+6W,'"-IE^9&V\T2(@;>.IW?1VPWB/B2&:+ST27W8?N<K9AQILQI0YJ$
M1!_Z%$RJRC/'5*K<.4B])%SH93I5CAY^'9O[S5WP+W_O0&1LWN@X /*=@QB+
MM?;-O(3Q&8=<;A$")3-P=V8:TTD8MS//EPV AWR??1:C[67U%@G0?EW\0BLN
M[3_2E\=,(P#",[V IGV;O<?QY'7R6A!X'CRG#%;'H^0)<?>PX ZN8*CQ1>F3
MIX@E90@+2U]5W0'S^:<\M)\PJ0VD?KCQB6-S:G*04Q6=I0ZIPSMB#V^*98A^
MN&.M4K)Q^*D5TH#4;%.TNX,]W!%[.'%=9[K!*I)1\Q@'8[@CQO"8&J+,-QR2
M^W=HZE5+F8+>MI(XFH2160=(\J+%ZJ.FR^].<ER/"O_5)9SSPCU!AU$:^A#/
MHZAG[:64U)2V5L'HG:S##4C5^FTX^8<%-I^\:>:5LB,\K[%VPR6><%=S9Q_3
M>85_R_EP$MU PSV?)TR5,#DM'$]>FIQ2D1TDP&FWCR^16Z[M>,'Y[G NS$[N
M>PYI4 5!2R\U^W?].K8SHUHIQ$LB\2TY)Z;*ZI.TO%!1@$3)FIJF$36BUXQ.
M#PRC3%21'C<E#<#$:U3.I[?!T_K#(CW1=-@(WU4?D(J^*%=*$M$9'#.EYLHD
M=CB=D7(.5#R\./]U(DA#I.S]BCH(.[L_5]BX!SO2 Y R3,D)][;$8!(/A<AK
MT3TE'"1[E.J;C7<S(4!?&YDRCTDPDAO*)D@M\UO1/:=[6LQU;C#(G:/D;" @
MQ(Q)E2"L]]I79HMH#5\C;Z8OI_WK(V1:%8N5-2W8GTA\)DP)N,=CKC$S"7_<
M9R%!F?U.SMFQ(Q[KY@U]P5JZ\6"IB7*W,6477*JR6%-OOW2 AA?'JV("4\VU
MF. P.KA;D$!Z&L:22DV88TER\"R6LAI\0F(2'-]IQ46F-IU]MS94=PD-9&HN
M$&W2(AU=E_@C5OVBU$8R7+)#I:JS>[>.LR=R!["<7GV$3N>QS"M-QG_+@W24
M[\XL5:R*N7NV33,A2)" @, >ZM279"4A#SGLZW_3SSA/O;54=+>76E3=(E08
ML*S"8-O.SEV=2MR0/G#F[+@4VLRYL64N0KS#W+]P$3&'7$QP[M7$8HJ6-0P[
M2;C";4VQ(?5MK>+#3F/8B0A>(NAIRS75*I;G^5Q:GK>$U8?95E)GM&SFO6_T
M=Z0/X0'ZX"^%DFG5E1>X1'AI$"]('IT^Q,!P<89A(S* U3DH-84PDSIT"L@7
M2\TG_"<EQT]/26:9[+K;EAOQFTSU$!ZJXG"5)HQ(EF!&&Z($*.9@ZJ+E,0-(
M90L5GZJ8$M*DV5:<L_:%;1 4D?.5&5[A\)(CJ7(WY(5<BKGLD5/902.0 /7G
M\"&><H!X&5'/]B$%+U6;"$LJ2T7;]4WS1]7"%;N+L..71.C2R8ZR&&N-O3Q?
M+H.NPJ";?FMO@Z;:9,3-@0M[/P<(VD Y35_A%6MQ<9!!"H33R?,U/' <WA?-
M@LAQA3+DA'F6'CUX\,7DWHL7)_=IE KP(ME5FWYK'$G^!C!-VR/4NY:K<'U(
MYS'9YRN28WTR\DM 3B9H5&A:)3=C,Z; 4K<"W1K^!>:W^9G\CC7)?)@VX343
MGF%'B _>M/!(,=?O2!\CHRBG<Z$-N$N(Z>:KHA-WS3?E^@PG]MCLTU8VWF?
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M]VFQ01P#=3BR]J(]H45$2M:DBU.&<;&B-9Q3QCN3YHI'*0*S?@U.? _Y @^
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M*@[YTYY$@%=*7T^EH1&Q9KB:2[%1+ZKL .H5GPUP&* L^$1O%DNFJZ;K]KS
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M";B3(B*?;B-K#[D5[=_3Z>;52^"8$:Y/>^9R85"8UHE&LYA=MF &/V)MH!G
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M)*S!O@6.[E27ITHZ4H7[]9QPAY7GX5OYH>JV VFAVP"J81(0]( "PARV"=H
MDO2H3]&E[8-%EH+WHQE&F5.G@LSGCECYB!)X!-#C#*MIP1F9D3"8%01&I1X)
MN"70I<3]+$W4*M9<0;_,\.;QQL6&\M372.B.N:A;V3WWS@8VP?0R"#:2['%4
M:6PWP%& 140+3L.?5'4(3.E4<@N2WFD/86GU3[*CLWY=X.3?%AL OZ*XE"6C
MR5[1?[5% MJ3,P_',"GH%JACU,U%)F+EBYFT.GY^0UHYIT6[0.\6*:#0JV"Q
M"><2<6@2/]!T<$^I<@A@^I 2_U/&9HN2Z3P60B8UE$9%&_E6U.;8@KVT6V*
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M.<+LDFPBHSXC9/B6M0G_\1(&?TQ.\V5.Z>Q!7Y$0 STV6?^$%2FFD;+"S;K
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MYL^U46+8R?4<"$T7BEU#DPB)_3:+UH1:RP#$HB6W=7OZ(AKNP>;NB,T]#:>
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MF@-H_#T\W\@#RL;"&9"B3A@AVV)=4@72>QK!FS>I=.?3%R=^T/6U?D+9<E6
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MU/^R30A(4>E1&2W.%0I8+ZT\1<B/AOV.PO3:L!!=).DQ&5DH#;INI\ R^4Y
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MCEB$6*L 7>35Q@QS\ A^RX[K+8)[#H'YE6T!/[^9CJ38M "J(R[Q;S;DU[$
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M=&B\MG:N0PP-Q]N:O)A@N_37H+N(H8X[$X'7/FU=#!ZGDZJF)" 1 ^*_? <
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MP*M5<Q%>YO\<T Y_QAQL#%*1+3WO5Q222T1KM!"+$,*$A4X)(K3XZ1<H)X0
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M>\*&=%9T[%&T+])S<X8 2J 8Y]"06V6MD*NRX!)P+*:X9O1)01*X'35 WH(
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MSQ>A)*\DXIOML29'$HN ,^^GBZ$X"KUBYG; 7<="5\Q&.(4ZF\E7SZ2<<^6
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MAPB*4W8'*Z<HK=#ELGE"H&+>TK4SAMETZ#;%QHYW0K>7@.5L/$2#Q^%<_A<
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MUATG>WJKG!ZK4%*AY(9,?WW0-Q5*;A5*[H:OM=M?4Q]]GDYNU%=3O8K'U(-
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M+<)[M*D?)'OD>RI_J)U&NPJ<2W=G%UN"%%N!)(>>A\J,61/;C[V(H!QP_
MY2_TIVOLM94>R#HL@58O5X3[>V2 T:KY10 B+XS=7+)S[KH;N#4*&P_..:J
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MAN=[=AP$?(R(S9Q;J2V+A=&]N"]KCGJD5-IB-$.EMLT%=]X&P-<3Q\<;)"1
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MW?/YXRI.N#8$VA7PH;798:M7A5/_!>QP-[0,](W^6)!!Z:/*"SB33!-,53A
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M+*7$#I<Q8#6XZYV^51P*I-*W5/I6U>E;>89#30>)86)L5+1UE=7A4\9=^/!
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MI'-Y ]QLRJ83R PH?=C)7>DV)XEZ@E0.DU2*Z>V_F;5-+)TQP:)Y&[M'4T7
ME]G(1"6ILRSFF(&U]#W&NF\5#2+!]RJH/A.)*7BN7:],]2#.I=.7R.WU4Y>>
M>V+='TX(LQU_. E+$$?X0/JKA=13O<SF2VBV C%BXT'!MAEKF#DU@+.[NQBD
M/D14TGXL7<?C21G4-HE'^#8>0NH!Q#_PSW+\[L,G^LAB>G>'U1!01<'53I)D
M1G',',=)&J7$IDGIDR&\/R'MW*G]D^+-D'@<=827]5"<2K]FC_A9>8_<HLPC
M!J5D$M_3Y$[F@H;<@^?\_^#O3I^  D%8Y=GT_D&"7Y+43:Q:WT[X*Z;W[XL/
M/?Z0I(\5J2@M(A;*PQ<3#_LC?LX^1'<N[NY.W&@8D=-\@--P<LAPV:< SR C
M43::R(,/$5/IR2U;4T'6%-76U&,AD D):LP,#NC14 :Y%5!@'K-48RP?GFA>
M/+',Z;,XA<.ES'U=9@ACTQP$(,BO!GE#DA4+U#"I5K"T7I(M!Y\6TR'3MFJ!
MJ&&"J1'_$LLT3K/D-_BC:4[O445="OS,/@O1S.X.G^T-S$Z*!<!KQ3("(;8$
MC$[(>PHJ'LA:\N[5ER6-2]\CO%0 Z/*>_)HU2']G<A42;I/!S^\*,["1I^F^
M',JF[LB!K1J^KOE^&-B6XOCN.YKWVF$N]:[.;LX\YXOD>-[%M_.;L_-?I,N+
M+V?>67#=[23KV1Z=(LE:)%GO'!,N\W@<5=G(E? M)E@\4P\&Y$#V^UD^(+*-
M6#'W<8KE[1!+>/P-:#8#<LF4Y+-BI0BK/,EX2'/BJ$'#M8N"J1<D117+09*F
M1EV\V%2:CL94.8@()G W,'[)+"</J4JS\-7QA$C[Z#89,EE<X@1QZS&@*+TT
M@Z3H#[."@D C_9;>C)67E?<CH #9,8!+#TDQR7+B#X(;YU@[Z\?UC.T8Z^:0
M-<,B\I":E=:SQN$F2Q=,'L4<UV1?\;V&4U9H4SRS4S0;=6Y?9I=2;6%"8182
MT:%*DEBF#16@VB]^UV=_6R,4LJ>C<1[CE9.D>KS9-*F)'B=-9%^ZE%ZMK&T*
M*O<=E +=3B<$E8?8XJ$1I1[+]R[I#33@FMV3W:>EVK XO1U .^O_<4*SB>&=
M\0M'/"<$BIBR'"PB8+7DK@1N2&>&?W+2(^_/$I8XL;'SJ#$#WJD^G !0W[0H
M>.$<628O!X"W ,.A3_-K(*T?RB0A^V/ @F)S&[^05V^K?*ZD$;J%=67#[S$M
M<1R!R[.>ZO7OZ> >[G J.;0U'M>M^B2I;)" .5.J;)@^B;W3(.E3*00]L#(8
M%FP"WO@XELZS24RM$X4'F;WZRL)R9=?ERF::R6^B*)#+/X'>E_2QZ+N>CD80
M/<)[>UW;":=ZZTOVUFNH:*U7%R]0<:X8J5]5I/Z&+[B9K5Y[@P:L*:WEY,Y"
M5NU<KX&MHAS;SEXV(.=..,20C9[4(H'Q<R*L IH-+?JE&;]3+(%&D-#]?L,G
MOON[<^W!.W_HL>Q?((8_XU(2$OP!PXL^2<IN(?>TH TP,Y*S >ENQ+EQGV4#
MFF_+4K-[M/*!00 U]; ""(ZF@@=9:X5,CU5^6\9=3W"'^$?_ <S),A]I[D&\
M9F* !2?4V] *TWB1/*>>CII]RO-D2:2X#QDG$-VENT(VA:>CTQ*F(9:Z!"[@
MY8I)/"X^2>_1!R[FG\K@<>V<JOW[++U79JYEMR<T5DM5Y4H/OQ7^I?JAMC2:
MEU5Z0D!=ZL?X(NT#9/MG?5Y>.W<-SZ98^;FDOEO_L(PX2%T(+=P%8_1) @PL
M[@"LHB4/P?@P*1\  ;%X7";Q BP6Q?)CIJ3&SHPDGI<WHOA<;5!6\-((FD:)
MV19?M63=1'>:P(*J=9+:-KK42I/AB4\+-I:E??/]KR6NE*GQBY\^NY-+KH+,
M:K:Y P:4PZ$TTPG@#CXK2QL74C3Q37"])*:E3XL?^8EEZ@_QNU.4*T,-#',Y
M93/G1S+@+1\@L;?TD9#=),Z0/DU/)9Z91:$-*F" PV:8J'K01BCQ;_QSS'([
M 8K-L6N7;W7)\HQ+<X9(VP+<S5C7RO%O2:X,=^K74^]XZ<'<+:B#CO$'$$X_
MKHM((+U*,-:Z/)!6$:0NJ%:-:Q%BO(WO86$/R7C<"&7-TE>C-(.H^*P&E7O5
MH"O'0X1)F"C*( RJ+X#[\P1; =BF.J5:XV\+X([ZP<?EJEGT ]L;S5<!ISU8
M20 &P#&LSHZ#)*9QK+\V8OU<P87ZAUM0='L2!K7\/H9N- 7)+,$&#*F&!!6?
MF$Q@>DRF>4H47B(!I;LX9B;#/125I"0IM[PCJ7/!(N1K#'412?DL\@/Z(3Z_
MRRB?2#ZF!GR#"*/J?33&%R:C6V@04AKKC 2VHNH6B'A1\Z@WYZU%>IHW<_B?
MFF^^]L(O&@1'ZJ/!>L($!%[@C)9VCK@+HM*BZD17IQI" Q65$<(I*6UA06&3
MY$G9 +:#TZ4W@2?T: W0':E5POK8M#]A\4#\ZP9^%G'MET2Y):7*TGT.YOYX
M5O \4F1>*(9.I>O&0L%5,"PR]GP>O7SV]A1WGV@;';Q(?%-!^2M;*$3(?-K4
MZB$QI5*)(UC/!1B/'=6$'998:2G@.2M@1/L.=)OE&$M8@1 $GO(RKOT]'C[U
M:!.I$]HA!M,O*7DI,DKN)?#P"EBL]%!/#<$$/NGL]HG<ES2B@ISUG-)V0X 2
M@F/B>/Z1M)"'X0'3#ZF8YA6'S)HIVUXU?L[47,Y:-;=>Y=E<@> G/%V:O\)B
MUNH8_:W/%K-.<9/[P-\$)"K(_[0QMTBUNW#3ALE1*K?[H'L3@<E+13EW@8>0
M2_1>+5]@/,4:?U]ZH#VK.&Q@.Q\;=%/F2\=4=Q<#R@SK[%@&*1F# .Q\3R)"
M4R&[_'HZ'N.'7/<?,-4.XU[%3(,$D]JD[@A<J+*=EHZ/^@)J\8/RAL1X8K0.
MAE^Y-R19)6&^=F(8+7H0S5_!*A?7S@H)MAD8<5HP[S]!8=![;^/)8QRG[)G4
M (S!Q$DFU+LY!A6L'C9HO CY]K;I+Z@O;UY,U!3&TN'!3<R%RUE95*P@)+87
M$-WBQ.R$*S#8 DW 1]Z/M^#)R[(J[H%E*]3*!C C3?.(1WI(#@[G3 HR$%\I
M4V>JZDWN ^LO>EFJLY'  :9S'J5Y8AT_%OR@:GO"!M?@\[[/HQ'%,J+Y\3+_
M*KI"_7OD,JQ[QC3((DT)GP^B2501(B;EJ %7T6"$>8'D[6 6WBP-2]=:<N6R
M]#3J,NF5B=IT(VJAN._@S*?P^= (F($!RUHF5>7-T0"H%A@ZJVKZX4A(IG<5
M?N1>)&9753TSZ U(S&0/<G\:K7Q("YQOUU+H.PM+^&K&/1<7]:VH91329I[X
M.N?F6TEM>*O"G-+Y9:W9R@3ZB[)KR!/ <5!*+F@>4G,!L.X*P$3TT?_! HS+
MO/'#4X&I/F+UB&59:^W!K#,2E>BT;.@'WK,!#53'1?DFA?0^<"Z+#S-EBU1Y
M)6(_IW$K:&J*]ZC>Z'0^T:!3"26:2"@1"24[S;]Z]W>PH)XJ$PH;],!-C/<F
MM!4GS_8H.RE$WZ-D2$\((E2T31[C8H"Z!.+8X(BH+/L*DB'GI/S]@M04<. /
M><'IOG0.N:HG*OA5HL+;9D!?_5<T&G_VJT0:[H:FSN>(2L9;K,O?)9.BF0M#
M*Z@@3M!P:RU-N[BC,%Q  ZTAM6-(:P("]DO;%-Y-T_Y<^Y$1<4$, <2C!+3Q
MH$P$ M\2]SW35R7YF)"M4.6W5@FF]4+"1BT/>2MHQE.U GE?L#[*1(OCI6.D
MC57S1I#6.J7*1>.RA/N'EUP\QG#(KZ?=>/BFE/5$,RW[X"7GSI OO]Z L=FA
MF\=J>6L4UHL2$)IS<)(VCN$]5:,(H\_6+7RHG-MP8U8Y=RJ!E[1\J5JY^!;[
M3"1%%2*IW;16F8XM(^_K!3.XJX?1)*\%#5[@,?#5M(CK1,;MUJKP/>8*#&G6
M16R'>W HQ\1+NVRYLTT\5EQ"Z70KJ:#A0*.K8\13:[\VWS.$,MAM_! -[_9!
MD;TFU12*C% 5#[W+^B1?C!!+O6=5M64L)9' !ULS/FO\:3R)(-4K&GP'",$[
M'?<?TFR8W9.4K1ARI.(!;Q7?IZE/&8@-O&&T3U4>C0GK7<P\G5><)RF)F+'^
M<,ALO,M,GX0EC=7@'F6[%M95:!]@[9J(>Y>(>Z\F[O> SAHQQF6P5;;))9DI
MCR2E"!\;JX8!)UP^+84LML"'V1./YU#_&3B%2]N>)$Y P]\3D#P2@)<$6: Q
MC;M 3@1]!LTQ?.92=B%MC5Z&?*-B\<MCV",U&V5C2.+-*)))V6F>F;T\>EMY
M[_"%($7@1]_!X@;!V.@J2=Z#PAHM:(1\Q%OP)$*V!3&A::(GRQ^B?]S%M%2#
MVG$ VF2Q]4P'=AKD9%AGU>8NK[!)+]UNM>TKMPV:7F*S=#*S:\SEPG)6XR&H
M&7"["?7UP:U&,3Y>%I-/:/_!/+NE\S,>F"NOGN515L94/3]I&UL(J+U$JTFM
M!326*YBS'N:U!#BPZU_(ITY==RASOU;._]T'4+EIY(?12MJ"I(?BB]A0D%IR
M.@$;H@+1C"5^O$T*:](2[^0]H'H-7$X[.U(;:6/W)>^52W4B%:,B@,W&M]LX
M ?+=WP';-O?" L%M\VACXQ]_VBA0QMPXC>+D6?)<#*NU![SXZ_H;I,#]PWF&
M>-=B[??,VV(&N(<>B?!ZT722\0_H"#+R"2T&M_136S7UG_@@)C+.9US$G_@_
MYK)^JZIR? GL_\_O3%Y-OJ"(G-6<VS_52LZ;WZ%GOC+>ZF<OE\.ST5>'/A#N
MT-?7'%TV/X-L%^N?ET:[T.'K<"(._#@.W!0'?EP'OFC4\\K8]:I33G=0O_2O
M#"(%$($7(UX[L_#-)GJVQ27O_FX8/TDGDF']U+VM.5J:>(5C-Q$<NVF+8^_J
MPG=S[!HY=G/1L;^I#;<#N+M*BC].[O*XUHL&/))"Y7OM VV/?)5310<"5DYM
M8Q/))0ZR(P>)3DV5'B12Q4'N]4'*,APD.K7EK4!EWXTK/X$<XW0@/27Q<%$3
MTTYM0)=H??^U*OET(>UW:N'BQ,6)BQ-O_<0/S6@*>'8*'^(;YR/I?9+2(/Z'
MCJ@R72+MO:%@_52V.[(^<7Z;>&JQ\=N1]8GS:^_\&MWF9\I@NI=!%K*<>9'3
MU8F<+EIQ\;T,[+&FK-)C5,NWG>GJ6KNZEJ17IJ42Q(>.9B0!G:1!#C.2V<F'
MO<3Y/1^*?D,ZC'V/ZQ.[D^9@>YDFJ.:+O;&0I=E(#/YVC6\:1\4T?Z*F-&FO
M1SNGLPQ1DN6*7X:D&IY*05DP7LNHE1YASG/CSKRD.,Z!IZ%(@/13YQWWRE\N
M7#@9YYR-\/D\D0Z=YN=B\49(LWO &H#BC2@+3LA\[5WPSN:$!!.R[Y.4I'B2
M!>WT/3?GM5ZM/T [QUVF-<<+5-]]*#YP6&=>7OVU!WG(K&J9=1,@52%E&XG9
M1L.0CPX56US\\'&:I.P?FGHGI-7E?(]@D#LTPYQ<7_8%9D_B@H],FB%YS%4V
M.R2@5[*3%@U5W:*K=H"D>HTT$LQIIC240M!N:X_09*HQ\OT6.G' 6R10?U.?
M"@)?LS:'=YQN24DAE/1%HS&?:0-R$9Y"JQ/80!W(/^==C<N)VN7.\BJXQ9T,
MYYJ30HN$LN2J66E%V\Y5I7F--M-SU5VT$JM>X'977<3;*Q?U!A&\-H*=>?-%
M66N0'ZR&L7QO_+JSR>FTIQ"O*XRD>[Q!0)U0-]<0$/"S<D9P5<G).W72=/CR
M24"OMW%"ZA.KO1IE:0*XRL=X8N*;EO>L[04IFZ!'7\R,+"*]I6<6QI^1TTI'
M@D70.Z:^B7Q87[T)!*-(FD%=5ET593_5//LW%7'E]#9,G?#RC)9 H\NA'579
M IT_A9)<H_]N)3C+IU/=H;9Z5K5,]H>^0SHEB@$9@;K@F=4O29\/_-_[#'Y-
MJJ6A!K<!4GRF%+T#Z^M=-%@(.H5#2X,_TNPQI5UR:!-7VA>#MMB@[3!H9UZ\
MD-[,FRZB;DXP95TB/[KH'BLYE!D?0 N+25<X4+F@P5?9WIT4$3<ZY9>"@C7P
M&=0;EP]K+3\:R^/29Q^0"O+OZVW'\RS%_^XW&I\[@PS&+'2[X\2L'2<Z3AQ/
MQXE=-"# ,MZ9WH,\ B6>BI]J.,#"CNYN!H6/[T/GVOV C:@"5*8%%TK?QL1<
M>N]<?_M [GZ"]%:[OY>C"PA11,6#% ZSQT)Z?Y.-D[ZDJ/*'3Y(WA"9/90=Z
MN))UER*_N*(# :ED)9]<LJK]+0P%-F1C,, B&F"?G&%9X0R ^B"!$XON7E&9
M/5FI5Y$Y@X-IOS*2$UK\.8!FTP4M?L6P"@78T(W'P?H O7)*MIW!<\$/HYP-
M0Z;'84+"]YHFQ0/9/BK/,4+=@N5)]XN58\*K9M/)'=E84)3*P7.-I@A$WRT?
M1E^!3,K ^$=-:%A45"HH=TF.2>X_4ZQ=4Z #]PM%4#87HRQO'3"CB/W-'U)-
M4UQTJU[=;*X-M]G<FORK<JKPT82;^VO(N!92*=HX /S6Y%S*)<WO,4P^Y/N0
M3(HE%:)$9^#DQ0IT^2X\1-!^O!H*MYP2REX3SQS5#2W')=KZ'3LE0H%U0@!G
M$.@5Y3/9/=DK[4/A*A:07[%E@Q>M,>F(Y5XI]JZ_D6].9/LMYEH0.4?=&S"E
M8G.R9 )KQ+H)/=!F_R>ET*G-F2E*'%@R$^BTOBN@9&+8QN15=8@8QORW\XW/
M2-^T<H# '26XY3,T2'N/JF?G"P,U2C=+<[)&:13-3]. A@!S#R6&T3^F0T(4
M>HTH8.8],<?)PTJI1TOC2</)E,[] 6F4E(7\1<VVH%W9FIXK>$8YT32B2FIC
MCY\3A)4-N(A7X^=9=:6!2/N@_@/*SPP>6F0!G./U_PY31Y=8 BMI9BT*GC"^
MQ>9A_E37S>:ECW$B*ZU*GR]D^BA7HRQ-V4*R@#$/929 3F2^!6E$"\P]CJ!3
M[!,;L#R"&7FL26=$=)FF#^CVJ2$OR(#4QB V\D%]'!L3),W9JQ5;TQ&K,^K.
M[ 16UGUQC,43::6]ZE"^T_K95+I7A&];P'@N.L*'#U*I]2?EC=SH<LH&4N^I
MN["^Q*</=#@:[1UUDMV=3/F.@(0!YP!]*U 6R#74!4'C"V1=PR<B<LA/RHY4
M]("(-V7!!C87AJ&^$G-4.2S 64%#="M)-0M2/'C')Q*?24:E7"R'#\&!L0_I
MLO$#X!"X;@C.5G#%32;0GZ-ATUA+^<8Z@0Y'+?+-#70@!IHX&Y$1X&5?&A@O
M@]EH:XN"^>: D-+XD;(1;5+"]X%[:/$#V,"AJN,R:0V#?UP_01;7*C>28!5U
M,C'R+,B IM&4NI%.>#RL;,W*53K,.BEUEU%R(08,V%DQ.2WXKNQN4F_Q2A],
ML(UT6N$4NGB!\&IE0Q;H6C.%>.*?',TPQ/W!XBW,-&(-;&F/,*H3D,$D!72!
MF=!IQ""48*X2G57U^!"3MG6@,N.?$E\V<1 S7:B:O$/F3A"$)/8D']H,0ZPH
M&_6;MB?5 1;?E?^8S)-2/_!C8TV,F%[^\@VJ?:2[PS:S>, :QPGA:OIF6,^)
MRX 4%W9L'%?I2GV,A]]AD"&,-Y?(905(M@$?/PA# QICR:9ED_&YO6]L/9U/
M.L'[/JD)'5AZFD$O#+)W&!*RE#>] 4V$O64$% G!T6'M(K+NV<E-I#_>#^+C
MA$'9,3TB(I#J(\[J/9T;JM)+8SR9Q=Q\S.8&IJ:=RMM;F/B=MG@%NX57(+9A
M'I=\FF9U<5%K]\1'V\_+B:CI!YB7$N23AB2K@.@?44J4)AKPM2E//<9\&BC,
M?V51@?H$V#D%&8Y_ 04LG G*7>IEJ\MR B!$*JJ?E*K_Z1KNQ[<T??\Q3>.7
MM$^DMHJBE??QK-;=[43RR.@@Z4M6U"+-FYJZI4I6G0U3)D<D X1T#V/&)#ZP
M/WE\B[;.I7S/="QZ*86L"3<^JYP6ZE2C@U;("$9\(7L&=]A4=BE=XI LL9&?
M4HX^3E+2HHR"X6TVA5%#,.H>)NHV6K0N'*9<CK6H^ILQS $,Q#*=S-Z%X6#3
M,5!JQ":\Q/VH*.&3:@"T2QE9%E=>RX!F8Y3T:9U27E 9G_F*ZI#+=$J)J9/V
MJ>2S(1002!T3VY^]U_TTH4V,V>%C9!M0H, "*,_**81TR%GY9T/X$!E23@9A
M\H-K'UM(D 7R $(OR>#G=X7F*<@('5,+=4U'NN,$ =(US?,-V]1TC_1TBCIM
M?I_=!%\ETV&SY>;_^S_?G/.;LQOGYNQ?@>2<^Q+^X O_VS^[]KY<7'^["JXE
MQ[WX=B-]=:[^&=Q(5V?7_]P#*>H0 NQ.IB*A1W 1$\,;_@'L@"F93NB(25]Q
M=D6?C<Z!O#[Z!?2@I*ZR;]=$@R/I<E@ \-0+K(X]L1[%T#MZP-JVTE^6 _16
M_3%A.#HSDTIE-A-F?MC./OB2NT8*)$=H(/U5T^53F=Z5*7\LS$KRG@$#8)YX
M 8&@<EXZQ=%;R-,KTRK)4"%,,N#$S5FJ)#HU]9^P30X),4C^26+^59*Q5,O&
M+,B;D.E,.86\[FP3AN1',J,=")$8&?"N4>4J948Q<Y@T>U32CLFWDS+XA3>)
M9GJDP%7DOLE+MX6;W$U)#^U21\[R>J1G#ZB?:#[1O[%20G4%DN &G5M)CES!
M>VF7TF4 C0TA#^G7[!'K-SFAUT%6]MSF4X)JLX:);&&#10A*]Y.XH17!_!'\
M@8O?(8%8;T:%#)8]_XCP>B#5Z_<80_VOI?8$1N[=< J)+^430"-*[E/^C*<J
M;) W\VGX48+WA1PF:Z%-31MJV8Y9' (OU!>=2SN7Y;[TN"@B+CMEC%-K4LT\
M"Y<:H*ZJ@18&JFLC5T>>;P>V;?NAJ=NAXFI(W1,-T%JJ "[[;WAV[IQ[9\X7
MZ1IK@\'7X/SFFBB(U]\N+[^0OYVKWR7?N7&ZG;8UV_U-I&T=3]K6FP)NW5]0
MIF9CX72&#4_*8]9LNW*0>)43YKKIY2+C*NF0>JRZ^S#DCH6/)C!SO'9?I,.A
MPSQM5J'S+ZK_X*<Y-!!^11P%H-^$,!\=R2?_?$8(FJ'J&ZXMFT&@Z*8?6)KM
MZ+)IR('O:+KE[HD0M)<*0>]7Y_P7;.2>G1,1A^U>YY>K@ F]W\YN?I4<S[OX
MAD4>?'!QSO\\._^%_* 2EI7)O =JX3DV^IXY=EG7D6E;H6NJLAZZBJOKIHN0
M;=B.X_BNO2_'OMS[X5V<WUQ=?*' =GEUX04^.#OV(*TB8/XO:B_Z20%E:V"D
M>-3]347&)93!#*#B:0^H$7P5=) /+2^A"0 DAC8=0P)0484A6=)F<T(H,VR\
MAR2^DX(?<7]*O(@7=W=)/Z9#9^EWE8AEW_7*>,1,!E'*BHZ(*5EM<K^^R>-R
MDYFAV16C@7J\24SQW<LOWWL'KS^([T@\"./)U708%PQ0U.@$Z>]CF@& ],&)
M1/^LSN@:;W=.TS\"KEP[U"6+;%7KD< 2RW(C.17UJSZ 7SXMFJ]&C<G:[E(?
M. R6YI.+Z-0N,I.\[D4O^%A;\HN%.$R# VQ7*"Y/9X+D29_YT]F3'R'/:TB<
MU,7T=I1,*CJ\#CP^3R7'"^SQ^C/X9SEJ8\"\_=1%WZM2+-@D8YYZP9*5J](8
M?/>_X9O#<=!QUW@Y?)I:A@U5<JKD%<DLLOIZ80Y-G^40L!> 88-3J&QA,9)L
MANTJBWUC9H*C'M,)5+2P)J/A9[+.(51O]0DSPX[=1[12J#R9BE)/);<JW8HF
MI<\?IK]UB]-ZF^X5'\G,=4 Z*'TU84.,X%J&]X2%@!;P 2EWW(=LP:\E(6**
MKY34,Q[<9>@F74!PM]K-*Q[<W3N8HV*C&$-:+(OX58F[)-A&BBH3DN="_A[
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M$&"=;6\>:\-R2Q%8=WA81]!D&T"S[>=2+5?+,+$6(!W-'9F#.L@X099EZ8K
MNBZQGUBJP+HW*R[0D&[SX@++4EK .E5@W4%BG=Y-K+/VK+) ) ^*I0I$VQFB
MF;)F(P5A1#-/D*JB-CR5FD"T@T0T<T-$DY[Q1);9'+RC/'=%TFHX225P9>X-
M7 FK1"QU0[CB3:A7;%O_%O,43'G[>0KKO:(8B]#&N;4R%D%T2A*=DO9=ZY4U
M4S-LI.%_6H;V,5(4_+^R^F?\XP3)_[N-TJL+I7>_E5Z> N8\1CE6/^_SN)H
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MI/3UHNDDXQ]004@^8:/M]5-;-?6?/M]F.<;.$XR;PVA<Q)_X/S[/RLAWI6Z
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M"]06W4<%R*T"<M(\OE4SN:W59G+O=B<6S2-Y<Q$A$$ L58!=5[)GMK$'55D
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M2W>3/8V-5WIM5-FD5\.+^_,BY3RW3QMMQRO+:J.2U;(?VD&@8]U'-Y'JZEZ
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MAYR&<0BUW0A\&6K4*P_K^4'$V/,@[S!YB%0<<7LD!WD.\ASDO3CDH0;R!(>
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M33A  @T@Z_)PS<XDT?>:UP[#'(8=&8:A!L-H%! 9(88BB<-8Q"@,B<$P%B)
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M.)1*HD@%@HOU_@JM9?UR>;985&77]* ]K0:HT[A(;R7=6Q)HQ\Q%K)%;(H
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M'\@H##%1(*"QI$PR1@SG<N@+Q,AVT;P#Y_:SRFIO,],<%[X-+FS5JM'RDT,
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M92N-#+,HC$GLQQQ*Z9-01: ^9J$H#]?"R<_DV>YU=XC  (F7=-J=H)Y^LC&
MX"'UW4MFWD5ZE4TF)G%E>NG=6A)VKH"G:P"M.E@4AIQ% 8Y0@$*IE7LN%QJ
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M13K+]Z;.F>I0Q*%(7U%$LWJK$1R$-(A#GT81)Q'"4M3%R^-(7_ET%.FN5,R
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M&034R, 9WAVP]MS#Y.<K[N&E22$[S!:V76S6-6:&:4T2.Y'78]^FQ2%5!(0
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M-@W)^UJA]K<2M8^F5-0CN=;PR:M6_B*HI)"G^EYSY !$LVLT0#0G)%B$N53
MCZF"D0@AI@QII<0/(B(!A6*KR=M0)7PP>_<?13[[QV_)/Z=YO3U%DWI1?Z16
M EEK3_+O?6UN7)OXYE(,X5SKF$5%^A4G_*JER/;;K4<CJJ&L7;M#G@;:-4L#
M\ZTY&D=0]N39_.GWY)S9*[*A; [/QR1 B D_B%$ 0T!B$.*2#2E4T%\O(7(P
M-O3?"!NBP[#AR<C/P,G/AQA7"\;&41LCS;AQ&/ PQ &."6(5XQ)M&Q'\<HP;
MO!'&A?+)C+MRQJZ#$V0;3O2M&^Z;<M_KGZX:]>O4O,5?V &QB]4Z:_;U.F^,
M]:OTPT6>)G]\2"[UD#XEX[ODOC FYW5>S69K>O.C1RF3IXS7N\X-Z?Q'$<6(
M8P%%I 2BF,8JIIHGPQA#$C$8@+V\H-:A8"(?4YLBWI1A2[J-;1W<3#S[?/Y;
M%'IGGX,OW[Y^^::^1^$A8G0'G\?G+]^C<^_[%R_X\OG\RZ]GH9F)%Y]]5I^#
M,_6K=_Y=?_!;]/G[N?=+4+O_WC]]JHMIO4RD$7U\_)SK^NOY_.;&'/O0Q'F^
M.(4Q\]30YA09YZY-ES$1DP<78K$<2_BSW;\G&$,1,,=>,0JDP$(KK8NPA@3L
M WG4][KUY[2O49$N(D9X.;@RRD8VV'&=_$C7'.VWN<FK+Y-3XE"92'X^_9&,
MS:ZK;V?_H_YO$)DPG=$)EH,H>3HV6S\U&0!9/OIPF^2S>^\FF<Q-"O \3ZLD
MX&)ND@/,.Y-RWWQO\U'J[^_K1)OE@$TV64D?;FZV="_S@9[#Y7Q\F8W']2VK
MZ$X9:ES)/]8T/+9!/[T--N)J#C?I=;F<F]O5>3QZB%4BT$=/>55B0Y7S4,83
MIY/B.KLM(U2/#G!@/DA,_HO688MT^699OLBR&#Q]:,\^"M22E4LTC3I#IRZR
M'BI5,<ZG-P9NC!+V_^EEKY6_'7+W,"< QE$D21QIFQ>IR(\KSE%8,M$*F@7(
M1P0+Q@5 1 4RBJ6J$B%\A'SV*/QL?<Y:T*R:F_>M/+T_LTFB^P:N=GG\<T;_
MG/R',\T!6H#D(YN 9ME&G0<> VQ0NY'+8&N]Q57ZP<( 63Y0V*IV4"/:W74Z
M,0E%M4%9'C,H[(SSZ;B*"M]D)MA\-9V.+*<6:?XC&Z;V#*+E4AO[+3,!M/9G
MEJ8,7M8G&,NU;P\E_7E;7F7/Z*4FTT#?:Y$.9<#/7+[V2#.:'_J6(PUY[=.8
M32AT01+E,<$\-S>\6:1F5'A4##4R6-BNU[,].@T:QK8I)]&$9R_-,(M9>EN4
M1RXSP_C9Y7T]U_86-&MJ3UXN7UO=OSRF>:'Q9#DGL[Z5/7/9FJ3YKIV2IL71
MT!S,).\]#7U3<XYK\S5UH'_GY]HSFO1]0S'+!&,6MJB*7<R,P"GTC8I+FV/Y
MP$.T2)@M'F"RU=+;]1.OB4EX*ZIL^XU[7U)BM9'VG.[BGF;,B[4RMY@6:4F3
M)H'NH:F;7RT>6Y^,M3=>HOO6.$S^Q2@K-" ,9\M"?F;6IL5D2<-G-N^O9)-*
MMF[8)#-6??-Z+Q?Y&5IT&6XQU+=Y&JN[\L!5^M[U1FG^B<WUXW&+<.T +LUG
MV:1.#7F43TP"4478F4UV?.C1GY;R3!:JDG[(2IK()E5,+_0\-[/3,L"J[)H<
M;1[,9%CJ*S8!LYBM9\&4:&:S8):YLWGB\W.2=I  SQ(@VW*26DJ)21;6&',
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M[E1D763--EESJFA7A\F6]K_>\G$&T[JIJ O1U0!;X@=T2_Q@GP4Z%98E=:-
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M!,D%\X9I<=*D#I]GS>!%SWI8=#_TY;<+!M*5%>#SAWBJ&FNB=7G;W%0+UZ=
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M1R]-Z7%Q*3"].'CGR(T-R"/7LP,[9BQ@) I58),P+(I<>&#3L-T,ZJG<V%%
MU#GO-/H%[>B"=O2FT(Y*4=2HZ1&A[=IH#CBN&RK'BP)>M)=0D6)\7;W=,]H$
MS.E1T>X#^.; CRY"ZB*DWI"08HU2)T5BY?NV[=A^'/G$8ZY3G&61'HGD04*J
MHS""ZA%^06C;#:'M.)AMA^*S=#2&"@$K=GCLN\HE<2P%D['''-MU(M]Q;=</
MJ$87>6T(6.+9FAO-DO'W(8)?Z8:2.Z)=*4\$Q Z49!X5@>(1%W$%H,-"OP%+
MY-.0>X$?^#YUPY#X3A@4M<R.'1(B-L(2;7W/BAY'Y83R'H+H'8IVM<L(#IG
MR:)=&;22O3N7EC GACC+[D![/Z[55JAH@*Z1D(;5GI=M40LL*NQ&>FLE?=U
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MMBN5[W+/5D'@$!GY3(D@]BNB]]W6N=4]UUYVM_;\>&L/[]7MN77/5RL%$7?
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MHKGEV780*.5M*>1^B=C"C[?">=M;PSR=\Q;X[=W#76JJ8#,=VFJX3@LIT3H
M=ERR9#76B.-2A]D,X9>!'D/"11@ 6?H.. *4\Q:^ZFDY\&^&1(^A'-8X\'E#
M,%>R=46R9[7)WY+R8/E\!W=X5H:ET6B%WT8=' '?1N6-_BKPI>\1X8=$1![U
M'%\JH/+(D;%T0>V\!E_WM='Z8;[N"H+OS-EMU_^-34HSF4Y'P[XN(%Y([*!K
M]<Z8/0M'P8#2T<L D5[8&EC.>S\UAE+E,J!'4;D3:WP1]&)6G!1:< I7O:8X
M]E[D9=<X)I/Q2K<D;<YWY<,Q>9NC\[VE\A9<96.]-4IP%XHPUH<'RF/[C;<:
MTU/[IN:I2\M^FPQ')FR7/!;/J.ZM]G/I>_U,G,T4*.QVJ%UH8U&NWCS]TTA+
MK4&1[ZLWHO4^D'%8B?>\!7BK8$*?NP)O=2E\'YZ"+G0ZFXW,2INXQ&)E\L;B
MYN7LR:H:YEZ1G9WGBT<_&Q%7?;X.Q-  D7H:W%'F3H?CU64.%L9NT%+#VHAA
M9F E])2F&,O2141]?>:I+,U$.0#L/?R1H#Z]LOYS\@#R%^0&<$$_71-KP+=@
M8K881MZ?3"N7I7@^\LGW^7" 01G#X[A$S0$/*QVPM [#?&'XY=C7C 5#2M9H
MF-QH\ N]M'CSS!REG8SQ^46!:Y)EC]JWJ^I-M)U0W5O=H 4(R/M^T3?GYK$H
M$2FY'U@Y,V%S'1&J(DOULW3T9#"! >)VZ*QS,FZFF)<':<;8>#".X48C9ADY
MD)A #=@D T2C27Z .-$B$'FY&8'?@&EV2K ?KGTX[,<%O>.E42\NZ!T7](XN
M<!PVPQ9NO9T=7U[EDWF&]0O&G@+W<P0_@I&<_8EXAS=YFOU(C%Z;SF?-(\3]
MNP1= 7AJ#B9;;A))92H"O!2='FAHPXW::EEM8/007+O4:-S-=H-6*8MYW?ID
M=%NMK5..5>7)=T05JX]?KTM-F/E@ICBO+EI5_+GN?0A5KQV-Y27!O)>!BC66
M0G6:L@1]UG<:K *$_H2K1L/;[E2VA:Y"L>A5 +H:Q'TZNYL,BLDOWSG,"S.M
M*#W51RW**K;AK.(%[2_<I^EL^>C&K8E'Z*>.8(S@'/23,J.UT0Z#)R,YYL69
M#UW25M<=3![&Q7.OK&6+9-,>K4M+%2Y-&9;'JCP]%"1%6"5]<&V EO)QCZZY
MHBX@B"+;C92*(_@I]D//94Y$?!*[;F@[CFS5_BR=E(YA0?X_7(\:H"<_CT-K
M^R&'V^X5.1Y(B6$QI-,VAV4%41TW'"<:J.ZAL&TE_= /;<\)7!Y&#O&I+>-0
M".&PS>&XC\6XO\"PJYQD'8\[ QIJA\[8KH$SM0(!]^# F?&T41)F:'R-'GM%
M'"0?#C"4VQ++FZ35L054G7+S'25CXA 6.9[#:*1XP(#,J.M+XMA>"]9A_=G:
M0F$:**7K6Y#GD9YR4,[X#(AN?V 0^XC8^T;OEP@SJ.]OTL)TV<5@T0B@:Y4J
M4K4IX@,#(AEJO(<Z!]?ID? E_+HEHI5U0@ZT*.%A;$=2>9[OA#1P\;0B$RH,
M.66[5]1^*:<4%HNWT/=0SW)34N[$R7;Y%-=@GB%RQR]_EU<V7T;+,\T##B;%
MEXVUGL"!Z_C0\O+90SH"R^,>OK\KFCGL;]*<3A>(V<0<I%Z20DN0Q&WY\PSJ
MT*G/0<L(&XLXH ?!.E<1C81G@V3A>,;%B9S6&=32SHK,=+8#7)^HJ#B\K8"X
M:I\^Z1#Z2@="3(%\FI<.JG8NYTVR B&.^#)-B*,/38PCDV31/FM#TE?I^M(&
MZR.6667196EYD:Z0+Q5M<5[4G'(9E+ZP[H0%"G@T>;BR]D-D_5I4I%W?ZJW$
M!VZ$954^#4@4NK8O ]<C0D1AT8?(B?S840U8UM!7@GH<2%]PM/>49U-S*1..
M[;@;(V-;W]."9?VV@!4Q*U((.H14;&(99EGP^I</*.AEOTE&>F^2 A9O-=CK
M]O#@+K,X9!'H?GW$.A6WUCM-C9-Y#B2<O_]U/4[]KD'5':9]T*H]0U!U9<_(
M)W7CV24]T,%2+JW%0D?*Y49V^+DYSC&*Z%$[!0"/-.S73T>CXE==4(6?<T3_
M+SZO6-%OPWN0N9_2!^O+Y#YI]>^\3[+OP[$97C*?3<HO3#M0_<W#<#"[^]5Q
MKQS)!%<*H?*Y_$O9UK /(B*9YNFOY1_-E=8-#'^I>EM7;>'Y+^L[7Q?O8W_Y
M6WG1\F]DPT]BI]M>M.'V,[=4K1:=_;)YKML:K;^2CMPKLEN>5CNM3D;K.F)N
M) R8[/:6\R?=GWWMZ$LZ(E=*_&6A!B/7YFM1.X+];="$?:8.Q1N&>XJ=>[>1
MQ@EW[#4N%;%YHQ6 C#P2T,AV;1X*7X#!R8DO0/,YQ!5AZQ#E5SR:E0[:2+$=
M=OP&"QB!8;KLT/MB)+:Q,^]6.?0JQ$TI573!P+*7-A]7@<XMVHMNT5Z=]O[N
MF.'>;>.X1NZ($!7 __'8#KR81V$L6 P<Y[MV[!'EK\@=[8#DW2'W.3W.N^2]
M-CV>0M/VY7*6BVU0<G&9J<!B0]VXY2"NW=H;O=/E/!E^;V"S^[X0DCI!X,B(
M4LIM$KG [T%(8ND3MK+E3QV$_*.6G^7.'(WS"16@=]L@^0?HW8-W_URDQ@(U
MDU.5#K_\_;>J[2 RO^[A>XQ]W\M/, _%*U8\\32=A5W7H?MI/Z]+0>P:A(Q&
M5$1QY#IVP+CB'HOMR(305  BII4 1I+[5J1&/DW&?7W2Z'A2CA'9$Z(-UW=,
M*?>RE+O1!_EW'7E<'W(]=IIW]]+OKM/1!Z9_?L=^&1JDY/JV2<+;4T*A&_J"
MA0XPB>T2ZL6T;+_G1"1PO&9*R/:$YS#F^(+'+O>EXQ>\1",6!>'&N/[6][12
M0MZ!Z9M=WGC(@$\A?=.S;N>Z4TI=NIRET^11EVR723*=%*N09HLO;X<HH$PM
M!WP!9L_W.]-V!8O/3 .AO$C)Y<M9HJ4(\)I<T?$3)#OMT3DF2)AS91,B7>':
MDC.JQ+$S))+NE2%ALJ,,R2L*0/TW]E"*S*G_97;_]:3C3D^>\-9TT,;)G'"\
M<]?X^K$\J,X,9M NRXW,+ZF3,TF=D$9GVS#R% ^)PQW/#X(@%#SRB"])9%,!
M6K*%/-,T$FOC\4ME.US??BXMBH_C3S##;[K8\'==:]B=._2O-)L,DOP.I8A#
M"?W;&\^SK&*_TQ8O=/G ]&FIM.,RH*J/1\2,1)YG4Y?'TB%"18CWY$OJ><KW
M_#8BV9,8$$V*;P^3U\%WI\]>YZ#6*3DT&?(:<QW;&-*M&1*1 #U7BEA2*DDL
MA50Q,"1C=LP"C[3:#SR=(>^R=+F.^T19\J(*GX4EZ=M5A934G$=EZ''")2-4
MVH3%KBM#Y#P5AU[@<7HPY\63>?8Z&._T^>LL="$K6PMEJ4;EN:C&-H.RFD&%
MX#*(8]^V'2HI*,B .L"@,I""*.''"YC63^?.X8_4&P^^5;MQJ<T[M]J\9PX4
M'CN#WZX^/\V05;<)_"?,^IE%52.N)5E,&*-^X-,8?!X1!A[&M92R[3CB3KS)
MEGA-<N<)6?L7H-:33MIW5C/\LL?!/XZM.+W)3+-HW2BZ"3\Y1\A%[*92YF_'
MZ:P&N:K KZJ*Y[4H#072Z^36P.1.YC-L&&+0>3%/#+__9YKUYR.X-DBF".)F
MO2N_*9JR5PGFYL4(@#W4W=4/![_9<@Z;T$;@C3M2"=LGQ EDS&,:, )^/F>Z
M58<7M'!)FI9+6TH4J VP$_C'IL/8U6%J(([KVR!+!\-99X>DA;AJBY?.X(O*
MQG8MO#-]C'ELH=HH&J0?>R.=&JM#1"+V?>9[H>>Y+G%MAA%4KCA(>Y]QM6"5
M+N]BG*8Y&)W7-3F7!^Y/<G_95;NRM;/M'8XMM&,_I+";MRG"63>YO#P!;PZM
M3ZMR$6N:PH;/'HM;S#EZN' ^,CV2K.3XQ%!CS-M"<ENWF0^DHBKT75_:8>1P
M+W(BOZWW_R,!LOAMDN=I?CV.?B+"W'R8W^'$5K%Y451%=%'5;KN9@T*%[S9C
M&QQS6T<3@P^>+LRN ALH4 4:_6!@VW0OF.H(XEK8S4...G=5,]<!7"<[#*Z3
M[Z.V-9!B!1G8QB74>_.N#[]^GV0:8DE#)/V6_DA'9O%I [L0)7/C&0LMP.?9
M= +D_1YAFQIXF0:+KBA4+9$_;Q/="K'JN%P^?ZGE%^COR<T,6,<,4_>$NT=@
M:PW:#V_(#=P*HM1K($K$V"Y>96 RIJ.DGUY99:W>GK3=-:@!3GOON^'5:GUI
MVUZEG8<2-M>X."MQ+VL<=[.%-<S68!$WPZCXJU75>DMF+V)2XR!S;M/8$T$<
M1IP)#EZ8(P)!(LH=GX"QY6/Y5G?0T ?;T.8C7KX!>WB]$%PK'/>KS:U[@^<&
MWD[C\53HG)MQ6F+!?!;Z@?*H\ FSE1>6=8W@]Y)&42Y7(7/"D :VZRD*RM'Q
M"MJ1/'9LM1EL8]M[6D6Y7[$18S&MOUIF8NM*='=&#-EA%(=,8JD(]' -)N2S
MD6M@6C=H:MI;HA5YC=,2THO^[5UR@,3>'%5B4CHJ=63M,CJVQ^,H(';H.H$?
M"J)L5F ;>1$)O3;6+FZ"W@--_[DW!YVHM?G6&)/I8;Y?GRIAZSC3+K&FI^O(
M=<W5JZGI9AJFAVNM<H[E A2;I!J]U*+ ]CT??'T*8LP+?%YM4AC+0&[8I,])
M=IU]G:$.U)C(G]-,[]LN <'ZVGUVS+ZRV[##!V_50>;,3LRA5..4!Q,18Q3\
M+U?$C,0BJ("_0N6L *)>8HZ&#WY4[E"J![*^)^@15GP-<V!X#2UX1-&O9WEE
M?:QC)KT*=NQ4Q2RBJF4_TF.3E%.?.@Y<Z;((;%GF!"SP&7&(3P07(96"1K)5
M$- @J2($:2CK2S'R>)+%^MC+QR+<N9K.JA".]Y!D@PKH4*,H1O?3T>0QQ41E
M6#:.UR^\-LV,6I&>0RC5[3&']-11>M*N)E3T(ZM8L 8Z- T'TJP_-!W'FB&A
MQ7[D13>GXPL=M[9BW<!W%8]!Y$0.$=+CCLT(XG]).U01CYZ70LIOX6DS,&A!
MC>@W_0&TD'_Y^D>GM$&IZCFT#3/^O)3Q T,8V*42&[>5DR[NP&GF5SN$B$ZJ
MC]-R>>2ECU.GSOJEC]-S]W':M\G1#N[Q0=[U-CS.X^1*C77T-9W.&L821NX6
M[1T,9XY2W<QE#()LD&8/\$!@"FLZOP&7&_.@:68DWV(H_$@JSZD/#"AA4T&5
M'S/A ^>'D2N+P(WKQZ1U8$"KH(_:  UUSS^#.F_TWJ?T0?^THG>Y^K\,EPD+
MGCM16(3W"&4]F%/G.LOL0*VX5B'\+K:]7$![-@'/:I>1*HJ;*L-G.+9NY]@S
MMLA^_T@SX/[19&92*=,"OOD92,%M@E3XG!.7^* #?"ZEC?GK@A2"B"JRD/EL
M^5M1,;EODS_JJ><?QS%,]/KV&J;HE3,TQNT*6PB(I"ORZ#F<'H4Z"HNFI[OQ
M%KUB"S#XBID[V;@M00K7KCT;Z84AB]W(54$@;-OW/44*>!&;N:J5IM0[IIM;
M;]V$@V,1U+DZ&H].T\QL1Q%-M[ZM8-75)2IY,JJ2%]6.ZF[*==NWBH=U64H!
M-55TKRL%=M$7('^N72>UMX+5:#Q2(K =EX=>;$M5A*94Z$2DM>N?JU*%2HA7
MZ'F[">R]P?;Y51M<ID.P?0T3T65GEZV[4)<&<B]F82@B7U$B47;"OX74]&W*
M6]B%GPM2C($2RRVXOFV(T^-N!5/J2AVOL\^SIO %WS.%OX,U>9 QND<*?Z<T
MS.>L +X\QTQ,=^GR4T\"N:QNN.C%W(V%)Q7!PC,;Q#8OQ4< F]0Z,5^1P//G
M@>CSY(&F%9&?0"K(935*;40)5X$,'3Q4YB@1QF!OF:T*;16VXL>+6W7)!CV9
M2QI=__Q(VL0/F.-%,N;,4Z(P=:3T*6UE@U9QB7%:.^40W:4,5OMAD@WR=/S+
MW\>3K=7XSU+*LXN&VL!RVJ!:DV5Z2N4."0(J"2%NK *A0JR'CBE(O,"/B..)
MZ#56[KC/5+E3U^AHZQ"]#+W<_S][;]K<-I*EC?X5A&?JG:H(6IW[XHZIB%P[
M/+?*KFNK^\9\ZJ ER.+;%*DA);L\O_YF B !B91(D2 %DEG34R5N #+SG.?L
MYWPJ!Y 56GM!V+H_S2]GNOVS^3R""VF@4DPZY[T"E&@YHPI$#&[D\SB.D&$
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MF7A@6.M!NW6:PK?G@Z ]1F2/R;TVA>^LPIXTCA3C:!E*&*RM!"@(1T(+ "S
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M[&TA^[*F\'MZV?/%/T"7U3 MN) &*L6D<]XK0(F6,YQ%Q.#H'7\&IE?^G*S
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MK5Y\LEBS.HW"L[5P%)U,DMZF,GFSU>XWM5KR.G6" \$LL@PRR)%S!#CKH73
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M&R'Q?%)B.H)5HLX'AE1P";R2SF"+)2"4^=*4D8A@G>*O26EYS4AJFJR]9VQ
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M'0(>HCI_F%N+*5' &PP0]Y@96DY$,2R\J7<[$>608NZ[4++H<;?!2Z7-'<:
MQFPTKBPEG%FBM7#0 XU -5"  D?%294VL];9G)RA5-I\HJI- JGM0(K6)0X<
M4B>\ L(AAHQ37HC*< NP9=GRY, C#7NW#U+L+&4P)Y!Z76;G==4"LXIHB9 $
MB"+EJ2*,5N/8C")RM\S>T5CU(M-O-8ZM!PGJ49@&LITHUW<UQ$P;D\X,\!"*
MP/#"&$,Q%C*FO!63VSW#G*40\_-(\62(F39:UZ;BYJ3Y=TX98*!6!H(F@$50
M  BV#&-@D+55XIJAUO-7;G'0X;AP^V8";:2F)(4A(=IK( -DC>"%UY0II:"
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M&LPNZ[H%(#TR&$E(/62>P3C N:I;$,BYW6:Y=#1:O<CTVT:K>4^VFO>7N/Z
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MPRDL4F7M[D"<>8V(\MI ZY +%$JME41*#0DT>F]464;*_'A2O16_!U_J3-Z
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M'<A>+"C,>X*U.25D73KH/I^?0'^DQ-V1NQOU"]C!V R;.\HYL%00KZM2$$R
MMT_DU+?$W>W;&Y3U$%XL+4O<G;C[9+A;U-SMO$)17F. .814.<?FZ>I&^]W*
M[O:U<TQ[ NVN5^$A<_?)!&Z*%M)=:7YX8,Z'55MP#-X)U)C[ 9'BB$(!;$ ]
M01$QOFK7@057J WEQOUY-^F'?1V,^I,?[^_RF^F'\2A"86Q.$'[ZONIXL!_;
M!I$>X+N;T+$)R70?.CN%F%URQR;(/!'(Q#5D*D@M]T@HZZ$FVEE.W"P Y85<
MF%VR7\C<08!*HI[<H4Z9(#-!9H+,XX-,VBB?$50#"B&GTC/AM"9X%@.SP>)N
M(\=H"\C<08R,LUY8;(+,EQOH#WM[M]'9:IU^U\7;Y1<?ET$M)INNZ/S3PNY(
M^NB!BW]?3V87N>U_S=]^F>3]?[WM7X5'>M<??N__F,;*E>M)M9J7/6+_)<^7
M74\BF_S;U'G$L8#"*8$HIEYY"F4P)3$DCD$#-O)>%#59XZLLLGW8\'J0<'L=
MP/:30/S^P^??G<W>?S ?/_WQ\9,Z=W87I;,[7\>'C^?N<W;^,3,?/WS^^-M[
M&U>2^?<?U ?S7OV6?3X/;_SN/IQ_SGZNL#J__.7E2^U^@[9F@[*GU]KH;]>
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M='*''0)'KI2LN*XMY$XRQS5'$CL"I;?45_D>5"MI^.Y9<B>J,Y%'SYLIA_K
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M<78.7_P2G9R?&6\#S>RC=X^?:C6M;B8A+W^/<B0;KIL6X)2"X>W_*CL(/7V
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MEP<.V;2VRBY2I(>&>[#'WGOC]<J]'64C>=PK[6>4F*"NHJ&JCFE+&[5A X,
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M.KF?4Y'G:#SAR'\II_)1S639U X10WXEXN,GTSJ"O]3\)S[MGZMWR3KGR[_
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MAEE*&7RX;QO6;:NI,9/^^=LJ[C(UKM-DI$.]BJ?RRT^+:0HCHN9!XCBKTS5
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M2;-Z@JK\4'[=I+B12BK#Y 9X_BA5B<%8OZ(L@P;+.,0Z&&-Y<%X^0Z;G5LN
MH5N-$A7ZZV/#J".6QW<#3/"NR%Z7FE"98'7J=56T1>913V>*6>H1[S=<:%\I
M63^G5\"?'_,9:+3X^E5]ZE%U#9HCMGEW 4Y/C7ZF;WZ,9:O-;*)*D,!_6S6!
M$IT<#K]_!NR=+0H MMMBD2',#<=)-FE6)1[+=;NIUZUDA:PN$@M".I/EK8;
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M?S$;W?WX?__Z_?5\,O[Q_P-02P$"% ,4    "  &/%9.7?0'U=$3   0UP
M$0              @ $     :6YS;2TR,#$X,3(S,2YX<V102P$"% ,4
M"  &/%9./8(1:\8B  #>:P$ %0              @ $ %   :6YS;2TR,#$X
M,3(S,5]C86PN>&UL4$L! A0#%     @ !CQ63NM$I0.X6@  /VX$ !4
M         ( !^38  &EN<VTM,C Q.#$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M  8\5DZ"MF&D:NH  !!O#  5              "  >21  !I;G-M+3(P,3@Q
M,C,Q7VQA8BYX;6Q02P$"% ,4    "  &/%9.YFOXHPN,   A_ 8 %0
M        @ &!? $ :6YS;2TR,#$X,3(S,5]P<F4N>&UL4$L! A0#%     @
M!CQ63FUWYA.)#P  \ST! !D              ( !OP@" &EN<VTM,C Q.#$R
M,S%X97@Q,#$U-"YH=&U02P$"% ,4    "  &/%9."5IMM-T%   $(0  &0
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M;G-M+3(P,3@Q,C,Q>&5X,S$Q+FAT;5!+ 0(4 Q0    (  8\5D[[0%L[AP<
M /<?   7              "  : N @!I;G-M+3(P,3@Q,C,Q>&5X,S$R+FAT
M;5!+ 0(4 Q0    (  8\5DXU)2VI9 4  (@5   7              "  5PV
M @!I;G-M+3(P,3@Q,C,Q>&5X,S(Q+FAT;5!+ 0(4 Q0    (  8\5DY^%M0S
M6 4  '87   7              "  ?4[ @!I;G-M+3(P,3@Q,C,Q>&5X,S(R
M+FAT;5!+ 0(4 Q0    (  8\5DYR$I2)GWD# '=S)  1              "
L 8)! @!I;G-M960Q,&LR,#$X+FAT;5!+!08     #@ . +8#  !0NP4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
